FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Wang, R Schoenfeld, DA Hoeppner, B Evins, AE AF Wang, Rui Schoenfeld, David A. Hoeppner, Bettina Evins, A. Eden TI Detecting treatment-covariate interactions using permutation methods SO STATISTICS IN MEDICINE LA English DT Article DE interactions; multiple covariates; permutation methods; subgroup analysis; variable selection ID CLINICAL-TRIALS; LINEAR-MODELS; COX MODEL; REGRESSION; SELECTION; TESTS; SUBSETS AB The primary objective of a Randomized Clinical Trial usually is to investigate whether one treatment is better than its alternatives on average. However, treatment effects may vary across different patient subpopulations. In contrast to demonstrating one treatment is superior to another on the average sense, one is often more concerned with the question that, for a particular patient, or a group of patients with similar characteristics, which treatment strategy is most appropriate to achieve a desired outcome. Various interaction tests have been proposed to detect treatment effect heterogeneity; however, they typically examine covariates one at a time, do not offer an integrated approach that incorporates all available information, and can greatly increase the chance of a false positive finding when the number of covariates is large. We propose a new permutation test for the null hypothesis of no interaction effects for any covariate. The proposed test allows us to consider the interaction effects of many covariates simultaneously without having to group subjects into subsets based on pre-specified criteria and applies generally to randomized clinical trials of multiple treatments. The test provides an attractive alternative to the standard likelihood ratio test, especially when the number of covariates is large. We illustrate the proposed methods using a dataset from the Treatment of Adolescents with Depression Study. Copyright (c) 2015John Wiley & Sons, Ltd. C1 [Wang, Rui] Brigham & Womens Hosp, Dept Med & Neurol, Div Sleep & Circadian Disorders, Boston, MA 02115 USA. [Wang, Rui] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Wang, Rui; Schoenfeld, David A.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Schoenfeld, David A.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA. [Hoeppner, Bettina; Evins, A. Eden] Massachusetts Gen Hosp, Ctr Addict Med, Boston, MA 02114 USA. RP Wang, R (reprint author), Brigham & Womens Hosp, Dept Med & Neurol, Div Sleep & Circadian Disorders, 221 Longwood Ave, Boston, MA 02115 USA. EM rwang8@partners.org FU National Institutes of Health [R01 AI24643, K24 DA030443] FX This research was supported by grants R01 AI24643 and K24 DA030443 from the National Institutes of Health. We are grateful to Dr Janet Wozniak for her help in identifying variables of interest in the TADS dataset. We thank the Editor, Associate Editor, two reviewers for their comments, which improved the paper. NR 32 TC 1 Z9 1 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD MAY 30 PY 2015 VL 34 IS 12 BP 2035 EP 2047 DI 10.1002/sim.6457 PG 13 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA CH6GJ UT WOS:000354134200005 PM 25736915 ER PT J AU Pace-Schott, EF Germain, A Milad, MR AF Pace-Schott, Edward F. Germain, Anne Milad, Mohammed R. TI Sleep and REM sleep disturbance in the pathophysiology of PTSD: the role of extinction memory SO BIOLOGY OF MOOD & ANXIETY DISORDERS LA English DT Review DE Extinction; Sleep; REM sleep; PTSD; Anxiety; Insomnia; Stress ID POSTTRAUMATIC-STRESS-DISORDER; CORTICOTROPIN-RELEASING-FACTOR; EYE-MOVEMENT SLEEP; OBSESSIVE-COMPULSIVE DISORDER; COGNITIVE-BEHAVIORAL THERAPY; MEDIAL PREFRONTAL CORTEX; PLACEBO-CONTROLLED TRIAL; HEALTHY CONTROL SUBJECTS; SOCIAL ANXIETY DISORDER; HEART-RATE-VARIABILITY AB Post-traumatic stress disorder (PTSD) is accompanied by disturbed sleep and an impaired ability to learn and remember extinction of conditioned fear. Following a traumatic event, the full spectrum of PTSD symptoms typically requires several months to develop. During this time, sleep disturbances such as insomnia, nightmares, and fragmented rapid eye movement sleep predict later development of PTSD symptoms. Only a minority of individuals exposed to trauma go on to develop PTSD. We hypothesize that sleep disturbance resulting from an acute trauma, or predating the traumatic experience, may contribute to the etiology of PTSD. Because symptoms can worsen over time, we suggest that continued sleep disturbances can also maintain and exacerbate PTSD. Sleep disturbance may result in failure of extinction memory to persist and generalize, and we suggest that this constitutes one, non-exclusive mechanism by which poor sleep contributes to the development and perpetuation of PTSD. Also reviewed are neuroendocrine systems that show abnormalities in PTSD, and in which stress responses and sleep disturbance potentially produce synergistic effects that interfere with extinction learning and memory. Preliminary evidence that insomnia alone can disrupt sleep-dependent emotional processes including consolidation of extinction memory is also discussed. We suggest that optimizing sleep quality following trauma, and even strategically timing sleep to strengthen extinction memories therapeutically instantiated during exposure therapy, may allow sleep itself to be recruited in the treatment of PTSD and other trauma and stress-related disorders. C1 [Pace-Schott, Edward F.; Milad, Mohammed R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp East, Dept Psychiat, Charlestown, MA 02129 USA. [Germain, Anne] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. RP Pace-Schott, EF (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp East, Dept Psychiat, CNY 149 13th St Room 2624, Charlestown, MA 02129 USA. EM epace-schott@mgh.harvard.edu FU NIMH NIH HHS [R01 MH097965, R21 MH101567, R21 MH090357] NR 268 TC 8 Z9 8 U1 9 U2 24 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2045-5380 J9 BIOL MOOD ANXIETY DI JI Biol. Mood Anxiety Disord. PD MAY 29 PY 2015 VL 5 AR 3 DI 10.1186/s13587-015-0018-9 PG 19 WC Behavioral Sciences SC Behavioral Sciences GA CL4IV UT WOS:000356916700001 PM 26034578 ER PT J AU Brito, H Martins, AC Lavrado, J Mendes, E Francisco, AP Santos, SA Ohnmacht, SA Kim, NS Rodrigues, CMP Moreira, R Neidle, S Borralho, PM Paulo, A AF Brito, Hugo Martins, Ana Claudia Lavrado, Joao Mendes, Eduarda Francisco, Ana Paula Santos, Sofia A. Ohnmacht, Stephan A. Kim, Nam-Soon Rodrigues, Cecilia M. P. Moreira, Rui Neidle, Stephen Borralho, Pedro M. Paulo, Alexandra TI Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate Indolo[3,2-b]quinoline Tri-Alkylamine Derivatives SO PLOS ONE LA English DT Article ID TELOMERIC G-QUADRUPLEX; RNA G-QUADRUPLEXES; COLORECTAL-CANCER; DRUG DISCOVERY; BINDING; DNA; ACTIVATION; APOPTOSIS; PROMOTER; STABILIZATION AB Background A guanine-rich strand within the promoter of the KRAS gene can fold into an intra-molecular G-quadruplex structure (G4), which has an important role in the regulation of KRAS transcription. We have previously identified indolo[3,2-b]quinolines with a 7-carboxylate group and three alkylamine side chains (IQ3A) as effective G4 stabilizers and promising selective anticancer leads. Herein we investigated the anticancer mechanism of action of these compounds, which we hypothesized due to stabilization of the G4 sequence in the KRAS promoter and subsequent down-regulation of gene expression. Methodology/Principal Findings IQ3A compounds showed greater stabilization of G4 compared to duplex DNA structures and reduced KRAS promoter activity in a dual luciferase reporter assay. Moreover, IQ3A compounds showed high anti-proliferative activity in HCT116 and SW620 colon cancer cells (IC50 < 2.69 mu M), without eliciting cell death in non-malignant HEK293T human embryonic kidney, and human colon fibroblasts CCD18co. IQ3A compounds significantly reduced KRAS mRNA and protein steady-state levels at IC50 concentrations, and increased p53 protein steady-state levels and cell death by apoptosis in HCT116 cells (mut KRAS, wt p53). Furthermore, KRAS silencing in HCT116 p53 wild-type (p53(+/+)) and null (p53(-/-)) isogenic cell lines induced a higher level of cell death, and a higher IQ3A-induced cell death in HCT116 p53(+/+) compared to HCT116 p53(-/-). Conclusions Herein we provide evidence that G4 ligands such as IQ3A compounds can target G4 motifs present in KRAS promoter, down-regulate the expression of the mutant KRAS gene through inhibition of transcription and translation, and induce cell death by apoptosis in colon cancer cell lines. Thus, targeting KRAS at the genomic level with G4 ligands may be a new anticancer therapy strategy for colon cancer. C1 [Brito, Hugo; Rodrigues, Cecilia M. P.; Borralho, Pedro M.] Univ Lisbon, Fac Pharm, Res Inst Med iMed ULisboa, Cell Funct & Therapeut Targeting Grp, P-1649003 Lisbon, Portugal. [Martins, Ana Claudia; Lavrado, Joao; Santos, Sofia A.; Moreira, Rui; Paulo, Alexandra] Univ Lisbon, Fac Pharm, Res Inst Med iMed ULisboa, Med Chem Grp, P-1649003 Lisbon, Portugal. [Mendes, Eduarda; Francisco, Ana Paula] Univ Lisbon, Fac Pharm, P-1649003 Lisbon, Portugal. [Santos, Sofia A.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Ohnmacht, Stephan A.; Neidle, Stephen] UCL, UCL Sch Pharm, London WC1N 1AX, England. [Kim, Nam-Soon] Korea Res Inst Biosci & Biotechnol, Med Genom Res Ctr, Taejon 305333, South Korea. RP Borralho, PM (reprint author), Univ Lisbon, Fac Pharm, Res Inst Med iMed ULisboa, Cell Funct & Therapeut Targeting Grp, Av Prof Gama Pinto, P-1649003 Lisbon, Portugal. EM mapaulo@ff.ulisboa.pt; borralho@ff.ulisboa.pt RI Moreira, Rui/G-7485-2011; Paulo, Alexandra/M-6683-2013; Francisco, Ana/M-4178-2013; Mendes, Eduarda/E-1398-2015; iMed.ULisboa, iMed.ULisboa/C-6292-2014; Rodrigues, Cecilia/M-3572-2013; iMed.ULisboa, MedChem /B-4834-2014; iMed.ULisboa, CellFun /A-4244-2014; Lavrado, Joao Paulo/D-6757-2011; PTMS, RNEM/C-1589-2014; Borralho, Pedro/C-2727-2011; OI Moreira, Rui/0000-0003-0727-9852; Paulo, Alexandra/0000-0003-1433-5402; Francisco, Ana/0000-0001-6602-2075; Mendes, Eduarda/0000-0002-7926-8821; Rodrigues, Cecilia/0000-0002-4829-754X; Lavrado, Joao Paulo/0000-0001-7746-5808; Borralho, Pedro/0000-0003-4488-7240; Brito, Hugo/0000-0002-4520-7203 FU Fundacao para a Ciencia e Tecnologia (FCT) Portugal [EXPL/QEQ-MED/0502/2012, HMSP-ICT/0018/2011, PEst-OE/SAU/UI4013/2014]; FCT [SFRH/BPD/72903/2010]; SAS [SFRH/BD/80162/2011]; Pancreatic Cancer Research Fund; Medical Research Council FX Authors from iMed-ULisboa acknowledge Fundacao para a Ciencia e Tecnologia (FCT), Portugal, for financial support through project grants EXPL/QEQ-MED/0502/2012, HMSP-ICT/0018/2011, and PEst-OE/SAU/UI4013/2014. HB, CMPR and PMB also thank Sociedade Portuguesa de Gastroenterologia and the Korea Human Gene Bank (KHGB), Medical Genomics Research Center, KRIBB, Republic of Korea. JL acknowledges FCT for the Post-Doctoral grant SFRH/BPD/72903/2010 and SAS for PhD grant SFRH/BD/80162/2011. The Neidle laboratory acknowledges support from the Pancreatic Cancer Research Fund and the Medical Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 36 TC 4 Z9 5 U1 2 U2 30 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 29 PY 2015 VL 10 IS 5 AR e0126891 DI 10.1371/journal.pone.0126891 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ2MQ UT WOS:000355319400025 PM 26024321 ER PT J AU Hu, CH Cheng, L Sepulcre, J Johnson, KA Fakhri, GE Lu, M Li, QZ AF Hu, Chenhui Cheng, Lin Sepulcre, Jorge Johnson, Keith A. Fakhri, Georges E. Lu, M. Li, Quanzheng TI A Spectral Graph Regression Model for Learning Brain Connectivity of Alzheimer's Disease SO PLOS ONE LA English DT Article ID INVERSE COVARIANCE ESTIMATION; FUNCTIONAL MRI; CORTICAL HUBS; NETWORKS; DEMENTIA; ORGANIZATION; CONNECTOME; FMRI; PET AB Understanding network features of brain pathology is essential to reveal underpinnings of neurodegenerative diseases. In this paper, we introduce a novel graph regression model (GRM) for learning structural brain connectivity of Alzheimer's disease (AD) measured by amyloid-beta deposits. The proposed GRM regards C-11-labeled Pittsburgh Compound-B (PiB) positron emission tomography (PET) imaging data as smooth signals defined on an unknown graph. This graph is then estimated through an optimization framework, which fits the graph to the data with an adjustable level of uniformity of the connection weights. Under the assumed data model, results based on simulated data illustrate that our approach can accurately reconstruct the underlying network, often with better reconstruction than those obtained by both sample correlation and l1-regularized partial correlation estimation. Evaluations performed upon PiB-PET imaging data of 30 AD and 40 elderly normal control (NC) subjects demonstrate that the connectivity patterns revealed by the GRM are easy to interpret and consistent with known pathology. Moreover, the hubs of the reconstructed networks match the cortical hubs given by functional MRI. The discriminative network features including both global connectivity measurements and degree statistics of specific nodes discovered from the AD and NC amyloid-beta networks provide new potential biomarkers for preclinical and clinical AD. C1 [Hu, Chenhui; Lu, M.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. [Cheng, Lin] Trinity Coll, Dept Engn, Hartford, CT 06106 USA. [Sepulcre, Jorge; Johnson, Keith A.] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. [Fakhri, Georges E.; Li, Quanzheng] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Div Nucl Med & Mol Imaging, Dept Radiol, Boston, MA 02114 USA. RP Li, QZ (reprint author), Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Div Nucl Med & Mol Imaging, Dept Radiol, Boston, MA 02114 USA. EM Li.Quanzheng@mgh.harvard.edu FU National Institutes of Health [R01EB013293, 1K23EB19023-01]; National Institute on Aging [P01AG036694, R01AG034556, R01AG037497]; Alzheimer's Association Zenith Award FX This work was funded by grants from the National Institutes of Health (R01EB013293 and 1K23EB19023-01), the National Institute on Aging Grants (P01AG036694, R01AG034556, and R01AG037497), and the Alzheimer's Association Zenith Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 58 TC 2 Z9 2 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 29 PY 2015 VL 10 IS 5 AR e0128136 DI 10.1371/journal.pone.0128136 PG 24 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ2MQ UT WOS:000355319400072 PM 26024224 ER PT J AU Pignon, JC Grisanzio, C Carvo, I Werner, L Regan, M Wilson, EL Signoretti, S AF Pignon, Jean-Christophe Grisanzio, Chiara Carvo, Ingrid Werner, Lillian Regan, Meredith Wilson, E. Lynette Signoretti, Sabina TI Cell Kinetic Studies Fail to Identify Sequentially Proliferating Progenitors as the Major Source of Epithelial Renewal in the Adult Murine Prostate SO PLOS ONE LA English DT Article ID INVOLVE SPECIALIZED PROGENITORS; ANDROGEN-INDUCED REGENERATION; STEM-CELLS; MOUSE PROSTATE; LUMINAL CELLS; REGIONAL-VARIATION; DUCTAL SYSTEM; RAT PROSTATE; BASAL-CELLS; BETA-CELLS AB There is evidence that stem cells and their progeny play a role in the development of the prostate. Although stem cells are also considered to give rise to differentiated progeny in the adult prostate epithelium ex vivo, the cohort of adult prostate stem cells in vivo as well as the mechanisms by which the adult prostate epithelium is maintained and regenerated remain highly controversial. We have attempted to resolve this conundrum by performing in vivo tracing of serially replicating cells after the sequential administration of two thymidine analogues to mice. Our results show that, during normal prostate homeostasis, sequentially proliferating cells are detected at a rate that is consistent with a stochastic process. These findings indicate that in vivo, under steady-state conditions, most adult prostate epithelial cells do not represent the progeny of a small number of specialized progenitors that generate sequentially replicating transit-amplifying (TA) cells but are formed by stochastic cell division. Similarly, no rapidly cycling TA cells were detected during regeneration following one cycle of androgen-mediated involution/regeneration of the prostate epithelium. These findings greatly enhance our understanding of the mechanisms regulating prostate epithelial cell renewal and may have significant implications in defining the cell of origin of proliferative prostatic diseases. C1 [Pignon, Jean-Christophe; Grisanzio, Chiara; Carvo, Ingrid; Signoretti, Sabina] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Pignon, Jean-Christophe; Grisanzio, Chiara; Werner, Lillian; Regan, Meredith; Signoretti, Sabina] Harvard Univ, Sch Med, Boston, MA USA. [Grisanzio, Chiara; Signoretti, Sabina] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Werner, Lillian; Regan, Meredith] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Wilson, E. Lynette] NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA. [Wilson, E. Lynette] NYU, Sch Med, Dept Urol, New York, NY 10003 USA. RP Signoretti, S (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. EM ssignoretti@partners.org FU National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases Grants [1R21DK72152, 1R01DK089975]; Harvard Stem Cell Institute [5R01CA132641] FX This work was supported by National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases Grants 1R21DK72152 and 1R01DK089975 and the Harvard Stem Cell Institute (SS) and 5R01CA132641 (ELW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 0 Z9 0 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 29 PY 2015 VL 10 IS 5 AR e0128489 DI 10.1371/journal.pone.0128489 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ2MQ UT WOS:000355319400093 PM 26024527 ER PT J AU Hepworth, MR Fung, TC Masur, SH Kelsen, JR McConnell, FM Dubrot, J Withers, DR Hugues, S Farrar, MA Reith, W Eberl, G Baldassano, RN Laufer, TM Elson, CO Sonnenberg, GF AF Hepworth, Matthew R. Fung, Thomas C. Masur, Samuel H. Kelsen, Judith R. McConnell, Fiona M. Dubrot, Juan Withers, David R. Hugues, Stephanie Farrar, Michael A. Reith, Walter Eberl, Gerard Baldassano, Robert N. Laufer, Terri M. Elson, Charles O. Sonnenberg, Gregory F. TI Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4(+) T cells SO SCIENCE LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; CLASS-II TRANSACTIVATOR; NEGATIVE SELECTION; DENDRITIC CELLS; IMMUNE-SYSTEM; PROMOTER-IV; HOMEOSTASIS; MICROBIOTA; RESPONSES; EXPRESSION AB Inflammatory CD4(+) T cell responses to self or commensal bacteria underlie the pathogenesis of autoimmunity and inflammatory bowel disease (IBD), respectively. Although selection of self-specific T cells in the thymus limits responses to mammalian tissue antigens, the mechanisms that control selection of commensal bacteria-specific T cells remain poorly understood. Here, we demonstrate that group 3 innate lymphoid cell (ILC3)-intrinsic expression of major histocompatibility complex class II (MHCII) is regulated similarly to thymic epithelial cells and that MHCII+ ILC3s directly induce cell death of activated commensal bacteria-specific T cells. Further, MHCII on colonic ILC3s was reduced in pediatric IBD patients. Collectively, these results define a selection pathway for commensal bacteria-specific CD4(+) T cells in the intestine and suggest that this process is dysregulated in human IBD. C1 [Hepworth, Matthew R.; Fung, Thomas C.; Sonnenberg, Gregory F.] Cornell Univ, Jill Roberts Inst Res Inflammatory Bowel Dis, Joan & Sanford I Weill Dept Med, Div Gastroenterol, New York, NY 10021 USA. [Hepworth, Matthew R.; Fung, Thomas C.; Sonnenberg, Gregory F.] Cornell Univ, Dept Microbiol & Immunol, Weill Cornell Med Coll, New York, NY 10021 USA. [Fung, Thomas C.; Laufer, Terri M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Masur, Samuel H.; Kelsen, Judith R.; Baldassano, Robert N.] Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA. [McConnell, Fiona M.; Withers, David R.] Univ Birmingham, MRC, Coll Med & Dent Sci, Ctr Immune Regulat, Birmingham, W Midlands, England. [Hugues, Stephanie; Reith, Walter] Univ Geneva, Sch Med, Dept Pathol & Immunol, CH-1211 Geneva, Switzerland. [Farrar, Michael A.] Univ Minnesota, Ctr Immunol, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Eberl, Gerard] Inst Pasteur, Microenvironm & Immun Unit, Paris, France. [Laufer, Terri M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Elson, Charles O.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Elson, Charles O.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. RP Sonnenberg, GF (reprint author), Cornell Univ, Jill Roberts Inst Res Inflammatory Bowel Dis, Joan & Sanford I Weill Dept Med, Div Gastroenterol, New York, NY 10021 USA. EM gfsonnenberg@med.cornell.edu RI Withers, David/C-7055-2015 OI Withers, David/0000-0003-3757-7594 FU National Institutes of Health [DP5OD012116, DK071176]; National Institute of Allergy and Infectious Diseases Mucosal Immunology Studies Team (MIST) Scholar Award in Mucosal Immunity; Institute for Translational Medicine and Therapeutics Transdisciplinary Program in Translational Medicine and Therapeutics (from the U.S. National Center for Research Resources) [UL1-RR024134]; Crohn's and Colitis Foundation of America (CCFA) [297365]; Cancer Research Institute Student Training and Research in Tumor immunology (STaRT) grant; Wellcome Trust Research Career Development Fellowship FX The authors thank members of the Sonnenberg laboratory for discussions and critical reading of the manuscript. We thank C. Hunter and S. Wagage (University of Pennsylvania) for the Ahr-deficient mice; I. Brodsky (University of Pennsylvania) for the Caspase 1/11-deficient mice; and M. Jenkins, J. Walter, and T. Dileepan (University of Minnesota) for tetramer reagents and protocols. Data presented in this manuscript are tabulated in the main paper and in the supplementary materials. Microarray data are accessible at Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo) via accession number GSE67076. CBir1 Tg mice are available from University of Alabama, Rorc(gamma t)-GfpTG and RorcCre mice are available from Institut Pasteur, STAT5-CA mice are available from University of Minnesota, IAbbSTOPfl/fl mice and CD11c Tg mice are available from University of Pennsylvania, and Il23a deficient mice are available from Janssen Research and Development LLC, all under Material Transfer Agreement. Research in the Sonnenberg laboratory is supported by the National Institutes of Health (DP5OD012116), the National Institute of Allergy and Infectious Diseases Mucosal Immunology Studies Team (MIST) Scholar Award in Mucosal Immunity, and the Institute for Translational Medicine and Therapeutics Transdisciplinary Program in Translational Medicine and Therapeutics (UL1-RR024134 from the U.S. National Center for Research Resources). M.R.H. is supported by a research fellowship from the Crohn's and Colitis Foundation of America (CCFA, no. 297365). T.C.F. is supported by a Cancer Research Institute Student Training and Research in Tumor immunology (STaRT) grant. D.R.W. is supported by a Wellcome Trust Research Career Development Fellowship. C.O.E. is supported by the National Institutes of Health (DK071176). NR 41 TC 59 Z9 62 U1 10 U2 33 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 EI 1095-9203 J9 SCIENCE JI Science PD MAY 29 PY 2015 VL 348 IS 6238 BP 1031 EP 1035 DI 10.1126/science.aaa4812 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ1WU UT WOS:000355276600048 PM 25908663 ER PT J AU Armand, P AF Armand, Philippe TI Immune checkpoint blockade in hematologic malignancies SO BLOOD LA English DT Review ID B-CELL LYMPHOMA; ACUTE MYELOID-LEUKEMIA; DEATH-LIGAND 1; REED-STERNBERG CELLS; T-CELLS; CANCER-IMMUNOTHERAPY; FOLLICULAR LYMPHOMA; ADVANCED MELANOMA; MYELODYSPLASTIC SYNDROMES; ANTI-PD-L1 ANTIBODY AB Therapeutic blockade of immune checkpoint pathways, in particular cytotoxic T-lymphocyte associated protein 4 and programmed-death 1 (PD-1), has become a paradigm-shifting treatment in solid tumor oncology. Hematologic malignancies (HMs), many of which are known to have clinically exploitable immune sensitivity, are a natural target for this type of treatment. Several clinical trials of checkpoint blockade have been conducted in HM, with preliminary results suggesting the therapeutic usefulness of this approach across several tumor types. In particular, the results of PD-1 blockade in Hodgkin lymphoma (HL) are remarkable, and raise hope that it may alter the treatment landscape in this disease. However, numerous questions remain about the optimal role of checkpoint blockade both in HL and beyond. Those questions are the focus of this review, in the hope that, if we are at the dawn of a new day in HM immunotherapy, we may begin to envision its morning. C1 [Armand, Philippe] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. RP Armand, P (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM parmand@partners.org FU Merck; Bristol-Myers Squibb FX Conflict-of-interest disclosure: P.A. has received research funding from Merck, Bristol-Myers Squibb, and consultancy fees from Merck. NR 71 TC 52 Z9 53 U1 2 U2 14 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD MAY 28 PY 2015 VL 125 IS 22 BP 3393 EP 3400 DI 10.1182/blood-2015-02-567453 PG 8 WC Hematology SC Hematology GA CK1PR UT WOS:000355979800010 PM 25833961 ER PT J AU Owens, EA Hyun, H Tawney, JG Choi, HS Henary, M AF Owens, Eric A. Hyun, Hoon Tawney, Joseph G. Choi, Hak Soo Henary, Maged TI Correlating Molecular Character of NIR Imaging Agents with Tissue-Specific Uptake SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID NEAR-INFRARED FLUOROPHORES; HUMAN SERUM-ALBUMIN; GUIDED SURGERY; CLICK REACTION; SIDE-CHAINS; BINDING; SYSTEM; HEAD; DYES; SPECT AB Near-infrared (NIR) fluorescent contrast agents are emerging in optical imaging as sensitive, cost-effective, and nonharmful alternatives to current agents that emit harmful ionizing radiation. Developing spectrally distinct NIR fluorophores to visualize sensitive vital tissues to selectively avoid them during surgical resection of diseased tissue is of great significance. Herein, we report the synthetic variation of pentamethine cyanine fluorophores with modifications of physicochemical, properties toward prompting tissue-specific uptake into sensitive tissues (i.e., endocrine glands). Tissue-specific targeting and biodistribution studies revealed localization of contrast agents in the adrenal and pituitary glands, pancreas, and lymph nodes with dependence on molecular characteristics. Incorporation of hydrophobic heterocyclic rings, alkyl groups, and halogens allowed a fine tuning capability to the hydrophobic character and dipole moment for observing perturbation in biological activity in response to minor structural alterations. These NIR contrast agents have potential for clinical translation for intraoperative imaging in the,delineation of delicate glands. C1 [Owens, Eric A.; Tawney, Joseph G.; Henary, Maged] Georgia State Univ, Ctr Biotechnol & Drug Design, Ctr Diagnost & Therapeut, Dept Chem, Atlanta, GA 30303 USA. [Hyun, Hoon; Choi, Hak Soo] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA. [Hyun, Hoon; Choi, Hak Soo] Harvard Univ, Sch Med, Boston, MA 02215 USA. RP Choi, HS (reprint author), BIDMC, Room SL-436A,330 Brookline Ave, Boston, MA 02215 USA. EM hchoi@bidmc.harvard.eduaddress; mhenaryl@gsu.edu RI Choi, Hak Soo/C-9954-2011 FU Georgia State University dissertation grant; Brains and Behavior grant; NIH/NIBIB grant [R01-EB-011523]; Center for Diagnostics and Therapeutics (CDT) at Georgia State University; Georgia State University Center for Diagnostics and Therapeutics FX This study was supported by the Georgia State University dissertation grant to E.A.O, the Brains and Behavior grant (M.H.) and the NIH/NIBIB grant no. R01-EB-011523 (HSC). E.A.O. was supported by a predoctoral fellowship through the Center for Diagnostics and Therapeutics (CDT) at Georgia State University. M.H. also appreciates the support from the Georgia State University Center for Diagnostics and Therapeutics. NR 33 TC 7 Z9 7 U1 5 U2 19 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 EI 1520-4804 J9 J MED CHEM JI J. Med. Chem. PD MAY 28 PY 2015 VL 58 IS 10 BP 4348 EP 4356 DI 10.1021/acs.jmedchem.5b00475 PG 9 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA CJ4YS UT WOS:000355495200017 PM 25923454 ER PT J AU Patch, AM Christie, EL Etemadmoghadam, D Garsed, DW George, J Fereday, S Nones, K Cowin, P Alsop, K Bailey, PJ Kassahn, KS Newell, F Quinn, MCJ Kazakoff, S Quek, K Wilhelm-Benartzi, C Curry, E Leong, HS Hamilton, A Mileshkin, L Au-Yeung, G Kennedy, C Hung, JL Chiew, YE Harnett, P Friedlander, M Quinn, M Pyman, J Cordner, S O'Brien, P Leditschke, J Young, G Strachan, K Waring, P Azar, W Mitchell, C Traficante, N Hendley, J Thorne, H Shackleton, M Miller, DK Arnau, GM Tothill, RW Holloway, TP Semple, T Harliwong, I Nourse, C Nourbakhsh, E Manning, S Idrisoglu, S Bruxner, TJC Christ, AN Poudel, B Holmes, O Anderson, M Leonard, C Lonie, A Hall, N Wood, S Taylor, DF Xu, QY Fink, JL Waddell, N Drapkin, R Stronach, E Gabra, H Brown, R Jewell, A Nagaraj, SH Markham, E Wilson, PJ Ellul, J McNally, O Doyle, MA Vedururu, R Stewart, C Lengyel, E Pearson, JV Waddell, N deFazio, A Grimmond, SM Bowtell, DDL AF Patch, Ann-Marie Christie, Elizabeth L. Etemadmoghadam, Dariush Garsed, Dale W. George, Joshy Fereday, Sian Nones, Katia Cowin, Prue Alsop, Kathryn Bailey, Peter J. Kassahn, Karin S. Newell, Felicity Quinn, Michael C. J. Kazakoff, Stephen Quek, Kelly Wilhelm-Benartzi, Charlotte Curry, Ed Leong, Huei San Hamilton, Anne Mileshkin, Linda Au-Yeung, George Kennedy, Catherine Hung, Jillian Chiew, Yoke-Eng Harnett, Paul Friedlander, Michael Quinn, Michael Pyman, Jan Cordner, Stephen O'Brien, Patricia Leditschke, Jodie Young, Greg Strachan, Kate Waring, Paul Azar, Walid Mitchell, Chris Traficante, Nadia Hendley, Joy Thorne, Heather Shackleton, Mark Miller, David K. Arnau, Gisela Mir Tothill, Richard W. Holloway, Timothy P. Semple, Timothy Harliwong, Ivon Nourse, Craig Nourbakhsh, Ehsan Manning, Suzanne Idrisoglu, Senel Bruxner, Timothy J. C. Christ, Angelika N. Poudel, Barsha Holmes, Oliver Anderson, Matthew Leonard, Conrad Lonie, Andrew Hall, Nathan Wood, Scott Taylor, Darrin F. Xu, Qinying Fink, J. Lynn Waddell, Nick Drapkin, Ronny Stronach, Euan Gabra, Hani Brown, Robert Jewell, Andrea Nagaraj, Shivashankar H. Markham, Emma Wilson, Peter J. Ellul, Jason McNally, Orla Doyle, Maria A. Vedururu, Ravikiran Stewart, Collin Lengyel, Ernst Pearson, John V. Waddell, Nicola deFazio, Anna Grimmond, Sean M. Bowtell, David D. L. CA Australian Ovarian Canc Study Grp TI Whole-genome characterization of chemoresistant ovarian cancer SO NATURE LA English DT Article ID GAMMA-RAY BURSTS; HUBBLE-SPACE-TELESCOPE; COPY-NUMBER ALTERATION; M87 JET; 3C 264; CHEMOTHERAPY RESISTANCE; MUTATIONAL PROCESSES; INTERNAL SHOCKS; CLINICAL-TRIALS; CARCINOMA AB Patients with high-grade serous ovarian cancer (HGSC) have experienced little improvement in overall survival, and standard treatment has not advanced beyond platinum-based combination chemotherapy, during the past 30 years. To understand the drivers of clinical phenotypes better, here we use whole-genome sequencing of tumour and germline DNA samples from 92 patients with primary refractory, resistant, sensitive and matched acquired resistant disease. We show that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance. CCNE1 amplification was common in primary resistant and refractory disease. We observed several molecular events associated with acquired resistance, including multiple independent reversions of germline BRCA1 or BRCA2 mutations in individual patients, loss of BRCA1 promoter methylation, an alteration in molecular subtype, and recurrent promoter fusion associated with overexpression of the drug efflux pump MDR1. C1 [Patch, Ann-Marie; Nones, Katia; Bailey, Peter J.; Kassahn, Karin S.; Newell, Felicity; Quinn, Michael C. J.; Kazakoff, Stephen; Quek, Kelly; Miller, David K.; Harliwong, Ivon; Nourse, Craig; Nourbakhsh, Ehsan; Manning, Suzanne; Idrisoglu, Senel; Bruxner, Timothy J. C.; Christ, Angelika N.; Poudel, Barsha; Holmes, Oliver; Anderson, Matthew; Leonard, Conrad; Wood, Scott; Taylor, Darrin F.; Xu, Qinying; Fink, J. Lynn; Waddell, Nick; Nagaraj, Shivashankar H.; Markham, Emma; Wilson, Peter J.; Pearson, John V.; Waddell, Nicola; Grimmond, Sean M.] Univ Queensland, Inst Mol Biosci, Queensland Ctr Med Genom, Brisbane, Qld 4067, Australia. [Patch, Ann-Marie; Nones, Katia; Quinn, Michael C. J.; Kazakoff, Stephen; Holmes, Oliver; Leonard, Conrad; Wood, Scott; Xu, Qinying; Pearson, John V.; Waddell, Nicola] QIMR Berghofer Med Res Inst, Brisbane, Qld 4006, Australia. [Christie, Elizabeth L.; Etemadmoghadam, Dariush; Garsed, Dale W.; Fereday, Sian; Cowin, Prue; Alsop, Kathryn; Leong, Huei San; Hamilton, Anne; Mileshkin, Linda; Au-Yeung, George; Azar, Walid; Mitchell, Chris; Traficante, Nadia; Hendley, Joy; Thorne, Heather; Shackleton, Mark; Arnau, Gisela Mir; Tothill, Richard W.; Holloway, Timothy P.; Semple, Timothy; Ellul, Jason; Doyle, Maria A.; Vedururu, Ravikiran; Bowtell, David D. L.] Peter MacCallum Canc Ctr, East Melbourne, Vic 3002, Australia. [Etemadmoghadam, Dariush; Waring, Paul; Bowtell, David D. L.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia. [Etemadmoghadam, Dariush; Mileshkin, Linda; Shackleton, Mark; Tothill, Richard W.; Bowtell, David D. L.] Univ Melbourne, Sir Peter MacCallum Canc Ctr, Dept Oncol, Parkville, Vic 3052, Australia. [George, Joshy] Jackson Lab Genom Med, Farmington, CT 06030 USA. [Bailey, Peter J.; Grimmond, Sean M.] Univ Glasgow, Inst Canc Sci, WolfsonWohl Canc Res Ctr, Glasgow G61 1QH, Lanark, Scotland. [Kassahn, Karin S.] SA Pathol, Technol Adv Unit, Genet & Mol Pathol, Adelaide, SA 5000, Australia. [Wilhelm-Benartzi, Charlotte; Curry, Ed; Stronach, Euan; Gabra, Hani; Brown, Robert; Bowtell, David D. L.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Ovarian Canc Act Res Ctr, London W12 0HS, England. [Hamilton, Anne] Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia. [Hamilton, Anne; Quinn, Michael; Pyman, Jan] Royal Womens Hosp, Parkville, Vic 3052, Australia. [Kennedy, Catherine; Hung, Jillian; Chiew, Yoke-Eng; McNally, Orla; deFazio, Anna] Univ Sydney, Westmead Millennium Inst, Ctr Canc Res, Sydney, NSW 2145, Australia. [Kennedy, Catherine; Hung, Jillian; Chiew, Yoke-Eng; McNally, Orla; deFazio, Anna] Westmead Hosp, Dept Gynaecol Oncol, Sydney, NSW 2145, Australia. [Harnett, Paul] Crown Princess Mary Canc Ctr, Sydney, NSW 2145, Australia. [Harnett, Paul] Univ Sydney, Westmead Hosp, Sydney, NSW 2145, Australia. [Friedlander, Michael] Univ New S Wales, Prince Wales Clin Sch, Sydney, NSW 2031, Australia. [Cordner, Stephen; O'Brien, Patricia; Leditschke, Jodie; Young, Greg; Strachan, Kate] Victorian Inst Forens Med, Southbank, Vic 3006, Australia. [Lonie, Andrew] Victorian Life Sci Computat Initiat, Carlton, Vic 3053, Australia. [Hall, Nathan] La Trobe Inst Mol Sci, Bundoora, Vic 3083, Australia. [Drapkin, Ronny] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jewell, Andrea; Lengyel, Ernst] Univ Chicago, Chicago, IL 60637 USA. [Stewart, Collin] Univ Western Australia, Crawley, WA 6009, Australia. [Bowtell, David D. L.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia. RP Bowtell, DDL (reprint author), Peter MacCallum Canc Ctr, East Melbourne, Vic 3002, Australia. EM david.bowtell@petermac.org RI Fink, Lynn/C-2031-2008; Nicklin, James/F-8035-2013; Drapkin, Ronny/E-9944-2016; Bowtell, David/H-1007-2016; Waddell, Nic/H-4929-2015; Grimmond, Sean/J-5304-2016; Pearson, John/F-2249-2011; Harnett, Paul/D-4090-2014; Wyld, David/B-8893-2015; OI Tothill, Richard/0000-0003-4522-1184; Wilhelm-Benartzi, Charlotte/0000-0003-4927-6158; Lonie, Andrew/0000-0002-2006-3856; Fink, Lynn/0000-0003-2912-6048; Nicklin, James/0000-0001-5378-496X; Drapkin, Ronny/0000-0002-6912-6977; Bowtell, David/0000-0001-9089-7525; Grimmond, Sean/0000-0002-8102-7998; Pearson, John/0000-0003-0904-4598; Harnett, Paul/0000-0001-7021-0642; Garsed, Dale/0000-0003-1223-0121; Wyld, David/0000-0001-9523-4333; Christie, Elizabeth/0000-0002-9959-7024 FU National Health and Medical Research Council of Australia (NHMRC) [ID631701, ID400413, ID400281]; Worldwide Cancer Research [09-0676]; Cancer Australia [1004673]; US Army Medical Research and Materiel Command [DAMD17-01-1-0729]; Cancer Council Victoria; Queensland Cancer Fund; Cancer Council New South Wales; Cancer Council South Australia; Cancer Foundation of Western Australia; Cancer Council Tasmania; Agar family; Ovarian Cancer Australia; Ovarian Cancer Action (UK); NHMRC [ID 310670, ID628903]; Cancer Institute of New South Wales; Peter MacCallum Cancer Centre Foundation FX The AOCS gratefully acknowledge the cooperation of the participating institutions in Australia, and also acknowledge the contribution of the study nurses, research assistants and all clinical and scientific collaborators including L. Galletta, C. Emmanuel, L. Bowes and J. Hallo. The authors acknowledge assistance from C. Anderson and D. Gwynne. The CASCADE investigators would like to thank the CASCADE Management Committee, all staff at the Victorian Institute of Forensic Medicine, D. Stevens and Tobin Brothers Funerals. The investigators would like to thank the Australia New Zealand Gynaecological Oncology Group (ANZGOG) and the women, and their families, who participated in these research programs. This work was supported by the National Health and Medical Research Council of Australia (NHMRC ID631701), Worldwide Cancer Research (09-0676) and Cancer Australia (1004673). The Australian Ovarian Cancer Study was supported by the US Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania and the National Health and Medical Research Council of Australia (NHMRC; ID400413, ID400281). The AOCS gratefully acknowledges additional support from S. Boldeman, the Agar family, Ovarian Cancer Australia and Ovarian Cancer Action (UK). The Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group, was supported by grants from the NHMRC (ID 310670, ID628903) and the Cancer Institute of New South Wales. The CASCADE study was supported by the Peter MacCallum Cancer Centre Foundation, and in kind by the Victorian Institute of Forensic Medicine and Tobin Brothers Funerals. NR 90 TC 156 Z9 159 U1 16 U2 92 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 EI 1476-4687 J9 NATURE JI Nature PD MAY 28 PY 2015 VL 521 IS 7553 BP 489 EP 494 DI 10.1038/nature14410 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ2AN UT WOS:000355286600037 PM 26017449 ER PT J AU Park, SY Yang, JS Schmider, AB Soberman, RJ Hsu, VW AF Park, Seung-Yeol Yang, Jia-Shu Schmider, Angela B. Soberman, Roy J. Hsu, Victor W. TI Coordinated regulation of bidirectional COPI transport at the Golgi by CDC42 SO NATURE LA English DT Article ID CISTERNAL MATURATION; MEMBRANE CURVATURE; VESICLE FORMATION; ARFGAP1 PROMOTES; APPARATUS; COMPLEX; YEAST AB The Golgi complex has a central role in the intracellular sorting of secretory proteins(1,2). Anterograde transport through the Golgi has been explained by the movement of Golgi cisternae, known as cisternal maturation(3-5). Because this explanation is now appreciated to be incomplete(6), interest has developed in understanding tubules that connect the Golgi cisternae(7-9). Here we show that the coat protein (COPI) complex sorts anterograde cargoes into these tubules in human cells. Moreover, the small GTPase CDC42 regulates bidirectional Golgi transport by targeting the dual functions of COPI in cargo sorting and carrier formation. CDC42 also directly imparts membrane curvature to promote COPI tubule formation. Our findings further reveal that COPI tubular transport complements cisternal maturation in explaining how anterograde Golgi transport is achieved, and that bidirectional COPI transport is modulated by environmental cues through CDC42. C1 [Park, Seung-Yeol; Yang, Jia-Shu; Hsu, Victor W.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA. [Park, Seung-Yeol; Yang, Jia-Shu; Schmider, Angela B.; Soberman, Roy J.; Hsu, Victor W.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Schmider, Angela B.; Soberman, Roy J.] Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA 02129 USA. [Schmider, Angela B.; Soberman, Roy J.] Massachusetts Gen Hosp, Dept Med, Charlestown, MA 02129 USA. [Soberman, Roy J.] Massachusetts Gen Hosp, Mol Imaging Core, Charlestown, MA 02129 USA. RP Hsu, VW (reprint author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA. EM vhsu@research.bwh.harvard.edu FU National Institutes of Health [R01GM058615, R01AI068871, R01AR065538, 1S10RR027931-01, K01DK089145]; National Research Foundation of Korea [2014R1A6A3A03056673] FX We thank J. Li, M. Bai, X. Michelet and C. Alves for discussions, and M. Ericsson for electron microscopy technical advice. This work was funded by grants from the National Institutes of Health to V.W.H. (R01GM058615), R.J.S. (R01AI068871, R01AR065538 and 1S10RR027931-01), A.B.S. (K01DK089145), and also by the Basic Science Research Program of the National Research Foundation of Korea to S.-Y.P. (2014R1A6A3A03056673). NR 24 TC 11 Z9 11 U1 4 U2 38 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 EI 1476-4687 J9 NATURE JI Nature PD MAY 28 PY 2015 VL 521 IS 7553 BP 529 EP U257 DI 10.1038/nature14457 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ2AN UT WOS:000355286600045 PM 25945738 ER PT J AU Halpern, SD French, B Small, DS Saulsgiver, K Harhay, MO Audrain-McGovern, J Loewenstein, G Brennan, TA Asch, DA Volpp, KG AF Halpern, Scott D. French, Benjamin Small, Dylan S. Saulsgiver, Kathryn Harhay, Michael O. Audrain-McGovern, Janet Loewenstein, George Brennan, Troyen A. Asch, David A. Volpp, Kevin G. TI Randomized Trial of Four Financial-Incentive Programs for Smoking Cessation SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID INSTRUMENTAL VARIABLES; ADAPTIVE DESIGNS; COLLECTIVE DYNAMICS; CLINICAL-TRIALS; WEIGHT-LOSS; BEHAVIOR; THERAPY; HEALTH; PAY; DEPENDENCE AB BACKGROUND Financial incentives promote many health behaviors, but effective ways to deliver health incentives remain uncertain. METHODS We randomly assigned CVS Caremark employees and their relatives and friends to one of four incentive programs or to usual care for smoking cessation. Two of the incentive programs targeted individuals, and two targeted groups of six participants. One of the individual-oriented programs and one of the group-oriented programs entailed rewards of approximately $800 for smoking cessation; the others entailed refundable deposits of $150 plus $650 in reward payments for successful participants. Usual care included informational resources and free smoking-cessation aids. RESULTS Overall, 2538 participants were enrolled. Of those assigned to reward-based programs, 90.0% accepted the assignment, as compared with 13.7% of those assigned to deposit-based programs (P<0.001). In intention-to-treat analyses, rates of sustained abstinence from smoking through 6 months were higher with each of the four incentive programs (range, 9.4 to 16.0%) than with usual care (6.0%) (P<0.05 for all comparisons); the superiority of reward-based programs was sustained through 12 months. Group-oriented and individual-oriented programs were associated with similar 6-month abstinence rates (13.7% and 12.1%, respectively; P = 0.29). Reward-based programs were associated with higher abstinence rates than deposit-based programs (15.7% vs. 10.2%, P<0.001). However, in instrumental-variable analyses that accounted for differential acceptance, the rate of abstinence at 6 months was 13.2 percentage points (95% confidence interval, 3.1 to 22.8) higher in the deposit-based programs than in the reward-based programs among the estimated 13.7% of the participants who would accept participation in either type of program. CONCLUSIONS Reward-based programs were much more commonly accepted than deposit-based programs, leading to higher rates of sustained abstinence from smoking. Group-oriented incentive programs were no more effective than individual-oriented programs. (Funded by the National Institutes of Health and CVS Caremark; ClinicalTrials.gov number, NCT01526265.) C1 [Halpern, Scott D.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Halpern, Scott D.; French, Benjamin; Saulsgiver, Kathryn; Harhay, Michael O.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Halpern, Scott D.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. [Audrain-McGovern, Janet] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Halpern, Scott D.; French, Benjamin; Small, Dylan S.; Saulsgiver, Kathryn; Audrain-McGovern, Janet; Loewenstein, George; Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Small, Dylan S.] Univ Penn, Ctr Hlth Equ Res & Promot, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin G.] Univ Penn, Ctr Hlth Equ Res & Promot, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin G.] Univ Penn Hlth Syst, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Asch, David A.; Volpp, Kevin G.] Univ Penn Hlth Syst, Ctr Hlth Care Innovat, Philadelphia, PA USA. [Loewenstein, George] Carnegie Mellon Univ, Ctr Behav Decis Res, Pittsburgh, PA 15213 USA. [Brennan, Troyen A.] CVS Caremark, Woonsocket, RI USA. RP Halpern, SD (reprint author), Univ Penn, Perelman Sch Med, 719 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM shalpern@exchange.upenn.edu FU NCI NIH HHS [R01 CA159932]; NIA NIH HHS [RC2 AG036592] NR 45 TC 55 Z9 56 U1 4 U2 25 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 28 PY 2015 VL 372 IS 22 BP 2108 EP 2117 DI 10.1056/NEJMoa1414293 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CJ0EI UT WOS:000355146800006 PM 25970009 ER PT J AU Kamdar, MM Doyle, KP Sequist, LV Rinehart, TJ Maytal, G Flores, EJ Mino-Kenudson, M AF Kamdar, Mihir M. Doyle, Kathleen P. Sequist, Lecia V. Rinehart, Todd J. Maytal, Guy Flores, Efren J. Mino-Kenudson, Mari TI Case 17-2015: A 44-Year-Old Woman with Intractable Pain Due to Metastatic Lung Cancer SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID OPIOID-INDUCED HYPERALGESIA; PALLIATIVE SEDATION; CLINICAL-TRIAL; GUIDELINES; DELIVERY; ADENOCARCINOMA; MECHANISMS; TOLERANCE; GEFITINIB; ERLOTINIB C1 [Kamdar, Mihir M.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Kamdar, Mihir M.; Doyle, Kathleen P.; Rinehart, Todd J.] Massachusetts Gen Hosp, Dept Palliat Care, Boston, MA 02114 USA. [Sequist, Lecia V.] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA. [Maytal, Guy] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Flores, Efren J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Mino-Kenudson, Mari] Harvard Univ, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA. [Kamdar, Mihir M.; Doyle, Kathleen P.; Rinehart, Todd J.] Harvard Univ, Sch Med, Dept Palliat Care, Boston, MA USA. [Sequist, Lecia V.] Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA USA. [Maytal, Guy] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Flores, Efren J.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Mino-Kenudson, Mari] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Kamdar, MM (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. NR 28 TC 3 Z9 3 U1 0 U2 3 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 28 PY 2015 VL 372 IS 22 BP 2137 EP 2147 DI 10.1056/NEJMcpc1404141 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CJ0EI UT WOS:000355146800012 PM 26017825 ER PT J AU Khalil, HA Lei, NY Nie, WX Lewis, MS Stelzner, MG Martin, MG Dunn, JCY Yoo, J AF Khalil, Hassan A. Lei, Nan Ye Nie, Wenxian Lewis, Michael S. Stelzner, Matthias G. Martin, Martin G. Dunn, James C. Y. Yoo, James TI Primary Myofibroblasts Maintain Short-Term Viability following Submucosal Injection in Syngeneic, Immune-Competent Mice Utilizing Murine Colonoscopy SO PLOS ONE LA English DT Article ID HUMAN COLONIC MYOFIBROBLASTS; TNF-ALPHA; EXPRESSION; MODELS; COX-2; EGFR AB The myofibroblast is an important stromal cell of the gastrointestinal tract. Current in vitro and in vivo models either do not accurately recreate stromal-epithelial interactions or are not specific to myofibroblasts. We sought to create an animal model that would allow the study of myofibroblast-epithelial interactions. We isolated and cultured colonic myofibroblasts from FVB mice. Cells were alpha-SMA and vimentin positive but desmin negative on immunoblot analysis. We injected the myofibroblasts into the colonic submucosa of syngeneic adult mice (n = 8) via a miniendoscopic system. We then isolated green fluorescent protein (GFP) positive colonic myofibroblasts from C57BL/6-Tg(CAG-EGFP) 1Osb/Jmice and injected them into the colonic lamina propria of C57BL/6J mice at 1x10(5) (n = 14), 1x10(6) (n = 9), or 5x10(6) cells/mL (n = 4). A subset of mice were injected with serum-free media and ink without cells (n = 3). Mice underwent repeat endoscopy and euthanasia one or 7 days after injection. Colons were isolated and either fixed in 10% formalin or the inked sites were individually excised and lysed for DNA. We assessed the injection sites via histology and immunohistochemical stains for alpha-SMA and GFP. We used qPCR to quantify GFP DNA transcripts at the lamina propria injection sites. Submucosal injection ofmyofibroblasts resulted in the formation of a subepithelial wheal on endoscopy, which persisted to day 7. Myofibroblasts injected either into the submucosa or lamina propria maintained viability on post-injection day 7 as evidenced by positive alpha-SMA staining. qPCR of lamina propria injections showed a dose-dependent increase in GFP DNA transcripts on post-injection day 1, whereas the number of transcripts on day 7 was equivalent for the concentrations injected. We demonstrate short-term survival of primary cultured colonic myofibroblasts in syngeneic mice. This may prove to be a valuable model for studying the role ofmyofibroblasts in states of health and disease. C1 [Khalil, Hassan A.; Lei, Nan Ye; Nie, Wenxian; Stelzner, Matthias G.; Dunn, James C. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Lewis, Michael S.] VA Greater Los Angeles Hlth Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Stelzner, Matthias G.] VA Greater Los Angeles Hlth Syst, Dept Surg, Los Angeles, CA USA. [Martin, Martin G.] Univ Calif Los Angeles, Dept Pediat, Div Gastroenterol & Nutr, Los Angeles, CA 90024 USA. [Yoo, James] Tufts Med Ctr, Dept Surg, Boston, MA 02111 USA. RP Yoo, J (reprint author), Tufts Med Ctr, Dept Surg, Boston, MA 02111 USA. EM JYoo@tuftsmedicalcenter.org OI Khalil, Hassan/0000-0002-3835-1290 FU National Institutes of Health K08 award [DK085136-03]; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases [DK085535] FX This project was funded by a National Institutes of Health K08 award #DK085136-03 (JY), and was performed as a project of the Intestinal Stem Cell Consortium (https://iscc.coh.org), a collaborative research project funded by the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Allergy and Infectious Diseases #DK085535 (MGM, JCYD, MS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 15 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 27 PY 2015 VL 10 IS 5 AR e0127258 DI 10.1371/journal.pone.0127258 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ0RO UT WOS:000355185600077 PM 26016485 ER PT J AU Traverso, G Langer, R AF Traverso, Giovanni Langer, Robert TI Engineering precision SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Editorial Material ID ADHERENCE; DELIVERY C1 [Traverso, Giovanni] Massachusetts Gen Hosp, Med, Div Gastroenterol, Boston, MA 02114 USA. [Traverso, Giovanni] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Langer, Robert] MIT, Cambridge, MA 02139 USA. RP Traverso, G (reprint author), Massachusetts Gen Hosp, Med, Div Gastroenterol, Boston, MA 02114 USA. EM ctraverso@partners.org NR 8 TC 3 Z9 3 U1 2 U2 16 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 EI 1946-6242 J9 SCI TRANSL MED JI Sci. Transl. Med. PD MAY 27 PY 2015 VL 7 IS 289 AR 289ed6 DI 10.1126/scitranslmed.aab1943 PG 2 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA CJ0PS UT WOS:000355179800001 PM 26019214 ER PT J AU O'Neill, BT Lauritzen, HPMM Hirshman, MF Smyth, G Goodyear, LJ Kahn, CR AF O'Neill, Brian T. Lauritzen, Hans P. M. M. Hirshman, Michael F. Smyth, Graham Goodyear, Laurie J. Kahn, C. Ronald TI Differential Role of Insulin/IGF-1 Receptor Signaling in Muscle Growth and Glucose Homeostasis SO CELL REPORTS LA English DT Article ID MOUSE SKELETAL-MUSCLE; LIVING MICE; GLUT4 TRANSLOCATION; T-TUBULES; IN-VIVO; IGF-I; TBC1D1; METABOLISM; RESISTANCE; TRANSPORT AB Insulin and insulin-like growth factor 1 (IGF-1) are major regulators of muscle protein and glucose homeostasis. To determine how these pathways interact, we generated mice with muscle-specific knockout of IGF-1 receptor (IGF1R) and insulin receptor (IR). These MIGIRKO mice showed >60% decrease in muscle mass. Despite a complete lack of insulin/IGF-1 signaling in muscle, MIGIRKO mice displayed normal glucose and insulin tolerance. Indeed, MIGIRKO mice showed fasting hypoglycemia and increased basal glucose uptake. This was secondary to decreased TBC1D1 resulting in increased Glut4 and Glut1 membrane localization. Interestingly, overexpression of a dominant-negative IGF1R in muscle induced glucose intolerance in MIGIRKO animals. Thus, loss of insulin/IGF-1 signaling impairs muscle growth, but not whole-body glucose tolerance due to increased membrane localization of glucose transporters. Nonetheless, presence of a dominant-negative receptor, even in the absence of functional IR/IGF1R, induces glucose intolerance, indicating that interactions between these receptors and other proteins in muscle can impair glucose homeostasis. C1 [O'Neill, Brian T.; Lauritzen, Hans P. M. M.; Hirshman, Michael F.; Smyth, Graham; Goodyear, Laurie J.; Kahn, C. Ronald] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02215 USA. RP Kahn, CR (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02215 USA. EM c.ronald.kahn@joslin.harvard.edu FU NIH [R01 DK-031036, R01AR42238]; NIDDK of the NIH [K08DK100543]; Mayo Clinic Metabolomics Resource Core grant from the NIDDK [U24DK100469]; Mayo Clinic CTSA grant from NCATS of the NIH [UL1 TR000135] FX This work was supported by NIH grants R01 DK-031036 (to C.R.K.) and R01AR42238 (to L.J.G.). B.T.O. was funded by a K08 training award from the NIDDK of the NIH (K08DK100543), Mayo Clinic Metabolomics Resource Core grant U24DK100469 from the NIDDK, which originates from the NIH Director's Common Fund, and Mayo Clinic CTSA grant UL1 TR000135 from NCATS of the NIH. The Joslin Diabetes Center DRC core facility was used for part of this work (P30 DK36836). NR 41 TC 7 Z9 8 U1 1 U2 5 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD MAY 26 PY 2015 VL 11 IS 8 BP 1220 EP 1235 DI 10.1016/j.celrep.2015.04.037 PG 16 WC Cell Biology SC Cell Biology GA CJ0CO UT WOS:000355140300008 PM 25981038 ER PT J AU Bhatt, AB Foster, E Kuehl, K Alpert, J Brabeck, S Crumb, S Davidson, WR Earing, MG Ghoshhajra, BB Karamlou, T Mital, S Ting, J Tseng, ZH AF Bhatt, Ami B. Foster, Elyse Kuehl, Karen Alpert, Joseph Brabeck, Stephen Crumb, Stephen Davidson, William R., Jr. Earing, Michael G. Ghoshhajra, Brian B. Karamlou, Tara Mital, Seema Ting, Jennifer Tseng, Zian H. CA Amer Heart Assoc Council TI Congenital Heart Disease in the Older Adult A Scientific Statement From the American Heart Association SO CIRCULATION LA English DT Editorial Material DE AHA Scientific Statements; congenital heart defect; cardiac surgical procedures; cardiac imaging techniques; cardiac arrhythmia; heart failure; cardiac valves ID PULMONARY VALVE-REPLACEMENT; ATRIAL SEPTAL-DEFECT; RADIOFREQUENCY CATHETER ABLATION; SYSTEMIC RIGHT VENTRICLE; SUDDEN CARDIAC DEATH; INTRAATRIAL REENTRANT TACHYCARDIA; ACUTE KIDNEY INJURY; ARTERIAL SWITCH OPERATION; ANOMALOUS AORTIC ORIGIN; CAUSE NOONAN-SYNDROME C1 [Alpert, Joseph] Univ Arizona, Tucson, AZ 85721 USA. [Bhatt, Ami B.; Ghoshhajra, Brian B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Brabeck, Stephen] Cardiopulm Associates, Macon, GA USA. [Davidson, William R., Jr.] Penn State Univ, Coll Med, University Pk, PA 16802 USA. [Earing, Michael G.] Med Coll Wisconsin, Milwaukee, WI USA. [Foster, Elyse; Karamlou, Tara; Tseng, Zian H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kuehl, Karen] Childrens Natl Med Ctr, Washington, DC USA. [Mital, Seema] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Ting, Jennifer] Penn State Hershey Heart & Vasc Inst, Hershey, PA USA. RP Bhatt, AB (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 424 TC 17 Z9 20 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD MAY 26 PY 2015 VL 131 IS 21 BP 1884 EP 1931 DI 10.1161/CIR.0000000000000204 PG 48 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CJ0PY UT WOS:000355180400017 PM 25896865 ER PT J AU Case, MA Volpp, KG Patel, MS AF Case, Meredith A. Volpp, Kevin G. Patel, Mitesh S. TI Electronic Devices and Applications to Track Physical Activity Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Case, Meredith A.] Univ Penn, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Patel, Mitesh S.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Case, MA (reprint author), Univ Penn, 423 Guardian Dr, Philadelphia, PA 19104 USA. EM mpatel@upenn.edu NR 3 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 26 PY 2015 VL 313 IS 20 BP 2080 EP 2080 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CJ0DC UT WOS:000355142400029 PM 26010644 ER PT J AU Malik, R Freilinger, T Anttila, V Vander Heiden, J Traylor, M de Vries, B Holliday, EG Terwindt, GM Sturm, J Bis, JC Hopewell, JC Ferrari, MD Rannikmae, K Wessman, M Kallela, M Kubisch, C Fornage, M Meschia, JF Lehtimaki, T Sudlow, C Clarke, R Chasman, DI Mitchell, BD Maguire, J Kaprio, J Farrall, M Raitakari, OT Kurth, T Ikram, MA Reiner, AP Longstreth, WT Rothwell, PM Strachan, DP Sharma, P Seshadri, S Quaye, L Cherkas, L Schurks, M Rosand, J Ligthart, L Boncoraglio, GB Smith, GD van Duijn, CM Stefansson, K Worrall, BB Nyholt, DR Markus, HS van den Maagdenberg, AMJM Cotsapas, C Zwart, JA Palotie, A Dichgans, M AF Malik, Rainer Freilinger, Tobias Anttila, Verneri Vander Heiden, Jason Traylor, Matthew de Vries, Boukje Holliday, Elizabeth G. Terwindt, Gisela M. Sturm, Jonathan Bis, Joshua C. Hopewell, Jemma C. Ferrari, Michel D. Rannikmae, Kristiina Wessman, Maija Kallela, Mikko Kubisch, Christian Fornage, Myriam Meschia, James F. Lehtimaki, Terho Sudlow, Cathie Clarke, Robert Chasman, Daniel I. Mitchell, Braxton D. Maguire, Jane Kaprio, Jaakko Farrall, Martin Raitakari, Olli T. Kurth, Tobias Ikram, M. Arfan Reiner, Alex P. Longstreth, W. T., Jr. Rothwell, Peter M. Strachan, David P. Sharma, Pankaj Seshadri, Sudha Quaye, Lydia Cherkas, Lynn Schuerks, Markus Rosand, Jonathan Ligthart, Lannie Boncoraglio, Giorgio B. Smith, George Davey van Duijn, Cornelia M. Stefansson, Kari Worrall, Bradford B. Nyholt, Dale R. Markus, Hugh S. van den Maagdenberg, Arn M. J. M. Cotsapas, Chris Zwart, John A. Palotie, Aarno Dichgans, Martin CA Int Headache Genetics Consortium METASTROKE Collaboration Int Strok TI Shared genetic basis for migraine and ischemic stroke: A genome-wide analysis of common variants SO NEUROLOGY LA English DT Article ID SUSCEPTIBILITY LOCI; CANDIDATE GENE; RISK-FACTORS; METAANALYSIS; ASSOCIATION; AURA; DISEASE; COMPLEX; SUBTYPE AB Objective:To quantify genetic overlap between migraine and ischemic stroke (IS) with respect to common genetic variation.Methods:We applied 4 different approaches to large-scale meta-analyses of genome-wide data on migraine (23,285 cases and 95,425 controls) and IS (12,389 cases and 62,004 controls). First, we queried known genome-wide significant loci for both disorders, looking for potential overlap of signals. We then analyzed the overall shared genetic load using polygenic scores and estimated the genetic correlation between disease subtypes using data derived from these models. We further interrogated genomic regions of shared risk using analysis of covariance patterns between the 2 phenotypes using cross-phenotype spatial mapping.Results:We found substantial genetic overlap between migraine and IS using all 4 approaches. Migraine without aura (MO) showed much stronger overlap with IS and its subtypes than migraine with aura (MA). The strongest overlap existed between MO and large artery stroke (LAS; p = 6.4 x 10(-28) for the LAS polygenic score in MO) and between MO and cardioembolic stroke (CE; p = 2.7 x 10(-20) for the CE score in MO).Conclusions:Our findings indicate shared genetic susceptibility to migraine and IS, with a particularly strong overlap between MO and both LAS and CE pointing towards shared mechanisms. Our observations on MA are consistent with a limited role of common genetic variants in this subtype. C1 [Malik, Rainer; Freilinger, Tobias; Dichgans, Martin] Univ Munich, Inst Stroke & Dementia Res, Munich, Germany. [Freilinger, Tobias] Univ Klinikum Tubingen, Abt Neurol Schwerpunkt Epileptol, Tubingen, Germany. [Freilinger, Tobias] Univ Klinikum Tubingen, Abt Neurol Schwerpunkt Epileptol, Tubingen, Germany. [Zwart, John A.] Oslo Univ Hosp, Dept Neurol, Oslo, Norway. [Zwart, John A.] Oslo Univ Hosp, FORMI, Oslo, Norway. Univ Oslo, N-0316 Oslo, Norway. [Anttila, Verneri; Palotie, Aarno] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Rosand, Jonathan; Palotie, Aarno] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Palotie, Aarno] Massachusetts Gen Hosp, Dept Psychiat, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA. [Anttila, Verneri; Rosand, Jonathan] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA. [Anttila, Verneri; Palotie, Aarno] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA. [Anttila, Verneri; Chasman, Daniel I.; Kurth, Tobias; Rosand, Jonathan] Harvard Univ, Sch Med, Boston, MA USA. [Vander Heiden, Jason] Yale Univ, Interdept Program Computat Biol & Bioinformat, New Haven, CT USA. [Traylor, Matthew; Markus, Hugh S.] Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 1TN, England. [de Vries, Boukje; van den Maagdenberg, Arn M. J. M.] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RA Leiden, Netherlands. [Terwindt, Gisela M.; Ferrari, Michel D.; van den Maagdenberg, Arn M. J. M.] Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RA Leiden, Netherlands. [Holliday, Elizabeth G.; Maguire, Jane] Univ Newcastle, Newcastle, NSW 2300, Australia. [Holliday, Elizabeth G.; Maguire, Jane] Hunter Med Res Inst, Newcastle, NSW, Australia. [Sturm, Jonathan] Univ Newcastle, Fac Hlth, Sch Hlth Sci, Newcastle, NSW 2300, Australia. [Maguire, Jane] Univ Newcastle, Fac Hlth & Med, Sch Nursing & Midwifery, Newcastle, NSW 2300, Australia. [Maguire, Jane] Univ Newcastle, Ctr Translat Neurosci & Mental Hlth, Newcastle, NSW 2300, Australia. [Sturm, Jonathan] Cent Coast Hlth Dist, Dept Neurosci, Gosford, Australia. [Bis, Joshua C.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Longstreth, W. T., Jr.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Longstreth, W. T., Jr.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Hopewell, Jemma C.; Clarke, Robert] Univ Oxford, Clin Trial Serv Unit, Oxford OX1 2JD, England. [Farrall, Martin] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England. [Farrall, Martin] Univ Oxford, Dept Cardiovasc Med, Oxford OX1 2JD, England. [Rothwell, Peter M.] Univ Oxford, Nuffield Dept Clin Neurosci, Stroke Prevent Res Unit, Oxford OX1 2JD, England. [Rannikmae, Kristiina; Sudlow, Cathie] Univ Edinburgh, Div Clin Neurosci, Ctr Clin Brain Sci, Edinburgh EH8 9YL, Midlothian, Scotland. [Wessman, Maija] Folkhalsan Res Ctr, Inst Genet, Helsinki, Finland. [Wessman, Maija; Kaprio, Jaakko; Palotie, Aarno] Univ Helsinki, FIMM, FIN-00014 Helsinki, Finland. [Kaprio, Jaakko] Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland. [Kallela, Mikko] Univ Helsinki, Dept Neurol, Cent Hosp, FIN-00014 Helsinki, Finland. [Kubisch, Christian] Univ Med Ctr Hamburg Eppendorf, Inst Human Genet, Hamburg, Germany. [Kubisch, Christian] Univ Ulm, Inst Human Genet, D-89069 Ulm, Germany. [Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Meschia, James F.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Lehtimaki, Terho] Univ Tampere, Dept Clin Chem, Sch Med, FIN-33101 Tampere, Finland. Univ Tampere, Fimlab Labs, Sch Med, FIN-33101 Tampere, Finland. [Chasman, Daniel I.; Kurth, Tobias; Schuerks, Markus] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA. [Mitchell, Braxton D.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Kaprio, Jaakko] Natl Inst Hlth & Welf, Dept Mental Hlth & Alcohol Res, Helsinki, Finland. [Raitakari, Olli T.] Univ Turku, Dept Clin Physiol & Nucl Med, SF-20500 Turku, Finland. [Raitakari, Olli T.] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, SF-20500 Turku, Finland. Turku Univ Hosp, Turku, Finland. [Kurth, Tobias] Res Ctr Epidemiol & Biostat, INSERM, U897, Team Neuroepidemiol, Bordeaux, France. [Kurth, Tobias] Univ Bordeaux, Coll Hlth Sci, Bordeaux, France. [Ikram, M. Arfan; van Duijn, Cornelia M.] Erasmus MC Univ Med Ctr, Dept Epidemiol, Rotterdam, Netherlands. [Ikram, M. Arfan] Erasmus MC Univ Med Ctr, Dept Neurol, Rotterdam, Netherlands. [Ikram, M. Arfan] Erasmus MC Univ Med Ctr, Dept Radiol, Rotterdam, Netherlands. [Ikram, M. Arfan; van Duijn, Cornelia M.] Netherlands Consortium Hlth Ageing, Leiden, Netherlands. [Reiner, Alex P.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Strachan, David P.] Univ London, Div Populat Hlth Sci & Educ, London WC1E 7HU, England. [Sharma, Pankaj] Univ London Imperial Coll Sci Technol & Med, ICCRU, London SW7 2AZ, England. [Seshadri, Sudha] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA. [Quaye, Lydia; Cherkas, Lynn] Kings Coll London, Dept Twin Res & Genet Epidemiol, London WC2R 2LS, England. [Schuerks, Markus] Univ Hosp Essen, Dept Neurol, Essen, Germany. [Ligthart, Lannie] Vrije Univ Amsterdam, Ctr Human Genet Res, Amsterdam, Netherlands. [Ligthart, Lannie] Vrije Univ Amsterdam, Div Neurocrit Care & Emergency Neurol, Dept Biol Psychol, Amsterdam, Netherlands. [Boncoraglio, Giorgio B.] Ist Neurol Carlo Besta, Fdn Ist Ricovero & Cura Carattere Sci IRCCS, Dept Cerebrovasc Dis, Milan, Italy. [Smith, George Davey] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol BS8 1TH, Avon, England. [Stefansson, Kari] deCODE Genet, Reykjavik, Iceland. [Worrall, Bradford B.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA. [Worrall, Bradford B.] Univ Virginia, Sch Med, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA. [Nyholt, Dale R.] QIMR Berghofer, Neurogenet Lab, Brisbane, Qld, Australia. [Cotsapas, Chris] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA. [Palotie, Aarno] Wellcome Trust Genome Campus, Wellcome Trust Sanger Inst, Cambridge, England. [Dichgans, Martin] Munich Cluster Syst Neurol SyNergy, Munich, Germany. RP Dichgans, M (reprint author), Univ Munich, Inst Stroke & Dementia Res, Munich, Germany. EM martin.dichgans@med.uni-muenchen.de RI Kubisch, Christian/F-1893-2011; Boncoraglio, Giorgio/B-8647-2011; Kurth, Tobias/A-9243-2012; OI Traylor, Matthew/0000-0001-6624-8621; Kubisch, Christian/0000-0003-4220-0978; Gillman, Matthew/0000-0002-2340-6930; Plomin, Robert/0000-0002-0756-3629; Cotsapas, Chris/0000-0002-7772-5910; Winsvold, Bendik Slagsvold/0000-0003-4171-8919; Davey Smith, George/0000-0002-1407-8314; Kurth, Tobias/0000-0001-7169-2620; Anttila, Verneri/0000-0002-0073-4675; Gormley, Padhraig/0000-0002-8908-6968; Seshadri, Sudha/0000-0001-6135-2622; Stefansson, Hreinn/0000-0002-9331-6666 FU University of Newcastle; Australian National and Medical Health Research Council (NHMRC) [569257]; Australian National Heart Foundation (NHF) [G 04S 1623]; Gladys M Brawn Fellowship scheme; Vincent Fairfax Family Foundation in Australia; National Heart, Lung, and Blood Institute [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL087641, R01HL59367, R01HL086694, N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021]; National Human Genome Research Institute [U01HG004402]; NIH [HHSN268200625226C, UL1RR025005, AA07535, AA07728, AA13320, AA13321, AA14041, AA11998, AA17688, DA012854, DA019951]; NIH Roadmap for Medical Research; Dept. of Health (UK); Henry Smith Charity; UK-India Education Research Institutive (UKIERI) from the British Council; National Institute of Neurological Disorders and Stroke; National Institute on Aging [AG-023629, AG-15928, AG-0098, AG-027058]; National Center for Research Resources at the National Center for Advancing Translational Sciences, Clinical and Translational Science Institute [UL1RR033176, UL1TR000124, DK063491]; European Community's Seventh Framework Programme (FP7); ENGAGE project [HEALTH-F4-2007-201413]; National Heart, Lung and Blood Institute's Framingham Heart Study [N01-HC-25195, N02-HL-6-4278]; National Institute of Neurological Disorders and Stroke [NS17950, U01 NS069208, NS-061836]; National Heart, Lung, and Blood Association [HL93029]; National Institute of Aging [AG033193]; NIH Genes, Environment and Health Initiative (GEI) as part of the GENEVA consortium under the NIH Genes, Environment and Health Initiative [U01 HG004436]; Mid-Atlantic Nutrition and Obesity Research Center [P30 DK072488]; Office of Research and Development, Medical Research Service; Baltimore Geriatrics Research, Education, and Clinical Center of the Department of Veterans Affairs; federal contract from the NIH [HHSN268200782096C]; Division of Adult and Community Health, Centers for Disease Control; NIH Office of Research on Women's Health [R01 NS45012, U01 NS069208-01]; UK Medical Research Council; British Heart Foundation; Merck Co.; Roche Vitamins Ltd.; British Heart Foundation Centre of Research Excellence, Oxford [RE/08/004]; Intramural Research Program of the National Institute on Aging, NIH [Z01 AG-000954-06, Z01 AG-000015-50]; NIH-National Institute of Neurological Disorders and Stroke [R01 NS-42733, R01 NS-39987]; American Heart Association/Bugher Foundation Centers for Stroke Prevention Research [0775010N]; National Heart, Lung, and Blood Institute's STAMPEED genomics research program [R01 HL087676]; National Center for Research Resources [U54 RR020278]; Italian Ministry of Health [RC 2007/LR6, RC 2008/LR6, RC 2009/LR8, RC 2010/LR8]; Netherlands Organization of Scientific Research [175.010.2005.011]; Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO); Netherlands Consortium for Healthy Ageing [050-060-810]; Erasmus Medical Center and Erasmus University, Rotterdam; Netherlands Organization for Health Research and Development; Research Institute for Diseases in the Elderly; Ministry of Education, Culture, and Science; Ministry for Health, Welfare, and Sports; European Commission; Municipality of Rotterdam; Netherlands Heart Foundation (Nederlandse Hartstichting) [2009B102]; Wellcome Trust, as part of the Wellcome Trust Case Control Consortium 2 project [085475/B/08/Z, 085475/Z/08/Z, WT084724MA]; Medical Research Council [G0000934]; Stroke Association; Dunhill Medical Trust; National Institute of Health Research (NIHR); IHR Biomedical Research Centre, Oxford; Wellcome Trust (clinician scientist award); Binks Trust; Scottish Funding Council; Chief Scientist Office; BHF Center of Research Excellence in Oxford; Wellcome Trust core award [090532/Z/09/Z]; NIHR Senior Investigator award; Wellcome Trust [WT088806, 068545/Z/02, 076113/B/04/Z, WT089062, 098051]; 23andMe; Sanger Centre; Centre National de Genotypage; Australian National Health and Medical Research Council [241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485, 552498]; Australian Research Council [A7960034, A79906588, A79801419, DP0770096, DP0212016, DP0343921]; EU [FP5-QLG2-CT-2002-01254, LSM-CT-2004-504837]; ENGAGE [HEALTH-F4-2007-201413, FP7-HEALTH-201413, FT0991022, 613674, HEALTHF4-2007-201413]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); National Human Genome Research Institute (NHGRI); National Institute of Child Health and Human Development (NICHD); Juvenile Diabetes Research Foundation International (JDRF); JDRF; National Institute for Health Research Cambridge Biomedical Research Centre; Wellcome Trust Strategic Award [079895]; European Commission Framework Programme 6 [018996]; French Ministry of Research; Netherlands Organization for Scientific Research (NWO); Erasmus MC; Netherlands Genomics Initiative (NGI); European Special Populations Research Network (EUROSPAN) through the European Commission FP6 STRP grant [018947, LSHG-CT-2006-01947]; Netherlands Organisation for Scientific Research (NWO); Centre for Medical Systems Biology [CMSB1, CMSB2]; Academy of Finland Center of Excellence in Complex Disease Genetics [213506, 129680]; Academy of Finland [205585, 141054, 134309, 126925, 121584, 124282, 129378, 117787, 41071, 00213, 200923, 251704, 139795]; ENGAGE-European Network for Genetic and Genomic Epidemiology, FP7-HEALTH-F4-2007 [201413]; U.S.- P.H.S. NIH [AA-12502, AA-00145, AA-09203, AA15416, K02AA018755]; South-Eastern Norway Regional Health Authority [2010075, 2011083]; Unger-Vetlesen Medical Fund; Ullevaal fund; Academy of Finland (Center of Excellence in Complex Disease Genetics and SALVE) [104781, 120315, 129269, 1114194, 139900/24300796]; University Hospital Oulu, Biocenter; University of Oulu, Finland [75617]; European Commission (EUROBLCS, Framework 5 award) [QLG1-CT-2000-01643]; NHLBI through the STAMPEED program [5R01HL087679-02, 1RL1MH083268-01]; NIH/NIMH [5R01MH63706: 02]; Medical Research Council, UK [G0500539, G0600705, G0600331, PrevMet-Syn/SALVE, PS0476]; Wellcome Trust, UK [GR069224, WT089549]; Biocentrum Helsinki; Netherlands Organization for Scientific Research (NWO: MagW/ZonMW grants) [904-61-090, 985-10-002, 904-61-193, 480-04-004, 400-05-717, Addiction-31160008 Middelgroot-911-09-032, Spinozapremie 56-464-14192]; Center for Medical Systems Biology (CSMB, NWO Genomics), NBIC/BioAssist/RK [2008.024]; Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL) [184.021.007]; VU University's Institute for Health and Care Research (EMGO+); Neuroscience Campus Amsterdam (NCA); European Science Foundation (ESF) [EU/QLRT-2001-01254]; European Community's Seventh Framework Program (FP7); European Science Council (ERC) [230374]; NIH (NIH) [R01D0042157-01A]; Genetic Association Information Network (GAIN) of the Foundation for the US NIH (NIMH) [MH081802]; Geestkracht program of the Netherlands Organisation for Health Research and Development (Zon-Mw) [10-000-1002]; VU University Medical Center; GGZ inGeest; Arkin; Leiden University Medical Center; GGZ Rivierduinen; University Medical Center Groningen; Lentis; GGZ Friesland; GGZ Drenthe; Scientific Institute for Quality of Healthcare [IQ healthcare]; Netherlands Institute for Health Services Research [NIVEL]; Netherlands Institute of Mental Health and Addiction [Trimbos Institute]); Research Institute for Diseases in the Elderly [014-93-015, RIDE2]; Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) [050-060-810]; Erasmus Medical Center; Erasmus University, Rotterdam; Netherlands Organization for the Health Research and Development (ZonMw); Research Institute for Diseases in the Elderly (RIDE); Ministry of Education, Culture and Science; Ministry for Health, Welfare and Sports; European Commission (DG XII); Netherlands Organization of Scientific Research (NWO) [918-46-615, 904-61-096, 904-61-133, 948-00-010]; Dept. of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award; King's College London; Chronic Disease Research Foundation; National Cancer Institute [CA-47988]; Social Insurance Institution of Finland, Kuopio, Tampere; Turku University Hospital Medical Funds [9M048, 9N035]; Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation of Cardiovascular Research; Finnish Cultural Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; German Federal Ministry of Education and Research (BMBF) [01GS08120, 01GS1103, 01GS08121]; German Federal Ministry of Education and Research; State of Bavaria; Munich Center of Health Sciences [MC Health] as part of LMUinnovativ); Helmholtz Center Munich; German Research Center for Environmental Health; Center for Molecular Medicine Cologne; Heinz Nixdorf Foundation for the Heinz Nixdorf Recall study; Deutsche Forschungsgemeinschaft (DFG); Academy of Finland Center of Excellence for Complex Disease Genetics; EuroHead project [LSM-CT-2004-504837]; Finnish Neurology Foundation; Biomedicum Helsinki Foundation; Orion Farmos Research Foundation; Academy of Finland, Center of Excellence in Complex Disease Genetics [213506, 129680]; ENGAGE Consortium [HEALTH-F4-2007-201413]; EU/SYNSYS-Synaptic Systems [242167]; Sigrid Juselius Foundation, Finland; Folkhalsan Research Foundation, Finland; Medicinska Understodsforeningen Liv Halsa; Helsinki University Central Hospital; Netherlands Organization for Health Research and Development (ZonMw) [90700217]; VIDI (ZonMw) [91711319]; Netherlands Organisation for Scientific Research (NWO) VICI [918.56.602]; Spinoza grants; EUROHEADPAIN [602633]; Center for Medical Systems Biology (CMSB); Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research (NGI/NWO) [050-060-409]; Vascular Dementia Research Foundation; [HL-093029]; [HHSN268201200036C]; [U01 DK062418]; [N01-HC-35129]; [N01 HC-15103]; [N01 HC-55222]; [N01-HC-75150]; [N01-HC-45133]; [N01-HC-85239]; [HL080295]; [HL087652]; [HL105756]; [R01 HL085251]; [R01 HL073410]; [HL-043851]; [HL-080467]; [HL-099355]; [N01-HC-85082]; [N01-HC-85083]; [N01-HC-85084]; [N01-HC-85085]; [N01-HC-85086]; [R01-HL087641]; [U01 HL096917]; [R01-HL093029]; [N01-HC-85079]; [N01-HC-85080]; [N01-HC-85081]; [N01-HC-55022] FX The Australian Stroke Genetics Collaboration (ASGC) Australian population control data were derived from the Hunter Community Study. The authors thank the University of Newcastle for funding and the men and women of the Hunter region who participated in this study. This research was funded by grants from the Australian National and Medical Health Research Council (NHMRC Project Grant ID: 569257), the Australian National Heart Foundation (NHF Project Grant ID: G 04S 1623), the University of Newcastle, the Gladys M Brawn Fellowship scheme, and the Vincent Fairfax Family Foundation in Australia. The Atherosclerosis Risk in Communities Study (ARIC) is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367, and R01HL086694; National Human Genome Research Institute contract U01HG004402; NIH contract HHSN268200625226C and National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022; and grants R01-HL087641, U01 HL096917 (Mosley), and R01-HL093029 (Fornage). Infrastructure was partly supported by Grant UL1RR025005, a component of the NIH and NIH Roadmap for Medical Research. ARIC analyses performed as part of the METASTROKE project were supported by grant HL-093029 to M. Fornage. Bio-Repository of DNA in Stroke (BRAINS) is partly funded by a Senior Fellowship from the Dept. of Health (UK) to Dr. Pankaj Sharma, the Henry Smith Charity and the UK-India Education Research Institutive (UKIERI) from the British Council. Cardiovascular Health Study (CHS) research was supported by National Heart, Lung, and Blood Institute contracts N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086; N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, and N01-HC-85239, and by HHSN268201200036C and National Heart, Lung, and Blood Institute grants HL080295, HL087652, and HL105756, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided through AG-023629, AG-15928, AG-0098, and AG-027058 from the National Institute on Aging. See also http://www.chs-nhlbi.org/pi.htm. DNA handling and genotyping at Cedars-Sinai Medical Center was supported in part by the National Center for Research Resources, grant UL1RR033176, and is now at the National Center for Advancing Translational Sciences, Clinical and Translational Science Institute grant UL1TR000124, in addition to the National Institute of Diabetes and Digestive and Kidney Disease grant DK063491 to the Southern California Diabetes Endocrinology Research Center. deCODE Genetics Work performed at deCODE was funded in part through a grant from the European Community's Seventh Framework Programme (FP7/2007-2013), the ENGAGE project grant agreement HEALTH-F4-2007-201413. Framingham Heart Study (FHS): this work was supported by the dedication of the Framingham Heart Study participants, the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract Nos. N01-HC-25195 and N02-HL-6-4278), and by grants from the National Institute of Neurological Disorders and Stroke (NS17950), the National Heart, Lung, and Blood Association (HL93029), and the National Institute of Aging (AG033193).; The Genetics of Early Onset Stroke (GEOS) Study, Baltimore, was supported by the NIH Genes, Environment and Health Initiative (GEI) Grant U01 HG004436, as part of the GENEVA consortium under the NIH Genes, Environment and Health Initiative, with additional support provided by the Mid-Atlantic Nutrition and Obesity Research Center (P30 DK072488); and the Office of Research and Development, Medical Research Service, and the Baltimore Geriatrics Research, Education, and Clinical Center of the Department of Veterans Affairs. Genotyping services were provided by The Johns Hopkins University Center for Inherited Disease Research (CIDR), which is fully funded through a federal contract from the NIH to The Johns Hopkins University (contract HHSN268200782096C). Assistance with data cleaning was provided by the GENEVA Coordinating Center (U01 HG 004446; PI Bruce S. Weir). Study recruitment and assembly of datasets were supported by a Cooperative Agreement with the Division of Adult and Community Health, Centers for Disease Control, and by grants from the National Institute of Neurological Disorders and Stroke and the NIH Office of Research on Women's Health (R01 NS45012, U01 NS069208-01). Heart Protection Study (HPS) (ISRCTN48489393) was supported by the UK Medical Research Council, British Heart Foundation, Merck & Co. (manufacturers of simvastatin), and Roche Vitamins Ltd. (manufacturers of vitamins). Genotyping was supported by a grant to Oxford University and CNG from Merck & Co. Jemma C. Hopewell acknowledges support from the British Heart Foundation Centre of Research Excellence, Oxford (RE/08/004). The Heart and Vascular Health Study (HVH) research reported in this article was funded by National Heart, Lung, and Blood Institute grants R01 HL085251 and R01 HL073410. The Ischemic Stroke Genetics Study (ISGS)/Siblings With Ischemic Stroke Study (SWISS): The ISGS/SWISS study was supported in part by the Intramural Research Program of the National Institute on Aging, NIH project Z01 AG-000954-06. ISGS/SWISS used samples and clinical data from the NIH-National Institute of Neurological Disorders and Stroke Human Genetics Resource Center DNA and Cell Line Repository (http://ccr.coriell.org/ninds), human subjects protocol numbers 2003-081 and 2004-147. ISGS/SWISS used stroke-free participants from the Baltimore Longitudinal Study of Aging (BLSA) as controls. The inclusion of BLSA samples was supported in part by the Intramural Research Program of the National Institute on Aging, NIH project Z01 AG-000015-50, human subjects protocol number 2003-078. The ISGS study was funded by NIH-National Institute of Neurological Disorders and Stroke Grant R01 NS-42733 (J.F. Meschia, PI). The SWISS study was funded by NIH-National Institute of Neurological Disorders and Stroke Grant R01 NS-39987 (J.F. Meschia, PI). This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the NIH (http://biowulf.nih.gov). The MGH Genes Affecting Stroke Risk and Outcome Study (MGH-GASROS): GASROS was supported by The National Institute of Neurological Disorders and Stroke (U01 NS069208), the American Heart Association/Bugher Foundation Centers for Stroke Prevention Research 0775010N, the NIH and National Heart, Lung, and Blood Institute's STAMPEED genomics research program (R01 HL087676), and a grant from the National Center for Research Resources. The Broad Institute Center for Genotyping and Analysis is supported by grant U54 RR020278 from the National Center for Research resources.; Milano-Besta Stroke Register Collection and genotyping of the Milan cases within CEDIR were supported by Annual Research Funding of the Italian Ministry of Health (grant numbers RC 2007/LR6, RC 2008/LR6; RC 2009/LR8; RC 2010/LR8). PROCARDIS control samples were supported by FP6 LSHM-CT-2007-037273. The Rotterdam Study was supported by the Netherlands Organization of Scientific Research (175.010.2005.011), the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO), Netherlands Consortium for Healthy Ageing (050-060-810), the Erasmus Medical Center and Erasmus University, Rotterdam, the Netherlands Organization for Health Research and Development, the Research Institute for Diseases in the Elderly, the Ministry of Education, Culture, and Science, the Ministry for Health, Welfare, and Sports, the European Commission, and the Municipality of Rotterdam to the Rotterdam Study. Further funding was obtained from the Netherlands Heart Foundation (Nederlandse Hartstichting) 2009B102. The Wellcome Trust Case-Control Consortium 2 (WTCCC2): The principal funding for the WTCCC2 stroke study was provided by the Wellcome Trust, as part of the Wellcome Trust Case Control Consortium 2 project (085475/B/08/Z and 085475/Z/08/Z and WT084724MA). The Stroke Association provided additional support for collection of some of the St George's, London cases. The Oxford cases were collected as part of the Oxford Vascular Study, which is funded by the Medical Research Council, Stroke Association, Dunhill Medical Trust, National Institute of Health Research (NIHR), and the NIHR Biomedical Research Centre, Oxford. The Edinburgh Stroke Study was supported by the Wellcome Trust (clinician scientist award to Dr. Sudlow) and the Binks Trust. Sample processing occurred in the Genetics Core Laboratory of the Wellcome Trust Clinical Research Facility, Western General Hospital, Edinburgh. Much of the neuroimaging occurred in the Scottish Funding Council Brain Imaging Research Centre (www.sbirc.ed.ac.uk), Division of Clinical Neurosciences, University of Edinburgh, a core area of the Wellcome Trust Clinical Research Facility and part of the SINAPSE (Scottish Imaging Network-A Platform for Scientific Excellence) collaboration (www.sinapse.ac.uk), funded by the Scottish Funding Council and the Chief Scientist Office. Collection of the Munich cases and data analysis was supported by the Vascular Dementia Research Foundation. Martin Farrall acknowledges support from the BHF Center of Research Excellence in Oxford and the Wellcome Trust core award (090532/Z/09/Z). Hugh Markus is supported by an NIHR Senior Investigator award. ALSPAC: The authors thank the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. The UK Medical Research Council and Wellcome Trust (092731), together with the University of Bristol, provide core support for the ALSPAC study. A grant from the Wellcome Trust funded collection of GWAS data in ALSPAC mothers (WT088806) and a grant from 23andMe, together with support from the Sanger Centre and Centre National de Genotypage funded GWAS data in the offspring.; Australian Twin Migraine: The Australian cohort was supported by NIH grants AA07535, AA07728, AA13320, AA13321, AA14041, AA11998, AA17688, DA012854, and DA019951; by grants from the Australian National Health and Medical Research Council (241944, 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485, and 552498); by grants from the Australian Research Council (A7960034, A79906588, A79801419, DP0770096, DP0212016, and DP0343921); and by the EU-funded GenomEUtwin (FP5-QLG2-CT-2002-01254) and ENGAGE (FP7-HEALTH-201413) projects. D.R.N. (FT0991022, 613674). The authors thank P. Visscher, D. Duffy, A. Henders, B. Usher, E. Souzeau, A. Kuot, A. McMellon, P.A.F. Madden, M.J. Wright, M.J. Campbell, A. Caracella, L. Bowdler, S. Smith, S. Gordon, B. Haddon, D. Smyth, H. Beeby, O. Zheng, and B. Chapman for their input into project management, databases, phenotype collection, and sample collection, processing, and genotyping. British 58 Birth Cohort: The authors acknowledge use of phenotype and genotype data from the British 1958 Birth Cohort DNA collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02 (http://www.b58cgene.sgul.ac.uk/). Genotyping for the B58C-WTCCC subset was funded by the Wellcome Trust grant 076113/B/04/Z. The B58C-T1DGC genotyping utilized resources provided by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Human Genome Research Institute (NHGRI), National Institute of Child Health and Human Development (NICHD), and Juvenile Diabetes Research Foundation International (JDRF) and supported by U01 DK062418. B58C-T1DGC. GWAS data were deposited by the Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research (CIMR), University of Cambridge, which is funded by JDRF, the Wellcome Trust and the National Institute for Health Research Cambridge Biomedical Research Centre; the CIMR is in receipt of a Wellcome Trust Strategic Award (079895). The B58C-GABRIEL genotyping was supported by a contract from the European Commission Framework Programme 6 (018996) and grants from the French Ministry of Research. Erasmus Rucphen Family: The Erasmus Rucphen Family was supported by grants from The Netherlands Organization for Scientific Research (NWO), Erasmus MC, and the Netherlands Genomics Initiative (NGI)-sponsored Center of Medical Systems Biology (CMSB). The genotyping for the ERF study was supported by European Special Populations Research Network (EUROSPAN) through the European Commission FP6 STRP grant (018947; LSHG-CT-2006-01947). The ERF study was further supported by grants from the Netherlands Organisation for Scientific Research (NWO), Erasmus MC, the Centre for Medical Systems Biology (CMSB1 and CMSB2), and the Netherlands Genomics Initiative (NGI). The authors thank all the patients and their relatives, general practitioners, and neurologists for their contributions and P. Veraart for her help in genealogy, Jeannette Vergeer for the supervision of the laboratory work, and P. Snijders for his help in data collection. FinnTwin: Academy of Finland Center of Excellence in Complex Disease Genetics (grant numbers 213506, 129680), the Academy of Finland (grants 205585 and 141054 to J.K.), ENGAGE-European Network for Genetic and Genomic Epidemiology, FP7-HEALTH-F4-2007, grant agreement number 201413, and U.S.- P.H.S.; NIH grants AA-12502, AA-00145, AA-09203, AA15416, and K02AA018755. HUNT: The Nord-Trondelag Health Study (The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology, NTNU), Nord-Trondelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Institute of Public Health. The current study was supported by the South-Eastern Norway Regional Health Authority (2010075 and 2011083 to B.S.W. and J.A.Z.), Unger-Vetlesen Medical Fund (to B.S.W.), and the Ullevaal fund (to B.S.W.). Genotyping was performed by Avazeh Tashakkori-Ghanbarian, Simon Potter, and Sarah Hunt (calling and quality control) and Douglas Simpkin (production) at Wellcome Trust Sanger Institute. Northern Finland Birth Cohort 1966 (NFBC1966): NFBC1966 received financial support from the Academy of Finland (project grants 104781, 120315, 129269, 1114194, 139900/24300796, Center of Excellence in Complex Disease Genetics and SALVE), University Hospital Oulu, Biocenter, University of Oulu, Finland (75617), the European Commission (EUROBLCS, Framework 5 award QLG1-CT-2000-01643), NHLBI grant 5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01), NIH/NIMH (5R01MH63706: 02), ENGAGE project and grant agreement HEALTH-F4-2007-201413, the Medical Research Council, UK (G0500539, G0600705, G0600331, PrevMet-Syn/SALVE, PS0476), and the Wellcome Trust (project grant GR069224, WT089549), UK. The DNA extractions, sample quality controls, biobank upkeeping, and aliquotting was performed in the National Public Health Institute, Biomedicum Helsinki, Finland, and supported financially by the Academy of Finland and Biocentrum Helsinki. The authors acknowledge the contribution of the late Academian of Science Leena Peltonen. NTR/NESDA: Funding was obtained from the Netherlands Organization for Scientific Research (NWO: MagW/ZonMW grants 904-61-090, 985-10-002, 904-61-193, 480-04-004, 400-05-717, Addiction-31160008 Middelgroot-911-09-032, Spinozapremie 56-464-14192), Center for Medical Systems Biology (CSMB, NWO Genomics), NBIC/BioAssist/RK (2008.024), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL, 184.021.007), the VU University's Institute for Health and Care Research (EMGO+) and Neuroscience Campus Amsterdam (NCA), the European Science Foundation (ESF, EU/QLRT-2001-01254), the European Community's Seventh Framework Program (FP7/2007-2013), ENGAGE (HEALTHF4-2007-201413), the European Science Council (ERC Advanced, 230374), and the NIH (NIH, R01D0042157-01A). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the US NIH (NIMH, MH081802). The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (Zon-Mw, grant number 10-000-1002) and is supported by participating universities and mental health care organizations (VU University Medical Center, GGZ inGeest, Arkin, Leiden University Medical Center, GGZ Rivierduinen, University Medical Center Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Scientific Institute for Quality of Healthcare [IQ healthcare], Netherlands Institute for Health Services Research [NIVEL], and Netherlands Institute of Mental Health and Addiction [Trimbos Institute]). Rotterdam studies: The generation and management of GWAS genotype data for the Rotterdam Study is supported by the Netherlands Organisation of Scientific Research NWO Investments (175.010.2005.; 011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project 050-060-810. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The Rotterdam Scan Study is supported by the Netherlands Organization of Scientific Research (NWO) project 918-46-615, 904-61-096, 904-61-133, and 948-00-010. TwinsUK: The study was funded by the Wellcome Trust, European Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE project grant agreement (HEALTH-F4-2007-201413). The study also receives support from the Dept. of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London. Genotyping was performed by The Wellcome Trust Sanger Institute, support of the National Eye Institute via an NIH/CIDR genotyping project. This project was partly funded by the Chronic Disease Research Foundation with money raised by the walking twins, Hazel Green and Christine Dafter. WGHS: Genetic analysis of migraine in the WGHS is supported by a grant from the National Institute of Neurological Disorders and Stroke (NS-061836). The Women's Health Study and the Women's Genome Health Study are supported by grants from the National Heart, Lung, and Blood Institute (HL-043851, HL-080467, and HL-099355) and the National Cancer Institute (CA-47988). Genome-wide genotyping and collaborative scientific support was provided by Amgen. Young Finns: The Young Finns Study has been financially supported by the Academy of Finland: grants 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi), the Social Insurance Institution of Finland, Kuopio, Tampere, and Turku University Hospital Medical Funds (grant 9M048 and 9N035 for TeLeht), Juho Vainio Foundation, Paavo Nurmi Foundation, Finnish Foundation of Cardiovascular Research and Finnish Cultural Foundation, Tampere Tuberculosis Foundation, and Emil Aaltonen Foundation (T.L). Technical assistance in the statistical analyses by Ville Aalto and Irina Lisinen is acknowledged. Cologne/Kiel/Ulm clinic-based studies (part of German MA and MO studies): This research was funded by the German Federal Ministry of Education and Research (BMBF) within the framework of the National Genome Research Network (NGFN-Plus; grants 01GS08120 and 01GS1103 to C.K.; the German Federal Ministry of Education and Research and by the State of Bavaria and supported within the Munich Center of Health Sciences [MC Health] as part of LMUinnovativ) for the KORA research platform, which was initiated by the Helmholtz Center Munich, German Research Center for Environmental Health, the Center for Molecular Medicine Cologne (to C.K.), and the Heinz Nixdorf Foundation for the Heinz Nixdorf Recall study, and the Deutsche Forschungsgemeinschaft (DFG; to C.K.). Finnish clinic-based study: This work was supported by the Wellcome Trust (grant WT089062) and, among others, by the Academy of Finland (200923 to A.P., 00213 to M.W.; ); the Academy of Finland Center of Excellence for Complex Disease Genetics; the EuroHead project (LSM-CT-2004-504837); the Finnish Cultural Foundation (to V.A.); the Finnish Neurology Foundation, Biomedicum Helsinki Foundation (to V.A.); the Orion Farmos Research Foundation (to V.A.); the Wellcome Trust (grant number 098051 to A.P.); the Academy of Finland (grant number 251704 to A.P., and 139795 to M.W.); the Academy of Finland, Center of Excellence in Complex Disease Genetics, (grant numbers 213506 and 129680 to A.P. and J.K.); the European Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE Consortium (grant agreement HEALTH-F4-2007-201413); EU/SYNSYS-Synaptic Systems (grant number 242167 to A.P.); the Sigrid Juselius Foundation, Finland (to A.P.); the Folkhalsan Research Foundation, Finland (to M.W.); Medicinska Understodsforeningen Liv & Halsa (to M.W.), and the Helsinki University Central Hospital (to M.K., V.A.). LUMINA clinic-based studies: Supported by the Netherlands Organization for Health Research and Development (ZonMw) no. 90700217 and VIDI (ZonMw) no. 91711319 (to G. M.T.); the Netherlands Organisation for Scientific Research (NWO) VICI (918.56.602) and Spinoza (2009) grants (to M.D.F.); the EU-funded EuroHead project (LSM-CT-2004-504837) and EUROHEADPAIN (no. 602633); and the Center for Medical Systems Biology (CMSB) established in the Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research (NGI/NWO), project 050-060-409 (to M.D.F. and A. M. J.M.v.d.M.). Munich clinic-based studies (part of German MA and MO studies): Supported by the German Federal Ministry of Education and Research (BMBF) (grant 01GS08121 to M.D. along with support in the context of the German National Genome Research Network, NGFN-2 and NGFN-plus, for the Heinz Nixdorf Recall Study) and an unrestricted grant of the Vascular Dementia Research Foundation (to M.D.). NR 38 TC 21 Z9 21 U1 1 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD MAY 26 PY 2015 VL 84 IS 21 BP 2132 EP 2145 DI 10.1212/WNL.0000000000001606 PG 14 WC Clinical Neurology SC Neurosciences & Neurology GA CJ2LT UT WOS:000355317000012 PM 25934857 ER PT J AU Filley, CM Brown, MS Onderko, K Ray, M Bennett, RE Berry-Kravis, E Grigsby, J AF Filley, Christopher M. Brown, Mark S. Onderko, Karen Ray, Megan Bennett, Rachael E. Berry-Kravis, Elizabeth Grigsby, Jim TI White matter disease and cognitive impairment in FMR1 premutation carriers SO NEUROLOGY LA English DT Article ID TREMOR/ATAXIA SYNDROME FXTAS; VOXEL-BASED ANALYSIS; PHENOTYPE; DEMENTIA; DYSFUNCTION; INSIGHTS; MALES AB Objective:This cross-sectional, observational study examined the role of white matter involvement in the cognitive impairment of individuals with the fragile X mental retardation 1 (FMR1) premutation.Methods:Eight asymptomatic premutation carriers, 5 participants with fragile X tremor/ataxia syndrome (FXTAS), and 7 noncarrier controls were studied. The mean age of the asymptomatic premutation carriers, participants with FXTAS, and noncarrier controls was 60, 71, and 67 years, respectively. Magnetic resonance spectroscopy (MRS) and diffusion tensor imaging (DTI) were used to examine the middle cerebellar peduncles (MCP) and the genu and splenium of the corpus callosum in relation to executive function and processing speed. MRS measures were N-acetyl aspartate/creatine (NAA/Cr) and choline/creatine, and fractional anisotropy (FA) was used for DTI. Executive function was assessed with the Behavioral Dyscontrol Scale and the Controlled Oral Word Association Test (COWAT), and processing speed with the Symbol Digit Modalities Test.Results:Among all 13 FMR1 premutation carriers, significant correlations were found between N-acetyl aspartate/creatine and choline/creatine in the MCP and COWAT scores, and between FA in the genu and performance on the Behavioral Dyscontrol Scale, COWAT, and Symbol Digit Modalities Test; a correlation was also found between FA in the splenium and COWAT performance. In all regions studied, participants with FXTAS had the lowest mean FA.Conclusion:Microstructural white matter disease as determined by MRS and DTI correlated with executive dysfunction and slowed processing speed in these FMR1 premutation carriers. Neuroimaging abnormalities in the genu and MCP suggest that disruption of white matter within frontocerebellar networks has an important role in the cognitive impairment associated with the FMR1 premutation. C1 [Filley, Christopher M.] Univ Colorado, Sch Med, Dept Neurol, Boulder, CO 80309 USA. [Filley, Christopher M.] Univ Colorado, Sch Med, Dept Psychiat, Boulder, CO 80309 USA. [Brown, Mark S.] Univ Colorado, Sch Med, Dept Radiol, Boulder, CO 80309 USA. [Bennett, Rachael E.; Grigsby, Jim] Univ Colorado, Sch Med, Dept Med, Boulder, CO 80309 USA. [Onderko, Karen; Ray, Megan; Grigsby, Jim] Univ Colorado Denver, Dept Psychol, Denver, CO USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Berry-Kravis, Elizabeth] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Berry-Kravis, Elizabeth] Rush Univ, Med Ctr, Dept Pediat, Chicago, IL 60612 USA. [Berry-Kravis, Elizabeth] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA. RP Filley, CM (reprint author), Univ Colorado, Sch Med, Dept Neurol, Boulder, CO 80309 USA. EM christopher.filley@ucdenver.edu FU Strategic Initiative Review Committee of the University of Colorado School of Medicine FX Funded by the Strategic Initiative Review Committee of the University of Colorado School of Medicine. NR 34 TC 9 Z9 9 U1 4 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD MAY 26 PY 2015 VL 84 IS 21 BP 2146 EP 2152 DI 10.1212/WNL.0000000000001612 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CJ2LT UT WOS:000355317000014 PM 25925982 ER PT J AU Growdon, ME Schultz, AP Dagley, AS Amariglio, RE Hedden, T Rentz, DM Johnson, KA Sperling, RA Albers, MW Marshall, GA AF Growdon, Matthew E. Schultz, Aaron P. Dagley, Alexander S. Amariglio, Rebecca E. Hedden, Trey Rentz, Dorene M. Johnson, Keith A. Sperling, Reisa A. Albers, Mark W. Marshall, Gad A. TI Odor identification and Alzheimer disease biomarkers in clinically normal elderly SO NEUROLOGY LA English DT Article ID MILD COGNITIVE IMPAIRMENT; PITTSBURGH COMPOUND-B; MINI-MENTAL-STATE; OLFACTORY DEFICITS; OLDER-ADULTS; DEMENTIA; DECLINE; AGE; NEURODEGENERATION; DEPOSITION AB Objectives:Our objective was to investigate cross-sectional associations between odor identification ability and imaging biomarkers of neurodegeneration and amyloid deposition in clinically normal (CN) elderly individuals, specifically testing the hypothesis that there may be an interaction between amyloid deposition and neurodegeneration in predicting odor identification dysfunction.Methods:Data were collected on 215 CN participants from the Harvard Aging Brain Study. Measurements included the 40-item University of Pennsylvania Smell Identification Test and neuropsychological testing, hippocampal volume (HV) and entorhinal cortex (EC) thickness from MRI, and amyloid burden using Pittsburgh compound B (PiB) PET. A linear regression model with backward elimination (p < 0.05 retention) evaluated the cross-sectional association between the University of Pennsylvania Smell Identification Test and amyloid burden, HV, and EC thickness, assessing for effect modification by PiB status. Covariates included age, sex, premorbid intelligence, APOE epsilon 4 carrier status, and Boston Naming Test.Results:In unadjusted univariate analyses, worse olfaction was associated with decreased HV (p < 0.001), thinner EC (p = 0.003), worse episodic memory (p = 0.03), and marginally associated with greater amyloid burden (binary PiB status, p = 0.06). In the multivariate model, thinner EC in PiB-positive individuals (interaction term) was associated with worse olfaction (p = 0.02).Conclusions:In CN elderly, worse odor identification was associated with markers of neurodegeneration. Furthermore, individuals with elevated cortical amyloid and thinner EC exhibited worse odor identification, elucidating the potential contribution of olfactory testing to detect preclinical AD in CN individuals. C1 [Growdon, Matthew E.; Amariglio, Rebecca E.; Hedden, Trey; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.; Albers, Mark W.; Marshall, Gad A.] Harvard Univ, Sch Med, Boston, MA 02138 USA. [Growdon, Matthew E.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Schultz, Aaron P.; Dagley, Alexander S.; Hedden, Trey; Sperling, Reisa A.; Albers, Mark W.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Schultz, Aaron P.; Dagley, Alexander S.; Amariglio, Rebecca E.; Rentz, Dorene M.; Sperling, Reisa A.; Albers, Mark W.; Marshall, Gad A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Schultz, Aaron P.; Dagley, Alexander S.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Hedden, Trey; Johnson, Keith A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Albers, Mark W.] Massachusetts Gen Hosp, MassGeneral Inst Neurodegenerat Dis, Boston, MA 02114 USA. [Amariglio, Rebecca E.; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.; Marshall, Gad A.] Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, Boston, MA 02115 USA. [Amariglio, Rebecca E.; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.; Marshall, Gad A.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. RP Marshall, GA (reprint author), Harvard Univ, Sch Med, Boston, MA 02138 USA. EM gamarshall@partners.org FU Harvard Aging Brain Study [P01 AGO36694, R01 AG037497]; Massachusetts Alzheimer's Disease Research Center [P50 AG005134]; [R01 AG027435]; [K23 AG033634]; [K24 AG035007]; [DP2 OD006662] FX This study was supported by the Harvard Aging Brain Study (P01 AGO36694, R01 AG037497), R01 AG027435, K23 AG033634, K24 AG035007, the Massachusetts Alzheimer's Disease Research Center (P50 AG005134), and DP2 OD006662. NR 40 TC 11 Z9 11 U1 0 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD MAY 26 PY 2015 VL 84 IS 21 BP 2153 EP 2160 DI 10.1212/WNL.0000000000001614 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA CJ2LT UT WOS:000355317000015 PM 25934852 ER PT J AU Gerlee, P Altrock, PM AF Gerlee, Philip Altrock, Philipp M. TI Complexity and stability in growing cancer cell populations SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Letter ID HETEROGENEITY; DYNAMICS C1 [Gerlee, Philip] Chalmers, Math Sci, SE-41296 Gothenburg, Sweden. [Gerlee, Philip] Univ Gothenburg, Math Sci, SE-40530 Gothenburg, Sweden. [Altrock, Philipp M.] Harvard Univ, Program Evolutionary Dynam, Cambridge, MA 02138 USA. [Altrock, Philipp M.] Dana Farber Canc Inst, Boston, MA 02215 USA. [Altrock, Philipp M.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02215 USA. RP Gerlee, P (reprint author), Chalmers, Math Sci, SE-41296 Gothenburg, Sweden. EM gerlee@chalmers.se NR 5 TC 3 Z9 3 U1 0 U2 2 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAY 26 PY 2015 VL 112 IS 21 BP E2742 EP E2743 DI 10.1073/pnas.1505115112 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ1AJ UT WOS:000355213200003 PM 25941414 ER PT J AU Harrison, MRM Bussmann, J Huang, Y Zhao, L Osorio, A Burns, CG Burns, CE Sucov, HM Siekmann, AF Lien, CL AF Harrison, Michael R. M. Bussmann, Jeroen Huang, Ying Zhao, Long Osorio, Arthela Burns, C. Geoffrey Burns, Caroline E. Sucov, Henry M. Siekmann, Arndt F. Lien, Ching-Ling TI Chemokine-Guided Angiogenesis Directs Coronary Vasculature Formation in Zebrafish SO DEVELOPMENTAL CELL LA English DT Article ID DOGFISH SCYLIORHINUS-CANICULA; HEART REGENERATION; ENDOTHELIAL-CELLS; ASSOCIATION ANALYSIS; PROEPICARDIAL ORGAN; NETWORK FORMATION; ARTERY-DISEASE; RECEPTOR CXCR4; MIGRATION; CARDIOMYOCYTES AB Interruption of the coronary blood supply severely impairs heart function with often fatal consequences for patients. However, the formation and maturation of these coronary vessels is not fully understood. Here we provide a detailed analysis of coronary vessel development in zebrafish. We observe that coronary vessels form in zebrafish by angiogenic sprouting of arterial cells derived from the endocardium at the atrioventricular canal. Endothelial cells express the CXC-motif chemokine receptor Cxcr4a and migrate to vascularize the ventricle under the guidance of the myocardium-expressed ligand Cxcl12b. cxcr4a mutant zebrafish fail to form a vascular network, whereas ectopic expression of Cxcl12b ligand induces coronary vessel formation. Importantly, cxcr4a mutant zebrafish fail to undergo heart regeneration following injury. Our results suggest that chemokine signaling has an essential role in coronary vessel formation by directing migration of endocardium-derived endothelial cells. Poorly developed vasculature in cxcr4a mutants likely underlies decreased regenerative potential in adults. C1 [Harrison, Michael R. M.; Huang, Ying; Osorio, Arthela; Lien, Ching-Ling] Childrens Hosp Los Angeles, Saban Res Inst, Heart Inst, Los Angeles, CA 90027 USA. [Harrison, Michael R. M.; Huang, Ying; Osorio, Arthela; Lien, Ching-Ling] Childrens Hosp Los Angeles, Program Dev Biol & Regenerat Med, Los Angeles, CA 90027 USA. [Bussmann, Jeroen; Siekmann, Arndt F.] Max Planck Inst Mol Biomed, D-48149 Munster, Germany. [Zhao, Long; Burns, C. Geoffrey; Burns, Caroline E.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA. [Zhao, Long; Burns, C. Geoffrey; Burns, Caroline E.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Sucov, Henry M.] Univ So Calif, Broad CIRM Ctr, Los Angeles, CA 90033 USA. [Sucov, Henry M.] Univ So Calif, Dept Stem Cell Biol & Regenerat Med, Los Angeles, CA 90033 USA. [Lien, Ching-Ling] Univ So Calif, Keck Sch Med, Dept Surg, Los Angeles, CA 90033 USA. [Lien, Ching-Ling] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA. RP Lien, CL (reprint author), Childrens Hosp Los Angeles, Saban Res Inst, Heart Inst, Los Angeles, CA 90027 USA. EM clien@chla.usc.edu RI Zhao, Long/A-6439-2014 FU National Heart, Lung and Blood Institute Grant [R01HL096121]; California Institute for Regenerative Medicine [TG2-01168]; Saban Research Institute; Max Planck Society; Deutsche Forschungsgemeinschaft [DFG SI-1374/3-1]; ERC [260794-ZebrafishAngio]; DFG Cells-in-Motion Cluster of Excellence, University of Munster, Germany [EXC 1003-CIM]; European Molecular Biology Organization long-term fellowship; [Sonderforschungsbereich (SFB) 629] FX We are grateful to G. Crump for providing the fli1a endothelial enhancer and S. Megason for providing the H2B-Cerulean fusion construct and for zebrafish lines from various groups. We also thank M. Chao, J. Chen, G. Crump, V. Kaartinen, and C. Pearson for critical reading of the manuscript. We acknowledge the assistance of E. Fernandez and the facilities of the CHLA microscopy core, S. Sumida and R. Kim for insightful comments, and D. Warburton and V. Starnes for helpful discussion and support. This work was supported by National Heart, Lung and Blood Institute Grant (R01HL096121 to C.-L. L.), a postdoctoral fellowship from the California Institute for Regenerative Medicine (TG2-01168; CIRM Scholar, M.R.M.H.), and a Research Career Development Fellowship from the Saban Research Institute (to M.R.M.H.). This work was furthermore funded by the Max Planck Society (to A.F.S.), the Deutsche Forschungsgemeinschaft (DFG SI-1374/3-1; to A.F.S.), the Sonderforschungsbereich (SFB) 629, and an ERC starting grant (260794-ZebrafishAngio; to A.F.S.). This work was supported by the DFG Cells-in-Motion Cluster of Excellence (EXC 1003-CIM), University of Munster, Germany. J.B. was supported by a European Molecular Biology Organization long-term fellowship. NR 56 TC 15 Z9 16 U1 2 U2 9 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1534-5807 EI 1878-1551 J9 DEV CELL JI Dev. Cell PD MAY 26 PY 2015 VL 33 IS 4 BP 442 EP 454 DI 10.1016/j.devcel.2015.04.001 PG 13 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA CJ0FT UT WOS:000355151900009 PM 26017769 ER PT J AU Yeh, RW Kereiakes, DJ Steg, PG Windecker, S Rinaldi, MJ Gershlick, AH Cutlip, DE Cohen, DJ Tanguay, JF Jacobs, A Wiviott, SD Massaro, JM Iancu, AC Mauri, L AF Yeh, Robert W. Kereiakes, Dean J. Steg, Philippe Gabriel Windecker, Stephan Rinaldi, Michael J. Gershlick, Anthony H. Cutlip, Donald E. Cohen, David J. Tanguay, Jean-Francois Jacobs, Alice Wiviott, Stephen D. Massaro, Joseph M. Iancu, Adrian C. Mauri, Laura CA DAPT Study Investigators TI Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE acute coronary syndromes; antiplatelet therapy; myocardial infarction; percutaneous coronary intervention; randomized clinical trial ID DRUG-ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CLINICAL-TRIAL; BARE-METAL; GUIDELINES; THROMBOSIS; METAANALYSIS; DEFINITIONS; MULTICENTER; PLACEMENT AB BACKGROUND The benefits and risks of prolonged dual antiplatelet therapy may be different for patients with acute myocardial infarction (MI) compared with more stable presentations. OBJECTIVES This study sought to assess the benefits and risks of 30 versus 12 months of dual antiplatelet therapy among patients undergoing coronary stent implantation with and without MI. METHODS The Dual Antiplatelet Therapy Study, a randomized double-blind, placebo-controlled trial, compared 30 versus 12 months of dual antiplatelet therapy after coronary stenting. The effect of continued thienopyridine on ischemic and bleeding events among patients initially presenting with versus without MI was assessed. The coprimary endpoints were definite or probable stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE). The primary safety endpoint was GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries) moderate or severe bleeding. RESULTS Of 11,648 randomized patients (9,961 treated with drug-eluting stents, 1,687 with bare-metal stents), 30.7% presented with MI. Between 12 and 30 months, continued thienopyridine reduced stent thrombosis compared with placebo in patients with and without MI at presentation (MI group, 0.5% vs. 1.9%, p < 0.001; no MI group, 0.4% vs. 1.1%, p < 0.001; interaction p = 0.69). The reduction in MACCE for continued thienopyridine was greater for patients with MI (3.9% vs. 6.8%; p < 0.001) compared with those with no MI (4.4% vs. 5.3%; p = 0.08; interaction p = 0.03). In both groups, continued thienopyridine reduced MI (2.2% vs. 5.2%, p < 0.001 for MI; 2.1% vs. 3.5%, p < 0.001 for no MI; interaction p = 0.15) but increased bleeding (1.9% vs. 0.8%, p = 0.005 for MI; 2.6% vs. 1.7%, p = 0.007 for no MI; interaction p = 0.21). CONCLUSIONS Compared with 12 months of therapy, 30 months of dual antiplatelet therapy reduced the risk of stent thrombosis and MI in patients with and without MI, and increased bleeding. (C) 2015 by the American College of Cardiology Foundation. C1 [Yeh, Robert W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Cutlip, Donald E.; Mauri, Laura] Harvard Clin Res Inst, Boston, MA USA. [Cutlip, Donald E.; Mauri, Laura] Harvard Univ, Sch Med, Boston, MA USA. [Kereiakes, Dean J.] Christ Hosp, Heart & Vasc Ctr, Cincinnati, OH 45219 USA. [Steg, Philippe Gabriel] Lindner Ctr Res & Educ, Cincinnati, OH 45219 USA. [Gershlick, Anthony H.] Univ Paris Diderot, INSERM, U 1148, Paris, France. [Rinaldi, Michael J.] Hop Bichat Claude Bernard, AP HP, Dept Hosp Univ FIRE, Paris, France. [Gershlick, Anthony H.] Royal Brompton Hosp, Imperial Coll, NHLI, London SW3 6LY, England. [Windecker, Stephan; Cutlip, Donald E.] Univ Hosp Bern, Bern, Switzerland. [Cohen, David J.] Carolinas HealthCare Syst, Sanger Heart & Vasc Inst, Charlotte, NC USA. [Cohen, David J.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England. [Tanguay, Jean-Francois] Univ Hosp Leicester, Natl Inst Hlth Res, Leicester Cardiovasc Biomed Res Unit, Leicester, Leics, England. [Jacobs, Alice] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Wiviott, Stephen D.] Univ Missouri, Kansas City Sch Med, St Lukes Mid Amer Heart Inst, Kansas City, MO 64110 USA. [Massaro, Joseph M.] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada. Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA. [Mauri, Laura] Brigham & Womens Hosp, Boston, MA 02115 USA. [Massaro, Joseph M.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Jacobs, Alice; Iancu, Adrian C.] Univ Med Iuliu Hatieganu, Inst Heart, Cluj Napoca, Romania. RP Mauri, L (reprint author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA. EM lmauri1@partners.org RI 刘, 李陆/H-8469-2015; bashzar, salman/R-5748-2016 FU Harvard Clinical Research Institute; Abbott; Boston Scientific Corporation; Cordis Corporation; Medtronic, Inc.; Bristol-Myers Squibb Company/Sanofi Pharmaceuticals Partnership; Eli Lilly and Company; Daiichi-Sankyo Company Limited; U.S. Department of Health and Human Services [1RO1FD003870-01]; Gilead Sciences; Merck; Amarin; AstraZeneca; Bayer; Boehringer-Ingelheim; Bristol-Myers Squibb; Daiichi-Sankyo; GlaxoSmithKline; Eli Lilly; Merck-Sharpe-Dohme; Novartis; Otsuka; Pfizer; Roche; Medtronic; Sanofi; Servier; Vivus; Janssen; Medicines Company; Orexigen; Sanofi and Servier; Biotronik; Boston Scientific; Edwards Lifesciences; St. Jude; Biosensors; Cordis Inc.; Abbott Vascular; National Heart, Lung, and Blood Institute; Ikaria; Arena; Eli Lilly/Daiichi-Sankyo; Eisai; Aegerion; Angelmed; Xoma; ICON Clinical; Boston Clinical Research Institute; Sanofi/Bristol-Myers Squibb; Recor; St. Jude Medical FX This research is sponsored by the Harvard Clinical Research Institute and funded by Abbott, Boston Scientific Corporation, Cordis Corporation, Medtronic, Inc., Bristol-Myers Squibb Company/Sanofi Pharmaceuticals Partnership, Eli Lilly and Company, and Daiichi-Sankyo Company Limited, and the U.S. Department of Health and Human Services (1RO1FD003870-01). Dr. Yeh is on the advisory board of Abbott Vascular; and has received consulting fees from Gilead Sciences and Merck. Dr. Kereiakes has served as a consultant for Boston Scientific and Abbott Vascular. Dr. Steg has received personal fees from Amarin, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Eli Lilly, Merck-Sharpe-Dohme, Novartis, Otsuka, Pfizer, Roche, Medtronic, Sanofi, Servier, Vivus, Janssen, The Medicines Company, and Orexigen; and has received grants from Sanofi and Servier. Dr. Windecker has received research grants to the institution from Abbott, Biotronik, Boston Scientific, Edwards Lifesciences, Medtronic, The Medicines Company, and St. Jude; and speaker fees from AstraZeneca, Eli Lilly, Abbott, Biotronik, Boston Scientific, Bayer, and Biosensors. Dr. Gershlick has received personal fees from Medtronic and Abbott; and grants from The Medicines Company. Dr. Cutlip has received other fees from Medtronic, Boston Scientific, Cordis Inc., and Abbott Vascular; and grants from the National Heart, Lung, and Blood Institute during the conduct of the study. Dr. Cohen has received research grant support to the institution from Eli Lilly, AstraZeneca, Daiichi-Sankyo, Abbott Vascular, Boston Scientific, and Medtronic; and consulting fees from Eli Lilly, AstraZeneca, Abbott Vascular, and Medtronic. Dr. Tanguay has received personal fees and other from Abbott Vascular, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and Sanofi; personal fees from Bayer, Roche, and Servier; and other fees from Ikaria and Merck. Dr. Wiviott has received grants and personal fees from AstraZeneca, Bristol-Myers Squibb, Arena, and Eli Lilly/Daiichi-Sankyo; grants from Eisai, Merck, and Sanofi; and personal fees from Aegerion, Angelmed, Janssen, Xoma, ICON Clinical, and the Boston Clinical Research Institute. Dr. Massaro has received personal fees from the Harvard Clinical Research Institute during the conduct of the study. Dr. Mauri has received institutional research grants from Abbott, Boston Scientific, Cordis, Medtronic, Eli Lilly/Daiichi-Sankyo, and Sanofi/Bristol-Myers Squibb; and personal fees from Medtronic, Recor, St. Jude Medical, and Biotronik. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. P. K. Shah, MD, served as Guest Editor for this paper. NR 25 TC 64 Z9 66 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAY 26 PY 2015 VL 65 IS 20 BP 2211 EP 2221 DI 10.1016/j.jacc.2015.03.003 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CI5DM UT WOS:000354773100009 PM 25787199 ER PT J AU Goldstein, JN Refaai, MA Milling, TJ Lewis, B Goldberg-Alberts, R Hug, BA Sarode, R AF Goldstein, Joshua N. Refaai, Majed A. Milling, Truman J., Jr. Lewis, Brandon Goldberg-Alberts, Robert Hug, Bruce A. Sarode, Ravi TI Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial SO LANCET LA English DT Article ID FRESH-FROZEN PLASMA; INTERNATIONAL NORMALIZED RATIO; WARFARIN REVERSAL; ANTICOAGULATION; SAFETY; METAANALYSIS; 3-FACTOR; SURGERY AB Background Rapid reversal of vitamin K antagonist (VKA)-induced anticoagulation is often necessary for patients needing urgent surgical or invasive procedures. The optimum means of VKA reversal has not been established in comparative clinical trials. We compared the efficacy and safety of four-factor prothrombin complex concentrate (4F-PCC) with that of plasma in VKA-treated patients needing urgent surgical or invasive procedures. Methods In a multicentre, open-label, phase 3b randomised trial we enrolled patients aged 18 years or older needing rapid VKA reversal before an urgent surgical or invasive procedure. We randomly assigned patients in a 1: 1 ratio to receive vitamin K concomitant with a single dose of either 4F-PCC (Beriplex/Kcentra/Confidex; CSL Behring, Marburg, Germany) or plasma, with dosing based on international normalised ratio (INR) and weight. The primary endpoint was effective haemostasis, and the co-primary endpoint was rapid INR reduction (<= 1.3 at 0.5 h after infusion end). The analyses were intended to evaluate, in a hierarchical fashion, first non-inferiority (lower limit 95% CI greater than -10% for group difference) for both endpoints, then superiority (lower limit 95% CI > 0%) if non-inferiority was achieved. Adverse events and serious adverse events were reported to days 10 and 45, respectively. This trial is registered at ClinicalTrials.gov, number NCT00803101. Findings 181 patients were randomised (4F-PCC n=90; plasma n=91). The intention-to-treat efficacy population comprised 168 patients (4F-PCC, n=87; plasma, n=81). Effective haemostasis was achieved in 78 (90%) patients in the 4F-PCC group compared with 61 (75%) patients in the plasma group, demonstrating both non-inferiority and superiority of 4F-PCC over plasma (difference 14.3%, 95% CI 2.8-25.8). Rapid INR reduction was achieved in 48 (55%) patients in the 4F-PCC group compared with eight (10%) patients in the plasma group, demonstrating both non-inferiority and superiority of 4F-PCC over plasma (difference 45.3%, 95% CI 31.9-56.4). The safety profile of 4F-PCC was generally similar to that of plasma; 49 (56%) patients receiving 4F-PCC had adverse events compared with 53 (60%) patients receiving plasma. Adverse events of interest were thromboembolic adverse events (six [7%] patients receiving 4F-PCC vs seven [8%] patients receiving plasma), fluid overload or similar cardiac events (three [3%] patients vs 11 [13%] patients), and late bleeding events (three [3%] patients vs four [5%] patients). Interpretation 4F-PCC is non-inferior and superior to plasma for rapid INR reversal and effective haemostasis in patients needing VKA reversal for urgent surgical or invasive procedures. C1 [Goldstein, Joshua N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Refaai, Majed A.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Milling, Truman J., Jr.] Univ Med Ctr Brackenridge, Seton UT Southwestern Clin Res Inst Austin, Dell Childrens Med Ctr, Austin, TX USA. [Lewis, Brandon] Texas A&M Hlth Sci Ctr, St Joseph Reg Hlth Ctr, Bryan, College Stn, TX USA. [Goldberg-Alberts, Robert; Hug, Bruce A.] CSL Behring LLC, King Of Prussia, PA USA. [Sarode, Ravi] UT Southwestern Med Ctr, Dallas, TX USA. RP Goldstein, JN (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA. EM jgoldstein@mgh.harvard.edu RI Goldstein, Joshua/H-8953-2016 FU CSL Behring FX Funding CSL Behring. NR 29 TC 64 Z9 64 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD MAY 23 PY 2015 VL 385 IS 9982 BP 2077 EP 2087 DI 10.1016/S0140-6736(14)61685-8 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CI7XK UT WOS:000354979100027 PM 25728933 ER PT J AU Khor, B Gagnon, JD Goel, G Roche, MI Conway, KL Tran, K Aldrich, LN Sundberg, TB Paterson, AM Mordecai, S Dombkowski, D Schirmer, M Tan, PH Bhan, AK Roychoudhuri, R Restifo, NP O'Shea, JJ Medoff, BD Shamji, AF Schreiber, SL Sharpe, AH Shaw, SY Xavier, RJ AF Khor, Bernard Gagnon, John D. Goel, Gautam Roche, Marly I. Conway, Kara L. Tran, Khoa Aldrich, Leslie N. Sundberg, Thomas B. Paterson, Alison M. Mordecai, Scott Dombkowski, David Schirmer, Melanie Tan, Pauline H. Bhan, Atul K. Roychoudhuri, Rahul Restifo, Nicholas P. O'Shea, John J. Medoff, Benjamin D. Shamji, Alykhan F. Schreiber, Stuart L. Sharpe, Arlene H. Shaw, Stanley Y. Xavier, Ramnik J. TI The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells SO ELIFE LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; PATHOGENIC T(H)17 CELLS; RETINOIC-ACID; TRANSCRIPTIONAL SIGNATURE; FOXP3 EXPRESSION; GENE-EXPRESSION; SMALL MOLECULES; NUCLEAR FACTOR; DOWN-SYNDROME; REG-CELLS AB The balance between Th17 and T regulatory (T-reg) cells critically modulates immune homeostasis, with an inadequate Treg response contributing to inflammatory disease. Using an unbiased chemical biology approach, we identified a novel role for the dual specificity tyrosinephosphorylation-regulated kinase DYRK1A in regulating this balance. Inhibition of DYRK1A enhances Treg differentiation and impairs Th17 differentiation without affecting known pathways of T-reg/Th17 differentiation. Thus, DYRK1A represents a novel mechanistic node at the branch point between commitment to either Treg or Th17 lineages. Importantly, both Treg cells generated using the DYRK1A inhibitor harmine and direct administration of harmine itself potently attenuate inflammation in multiple experimental models of systemic autoimmunity and mucosal inflammation. Our results identify DYRK1A as a physiologically relevant regulator of T-reg cell differentiation and suggest a broader role for other DYRK family members in immune homeostasis. These results are discussed in the context of human diseases associated with dysregulated DYRK activity. C1 [Khor, Bernard; Conway, Kara L.; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA. [Khor, Bernard; Conway, Kara L.; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Study Inflammatory Bowel Dis, Boston, MA USA. [Khor, Bernard; Goel, Gautam; Conway, Kara L.; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA USA. [Khor, Bernard; Gagnon, John D.; Conway, Kara L.; Aldrich, Leslie N.; Sundberg, Thomas B.; Schirmer, Melanie; Shamji, Alykhan F.; Schreiber, Stuart L.; Xavier, Ramnik J.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Khor, Bernard; Mordecai, Scott; Dombkowski, David; Bhan, Atul K.] Massachusetts Gen Hosp, Pathol Serv, Boston, MA 02114 USA. [Roche, Marly I.; Medoff, Benjamin D.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. [Tran, Khoa; Tan, Pauline H.; Shaw, Stanley Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA. [Aldrich, Leslie N.; Schreiber, Stuart L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA. [Paterson, Alison M.; Sharpe, Arlene H.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA. [Paterson, Alison M.; Sharpe, Arlene H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Roychoudhuri, Rahul; Restifo, Nicholas P.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [O'Shea, John J.] NIAMSD, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA. RP Xavier, RJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA. EM xavier@molbio.mgh.harvard.edu RI Roychoudhuri, Rahul/A-7442-2010; OI Roychoudhuri, Rahul/0000-0002-5392-1853; Gagnon, John/0000-0001-6208-5781; Schirmer, Melanie/0000-0001-6456-3679; Khor, Bernard/0000-0003-4689-5092; Restifo, Nicholas P./0000-0003-4229-4580 NR 84 TC 5 Z9 5 U1 0 U2 0 PU ELIFE SCIENCES PUBLICATIONS LTD PI CAMBRIDGE PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND SN 2050-084X J9 ELIFE JI eLife PD MAY 22 PY 2015 VL 4 AR e05920 DI 10.7554/eLife.05920 PG 27 WC Biology SC Life Sciences & Biomedicine - Other Topics GA DJ5QI UT WOS:000374264300001 ER PT J AU de Figueiredo, ASP Salmon, AB Bruno, F Jimenez, F Martinez, HG Halade, GV Ahuja, SS Clark, RA DeFronzo, RA Abboud, HE El Jamali, A AF de Figueiredo, Alvaro Souto Padron Salmon, Adam B. Bruno, Francesca Jimenez, Fabio Martinez, Herman G. Halade, Ganesh V. Ahuja, Seema S. Clark, Robert A. DeFronzo, Ralph A. Abboud, Hanna E. El Jamali, Amina TI Nox2 Mediates Skeletal Muscle Insulin Resistance Induced by a High Fat Diet SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NADPH OXIDASE ACTIVITY; ELECTRON-TRANSPORT; DIABETES-MELLITUS; OXIDATIVE STRESS; PLASMA-MEMBRANE; NAD(P)H OXIDASE; L6 MYOTUBES; GLUCOSE; GLUT4; DYSFUNCTION AB Inflammation and oxidative stress through the production of reactive oxygen species (ROS) are consistently associated with metabolic syndrome/type 2 diabetes. Although the role of Nox2, a major ROS-generating enzyme, is well described in host defense and inflammation, little is known about its potential role in insulin resistance in skeletal muscle. Insulin resistance induced by a high fat diet was mitigated in Nox2-null mice compared with wild-type mice after 3 or 9 months on the diet. High fat feeding increased Nox2 expression, superoxide production, and impaired insulin signaling in skeletal muscle tissue of wild-type mice but not in Nox2-null mice. Exposure of C2C12 cultured myotubes to either high glucose concentration, palmitate, or H2O2 decreases insulin-induced Akt phosphorylation and glucose uptake. Pretreatment with catalase abrogated these effects, indicating a key role for H2O2 in mediating insulin resistance. Down-regulation of Nox2 in C2C12 cells by shRNA prevented insulin resistance induced by high glucose or palmitate but not H2O2. These data indicate that increased production of ROS in insulin resistance induced by high glucose in skeletal muscle cells is a consequence of Nox2 activation. This is the first report to show that Nox2 is a key mediator of insulin resistance in skeletal muscle. C1 [de Figueiredo, Alvaro Souto Padron; Bruno, Francesca; Jimenez, Fabio; Martinez, Herman G.; Halade, Ganesh V.; Ahuja, Seema S.; Clark, Robert A.; DeFronzo, Ralph A.; Abboud, Hanna E.; El Jamali, Amina] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Salmon, Adam B.] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Salmon, Adam B.; Ahuja, Seema S.; Clark, Robert A.; DeFronzo, Ralph A.; Abboud, Hanna E.] South Texas Vet Hlth Care Syst, Audie L Murphy Hosp, San Antonio, TX 78229 USA. RP El Jamali, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM AkoulouzeBik@uthscsa.edu RI Regan, Clinton/E-6250-2012 FU National Institutes of Health [P30 CA054174, P30 AG013319, P01 AG019316] FX The confocal microscopy studies were performed in the Institutional Optical Imaging Facility of the University of Texas Health Science Center at San Antonio, which is supported by National Institutes of Health Grants P30 CA054174 (Cancer Therapy and Research Center), P30 AG013319 (Nathan Shock Center), and P01 AG019316 (Aging, Oxidative Stress, and Cell Death). We thank Drs. Alain Virion for helpful discussions, Dr. John Cornell for insightful advice on statistical analysis, Dr. James Lechleiter for expert guidance on the confocal microscope image acquisition and analysis, and Yimin Wu, Maria Gamez, and Jacob Crandall for expert technical assistance. NR 48 TC 10 Z9 10 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 22 PY 2015 VL 290 IS 21 BP 13427 EP 13439 DI 10.1074/jbc.M114.626077 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CI7WL UT WOS:000354975700038 ER PT J AU Rotem, A Ram, O Shoresh, N Sperling, RA Schnall-Levin, M Zhang, HD Basu, A Bernstein, BE Weitz, DA AF Rotem, Assaf Ram, Oren Shoresh, Noam Sperling, Ralph A. Schnall-Levin, Michael Zhang, Huidan Basu, Anindita Bernstein, Bradley E. Weitz, David A. TI High-Throughput Single-Cell Labeling (Hi-SCL) for RNA-Seq Using Drop-Based Microfluidics SO PLOS ONE LA English DT Article ID EMBRYONIC STEM-CELLS; HETEROGENEITY; SURFACTANTS; EMULSIONS; EVOLUTION; CYTOMETRY; IMMUNE; CANCER; GENES; MASS AB The importance of single-cell level data is increasingly appreciated, and significant advances in this direction have been made in recent years. Common to these technologies is the need to physically segregate individual cells into containers, such as wells or chambers of a micro-fluidics chip. High-throughput Single-Cell Labeling (Hi-SCL) in drops is a novel method that uses drop-based libraries of oligonucleotide barcodes to index individual cells in a population. The use of drops as containers, and a microfluidics platform to manipulate them en-masse, yields a highly scalable methodological framework. Once tagged, labeled molecules from different cells may be mixed without losing the cell-of-origin information. Here we demonstrate an application of the method for generating RNA-sequencing data for multiple individual cells within a population. Barcoded oligonucleotides are used to prime cDNA synthesis within drops. Barcoded cDNAs are then combined and subjected to second generation sequencing. The data are deconvoluted based on the barcodes, yielding single-cell mRNA expression data. In a proof-of-concept set of experiments we show that this method yields data comparable to other existing methods, but with unique potential for assaying very large numbers of cells. C1 [Rotem, Assaf; Sperling, Ralph A.; Zhang, Huidan; Basu, Anindita; Weitz, David A.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA. [Rotem, Assaf; Sperling, Ralph A.; Zhang, Huidan; Basu, Anindita; Weitz, David A.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. [Rotem, Assaf; Ram, Oren; Shoresh, Noam; Schnall-Levin, Michael; Basu, Anindita; Bernstein, Bradley E.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Bernstein, Bradley E.] Howard Hughes Med Inst, Chevy Chase, MD USA. [Ram, Oren; Bernstein, Bradley E.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Ram, Oren; Bernstein, Bradley E.] Harvard Univ, Sch Med, Boston, MA USA. [Bernstein, Bradley E.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Bernstein, Bradley E.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA. RP Rotem, A (reprint author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA. EM acerotem@gmail.com RI Zhang, Huidan/K-8399-2015 FU Harvard Materials Science Research and Engineering Center [DMR-0820484]; National Science Foundation [DMR-1310266]; Defense Advanced Research Projects Agency [HR0011-11-C-0093]; German Research Foundation [SP 1282/1-1]; National Heart, Lung and Blood Institute [U01 HL100395]; National Human Genome Research Institute [P50HG006193] FX Harvard Materials Science Research and Engineering Center (DMR-0820484), National Science Foundation (DMR-1310266), Defense Advanced Research Projects Agency (HR0011-11-C-0093), German Research Foundation (SP 1282/1-1), the National Heart, Lung and Blood Institute (U01 HL100395), and the National Human Genome Research Institute (P50HG006193). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 18 Z9 18 U1 4 U2 26 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 22 PY 2015 VL 10 IS 5 AR e0116328 DI 10.1371/journal.pone.0116328 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CI7GR UT WOS:000354931700001 PM 26000628 ER PT J AU Guo, W Hight, AE Chen, JX Klapoetke, NC Hancock, KE Shinn-Cunningham, BG Boyden, ES Lee, DJ Polley, DB AF Guo, Wei Hight, Ariel E. Chen, Jenny X. Klapoetke, Nathan C. Hancock, Kenneth E. Shinn-Cunningham, Barbara G. Boyden, Edward S. Lee, Daniel J. Polley, Daniel B. TI Hearing the light: neural and perceptual encoding of optogenetic stimulation in the central auditory pathway SO SCIENTIFIC REPORTS LA English DT Article ID BRAIN-STEM IMPLANT; INFERIOR COLLICULUS; FUNCTIONAL-ORGANIZATION; SPEECH RECOGNITION; SENSORY RESPONSES; COCHLEAR IMPLANTS; VISUAL-CORTEX; MOUSE; NEURONS; ACTIVATION AB Optogenetics provides a means to dissect the organization and function of neural circuits. Optogenetics also offers the translational promise of restoring sensation, enabling movement or supplanting abnormal activity patterns in pathological brain circuits. However, the inherent sluggishness of evoked photocurrents in conventional channelrhodopsins has hampered the development of optoprostheses that adequately mimic the rate and timing of natural spike patterning. Here, we explore the feasibility and limitations of a central auditory optoprosthesis by photoactivating mouse auditory midbrain neurons that either express channelrhodopsin-2 (ChR2) or Chronos, a channelrhodopsin with ultra-fast channel kinetics. Chronos-mediated spike fidelity surpassed ChR2 and natural acoustic stimulation to support a superior code for the detection and discrimination of rapid pulse trains. Interestingly, this midbrain coding advantage did not translate to a perceptual advantage, as behavioral detection of midbrain activation was equivalent with both opsins. Auditory cortex recordings revealed that the precisely synchronized midbrain responses had been converted to a simplified rate code that was indistinguishable between opsins and less robust overall than acoustic stimulation. These findings demonstrate the temporal coding benefits that can be realized with next-generation channelrhodopsins, but also highlight the challenge of inducing variegated patterns of forebrain spiking activity that support adaptive perception and behavior. C1 [Guo, Wei; Hight, Ariel E.; Chen, Jenny X.; Hancock, Kenneth E.; Lee, Daniel J.; Polley, Daniel B.] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA. [Guo, Wei; Shinn-Cunningham, Barbara G.; Polley, Daniel B.] Boston Univ, Ctr Computat Neurosci & Neural Technol, Boston, MA 02215 USA. [Hight, Ariel E.] Harvard Univ, Med Sch HMS, Program Speech Hearing Biosci & Technol, Boston, MA 02115 USA. [Chen, Jenny X.] HMS, New Pathway MD Program, Boston, MA 02115 USA. [Klapoetke, Nathan C.; Boyden, Edward S.] MIT, Synthet Neurobiol Grp, MIT Media Lab, Cambridge, MA 02139 USA. [Klapoetke, Nathan C.; Boyden, Edward S.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA. [Hancock, Kenneth E.; Lee, Daniel J.; Polley, Daniel B.] HMS, Dept Otol & Laryngol, Boston, MA 02114 USA. [Shinn-Cunningham, Barbara G.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. RP Guo, W (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA. EM weiguo@bu.edu; daniel_polley@meei.harvard.edu FU NIH [R21012894, P30 DC5029, T32 DC000038]; HHMI international student research fellowship FX This work is supported by NIH grants R21012894 (D.P.), P30 DC5029, T32 DC000038 (A.E.H.), and an HHMI international student research fellowship (W.G.) NR 60 TC 7 Z9 8 U1 1 U2 16 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD MAY 22 PY 2015 VL 5 AR 10319 DI 10.1038/srep10319 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ5GX UT WOS:000355516800001 PM 26000557 ER PT J AU Burton, MJ Curtis, JR Yang, S Chen, L Singh, JA Mikuls, TR Winthrop, KL Baddley, JW AF Burton, Mary Jane Curtis, Jeffrey R. Yang, Shuo Chen, Lang Singh, Jasvinder A. Mikuls, Ted R. Winthrop, Kevin L. Baddley, John W. TI Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study SO ARTHRITIS RESEARCH & THERAPY LA English DT Article ID LONG-TERM SAFETY; IMMUNOSUPPRESSIVE THERAPY; POSITIVE PATIENTS; OCCULT CARRIERS; REACTIVATION; RECOMMENDATIONS; HEPATOTOXICITY; MANAGEMENT; ANTIGEN; RISK AB Introduction: We evaluated the safety of current treatment regimens for patients with RA and HBV in a large US cohort. Methods: We identified biologic and nonbiologic treatment episodes of RA patients using 1997 to 2011 national data from the US Veterans Health Administration. Eligible episodes had evidence of HBV infection (HBV surface antigen, HBV core antibody, HBV e-antibody and/or HBV DNA) and had a baseline alanine aminotransferase (ALT) < 1.5 times the upper limit of laboratory normal within 90 days prior to initiation of a new biologic or nonbiologic DMARD. The main outcome of interest was hepatotoxicity, defined as ALT elevation > 100 IU/mL. Results were reported as the cumulative incidence of treatment episodes achieving hepatotoxicity at 3, 6 and 12 months post biologic exposure. Results: Five hundred sixty-six unique RA patients with HBV contributed 959 treatment episodes. Mean age was 62.1 +/- 10.3 years; 91.8% were male. Hepatotoxicity was uncommon, with 26 events identified among 959 episodes (2.7%) within 12 months. Hepatotoxicity was comparable between biologic and nonbiologic DMARDs (2.6% vs. 2.8%, P = 0.87). The median time between HBV screening and starting a new RA drug was 504 days (IQR 144, 1,163). Follow-up HBV testing occurred among 14 hepatotoxicity episodes (53.8%) at a median of 202 days (IQR 82, 716) from the date of ALT elevation. A total of 146 (15.2%) treatment episodes received at least one test for HBV DNA at any point in the observation period. Conclusions: Among US veterans with RA and HBV the risk of hepatotoxicity is low (2.7%), and comparable between biologic and nonbiologic DMARDS (2.8% vs. 2.6%, P = 0.87). HBV testing associated with DMARD initiation or hepatotoxicity was infrequent. C1 [Burton, Mary Jane] GV Sonny Montgomery VA Med Ctr, Jackson, MS 39216 USA. [Burton, Mary Jane] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. [Curtis, Jeffrey R.; Yang, Shuo; Chen, Lang; Singh, Jasvinder A.; Baddley, John W.] Birmingham VAMC, Birmingham, AL 35233 USA. [Curtis, Jeffrey R.; Yang, Shuo; Chen, Lang; Singh, Jasvinder A.; Baddley, John W.] Univ Alabama Birmingham, Birmingham, AL 35233 USA. [Mikuls, Ted R.] UNMC, Omaha VAMC, Omaha, NE 68105 USA. [Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. RP Burton, MJ (reprint author), GV Sonny Montgomery VA Med Ctr, 1500 E Woodrow Wilson Ave, Jackson, MS 39216 USA. EM Mary.burton2@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; Bristol Myers Squibb; Veterans Affairs Clinical Science Research and Development (VA CSRD) [1IK2CX00536]; Agency for Healthcare Research and Quality (AHRQ) [R01 HS018517]; Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34 AR062891]; National Institute of Aging (NIA) [U01 AG018947]; National Cancer Institute (NCI) [U10 CA149950]; Patient-Centered Outcomes Research Institute (PCORI) [CE-1304-6631]; VA CSR&D Merit Review Awards FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development as well as an investigator-initiated grant from Bristol Myers Squibb. Dr. Burton's work was supported by Veterans Affairs Clinical Science Research and Development (VA CSR&D) (Grant 1IK2CX00536, PI-Burton). Dr. Curtis was supported by the Agency for Healthcare Research and Quality (AHRQ) (R01 HS018517). Dr. Singh is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging (NIA) U01 AG018947, National Cancer Institute (NCI) U10 CA149950, and research contract CE-1304-6631 from the Patient-Centered Outcomes Research Institute (PCORI). Dr. Mikuls is supported by VA CSR&D Merit Review Awards. Funding organizations did not contribute to study design, data collection, data analysis and interpretation, or manuscript preparation and submission. NR 35 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD MAY 22 PY 2015 VL 17 AR 136 DI 10.1186/s13075-015-0628-z PG 9 WC Rheumatology SC Rheumatology GA CI7UU UT WOS:000354971100001 PM 26001631 ER PT J AU Wyllie, E Rincon, SP Pierce, VM AF Wyllie, Elaine Rincon, Sandra P. Pierce, Virginia M. TI Case 16-2015: A 9-Year-Old Girl with Loss of Consciousness and Seizures SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID CAT-SCRATCH DISEASE; BARTONELLA-HENSELAE DNA; EHLERS-DANLOS-SYNDROME; STATUS EPILEPTICUS; ACUTE ENCEPHALOPATHY; CHILDREN; ENCEPHALITIS; DIAGNOSIS; MANAGEMENT; EPIDEMIOLOGY C1 [Wyllie, Elaine] Cleveland Clin, Epilepsy Ctr, Neurol Inst, Cleveland, OH 44106 USA. [Wyllie, Elaine] Cleveland Clin, Inst Pediat, Cleveland, OH USA. [Wyllie, Elaine] Case Western Reserve Univ, Cleveland Clin Lerner, Coll Med, Cleveland, OH 44106 USA. [Rincon, Sandra P.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Pierce, Virginia M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Pierce, Virginia M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Rincon, Sandra P.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Pierce, Virginia M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Pierce, Virginia M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. RP Wyllie, E (reprint author), Cleveland Clin, Epilepsy Ctr, Neurol Inst, Cleveland, OH 44106 USA. NR 47 TC 0 Z9 0 U1 2 U2 3 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 21 PY 2015 VL 372 IS 21 BP 2050 EP 2058 DI 10.1056/NEJMcpc1501149 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CI5PD UT WOS:000354809300013 PM 25992750 ER PT J AU Grytdal, SP Rimland, D Shirley, SH Rodriguez-Barradas, MC Goetz, MB Brown, ST Lucero-Obusan, C Holodniy, M Graber, C Parashar, U Vinje, J Lopman, B AF Grytdal, Scott P. Rimland, David Shirley, S. Hannah Rodriguez-Barradas, Maria C. Goetz, Matthew Bidwell Brown, Sheldon T. Lucero-Obusan, Cynthia Holodniy, Mark Graber, Christopher Parashar, Umesh Vinje, Jan Lopman, Ben TI Incidence of Medically-Attended Norovirus-Associated Acute Gastroenteritis in Four Veteran's Affairs Medical Center Populations in the United States, 2011-2012 SO PLOS ONE LA English DT Article ID INFECTIOUS INTESTINAL DISEASE; SURVEILLANCE; COMMUNITY; ENGLAND; DEATHS AB An estimated 179 million acute gastroenteritis (AGE) illnesses occur annually in the United States. The role of noroviruses in hospital-related AGE has not been well-documented in the U. S. We estimated the population incidence of community-acquired outpatient and inpatient norovirus AGE encounters, as well as hospital-acquired inpatient norovirus AGE among inpatients at four Veterans Affairs (VA) Medical Centers (VAMCs). Fifty (4%) of 1,160 stool specimens collected <= 7 days from symptom onset tested positive for norovirus. During a one year period, the estimated incidence of outpatient, community-and hospital-acquired inpatient norovirus AGE was 188 cases, 11 cases, and 54 cases/100,000 patients, respectively. This study demonstrates the incidence of outpatient and community- and hospital-acquired inpatient norovirus AGE among the VA population seeking care at these four VAMCs. C1 [Grytdal, Scott P.; Shirley, S. Hannah; Parashar, Umesh; Vinje, Jan; Lopman, Ben] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Shirley, S. Hannah] Atlanta Res & Educ Fdn, Decatur, GA USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Goetz, Matthew Bidwell; Graber, Christopher] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell; Graber, Christopher] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA. [Lucero-Obusan, Cynthia; Holodniy, Mark] VA Off Publ Hlth, Washington, DC USA. [Lucero-Obusan, Cynthia; Holodniy, Mark] VA Off Publ Hlth, Palo Alto, CA USA. [Holodniy, Mark] Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Grytdal, SP (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. EM spgrytdal@cdc.gov OI Goetz, Matthew/0000-0003-4542-992X FU Centers for Disease Control and Prevention FX Funding provided by Centers for Disease Control and Prevention. The funders participated in the study design, data analysis, decision to publish, and preparation of the manuscript. NR 17 TC 1 Z9 1 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 21 PY 2015 VL 10 IS 5 AR e0126733 DI 10.1371/journal.pone.0126733 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK7VW UT WOS:000356444000030 PM 25996826 ER PT J AU Viollet, L Glusman, G Murphy, KJ Newcomb, TM Reyna, SP Sweney, M Nelson, B Andermann, F Andermann, E Acsadi, G Barbano, RL Brown, C Brunkow, ME Chugani, HT Cheyette, SR Collins, A DeBrosse, SD Galas, D Friedman, J Hood, L Huff, C Jorde, LB King, MD LaSalle, B Leventer, RJ Lewelt, AJ Massart, MB Merida, MR Ptacek, LJ Roach, JC Rust, RS Renault, F Sanger, TD de Menezes, MAS Tennyson, R Uldall, P Zhang, Y Zupanc, M Xin, WN Silver, K Swoboda, KJ AF Viollet, Louis Glusman, Gustavo Murphy, Kelley J. Newcomb, Tara M. Reyna, Sandra P. Sweney, Matthew Nelson, Benjamin Andermann, Frederick Andermann, Eva Acsadi, Gyula Barbano, Richard L. Brown, Candida Brunkow, Mary E. Chugani, Harry T. Cheyette, Sarah R. Collins, Abigail DeBrosse, Suzanne D. Galas, David Friedman, Jennifer Hood, Lee Huff, Chad Jorde, Lynn B. King, Mary D. LaSalle, Bernie Leventer, Richard J. Lewelt, Aga J. Massart, Mylynda B. Merida, Mario R., II Ptacek, Louis J. Roach, Jared C. Rust, Robert S. Renault, Francis Sanger, Terry D. de Menezes, Marcio A. Sotero Tennyson, Rachel Uldall, Peter Zhang, Yue Zupanc, Mary Xin, Winnie Silver, Kenneth Swoboda, Kathryn J. TI Alternating Hemiplegia of Childhood: Retrospective Genetic Study and Genotype-Phenotype Correlations in 187 Subjects from the US AHCF Registry SO PLOS ONE LA English DT Article ID ONSET DYSTONIA-PARKINSONISM; GLUTAMATE TRANSPORTER EAAT1; DE-NOVO MUTATIONS; ATP1A3 MUTATION; CLINICAL-MANIFESTATIONS; ALPHA-3 ISOFORM; NA+ INTERACTION; K+-ATPASE; SPECTRUM; AFFINITY AB Mutations in ATP1A3 cause Alternating Hemiplegia of Childhood (AHC) by disrupting function of the neuronal Na+/K+ ATPase. Published studies to date indicate 2 recurrent mutations, D801N and E815K, and a more severe phenotype in the E815K cohort. We performed mutation analysis and retrospective genotype-phenotype correlations in all eligible patients with AHC enrolled in the US AHC Foundation registry from 1997-2012. Clinical data were abstracted from standardized caregivers' questionnaires and medical records and confirmed by expert clinicians. We identified ATP1A3 mutations by Sanger and whole genome sequencing, and compared phenotypes within and between 4 groups of subjects, those with D801N, E815K, other ATP1A3 or no ATP1A3 mutations. We identified heterozygous ATP1A3 mutations in 154 of 187 (82%) AHC patients. Of 34 unique mutations, 31 (91%) are missense, and 16 (47%) had not been previously reported. Concordant with prior studies, more than 2/3 of all mutations are clustered in exons 17 and 18. Of 143 simplex occurrences, 58 had D801N (40%), 38 had E815K (26%) and 11 had G937R (8%) mutations. Patients with an E815K mutation demonstrate an earlier age of onset, more severe motor impairment and a higher prevalence of status epilepticus. This study further expands the number and spectrum of ATP1A3 mutations associated with AHC and confirms a more deleterious effect of the E815K mutation on selected neurologic outcomes. However, the complexity of the disorder and the extensive phenotypic variability among subgroups merits caution and emphasizes the need for further studies. C1 [Viollet, Louis; Murphy, Kelley J.; Newcomb, Tara M.; Reyna, Sandra P.; Sweney, Matthew; Nelson, Benjamin; Tennyson, Rachel; Swoboda, Kathryn J.] Univ Utah, Dept Neurol, Pediat Motor Disorders Res Program, Salt Lake City, UT 84112 USA. [Viollet, Louis; Murphy, Kelley J.; Newcomb, Tara M.; Reyna, Sandra P.; Sweney, Matthew; Nelson, Benjamin; Tennyson, Rachel; Swoboda, Kathryn J.] Univ Utah, Dept Pediat, Pediat Motor Disorders Res Program, Salt Lake City, UT USA. [Glusman, Gustavo; Brunkow, Mary E.; Hood, Lee; Roach, Jared C.] Inst Syst Biol, Seattle, WA USA. [Andermann, Frederick; Andermann, Eva] McGill Univ, Montreal Neurol Inst & Hosp, Neurogenet Unit, Montreal, PQ, Canada. [Acsadi, Gyula] Connecticut Childrens Med Ctr, Dept Pediat, Hartford, CT USA. [Acsadi, Gyula] Connecticut Childrens Med Ctr, Dept Neurol, Hartford, CT USA. [Barbano, Richard L.] Univ Connecticut, Sch Med, Hartford, CT 06112 USA. [Brown, Candida] Univ Rochester, Sch Med, Dept Neurol, Rochester, NY USA. [Chugani, Harry T.] Affiliate Stanford Hlth Alliance, Diablo Valley Child Neurol, Pleasant Hill, CA USA. [Cheyette, Sarah R.] Wayne State Univ, Childrens Hosp Michigan, Div Pediat Neurol, Detroit, MI USA. [Collins, Abigail] Palo Alto Med Fdn Redwood City Clin, Dept Child Neurol, Redwood City, CA USA. [DeBrosse, Suzanne D.] Univ Colorado Hosp, Childrens Hosp Colorado, Dept Pediat Neurol, Aurora, CO USA. [DeBrosse, Suzanne D.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA. [Galas, David] Case Western Reserve Univ, Dept Genome Sci Pediat & Neurol, Cleveland, OH 44106 USA. [Friedman, Jennifer] Pacific Northwest Diabet Res Inst, Seattle, WA USA. [Friedman, Jennifer] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Huff, Chad] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA. [Jorde, Lynn B.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA. [King, Mary D.] Univ Utah, Dept Human Genet, Salt Lake City, UT USA. [King, Mary D.] Univ Coll Dublin, Sch Med & Med Sci, Dept Pediat, Dublin 2, Ireland. [LaSalle, Bernie] Univ Coll Dublin, Sch Med & Med Sci, Dept Neurol, Dublin 2, Ireland. [Leventer, Richard J.] Univ Utah, Sch Med, Dept Biomed Informat, Salt Lake City, UT USA. [Lewelt, Aga J.] Univ Melbourne, Royal Childrens Hosp, Childrens Neurosci Ctr, Murdoch Childrens Res Inst,Dept Paediat, Parkville, Vic 3052, Australia. [Massart, Mylynda B.] Univ Florida, Coll Med, Dept Pediat, Jacksonville, FL USA. [Merida, Mario R., II] Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA USA. [Ptacek, Louis J.] Stevens Henager Coll, Salt Lake City, UT USA. [Rust, Robert S.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Renault, Francis] Univ Virginia UVA Hlth Syst, Ctr Med Eth & Humanities Med, Charlottesville, VA USA. [Sanger, Terry D.] Hop Armand Trousseau, AP HP, Dept Neurophysiol, Paris, France. [de Menezes, Marcio A. Sotero] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA. [Uldall, Peter] Swedish Neurosci Inst, Swedish Med Ctr, Seattle, WA USA. [Zhang, Yue] Univ Copenhagen, Rigshosp, Juliane Marie Ctr, Dept Paediat & Adolescent Med, DK-2100 Copenhagen, Denmark. [Zupanc, Mary] Univ Utah, Study Design & Biostat Ctr, Salt Lake City, UT USA. [Zupanc, Mary] Univ Calif, Childrens Hosp, Dept Neurol, Orange, CA USA. [Xin, Winnie] Univ Calif, Dept Pediat, Orange, CA USA. [Xin, Winnie] Massachusetts Gen Hosp, Ctr Human Genet Res, Dept Neurol, Boston, MA 02114 USA. [Silver, Kenneth] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA. [Silver, Kenneth] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA. [Silver, Kenneth] Comer Childrens Hosp, Chicago, IL USA. RP Swoboda, KJ (reprint author), Univ Utah, Dept Neurol, Pediat Motor Disorders Res Program, Salt Lake City, UT 84112 USA. EM swoboda@genetics.utah.edu OI Glusman, Gustavo/0000-0001-8060-5955 FU Alternating Hemiplegia of Childhood Foundation; University of Luxembourg-Institute for Systems Biology Strategic Partnership; Luxembourg Centre for Systems Biomedicine; National Institute of General Medical Sciences Center for Systems Biology [P50 GM076547] FX The Alternating Hemiplegia of Childhood Foundation (http://ahckids.org/). Funds were received by KJS. The association Genetique Actions (http://www.genetique-actions.fr/). Funds were received by LV. The University of Luxembourg-Institute for Systems Biology Strategic Partnership (http://www.partnerships.systemsbiology.net/517/). Funds were received by LH. The Luxembourg Centre for Systems Biomedicine (http://wwwfr.uni.lu/lcsb). Funds were received by LH. The National Institute of General Medical Sciences Center for Systems Biology (http://www.nigms.nih.gov/research/specificareas/sysbio/Pages/default.as px) P50 GM076547. Funds were received by LH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 52 TC 10 Z9 12 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 21 PY 2015 VL 10 IS 5 AR e0127045 DI 10.1371/journal.pone.0127045 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK7VW UT WOS:000356444000041 PM 25996915 ER PT J AU Yeh, RW Cohen, DJ Mauri, L AF Yeh, Robert W. Cohen, David J. Mauri, Laura TI Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy SO EUROPEAN HEART JOURNAL LA English DT Editorial Material ID PERCUTANEOUS CORONARY INTERVENTION; ELEVATION MYOCARDIAL-INFARCTION; DRUG-ELUTING STENTS; TRIAL; CLOPIDOGREL C1 [Yeh, Robert W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Cohen, David J.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Mauri, Laura] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA. RP Mauri, L (reprint author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA. EM lmauri1@partners.org NR 15 TC 3 Z9 3 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD MAY 21 PY 2015 VL 36 IS 20 BP 1216 EP 1218 DI 10.1093/eurheartj/ehv082 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CK4HW UT WOS:000356185900009 PM 25796054 ER PT J AU Veenstra, RG Flynn, R Kreymborg, K McDonald-Hyman, C Saha, A Taylor, PA Osborn, MJ Panoskaltsis-Mortari, A Schmitt-Graeff, A Lieberknect, E Murphy, WJ Serody, JS Munn, DH Freeman, GJ Allison, JP Mak, TW van den Brink, M Zeiser, R Blazar, BR AF Veenstra, Rachelle G. Flynn, Ryan Kreymborg, Katharina McDonald-Hyman, Cameron Saha, Asim Taylor, Patricia A. Osborn, Mark J. Panoskaltsis-Mortari, Angela Schmitt-Graeff, Annette Lieberknect, Elisabeth Murphy, William J. Serody, Jonathan S. Munn, David H. Freeman, Gordon J. Allison, James P. Mak, Tak W. van den Brink, Marcel Zeiser, Robert Blazar, Bruce R. TI B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality SO BLOOD LA English DT Article ID IFN-GAMMA; B7 FAMILY; IN-VIVO; ACTIVATION; RESPONSES; DIFFERENTIATION; BLOCKADE; MOLECULE; MEMBER AB Members of the B7 family have been shown to be important for regulating immune responses by providing either positive or negative costimulatory signals. The function of B7-H3 has been controversial. We show that B7-H3 is upregulated in graft-versus-host disease (GVHD) target organs, including the colon, liver, and lung. Infusion of allogeneic donor T cells into B7-H3(-/-) vs wild-type (WT) recipients resulted in increased GVHD lethality associated with increased T-cell proliferation, colonic inflammatory cytokines, and destruction of epithelial barriers. Allogeneic B7-H3(-/-) vs WT donor T cells also had increased T-cell proliferation and GVHD lethality associated with increased proliferation and cytokine secretion in the spleen, intraepithelial lymphocyte inflammatory cytokines, and intestinal permeability. Both resting and activated regulatory T cells (Tregs) lack B7-H3 messenger RNA. Consistent with these data, GVHD was augmented in recipients of B7-H3(-/-) Treg-depleted grafts. In two delayed lymphocyte infusion (DLI) models, T cells lacking B7-H3 are capable of providing graft-versus-leukemia (GVL) effects. We conclude that B7-H3 is responsible for providing a negative costimulatory signal. Our studies provide support for developing and testing new therapies directed toward the B7-H3 pathway, including approaches to augmenthost B7-H3 early after bone marrow transplantation to prevent GVHD and to develop potent antagonistic antibodies later after transplant to facilitate DLI-mediated GVL without GVHD complications. C1 [Veenstra, Rachelle G.; Flynn, Ryan; McDonald-Hyman, Cameron; Saha, Asim; Taylor, Patricia A.; Osborn, Mark J.; Panoskaltsis-Mortari, Angela; Blazar, Bruce R.] Univ Minnesota, Dept Pediat, Div Blood & Marrow Transplantat, Ctr Canc, Minneapolis, MN 55455 USA. [Kreymborg, Katharina; Allison, James P.; van den Brink, Marcel] Mem Sloan Kettering Canc Ctr, Dept Immunol & Med, New York, NY 10021 USA. [Schmitt-Graeff, Annette] Univ Freiburg, Med Ctr, Dept Pathol, Freiburg, Germany. [Lieberknect, Elisabeth; Zeiser, Robert] Univ Freiburg, Med Ctr, Dept Hematol & Oncol, Freiburg, Germany. [Murphy, William J.] Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA. [Serody, Jonathan S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA. [Munn, David H.] Med Coll Georgia, Dept Pediat, Immunotherapy Ctr, Augusta, GA 30912 USA. [Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Allison, James P.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA. [Mak, Tak W.] Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5S 1A1, Canada. RP Blazar, BR (reprint author), Univ Minnesota, Dept Pediat, MMC 109, Minneapolis, MN 55455 USA. EM blaza001@umn.edu FU National Institutes of Health from the National Heart, Lung, and Blood Institute [R01 HL56067]; National Institute of Allergy and Infectious Diseases [R01 AI 34495, P01 AI 056299, T32 AI 007313] FX This work was supported in part by National Institutes of Health grants R01 HL56067 from the National Heart, Lung, and Blood Institute, and R01 AI 34495, P01 AI 056299, and T32 AI 007313 from the National Institute of Allergy and Infectious Diseases. NR 25 TC 10 Z9 11 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD MAY 21 PY 2015 VL 125 IS 21 BP 3335 EP 3346 DI 10.1182/blood-2014-09-603357 PG 12 WC Hematology SC Hematology GA CJ7QF UT WOS:000355691700018 PM 25814530 ER PT J AU Underhill, M Berry, D Dalton, E Schienda, J Syngal, S AF Underhill, Meghan Berry, Donna Dalton, Emily Schienda, Jaclyn Syngal, Sapna TI Patient experiences living with pancreatic cancer risk SO HEREDITARY CANCER IN CLINICAL PRACTICE LA English DT Article DE Pancreatic cancer risk; Qualitative research; Patient reported experience ID HEREDITARY BREAST; COLORECTAL-CANCER; FAMILY-MEMBERS; RECEPTIVITY; SURVEILLANCE; PROGRAMS AB Background: Pancreatic cancer (PancCa) is recognized as a component of many well-described hereditary cancer syndromes. Minimal research has focused on patient needs and experiences living with this risk. Purpose: To understand the meaning and experience of living with familial PancCa risk and to explore experiences related to screening and prevention of PancCa. Methods: Participants underwent semi-structured, in-depth interviews. Adults without PancCa and who met familial or hereditary risk criteria were eligible. Thematic analysis was completed on the transcripts in order to identify patterns, consistencies, and differences. Narrative review of existing literature related to women living with hereditary breast and ovarian cancer (HBOC) risk was completed to explore similarities and differences between published findings and our current findings. Results: Nineteen individuals (9 male, 10 female) participated. Major themes addressed participants' family experiences with PancCa and PancCa death and the associated grief from the experiences. Family experiences impacted how participants interpreted and approached their own cancer risk and participated in the cancer screening program. Participants wanted to control their cancer risk and sought information and resources to prevent PancCa or PancCa related death. Distress related to risk was not described as constant but occurred around salient time points. Conclusion & future implications: Study results begin to describe the lived experience of individuals with PancCa risk. Through this research we have uncovered important variables to further understand, measure, and intervene upon in future research. Distress related to risk was not described as ongoing, but occurred around specific and salient time points that brought risk to the forefront. Individuals with familial PancCa risk may have a unique experience compared to other hereditary cancer syndromes due to the high mortality of the disease and uncertainty related to prevention and early detection outcomes. C1 [Underhill, Meghan; Berry, Donna; Schienda, Jaclyn; Syngal, Sapna] Dana Farber Canc Inst, Boston, MA 02115 USA. [Dalton, Emily] Dana Farber Canc Inst, Ambry Genet, Boston, MA 02115 USA. RP Underhill, M (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. EM Meghanl_underhill@dfci.harvard.edu FU Daisy Foundation's J. Patrick Bames Grants for Nursing Research and Evidence-Based Practice Projects [JPB-2011-65-A]; National Cancer Institute Cancer & Health Disparities Fellowship Funding [NCIU54CA156732]; NCI [K24113433, R01CA097075] FX The Daisy Foundation's J. Patrick Bames Grants for Nursing Research and Evidence-Based Practice Projects (JPB-2011-65-A); National Cancer Institute Cancer & Health Disparities Fellowship Funding (NCIU54CA156732), and NCI Grants K24113433 and R01CA097075. NR 28 TC 3 Z9 3 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1731-2302 EI 1897-4287 J9 HERED CANCER CLIN PR JI Hered. Cancer Clin. Pract. PD MAY 21 PY 2015 VL 13 AR 13 DI 10.1186/s13053-015-0034-1 PG 9 WC Oncology SC Oncology GA CJ9AF UT WOS:000355794000001 PM 26029287 ER PT J AU Weinberger, AD Gilmore, MS AF Weinberger, Ariel D. Gilmore, Michael S. TI A CRISPR View of Cleavage SO CELL LA English DT Editorial Material ID CAS SYSTEM; THERMOPHILUS; PROKARYOTES; COMPLEX AB Seminal studies showed that CRISPR-Cas systems provide adaptive immunity in prokaryotes and promising gene-editing tools from bacteria to humans. Yet, reports diverged on whether some CRISPR systems naturally target DNA or RNA. Here, Samai and colleagues unify the studies, showing that a single type III CRISPR-Cas system cleaves both DNA and RNA targets, independently. C1 [Weinberger, Ariel D.] Harvard Univ, Sch Med, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA. [Gilmore, Michael S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA. [Gilmore, Michael S.] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Boston, MA 02115 USA. RP Weinberger, AD (reprint author), Harvard Univ, Sch Med, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA. EM ariel.weinberger@wyss.harvard.edu FU NIAID NIH HHS [F32AI102520]; NIGMS NIH HHS [GM106337] NR 9 TC 1 Z9 1 U1 2 U2 26 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD MAY 21 PY 2015 VL 161 IS 5 BP 964 EP 966 DI 10.1016/j.cell.2015.05.003 PG 3 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CJ0GA UT WOS:000355152600005 PM 26000476 ER PT J AU Liu, JL Lee, J Hernandez, MAS Mazitschek, R Ozcan, U AF Liu, Junli Lee, Jaemin Hernandez, Mario Andres Salazar Mazitschek, Ralph Ozcan, Umut TI Treatment of Obesity with Celastrol SO CELL LA English DT Article ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; GLUCOSE-HOMEOSTASIS; LEPTIN RESISTANCE; ENERGY-BALANCE; ER STRESS; MICE; WEIGHT; GENE AB Despite all modern advances in medicine, an effective drug treatment of obesity has not been found yet. Discovery of leptin two decades ago created hopes for treatment of obesity. However, development of leptin resistance has been a big obstacle, mitigating a leptin-centric treatment of obesity. Here, by using in silico drug-screening methods, we discovered that Celastrol, a pentacyclic triterpene extracted from the roots of Tripterygium Wilfordi (thunder god vine) plant, is a powerful anti-obesity agent. Celastrol suppresses food intake, blocks reduction of energy expenditure, and leads to up to 45% weight loss in hyperleptinemic diet-induced obese (DIO) mice by increasing leptin sensitivity, but it is ineffective in leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mouse models. These results indicate that Celastrol is a leptin sensitizer and a promising agent for the pharmacological treatment of obesity. C1 [Liu, Junli; Lee, Jaemin; Hernandez, Mario Andres Salazar; Ozcan, Umut] Harvard Univ, Boston Childrens Hosp, Sch Med, Div Endocrinol, Boston, MA 02130 USA. [Mazitschek, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Mazitschek, Ralph] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA. RP Ozcan, U (reprint author), Harvard Univ, Boston Childrens Hosp, Sch Med, Div Endocrinol, Boston, MA 02130 USA. EM umut.ozcan@childrens.harvard.edu OI Lee, Jaemin/0000-0002-0224-7141 FU Department of Medicine, Boston Children's Hospital; National Institutes of Health [R01DK098496]; American Diabetes Association Career Development grant [7-09-CD-10]; Fidelity Biosciences Research Initiative FX We greatly appreciate the time of Morris F. White and Joseph A. Majzoub for critical reading of our manuscript and for their contributions and suggestions. We thank Serkan Cabi, Isin Cakir, and Safak Mert for their experimental contributions to this work. This work was mainly supported by the funds provided to U.O. from Department of Medicine, Boston Children's Hospital and also by grant R01DK098496 provided to U.O. by the National Institutes of Health, American Diabetes Association Career Development grant #7-09-CD-10, and support from Fidelity Biosciences Research Initiative. U.O. is a scientific founder, shareholder, and scientific advisory board and board of directors member of ERX Pharmaceuticals Inc. NR 30 TC 46 Z9 53 U1 9 U2 59 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD MAY 21 PY 2015 VL 161 IS 5 BP 999 EP 1011 DI 10.1016/j.cell.2015.05.011 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CJ0GA UT WOS:000355152600009 PM 26000480 ER PT J AU Zomer, A Maynard, C Verweij, FJ Kamermans, A Schafer, R Beerling, E Schiffelers, RM de Wit, E Berenguer, J Ellenbroek, SIJ Wurdinger, T Pegtel, DM van Rheenen, J AF Zomer, Anoek Maynard, Carrie Verweij, Frederik Johannes Kamermans, Alwin Schafer, Ronny Beerling, Evelyne Schiffelers, Raymond Michel de Wit, Elzo Berenguer, Jordi Ellenbroek, Saskia Inge Johanna Wurdinger, Thomas Pegtel, Dirk Michiel van Rheenen, Jacco TI In Vivo Imaging Reveals Extracellular Vesicle-Mediated Phenocopying of Metastatic Behavior SO CELL LA English DT Article ID EXOSOMES; CANCER; CELLS; MICROVESICLES; MICROENVIRONMENT; HALLMARKS; PROGRESSION; BIOMARKERS; INVASION; TUMORS AB Most cancer cells release heterogeneous populations of extracellular vesicles (EVs) containing proteins, lipids, and nucleic acids. In vitro experiments showed that EV uptake can lead to transfer of functional mRNA and altered cellular behavior. However, similar in vivo experiments remain challenging because cells that take up EVs cannot be discriminated from non-EV-receiving cells. Here, we used the Cre-LoxP system to directly identify tumor cells that take up EVs in vivo. We show that EVs released by malignant tumor cells are taken up by less malignant tumor cells located within the same and within distant tumors and that these EVs carry mRNAs involved in migration and metastasis. By intravital imaging, we show that the less malignant tumor cells that take up EVs display enhanced migratory behavior and metastatic capacity. We postulate that tumor cells locally and systemically share molecules carried by EVs in vivo and that this affects cellular behavior. C1 [Zomer, Anoek; Maynard, Carrie; Kamermans, Alwin; Schafer, Ronny; Beerling, Evelyne; de Wit, Elzo; Ellenbroek, Saskia Inge Johanna; van Rheenen, Jacco] Hubrecht Inst KNAW, Canc Genom Netherlands, NL-3584 CT Utrecht, Netherlands. [Zomer, Anoek; Maynard, Carrie; Kamermans, Alwin; Schafer, Ronny; Beerling, Evelyne; de Wit, Elzo; Ellenbroek, Saskia Inge Johanna; van Rheenen, Jacco] Univ Med Ctr Utrecht, NL-3584 CT Utrecht, Netherlands. [Verweij, Frederik Johannes; Pegtel, Dirk Michiel] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Pathol, NL-1081 HV Amsterdam, Netherlands. [Schiffelers, Raymond Michel] Univ Med Ctr Utrecht, Lab Clin Chem & Haematol, NL-3584 CX Utrecht, Netherlands. [Berenguer, Jordi; Wurdinger, Thomas] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Neurosurg, NL-1081 HV Amsterdam, Netherlands. [Wurdinger, Thomas] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA. [Wurdinger, Thomas] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP van Rheenen, J (reprint author), Hubrecht Inst KNAW, Canc Genom Netherlands, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands. EM j.vanrheenen@hubrecht.eu RI Pegtel, Dirk/M-8393-2015; OI Pegtel, Dirk/0000-0002-7357-4406; de Wit, Elzo/0000-0003-2883-1415; Zomer, Anoek/0000-0001-7209-6476 FU VENI fellowships [91696087, 700.10.402]; VIDI fellowships [91710330, 91711366]; Dutch Organization of Scientific Research (NWO) [823.02.017, 175.010.2007.00, 834.11.002]; Dutch Cancer Society (KWF) [HUBR 2009-4621, VU 2009-3775]; European Research Council [260627, 336540]; Association for International Cancer Research (AICR) [13-0297] FX We thank all members of the van Rheenen group for critically reading this manuscript, and we thank Anko de Graaff and the Hubrecht Imaging Center for imaging support. We thank Wouter Karthaus for his help with cloning the floxed-DsRed-floxed-eGFP construct, Chloe Prunier for imaging assistance, and Marcel Fens for assistance at the nanosight. This work was supported by the VENI fellowships 91696087 (M.P.) and 700.10.402 (E.d.W.); VIDI fellowships 91710330 (J.v.R.), 91711366 (T.W.), and a research grant 823.02.017 (J.v.R. from the Dutch Organization of Scientific Research (NWO); grants from the Dutch Cancer Society (KWF): HUBR 2009-4621 (A.Z. and J.v.R.) and VU 2009-3775 (M.P. and F.V.); European Research Council Starting Researchers grants 260627 (R.S.) and 336540 (T.W.); Association for International Cancer Research (AICR; 13-0297; J.v.R.); and equipment grants (175.010.2007.00 and 834.11.002) from the Dutch Organization of Scientific Research (NWO). NR 29 TC 84 Z9 87 U1 16 U2 62 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD MAY 21 PY 2015 VL 161 IS 5 BP 1046 EP 1057 DI 10.1016/j.cell.2015.04.042 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CJ0GA UT WOS:000355152600013 PM 26000481 ER PT J AU Macosko, EZ Basu, A Satija, R Nemesh, J Shekhar, K Goldman, M Tirosh, I Bialas, AR Kamitaki, N Martersteck, EM Trombetta, JJ Weitz, DA Sanes, JR Shalek, AK Regev, A McCarroll, SA AF Macosko, Evan Z. Basu, Anindita Satija, Rahul Nemesh, James Shekhar, Karthik Goldman, Melissa Tirosh, Itay Bialas, Allison R. Kamitaki, Nolan Martersteck, Emily M. Trombetta, John J. Weitz, David A. Sanes, Joshua R. Shalek, Alex K. Regev, Aviv McCarroll, Steven A. TI Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets SO CELL LA English DT Article ID SINGLE-CELL; RNA-SEQ; MAMMALIAN RETINA; AMACRINE CELLS; DIGITAL PCR; GENE; DNA; CRYSTALLIN; LENS AB Cells, the basic units of biological structure and function, vary broadly in type and state. Single-cell genomics can characterize cell identity and function, but limitations of ease and scale have prevented its broad application. Here we describe Drop-seq, a strategy for quickly profiling thousands of individual cells by separating them into nanoliter-sized aqueous droplets, associating a different barcode with each cell's RNAs, and sequencing them all together. Drop-seq analyzes mRNA transcripts from thousands of individual cells simultaneously while remembering transcripts' cell of origin. We analyzed transcriptomes from 44,808 mouse retinal cells and identified 39 transcriptionally distinct cell populations, creating a molecular atlas of gene expression for known retinal cell classes and novel candidate cell subtypes. Drop-seq will accelerate biological discovery by enabling routine transcriptional profiling at single-cell resolution. C1 [Macosko, Evan Z.; Nemesh, James; Goldman, Melissa; Kamitaki, Nolan; McCarroll, Steven A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Macosko, Evan Z.; Nemesh, James; Goldman, Melissa; Kamitaki, Nolan; McCarroll, Steven A.] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA. [Macosko, Evan Z.; Nemesh, James; Kamitaki, Nolan; McCarroll, Steven A.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA. [Basu, Anindita; Satija, Rahul; Shekhar, Karthik; Tirosh, Itay; Trombetta, John J.; Shalek, Alex K.; Regev, Aviv] Broad Inst Harvard & MIT, Klarman Cell Observ, Cambridge, MA 02142 USA. [Basu, Anindita; Weitz, David A.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. [Satija, Rahul] New York Genome Ctr, New York, NY 10013 USA. [Satija, Rahul] NYU, Dept Biol, New York, NY 10003 USA. [Bialas, Allison R.] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. [Martersteck, Emily M.; Sanes, Joshua R.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA. [Martersteck, Emily M.; Sanes, Joshua R.] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA. [Weitz, David A.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA. [Shalek, Alex K.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA. [Shalek, Alex K.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA. [Shalek, Alex K.] MIT, Dept Chem, Cambridge, MA 02139 USA. [Regev, Aviv] MIT, Dept Biol, Cambridge, MA 02139 USA. [Regev, Aviv] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. RP Macosko, EZ (reprint author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. EM emacosko@genetics.med.harvard.edu; mccarroll@genetics.med.harvard.edu OI Shalek, Alex K./0000-0001-5670-8778 FU Stanley Center for Psychiatric Research; MGH Psychiatry Residency Research Program; Stanley-MGH Fellowship in Psychiatric Neuroscience; Stewart Trust Fellows Award; Simons Foundation; NHGRI CEGS [P50 HG006193]; Klarman Cell Observatory; NIMH [U01MH105960, R25MH094612]; NIH [F32 HD075541]; National Science Foundation [ECS-0335765, DMR-1310266]; Harvard Materials Research Science and Engineering Center [DMR-1420570] FX This work was supported by the Stanley Center for Psychiatric Research (to S.M.), the MGH Psychiatry Residency Research Program and Stanley-MGH Fellowship in Psychiatric Neuroscience (to E.Z.M.), a Stewart Trust Fellows Award (to S.M.), a grant from the Simons Foundation to the Simons Center for the Social Brain at MIT (to A.R., S.M., and D.W.), an NHGRI CEGS P50 HG006193 (to A.R.), the Klarman Cell Observatory (to A.R. and A.B.), NIMH grant U01MH105960 (to S.M., A.R. and J.R.S.), NIMH grant R25MH094612 (to E.M.), NIH F32 HD075541 (to R.S.). AR is an investigator of the Howard Hughes Medical Institute. Microfluidic device fabrication was performed at the Harvard Center for Nanoscale Systems (CNS), a member of the National Nanotechnology Infrastructure Network (National Science Foundation award no. ECS-0335765), with support from the National Science Foundation (DMR-1310266) and the Harvard Materials Research Science and Engineering Center (DMR-1420570). We thank Christina Usher and Leslie Gaffney for contributions to the manuscript figures and Chris Patil for helpful comments on the manuscript. We thank Connie Cepko for helpful conversations about the retina data, Beth Stevens for advice on retinal dissociations, and Assaf Rotem and Huidan Zhang for advice on microfluidics design and fabrication. A.R. is a member of the Scientific Advisory Board for Thermo Fisher Scientific and Syros Pharmaceuticals and a consultant for Driver Genomics. NR 41 TC 291 Z9 297 U1 46 U2 187 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD MAY 21 PY 2015 VL 161 IS 5 BP 1202 EP 1214 DI 10.1016/j.cell.2015.05.002 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CJ0GA UT WOS:000355152600025 PM 26000488 ER PT J AU Robinson, D Van Allen, EM Wu, YM Schultz, N Lonigro, RJ Mosquera, JM Montgomery, B Taplin, ME Pritchard, CC Attard, G Beltran, H Abida, W Bradley, RK Vinson, J Cao, XH Vats, P Kunju, LP Hussain, M Feng, FY Tomlins, SA Cooney, KA Smith, DC Brennan, C Siddiqui, J Mehra, R Chen, Y Rathkopf, DE Morris, MJ Solomon, SB Durack, JC Reuter, VE Gopalan, A Gao, JJ Loda, M Lis, RT Bowden, M Balk, SP Gaviola, G Sougnez, C Gupta, M Yu, EY Mostaghel, EA Cheng, HH Mulcahy, H True, LD Plymate, SR Dvinge, H Ferraldeschi, R Flohr, P Miranda, S Zafeiriou, Z Tunariu, N Mateo, J Perez-Lopez, R Demichelis, F Robinson, BD Schiffman, M Nanus, DM Tagawa, ST Sigaras, A Eng, KW Elemento, O Sboner, A Heath, EI Scher, HI Pienta, KJ Kantoff, P de Bono, JS Rubin, MA Nelson, PS Garraway, LA Sawyers, CL Chinnaiyan, AM AF Robinson, Dan Van Allen, Eliezer M. Wu, Yi-Mi Schultz, Nikolaus Lonigro, Robert J. Mosquera, Juan-Miguel Montgomery, Bruce Taplin, Mary-Ellen Pritchard, Colin C. Attard, Gerhardt Beltran, Himisha Abida, Wassim Bradley, Robert K. Vinson, Jake Cao, Xuhong Vats, Pankaj Kunju, Lakshmi P. Hussain, Maha Feng, Felix Y. Tomlins, Scott A. Cooney, Kathleen A. Smith, David C. Brennan, Christine Siddiqui, Javed Mehra, Rohit Chen, Yu Rathkopf, Dana E. Morris, Michael J. Solomon, Stephen B. Durack, Jeremy C. Reuter, Victor E. Gopalan, Anuradha Gao, Jianjiong Loda, Massimo Lis, Rosina T. Bowden, Michaela Balk, Stephen P. Gaviola, Glenn Sougnez, Carrie Gupta, Manaswi Yu, Evan Y. Mostaghel, Elahe A. Cheng, Heather H. Mulcahy, Hyojeong True, Lawrence D. Plymate, Stephen R. Dvinge, Heidi Ferraldeschi, Roberta Flohr, Penny Miranda, Susana Zafeiriou, Zafeiris Tunariu, Nina Mateo, Joaquin Perez-Lopez, Raquel Demichelis, Francesca Robinson, Brian D. Schiffman, Marc Nanus, David M. Tagawa, Scott T. Sigaras, Alexandros Eng, Kenneth W. Elemento, Olivier Sboner, Andrea Heath, Elisabeth I. Scher, Howard I. Pienta, Kenneth J. Kantoff, Philip de Bono, Johann S. Rubin, Mark A. Nelson, Peter S. Garraway, Levi A. Sawyers, Charles L. Chinnaiyan, Arul M. TI Integrative Clinical Genomics of Advanced Prostate Cancer SO CELL LA English DT Article ID ETS GENE FUSIONS; INCREASED SURVIVAL; MUTATIONS; REARRANGEMENTS; ENZALUTAMIDE; CHEMOTHERAPY; ABIRATERONE; INHIBITION; DISCOVERY; HETEROGENEITY AB Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, beta-catenin, and ZBTB16/PLZF. Moreover, aberrations of BRCA2, BRCA1, and ATM were observed at substantially higher frequencies (19.3% overall) compared to those in primary prostate cancers. 89% of affected individuals harbored a clinically actionable aberration, including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. This cohort study provides clinically actionable information that could impact treatment decisions for these affected individuals. C1 [Robinson, Dan; Wu, Yi-Mi; Lonigro, Robert J.; Cao, Xuhong; Vats, Pankaj; Kunju, Lakshmi P.; Feng, Felix Y.; Tomlins, Scott A.; Brennan, Christine; Siddiqui, Javed; Mehra, Rohit; Chinnaiyan, Arul M.] Univ Michigan, Sch Med, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA. [Robinson, Dan; Wu, Yi-Mi; Kunju, Lakshmi P.; Tomlins, Scott A.; Mehra, Rohit; Chinnaiyan, Arul M.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA. [Van Allen, Eliezer M.; Taplin, Mary-Ellen; Loda, Massimo; Lis, Rosina T.; Bowden, Michaela; Kantoff, Philip; Garraway, Levi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Van Allen, Eliezer M.; Loda, Massimo; Sougnez, Carrie; Gupta, Manaswi; Garraway, Levi A.] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02142 USA. [Schultz, Nikolaus] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA. [Mosquera, Juan-Miguel; Robinson, Brian D.; Sboner, Andrea; Rubin, Mark A.] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA. [Mosquera, Juan-Miguel; Beltran, Himisha; Demichelis, Francesca; Robinson, Brian D.; Schiffman, Marc; Nanus, David M.; Tagawa, Scott T.; Sigaras, Alexandros; Eng, Kenneth W.; Sboner, Andrea; Rubin, Mark A.] Cornell Univ, Weill Med Coll, Inst Precis Med, New York, NY 10021 USA. [Mosquera, Juan-Miguel; Beltran, Himisha; Robinson, Brian D.; Nanus, David M.; Tagawa, Scott T.; Rubin, Mark A.] New York Presbyterian Hosp, New York, NY 10021 USA. [Montgomery, Bruce; Bradley, Robert K.; Mostaghel, Elahe A.; Cheng, Heather H.; Dvinge, Heidi] Univ Washington, Computat Biol Program, Div Publ Hlth Sci, Fred Hutchinson Canc Ctr, Seattle, WA 98109 USA. [Montgomery, Bruce; Bradley, Robert K.; Mostaghel, Elahe A.; Cheng, Heather H.; Dvinge, Heidi] Univ Washington, Div Basic Sci, Fred Hutchinson Canc Ctr, Seattle, WA 98109 USA. [Montgomery, Bruce; Yu, Evan Y.; Mostaghel, Elahe A.; Cheng, Heather H.; Plymate, Stephen R.; Nelson, Peter S.] Univ Washington, Dept Med, Seattle, WA 98109 USA. [Montgomery, Bruce; Yu, Evan Y.; Mostaghel, Elahe A.; Cheng, Heather H.; Plymate, Stephen R.; Nelson, Peter S.] Univ Washington, VAPSHCS, Seattle, WA 98109 USA. [Attard, Gerhardt; Ferraldeschi, Roberta; Flohr, Penny; Miranda, Susana; Zafeiriou, Zafeiris; Tunariu, Nina; Mateo, Joaquin; Perez-Lopez, Raquel; de Bono, Johann S.] Inst Canc Res, Div Clin Studies, Canc Biomarkers Team, London SM2 5NG, England. [Attard, Gerhardt; Ferraldeschi, Roberta; Flohr, Penny; Miranda, Susana; Zafeiriou, Zafeiris; Tunariu, Nina; Mateo, Joaquin; Perez-Lopez, Raquel; de Bono, Johann S.] Royal Marsden NHS Fdn Trust, Prostate Canc Targeted Therapy Grp, London SM2 5NG, England. [Attard, Gerhardt; Ferraldeschi, Roberta; Flohr, Penny; Miranda, Susana; Zafeiriou, Zafeiris; Tunariu, Nina; Mateo, Joaquin; Perez-Lopez, Raquel; de Bono, Johann S.] Royal Marsden NHS Fdn Trust, Drug Dev Unit, London SM2 5NG, England. [Beltran, Himisha; Chen, Yu; Rathkopf, Dana E.; Morris, Michael J.; Nanus, David M.; Tagawa, Scott T.; Scher, Howard I.] Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA. [Abida, Wassim; Chen, Yu; Sawyers, Charles L.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA. [Vinson, Jake] Mem Sloan Kettering Canc Ctr, Prostate Canc Clin Trials Consortium, New York, NY 10065 USA. [Hussain, Maha; Cooney, Kathleen A.; Smith, David C.] Univ Michigan, Sch Med, Div Hematol Oncol, Dept Internal Med, Ann Arbor, MI 48109 USA. [Kunju, Lakshmi P.; Hussain, Maha; Feng, Felix Y.; Tomlins, Scott A.; Cooney, Kathleen A.; Smith, David C.; Chinnaiyan, Arul M.] Univ Michigan, Sch Med, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA. [Hussain, Maha; Tomlins, Scott A.; Cooney, Kathleen A.; Smith, David C.; Chinnaiyan, Arul M.] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA. [Feng, Felix Y.] Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA. [Abida, Wassim; Chen, Yu; Rathkopf, Dana E.; Morris, Michael J.; Scher, Howard I.] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, Dept Med, Genitourinary Oncol Serv, New York, NY 10065 USA. [Solomon, Stephen B.; Durack, Jeremy C.] Mem Sloan Kettering Canc Ctr, Dept Radiol Serv, Intervent Radiol, New York, NY 10065 USA. [Reuter, Victor E.; Gopalan, Anuradha] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA. [Loda, Massimo; Lis, Rosina T.; Bowden, Michaela] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02215 USA. [Balk, Stephen P.] Harvard Univ, Sch Med, Div Hematol Oncol, Dept Med,Beth Israel Deaconess Canc Ctr,Beth Isra, Boston, MA 02215 USA. [Gaviola, Glenn] Brigham & Womens Hosp, Dept Musculoskeletal Radiol, Boston, MA 02115 USA. [Pritchard, Colin C.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Mulcahy, Hyojeong] Univ Washington, Dept Radiol, Seattle, WA 98109 USA. [True, Lawrence D.] Univ Washington, Dept Pathol, Med Ctr, Seattle, WA 98109 USA. [Demichelis, Francesca] Univ Trento, Ctr Integrat Biol, CIBIO, Lab Computat Oncol, I-38123 Mattarello Tn, Italy. [Sigaras, Alexandros; Eng, Kenneth W.; Elemento, Olivier; Sboner, Andrea] Cornell Univ, Dept Physiol & Biophys, Inst Computat Biomed, Weill Med Coll, New York, NY 10021 USA. [Schiffman, Marc] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Radiol, Div Intervent Radiol, New York, NY 10021 USA. [Sigaras, Alexandros; Eng, Kenneth W.] Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA. [Heath, Elisabeth I.] Wayne State Univ, Dept Oncol, Sch Med, Detroit, MI 48201 USA. [Heath, Elisabeth I.] Barbara Ann Karmanos Canc Inst, Mol Therapeut Program, Detroit, MI 48201 USA. [Pienta, Kenneth J.] Johns Hopkins Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA. [Pienta, Kenneth J.] Johns Hopkins Sch Med, Dept Urol, Baltimore, MD USA. [Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA. [Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Mosquera, Juan-Miguel; Beltran, Himisha; Robinson, Brian D.; Schiffman, Marc; Nanus, David M.; Tagawa, Scott T.; Sboner, Andrea; Rubin, Mark A.; Nelson, Peter S.] Cornell Univ, Weill Med Coll, Meyer Canc, New York, NY 10021 USA. [Loda, Massimo; Bowden, Michaela] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Schultz, Nikolaus; Gao, Jianjiong] Mem Sloan Kettering Canc Ctr, Marie Josee & Henry R Kravis Ctr Mol Oncol, New York, NY 10065 USA. [Sawyers, Charles L.] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10065 USA. [Cao, Xuhong; Chinnaiyan, Arul M.] Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA. RP Sawyers, CL (reprint author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA. EM sawyersc@mskcc.org; arul@umich.edu RI Sawyers, Charles/G-5327-2016; OI Rathkopf, Dana/0000-0002-4503-7582; Dvinge, Heidi/0000-0003-1741-0738; Bradley, Robert/0000-0002-8046-1063; Rubin, Mark/0000-0002-8321-9950; Attard, Gerhardt/0000-0002-4811-7983; Demichelis, Francesca/0000-0002-8266-8631; Durack, Jeremy/0000-0002-0672-9586; Morris, Michael J./0000-0002-9454-0096 FU Stand Up To Cancer-Prostate Cancer Foundation Prostate Dream Team Translational Cancer Research Grant; NIH: Clinical Sequencing Exploratory Research (CSER) [UM1HG006508]; NIH: Early Detection Research Network grant [UO1 CA111275]; NIH: Prostate SPORE [P50 CA186786, P50 CA092629, P50 CA90381, P50 CA097186, P01 CA163227, R01 CA116337, R01 CA155169, R01 CA092629]; DoD [W81XWH-09-1-0147, DOD PC121341, PC131820]; Starr Cancer Consortium; Damon Runyon Cancer Research Foundation [CI-67-13]; PCF Young Investigator Award; NIH [1K08CA188615]; Prostate Cancer Foundation Young Investigator Awards; Movember Foundation; ECMC network from Cancer Research UK; Department of Health in the UK; BRC grant; Prostate Cancer UK, PCF FX We thank the affected individuals who participated in this study to better understand the feasibility and utility of precision medicine approaches for advanced prostate cancer. Individuals at our respective institutions who helped with this study are listed by institution. University of Michigan: Karen Giles, Lynda Hodges, Erica Rabban, Ning Yu, Fengyun Su, Rui Wang, Brendan Veeneman, and Moshe Talpaz. MSKCC: Brett Carver, Kristen Curtis, and Julie Filipenko. DFCI/Broad: Zhenwei Zhang, Daniele Depalo, and Joseph Kramkowski. University of Washington: Jina Taub, Hiep Nguyen, Colm Morrissey, and Robert Vessella. ICR/Royal Marsden: Suzanne Carreira, Ines Figueiredo, and Daniel Nava Rodrigues. This work was supported by a Stand Up To Cancer-Prostate Cancer Foundation Prostate Dream Team Translational Cancer Research Grant. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research (SU2C-AACR-DT0712). The project was also supported by the following NIH awards: Clinical Sequencing Exploratory Research (CSER) UM1HG006508 (A.M.C.), Early Detection Research Network grant UO1 CA111275(A.M.C.), Prostate SPORE grants P50 CA186786 (A.M.C.), P50 CA092629 (H.I.S., C.L.S., and Y.C.), P50 CA90381 (P.K.), and P50 CA097186 (P.S.N., B.M., E.A.M., and L.D.T.), P01 CA163227 (P.S.N., S.P., R.K.B., H.D.), R01 CA116337 (M.A.R., H.B., F.D.), R01 CA155169 (C.L.S.), R01 CA092629, P50 CA092629 (H.I.S., C.L.S., and Y.C.), and R01 CA155169 (C.L.S.). This work was supported by the following DoD awards: W81XWH-09-1-0147 (PCCTC) and DOD PC121341 (H.B.). This work was also supported by the Starr Cancer Consortium (N.S., M.R., C.S., Y.C., L.A.G.). A.M.C. is an A. Alfred Taubman Scholar and an American Cancer Society Professor. H.B. is supported by Damon Runyon Cancer Research Foundation CI-67-13. C.P. is supported by a PCF Young Investigator Award and DoD PC131820. E.M.V. is supported by a NIH 1K08CA188615. E.M.V., N.S., and F.Y.F. are supported by Prostate Cancer Foundation Young Investigator Awards. The RM and ICR team is supported by the Movember Foundation and Prostate Cancer UK, PCF, the ECMC network from Cancer Research UK, the Department of Health in the UK, and BRC grant funding. NR 64 TC 320 Z9 324 U1 23 U2 88 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD MAY 21 PY 2015 VL 161 IS 5 BP 1215 EP 1228 DI 10.1016/j.cell.2015.05.001 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CJ0GA UT WOS:000355152600026 PM 26000489 ER PT J AU Wang, JH Gray, NS AF Wang, Jinhua Gray, Nathanael S. TI SnapShot: Kinase Inhibitors I SO MOLECULAR CELL LA English DT Editorial Material ID SELECTIVITY; UPDATE C1 [Wang, Jinhua; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. [Wang, Jinhua; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. RP Wang, JH (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. NR 9 TC 2 Z9 2 U1 2 U2 5 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1097-2765 EI 1097-4164 J9 MOL CELL JI Mol. Cell PD MAY 21 PY 2015 VL 58 IS 4 BP 708 EP U161 DI 10.1016/j.molcel.2015.05.001 PG 2 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CJ0GO UT WOS:000355154000017 ER PT J AU Wang, JH Gray, NS AF Wang, Jinhua Gray, Nathanael S. TI SnapShot: Kinase Inhibitors II SO MOLECULAR CELL LA English DT Editorial Material ID SELECTIVITY; UPDATE C1 [Wang, Jinhua; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. [Wang, Jinhua; Gray, Nathanael S.] Harvard Univ, Dept Biol Chem & Mol Pharmacol, Sch Med, Boston, MA 02115 USA. RP Wang, JH (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. NR 9 TC 2 Z9 2 U1 0 U2 1 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1097-2765 EI 1097-4164 J9 MOL CELL JI Mol. Cell PD MAY 21 PY 2015 VL 58 IS 4 BP 710 EP U163 DI 10.1016/j.molcel.2015.05.002 PG 2 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CJ0GO UT WOS:000355154000018 ER PT J AU Lin, YT McMahon, SJ Paganetti, H Schuemann, J AF Lin, Yuting McMahon, Stephen J. Paganetti, Harald Schuemann, Jan TI Biological modeling of gold nanoparticle enhanced radiotherapy for proton therapy SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article DE gold nanoparticle; radiotherapy; proton therapy; local effect model; biological model ID MONTE-CARLO-SIMULATION; RADIATION-THERAPY; DOSE ENHANCEMENT; ION IRRADIATION; BEAM THERAPY; CELLS; RADIOSENSITIZATION; ENERGY; SIZE; SENSITIVITY AB Gold nanoparticles (GNPs) have shown potential as a radiosensitizer for radiation therapy using photon beams. Recently, experimental studies have been carried out using proton beams showing the GNP enhanced responses in proton therapy. In this work, we established a biological model to investigate the change in survival of irradiated cells due to the radiosensitizing effect of gold nanoparticles. Results for proton, megavoltage (MV) photon and kilovoltage (kV) photon beams are compared. For each particle source, we assessed various treatment depths, GNP cellular uptakes and sizes. We showed that kilovoltage photons caused the highest enhancement due to the high interaction probability between GNPs and kV photons. The cell survival fraction can be significantly reduced for both proton and MV photon irradiations if GNPs accumulate in the cell. For instance, the sensitizer enhancement ratio (SER) is 1.33 for protons in the middle of a spread out Bragg peak for 1 mu M of internalized 50 nm GNPs. If the GNPs can all be internalized into the cell nucleus, the SER for proton therapy increases from 1.33 to 1.81. The results also show that for the same mass of GNPs in the cells, one can expect the greatest sensitization by smaller GNPs, i.e. a SER of 1.33 for 1 mu M of internalized 50 nm GNPs and a SER of 3.98 for the same mass of 2 nm GNPs. We concluded that if the GNPs cannot be internalized into the cytoplasm, no GNP enhancement will be observed for proton treatment. Meanwhile, proton radiotherapy can potentially be enhanced with GNPs if they can be internalized into cells, and especially the cell nucleus. C1 [Lin, Yuting; McMahon, Stephen J.; Paganetti, Harald; Schuemann, Jan] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Lin, Yuting; McMahon, Stephen J.; Paganetti, Harald; Schuemann, Jan] Harvard Univ, Sch Med, Boston, MA 02115 USA. [McMahon, Stephen J.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7AE, Antrim, North Ireland. RP Lin, YT (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. EM ylin20@partners.org NR 47 TC 9 Z9 11 U1 6 U2 28 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 EI 1361-6560 J9 PHYS MED BIOL JI Phys. Med. Biol. PD MAY 21 PY 2015 VL 60 IS 10 BP 4149 EP 4168 DI 10.1088/0031-9155/60/10/4149 PG 20 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA CJ0XI UT WOS:000355203100019 PM 25953956 ER PT J AU Sawyer, RG Claridge, JA Nathens, AB Rotstein, OD Duane, TM Evans, HL Cook, CH O'Neill, PJ Mazuski, JE Askari, R Wilson, MA Napolitano, LM Namias, N Miller, PR Dellinger, EP Watson, CM Coimbra, R Dent, DL Lowry, SF Cocanour, CS West, MA Banton, KL Cheadle, WG Lipsett, PA Guidry, CA Popovsky, K AF Sawyer, R. G. Claridge, J. A. Nathens, A. B. Rotstein, O. D. Duane, T. M. Evans, H. L. Cook, C. H. O'Neill, P. J. Mazuski, J. E. Askari, R. Wilson, M. A. Napolitano, L. M. Namias, N. Miller, P. R. Dellinger, E. P. Watson, C. M. Coimbra, R. Dent, D. L. Lowry, S. F. Cocanour, C. S. West, M. A. Banton, K. L. Cheadle, W. G. Lipsett, P. A. Guidry, C. A. Popovsky, K. TI Trial of Short-Course Antimicrobial Therapy for Intraabdominal Infection SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID ANTIBIOTIC-THERAPY; CHILDREN GUIDELINES; DISEASES SOCIETY; RANDOMIZED-TRIAL; MANAGEMENT; MORTALITY; SEPSIS; ADULTS; DIAGNOSIS; BACTERIAL AB BACKGROUND The successful treatment of intraabdominal infection requires a combination of anatomical source control and antibiotics. The appropriate duration of antimicrobial therapy remains unclear. METHODS We randomly assigned 518 patients with complicated intraabdominal infection and adequate source control to receive antibiotics until 2 days after the resolution of fever, leukocytosis, and ileus, with a maximum of 10 days of therapy (control group), or to receive a fixed course of antibiotics (experimental group) for 4 +/- 1 calendar days. The primary outcome was a composite of surgical-site infection, recurrent intraabdominal infection, or death within 30 days after the index source-control procedure, according to treatment group. Secondary outcomes included the duration of therapy and rates of subsequent infections. RESULTS Surgical-site infection, recurrent intraabdominal infection, or death occurred in 56 of 257 patients in the experimental group (21.8%), as compared with 58 of 260 patients in the control group (22.3%) (absolute difference, -0.5 percentage point; 95% confidence interval [CI], -7.0 to 8.0; P = 0.92). The median duration of antibiotic therapy was 4.0 days (interquartile range, 4.0 to 5.0) in the experimental group, as compared with 8.0 days (interquartile range, 5.0 to 10.0) in the control group (absolute difference, -4.0 days; 95% CI, -4.7 to -3.3; P<0.001). No significant between-group differences were found in the individual rates of the components of the primary outcome or in other secondary outcomes. CONCLUSIONS In patients with intraabdominal infections who had undergone an adequate source-control procedure, the outcomes after fixed-duration antibiotic therapy (approximately 4 days) were similar to those after a longer course of antibiotics (approximately 8 days) that extended until after the resolution of physiological abnormalities. C1 [Sawyer, R. G.; Guidry, C. A.; Popovsky, K.] Univ Virginia Hlth Syst, Dept Surg, Charlottesville, VA 22908 USA. [Duane, T. M.] Virginia Commonwealth Univ, Dept Surg, Richmond, VA USA. [Claridge, J. A.] Case Western Reserve Univ, Dept Surg, Cleveland, OH 44106 USA. [Nathens, A. B.; Rotstein, O. D.] Univ Toronto, Dept Surg, Toronto, ON, Canada. [Evans, H. L.; Dellinger, E. P.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Cook, C. H.] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA. [Askari, R.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [O'Neill, P. J.] Maricopa Integrated Hlth Syst, Dept Surg, Phoenix, AZ USA. [Mazuski, J. E.] Washington Univ, Dept Surg, St Louis, MO USA. [Wilson, M. A.] VA Pittsburgh Healthcare Syst, Dept Surg, Pittsburgh, PA USA. [Napolitano, L. M.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA. [Namias, N.] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA. [Miller, P. R.] Wake Forest Sch Med, Dept Surg, Winston Salem, NC USA. [Watson, C. M.] Univ S Carolina, Dept Surg, Columbia, SC 29208 USA. [Coimbra, R.] Univ Calif San Diego, San Diego, CA 92103 USA. [Cocanour, C. S.] Univ Calif Davis, Med Ctr, Dept Surg, Sacramento, CA 95817 USA. [West, M. A.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. [Dent, D. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Lowry, S. F.] Univ Med & Dent New Jersey, Dept Surg, Newark, NJ 07103 USA. [Banton, K. L.] Univ Minnesota, Sch Med, Dept Surg, Minneapolis, MN 55455 USA. [Cheadle, W. G.] Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA. [Lipsett, P. A.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA. RP Sawyer, RG (reprint author), Univ Virginia Hlth Syst, Dept Surg, Box 800709, Charlottesville, VA 22908 USA. EM rws2k@virginia.edu FU National Institutes of Health [R01GM081510, T32 AI078875]; 3M; Pfizer; Bayer; Merck; AstraZeneca; Baxter; Ortho-McNeil; Targanta Therapeutics; Schering-Plough; Astellas; CareFusion; Durata Therapeutics; Rib-X Pharmaceuticals; Affinium Pharmaceuticals; Tetraphase Pharmaceuticals; R-Pharm; Applied Medical FX Supported by grants (R01GM081510 and T32 AI078875) from the National Institutes of Health.; Dr. Sawyer reports receiving consulting fees from 3M and Pfizer; Dr. Duane, lecture fees from Pfizer; Dr. O'Neill, fees for serving on a surgical review panel for Cubist; Dr. Mazuski, fees for serving on advisory boards from AstraZeneca, Cubist, Merck, and Pfizer, consulting fees from Bayer, lecture fees from Merck, and grant support from AstraZeneca, Bayer, Merck, and Pfizer; and Dr. Dellinger, fees for serving on advisory boards from Merck, Baxter, Ortho-McNeil, Targanta Therapeutics, Schering-Plough, Astellas, CareFusion, Durata Therapeutics, Pfizer, Rib-X Pharmaceuticals, Affinium Pharmaceuticals, Tetraphase Pharmaceuticals, and R-Pharm, and lecture fees from Applied Medical. No other potential conflict of interest relevant to this article was reported. NR 18 TC 74 Z9 79 U1 0 U2 12 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 21 PY 2015 VL 372 IS 21 BP 1996 EP 2005 DI 10.1056/NEJMoa1411162 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CI5PD UT WOS:000354809300006 PM 25992746 ER PT J AU Postow, MA Chesney, J Pavlick, AC Robert, C Grossmann, K McDermott, D Linette, GP Meyer, N Giguere, JK Agarwala, SS Shaheen, M Ernstoff, MS Minor, D Salama, AK Taylor, M Ott, PA Rollin, LM Horak, C Gagnier, P Wolchok, JD Hodi, FS AF Postow, Michael A. Chesney, Jason Pavlick, Anna C. Robert, Caroline Grossmann, Kenneth McDermott, David Linette, Gerald P. Meyer, Nicolas Giguere, Jeffrey K. Agarwala, Sanjiv S. Shaheen, Montaser Ernstoff, Marc S. Minor, David Salama, April K. Taylor, Matthew Ott, Patrick A. Rollin, Linda M. Horak, Christine Gagnier, Paul Wolchok, Jedd D. Hodi, F. Stephen TI Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID MEK INHIBITION; COMBINED BRAF; OPEN-LABEL; MUTATION; VEMURAFENIB; RESPONSES; SAFETY; PD-1; ASSOCIATION; DABRAFENIB AB BACKGROUND In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma. METHODS In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2: 1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects. The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors. RESULTS Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the group that received ipilimumab and placebo (ipilimumab-monotherapy group) (P<0.001), with complete responses reported in 16 patients (22%) in the combination group and no patients in the ipilimumab-monotherapy group. The median duration of response was not reached in either group. The median progression-free survival was not reached with the combination therapy and was 4.4 months with ipilimumab monotherapy (hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death, 0.40; 95% confidence interval, 0.23 to 0.68; P<0.001). Similar results for response rate and progression-free survival were observed in 33 patients with BRAF mutation-positive tumors. Drug-related adverse events of grade 3 or 4 were reported in 54% of the patients who received the combination therapy as compared with 24% of the patients who received ipilimumab monotherapy. Select adverse events with potential immunologic causes were consistent with those in a phase 1 study, and most of these events resolved with immune-modulating medication. CONCLUSIONS The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy. Combination therapy had an acceptable safety profile. C1 [Postow, Michael A.; Wolchok, Jedd D.] NYU, Mem Sloan Kettering Canc Ctr, New York, NY USA. [Postow, Michael A.; Wolchok, Jedd D.] NYU, Weill Cornell Med Coll, New York, NY USA. [Pavlick, Anna C.] NYU, Perlmutter Canc Ctr, New York, NY USA. [Chesney, Jason] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA. [Robert, Caroline] Inst Gustave Roussy, Villejuif, France. [Robert, Caroline] Univ Paris 11, Orsay, France. [Meyer, Nicolas] Inst Univ Canc, Toulouse, France. [Grossmann, Kenneth] Huntsman Canc Inst, Salt Lake City, UT USA. [McDermott, David] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Ott, Patrick A.; Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02215 USA. [Linette, Gerald P.] Washington Univ, St Louis, MO USA. [Giguere, Jeffrey K.] Greenville Hlth Syst, Greenville, SC USA. [Agarwala, Sanjiv S.] St Lukes Canc Ctr, Bethlehem, PA USA. [Shaheen, Montaser] Univ New Mexico, Albuquerque, NM 87131 USA. [Ernstoff, Marc S.] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH 44195 USA. [Minor, David] Calif Pacific Ctr Melanoma Res, San Francisco, CA USA. [Salama, April K.] Duke Univ, Durham, NC USA. [Taylor, Matthew] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Horak, Christine] Bristol Myers Squibb Co, Lawrenceville, NJ USA. [Rollin, Linda M.; Gagnier, Paul] Bristol Myers Squibb Co, Wallingford, CT 06492 USA. RP Hodi, FS (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM wolchokj@mskcc.org; stephen_hodi@dfci.harvard.edu FU Bristol-Myers Squibb FX Supported by Bristol-Myers Squibb. NR 25 TC 499 Z9 510 U1 5 U2 34 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 21 PY 2015 VL 372 IS 21 BP 2006 EP 2017 DI 10.1056/NEJMoa1414428 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA CI5PD UT WOS:000354809300007 PM 25891304 ER PT J AU Garon, EB Rizvi, NA Hui, RN Leighl, N Balmanoukian, AS Eder, JP Patnaik, A Aggarwal, C Gubens, M Horn, L Carcereny, E Ahn, MJ Felip, E Lee, JS Hellmann, MD Hamid, O Goldman, JW Soria, JC Dolled-Filhart, M Rutledge, RZ Zhang, J Lunceford, JK Rangwala, R Lubiniecki, GM Roach, C Emancipator, K Gandhi, L AF Garon, Edward B. Rizvi, Naiyer A. Hui, Rina Leighl, Natasha Balmanoukian, Ani S. Eder, Joseph Paul Patnaik, Amita Aggarwal, Charu Gubens, Matthew Horn, Leora Carcereny, Enric Ahn, Myung-Ju Felip, Enriqueta Lee, Jong-Seok Hellmann, Matthew D. Hamid, Omid Goldman, Jonathan W. Soria, Jean-Charles Dolled-Filhart, Marisa Rutledge, Ruth Z. Zhang, Jin Lunceford, Jared K. Rangwala, Reshma Lubiniecki, Gregory M. Roach, Charlotte Emancipator, Kenneth Gandhi, Leena CA KEYNOTE-001 Investigators TI Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID ANTI-PD-L1 ANTIBODY; PD-L1 EXPRESSION; BLOCKADE; CHEMOTHERAPY; B7-H1; ACTIVATION; MELANOMA; SAFETY; CRIZOTINIB; RESPONSES AB BACKGROUND We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of the PD-1 ligand 1 (PD-L1) that is associated with the likelihood of clinical benefit. METHODS We assigned 495 patients receiving pembrolizumab (at a dose of either 2 mg or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182 patients) or a validation group (313 patients). We assessed PD-L1 expression in tumor samples using immunohistochemical analysis, with results reported as the percentage of neoplastic cells with staining for membranous PD-L1 (proportion score). Response was assessed every 9 weeks by central review. RESULTS Common side effects that were attributed to pembrolizumab were fatigue, pruritus, and decreased appetite, with no clear difference according to dose or schedule. Among all the patients, the objective response rate was 19.4%, and the median duration of response was 12.5 months. The median duration of progression-free survival was 3.7 months, and the median duration of overall survival was 12.0 months. PD-L1 expression in at least 50% of tumor cells was selected as the cutoff from the training group. Among patients with a proportion score of at least 50% in the validation group, the response rate was 45.2%. Among all the patients with a proportion score of at least 50%, median progression-free survival was 6.3 months; median overall survival was not reached. CONCLUSIONS Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. C1 [Garon, Edward B.; Goldman, Jonathan W.] UCLA, David Geffen Sch Med, Santa Monica, CA 90404 USA. [Balmanoukian, Ani S.; Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA. [Gubens, Matthew] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Roach, Charlotte] Dako, Carpinteria, CA USA. [Rizvi, Naiyer A.] Columbia Univ, New York, NY USA. [Hellmann, Matthew D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Hellmann, Matthew D.] Weill Cornell Med Coll, New York, NY USA. [Hui, Rina] Univ Sydney, Westmead Hosp, Westmead, NSW 2145, Australia. [Leighl, Natasha] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Eder, Joseph Paul] Yale Univ, New Haven, CT USA. [Patnaik, Amita] South Texas Accelerated Res Therapeut, San Antonio, TX USA. [Aggarwal, Charu] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Horn, Leora] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Carcereny, Enric] Catalan Inst Oncol Badalona, Badalona, Spain. [Felip, Enriqueta] Vall dHebron Univ Hosp, Barcelona, Spain. [Felip, Enriqueta] Vall dHebron Inst Oncol, Barcelona, Spain. [Ahn, Myung-Ju] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea. [Lee, Jong-Seok] Seoul Natl Univ, Seoul, South Korea. [Soria, Jean-Charles] Inst Gustave Roussy, Villejuif, France. [Soria, Jean-Charles] Univ Paris 11, Villejuif, France. [Dolled-Filhart, Marisa; Rutledge, Ruth Z.; Zhang, Jin; Lunceford, Jared K.; Rangwala, Reshma; Lubiniecki, Gregory M.; Emancipator, Kenneth] Merck, Kenilworth, NJ USA. [Gandhi, Leena] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Garon, EB (reprint author), UCLA, David Geffen Sch Med, Translat Oncol Res Lab, 2825 Santa Monica Blvd,Suite 200, Santa Monica, CA 90404 USA. EM egaron@mednet.ucla.edu RI Garassino, Marina/D-7128-2017; Zhang, Jin/E-8298-2017; OI Garassino, Marina/0000-0002-3821-5598; Santini, Daniele/0000-0002-9118-3337; Gandhi, Leena/0000-0002-2398-9179 FU Merck Sharp & Dohme, a subsidiary of Merck FX Supported by Merck Sharp & Dohme, a subsidiary of Merck. NR 40 TC 725 Z9 760 U1 45 U2 121 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 21 PY 2015 VL 372 IS 21 BP 2018 EP 2028 DI 10.1056/NEJMoa1501824 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CI5PD UT WOS:000354809300008 PM 25891174 ER PT J AU Olfson, M Druss, BG Marcus, SC AF Olfson, Mark Druss, Benjamin G. Marcus, Steven C. TI Trends in Mental Health Care among Children and Adolescents SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID PSYCHOSOCIAL TREATMENTS; IMPAIRMENT; DEPRESSION; MEDICATION; DISORDER; AMERICANS AB BACKGROUND Increasing mental health treatment of young people and broadening conceptualizations of psychopathology have triggered concerns about a disproportionate increase in the treatment of youths with low levels of mental health impairment. METHODS We analyzed the 1996-1998, 2003-2005, and 2010-2012 Medical Expenditure Panel Surveys, which were nationally representative surveys of U.S. households, for trends in outpatient use of mental health services by persons 6 to 17 years of age; 53,622 persons were included in the analysis. Mental health impairment was measured with the use of the Columbia Impairment Scale (range, 0 to 52, with higher scores indicating more severe impairment); we classified youths with scores of 16 or higher as having more severe impairment and those with scores of less than 16 as having less severe impairment. RESULTS The percentage of youths receiving any outpatient mental health service increased from 9.2% in 1996-1998 to 13.3% in 2010-2012 (odds ratio, 1.52; 95% confidence interval, 1.35 to 1.72). The proportionate increase in the use of mental health services among youths with more severe impairment (from 26.2% to 43.9%) was larger than that among youths with less severe or no impairment (from 6.7% to 9.6%). However, the absolute increase in annual service use was larger among youths with less severe or no impairment (from 2.74 million to 4.19 million) than among those with more severe impairment (from 1.56 million to 2.28 million). Significant overall increases occurred in the use of psychotherapy (from 4.2% to 6.0%) and psychotropic medications (from 5.5% to 8.9%), including stimulants and related medications (from 4.0% to 6.6%), antidepressants (from 1.5% to 2.6%), and antipsychotic drugs (from 0.2% to 1.2%). CONCLUSIONS Outpatient mental health treatment and psychotropic-medication use in children and adolescents increased in the United States between 1996-1998 and 2010-2012. Although youths with less severe or no impairment accounted for most of the absolute increase in service use, youths with more severe impairment had the greatest relative increase in use, yet fewer than half accessed services in 2010-2012. C1 [Olfson, Mark] Columbia Univ, Dept Psychiat, Coll Phys & Surg, New York, NY 10032 USA. [Olfson, Mark] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Druss, Benjamin G.] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. [Marcus, Steven C.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Sch Social Practice & Policy, Philadelphia, PA 19104 USA. RP Olfson, M (reprint author), Columbia Univ, New York State Psychiat Inst, Dept Psychiat, Coll Phys & Surg, 1051 Riverside Dr, New York, NY 10032 USA. EM mo49@cumc.columbia.edu FU Agency for Healthcare Research and Quality [U19 HS021112]; New York State Psychiatric Institute FX Supported by a grant (U19 HS021112) from the Agency for Healthcare Research and Quality and by the New York State Psychiatric Institute. NR 39 TC 27 Z9 28 U1 5 U2 15 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 21 PY 2015 VL 372 IS 21 BP 2029 EP 2038 DI 10.1056/NEJMsa1413512 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CI5PD UT WOS:000354809300009 PM 25992747 ER PT J AU Jung, M Lin, L Viswanath, K AF Jung, Minsoo Lin, Leesa Viswanath, Kasisomayajula TI Effect of media use on mothers' vaccination of their children in sub-Saharan Africa SO VACCINE LA English DT Article DE Immunizations; Child health; Media use; Health communication; Sub-Saharan African countries ID HEALTH; IMMUNIZATION; INFLUENZA; PARENTS; COVERAGE; PROGRAMS; DETERMINANTS; BEHAVIORS; KNOWLEDGE AB While several studies have examined the crucial role that parents' vaccination behaviors play in reducing disease spread and severity among children, few have evaluated the connection between parents' media use and their decision on whether or not to vaccinate their child, specifically in relation to the BCG (Bacillus Calmetter Guerin), DPT (Diptheria, Pertussis, Tetanus) polio, and measles vaccines. Media channels are a critical source of health information for parents, which is especially true in Sub-Saharan Africa, as there is often a dearth of local healthcare providers. The aim of this paper is to investigate the role that media use plays in a mothers' choice to vaccinate their infant children in sub-Saharan Africa, specifically focusing on whether media use is associated with socioeconomic status (SES) and a mothers' vaccination of their children. Cross-sectional data from the Demographic Health Surveys of 13 sub-Saharan countries (2004-2010) were pooled. A multivariate Poisson regression of 151,209 women was used to calculate adjusted relative ratios and 95% confidence intervals for the associations among SES, media use, and immunization. Education and wealth were found to be strongly and positively associated with vaccine-uptake behaviors. The effects of media use (radio and television) were found to be associated with the relationships between SES and vaccine uptake. However, it did not reduce the impact of SES on vaccination. These findings indicate that mass media may be an important tool for future efforts to reduce the health discrepancies between children from high- and low-socioeconomic backgrounds. Going forward, immunization strategies should include communication plans that will address and mitigate potential immunization disparities among parents of different SES backgrounds. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Jung, Minsoo] Dongduk Womens Univ, Dept Hlth Sci, Seoul, South Korea. [Lin, Leesa; Viswanath, Kasisomayajula] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. [Lin, Leesa; Viswanath, Kasisomayajula] Harvard Univ, Dept Social & Behav Sci, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. RP Jung, M (reprint author), Dongduk Womens Univ, Dept Hlth Sci, Seoul, South Korea. EM mins.jung@gmail.com OI Jung, Minsoo/0000-0003-3317-6507 NR 50 TC 1 Z9 1 U1 2 U2 10 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAY 21 PY 2015 VL 33 IS 22 BP 2551 EP 2557 DI 10.1016/j.vaccine.2015.04.021 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CI8SA UT WOS:000355040800007 PM 25896379 ER PT J AU Shen, Y Li, J Nitta, M Futalan, D Steed, T Treiber, JM Taich, Z Stevens, D Wykosky, J Chen, HZ Carter, BS Becher, OJ Kennedy, R Esashi, F Sarkaria, JN Furnari, FB Cavenee, WK Desai, A Chen, CC AF Shen, Ying Li, Jie Nitta, Masayuki Futalan, Diahnn Steed, Tyler Treiber, Jeffrey M. Taich, Zack Stevens, Deanna Wykosky, Jill Chen, Hong-Zhuan Carter, Bob S. Becher, Oren J. Kennedy, Richard Esashi, Fumiko Sarkaria, Jann N. Furnari, Frank B. Cavenee, Webster K. Desai, Arshad Chen, Clark C. TI Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition SO ONCOTARGET LA English DT Article DE EGFR; EGFRvIII; glioblastoma; synthetic lethality ID GROWTH-FACTOR RECEPTOR; SYNTHETIC LETHAL INTERACTIONS; DNA-DAMAGE RESPONSE; STRAND BREAK REPAIR; KINASE INHIBITORS; TUMOR-SUPPRESSOR; UP-REGULATION; CANCER; CELLS; ONCOGENE AB We identified a synthetic lethality between PLK1 silencing and the expression of an oncogenic Epidermal Growth Factor Receptor, EGFRvIII. PLK1 promoted homologous recombination (HR), mitigating EGFRvIII induced oncogenic stress resulting from DNA damage accumulation. Accordingly, PLK1 inhibition enhanced the cytotoxic effects of the DNA damaging agent, temozolomide (TMZ). This effect was significantly more pronounced in an Ink4a/Arf(-/-) EGFRvIII glioblastoma model relative to an Ink4a/Arf(-/-) PDGF-beta model. The tumoricidal and TMZ-sensitizing effects of BI2536 were uniformly observed across Ink4a/Arf(-/-) EGFRvIII glioblastoma clones that acquired independent resistance mechanisms to EGFR inhibitors, suggesting these resistant clones retain oncogenic stress that required PLK1 compensation. Although BI2536 significantly augmented the anti-neoplastic effect of EGFR inhibitors in the Ink4a/Arf(-/-) EGFRvIII model, durable response was not achieved until TMZ was added. Our results suggest that optimal therapeutic effect against glioblastomas requires a "multi-orthogonal" combination tailored to the molecular physiology associated with the target cancer genome. C1 [Shen, Ying; Li, Jie; Futalan, Diahnn; Steed, Tyler; Treiber, Jeffrey M.; Taich, Zack; Carter, Bob S.; Chen, Clark C.] Univ Calif San Diego, Ctr Theoret & Appl Neurooncol, Moores Canc Ctr, Div Neurosurg, San Diego, CA 92103 USA. [Shen, Ying; Chen, Hong-Zhuan] Shanghai Jiao Tong Univ, Dept Pharmacol & Chem Biol, Sch Med, Shanghai 200030, Peoples R China. [Shen, Ying; Chen, Hong-Zhuan] Shanghai Jiao Tong Univ, Collaborat Innovat Ctr Translat Med, Sch Med, Shanghai 200030, Peoples R China. [Nitta, Masayuki] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Stevens, Deanna; Wykosky, Jill; Furnari, Frank B.; Cavenee, Webster K.; Desai, Arshad] Univ Calif San Diego, San Diego Branch, Ludwig Inst Canc Res, San Diego, CA 92103 USA. [Becher, Oren J.] Duke Univ, Med Ctr, Dept Pediat, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA. [Becher, Oren J.] Duke Univ, Med Ctr, Dept Pathol, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA. [Kennedy, Richard] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland. [Esashi, Fumiko] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England. [Sarkaria, Jann N.] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA. RP Chen, CC (reprint author), Univ Calif San Diego, Ctr Theoret & Appl Neurooncol, Moores Canc Ctr, Div Neurosurg, San Diego, CA 92103 USA. EM clarkchen@ucsd.edu RI Li, Jie/L-1737-2015 OI Li, Jie/0000-0002-0590-9817 FU Doris Duke Charitable Foundation Clinical Scientist Development Award; Sontag Foundation Distinguished Scientist Award; Burroughs Welcome Fund Career Awards for Medical Scientists; Kimmel Scholar award; Discovery Grant from the American Brain Tumor Association; Accelerated Brain Cancer Cure; William Guy Forbeck Research Foundation; National Natural Science Foundation of China [81473232]; National Basic Research Program of China (973 Program) [2010CB529800]; James S. McDonnell Foundation; [P01-CA95616/NIH]; [R01-NS080939/NIH] FX We are grateful to the reagent donators (Dr. David Pellman and Dr. David Weinstock). CCC is supported by the Doris Duke Charitable Foundation Clinical Scientist Development Award (http://www.ddcf.org), the Sontag Foundation Distinguished Scientist Award (http://www.sontagfoundation.com), the Burroughs Welcome Fund Career Awards for Medical Scientists (http://www.bwfund.org), the Kimmel Scholar award (http://www.kimmel.org), a Discovery Grant from the American Brain Tumor Association (http://www.abta.org), a Grant from Accelerated Brain Cancer Cure (http://abc2.org/) and the William Guy Forbeck Research Foundation (http://wgfrf.org/). SY is supported by National Natural Science Foundation of China (81473232) and National Basic Research Program of China (973 Program) (2010CB529800). WKC and FBF are supported by P01-CA95616/NIH and R01-NS080939/NIH. FBF is supported by James S. McDonnell Foundation (https://www.jsmf.org/). NR 47 TC 4 Z9 5 U1 0 U2 2 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD MAY 20 PY 2015 VL 6 IS 14 BP 11751 EP 11767 PG 17 WC Oncology; Cell Biology SC Oncology; Cell Biology GA CO2SZ UT WOS:000359008200004 PM 26059434 ER PT J AU Cirenajwis, H Ekedahl, H Lauss, M Harbst, K Carneiro, A Enoksson, J Rosengren, F Werner-Hartman, L Torngren, T Kvist, A Fredlund, E Bendahl, PO Jirstrom, K Lundgren, L Howlin, J Borg, A Gruvberger-Saal, SK Saal, LH Nielsen, K Ringner, M Tsao, H Olsson, H Ingvar, C Staaf, J Jonsson, G AF Cirenajwis, Helena Ekedahl, Henrik Lauss, Martin Harbst, Katja Carneiro, Ana Enoksson, Jens Rosengren, Frida Werner-Hartman, Linda Torngren, Therese Kvist, Anders Fredlund, Erik Bendahl, Par-Ola Jirstrom, Karin Lundgren, Lotta Howlin, Jillian Borg, Ake Gruvberger-Saal, Sofia K. Saal, Lao H. Nielsen, Kari Ringner, Markus Tsao, Hensin Olsson, Hakan Ingvar, Christian Staaf, Johan Jonsson, Goran TI Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy SO ONCOTARGET LA English DT Article DE gene expression; melanoma; BRAF; BRAF inhibitor; mutation ID STAGE-III MELANOMA; CUTANEOUS MELANOMA; CANCER GENOMICS; BRAF INHIBITOR; RESISTANCE; MUTATIONS; LANDSCAPE AB Melanoma is currently divided on a genetic level according to mutational status. However, this classification does not optimally predict prognosis. In prior studies, we have defined gene expression phenotypes (high-immune, pigmentation, proliferative and normal-like), which are predictive of survival outcome as well as informative of biology. Herein, we employed a population-based metastatic melanoma cohort and external cohorts to determine the prognostic and predictive significance of the gene expression phenotypes. We performed expression profiling on 214 cutaneous melanoma tumors and found an increased risk of developing distant metastases in the pigmentation (HR, 1.9; 95% CI, 1.05-3.28; P=0.03) and proliferative (HR, 2.8; 95% CI, 1.43-5.57; P=0.003) groups as compared to the high-immune response group. Further genetic characterization of melanomas using targeted deep-sequencing revealed similar mutational patterns across these phenotypes. We also used publicly available expression profiling data from melanoma patients treated with targeted or vaccine therapy in order to determine if our signatures predicted therapeutic response. In patients receiving targeted therapy, melanomas resistant to targeted therapy were enriched in the MITF-low proliferative subtype as compared to pretreatment biopsies (P=0.02). In summary, the melanoma gene expression phenotypes are highly predictive of survival outcome and can further help to discriminate patients responding to targeted therapy. C1 [Cirenajwis, Helena; Lauss, Martin; Harbst, Katja; Carneiro, Ana; Rosengren, Frida; Werner-Hartman, Linda; Torngren, Therese; Kvist, Anders; Bendahl, Par-Ola; Lundgren, Lotta; Howlin, Jillian; Borg, Ake; Gruvberger-Saal, Sofia K.; Saal, Lao H.; Ringner, Markus; Olsson, Hakan; Staaf, Johan; Jonsson, Goran] Lund Univ, Div Oncol & Pathol, Dept Clin Sci, Lund, Sweden. [Ekedahl, Henrik; Ingvar, Christian] Lund Univ, Dept Clin Sci, Div Surg, Lund, Sweden. [Carneiro, Ana; Lundgren, Lotta; Olsson, Hakan] Lund Univ, Dept Oncol, Skane Univ Hosp, Lund, Sweden. [Enoksson, Jens; Jirstrom, Karin] Lund Univ, Dept Clin Pathol, Skane Univ Hosp, Lund, Sweden. [Fredlund, Erik] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden. [Nielsen, Kari] Helsingborg Gen Hosp, Dept Dermatol, Helsingborg, Sweden. [Tsao, Hensin] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Tsao, Hensin] Massachusetts Gen Hosp, MGH Canc Ctr, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Jonsson, G (reprint author), Lund Univ, Div Oncol & Pathol, Dept Clin Sci, Lund, Sweden. EM goran_b.jonsson@med.lu.se RI Ringner, Markus/G-3641-2011; OI Ringner, Markus/0000-0001-5469-8940; Saal, Lao/0000-0002-0815-1896 FU Swedish Cancer Society; Swedish Research Council; BioCARE; Berta Kamprad Foundation; King Gustaf V Jubilee foundation; Gunnar Nilsson Cancer foundation; Mats Paulsson's foundation; Stefan Paulsson's foundation; ALF; European council [ERC-2011-294576] FX The study was supported by the Swedish Cancer Society, the Swedish Research Council, BioCARE, the Berta Kamprad Foundation, the King Gustaf V Jubilee foundation, the Gunnar Nilsson Cancer foundation, Mats Paulsson's foundation, Stefan Paulsson's foundation and the governmental funding for healthcare research (ALF). The United States NIH (K24 CA149202 to HT). HO was supported by the European council ERC-2011-294576. We wish to thank Kristina Lovgren, Inger Remse and Bjorn Nodin for their assistance with the immunohistochemical staining. NR 36 TC 15 Z9 15 U1 0 U2 2 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD MAY 20 PY 2015 VL 6 IS 14 BP 12297 EP 12309 PG 13 WC Oncology; Cell Biology SC Oncology; Cell Biology GA CO2SZ UT WOS:000359008200041 PM 25909218 ER PT J AU Abou-Alfa, GK Mayer, RJ Cosgrove, D Capanu, M Choti, MA Atreya, CE Ang, C Kelley, RK Do, RKG Gordan, JD Zhu, AX Ly, M Nolan, P Lubin, L Harding, JJ Saltz, L Venook, AP AF Abou-Alfa, Ghassan K. Mayer, Robert J. Cosgrove, David Capanu, Marinela Choti, Michael A. Atreya, Chloe Evelyn Ang, Celina Kelley, Robin Kate Do, Richard Kinh Gian Gordan, John Dozier Zhu, Andrew X. Ly, Michele Nolan, Patrick Lubin, Lakeisha Harding, James J. Saltz, Leonard Venook, Alan P. TI Randomized phase II study of everolimus (E), leuprolide plus letrozole (LL), and E plus LL (ELL) in patients (pts) with unresectable fibrolamellar carcinoma (FLC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Weill Cornell Med Coll, New York, NY USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Sidney Kimmel Comp Canc Ctr, Baltimore, MD USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15149 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902918 ER PT J AU Abramson, JS Arnason, JE LaCasce, AS Redd, R Barnes, JA Sokol, L Joyce, R Avigan, D Neuberg, DS Takvorian, T Hochberg, EP Bello, CM AF Abramson, Jeremy S. Arnason, Jon E. LaCasce, Ann S. Redd, Robert Barnes, Jeffrey A. Sokol, Lubomir Joyce, Robin Avigan, David Neuberg, Donna S. Takvorian, Tak Hochberg, Ephraim P. Bello, Celeste M. TI Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: A phase II trial. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8505 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901818 ER PT J AU Abramson, JS Davids, MS Werner, L Fisher, DC Armand, P Amrein, PC Neuberg, DS Hochberg, EP Brown, JR AF Abramson, Jeremy S. Davids, Matthew Steven Werner, Lillian Fisher, David Christopher Armand, Philippe Amrein, Philip C. Neuberg, Donna S. Hochberg, Ephraim P. Brown, Jennifer R. TI Lenalidomide added to bendamustine-rituximab for untreated chronic lymphocytic leukemia (CLL): A phase 1 study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7082 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901618 ER PT J AU Abu Zaid, MI Sesso, HD Fung, C Feldman, DR Hamilton, RJ Vaughn, DJ Beard, C Moore, MJ Sahasrabudhe, DM Johnson, E Fossa, S Einhorn, LH Travis, LB AF Abu Zaid, Mohammad Issam Sesso, Howard D. Fung, Chunkit Feldman, Darren Richard Hamilton, Robert James Vaughn, David J. Beard, Clair Moore, Malcolm J. Sahasrabudhe, Deepak M. Johnson, Eileen Fossa, Sophie Einhorn, Lawrence H. Travis, Lois B. CA Platinum Study Grp TI Chronic health conditions (CHCs) following cisplatin-based chemotherapy (CHEM): A multi-institutional study of 680 testicular cancer survivors (TCS) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Indiana Univ Sch Med, Indianapolis, IN 46202 USA. Harvard Univ, Sch Med, Div Prevent Med, Boston, MA USA. Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Toronto, Princess Margaret Hosp, Div Surg Oncol, Toronto, ON, Canada. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Princess Margaret Canc Ctr, Toronto, ON, Canada. Univ Rochester, Wilmot Canc Ctr, Rochester, NY USA. Univ Rochester, Sch Med & Dent, Rochester, NY USA. Oslo Univ Hosp, Oslo, Norway. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9519 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902014 ER PT J AU Aghajanian, C Filiaci, VL Dizon, DS Carlson, J Powell, MA Secord, AA Tewari, KS Bender, D O'Malley, DM Stuckey, A Rotmensch, J Levine, DA Lankes, HA Moore, KN AF Aghajanian, Carol Filiaci, Virginia L. Dizon, Don S. Carlson, Jay Powell, Matthew A. Secord, Angeles Alvarez Tewari, Krishnansu Sujata Bender, David O'Malley, David M. Stuckey, Ashley Rotmensch, Jacob Levine, Douglas A. Lankes, Heather A. Moore, Kathleen N. TI A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Weill Cornell Med Coll, New York, NY USA. NRG Oncol, Buffalo, NY USA. GOG Fdn Inc SDMC, Buffalo, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Canc Res Ozarks, Springfield, MO USA. Washington Univ, Sch Med, St Louis, MO USA. Duke Univ, Med Ctr, Duke Canc Inst, Div Gynecol Oncol, Durham, NC USA. UC Irvine, Med Ctr, Orange, CA USA. Univ Iowa, Iowa City, IA USA. Ohio State Univ, Coll Med, Columbus, OH 43210 USA. Brown Univ, Women & Infants Hosp, Providence, RI USA. Univ Gyn Onc Assoc, Chicago, IL USA. Gyn Onc Grp, Buffalo, NY USA. Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. RI OMalley, David/E-3789-2011 NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5500 PG 2 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901158 ER PT J AU Alabi, SF Vasquez, R Antillon, F Polanco, AC Orellana, E Perez-Atayde, A Albanti, I Friedrich, P Rodriguez-Galindo, C Ribeiro, K Frazier, AL Garrido, C AF Alabi, Soad Fuentes Vasquez, Roberto Antillon, Federico Polanco, Ana C. Orellana, Elisabeth Perez-Atayde, Antonio Albanti, Irini Friedrich, Paola Rodriguez-Galindo, Carlos Ribeiro, Karina Frazier, A. Lindsay Garrido, Claudia TI Implementation of pediatric population-based cancer registries (PBCR) in Central America (CA). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Hosp Benjamin Bloom, San Salvador, El Salvador. Unidad Nacl Oncol Pediat, Guatemala City, Guatemala. Boston Childrens Hosp, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Childrens Hosp, Boston, MA 02115 USA. Santa Casa Sch Med, Sao Paulo, Brazil. Fundacao Oncoctr, Sao Paulo, Brazil. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e12624 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902422 ER PT J AU Albiges, L Xie, WL Chen, YH Boher, JM Valenca, LB Bernard, BD Culine, S Habibian, M Carducci, MA DiPaola, RS Liu, G Pomerantz, M Nakabayashi, M Kantoff, PW Fizazi, K Gravis, G Sweeney, C AF Albiges, Laurence Xie, Wanling Chen, Yu-Hui Boher, Jean-Marie Valenca, Loana Bueno Bernard, Brandon David Culine, Stephane Habibian, Muriel Carducci, Michael Anthony DiPaola, Robert S. Liu, Glenn Pomerantz, Mark Nakabayashi, Mari Kantoff, Philip W. Fizazi, Karim Gravis, Gwenaelle Sweeney, Christopher TI Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Dana Farber Canc Inst, Brookline, MA USA. Aix Marseille Univ, Inst J Paoli I Calmettes, Biostat, Marseille, France. Clin Cehon, Salvador, BA, Brazil. Dana Farber Canc Inst, Boston, MA 02115 USA. Hop St Louis, Dept Med Oncol, Paris, France. UNICANC, Paris, France. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc, Baltimore, MD USA. Rutgers Canc Inst New Jersey, New Brunswick, NJ USA. Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Paris Sud, Inst Gustave Roussy, Dept Canc Med, Villejuif, France. Hop Jour, Inst J Paoli I Calmettes, Med Oncol, Marseille, France. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5052 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901096 ER PT J AU Albiges, L Murray, B Brooks, A Cherniack, A Berger, A Creighton, CJ Ricketts, C Bottaro, DP Srinivasan, R Schmidt, LS Meyerson, M Spellman, P Linehan, WM Choueiri, TK AF Albiges, Laurence Murray, Bradley Brooks, Angela Cherniack, Andrew Berger, Alice Creighton, Chad J. Ricketts, Christopher Bottaro, Donald P. Srinivasan, Ramaprasad Schmidt, Laura S. Meyerson, Matthew Spellman, Paul Linehan, W. Marston Choueiri, Toni K. CA Canc Genome Atlas TCGA Kidney TI Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. Broad Inst, Boston, MA USA. Broad Inst, Cambridge, MA USA. Baylor Coll Med, Houston, TX 77030 USA. NCI, Urol Oncol Branch, Bethesda, MD 20892 USA. NCI, Bethesda, MD 20892 USA. NIH, Bethesda, MD 20892 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dana Farber Canc Inst,Brigham & Womens Hosp,Broad, Boston, MA USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NCI, NIH, Bethesda, MD 20892 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4521 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900989 ER PT J AU Amin, A Lawson, DH Salama, AK Koon, HB Guthrie, TH Thomas, SS O'Day, S Shaheen, MF Zhang, B Francis, S Hodi, FS AF Amin, Asim Lawson, David H. Salama, April K. Koon, Henry B. Guthrie, Troy H. Thomas, Sajeve Samuel O'Day, Steven Shaheen, Montaser F. Zhang, Bin Francis, Stephen Hodi, F. Stephen TI A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA. Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Duke Univ, Med Ctr, Durham, NC USA. Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA. Baptist Canc Inst, Jacksonville, FL USA. Univ Texas MD Anderson Canc Ctr, Orlando, FL USA. Beverly Hills Canc Ctr, Los Angeles Skin Canc Inst, Beverly Hills, CA USA. Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA. Bristol Myers Squibb, Wallingford, NJ USA. Bristol Myers Squibb, Braine Lalleud, Belgium. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9032 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901942 ER PT J AU Antonarakis, ES Kibel, AS Adams, GW Karsh, LI Elfiky, A Shore, ND Vogelzang, NJ Corman, JM Maher, JC DeVries, T McCoy, C Sheikh, NA Drake, CG AF Antonarakis, Emmanuel S. Kibel, Adam S. Adams, George W. Karsh, Lawrence Ivan Elfiky, Aymen Shore, Neal D. Vogelzang, Nicholas J. Corman, John M. Maher, Johnathan Cartwright DeVries, Todd McCoy, Candice Sheikh, Nadeem A. Drake, Charles G. TI Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Harvard Univ, Brigham & Womens Hosp, Urol Surg, Boston, MA 02115 USA. Urol Ctr Alabama, Homewood, AL USA. Urol Ctr Colorado, Clin Res, Denver, CO USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Carolina Urol Res Ctr, Myrtle Beach, SC USA. US Oncol Res Comprehens Canc Ctr Nevada, Las Vegas, NV USA. Virginia Mason Hosp, Seattle, WA USA. Seattle Med Ctr, Seattle, WA USA. Dendreon Corp, Seattle, WA USA. Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Oncol, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5030 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901073 ER PT J AU Antonia, SJ Bendell, JC Taylor, MH Calvo, E Jaeger, D De Braud, FG Ott, PA Pietanza, MC Horn, L Le, DT Morse, M Lopez-Martin, JA Ascierto, PA Christensen, O Grosso, J Simon, JS Lin, CS Eder, JP AF Antonia, Scott Joseph Bendell, Johanna C. Taylor, Matthew Hiram Calvo, Emiliano Jaeger, Dirk De Braud, Filippo G. Ott, Patrick Alexander Pietanza, M. Catherine Horn, Leora Le, Dung T. Morse, Michael Lopez-Martin, Jose A. Ascierto, Paolo Antonio Christensen, Olaf Grosso, Joseph Simon, Jason S. Lin, Chen-Sheng Eder, Joseph Paul TI Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Sarah Cannon Res Inst, Nashville, TN USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. START Madrid, Ctr Integral Oncol Clara Campal, Madrid, Spain. Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany. Fdn IRCCS Ist Nazl Tumori, Milan, Italy. Dana Farber Canc Inst, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. Duke Univ, Med Ctr, Durham, NC USA. Hosp 12 Octubre, E-28041 Madrid, Spain. Ist Nazl Tumori IRCCS, Naples, Italy. Bristol Myers Squibb Co, Princeton, NJ USA. Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA. NR 0 TC 2 Z9 2 U1 4 U2 6 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7503 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901633 ER PT J AU Argiris, A Li, SL Savvides, P Forastiere, AA Burtness, B AF Argiris, Athanassios Li, Shuli Savvides, Panayiotis Forastiere, Arlene A. Burtness, Barbara TI Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. James Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Yale Univ, Sch Med, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6022 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901335 ER PT J AU Armstrong, TS Wen, PY Reardon, DA Phuphanich, S Aiken, R Landolfi, JC Curry, WT Zhu, JJ Glantz, MJ Peereboom, DM Markert, J LaRocca, RV O'Rourke, D Fink, KL Kim, LJ Gruber, ML Lesser, GJ Pan, E Kesari, S Yu, J AF Armstrong, Terri S. Wen, Patrick Y. Reardon, David A. Phuphanich, Surasak Aiken, Robert Landolfi, Joseph C. Curry, William T. Zhu, Jay-Jiguang Glantz, Michael J. Peereboom, David M. Markert, James LaRocca, Renato V. O'Rourke, Donald Fink, Karen L. Kim, Lyndon J. Gruber, Michael L. Lesser, Glenn Jay Pan, Edward Kesari, Santosh Yu, John TI Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas Hlth Sci Ctr Houston, Sch Nursing, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Ctr Inst, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Rush Univ, Med Ctr, Chicago, IL 60612 USA. JFK Medcl Ctr, NJ Neurosci Inst, Edison, NJ USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Texas Houston, Med Sch Houston, Houston, TX USA. Penn State Milton S Hershey Medel Ctr, Hinsdale, MA USA. Cleveland Clin, Fndtn Desk, Cleveland, OH 44106 USA. Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA. Norton Canc Inst, Louisville, KY USA. Univ Penn, Philadelphia, PA 19104 USA. Baylor Res Inst, Dallas, TX USA. Thomas Jefferson Univ, Philadelphia, PA 19107 USA. NYU, Ctr Clin Canc, Englewood, NJ USA. Wake Forest Univ, Winston Salem, NC 27109 USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Univ Calif San Diego, La Jolla, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2036 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900495 ER PT J AU Arney, J Chen, GQJ Helm, A Braun, U Richardson, PA Chen, P Hayes, TG AF Arney, Jennifer Chen, Guoqing J. Helm, Ashley Braun, Ursula Richardson, Peter A. Chen, Ping Hayes, Teresa Gray TI Oncologists perceptions and behaviors regarding genomic-based targeted therapy: Findings of a pilot study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Houston Clear Lake City, Dept Sociol, Houston, TX 77058 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Univ Kansas, Sch Med, Kansas City, KS USA. Kansas City VA Med Ctr, Dept Vet Affairs, Vet Hlth Adm, Off Res & Dev, Kansas City, KS USA. Effectiveness & Safety Michael E DeBakey VAMC, Dept Vet Affairs, Vet Hlth Adm, Off Res & Development, Houston, TX USA. Effectiveness & Safety Michael E DeBakey VAMC, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Univ Massachusetts, Boston, MA 02125 USA. Michael E DeBakey VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e17560 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903530 ER PT J AU Atkins, MB Choueiri, TK Hodi, FS Thompson, JA Hwu, WJ McDermott, DF Brookes, M Tosolini, A Ebbinghaus, S Yang, ZJ Gause, CK Perini, RF Ribas, A AF Atkins, Michael B. Choueiri, Toni K. Hodi, F. Stephen Thompson, John A. Hwu, Wen-Jen McDermott, David F. Brookes, Melissa Tosolini, Alessandra Ebbinghaus, Scot Yang, Zijiang Gause, Christine K. Perini, Rodolfo F. Ribas, Antoni TI Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Washington, Seattle, WA 98195 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Merck & Co Inc, Kenilworth, NJ USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 5 Z9 5 U1 2 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3009 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900643 ER PT J AU Atreya, CE Van Cutsem, E Bendell, JC Andre, T Schellens, JHM Gordon, MS Mcree, AJ O'Dwyer, PJ Muro, K Tabernero, J van Geel, R Sidhu, R Greger, JG Rangwala, FA Motwani, M Wu, YH Orford, KW Corcoran, RB AF Atreya, Chloe Evelyn Van Cutsem, Eric Bendell, Johanna C. Andre, Thierry Schellens, Jan H. M. Gordon, Michael S. McRee, Autumn Jackson O'Dwyer, Peter J. Muro, Kei Tabernero, Josep van Geel, Robin Sidhu, Roger Greger, James G. Rangwala, Fatima A. Motwani, Monica Wu, Yuehui Orford, Keith W. Corcoran, Ryan Bruce TI Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Hosp Leuven, Leuven, Belgium. Sarah Cannon Res Inst, Nashville, TN USA. Hop St Antoine, F-75571 Paris, France. Netherlands Canc Inst, Amsterdam, Netherlands. Pinnacle Oncol Hematol, Scottsdale, AZ USA. Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. Univ Penn, Philadelphia, PA 19104 USA. Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan. Vall dHebron Univ Hosp, Barcelona, Spain. Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands. Amgen Inc, Thousand Oaks, CA 91320 USA. GlaxoSmithKline, Collegeville, PA USA. GlaxoSmithKline, Res Triangle Pk, NC USA. GlaxoSmithKline, Audubon, PA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 103 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900112 ER PT J AU Atri, M Zhang, Z Dehdashti, F Lee, S Ali, S Koh, WJ Moore, KN Landrum, LM Kim, JW DiSilvestro, P Eisenhauer, EL Schnell, FM Gold, M AF Atri, Mostafa Zhang, Zheng Dehdashti, Farrokh Lee, Susanna Ali, Shamshad Koh, Wui-Jin Moore, Kathleen N. Landrum, Lisa Michelle Kim, Jae-Weon DiSilvestro, Paul Eisenhauer, Eric Lawernce Schnell, Frederick M. Gold, Michael TI Utility of PET-CT vs CT alone to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Hlth Network, Toronto, ON, Canada. Brown Univ, Providence, RI 02912 USA. Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Rosewell Pk Canc Inst, Buffalo, NY USA. Univ Washington, Seattle, WA 98195 USA. Peggy & Charles Stephenson Oklahoma Canc Ctr, Oklahoma City, OK USA. Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. Seoul Natl Univ, Seoul, South Korea. Brown Univ, Women & Infants Hosp, Warren Alpert Med Sch, Providence, RI USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Cent Georgia Canc Care PC, Macon, GA USA. Tulsa Canc Inst, Tulsa, OK USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5585 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901251 ER PT J AU Babu, KG Majumder, B Thiyagarajan, S Ulaganathan, B Surindran, R Shenoy, A Kuriakose, MA Loda, M Beroukhim, R Horowitz, P Agarwal, S Radhakrishnan, P Sundaram, M Sengupta, S Majumder, PK AF Babu, Kanaka Govind Majumder, Biswanath Thiyagarajan, Saravanan Ulaganathan, Baraneedharan Surindran, Rajagopal Shenoy, Ashok Kuriakose, Moni A. Loda, Massimo Beroukhim, Rameen Horowitz, Peleg Agarwal, Shivani Radhakrishnan, Padhma Sundaram, Mallik Sengupta, Shiladitya Majumder, Pradip K. TI Application of a robust and novel ex vivo platform mimicking patient heterogenous tumor microenvironment for personalized cancer treatment. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Kidwai Mem Inst Oncol, Bangalore, Karnataka, India. Mitra Biotech, Bangalore, Karnataka, India. Mitra Biotech Private Ltd, Kiran Mazumdar Shaw Canc Ctr, Bangalore, Karnataka, India. Mitra Biotech, Zion, IL USA. Stanley Med Coll, Madras, Tamil Nadu, India. 1Kidwai Mem Inst Oncol, Bangalore, Karnataka, India. Narayana Hrudayalaya Hosp, Majumdar Shaw Canc Inst, Bangalore, Karnataka, India. Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Indian Inst Sci, Bangalore 560012, Karnataka, India. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Mitra Biotech, Brookline, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6029 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901342 ER PT J AU Bajorin, DF Plimack, ER Siefker-Radtke, AO Choueiri, TK De Wit, R Sonpavde, G Gipson, A Brown, H Mai, YB Pang, L Perini, RF Bellmunt, J AF Bajorin, Dean F. Plimack, Elizabeth R. Siefker-Radtke, Arlene O. Choueiri, Toni K. De Wit, Ronald Sonpavde, Guru Gipson, Adrianna Brown, Holly Mai, Yabing Pang, Lei Perini, Rodolfo F. Bellmunt, Joaquim TI KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Fox Chase Canc Ctr, Genitourinary Clin Res, Philadelphia, PA 19111 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Erasmus MC Canc Inst, Rotterdam, Netherlands. Univ Alabama Birmingham UAB, Med, Ctr Comprehens Canc, Birmingham, AL USA. Merck & Co Inc, Kenilworth, NJ USA. Dana Farber Canc Inst Dana Farber, Bladder Canc Ctr, Brigham & Womens Canc Ctr, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS4572 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904764 ER PT J AU Bambury, RM Jordan, E Zabor, EC Bouvier, N Al-Ahmadie, H Boyd, ME Mullane, SA Cha, EK Ostrovnaya, I Hyman, DM Bochner, BH Arcila, ME Solit, DB Bajorin, DF Bellmunt, J Berger, MF Iyer, G Rosenberg, JE AF Bambury, Richard Martin Jordan, Emmet Zabor, Emily Craig Bouvier, Nancy Al-Ahmadie, Hikmat Boyd, Mariel Elena Mullane, Stephanie A. Cha, Eugene K. Ostrovnaya, Irina Hyman, David Michael Bochner, Bernard H. Arcila, Maria E. Solit, David B. Bajorin, Dean F. Bellmunt, Joaquim Berger, Michael F. Iyer, Gopa Rosenberg, Jonathan E. TI Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Weill Cornell Med Coll, New York, NY USA. Mem Sloan Kettering Canc Ctr, Enniscorthy, Wexford, Ireland. Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4532 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901003 ER PT J AU Bardia, A Vahdat, LT Diamond, JR Starodub, A Moroose, RL Isakoff, SJ Ocean, AJ Berlin, J Messersmith, WA Thomas, SS Wilhelm, F Wegener, WA Maliakal, PP Sharkey, RM Goldenberg, DM Mayer, IA AF Bardia, Aditya Vahdat, Linda T. Diamond, Jennifer Robinson Starodub, Alexander Moroose, Rebecca L. Isakoff, Steven J. Ocean, Allyson J. Berlin, Jordan Messersmith, Wells A. Thomas, Sajeve Samuel Wilhelm, Francois Wegener, William A. Maliakal, Pius P. Sharkey, Robert M. Goldenberg, David M. Mayer, Ingrid A. TI Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Weill Cornell Med Coll, New York, NY USA. Univ Colorado Denver, Aurora, CO USA. Indiana Univ Hlth, Goshen Ctr Canc Care, Goshen, IN USA. Univ Texas MD Anderson Canc Ctr, Winter Pk, FL USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Univ Colorado Canc Ctr, Aurora, CO USA. Univ Florida Hlth Canc Ctr Orlando Hlth, Orlando, FL USA. Immunomedics Inc, Morris Plains, NJ USA. Garden State Canc Ctr, Ctr Mol Med & Immunol, Morris Plains, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1016 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900097 ER PT J AU Barr, PM Brown, JR Hillmen, P O'Brien, S Barrientos, JC Reddy, NM Coutre, S Mulligan, SP Jager, U Furman, RR Cymbalista, F Montillo, M Dearden, C Robak, T Moreno, C Pagel, J Burger, JA Suzuki, S James, DF Byrd, JC AF Barr, Paul M. Brown, Jennifer R. Hillmen, Peter O'Brien, Susan Barrientos, Jacqueline Claudia Reddy, Nishitha M. Coutre, Steven Mulligan, Stephen P. Jaeger, Ulrich Furman, Richard R. Cymbalista, Florence Montillo, Marco Dearden, Claire Robak, Tadeusz Moreno, Carol Pagel, John Burger, Jan Andreas Suzuki, Samuel James, Danelle Frances Byrd, John C. TI Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Rochester, Wilmot Canc Inst, Rochester, NY USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. North Shore LIJ Canc Inst, Lake Success, NY USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Stanford Univ, Sch Med, Stanford, CA 94305 USA. Royal N Shore Hosp, Sydney, NSW, Australia. Med Univ Vienna, Vienna, Austria. New York Presbyterian Hosp, Weill Cornell Med College, New York, NY USA. Hop Avicenne, Paris, France. Osped Niguarda Ca Granda, Milan, Italy. Royal Marsden Hosp, London SW3 6JJ, England. Med Univ Lodz, Lodz, Poland. Hosp Santa Creu & Sant Pau, Barcelona, Spain. Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Med Oncol, Seattle, WA 98195 USA. Pharmacyclics Inc, Sunnyvale, CA USA. Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. NR 0 TC 2 Z9 2 U1 1 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7012 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901548 ER PT J AU Barrett, ED Olivier, KM Saylor, PJ Michaelson, MD Lee, RJ AF Barrett, Erika D. Olivier, Kara M. Saylor, Philip James Michaelson, M. Dror Lee, Richard J. TI Activity of gemcitabine and vinorelbine in patients with metastatic urothelial carcinoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15507 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903057 ER PT J AU Baselga, J Cortes, J De Laurentiis, M Dieras, V Harbeck, N Im, YH Jacot, W Krop, IE Verma, S Wilson, TR Lin, R Schimmoller, F Hsu, JY AF Baselga, Jose Cortes, Javier De Laurentiis, Michelino Dieras, Veronique Harbeck, Nadia Im, Young-Hyuck Jacot, William Krop, Ian E. Verma, Sunil Wilson, Timothy R. Lin, Ray Schimmoller, Frauke Hsu, Jerry Y. TI SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. DHebron Univ Hosp, Barcelona, Spain. Fdn G Pascale, Ist Nazl Tumori, Naples, Italy. Inst Curie, Paris, France. Brustzentrum Univ Munchen, Munich, Germany. Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea. Inst Canc Montpellier, Montpellier, France. Dana Farber Canc Inst, Boston, MA 02115 USA. Div Med Oncol, Toronto, ON, Canada. Genentech Inc, San Francisco, CA 94080 USA. Genentech Inc, San Mateo, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS629 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904821 ER PT J AU Bauer, TM Shaw, AT Solomon, B Besse, B James, LP Clancy, JS Mugundu, G Martini, JF Abbattista, A Felip, E AF Bauer, Todd Michael Shaw, Alice Tsang Solomon, Ben Besse, Benjamin James, Leonard P. Clancy, Jill S. Mugundu, Ganesh Martini, Jean-Francois Abbattista, Antonello Felip, Enriqueta TI Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Tennessee Oncol, Nashville, TN USA. Sarah Cannon Res Inst, Nashville, TN USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Peter MacCallum Canc Ctr, East Melbourne, Australia. Gustave Roussy, Villejuif, France. Pfizer, New York, NY USA. Inventiv Clin, Princeton, NJ USA. Pfizer, San Diego, CA USA. Pfizer, Milan, Italy. Vall dHebron Univ Hosp, Barcelona, Spain. NR 0 TC 1 Z9 1 U1 3 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS2620 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904698 ER PT J AU Bauman, JR Piotrowska, Z Scribner, E Temel, B Sequist, LV Heist, RS Temel, JS AF Bauman, Jessica Ruth Piotrowska, Zofia Scribner, Emily Temel, Brandon Sequist, Lecia V. Heist, Rebecca Suk Temel, Jennifer S. TI End of life (EOL) care in patients with metastatic lung cancer harboring EGFR-mutations. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e20508 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904141 ER PT J AU Bedard, PL Davies, MA Kopetz, S Flaherty, KT Shapiro, G Luke, JJ Spreafico, A Wu, B Gomez, C Cartot-Cotton, S Mazuir, F Micallef, S Demers, B Juric, D AF Bedard, Philippe L. Davies, Michael A. Kopetz, Scott Flaherty, Keith T. Shapiro, Geoffrey Luke, Jason John Spreafico, Anna Wu, Bin Gomez, Corinne Cartot-Cotton, Sylvaine Mazuir, Florent Micallef, Sandrine Demers, Brigitte Juric, Dejan TI First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Princess Margaret Canc Ctr, Toronto, ON, Canada. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Chicago Med, Chicago, IL USA. Agios Pharmaceut, Cambridge, MA USA. Sanofi R&D, Alfortville, France. Sanofi R&D, Vitry Sur Seine, France. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2564 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900597 ER PT J AU Bellmunt, J Sonpavde, G De Wit, R Choueiri, TK Siefker-Radtke, AO Plimack, ER Lewis, NM Brown, H Mai, YB Gause, CK Kaufman, DR Bajorin, DF AF Bellmunt, Joaquim Sonpavde, Guru De Wit, Ronald Choueiri, Toni K. Siefker-Radtke, Arlene O. Plimack, Elizabeth R. Lewis, Nicole M. Brown, Holly Mai, Yabing Gause, Christine K. Kaufman, David Ross Bajorin, Dean F. TI KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA. Erasmus MC Canc Inst, Rotterdam, Netherlands. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Merck & Co Inc, Kenilworth, NJ USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS4571 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904763 ER PT J AU Bellmunt, J Valderrama, BP Font, A Virizuela, JA Climent, MA Polo, SH Mellado, B Lainez, N del Alba, AG Arranz, JA Guzman, JCV LLorente, MDM Castellano, DE Gallardo, E del Muro, XG Anido, U Domenech, M Puente, J Gracia, JLP Garcia-Donas, J AF Bellmunt, Joaquim Perez Valderrama, Begona Font, Albert Antonio Virizuela, Juan Angel Climent, Miguel Hernando Polo, Susana Mellado, Begona Lainez, Nuria Gonzalez del Alba, Aranzazu Angel Arranz, Jose Villa Guzman, Jose Carlos del Mar LLorente, Maria Castellano, Daniel E. Gallardo, Enrique Garcia del Muro, Xavier Anido, Urbano Domenech, Montserrat Puente, Javier Perez Gracia, Jose Luis Garcia-Donas, Jesus TI Maintenance vinflunine post cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC): Preliminary analysis of a randomized placebo controlled phase II trial (MAJA trial)-SOGUG 2011-02 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Hosp Univ Virgen Rocio, Seville, Spain. Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Barcelona, Spain. Hosp Univ Virgen Macarena, Seville, Spain. Fdn Inst Valenciano Oncol, Valencia, Spain. Hosp Univ Fdn Alcorcon, Alcorcon, Spain. Hosp Clin Barcelona, Translat Genom & Targeted Therapeut Oncology, IDIBAPS, Dept Med Oncol, Barcelona, Spain. Complejo Hosp Navarra, Pamplona, Spain. Hosp Univ Son Espases, Palma De Mallorca, Spain. Hosp Gen Univ Gregorio Maranon, Madrid, Spain. Hosp Gen Univ Ciudad Real, Ciudad Real, Spain. Hosp Gen Elda Virgen Salud, Elda, Spain. Hosp Univ 12 Octubre, Madrid, Spain. Corp Sanitaria Parc Tauli, Sabadell, Spain. Inst Catala Oncol, Dept Med Oncol, Barcelona, Spain. Complexo Hosp Univ Santiago de Compostela, Santiago De Compostela, Spain. Hosp Althaia, Manresa, Spain. Hosp Clin Univ San Carlos, Madrid, Spain. Univ Navarra Clin, Madrid, Spain. Ctr Integral Oncol Clara Campal, Madrid, Spain. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4529 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900997 ER PT J AU Bellmunt, J Eigl, BJ Senkus-Konefka, E Loriot, Y Twardowski, P Castellano, DE Blais, N Sridhar, SS Sternberg, CN Retz, M Blumenstein, BA Jacobs, C Stewart, PS Petrylak, DP AF Bellmunt, Joaquim Eigl, Bernhard J. Senkus-Konefka, Elzbieta Loriot, Yohann Twardowski, Przemyslaw Castellano, Daniel E. Blais, Normand Sridhar, Srikala S. Sternberg, Cora N. Retz, Margitta Blumenstein, Brent A. Jacobs, Cindy Stewart, Patricia S. Petrylak, Daniel Peter TI First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. BC Canc Agcy, Vancouver, BC, Canada. Med Univ Gdansk, Gdansk, Poland. Grand Paris, Gustave Roussy, Dept Canc Med, Villejuif, France. City Hope Natl Med Ctr, Duarte, CA USA. Hosp Univ 12 Octubre, Madrid, Spain. Hop Notre Dame CHUM, Montreal, PQ, Canada. Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. San Camillo Forlanini Hosp, Rome, Italy. Tech Univ Munich, Dept Urol, Klinikum Rechts Isar, Munich, Germany. Trial Architecture Consulting, Washington, DC USA. OncoGenex Pharmaceut Inc, Bothell, WA USA. Yale Comprehens Canc Ctr, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4503 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900971 ER PT J AU Beltran, H Prandi, D Mosquera, JM Giannopoulou, E Puca, L Marotz, C Nanus, DM Tagawa, ST Elemento, O Van Allen, EM Sboner, A Garraway, LA Rubin, MA Demichelis, F AF Beltran, Himisha Prandi, Davide Mosquera, Juan Miguel Giannopoulou, Eugenia Puca, Loredana Marotz, Clarisse Nanus, David M. Tagawa, Scott T. Elemento, Olivier Van Allen, Eliezer Mendel Sboner, Andrea Garraway, Levi A. Rubin, Mark A. Demichelis, Francesca TI Defining a molecular subclass of treatment resistant prostate cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Weill Cornell Med Coll, New York, NY USA. Univ Trento, Trento, Italy. Weill Cornell Med Coll, Dept Med, Inst Precis Med, New York, NY USA. New York Presbyterian Hosp, New York, NY USA. Cornell Univ, Weill Med Coll, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Weill Cornell Med Coll, Dept Pathol & Lab Med, Inst Computat Biomed, Dept Med,Inst Precis Med, New York, NY USA. Univ Trento, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5004 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901045 ER PT J AU Bernard, BD Markt, SC Albiges, L Miller, R Pettersson, A Beard, C Sweeney, C AF Bernard, Brandon David Markt, Sarah C. Albiges, Laurence Miller, Rowan Pettersson, Andreas Beard, Clair Sweeney, Christopher TI Sunlight and testicular germ cell tumor rates in the USA SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. Mt Vernon Canc Ctr, London, England. Karolinska Inst, Stockholm, Sweden. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15565 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903111 ER PT J AU Bernard, BD Markt, SC Albiges, L Miller, R Beard, C Sweeney, C AF Bernard, Brandon David Markt, Sarah C. Albiges, Laurence Miller, Rowan Beard, Clair Sweeney, Christopher TI Melanoma risk in men with testicular germ cell tumors in the United States SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. Mt Vernon Canc Ctr, London, England. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15554 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903101 ER PT J AU Berry, DL Hong, FX Halpenny, B AF Berry, Donna Lynn Hong, Fangxin Halpenny, Barbara TI Psychosocial outcomes of the electronic self-report assessment for cancer-II randomized trial SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Biostat Core, Boston, MA 02115 USA. Dana Farber Canc Inst, Phyllis F Cantor Ctr Res Nursing & Patient Care S, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6515 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901430 ER PT J AU Best, M Sol, N Kooi, I Nilsson, J Westerman, B Ylstra, B Dorsman, J Smit, EF Verheul, HMW Reijneveld, JC Tannous, BA Wesseling, P Wurdinger, T AF Best, Myron Sol, Nik Kooi, Irsan Nilsson, Jonas Westerman, Bart Ylstra, Bauke Dorsman, Josephine Smit, Egbert F. Verheul, Henk M. W. Reijneveld, Jaap C. Tannous, Bakhos A. Wesseling, Pieter Wurdinger, Thomas TI Allowance of tumor-educated platelets for multiclass liquid biopsy-based diagnosis of cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, Amsterdam, Netherlands. Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands. Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, Amsterdam, Netherlands. Umea Univ, Dept Radiat Sci, Oncol, Umea, Sweden. Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands. Netherlands Canc Inst, Amsterdam, Netherlands. Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Amsterdam, Netherlands. Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Neurosci Program, Cambridge, MA 02138 USA. RI Wesseling, P./H-8114-2014; Ylstra, Bauke/D-2906-2012 OI Wesseling, P./0000-0001-5453-5201; Ylstra, Bauke/0000-0001-9479-3010 NR 0 TC 0 Z9 0 U1 1 U2 7 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 11058 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900317 ER PT J AU Birrer, MJ Choi, Y Brady, MF Mannel, RS Burger, RA Wei, W Husain, A Bais, C AF Birrer, Michael J. Choi, YounJeong Brady, Mark F. Mannel, Robert S. Burger, Robert Allen Wei, Wei Husain, Amreen Bais, Carlos CA NRG Oncol Gynecologic Oncology Grp TI Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin-paclitaxel (CP) +/- bevacizumab (BEV) for epithelial ovarian cancer (EOC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Dana Farber Canc Inst, Boston, MA 02114 USA. Genentech Inc, San Francisco, CA 94080 USA. NRG Stat & Data Ctr, Roswell Pk Canc Inst, Buffalo, NY USA. Univ Oklahoma, Oklahoma City, OK USA. Univ Penn, Dept Obstet & Gynecol, Div Gynecol Oncol, Philadelphia, PA 19104 USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc Res,Gillette Ctr Gynecol Oncol, Boston, MA USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5505 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901163 ER PT J AU Blachly, JS Brown, JR Barrientos, JC Jain, N Kelly, V Garnick, S Rodstrom, J Sweeney, J Tang, S Byrd, JC AF Blachly, James Stewart Brown, Jennifer R. Barrientos, Jacqueline Claudia Jain, Nitin Kelly, Virginia Garnick, Stephanie Rodstrom, Jill Sweeney, Jennifer Tang, Shijie Byrd, John C. TI A phase 1b trial of duvelisib, a PI3K-delta,gamma inhibitor, in combination with obinutuzumab in patients with CLL/SLL previously treated with a Bruton's tyrosine kinase inhibitor (BTKi). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Hofstra North Shore LIJ Sch Med, New Hyde Pk, NY USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Infin Pharmaceut, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS7100 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904843 ER PT J AU Borghaei, H O'Malley, DM Seward, SM Bauer, TM Perez, RP Oza, AM Jeong, W Michenzie, MF Kirby, MW Chandorkar, G Ruiz-Soto, R Birrer, MJ Moore, KN AF Borghaei, Hossein O'Malley, David M. Seward, Shelly Marie Bauer, Todd Michael Perez, Raymond P. Oza, Amit M. Jeong, Woondong Michenzie, Mary F. Kirby, Maurice William Chandorkar, Gurudatt Ruiz-Soto, Rodrigo Birrer, Michael J. Moore, Kathleen N. TI Phase 1 study of IMGN853, a folate receptor alpha (FR alpha)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Ohio State Univ, Coll Med, Columbus, OH 43210 USA. Wayne State Univ, Karmanos Canc Inst, Huntington Woods, MI USA. Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. Univ Kansas, Fairway, KS USA. Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. Westchester Hem Onc Grp, Westchester, NY USA. ImmunoGen Inc, Dedham, MA USA. ImmunoGen Inc, Waltham, MA USA. Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA. Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. RI OMalley, David/E-3789-2011; Perez, Raymond/R-6159-2016 OI Perez, Raymond/0000-0002-7432-2411 NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5558 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901221 ER PT J AU Braunstein, LZ Galland, S Goldberg, S Sadek, BT Shenouda, M Abi-Raad, R MacDonald, SM Taghian, AG AF Braunstein, Lior Zvi Galland, Sigolene Goldberg, Saveli Sadek, Betro T. Shenouda, Mina Abi-Raad, Rita MacDonald, Shannon M. Taghian, Alphonse G. TI Breast cancer with extensive regional lymph node involvement: Toward optimizing local management. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Rad Onc Prog, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Perrysburg, OH USA. Yale Univ, New Haven, CT USA. Francis H Burr Proton Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1053 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900166 ER PT J AU Brose, MS Schlumberger, M Tahara, M Wirth, LJ Robinson, B Elisei, R Newbold, K Kiyota, N Hoff, AO Dutcus, C Song, J Sherman, SI Taylor, MH AF Brose, Marcia S. Schlumberger, Martin Tahara, Makoto Wirth, Lori J. Robinson, Bruce Elisei, Rossella Newbold, Kate Kiyota, Naomi Hoff, Ana O. Dutcus, Corina Song, James Sherman, Steven I. Taylor, Matthew Hiram TI Effect of age and lenvatinib treatment on overall survival for patients with I-131-refractory differentiated thyroid cancer in SELECT SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Gustave Roussy, Dept Nucl Med & Endocrine Oncol, Villejuif, France. Univ Paris Sud, Villejuif, France. Natl Canc Ctr Hosp East, Dept Head & Neck Med Oncol, Kashiwa, Chiba, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Sydney, Kolling Inst Med Res, Sydney, NSW 2006, Australia. Univ Pisa, Dept Clin & Expt Med, Endocrine Unit, Pisa, Italy. Royal Marsden Hosp Natl Hlth Serv Trust, London, England. Kobe Univ Hosp, Dept Med Oncol & Hematol, Kobe, Hyogo, Japan. Univ Sao Paulo, Inst Canc Estado Sao Paulo, Dept Endocrinol, Sao Paulo, Brazil. Eisai Inc, Woodcliff Lake, NJ USA. Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Div Internal Med, Houston, TX 77030 USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. RI Kiyota, Naomi/K-3226-2016 NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6048 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901363 ER PT J AU Burgess, MA Crowley, J Reinke, DK Riedel, RF George, S Movva, S Van Tine, BA Davis, LE Schuetze, S Hu, J Attia, S Priebat, DA Reed, DR D'Angelo, SP Okuno, SH Maki, RG Patel, S Baker, LH Tawbi, HAH AF Burgess, Melissa Amber Crowley, John Reinke, Denise K. Riedel, Richard F. George, Suzanne Movva, Sujana Van Tine, Brian Andrew Davis, Lara Emily Schuetze, Scott Hu, James Attia, Steven Priebat, Dennis A. Reed, Damon R. D'Angelo, Sandra P. Okuno, Scott H. Maki, Robert G. Patel, Shreyaskumar Baker, Laurence H. Tawbi, Hussein Abdul-Hassan TI SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Pittsburgh Phys, Pittsburgh, PA USA. Canc Rsrch & Biostat, Seattle, WA USA. SARC, Ann Arbor, MI USA. Duke Univ, Med Ctr, Durham, NC USA. Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Washington Univ, St Louis, MO USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ So Calif, Norris Comp Canc Ctr, Los Angeles, CA USA. Mayo Clin, Jacksonville, FL 32224 USA. Washington Hosp Ctr, Washington, DC 20010 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Mayo Clin, Rochester, MN USA. Icahn Sch Med Mt Sinai, New York, NY 10029 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS10578 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904654 ER PT J AU Burris, HA Brose, MS Shaw, AT Bauer, TM Farago, AF Doebele, RC Smith, S Fernandes, M Cruickshank, S Low, JA AF Burris, Howard A. Brose, Marcia S. Shaw, Alice Tsang Bauer, Todd Michael Farago, Anna F. Doebele, Robert Charles Smith, Steven Fernandes, Michele Cruickshank, Scott Low, Jennifer A. TI A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Colorado, Aurora, CO USA. Loxo Oncol, San Francisco, CA USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS2624 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904702 ER PT J AU Burris, HA Hurwitz, H Perez, EA Spigel, D Swanton, C Hainsworth, JD Leon, L Beattie, M Brammer, M Sweeney, C AF Burris, Howard A. Hurwitz, Herbert Perez, Edith A. Spigel, David Swanton, Charles Hainsworth, John D. Leon, Larry Beattie, Mary Brammer, Melissa Sweeney, Christopher TI MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. Duke Univ, Med Ctr, Durham, NC USA. Mayo Clin, Jacksonville, FL 32224 USA. Canc Res UK London Res Inst, London WC2A 3PX, England. Genentech Inc, San Francisco, CA 94080 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS11111 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904669 ER PT J AU Buzaglo, JS Karten, C Miller, MF Greer, JA Weiss, ES Mauro, MJ AF Buzaglo, Joanne S. Karten, Clare Miller, Melissa F. Greer, Joseph A. Weiss, Elisa S. Mauro, Michael J. TI Treatment-adherence beliefs and behaviors in patients with chronic myeloid leukemia (CML). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Res & Training Inst, Canc Support Community, Philadelphia, PA USA. CTK Consults, Hartsdale, NY USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Leukemia & Lymphoma Soc, White Plains, NY USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9558 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902053 ER PT J AU Cai, XZ Chandra, V Ou, YM Emblem, KE Muzikansky, A Evans, J Kalpathy-Cramer, J Dietrich, J Chi, AS Wen, PY Rosen, BR Batchelor, T Gerstner, ER AF Cai, Xuezhu Chandra, Vyshak Ou, Yangming Emblem, Kyrre E. Muzikansky, Alona Evans, John Kalpathy-Cramer, Jayashree Dietrich, Jorg Chi, Andrew S. Wen, Patrick Y. Rosen, Bruce R. Batchelor, Tracy Gerstner, Elizabeth Robins TI Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. VCU Sch Medcn, Richmond, VA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. AA Martinos Ctr Biomed Imaging, Boston, MA USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Martinos Ctr Biomed Imaging, Charlestown, MA USA. Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2025 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900484 ER PT J AU Calip, GS Law, E Winer, EP Ko, N AF Calip, Gregory Sampang Law, Ernest Winer, Eric P. Ko, Naomi TI Racial and ethnic differences in risk of second primary cancers among breast cancer survivors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Illinois, Chicago, IL USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Boston Med Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e12592 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902396 ER PT J AU Calkins, A Szalat, R Dreze, M Schnorenberg, M Ceccaldi, R Iglehart, JD Lazaro, JB AF Calkins, Anne Szalat, Raphael Dreze, Matija Schnorenberg, Mathew Ceccaldi, Raphael Iglehart, J. Dirk Lazaro, Jean-Bernard TI Measurement of nucleotide excision repair activity and correlation with cisplatin sensitivity. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Tennessee, Coll Med, Memphis, TN USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1077 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900236 ER PT J AU Camidge, DR Bazhenova, L Salgia, R Langer, CJ Gold, KA Rosell, R Shaw, AT Weiss, GJ Narasimhan, NI Dorer, DJ Rivera, VM Clackson, TP Conlan, MG Kerstein, D Haluska, FG Gettinger, SN AF Camidge, D. Ross Bazhenova, Lyudmila Salgia, Ravi Langer, Corey J. Gold, Kathryn A. Rosell, Rafael Shaw, Alice Tsang Weiss, Glen J. Narasimhan, Narayana I. Dorer, David J. Rivera, Victor M. Clackson, Timothy Piers Conlan, Maureen G. Kerstein, David Haluska, Frank G. Gettinger, Scott N. TI Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK plus non-small cell lung cancer (NSCLC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Colorado, Ctr Canc, Aurora, CO USA. UC San Diego Moores Canc Ctr, La Jolla, CA USA. Univ Chicago, Chicago, IL 60637 USA. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Hosp Badalona Germans Trias & Pujol, Canc Biol & Precis Med Program, Catalan Inst Oncol, Barcelona, Spain. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Canc Treatment Ctr Amer, Western Reg Med Ctr, Goodyear, AZ USA. ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA. Yale Univ, Sch Med, New Haven, CT USA. NR 0 TC 23 Z9 23 U1 1 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8062 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901774 ER PT J AU Cash, T McIlvaine, E Krailo, MD Lessnick, SL Lawlor, ER Laack, NN Sorger, J Marina, N Grier, HE Granowetter, L Womer, RB DuBois, SG AF Cash, Thomas McIlvaine, Elizabeth Krailo, Mark D. Lessnick, Stephen L. Lawlor, Elizabeth R. Laack, Nadia N. Sorger, Joel Marina, Neyssa Grier, Holcombe E. Granowetter, Linda Womer, Richard B. DuBois, Steven G. TI Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Emory Univ, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA. Childrens Oncol Grp, Monrovia, CA USA. Childrens Onc Grp, Arcadia, CA USA. Huntsman Canc Inst, Salt Lake City, UT USA. Univ Michigan, Ann Arbor, MI 48109 USA. Mayo Clin, Rochester, MN USA. Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NYU, Med Ctr, New York, NY USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10051 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900059 ER PT J AU Cassier, PA Maki, RG Wagner, AJ Bompas, E Gelderblom, H Kroep, JR Thomas, DM Italiano, A Seddon, BM Van der Graaf, WTA Domont, J Blay, JY Stacchiotti, S AF Cassier, Philippe Alexandre Maki, Robert G. Wagner, Andrew J. Bompas, Emmanuelle Gelderblom, Hans Kroep, Judith R. Thomas, David Morgan Italiano, Antoine Seddon, Beatrice M. Van der Graaf, Winette T. A. Domont, Julien Blay, Jean-Yves Stacchiotti, Silvia TI Imatinib mesylate (IM) activity in patients (pts) with locally advanced tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Ctr Leon Berard, Dept Med, F-69373 Lyon, France. Icahn Sch Med Mt Sinai, New York, NY 10029 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Ctr Rene Gauducheau, Dept Med Oncol, St Herblain, France. Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands. Leiden Univ, Med Ctr, Amstelveen, Netherlands. Peter MacCallum Canc Ctr, East Melbourne, Australia. CLCC Inst Bergonie, Bordeaux, France. Univ Coll Hosp, New Malden, England. Radboudumc, Nijmegen, Netherlands. Inst Gustave Roussy, Villejuif, France. Ist Nazl Tumori, I-20133 Milan, Italy. RI van der Graaf, Winette/A-5006-2014; Blay, Jean-Yves/N-3966-2016 OI Blay, Jean-Yves/0000-0001-7190-120X NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10561 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900201 ER PT J AU Castillo, JJ Glezerman, IG Boklage, SH Chiodo, JA Tidwell, BA Lamerato, LE Schulman, KL AF Castillo, Jorge J. Glezerman, Ilya G. Boklage, Susan H. Chiodo, Joseph A. Tidwell, Beni A. Lamerato, Lois E. Schulman, Kathy L. TI Prognostic significance of hypervolemic or euvolemic hyponatremia in patients with lymphoma, breast, lung, or colorectal cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Weill Cornell Med Coll, New York, NY USA. Otsuka Amer Pharmaceut Inc, Princeton, NJ USA. Outcomes Res Solut Inc, Waltham, MA USA. Henry Ford Hlth Syst, Detroit, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e17554 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903525 ER PT J AU Cejas, P Mullane, SA Van Allen, EM Barletta, JA Bowden, M Taplin, ME Pomerantz, M Choueiri, TK Kwiatkowski, DJ Long, H Bellmunt, J AF Cejas, Paloma Mullane, Stephanie A. Van Allen, Eliezer Mendel Barletta, Justine A. Bowden, Michaela Taplin, Mary-Ellen Pomerantz, Mark Choueiri, Toni K. Kwiatkowski, David J. Long, Henry Bellmunt, Joaquim TI Evaluating the frequency and functional consequences of epigenetic mutations on outcome derived from urothelial tumor sequencing in non-muscle invasive bladder cancer (NMIBC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15519 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903067 ER PT J AU Chan, A Delaloge, S Holmes, FA Moy, B Iwata, H Harvey, VJ Robert, NJ Silovski, T Gokmen, E Von Minckwitz, G Ejlertsen, B Chia, SKL Mansi, J Barrios, CH Gnant, M Wong, A Bryce, R Yao, B Martin, M AF Chan, Arlene Delaloge, Suzette Holmes, Frankie Ann Moy, Beverly Iwata, Hiroji Harvey, Vernon J. Robert, Nicholas J. Silovski, Tajana Gokmen, Erhan Von Minckwitz, Gunter Ejlertsen, Bent Chia, Stephen K. L. Mansi, Janine Barrios, Carlos H. Gnant, Michael Wong, Alvin Bryce, Richard Yao, Bin Martin, Miguel TI Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Breast Canc Res Ctr WA, Perth, WA, Australia. Curtin Univ, Perth, WA 6845, Australia. Inst Gustave Roussy, Villejuif, France. Texas Oncol PA, Houston, TX USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Aichi Canc Ctr, Chikusa Ku, Nagoya, Aichi 464, Japan. Auckland Hosp, Auckland, New Zealand. US Oncol Network, Virginia Canc Specialists, Fairfax, VA USA. Univ Hosp Tumors, UHC Sestre Milosrdnice, Zagreb, Croatia. Ege Univ, Fac Med, Div Med Oncol, Izmir, Turkey. GBG Forschungs GmbH, Luisenkrankenhaus, Dusseldorf, Neu Isenburg, Germany. Rigshosp, DK-2100 Copenhagen, Denmark. BC Canc Agcy, Vancouver, BC, Canada. Guys Hosp, London SE1 9RT, England. PUCRS Sch Med, Porto Alegre, RS, Brazil. Med Univ Vienna, Vienna, Austria. Puma Biotechnol Inc, Los Angeles, CA USA. Univ Complutense Madrid, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain. NR 0 TC 1 Z9 1 U1 0 U2 6 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 508 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901115 ER PT J AU Chang, SM Zhang, PX Cairncross, JG Gilbert, MR Bahary, JP Dolinskas, C Aldape, KD Chakravarti, A Schiff, D Jaeckle, KA Brown, PD Barger, G Werner-Wasik, M Shih, HA Brachman, D Penas-Prado, M Robins, HI Belanger, K Schultz, CJ Mehta, MP AF Chang, Susan Marina Zhang, Peixin Cairncross, J. Gregory Gilbert, Mark R. Bahary, Jean-Paul Dolinskas, Carol Aldape, Kenneth D. Chakravarti, Arnab Schiff, David Jaeckle, Kurt A. Brown, Paul D. Barger, Geoffrey Werner-Wasik, Maria Shih, Helen Alice Brachman, David Penas-Prado, Marta Robins, H. Ian Belanger, Karl Schultz, Christopher J. Mehta, Minesh P. TI Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 UC San Francisco, San Francisco, CA USA. NRG Oncol, Philadelphia, PA USA. Southern Alberta Canc Rsrch Inst, Calgary, AB, Canada. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Ctr Hosp Univ Montreal, Montreal, PQ, Canada. Univ Penn, Philadelphia, PA 19104 USA. Ohio State Univ, Arthur G James Canc Ctr, Dublin, OH USA. Univ Virginia, Med Ctr, Charlottesville, VA USA. Mayo Clin Florida, Jacksonville, FL USA. Wayne State Univ, Sch Med, Detroit, MI USA. Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Arizona Oncol Serv Fdn, Phoenix, AZ USA. Univ Wisconsin, Comp Canc Ctr, Madison, WI USA. Hop Notre Dame de Bon Secours, Montreal, PQ H2L 4K8, Canada. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Univ Maryland Med Syst, Baltimore, MD USA. RI Gilbert, Mark/J-7494-2016 OI Gilbert, Mark/0000-0003-2556-9722 NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2002 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900461 ER PT J AU Chau, I Peck-Radosavljevic, M Borg, C Malfertheiner, P Seitz, JF Park, JO Ryoo, BY Yen, CJ Kudo, M Poon, RTP Pastorelli, D Blanc, JF Chung, HC Baron, AD Okusaka, T Cui, ZLL Girvan, AC Abada, P Yang, L Zhu, AX AF Chau, Ian Peck-Radosavljevic, Markus Borg, Christophe Malfertheiner, Peter Seitz, Jean Francois Park, Joon Oh Ryoo, Baek-Yeol Yen, Chia-Jui Kudo, Masatoshi Poon, Ronnie Tung-Ping Pastorelli, Davide Blanc, Jean-Frederic Chung, Hyun Cheol Baron, Ari David Okusaka, Takuji Cui, Zhanglin Lin Girvan, Allicia C. Abada, Paolo Yang, Ling Zhu, Andrew X. TI Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Royal Marsden, London, England. Royal Marsden, Surrey, England. Vienna Gen Hosp, Dept Gastroenterol & Hepatol, Vienna, Austria. Med Univ, Vienna, Austria. Univ Hosp Besancon, Besancon, France. Univ Magdeburg, D-39106 Magdeburg, Germany. Hop Enfants La Timone, Marseille, France. Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea. Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea. Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan. Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, Osaka, Japan. Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China. IRCCS, Ist Oncol Veneto, Oncol Med 1, Padua, Italy. Hop St Andre, Bordeaux, France. Yonsei Univ, Coll Med, Dept Internal Med, Yonsei Canc Ctr,Inst Canc Res,Div Med Oncol, Seoul, South Korea. Calif Pacific Med Ctr, San Francisco, CA USA. Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan. Eli Lilly & Co, Indianapolis, IN 46285 USA. Eli Lilly & Co, Bridgewater, NJ USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4077 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900915 ER PT J AU Chawla, SP Schoffski, P Blay, JY Jones, RL Gelderblom, H Attia, S Chmielowski, B Van Tine, BA Trent, JC Patel, S Wagner, AJ Viele, JK Chugh, R Le Cesne, A Tinoco, G Sankhala, KK Falcone, J Schweizer, C Weil, S Maki, RG AF Chawla, Sant P. Schoffski, Patrick Blay, Jean-Yves Jones, Robin Lewis Gelderblom, Hans Attia, Steven Chmielowski, Bartosz Van Tine, Brian Andrew Trent, Jonathan C. Patel, Shreyaskumar Wagner, Andrew J. Viele, James Kert Chugh, Rashmi Le Cesne, Axel Tinoco, Gabriel Sankhala, Kamalesh Kumar Falcone, Julianne Schweizer, Charles Weil, Susan Maki, Robert G. TI A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Sarcoma Oncol Ctr, Santa Monica, CA USA. Univ Hosp Leuven, Leuven, Belgium. Univ Lyon 1, F-69365 Lyon, France. Ctr Leon Berard, F-69373 Lyon, France. Royal Marsden Hosp, London SW3 6JJ, England. Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands. Mayo Clin, Jacksonville, FL 32224 USA. Univ Calif Los Angeles, Los Angeles, CA USA. Washington Univ, St Louis, MO USA. Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Berry Consultants, College Stn, TX USA. Univ Michigain Hlth Syst, Ann Arbor, MI USA. Inst Gustave Roussy, Villejuif, France. Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA. Morphotek Inc, Exton, PA USA. Icahn Sch Med Mt Sinai, New York, NY 10029 USA. RI Blay, Jean-Yves/N-3966-2016 OI Blay, Jean-Yves/0000-0001-7190-120X NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS10577 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904653 ER PT J AU Chen, AB Li, L Cronin, A Brooks, G Kavanagh, BD Schrag, D AF Chen, Aileen B. Li, Ling Cronin, Angel Brooks, Gabriel Kavanagh, Brian D. Schrag, Deborah TI How should we estimate costs of care attributable to cancer? SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Colorado, Ctr Canc, Denver, CO 80262 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6503 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901418 ER PT J AU Chen, YW Gelpi-Hammerschmidt, F Wu, CP Bellmunt, J Chang, SL AF Chen, Yu-Wei Gelpi-Hammerschmidt, Francisco Wu, Chao-Ping Bellmunt, Joaquim Chang, Steven L. TI Contemporary use of lymph node dissection at nephroureterectomy in treating upper tract urothelial carcinoma: A US population-based analysis. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. Urol Oncol, Boston, MA USA. Albert Einstein Coll Med, Dept Med, Jacobi Med Ctr, Bronx, NY 10467 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Urol,Dept Surg, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15634 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903172 ER PT J AU Choueiri, TK Hahn, NM Alva, AS Lauer, RC Dreicer, R Picus, J Pili, R Balar, AV Sonpavde, G Hoffman-Censits, JH Guancial, EA Alter, R Regan, MM Jacobs, C Stewart, PS Pal, SK Rosenberg, JE AF Choueiri, Toni K. Hahn, Noah M. Alva, Ajjai Shivaram Lauer, Richard C. Dreicer, Robert Picus, Joel Pili, Roberto Balar, Arjun Vasant Sonpavde, Guru Hoffman-Censits, Jean H. Guancial, Elizabeth A. Alter, Robert Regan, Meredith M. Jacobs, Cindy Stewart, Patricia S. Pal, Sumanta Kumar Rosenberg, Jonathan E. TI The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Johns Hopkins Med Inst, Indianapolis, IN USA. Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA. Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA. Cleveland Clin, Cleveland, OH 44106 USA. Washington Univ, Div Oncol, St Louis, MO USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. NYU Langone Med Ctr, Perlmutter Canc Ctr, New York, NY USA. Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA. Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA. Univ Rochester, Wilmot Canc Inst, Rochester, NY USA. John Theurer Canc Ctr, Hackensack, NJ USA. Dana Farber Canc Inst, Boston, MA 02115 USA. OncoGenex Pharmaceut Inc, Bothell, WA USA. City Hope Natl Med Ctr, Duarte, CA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS4577 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904769 ER PT J AU Choueiri, TK Fishman, MN Escudier, B McDermott, DF Kluger, HM Stadler, WM Perez-Gracia, JL McNeel, DG Curti, BD Harrison, MR Plimack, ER Appleman, LJ Fong, L Drake, CG Young, TC Chasalow, SD Ross-Macdonald, P Simon, JS Walker, D Sznol, M AF Choueiri, Toni K. Fishman, Mayer N. Escudier, Bernard McDermott, David F. Kluger, Harriet M. Stadler, Walter Michael Perez-Gracia, Jose Luis McNeel, Douglas G. Curti, Brendan D. Harrison, Michael Roger Plimack, Elizabeth R. Appleman, Leonard Joseph Fong, Lawrence Drake, Charles G. Young, Tina C. Chasalow, Scott D. Ross-Macdonald, Petra Simon, Jason S. Walker, Dana Sznol, Mario TI Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. Inst Gustave Roussy, Villejuif, France. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Yale Canc Ctr, New Haven, CT USA. Univ Chicago Med, Chicago, IL USA. Univ Navarra Clin, Pamplona, Spain. Univ Wisconsin, Dept Med, Madison, WI USA. Providence Canc Ctr, Earle Chiles Res Inst, Portland, OR USA. Duke Univ, Med Ctr, Durham, NC USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Univ Pittsburgh, Med Ctr UPMC Canc Pavil, Pittsburgh, PA USA. Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Bristol Myers Squibb Co, Princeton, NJ USA. Yale Univ, Sch Med, New Haven, CT USA. Yale Canc Ctr, New Haven, CT USA. NR 0 TC 12 Z9 12 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4500 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900968 ER PT J AU Cleary, JM Mayer, RJ Van Cutsem, E Yamashita, F Yoshisue, K Ieiri, I Ohtsu, A Lenz, HJ AF Cleary, James M. Mayer, Robert J. Van Cutsem, Eric Yamashita, Fumiaki Yoshisue, Kunihiro Ieiri, Ichiro Ohtsu, Atsushi Lenz, Heinz-Josef TI Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECOURSE trial. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Hosp Leuven, Leuven, Belgium. Taiho Pharmaceut Co Ltd, Tokyo, Japan. Kyushu Univ, Fukuoka 812, Japan. Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan. Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2579 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900612 ER PT J AU Cmelak, A Li, SL Marur, S Zhao, WQ Westra, WH Chung, CH Gillison, ML Gilbert, J Bauman, JE Wagner, LI Ferris, RL Trevarthen, DR Murphy, BA Galloway, T Burtness, B AF Cmelak, Anthony Li, Shuli Marur, Shanthi Zhao, Weiqiang Westra, William H. Chung, Christine H. Gillison, Maura L. Gilbert, Jill Bauman, Julie E. Wagner, Lynne I. Ferris, Robert L. Trevarthen, David R. Murphy, Barbara A. Galloway, Thomas Burtness, Barbara TI Symptom reduction from IMRT dose deintensification: Results from ECOG 1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHNSS V2). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Johns Hopkins, Kimmel Canc Ctr, Baltimore, MD USA. Ohio State Univ, Columbus, OH 43210 USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Vanderbilt Univ, Nashville, TN 37235 USA. Univ Pittsburgh, Pittsburgh, PA USA. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. Colorado Canc Res Program, Denver, CO USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Yale Univ, Sch Med, New Haven, CT USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6021 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901334 ER PT J AU Cohen, EEW Licitra, LF Fayette, J Gauler, TC Clement, PM Grau, JJ Del Campo, JM Mailliez, A Haddad, RI Vermorken, JB Tahara, M Guigay, J Geoffrois, L Merlano, MC Dupuis, NF Burtness, B Gibson, N Solca, F Ehrnrooth, E Machiels, JPH AF Cohen, Ezra E. W. Licitra, Lisa F. Fayette, Jerome Gauler, Thomas Christoph Clement, Paul M. Jose Grau, Juan Maria Del Campo, Jose Mailliez, Audrey Haddad, Robert I. Vermorken, Jan B. Tahara, Makoto Guigay, Joel Geoffrois, Lionnel Merlano, Marco C. Dupuis, Nicholas F. Burtness, Barbara Gibson, Neil Solca, Flavio Ehrnrooth, Eva Machiels, Jean-Pascal H. TI Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 UC San Diego Moores Canc Ctr, La Jolla, CA USA. Fdn IRCCS Ist Nazl Tumori, Milan, Italy. Univ Lyon, Leon Berard Ctr, Lyon, France. Univ Lyon, Hosp Civils Lyon, Lyon, France. Univ Hosp Essen, West German Canc Ctr, Essen, Germany. Katholieke Univ Leuven, Dept Oncol, Leuven, Germany. Univ Barcelona, Hosp Clin Barcelona, Barcelona, Spain. Hosp Univ Vall DHebron, Dept Med Oncol, Barcelona, Spain. Ctr Oscar Lambret, F-59020 Lille, France. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. Univ Antwerp Hosp, Edegem, Netherlands. East Hosp, Natl Canc Ctr, Kashiwa, Chiba, Japan. Gustave Roussy, Villejuif, France. Ctr Antoine Lacassagne, F-06054 Nice, France. Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France. Azienda Osped Santa Croce & Carle, Cuneo, Italy. Biodesix Inc, Boulder, CO USA. Fox Chase Canc Ctr, New Haven, CT USA. Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany. Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. Boehringer Ingelheim Denmark AS, Copenhagen, Denmark. Catholic Univ Louvain, Inst Roi Albert II, Serv Oncol Med, Clin Univ St Luc, B-1200 Brussels, Belgium. Catholic Univ Louvain, Inst Rech Clin & Expt Pole MIRO, B-1200 Brussels, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6023 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901336 ER PT J AU Colleoni, M Gray, KP Gelber, SI Lang, I Thurlimann, BJK Gianni, L Abdi, EA Price, KN Gelber, RD Viale, G Coates, AS Goldhirsch, A AF Colleoni, Marco Gray, Kathryn P. Gelber, Shari I. Lang, Istvan Thurlimann, Beat J. K. Gianni, Lorenzo Abdi, Ehtesham A. Price, Karen N. Gelber, Richard D. Viale, Giuseppe Coates, Alan S. Goldhirsch, Aron CA Int Breast Canc Study Grp TI Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 European Inst Oncol, Milan, MI, Italy. Dana Farber Canc Inst, Boston, MA 02115 USA. Natl Inst Oncol, Budapest, Hungary. Kantonsspital, St Gallen, Switzerland. Onc Dept Infermi Hosp, Cesena, FC, Italy. Tweed Hosp, Tweed Heads, NSW, Australia. Dana Farber Canc Inst, Boston, MA 02115 USA. European Inst Oncol, Div Pathol, Milan, Italy. Univ Sydney, Sydney, NSW 2006, Australia. European Inst Oncol, Milan, Italy. NR 0 TC 3 Z9 3 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1002 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900024 ER PT J AU Connolly, RM Zhao, FM Miller, K Tevaarwerk, A Wagner, LI Lee, MJ Murray, J Gray, RJ Piekarz, R Zujewski, JA Sparano, JA AF Connolly, Roisin M. Zhao, Fengmin Miller, Kathy Tevaarwerk, Amye Wagner, Lynne I. Lee, Min-Jung Murray, Judy Gray, Robert James Piekarz, Richard Zujewski, Jo Anne Sparano, Joseph A. TI E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. Dana Farber Canc Inst, Malden, MA USA. Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA. Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. Northwestern Univ, Feinberg Sch, Chicago, IL 60611 USA. NIH, Bethesda, MD 20892 USA. Johns Hopkins Univ, Baltimore, MD USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NCI, Canc Therapy Evaluat Program, NIH, Bethesda, MD 20892 USA. NCI, NIH, Bethesda, MD 20892 USA. Montefiore Med Ctr, Bronx, NY 10467 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS636 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904828 ER PT J AU Coutre, S Barrientos, JC Brown, JR De Vos, S Furman, RR Keating, MJ O'Brien, SM Pagel, JM Sharman, JP Zelenetz, AD Newcomb, T Cho, Y Aguilar, C Dreiling, L AF Coutre, Steven Barrientos, Jacqueline Claudia Brown, Jennifer R. De Vos, Sven Furman, Richard R. Keating, Michael J. O'Brien, Susan Mary Pagel, John M. Sharman, Jeff Porter Zelenetz, Andrew David Newcomb, Terry Cho, Yoonjin Aguilar, Christopher Dreiling, Lyndah TI Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA. Hofstra North Shore LIJ Sch Med, New Hyde Pk, NY USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Hematol Oncol, Los Angeles, CA 90095 USA. New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. UC Irvine Hlth, Chao Family Comprehens Canc Ctr, Orange, CA USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Willamette Valley Canc Inst & Res Ctr, Springfield, OR USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Gilead Sci Inc, Foster City, CA 94404 USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e18030 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903763 ER PT J AU Coyne, GHO Kummar, S Do, KT Holbeck, S Hollingshead, MG Horneffer, Y Juwara, L Srivastava, AK Rubinstein, L Piekarz, R Sharon, E Streicher, H Conley, BA Antony, R Collins, JM Chen, A Doroshow, JH AF Coyne, Geraldine Helen O'Sullivan Kummar, Shivaani Khanh Tu Do Holbeck, Susan Hollingshead, Melinda G. Horneffer, Yvonne Juwara, Lamin Srivastava, Apurva K. Rubinstein, Larry Piekarz, Richard Sharon, Elad Streicher, Howard Conley, Barbara A. Antony, Ramya Collins, Jerry M. Chen, Alice Doroshow, James H. TI Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Early Clin Trials Dev Program, Bethesda, MD USA. Stanford Univ, Sch Med, Phase Clin Res Program 1, Stanford, CA 94305 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA. NCI, Div Canc Treatment & Diag, NIH, Frederick, MD 21701 USA. NCI, Bethesda, MD 20892 USA. Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD USA. Div Canc Treatment & Diag, Bethesda, MD USA. NCI, Canc Therapy Evaluat Program, NIH, Bethesda, MD 20892 USA. NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA. NCI, Rockville, MD USA. Leidos Biomed Res Inc, Frederick, MD USA. NCI, DCTD, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 6 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS2614 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904692 ER PT J AU Currow, DC Temel, JS Fearon, K Yan, Y Friend, J Abernethy, AP AF Currow, David Christopher Temel, Jennifer S. Fearon, Kenneth Yan, Ying Friend, John Abernethy, Amy Pickar TI A safety extension study of anamorelin in advanced non-small cell lung cancer patients with cachexia: ROMANA 3. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Flinders Univ S Australia, Adelaide, SA 5001, Australia. Massachusetts Gen Hosp, Boston, MA 02114 USA. Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland. Helsinn Therapeut US Inc, Bridgewater, NJ USA. Duke Univ, Durham, NC USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e20715 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904316 ER PT J AU D'Agostino, NM Edelstein, K Zhang, N Recklitis, CJ Brinkman, TM Srivastava, D Leisenring, WM Robison, LL Armstrong, GT Krull, KR AF D'Agostino, Norma Mammone Edelstein, Kim Zhang, Nan Recklitis, Christopher J. Brinkman, Tara M. Srivastava, Deokumar Leisenring, Wendy M. Robison, Leslie L. Armstrong, Gregory T. Krull, Kevin R. TI Patterns and predictors of psychological distress in adult survivors of childhood cancer: A Childhood Cancer Survivor Study (CCSS). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. St Jude Childrens Res Hosp, Memphis, TN 38105 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10065 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900074 ER PT J AU Daud, A Weber, JS Sosman, JA Kim, K Gonzalez, R Hamid, O Infante, JR Cebon, JS Schuchter, LM Long, GV Algazi, AP Kudchadkar, RR Puzanov, I Lawrence, DP Kefford, R Kline, AS Del Buono, HL Sun, P McDowell, DO Flaherty, K AF Daud, Adil Weber, Jeffrey S. Sosman, Jeffrey Alan Kim, Kevin Gonzalez, Rene Hamid, Omid Infante, Jeffrey R. Cebon, Jonathan S. Schuchter, Lynn Mara Long, Georgina V. Algazi, Alain Patrick Kudchadkar, Ragini Reiney Puzanov, Igor Lawrence, Donald P. Kefford, Richard Kline, Amy S. Del Buono, Heather Lynn Sun, Peng McDowell, Diane Opatt Flaherty, Keith TI Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 UC San Francisco, San Francisco, CA USA. Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Angeles Clin & Res Inst, Los Angeles, CA USA. Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA. Austin Hosp, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Melanoma Inst Australia, Sydney, NSW, Australia. Univ Sydney, Sydney, NSW, Australia. Univ Calif San Francisco, San Francisco, CA 94143 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Crown Princess Mary Canc Ctr, Sydney, NSW, Australia. GlaxoSmithKline, Collegeville, PA USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9036 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901946 ER PT J AU Daud, A Ribas, A Robert, C Hodi, FS Wolchok, JD Joshua, AM Hwu, WJ Weber, JS Gangadhar, TC Joseph, RW Dronca, RS Patnaik, A Zarour, HM Kefford, R Lindia, JA Li, XN Ebbinghaus, S Kang, SP Hamid, O AF Daud, Adil Ribas, Antoni Robert, Caroline Hodi, F. Stephen Wolchok, Jedd D. Joshua, Anthony M. Hwu, Wen-Jen Weber, Jeffrey S. Gangadhar, Tara C. Joseph, Richard Wayne Dronca, Roxana Stefania Patnaik, Amita Zarour, Hassane M. Kefford, Richard Lindia, Jill Ann Li, Xiaoyun Nicole Ebbinghaus, Scot Kang, Soonmo Peter Hamid, Omid TI Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 UC San Francisco, San Francisco, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Gustave Roussy, Villejuif, France. Dana Farber Canc Inst, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Princess Margaret Canc Ctr, Toronto, ON, Canada. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Mayo Clin Jacksonville, Jacksonville, FL 32224 USA. Mayo Clin, Rochester, MN USA. START, San Antonio, TX USA. Univ Pittsburgh, Pittsburgh, PA USA. Crown Princess Mary Canc Ctr, Sydney, NSW, Australia. Merck & Co Inc, Kenilworth, NJ USA. Angeles Clin, Los Angeles, CA USA. Res Inst, Los Angeles, CA USA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9005 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901915 ER PT J AU Davis, ID Stockler, MR Martin, AJ Marchesin, V Deignan, O McDermott, R Parulekar, WR North, SA Graham, B Long, AP Roncolato, FT Yip, S Hague, W Dazo, C Coskinas, X Sweeney, C AF Davis, Ian D. Stockler, Martin R. Martin, Andrew James Marchesin, Vittorio Deignan, Olwyn McDermott, Ray Parulekar, Wendy R. North, Scott A. Graham, Barbara Long, Anne Poh Roncolato, Felicia T. Yip, Sonia Hague, Wendy Dazo, Carlo Coskinas, Xanthi Sweeney, Christopher TI Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Monash Univ, Eastern Hlth Clin Sch, Box Hill, Vic, Australia. Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia. ICORG, Dublin, Ireland. Queens Univ, NCIC Clin Trials Grp, Canc Res Inst, Kingston, ON, Canada. Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada. Queens Univ, Kingston, ON, Canada. Royal Perth Hosp, Willetton, WA, Australia. NHMRC Clin Trials Ctr, Camperdown, NSW, Australia. Sydney Catalyst Translat Canc Res Ctr, Sydney, NSW, Australia. NHMRC Clin Trials Ctr, Sydney, NSW, Australia. Dana Farber Canc Inst, Boston, MA 02115 USA. RI Stockler, Martin/N-3859-2016 OI Stockler, Martin/0000-0003-3793-8724 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS5077 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904786 ER PT J AU de Velasco, G Fay, AP Culhane, A Hakimi, AA Voss, MH Tannir, NM Tamboli, P Appleman, LJ Bellmunt, J Rathmell, K Albiges, LK Hsieh, J Heng, DYC Signoretti, S Choueiri, TK AF de Velasco, Guillermo Fay, Andre Poisl Culhane, Aedin Hakimi, A. Ari Voss, Martin Henner Tannir, Nizar M. Tamboli, Pheroze Appleman, Leonard Joseph Bellmunt, Joaquim Rathmell, Kimryn Albiges, Laurence K. Hsieh, James Heng, Daniel Yick Chin Signoretti, Sabina Choueiri, Toni K. TI Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. HSL PUCRS, Oncol Serv, Porto Alegre, RS, Brazil. HSL PUCRS, Oncol Res Unit, Porto Alegre, RS, Brazil. Harvard Univ, Brookline, MA USA. Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Univ N Carolina, Chapel Hill, NC USA. Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4560 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901031 ER PT J AU Demetri, GD von Mehren, M Jones, RL Hensley, ML Schuetze, S Staddon, AP Milhem, MM Elias, AD Ganjoo, KN Tawbi, HAH Van Tine, BA Spira, AI Dean, AP Khokhar, NZ Park, YC Knoblauch, RE Parekh, TV Maki, RG Patel, S AF Demetri, George D. von Mehren, Margaret Jones, Robin Lewis Hensley, Martee Leigh Schuetze, Scott Staddon, Arthur P. Milhem, Mohammed M. Elias, Anthony D. Ganjoo, Kristen N. Tawbi, Hussein Abdul-Hassan Van Tine, Brian Andrew Spira, Alexander I. Dean, Andrew Peter Khokhar, Nushmia Z. Park, Youn Choi Knoblauch, Roland Elmar Parekh, Trilok V. Maki, Robert G. Patel, Shreyaskumar TI A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA. Seattle Canc Care Alliance, Seattle, WA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Weill Cornell Med Coll, New York, NY USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Penn, Philadelphia, PA 19104 USA. Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA. Univ Colorado Canc Ctr, Aurora, CO USA. Stanford Univ, Stanford, CA 94305 USA. Univ Pittsburgh Canc Inst, Pittsburgh, PA USA. Washington Univ, St Louis, MO USA. US Oncol Res, Virginia Canc Specialists Res Inst, Fairfax, VA USA. St John God Hosp Subiaco, Subiaco, WA, Australia. Janssen Pharmaceut, Raritan, NJ USA. Janssen Res & Dev LLC, Raritan, NJ USA. Icahn Sch Med Mt Sinai, New York, NY 10029 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 5 Z9 5 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10503 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900137 ER PT J AU Dickler, MN Barry, WT Cirrincione, CT Ellis, MJ Moynahan, ME Innocenti, F Hurria, A Rugo, HS Lake, D Hahn, OM Schneider, BP Tripathy, D Winer, EP Hudis, CA AF Dickler, Maura N. Barry, William Thomas Cirrincione, Constance T. Ellis, Matthew James Moynahan, Mary Ellen Innocenti, Federico Hurria, Arti Rugo, Hope S. Lake, Diana Hahn, Olwen Mary Schneider, Bryan P. Tripathy, Debu Winer, Eric P. Hudis, Clifford A. TI Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Duke Univ, Alliance Stat Ctr, Durham, NC USA. Washington Univ, St Louis, MO USA. Univ N Carolina, Chapel Hill, NC USA. City Hope Natl Med Ctr, Duarte, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Chicago, Chicago, IL 60637 USA. Indiana Univ Simon Canc Ctr, Indianapolis, IN USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 501 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901051 ER PT J AU Diefenbach, CSM Li, HL Kahl, BS Robertson, MJ Cohen, J Advani, RH Ambinder, R Fenske, TS Ansell, SM AF Diefenbach, Catherine S. Magid Li, Hailun Kahl, Brad S. Robertson, Michael J. Cohen, Jonathan Advani, Ranjana H. Ambinder, Richard Fenske, Timothy S. Ansell, Stephen Maxted TI A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 NYU, Sch Med, Perlmutter Canc Ctr, New York, NY USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA. Emory Univ, Atlanta, GA 30322 USA. Stanford Univ, Sch Med, Div Oncol, Stanford, CA 94305 USA. Johns Hopkins Sch Med, Baltimore, MD USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS8602 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904864 ER PT J AU Dimopoulos, MA Leleu, X Matous, J MacDonald, D Trotman, J Oriol, A Shustik, C Tedeschi, A Garcia-Sanz, R Heffner, LT Ma, S Mahe, B Tam, C Tournilhac, O Li, JL Singh, P Bilotti, E Graef, T Treon, SP Buske, C AF Dimopoulos, Meletios A. Leleu, Xavier Matous, Jeffrey MacDonald, David Trotman, Judith Oriol, Albert Shustik, Chaim Tedeschi, Alessandra Garcia-Sanz, Ramon Heffner, Leonard T. Ma, Shuo Mahe, Beatrice Tam, Constantine Tournilhac, Olivier Li, Jianling Singh, Priyanka Bilotti, Elizabeth Graef, Thorsten Treon, Steven P. Buske, Christian TI A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom's macroglobulinemia (PCYC-1127-CA). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece. Hop Claude Huriez, Serv Malad Sang, Lille, France. Colorado Blood Canc Inst, Denver, CO USA. Dalhousie Univ, Div Hematol, Halifax, NS, Canada. Concord Hosp, Dept Haematol, Sydney, NSW, Australia. Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain. Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada. Osped Niguarda Ca Granda, Dept Hematol, Milan, Italy. Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain. Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA. Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. Univ Hosp, Hematol, Nantes, France. Peter MacCallum Canc Ctr, East Melbourne, Australia. St Vincents Hosp, East Melbourne, Australia. Univ Auvergne, UFR Med, INSERM CIC 501, CREaT,EA3846, Clermont Ferrand, France. Pharmacyclics Inc, Sunnyvale, CA USA. Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. Univ Ulm, Inst Expt Canc Res, D-89069 Ulm, Germany. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS8599 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904861 ER PT J AU Dizon, DS Brady, WE Lankes, HA Jandial, DA Howell, SB Schilder, RJ Beumer, JH Christner, SM Strychor, S Powell, MA Hagemann, AR Moore, KN Walker, JL DiSilvestro, P Fracasso, PM AF Dizon, Don S. Brady, William E. Lankes, Heather A. Jandial, Danielle A. Howell, Stephen B. Schilder, Russell J. Beumer, Jan Hendrik Christner, Susan M. Strychor, Sandra Powell, Matthew A. Hagemann, Andrea R. Moore, Kathleen N. Walker, Joan L. DiSilvestro, Paul Fracasso, Paula M. CA NRG Oncology TI Results of a phase I pharmacokinetic study of intraperitoneal bortezomib (B) and carboplatin (C) in patients with persistent or recurrent ovarian cancer (OC): An NRG/Gynecologic Oncology Group study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Gyn Onc Grp, Buffalo, NY USA. UC Irvine, Orange, CA USA. UC San Diego Moores Canc Ctr, La Jolla, CA USA. Thomas Jefferson Univ, Philadelphia, PA 19107 USA. Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. Univ Pittsburgh, Pittsburgh, PA USA. Washington Univ, Sch Med, St Louis, MO USA. Siteman Canc Ctr, St Louis, MO USA. Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. OUHSC, Stephenson Canc Ctr, Oklahoma City, OK USA. Brown Univ, Warren Alpert Med Sch, Women & Infants Hosp, Providence, RI 02912 USA. Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5515 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901174 ER PT J AU El-Jawahri, A Shin, J Traeger, L Knight, H Fishbein, JN VanDusen, H Keenan, T Jackson, VA Volandes, AE Temel, JS AF El-Jawahri, Areej Shin, Jennifer Traeger, Lara Knight, Helen Fishbein, Joel Nathan VanDusen, Harry Keenan, Tanya Jackson, Vicki A. Volandes, Angelo E. Temel, Jennifer S. TI Qualitative study of patients' and family caregivers' (FC) perceptions and information preferences about hospice. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e20501 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904134 ER PT J AU El-Jawahri, A Temel, JS Ramchandran, K Jackson, VA Chang, Y Walker-Corkery, E Mann, E Volandes, AE AF El-Jawahri, Areej Temel, Jennifer S. Ramchandran, Kavitha Jackson, Vicki A. Chang, Yuchiao Walker-Corkery, Elizabeth Mann, Eileen Volandes, Angelo E. TI A randomized, controlled trial of a cardiopulmonary resuscitation (CPR) video decision support tool for seriously ill hospitalized patients with advanced cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Stanford Univ, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9516 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902011 ER PT J AU Ellisen, LW Kurian, AW Desmond, AJ Mills, M Lincoln, SE Shannon, KM Gabree, M Tung, NM Ford, JM AF Ellisen, Leif W. Kurian, Allison W. Desmond, Andrea J. Mills, Meredith Lincoln, Stephen E. Shannon, Kristen M. Gabree, Michele Tung, Nadine M. Ford, James M. TI Clinical impact of multi-gene panel testing for hereditary breast and ovarian cancer risk assessment SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. Stanford Univ, Med Ctr, Stanford, CA 94305 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Stanford Univ, Stanford, CA 94305 USA. InVitae, San Francisco, CA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Stanford Univ, Sch Med, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1513 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900380 ER PT J AU Enzinger, PC Abrams, TA Chan, JA McCleary, NJ Zheng, H Kwak, EL Yurgelun, M Blaszkowsky, LS Cleary, JM Wolpin, BM Meyerhardt, JA Regan, E Graham, C Straw, K Fuchs, CS Kelly, RJ AF Enzinger, Peter C. Abrams, Thomas Adam Chan, Jennifer A. McCleary, Nadine Jackson Zheng, Hui Kwak, Eunice Lee Yurgelun, Matthew Blaszkowsky, Lawrence Scott Cleary, James M. Wolpin, Brian M. Meyerhardt, Jeffrey A. Regan, Eileen Graham, Christopher Straw, Katharine Fuchs, Charles S. Kelly, Ronan Joseph TI Multicenter phase 2: Capecitabine (CAP) plus oxaliplatin (OX) plus bevacizumab (BEV) plus trastuzumab (TRAS) for patients (pts) with metastatic esophagogastric cancer (MEGCA) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4038 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900877 ER PT J AU Farago, AF Zheng, ZL Muzikansky, A Gainor, JF Iafrate, AJ Engelman, JA Le, LP Shaw, AT AF Farago, Anna F. Zheng, Zongli Muzikansky, Alona Gainor, Justin F. Iafrate, A. John Engelman, Jeffrey A. Le, Long P. Shaw, Alice Tsang TI Clinical implementation of anchored multiplex PCR with targeted next-generation sequencing for detection of ALK, ROS1, RET and NTRK1 fusions in non-small cell lung carcinoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8095 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901807 ER PT J AU Faustman, DL AF Faustman, Denise L. TI Inactivation of highly potent regulatory T cells (Tregs) with TNFR2 antagonist antibodies as a novel cancer immunotherapy approach. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Charlestown, MA USA. Harvard Med, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 3 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e14020 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902611 ER PT J AU Fay, AP Kwiatkowski, DJ Gray, KP Thorner, A Rini, BI Agarwal, N Ho, TH Song, JX Barrios, PM Albiges, L Van Allen, EM Krajewski, KM Porta, C Pal, SK Bellmunt, J McDermott, DF Heng, DYC Signoretti, S Choueiri, TK AF Fay, Andre Poisl Kwiatkowski, David J. Gray, Kathryn P. Thorner, Aaron Rini, Brian I. Agarwal, Neeraj Ho, Thai Huu Song, Jiaxi Barrios, Pablo M. Albiges, Laurence Van Allen, Eliezer Mendel Krajewski, Katherine Maragaret Porta, Camillo Pal, Sumanta Kumar Bellmunt, Joaquim McDermott, David F. Heng, Daniel Yick Chin Signoretti, Sabina Choueiri, Toni K. TI Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 HSL PUCRS, Oncol Serv, Porto Alegre, RS, Brazil. HSL PUCRS, Oncol Res Unit, Porto Alegre, RS, Brazil. Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. Mayo Clin, Scottsdale, AZ USA. Brigham & Womens Hosp, Boston, MA 02115 USA. PUCRS Sch Med, Porto Alegre, RS, Brazil. Univ Paris Sud, Inst Gustave Roussy, Villejuif, France. IRCCS San Matteo Univ Hosp Fdn, Pavia, Italy. City Hope Natl Med Ctr, Duarte, CA USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada. Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4519 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900987 ER PT J AU Felip, E Orlov, S Park, K Yu, CJ Tsai, CM Nishio, M Dols, MC McKeage, MJ Su, WC Mok, T Scagliotti, GV Spigel, D Branle, F Emeremni, C Quadrigli, M Shaw, AT AF Felip, Enriqueta Orlov, Sergey Park, Keunchil Yu, Chong-Jen Tsai, Chun-Ming Nishio, Makoto Dols, Manuel Cobo McKeage, Mark James Su, Wu-Chou Mok, Tony Scagliotti, Giorgio V. Spigel, David Branle, Fabrice Emeremni, Chetachi Quadrigli, Massimiliano Shaw, Alice Tsang TI ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naive adult patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Vall dHebron Univ, Barcelona, Spain. St Petersburg State Med Univ, Dept Thorac Oncol, St Petersburg, Russia. Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol & Oncol, Seoul, South Korea. Natl Taiwan Univ, Taipei 10764, Taiwan. Taipei Vet Gen Hosp, Taipei, Taiwan. Japanese Fdn Canc Res, Tokyo, Japan. Hosp Reg Univ Carlos Haya, Med Oncol Sect, Malaga, Spain. Auckland City Hosp, Auckland, New Zealand. Univ Auckland, Auckland 1, New Zealand. Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan. Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China. Univ Turin, Turin, Italy. Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA. Novartis Pharma AG, Basel, Switzerland. Novartis Pharmaceut, E Hanover, NJ USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 26 Z9 26 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8060 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901772 ER PT J AU Fenaux, P Al-Kali, A Baer, MR Sekeres, MA Roboz, GJ Gaidano, G Silverman, LR Scott, BL Greenberg, P Platzbecker, U Steensma, DP Kreuzer, KA Godley, LA Collins, R Atallah, EL Azarnia, N Garcia-Manero, G AF Fenaux, Pierre Al-Kali, Aref Baer, Maria R. Sekeres, Mikkael A. Roboz, Gail J. Gaidano, Gianluca Silverman, Lewis R. Scott, Bart L. Greenberg, Peter Platzbecker, Uwe Steensma, David P. Kreuzer, Karl A. Godley, Lucy A. Collins, Robert Atallah, Ehab L. Azarnia, Nozar Garcia-Manero, Guillermo TI Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Hosp St Louis, Paris, France. Mayo Clin, Rochester, MN USA. Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA. Cleveland Clin, Leukemia Program, Dept Hematol & Oncol, Cleveland, OH 44106 USA. Weill Cornell Med Coll, New York, NY USA. Amedeo Avogadro Univ Eastern Piedmont, Novara, Italy. Mt Sinai Med Ctr, New York, NY 10029 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Stanford Univ, Stanford, CA 94305 USA. Univ Hosp Carl Gustav Carus TUD, Dresden, Germany. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Hosp Cologne, Cologne, Germany. Univ Chicago, Chicago, IL 60637 USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Onconova Therapeut Inc, Pennington, NJ USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e18079 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903801 ER PT J AU Ferrari, AC Alumkal, JJ Stein, MN Mayer, TM Torneten, S Babb, J Taplin, ME DiPaola, RS Beer, TM AF Ferrari, Anna C. Alumkal, Joshi J. Stein, Mark N. Mayer, Tina M. Torneten, Sarah Babb, James Taplin, Mary-Ellen DiPaola, Robert S. Beer, Tomasz M. TI LBH589 (LBH) and bicalutamide (Bic) in castration-resistant prostate cancer (CRPC) patients (pts) progressing on second line anti-androgen (AA): NYU-08479/PCCTC. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 NYU, Perlmutter Canc Ctr, Langone Med Ctr, New York, NY USA. OHSU, Portland, OR USA. Canc Inst New Jersey, New Brunswick, NJ USA. Rutgers Canc Inst New Jersey, New Brunswick, NJ USA. NYU, New York, NY USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5050 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901094 ER PT J AU Ferrario, C Welch, S Chaves, JM Walker, LN Krop, IE Hamilton, EP Borges, VF Moulder, SL AF Ferrario, Cristiano Welch, Stephen Chaves, Jorge M. Walker, Luke N. Krop, Ian E. Hamilton, Erika Paige Borges, Virginia F. Moulder, Stacy L. TI ONT-380 in the treatment of HER2+breast cancer central nervous system (CNS) metastases (mets) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada. London Reg Canc Prog, London, ON, Canada. Northwest Med Specialties PLLC, Tacoma, WA USA. Oncothyreon, Seattle, WA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. Univ Colorado, Ctr Canc, Aurora, CO USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 612 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901404 ER PT J AU Fishbein, JN Nipp, RD El-Jawahri, A Pirl, WF Moran, S McCarty, C Eusebio, J Gallagher, ER Park, ER Jackson, VA Greer, JA Temel, JS AF Fishbein, Joel Nathan Nipp, Ryan David El-Jawahri, Areej Pirl, William F. Moran, Samantha McCarty, Caitlin Eusebio, Justin Gallagher, Emily R. Park, Elyse R. Jackson, Vicki A. Greer, Joseph A. Temel, Jennifer S. TI Depression and anxiety among family caregivers of patients with advanced cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Harvard Canc Ctr, Boston, MA USA. Massachusetts Gen Hosp, Brookline, MA USA. MGH Canc Ctr, Boston, MA USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9514 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902009 ER PT J AU Fizazi, K Shore, ND Tammela, TLJ Sarapohja, T Vuorela, A Kuss, I Snapir, A Smith, MR AF Fizazi, Karim Shore, Neal D. Tammela, Teuvo L. J. Sarapohja, Toni Vuorela, Annamari Kuss, Iris Snapir, Amir Smith, Matthew Raymond CA ARAMIS Investigators TI ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Paris 11, Inst Gustave Roussy, Dept Canc Med, Villejuif, France. Carolina Urol Res Ctr, Myrtle Beach, SC USA. Tampere Univ Hosp, Dept Urol, Tampere, Finland. Orion Corp Orion Pharma, Turku, Finland. Orion Corp Orion Pharma, Espoo, Finland. Bayer HealthCare Pharmaceut Inc, Berlin, Germany. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS5080 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904789 ER PT J AU Fuchs, CS Tabernero, J Al-Batran, SE Chau, I Ilson, DH Van Cutsem, E Ferry, D Emig, M Melemed, AS Vanvoorden, V Hsu, YZ Xu, YH Sashegyi, A Das, M Shah, MA AF Fuchs, Charles S. Tabernero, Josep Al-Batran, Salah-Eddin Chau, Ian Ilson, David H. Van Cutsem, Eric Ferry, David Emig, Michael Melemed, Allen S. Vanvoorden, Veerle Hsu, Yanzhi Xu, Yihuan Sashegyi, Andreas Das, Mayukh Shah, Manish A. TI A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Vall dHebron Univ Hosp, Barcelona, Spain. Univ Canc Ctr, Inst Clin Res UCT, Frankfurt, Germany. Royal Marsden, London, England. Royal Marsden, Surrey, England. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Hosp Gasthuisberg, Digest Oncol, Leuven, Belgium. Eli Lilly & Co, Bridgewater, NJ USA. Lilly Deutschland GmbH, Bad Homburg, Germany. Eli Lilly & Co, Indianapolis, IN 46285 USA. Eli Lilly & Co, Brussels, Belgium. Weill Cornell Med Coll, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS4131 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904739 ER PT J AU Fuchs, CS Denker, AE Tabernero, J Van Cutsem, E Ohtsu, A Lam, B Koshiji, M Bang, YJ AF Fuchs, Charles S. Denker, Andrew E. Tabernero, Josep Van Cutsem, Eric Ohtsu, Atsushi Lam, Baohoang Koshiji, Minori Bang, Yung-Jue TI Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Merck & Co Inc, Kenilworth, NJ USA. Vall dHebron Univ Hosp, Barcelona, Spain. Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium. Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan. Seoul Natl Univ, Coll Med, Seoul, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS4135 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904743 ER PT J AU Fuchs, CS Tabernero, J Tomasek, J Chau, I Melichar, B Safran, H Tehfe, MA Dumitru, F Topuzov, E Schlittler, L Udrea, AA Campbell, W Brincat, S Emig, M Melemed, SA Hozak, RR Ferry, D Caldwell, W Ajani, JA AF Fuchs, Charles S. Tabernero, Josep Tomasek, Jiri Chau, Ian Melichar, Bohuslav Safran, Howard Tehfe, Mustapha Ali Dumitru, Filip Topuzov, Eldar Schlittler, Luis Udrea, Anghel Adrian Campbell, William Brincat, Stephen Emig, Michael Melemed, Symantha A. Hozak, Rebecca R. Ferry, David Caldwell, William Ajani, Jaffer A. TI Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Vall dHebron Univ Hosp, Barcelona, Spain. Masaryk Univ, Masaryk Mem Canc Inst, Fac Med, Brno, Czech Republic. Royal Marsden, London, England. Royal Marsden, London, Surrey, England. Univ Palackeho, Fak Nemocnice, Onkol Klin, Lekarska Fak, Olomouc, Czech Republic. Brown Univ, Oncol Res Grp, Providence, RI 02912 USA. CHUM, Montreal, PQ, Canada. Spitalul Judetean Urgenta, Baia Mare, Romania. Hosp Cida Passo Fundo, Passo Fundo, Brazil. Medisprof SRL, Cluj Napoca, Romania. Hosp Herrera Llerandi, Guatemala City, Guatemala. Sir Paul Boffa Hosp, Taxbiex, Malta. Lilly Deutschland GmbH, Bad Homburg, Germany. Eli Lilly & Co, Indianapolis, IN 46285 USA. Eli Lilly & Co, Bridgewater, NJ USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4029 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900868 ER PT J AU Fuchs, CS Muro, K Tomasek, J Van Cutsem, E Cho, JY Oh, SC Safran, H Bodoky, G Chau, I Shimada, Y Dumitru, F Al-Batran, SE Passalacqua, R Ohtsu, A Emig, M Ferry, D Chandrawansa, K Hsu, YZ Sashegyi, A Wilke, H AF Fuchs, Charles S. Muro, Kei Tomasek, Jiri Van Cutsem, Eric Cho, Jae Yong Oh, Sang Cheul Safran, Howard Bodoky, Gyorgy Chau, Ian Shimada, Yasuhiro Dumitru, Filip Al-Batran, Salah-Eddin Passalacqua, Rodolfo Ohtsu, Atsushi Emig, Michael Ferry, David Chandrawansa, Kumari Hsu, Yanzhi Sashegyi, Andreas Wilke, Hansjochen TI Prognostic factor analysis of overall survival (OS) in gastric cancer from two phase III studies of second-line ramucirumab (RAM) (REGARD and RAINBOW) using pooled individual patient (pt) data SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan. Masaryk Univ, Fac Med, Masaryk Mem Canc Inst, Brno, Czech Republic. Univ Hosp Gasthuisberg, Digest Oncol, Leuven, Belgium. Gangnam Severance Hosp, Seoul, South Korea. Korea Univ Guro Hosp, Seoul, South Korea. Brown Univ, Oncol Res Grp, Providence, RI 02912 USA. Szent Laszlo Hosp, Budapest, Hungary. Royal Marsden, London, England. Royal Marsden, London, Surrey, England. Natl Canc Ctr, Tokyo, Japan. Spitalul Judetean Urgenta, Baia Mare, Romania. Univ Canc Ctr, Inst Clin Res, Frankfurt, Germany. Ist Ospitalieri Cremona, Cremona, Italy. Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan. Lilly Deutschland GmbH, Bad Homburg, Germany. Eli Lilly & Co, Indianapolis, IN 46285 USA. Eli Lilly & Co, Bridgewater, NJ USA. Kliniken Essen Mitte Ctr Pallat Care, Essen, Germany. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4028 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900867 ER PT J AU Gainor, JF Sequist, LV Shaw, AT Azzoli, CG Piotrowska, Z Huynh, T Fulton, L Schultz, K Hata, AN Engelman, JA Mino-Kenudson, M AF Gainor, Justin F. Sequist, Lecia V. Shaw, Alice Tsang Azzoli, Christopher G. Piotrowska, Zofia Huynh, Tiffany Fulton, Linnea Schultz, Katherine Hata, Aaron N. Engelman, Jeffrey A. Mino-Kenudson, Mari TI Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 7 Z9 7 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8012 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901725 ER PT J AU Gakis, G Morgan, TM Daneshmand, S Keegan, KA Clayman, RH Mischinger, J Zaid, HB Hrbacek, J Ali-El-Dein, B Galland, S Olugbade, K Rink, M Fristche, HM Burger, M Chang, S Babjuk, M Thalmann, GN Stenzl, A Efstathiou, JA AF Gakis, Georgios Morgan, Todd Matthew Daneshmand, Siamak Keegan, Kirk A. Clayman, Rebecca Helen Mischinger, Johannes Zaid, Harras B. Hrbacek, Jan Ali-El-Dein, Bedeir Galland, Sigolene Olugbade, Kola Rink, Michael Fristche, Hans-Martin Burger, Maximilian Chang, Sam Babjuk, Marek Thalmann, George N. Stenzl, Arnulf Efstathiou, Jason Alexander TI Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Eberhard Karls Univ Tuebingen, Tubingen, Germany. Univ Michigan, Ann Arbor, MI 48109 USA. Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Univ Tubingen, Dept Urol, Tubingen, Germany. Charles Univ Prague, Dept Urol, Sch Med 2, Prague, Czech Republic. Mansoura Clin, Urol & Nephrol Ctr, Mansoura, Egypt. Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA. Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany. Univ Regensburg, D-93053 Regensburg, Germany. Charles Univ Prague, Fac Med 2, Dept Urol, Prague, Czech Republic. Univ Hosp Motol, Prague, Czech Republic. Univ Hosp Bern, Dept Urol, CH-3010 Bern, Switzerland. Univ Tubingen, Dept Urol, Tubingen, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4568 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901039 ER PT J AU Gan, HK Papadopoulos, KP Fichtel, L Lassman, AB Merrell, R Van Den Bent, MJ Kumthekar, P Scott, AM Pedersen, M Gomez, EJ Fischer, JS Ames, W Xiong, H Lee, HJ Munasinghe, W Roberts-Rapp, L Ansell, P Holen, KD Lai, R Reardon, DA AF Gan, Hui K. Papadopoulos, Kyriakos P. Fichtel, Lisa Lassman, Andrew B. Merrell, Ryan Van Den Bent, Martin J. Kumthekar, Priya Scott, Andrew M. Pedersen, Michelle Gomez, Erica J. Fischer, Judee S. Ames, William Xiong, Hao Lee, Ho-Jin Munasinghe, Wijith Roberts-Rapp, Lisa Ansell, Peter Holen, Kyle D. Lai, Rose Reardon, David A. TI Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Austin Hlth, Melbourne, Vic, Australia. Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia. South Texas Oncol & Hematol, San Antonio, TX USA. Columbia Univ, Med Ctr, New York, NY USA. Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA. NorthShore Univ Hlth Syst, Evanston, IL USA. Erasmus MC Canc Ctr, Rotterdam, Netherlands. Northwestern Univ, Chicago, IL 60611 USA. AbbVie Inc, N Chicago, IL USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2016 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900475 ER PT J AU Gandhi, L Shaw, A Gadgeel, SM Riely, G Cetnar, J West, HJ Camidge, DR Socinski, MA Chiappori, A Mekhail, T Chao, BH Borghaei, H Gold, KA Zeaiter, AH Bordogna, W Balas, B Puig, O Henschel, V Ou, SHI AF Gandhi, Leena Shaw, Alice Gadgeel, Shirish M. Riely, Gregory Cetnar, Jeremy West, Howard Jack Camidge, D. Ross Socinski, Mark A. Chiappori, Alberto Mekhail, Tarek Chao, Bo H. Borghaei, Hossein Gold, Kathryn A. Zeaiter, Ali Hassan Bordogna, Walter Balas, Bogdana Puig, Oscar Henschel, Volkmar Ou, Sai-Hong Ignatius CA NP28761 Study Investigators TI A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK plus non-small-cell lung cancer (NSCLC) US/Canadian population who had progressed on crizotinib (NP28761). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Swedish Canc Inst, Seattle, WA USA. Univ Colorado, Ctr Canc, Aurora, CO USA. Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Florida Hosp, Inst Canc, Orlando, FL USA. Ohio State Univ, Columbus, OH 43210 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. F Hoffmann La Roche Ltd, Basel, Switzerland. Roche, New York, NY USA. UC Irvine Sch Med, Irvine, CA USA. NR 0 TC 11 Z9 11 U1 1 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8019 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901732 ER PT J AU Gangadhar, TC Mehnert, J Patnaik, A Hamid, O Carlino, MS Hodi, FS Blank, CU Ribas, A Robert, C Kondic, AG Ahamadi, M Freshwater, T de Greef, R van Vugt, M Lubiniecki, G Ebbinghaus, S Kang, SP Daud, A AF Gangadhar, Tara C. Mehnert, Janice Patnaik, Amita Hamid, Omid Carlino, Matteo S. Hodi, F. Stephen Blank, Christian U. Ribas, Antoni Robert, Caroline Kondic, Anna Georgieva Ahamadi, Malidi Freshwater, Tomoko de Greef, Rik van Vugt, Marianne Lubiniecki, Gregory Ebbinghaus, Scot Kang, Soonmo Peter Daud, Adil TI Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Rutgers Canc Inst New Jersey, New Brunswick, NJ USA. START, San Antonio, TX USA. Angeles Clin & Res Inst, Los Angeles, CA USA. Westmead Hosp, Baulkham Hills, Australia. Dana Farber Canc Inst, Boston, MA 02115 USA. Netherlands Canc Inst, Amsterdam, Netherlands. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Gustave Roussy, Villejuif, France. Merck & Co Inc, Kenilworth, NJ USA. UC San Francisco, San Francisco, CA USA. NR 0 TC 1 Z9 1 U1 1 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3058 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900692 ER PT J AU Garber, JE Tung, NM Elkin, EP Allen, B Hartman, AR Singh, N Wenstrup, RJ Winer, EP Lin, NU AF Garber, Judy Ellen Tung, Nadine M. Elkin, Eric P. Allen, Brian Hartman, Anne-Renee Singh, Nanda Wenstrup, Richard J. Winer, Eric P. Lin, Nancy U. TI Predisposing germline mutations in high grade ER+HER2-breast cancer (BC) patients diagnosed (Dx) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Myriad Genet Inc, Salt Lake City, UT USA. Myriad Genet Labs Inc, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1503 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900370 ER PT J AU Garcia-Manero, G Schiffer, CA Godley, LA Paquette, R Platzbecker, U Robbins, PB Norton, J Karakunnel, JJ Lindsley, RC AF Garcia-Manero, Guillermo Schiffer, Charles Alan Godley, Lucy A. Paquette, Ronald Platzbecker, Uwe Robbins, Paul B. Norton, Jonathan Karakunnel, Joyson Joseph Lindsley, Robert Coleman TI Phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in myelodysplastic syndrome (MDS) after treatment with hypomethylating agents. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI USA. Univ Chicago, Chicago, IL 60637 USA. Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA. TUD, Univ Hosp Carl Gustav Carus, Dresden, Germany. MedImmune, Gaithersburg, MD USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS7103 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904846 ER PT J AU Gelhorn, H Tong, S Maclaine, G Healey, JH Bukata, SV Keedy, VL Anthony, SP Wagner, AJ Von Hoff, DD Singh, AS Becerra, C Hanlon, J Lenderking, W Murray, L Hsu, HH Lin, PS Tap, WD AF Gelhorn, Heather Tong, Sandra Maclaine, Grant Healey, John H. Bukata, Susan V. Keedy, Vicki Leigh Anthony, Stephen Patrick Wagner, Andrew J. Von Hoff, Daniel D. Singh, Arun S. Becerra, Carlos Hanlon, Jennifer Lenderking, William Murray, Lindsey Hsu, Henry H. Lin, Paul S. Tap, William D. TI Patient-reported outcome instruments meaningful and relevant for tenosynovial giant cell tumor (TGCT): A qualitative study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Evidera, Bethesda, MD USA. Plexxikon Inc, Berkeley, CA USA. Sankyo UK Ltd, Gerrards Cross, Bucks, England. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Calif Los Angeles, Los Angeles, CA USA. Vanderbilt Univ Sch Med, Nashville, TN USA. Evergreen Hematol & Oncol US Oncol, Spokane, WA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Virginia G Piper Canc Ctr, Scottsdale, AZ USA. TGen, Scottsdale, AZ USA. Sammons Canc Ctr US Oncol, Dallas, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10521 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900157 ER PT J AU Gerber, DE Oxnard, GR Mandrekar, SJ Dahlberg, SE Malik, SM Mooney, MM Abrams, JS Janne, PA Li, TH Ramalingam, SS Vokes, EE Govindan, R AF Gerber, David E. Oxnard, Geoffrey R. Mandrekar, Sumithra J. Dahlberg, Suzanne Eleanor Malik, Shakun M. Mooney, Margaret M. Abrams, Jeffrey S. Janne, Pasi A. Li, Tianhong Ramalingam, Suresh S. Vokes, Everett E. Govindan, Ramaswamy TI ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Mayo Clin, Rochester, MN USA. Clin Invest Branch CTEP DCTD, Rockville, MD USA. NCI, Bethesda, MD 20892 USA. UC Davis Comprehens Canc Ctr, Sacramento, CA USA. Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Univ Chicago, Dept Med, Chicago, IL 60637 USA. Washington Univ, Sch Med, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS7583 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904847 ER PT J AU Gerstner, ER Zhang, Z Fink, JR Muzi, M Hanna, L Greco, E Mintz, A Kostakoglu, L Eikman, EA Prah, M Schmainda, KM Sorensen, GA Barboriak, D Mankoff, DA AF Gerstner, Elizabeth Robins Zhang, Zheng Fink, James R. Muzi, Mark Hanna, Lucy Greco, Erin Mintz, Akiva Kostakoglu, Lale Eikman, Edward A. Prah, Melissa Schmainda, Kathleen M. Sorensen, Gregory A. Barboriak, Daniel Mankoff, David A. TI ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using FMISO PET and MRI. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Brown Univ, Providence, RI 02912 USA. Univ Washington, Seattle, WA 98195 USA. Wake Forest Univ, Winston Salem, NC 27109 USA. Icahn Sch Med Mt Sinai, New York, NY 10029 USA. Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Duke Univ, Durham, NC USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2024 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900483 ER PT J AU Ghiaseddin, A Reardon, DA Massey, W Mannerino, A Lipp, ES Herndon, JE McSherry, F Desjardins, A Randazzo, DM Vlahovic, G Friedman, HS Peters, KB AF Ghiaseddin, Ashley Reardon, David A. Massey, Woody Mannerino, Alexandra Lipp, Eric S. Herndon, James E. McSherry, Frances Desjardins, Annick Randazzo, Dina M. Vlahovic, Gordana Friedman, Henry S. Peters, Katherine B. TI Phase II study of bevacizumab and vorinostat for recurrent glioblastoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Duke Univ, Med Ctr, Durham, NC USA. Dana Farber Canc Ctr Inst, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2034 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900493 ER PT J AU Giannakis, M Shukla, S Mu, JX Nishihara, R Yamauchi, M Sukawa, Y Qian, ZR Nosho, K Inamura, K Bahl, S Ng, K Chan, AT Meyerhardt, JA Gabriel, SB Lander, E Wu, C Getz, G Fuchs, CS Ogino, S Garraway, LA AF Giannakis, Marios Shukla, Sachet Mu, Jasmine Xinmeng Nishihara, Reiko Yamauchi, Mai Sukawa, Yasutaka Qian, Zhi Rong Nosho, Katsuhiko Inamura, Kentaro Bahl, Samira Ng, Kimmie Chan, Andrew T. Meyerhardt, Jeffrey A. Gabriel, Stacey B. Lander, Eric Wu, Catherine Getz, Gad Fuchs, Charles S. Ogino, Shuji Garraway, Levi A. TI Comprehensive molecular characterization of colorectal cancer reveals genomic predictors of immune cell infiltrates. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Broad Inst MIT & Harvard, Cambridge, MA USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Broad Inst, Cambridge, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3505 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900725 ER PT J AU Gitlitz, BJ Morosini, D Sable-Hunt, AL Addario, BJ Jennings, MB Mach, SL Oxnard, GR AF Gitlitz, Barbara J. Morosini, Deborah Sable-Hunt, Alicia L. Addario, Bonnie J. Jennings, Mark Byron Mach, Stacy L. Oxnard, Geoffrey R. TI The genomics of Young Lung Cancer Study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. Fdn Med Inc, Cambridge, MA USA. ALCMI, San Carlos, CA USA. Bonnie J Addario Lung Canc Fdn, San Carlos, CA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS11110 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904668 ER PT J AU Goldwirt, L Verreault, M Levasseur, C Schmitt, C Guehennec, J Labussiere, M Haidar, S Mokhtari, K Mourah, S Hoang-Xuan, K Sanson, M Wen, PY Ligon, KL Delattre, JY Idbaih, A AF Goldwirt, Lauriane Verreault, Maite Levasseur, Camille Schmitt, Charlotte Guehennec, Jeremy Labussiere, Marianne Haidar, Sam Mokhtari, Karima Mourah, Samia Hoang-Xuan, Khe Sanson, Marc Wen, Patrick Y. Ligon, Keith L. Delattre, Jean-Yves Idbaih, Ahmed TI Brain distribution of the MDM2 inhibitor, RG7112: Single dose escalation and repeated doses studies. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Hop St Louis, AP HP, Dept Pharmacol, Paris, France. Univ Paris 06, INSERM, CRICM, UMR S975,U975,CNRS,UMR 7225, Paris, France. Ctr Rech Inst Cerveau & Moelle Epiniere, UMR U975, Paris, France. Dana Farber Canc Inst, Boston, MA 02115 USA. Hop La Pitie Salpetriere, Paris, France. Hop St Louis, AP HP, Pharmacol & Genet Deparment, Paris, France. UPMC, AP HP, CRIMC, Paris, France. Univ Paris 06, CRICM, Neurol 2, Paris, France. DFCI, Boston, MA USA. Univ Paris 06, Pitie Salpetriere Hosp, Paris, France. Univ Paris 06, Paris, France. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e13582 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902575 ER PT J AU Golshan, M Cirrincione, CT Carey, LA Sikov, WM Berry, DA Burstein, HJ Overmoyer, B Henry, NL Somlo, G Port, ER Winer, EP Hudis, CA Ollila, DW AF Golshan, Mehra Cirrincione, Constance T. Carey, Lisa A. Sikov, William M. Berry, Donald A. Burstein, Harold J. Overmoyer, Beth Henry, Norah Lynn Somlo, George Port, Elisa R. Winer, Eric P. Hudis, Clifford A. Ollila, David W. TI Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. Duke Univ, Alliance Stat Ctr, Durham, NC USA. Brown Univ, Women & Infants Hosp, Providence, RI 02905 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. City Hope Natl Med Ctr, Duarte, CA USA. Mt Sinai Med Ctr, New York, NY 10029 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1007 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900079 ER PT J AU Goodman, LM Moeller, M Dalby, CK Azzouqa, A Guthrie, AE Earl, MA Velcheti, V Shapiro, MA Pennell, NA Stevenson, J AF Goodman, Lindsey Martin Moeller, Machelle Dalby, Carole Kathleen Azzouqa, Abdel Guthrie, Amy E. Earl, Marc A. Velcheti, Vamsidhar Shapiro, Marc A. Pennell, Nathan A. Stevenson, James TI Effect of improving guideline-based prophylactic growth factor (pGCSF) use with chemotherapy (CT) on the risk of febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients (pts): A Cleveland Clinic Taussig Cancer Institute (TCI) Quality Improvement (QI) Project SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Cleveland Clin, Cleveland Hts, OH USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Cleveland Clin, Dept Pharm, Cleveland, OH 44106 USA. Cleveland Clin, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6565 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901480 ER PT J AU Gore, ME Hackshaw, A Brady, WE Penson, RT Zaino, RJ McCluggage, WG Ganesan, R Wilkinson, N Perren, T Montes, A Summers, J Lord, R Dark, GG Rustin, GJS Mackean, MJ Reed, N Kehoe, S Christensen, H Ledermann, JA Gershenson, DM AF Gore, Martin Eric Hackshaw, Allan Brady, William E. Penson, Richard T. Zaino, Richard J. McCluggage, W. Glenn Ganesan, Raji Wilkinson, Nafisa Perren, Timothy Montes, Ana Summers, Jeffrey Lord, Rosemary Dark, Graham G. Rustin, Gordon J. S. Mackean, Melanie J. Reed, Nicholas Kehoe, Sean Christensen, Helen Ledermann, Jonathan A. Gershenson, David Marc TI Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Royal Marsden Hosp NHS Trust, London, England. UCL, Canc Inst CRUK, London, England. UCL Canc Trials Ctr, London, England. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Massachusetts Gen Hosp, Braintree, MA USA. Harvard Med Sch, Braintree, MA USA. Hershey Med Ctr, Hershey, PA USA. Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland. Birmingham Womens NHS Fdn Trust, Birmingham, W Midlands, England. Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England. St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England. Guys & St Thomas NHS Trust, London, England. Maidstone Maritime Hosp, Maidstone, Kent, England. Clatterbridge Canc Ctr, Bebington, England. Newcastle Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England. Mt Vernon Hosp, Northwood, Middx, England. Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland. Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland. Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England. CR UK & UCL Canc Trials Ctr, London, England. UCL, Inst Canc, London, England. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5528 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901188 ER PT J AU Goss, GD Vokes, EE Gordon, MS Gandhi, L Papadopoulos, KP Rasco, DW Pedersen, M Fischer, JS Chu, K Ames, W Xiong, H Lee, HJ Zeng, JW Roberts-Rapp, L Ansell, P Reilly, E Holen, KD Tolcher, AW AF Goss, Glenwood D. Vokes, Everett E. Gordon, Michael S. Gandhi, Leena Papadopoulos, Kyriakos P. Rasco, Drew Warren Pedersen, Michelle Fischer, Judee S. Chu, Katharine Ames, William Xiong, Hao Lee, Ho-Jin Zeng, Jiewei Roberts-Rapp, Lisa Ansell, Peter Reilly, Ed Holen, Kyle D. Tolcher, Anthony W. TI ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Ottawa Hosp Canc Ctr, Ottawa, ON, Canada. Univ Chicago, Chicago, IL 60637 USA. Pinnacle Oncol Hematol, Scottsdale, AZ USA. Dana Farber Canc Inst, Boston, MA 02115 USA. South Texas Accelerated Res Therapeut, San Antonio, TX USA. AbbVie Inc, N Chicago, IL USA. AbbVie, N Chicago, IL USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2510 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900543 ER PT J AU Goyal, L Zheng, H Yurgelun, M Abrams, TA Kwak, EL Cleary, JM Knowles, M Regan, E Gisondi, A Sheehan, S Khachatryan, A Nardi, V Borger, DR Duda, GD Zhu, AX AF Goyal, Lipika Zheng, Hui Yurgelun, Matthew Abrams, Thomas Adam Kwak, Eunice Lee Cleary, James M. Knowles, Michelle Regan, Eileen Gisondi, Amy Sheehan, Susan Khachatryan, Anna Nardi, Valentina Borger, Darrell R. Duda, Gabriel Dan Zhu, Andrew X. TI A phase II and biomarker study of cabozantinib (XL-184) in patients (pts) with advanced cholangiocarcinoma (CCA) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 MGH Canc Ctr, Brookline, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. MGH Canc Ctr, Boston, MA USA. MGH, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15124 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902897 ER PT J AU Grimm, SA Kumthekar, P Chamberlain, MC Schiff, D Wen, PY Iwamoto, FM Reardon, DA Purow, B Raizer, JJ AF Grimm, Sean Aaron Kumthekar, Priya Chamberlain, Marc C. Schiff, David Wen, Patrick Y. Iwamoto, Fabio Massaiti Reardon, David A. Purow, Benjamin Raizer, Jeffrey J. TI Phase II trial of bevacizumab in patients with surgery and radiation refractory progressive meningioma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. Northwestern Univ, Chicago, IL 60611 USA. Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA. Univ Virginia, Med Ctr, Charlottesville, VA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Columbia Univ, Med Ctr, New York, NY USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. Northwestern Univ, Lurie Comp Canc Ctr, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2055 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900513 ER PT J AU Grushko, TA Filiaci, VL Montag, AG Apushkin, MA Marzullo, B Monovich, L Ramirez, NC Birrer, MJ Olopade, OI Fleming, GF AF Grushko, Tatyana A. Filiaci, Virginia L. Montag, Anthony G. Apushkin, Marsha A. Marzullo, Brandon Monovich, Laura Ramirez, Nilsa C. Birrer, Michael J. Olopade, Olufunmilayo I. Fleming, Gini F. CA NRG Oncology Gynecologic Oncology TI The value of TOP2A as a target for anthracycline-based chemotherapy in advanced endometrial carcinoma (EC): NRG Oncology/Gynecology Oncology Group study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Chicago, Med Ctr, Chicago, IL 60637 USA. NRG Oncol, Buffalo, NY USA. GOG Fdn Inc SDMC, Buffalo, NY USA. Illinois Pathol Inc, Berwyn, IL USA. SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA. SUNY Buffalo, Ctr Excellence Bioinformat & Life Sci, Buffalo, NY 14260 USA. Nationwide Childrens Hosp, Res Inst, Biopathol Ctr, Gynecol Oncol Grp,Tissue Bank, Columbus, OH USA. Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e16509 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903306 ER PT J AU Guarino, MJ Starodub, A Masters, GA Heist, RS Messersmith, WA Bardia, A Ocean, AJ Thomas, SS Maliakal, PP Wegener, WA Sharkey, RM Wilhelm, F Goldenberg, DM AF Guarino, Michael J. Starodub, Alexander Masters, Gregory A. Heist, Rebecca Suk Messersmith, Wells A. Bardia, Aditya Ocean, Allyson J. Thomas, Sajeve Samuel Maliakal, Pius P. Wegener, William A. Sharkey, Robert M. Wilhelm, Francois Goldenberg, David M. TI Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA. Indiana Univ Hlth, Goshen Ctr Canc Care, Goshen, IN USA. Helen F Graham Canc Ctr, Newark, DE USA. Massachusetts Gen Hosp Canc Ctr, Boston, MA USA. Univ Colorado Canc Ctr, Aurora, CO USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Weill Cornell Med Coll, New York, NY USA. Univ Florida, Windermere, FL USA. Immunomedics Inc, Morris Plains, NJ USA. Garden State Canc Ctr, Ctr Mol Med & Immunol, Morris Plains, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2504 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900537 ER PT J AU Gulley, JL Giacchino, JL Breitmeyer, JB Franzusoff, AJ Panicali, D Schlom, J Kantoff, PW AF Gulley, James L. Giacchino, Jeannie Lorraine Breitmeyer, James Bradley Franzusoff, Alexis J. Panicali, Dennis Schlom, Jeffrey Kantoff, Philip W. TI Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 NCI, NIH, Bethesda, MD 20892 USA. Bavarian Nord AS, Mountain View, CA USA. Bavarian Nord Inc, Mountain View, CA USA. Bavarian Nord Inc, Mountain View, CA USA. NCI, Lab Tumor Immunol & Biol, NIH, Bethesda, MD 20892 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. RI Gulley, James/K-4139-2016 OI Gulley, James/0000-0002-6569-2912 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS5081 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904790 ER PT J AU Gunturi, A Aung, S McDermott, DF Buchbinder, EI AF Gunturi, Anasuya Aung, Sandra McDermott, David F. Buchbinder, Elizabeth Iannotti TI A retrospective analysis of high-dose aldesleukin (HD IL-2) following immune checkpoint blockade (ICB) in metastatic melanoma (MM) and metastatic renal cell carcinoma (mRCC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Prometheus Labs, San Diego, CA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3053 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900687 ER PT J AU Haas, NB Manola, J Flaherty, K Uzzo, RG Atkins, MB Dutcher, JP Wood, CG Kane, CJ Jewett, MAS Coomes, B Matin, SF Kuzel, T Sexton, WJ Wong, YN Choueiri, TK Pili, R Puzanov, I Kohli, M Stadler, WM DiPaola, RS AF Haas, Naomi B. Manola, Judith Flaherty, Keith Uzzo, Robert G. Atkins, Michael B. Dutcher, Janice P. Wood, Christopher G. Kane, Christopher J. Jewett, Michael A. S. Coomes, Bob Matin, Surena F. Kuzel, Timothy Sexton, Wade Jeffers Wong, Yu-Ning Choueiri, Toni K. Pili, Roberto Puzanov, Igor Kohli, Manish Stadler, Walter Michael DiPaola, Robert S. CA ECOG ACRIN 2805 Authors Grp TI Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Lombardi Comprehens Canc Ctr, Washington, DC USA. Our Lady Mercy Canc Ctr, New York, NY USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. UC San Diego Moores Canc Ctr, La Jolla, CA USA. Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada. Canc Res Patient Advocate, Atlanta, GA USA. Northwestern Univ, Chicago, IL 60611 USA. Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, Tampa, FL 33612 USA. Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Mayo Clin, Rochester, MN USA. Univ Chicago, Chicago, IL 60637 USA. Rutgers Canc Inst New Jersey, New Brunswick, NJ USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4508 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900976 ER PT J AU Hahn, NM Picus, J Bambury, RM Pal, SK Hart, LL Grivas, P Milowsky, MI Alva, AS Sonpavde, G Mortazavi, A Bellmunt, J Guancial, EA Gupta, S Chao, RC Collier, MA Christensen, J Chen, I Rosenberg, JE AF Hahn, Noah M. Picus, Joel Bambury, Richard Martin Pal, Sumanta Kumar Hart, Lowell L. Grivas, Petros Milowsky, Matthew I. Alva, Ajjai Shivaram Sonpavde, Guru Mortazavi, Amir Bellmunt, Joaquim Guancial, Elizabeth A. Gupta, Sumati Chao, Richard C. Collier, Mary A. Christensen, James Chen, Isan Rosenberg, Jonathan E. TI A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA. Washington Univ, Div Oncol, St Louis, MO USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. City Hope Natl Med Ctr, Duarte, CA USA. Florida Canc Specialists, Ft Myers, FL USA. Cleveland Clin, Cleveland, OH 44106 USA. Univ N Carolina, Chapel Hill, NC USA. Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA. Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA. Ohio State Univ, Wexner Med Ctr, Arthur G James Canc Hosp, Columbus, OH 43210 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Rochester, Wilmot Canc Inst, Rochester, NY USA. Huntsman Canc Inst, Fruit Hts, UT USA. Mirati Therapeut Inc, San Diego, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS4575 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904767 ER PT J AU Hamilton, EP Birrer, MJ DiCarlo, BA Gaillard, S Martin, LP Nemunaitis, JJ Perez, RP Schilder, RJ Annunziata, CM Begley, CG Hager, SJ AF Hamilton, Erika Paige Birrer, Michael J. DiCarlo, Brian Anthony Gaillard, Stephanie Martin, Lainie P. Nemunaitis, John J. Perez, Raymond P. Schilder, Russell J. Annunziata, Christina M. Begley, Colin G. Hager, Steven Jeffrey TI A phase 1b, open-label, non-randomized multicenter study of birinapant in combination with conatumumab in subjects with relapsed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA. Coastal Integrat Canc Care, San Luis Obispo, CA USA. Duke Canc Inst, Durham, NC USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Mary Crowley Canc Res Ctr, Dallas, TX USA. Univ Kansas, Fairway, KS USA. Thomas Jefferson Univ, Philadelphia, PA 19107 USA. NCI, NIH, Bethesda, MD 20892 USA. TetraLog Pharmaceut, Westlake Village, CA USA. Calif Canc Associates Res & Excellence, Fresno, CA USA. RI Annunziata, Christina/L-3219-2016; Perez, Raymond/R-6159-2016 OI Annunziata, Christina/0000-0003-2033-6532; Perez, Raymond/0000-0002-7432-2411 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5571 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901236 ER PT J AU Harshman, LC Wang, XD Nakabayashi, M Xie, WL Valenca, LB Werner, L Yu, YJ Kantoff, A Sweeney, C Mucci, LA Pomerantz, M Lee, GSM Kantoff, PW AF Harshman, Lauren Christine Wang, Xiaodong Nakabayashi, Mari Xie, Wanling Valenca, Loana Bueno Werner, Lillian Yu, Yongjiang Kantoff, Aaron Sweeney, Christopher Mucci, Lorelei A. Pomerantz, Mark Lee, Gwo-Shu Mary Kantoff, Philip W. TI Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Shanghai 200030, Peoples R China. Apple Tree Partners, New York, NY USA. Harvard TH Chan Sch Publ Hlth, Boston, MA USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5024 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901066 ER PT J AU Harshman, LC Werner, L Wong, YN Yu, EY Alva, AS Crabb, SJ Powles, T Rosenberg, JE Baniel, J Vaishampayan, UN Berthold, DR Ladoire, S Hussain, SA Milowsky, MI Agarwal, N Necchi, A Pal, SK Recine, F Bellmunt, J Galsky, MD AF Harshman, Lauren Christine Werner, Lillian Wong, Yu-Ning Yu, Evan Y. Alva, Ajjai Shivaram Crabb, Simon J. Powles, Thomas Rosenberg, Jonathan E. Baniel, Jack Vaishampayan, Ulka N. Berthold, Dominik R. Ladoire, Sylvain Hussain, Syed A. Milowsky, Matthew I. Agarwal, Neeraj Necchi, Andrea Pal, Sumanta Kumar Recine, Federica Bellmunt, Joaquim Galsky, Matt D. CA RISC Investigators TI Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA. Univ Southampton, Southampton, Hants, England. Barts Hlth, Barts Canc Inst, London, England. Royal Free NHS Trust, London, England. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Rabin Med Ctr, Petah Tivka, Israel. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. CHU Vaudois, Lausanne, Switzerland. Georges Francois Leclerc Canc Ctr, Dijon, France. Univ Liverpool, Clatterbridge Canc Ctr, Liverpool L69 3BX, Merseyside, England. Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. Ist Nazl Tumori Milan, Milan, MI, Italy. City Hope Natl Med Ctr, Duarte, CA USA. San Camillo Forlanini Hosp, Rome, Italy. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Icahn Sch Med Mt Sinai, New York, NY 10029 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4524 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900992 ER PT J AU Heinemann, V Niedzwiecki, D Pearline, RV Grothey, A Hochster, HS Goldberg, RM Innocenti, F Mayer, RJ Schilsky, RL Blanke, CD Bertagnolli, MM Venook, AP Stinzing, S O'Neil, BH AF Heinemann, Volker Niedzwiecki, Donna Pearline, Rachel V. Grothey, Axel Hochster, Howard S. Goldberg, Richard M. Innocenti, Federico Mayer, Robert J. Schilsky, Richard L. Blanke, Charles David Bertagnolli, Monica M. Venook, Alan P. Stinzing, Sebastian O'Neil, Bert H. TI Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, D-80539 Munich, Germany. Univ Munich, Klinikum Grosshadern, Ctr Comprehens Canc, D-80539 Munich, Germany. Duke Univ, Cary, NC USA. UC San Francisco, San Francisco, CA USA. Mayo Clin, Rochester, MN USA. Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA. Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA. Richard J Solove Res Inst, Columbus, OH USA. Univ N Carolina, Chapel Hill, NC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Amer Soc Clin Oncol, Alexandria, VA USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. LMU, Munich, Germany. Indiana Univ Hlth Univ Hosp, Indianapolis, IN USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3585 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900804 ER PT J AU Heinrich, MC von Mehren, M Demetri, GD Fletcher, JA Sun, JCG Kerstein, D Conlan, MG George, S AF Heinrich, Michael C. von Mehren, Margaret Demetri, George D. Fletcher, Jonathan A. Sun, Jichao G. Kerstein, David Conlan, Maureen G. George, Suzanne TI Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA. Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. Ariad Pharmaceut Inc, Cambridge, MA USA. ARIAD Pharmaceut Inc, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10535 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900172 ER PT J AU Heinrich, MC Hodgson, JG von Mehren, M Demetri, GD Fletcher, JA Sun, JCG Pritchard, JR Zhang, S Rivera, VM George, S AF Heinrich, Michael C. Hodgson, J. Graeme von Mehren, Margaret Demetri, George D. Fletcher, Jonathan A. Sun, Jichao G. Pritchard, Justin R. Zhang, Sen Rivera, Victor M. George, Suzanne TI Detection of KIT mutants in circulating tumor DNA (ctDNA) and their association with ponatinib anti-tumor activity in patients (pts) with advanced gastrointestinal stromal tumors (GIST) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA. Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA. Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10517 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900152 ER PT J AU Heng, DYC Stukalin, I Wells, C Donskov, F Rini, BI Lee, JL Bjarnason, GA Beuselinck, B Smoragiewicz, M Alva, AS Srinivas, S Wood, L Brugarolas, J Pal, SK Yuasa, T Broom, RJ Kanesvaran, R Bamias, A Knox, JJ Choueiri, TK AF Heng, Daniel Yick Chin Stukalin, Igor Wells, Connor Donskov, Frede Rini, Brian I. Lee, Jae-Lyun Bjarnason, Georg A. Beuselinck, Benoit Smoragiewicz, Martin Alva, Ajjai Shivaram Srinivas, Sandy Wood, Lori Brugarolas, James Pal, Sumanta Kumar Yuasa, Takeshi Broom, Reuben James Kanesvaran, Ravindran Bamias, Aristotelis Knox, Jennifer J. Choueiri, Toni K. TI Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada. Tom Baker Canc Clin, Calgary, AB, Canada. Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark. Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea. Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium. BC Canc Agcy, Vancouver, BC, Canada. Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA. Stanford Univ, Med Ctr, Stanford, CA 94305 USA. Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Japanese Fdn Canc Res, Canc Inst Hosp, Dept Urol, Tokyo, Japan. Auckland City Hosp, Auckland, New Zealand. Natl Canc Ctr Singapore, Singapore, Singapore. Univ Athens, Dept Clin Therapeut, Athens, Greece. Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15578 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903121 ER PT J AU Hertz, DL Kidwell, KM Thibert, JN Gersch, CL Regan, MM Skaar, TC Henry, NL Hayes, D Van Poznak, C Rae, JM AF Hertz, Daniel Louis Kidwell, Kelley M. Thibert, Jacklyn N. Gersch, Christina L. Regan, Meredith M. Skaar, Todd C. Henry, Norah Lynn Hayes, Daniel Van Poznak, Catherine Rae, James M. TI Comparison of genotyping performance in DNA extracted from matched FFPE tumor, FFPE lymph node, and whole blood for pharmacogenetic analyses SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Michigan, Ann Arbor, MI 48109 USA. Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Indiana Univ Sch Med, Indianapolis, IN USA. Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. Univ Michigain Hlth Syst, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1528 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900395 ER PT J AU Hodi, FS Postow, MA Chesney, JA Pavlick, AC Robert, C Grossmann, KF McDermott, DF Linette, GP Meyer, N Giguere, JK Agarwala, SS Shaheen, MF Ernstoff, MS Minor, DR Salama, A Taylor, MH Ott, PA Horak, CE Gagnier, P Wolchok, JD AF Hodi, F. Stephen Postow, Michael Andrew Chesney, Jason Alan Pavlick, Anna C. Robert, Caroline Grossmann, Kenneth F. McDermott, David F. Linette, Gerald P. Meyer, Nicolas Giguere, Jeffrey K. Agarwala, Sanjiv S. Shaheen, Montaser F. Ernstoff, Marc S. Minor, David R. Salama, April Taylor, Matthew Hiram Ott, Patrick Alexander Horak, Christine E. Gagnier, Paul Wolchok, Jedd D. TI Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Weill Cornell Med Coll, New York, NY USA. Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA. NYU, Perlmutter Canc Ctr, New York, NY USA. Gustave, Roussy, France. Univ Paris Sud, Villejuif Paris Sud, France. Huntsman Canc Inst, Salt Lake City, UT USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Washington Univ, St Louis, MO USA. Inst Univ Canc, Toulouse, France. NCORP Carolinas, Greenville, SC USA. St Lukes Canc Ctr, Bethlehem, PA USA. Univ New Mexico, Albuquerque, NM 87131 USA. Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH 44195 USA. Calif Pacific Melanoma Ctr, San Francisco, CA USA. Duke Univ, Durham, NC USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Bristol Myers Squibb Co, Princeton, NJ USA. Bristol Myers Squibb Co, Wallingford, CT 06492 USA. NR 0 TC 1 Z9 1 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9004 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901914 ER PT J AU Holdhoff, M Ye, XB Nabors, LB Desai, AS Mikkelsen, T Lesser, G Read, WL Lieberman, FS Supko, J Fisher, JD Desideri, S Grossman, SA Schiff, D AF Holdhoff, Matthias Ye, Xiaobu Nabors, Louis B. Desai, Arati Suvas Mikkelsen, Tom Lesser, Glenn Read, William L. Lieberman, Frank S. Supko, Jeff Fisher, Joy D. Desideri, Serena Grossman, Stuart A. Schiff, David CA ABTC Investigators TI Timed-sequential therapy with mibefradil and temozolomide in patients with recurrent high-grade gliomas: A phase I Adult Brain Tumor Consortium study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. Univ Alabama Birmingham, Birmingham, AL USA. Univ Penn, Philadelphia, PA 19104 USA. Henry Ford Hlth Syst, Detroit, MI USA. Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. Emory Univ, Atlanta, GA 30322 USA. Univ Pittsburgh, Pittsburgh, PA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Virginia, Med Ctr, Charlottesville, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2033 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900492 ER PT J AU Holstein, SA Owzar, K Richardson, PG Jiang, C Hofmeister, CC Hassoun, H Hurd, DD Stadtmauer, EA Giralt, S Devine, SM Hars, V Postiglione, JR Weisdorf, DJ Vij, R Moreb, JS Callander, NS Martin, TG Shea, TC Anderson, KC McCarthy, PL AF Holstein, Sarah A. Owzar, Kouros Richardson, Paul G. Jiang, Chen Hofmeister, Craig C. Hassoun, Hani Hurd, David Duane Stadtmauer, Edward Allen Giralt, Sergio Devine, Steven M. Hars, Vera Postiglione, John R. Weisdorf, Daniel Jordan Vij, Ravi Moreb, Jan S. Callander, Natalie Scott Martin, Thomas G. Shea, Thomas C. Anderson, Kenneth Carl McCarthy, Philip L. TI Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Ohio State Univ, Columbus, OH 43210 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Wake Forest Univ, Winston Salem, NC 27109 USA. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Univ Minnesota, Minneapolis, MN USA. Washington Univ, Sch Med, St Louis, MO USA. Univ Florida, Gainesville, FL USA. Univ Wisconsin, Fitchburg, WI USA. UC San Francisco, San Francisco, CA USA. Univ N Carolina, Chapel Hill, NC USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8523 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901835 ER PT J AU Hong, DS Garrido-Laguna, I Krop, IE Subbiah, V Werner, TL Cotter, CM Hamilton, EP Velastegui, K Xuan, DW Bugarini, R Gollerkeri, A Burris, HA AF Hong, David S. Garrido-Laguna, Ignacio Krop, Ian E. Subbiah, Vivek Werner, Theresa Louise Cotter, Christine M. Hamilton, Erika Paige Velastegui, Karen Xuan, Dawei Bugarini, Roberto Gollerkeri, Ashwin Burris, Howard A. TI First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA. Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Utah, Salt Lake City, UT USA. Sarah Cannon Res Inst, Brentwood, TN USA. Pfizer, La Jolla, CA USA. Pfizer Inc, Clin Pharmacol, Biotechnol Clin Dev, La Jolla, CA USA. Pfizer Biotechnol Clin Dev, La Jolla, CA USA. Pfizer BioTherapeut, Cambridge, MA USA. Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2520 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900553 ER PT J AU Hong, TS Wo, JYL Yeap, BY Ben-Josef, E McDonnell, EI Drapek, LC Blaszkowsky, LS Kwak, EL Clark, JW Goyal, L Ryan, DP Javle, MM Wolfgang, JA Arellano, R Mullen, JT Ferrone, C Tanabe, K DeLaney, TF Crane, CH Zhu, AX AF Hong, Theodore S. Wo, Jennifer Yon-Li Yeap, Beow Y. Ben-Josef, Edgar McDonnell, Erin I. Drapek, Lorraine C. Blaszkowsky, Lawrence Scott Kwak, Eunice Lee Clark, Jeffrey W. Goyal, Lipika Ryan, David P. Javle, Milind M. Wolfgang, John A. Arellano, Ronald Mullen, John Thomas Ferrone, Cristina Tanabe, Kenneth DeLaney, Thomas F. Crane, Christopher H. Zhu, Andrew X. TI Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Waban, MA USA. Univ Penn, Philadelphia, PA 19104 USA. Massachusetts Gen Hosp, Danvers, MA USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. MGH Canc Ctr, Brookline, MA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4020 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900859 ER PT J AU Horn, L Spigel, DR Gettinger, SN Antonia, SJ Gordon, MS Herbst, RS Sequist, LV Chappey, C Kowanetz, M Sandler, A Soria, JC AF Horn, Leora Spigel, David R. Gettinger, Scott N. Antonia, Scott Joseph Gordon, Michael S. Herbst, Roy S. Sequist, Lecia V. Chappey, Colombe Kowanetz, Marcin Sandler, Alan Soria, Jean-Charles TI Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Sarah Cannon Res Inst, Nashville, TN USA. Yale Sch Med, New Haven, CT USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Pinnacle Oncol Hematol, Scottsdale, AZ USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Genentech Inc, San Francisco, CA 94080 USA. Gustave Roussy Canc Campus, Drug Dev Dept, Villejuif, France. NR 0 TC 23 Z9 24 U1 2 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8029 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901742 ER PT J AU Howitt, BE Sholl, LM Ritterhouse, L Watkins, JC Rodig, SJ Strickland, K D'Andrea, AD Matulonis, U Konstantinopoulos, P AF Howitt, Brooke E. Sholl, Lynette M. Ritterhouse, Lauren Watkins, Jaclyn C. Rodig, Scott J. Strickland, Kyle D'Andrea, Alan D. Matulonis, Ursula Konstantinopoulos, Panagiotis TI Association of POLE-mutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematopathol,Dept Pathol, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5511 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901170 ER PT J AU Hungria, VTM San Miguel, JF Yoon, SS Beksac, M Dimopoulos, MA Elghandour, A Jedrzejczak, WW Guenther, A Nakorn, TN Siritanaratkul, N Schlossman, RL Hou, J Moreau, P Lonial, S Lee, JH Einsele, H Sopala, M Bengoudifa, BR Corrado, C Richardson, PG AF Hungria, Vania T. M. San Miguel, Jesus F. Yoon, Sung-Soo Beksac, Meral Dimopoulos, Meletios A. Elghandour, Ashraf Jedrzejczak, Wieslaw W. Guenther, Andreas Nakorn, Thanyaphong Na Siritanaratkul, Noppadol Schlossman, Robert L. Hou, Jian Moreau, Philippe Lonial, Sagar Lee, Jae Hoon Einsele, Hermann Sopala, Monika Bengoudifa, Bourras-Rezki Corrado, Claudia Richardson, Paul G. TI Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil. Univ Navarra Clin, Pamplona, Spain. Seoul Natl Univ Hosp, Seoul 110744, South Korea. Ankara Univ, TR-06100 Ankara, Turkey. Hellen Cooperat Oncol Grp HeCOG, Athens, Greece. Univ Alexandria, Alexandria, Egypt. Med Univ Warsaw, Warsaw, Poland. 2nd Dept Med, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany. Chulalongkorn Univ, Bangkok, Timor Leste, Thailand. Siriraj Hosp, Bangkok, Thailand. Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. Chang Zheng Hosp, Shanghai, Peoples R China. CHU Nantes, Hotel Dieu HME, F-44035 Nantes 01, France. Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. Gachon Univ, Inchon, South Korea. Univ Hosp Wuerzburg, Wurzburg, Germany. Novartis Pharma AG, Basel, Switzerland. Dana Farber Canc Inst, Boston, MA 02115 USA. RI richard, chrystelle/K-8595-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8575 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901887 ER PT J AU Hurley, J Hu, L Brock, G Sinclair, I Sullivan, RJ O'Neill, VJ Skog, J Flaherty, K AF Hurley, James Hu, Lan Brock, Graham Sinclair, Ian Sullivan, Ryan J. O'Neill, Vincent J. Skog, Johan Flaherty, Keith TI Profiling exosomal mRNAs in patients undergoing immunotherapy for malignant melanoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Exosome Diagnost, Cambridge, MA USA. Exosome Diagnost, St Paul, MN USA. Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. Exosome Diagnost, New York, NY USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e22159 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904538 ER PT J AU Huynh, T Chi, A Oyarvide, VM Gainor, JF Hata, AN Lanuti, M Mark, EJ Engelman, JA Mino-Kenudson, M AF Huynh, Tiffany Chi, Anthony Oyarvide, Vicente Morales Gainor, Justin F. Hata, Aaron N. Lanuti, Michael Mark, Eugene J. Engelman, Jeffrey A. Mino-Kenudson, Mari TI Clinicopathological characteristics of squamous cell carcinoma of the lung with programmed cell death ligand 1 (PD-L1) protein expression. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hostpital, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7554 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901684 ER PT J AU Huynh, T Oyarvide, VM Uruga, H Bozkurtlar, E Gainor, JF Hata, AN Mark, EJ Lanuti, M Engelman, JA Mino-Kenudson, M AF Huynh, Tiffany Oyarvide, Vicente Morales Uruga, Hironori Bozkurtlar, Emine Gainor, Justin F. Hata, Aaron N. Mark, Eugene J. Lanuti, Michael Engelman, Jeffrey A. Mino-Kenudson, Mari TI Clinicopathological and molecular parameters of lung adenocarcinomas (ADC) associated with programmed cell death ligand 1 (PD-L1) protein expression. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hostpital, Boston, MA USA. Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7555 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901685 ER PT J AU Infante, JR Naing, A Papadopoulos, KP Autio, KA Ott, PA Wong, DJL Falchook, GS Patel, MR Pant, S Whiteside, M Bendell, JC Bauer, TM Janku, F Javle, MM Hong, DS Oft, M AF Infante, Jeffrey R. Naing, Aung Papadopoulos, Kyriakos P. Autio, Karen A. Ott, Patrick Alexander Wong, Deborah Jean Lee Falchook, Gerald Steven Patel, Manish R. Pant, Shubham Whiteside, Melinda Bendell, Johanna C. Bauer, Todd Michael Janku, Filip Javle, Milind M. Hong, David S. Oft, Martin TI A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. START Ctr Canc Care, San Antonio, TX USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calif Los Angeles, Los Angeles, CA USA. Sarah Cannon Res Inst HealthONE, Denver, CO USA. Sarah Cannon Res Inst Florida Canc Specialists, Sarasota, FL USA. Univ Oklahoma, Hlth Sci Ctr, Sarah Cannon Res Inst, Oklahoma City, OK USA. ARMO BioSci, Redwood City, CA USA. Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3017 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900651 ER PT J AU Infante, JR Janku, F Tolcher, AW Patel, MR Sullivan, RJ Flaherty, K Carvajal, RD Varghese, AM Wong, DJL Sznol, M Sosman, JA Wang-Gillam, A Burris, HA Ribas, A Patel, SP Welsch, DJ Saha, S AF Infante, Jeffrey R. Janku, Filip Tolcher, Anthony W. Patel, Manish R. Sullivan, Ryan J. Flaherty, Keith Carvajal, Richard D. Varghese, Anna M. Wong, Deborah Jean Lee Sznol, Mario Sosman, Jeffrey Alan Wang-Gillam, Andrea Burris, Howard A. Ribas, Antoni Patel, Sapna Pradyuman Welsch, Dean J. Saha, Saurabh TI Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA. Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA. START, San Antonio, TX USA. Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA. Harvard Univ, Sch Med, Massachusetts Gen Hosp Canc Ctr, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Columbia Univ Medcl Ctr, New York, NY USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Calif Los Angeles, Los Angeles, CA USA. Yale Univ, New Haven, CT USA. Vanderbilt Univ Sch Med, Nashville, TN USA. Washington Univ, Div Oncol, St Louis, MO USA. Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. BioMed Valley Discoveries, Kansas City, MO USA. BioMed Valley Discoveries, Wellesley, MA USA. NR 0 TC 4 Z9 4 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2506 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900539 ER PT J AU Irwin, ML Cartmel, B Harrigan, M Sanft, TB Wong, C Hughes, M Hootsmans, N Winterhalter, B Shockro, L O'Connor, K Tolaney, SM Mayer, EL Yung, RL Freedman, RA Ligibel, JA AF Irwin, Melinda L. Cartmel, Brenda Harrigan, Maura Sanft, Tara Beth Wong, Celeste Hughes, Meghan Hootsmans, Norbert Winterhalter, Bridget Shockro, Laura O'Connor, Keelin Tolaney, Sara M. Mayer, Erica L. Yung, Rachel Lynn Freedman, Rachel A. Ligibel, Jennifer A. TI Impact of the LIVESTRONG at the YMCA Program on physical activity, fitness, and quality of life in cancer survivors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Yale Univ, Sch Publ Hlth, New Haven, CT USA. Yale Canc Ctr, New Haven, CT USA. Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Waban, MA USA. Dana Farber Canc Inst, Brookline, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9508 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902003 ER PT J AU Ivanova, JI Saverno, K Sung, J Duh, MS Zhao, C Cai, XP Vekeman, F Peevyhouse, A Dhawan, R Fuchs, CS AF Ivanova, Jasmina I. Saverno, Kimberly Sung, Jennifer Duh, Mei Sheng Zhao, Chen Cai, Xiaopeng Vekeman, Francis Peevyhouse, Aaron Dhawan, Ravinder Fuchs, Charles S. TI Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) treated with ziv-aflibercept (Z) in community oncology practices in the United States (US). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Anal Grp Inc, New York, NY USA. Vector Oncol, Memphis, TN USA. Sanofi US, Bridgewater, NJ USA. Anal Grp Inc, Boston, MA USA. Anal Grp Inc, Montreal, PQ, Canada. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e14554 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902670 ER PT J AU Jakubowiak, AJ Offidani, M Pegourie, B De La Rubia, J Garderet, L Laribi, K Bosi, A Marasca, R Laubach, J Mohrbacher, A Carella, AM Singhal, AK Tsao, C Lynch, MJ Bleickardt, EW Jou, YM Palumbo, A AF Jakubowiak, Andrzej J. Offidani, Massimo Pegourie, Brigitte De La Rubia, Javier Garderet, Laurent Laribi, Kamel Bosi, Alberto Marasca, Roberto Laubach, Jacob Mohrbacher, Ann Carella, Angelo Michele Singhal, Anil K. Tsao, Claire Lynch, Mark John Bleickardt, Eric W. Jou, Ying-Ming Palumbo, Antonio TI A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Chicago, Med Ctr, Chicago, IL 60637 USA. Azienda Osped Univ Osped Riuniti Ancona, Ancona, Italy. CHU Grenoble, Hop Albert Michallon, F-38043 Grenoble, France. HUP La Fe, Valencia, Spain. Hop St Antoine, F-75571 Paris, France. Ctr Hosp, Le Mans, France. Azienda Osped Univ Careggi, Florence, Italy. Azienda Osped Univ, Policlin Modena, Modena, Italy. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA. IRCCS San Martino IST, Genoa, Italy. AbbVie Biotherapeut Inc ABR, Redwood City, CA USA. Bristol Myers Squibb Co, Wallingford, CT 06492 USA. Osped Molinette, AOU San Giovanni Battista Torino, Turin, Italy. RI Marasca, Roberto/I-8072-2013 OI Marasca, Roberto/0000-0002-6431-6878 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8573 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901885 ER PT J AU Jalbut, MM Brunner, AM Amrein, PC Attar, EC Ballen, KK Hobbs, G Perry, AM Joseph, CP Neuberg, DS Fathi, AT AF Jalbut, Marla M. Brunner, Andrew Mark Amrein, Philip C. Attar, Eyal C. Ballen, Karen K. Hobbs, Gabriela Perry, Ashley M. Joseph, Christelle P. Neuberg, Donna S. Fathi, Amir Tahmasb TI Infectious complications in AML patients treated with induction vs. hypomethylating therapy. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Agios, Cambridge, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7065 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901601 ER PT J AU Je, YJ Ghatalia, P Nguyen, PL Trinh, QD Choueiri, TK Sonpavde, G AF Je, Youjin Ghatalia, Pooja Paul Linh Nguyen Quoc-Dien Trinh Choueiri, Toni K. Sonpavde, Guru TI Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with malignancies: A meta-analysis of randomized clinical trials SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Kyung Hee Univ, Seoul, South Korea. Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Urol,Dept Surg, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15583 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903126 ER PT J AU Jemal, A Freedman, RA Lin, CC Sineshaw, H DeSantis, C Ward, EM AF Jemal, Ahmedin Freedman, Rachel A. Lin, Chun Chieh Sineshaw, Helmneh DeSantis, Carol Ward, Elizabeth Mary TI Temporal trends in and predictors of receipt of contralateral breast mastectomy among US men diagnosed with breast cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Amer Canc Soc, Atlanta, GA 30329 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e17522 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903495 ER PT J AU Jhaveri, KL Hamilton, EP Miller, K Roche, M Berger, MS Winer, EP Lin, NU AF Jhaveri, Komal L. Hamilton, Erika Paige Miller, Kathy Roche, Maria Berger, Mark S. Winer, Eric P. Lin, Nancy U. TI A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+metastatic breast cancer (MBC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 NYU, Inst Canc, New York, NY USA. Sarah Cannon Res Inst, Brentwood, Essex, England. Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA. Kadmon Corp, Wilmington, MA USA. Kadmon Corp, New York, NY USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 608 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901397 ER PT J AU Johnson, DB Menzies, AM Zimmer, L Eroglu, Z Ye, F Zhao, SL Sucker, A Rizos, H Hugo, W Gutzmer, R Kefford, R Gogas, H Kong, XJ Scolyer, RA Garraway, LA Sosman, JA Ribas, A Lo, R Long, GV Schadendorf, D AF Johnson, Douglas Buckner Menzies, Alexander M. Zimmer, Lisa Eroglu, Zeynep Ye, Fei Zhao, Shilin Sucker, Antje Rizos, Helen Hugo, Willy Gutzmer, Ralf Kefford, Richard Gogas, Helen Kong, Xiangju Scolyer, Richard A. Garraway, Levi A. Sosman, Jeffrey Alan Ribas, Antoni Lo, Roger Long, Georgina V. Schadendorf, Dirk TI BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Vanderbilt Univ, Nashville, TN 37235 USA. Melanoma Inst Australia, Mosman, NSW, Australia. Univ Duisburg Essen, Univ Hosp, Dept Dermatol, Essen, Germany. City Hope Natl Med Ctr, Pasadena, CA USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Univ Hosp Essen, Essen, Germany. Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia. Univ Calif Los Angeles, Los Angeles, CA USA. Hannover Med Sch, D-30623 Hannover, Germany. Crown Princess Mary Canc Ctr, Sydney, NSW, Australia. Hellen Cooperat Oncol Grp HeCOG, Athens, Greece. Univ Sydney, Royal Prince Alfred Hosp, Melanoma Inst Australia, Sydney, NSW 2006, Australia. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Melanoma Inst Australia, Sydney, NSW, Australia. Univ Sydney, Sydney, NSW, Australia. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9008 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901918 ER PT J AU Jones, JA Wach, M Robak, T Brown, JR Menter, AR Vandenberghe, E Ysebaert, L Wagner-Johnston, ND Polikoff, J Salman, HS Taylor, KM Coutre, S Spurgeon, SEF Kendall, SD Flinn, I Dreiling, L Dubowy, R Cho, YJ Peterman, S Owen, C AF Jones, Jeffrey Alan Wach, Malgorzata Robak, Tadeusz Brown, Jennifer R. Menter, Alexander R. Vandenberghe, Elizabeth Ysebaert, Loic Wagner-Johnston, Nina D. Polikoff, Jonathan Salman, Huda S. Taylor, Kerry McDonald Coutre, Steven Spurgeon, Stephen Edward Forbes Kendall, Stephan Disean Flinn, Ian Dreiling, Lyndah Dubowy, Ronald Cho, Yoonjin Peterman, Sissy Owen, Carolyn TI Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Ohio State Univ, Columbus, OH 43210 USA. Med Univ Lublin, Lublin, Poland. Med Univ Lodz, Lodz, Poland. Dana Farber Canc Inst, Boston, MA 02115 USA. Kaiser Permanente Med Grp, Denver, CO USA. St James Hosp, Dublin 8, Ireland. CHU Toulouse, Toulouse, France. Washington Univ, Sch Med, Dept Med, St Louis, MO USA. Kaiser Hosp San Diego, San Marcos, CA USA. GRU Canc Ctr, Augusta, GA USA. Haematol & Oncol Clin Australia Mater, South Brisbane, Australia. Stanford Univ, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. UCS Canc Ctr, Utah Canc Specialists, Salt Lake City, UT USA. Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA. Gilead Sci Inc, Foster City, CA USA. Alberta Hlth Serv, Calgary, AB, Canada. NR 0 TC 13 Z9 13 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7023 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901559 ER PT J AU Jonker, DJ Laurie, SA Cote, GM Flaherty, K Fuchs, CS Chugh, R Smith, DC Edenfield, WJ Conkling, PR Mier, JW Goodwin, RA Kwak, EL Abrams, TA Goel, R Cleary, JM Li, W Li, YZ Jemison, J Hitron, M Li, C AF Jonker, Derek J. Laurie, Scott Andrew Cote, Gregory Michael Flaherty, Keith Fuchs, Charles S. Chugh, Rashmi Smith, David C. Edenfield, William Jeffery Conkling, Paul R. Mier, James Walter Goodwin, Rachel Anne Kwak, Eunice Lee Abrams, Thomas Adam Goel, Rakesh Cleary, James M. Li, Wei Li, Youzhi Jemison, Jamileh Hitron, Matthew Li, Chiang TI Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Ottawa Hosp Canc Ctr, Ottawa, ON, Canada. Univ Ottawa, Ottawa Hosp Canc Ctr, Ottawa, ON, Canada. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA. Greenville Hosp Syst Univ Med Ctr, Inst Translat Oncol Res, Greenville, SC USA. Virginia Oncol Associates, Norfolk, VA USA. Beth Israel Deaconess Med Ctr, Dana Farber Harvard Canc Ctr, Dept Med, Boston, MA 02215 USA. Ottawa Hosp, NCIC CTG, Ottawa, ON, Canada. Massachusetts Gen Hosp Canc Ctr, Boston, MA USA. Ottawa Hosp, Ottawa, ON, Canada. Boston Biomed Inc, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3615 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900834 ER PT J AU Juric, D De Bono, JS LoRusso, P Nemunaitis, JJ Heath, EI Kwak, EL Macarulla, T Geuna, E Luken, MJD Patel, C Kuida, K Sankoh, S Zohren, F Shou, YP Tabernero, J AF Juric, Dejan De Bono, Johann Sebastian LoRusso, Patricia Nemunaitis, John J. Heath, Elisabeth I. Kwak, Eunice Lee Macarulla, Teresa Geuna, Elena Luken, Maria Jose de Miguel Patel, Chirag Kuida, Keisuke Sankoh, Serap Zohren, Fabian Shou, Yaping Tabernero, Josep TI First-in-human, phase I, dose-escalation study of selective PI3K alpha isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Inst Canc Res, Sutton, Surrey, England. Royal Marsden NHS Fdn Trust, Sutton, Surrey, England. Yale Canc Ctr, New Haven, CT USA. Mary Crowley Canc Res Ctr, Dallas, TX USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Massachusetts Gen Hosp Canc Ctr, Boston, MA USA. Vall dHebron Univ Hosp, VHIO, Barcelona, Spain. Fdn Piemonte Oncol Candiolo Canc Inst, Candiolo, Italy. Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England. Millennium Pharmaceut Inc, Cambridge, MA USA. VHIO, Barcelona, Spain. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2501 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900535 ER PT J AU Karachaliou, N Nilsson, RJA Berenguer, J Capitan, AG Schellen, P Teixido, C Kuiper, JL Drees, E Grabowska, M van Keulen, M Tannous, JM Heideman, D Thunnissen, E Dingemans, AMC Ramirez, SV Tannous, BA Drozdowskyj, A Smit, EF Wurdinger, T Rosell, R AF Karachaliou, Niki Nilsson, R. Jonas A. Berenguer, Jordi Capitan, Ana Gimenez Schellen, Pepijn Teixido, Cristina Kuiper, Justine Leonie Drees, Esther Grabowska, Magda van Keulen, Marte Tannous, Jihane M. Heideman, Danielle Thunnissen, Erik Dingemans, Anne-Marie C. Ramirez, Santiago Viteri Tannous, Bakhos A. Drozdowskyj, Ana Smit, Egbert F. Wurdinger, Thomas Rosell, Rafael TI EML4-ALK rearrangement in blood platelets and outcome to crizotinib in non-small-cell lung cancer patients. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Quiron Dexeus Univ Inst, Translat Res Unit, Barcelona, Spain. VU Canc Ctr Amsterdam, Neurooncol Res Grp, Dept Neurosurg, Amsterdam, Netherlands. Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Neurosurg, Amsterdam, Netherlands. Pangaea Biotech SL, Barcelona, Spain. Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands. Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA. Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands. Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands. Maastricht Univ, Med Ctr, Maastricht, Netherlands. Med Oncol Serv, Barcelona, Spain. Pivotal, Madrid, Spain. VU Univ Med, Canc Ctr Amsterdam, Dept Pulm Dis, Amsterdam, Netherlands. Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, Amsterdam, Netherlands. Hosp Badalona Germans Trias & Pujol, Canc Biol & Precis Med Program, Catalan Inst Oncol, Barcelona, Spain. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8082 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901794 ER PT J AU Katz, MS Utengen, A Anderson, PF Thompson, MA Fisch, M Johnston, C Attai, DJ Aase, L Miller, RS Lee, T Dizon, DS AF Katz, Matthew S. Utengen, Audun Anderson, Patricia F. Thompson, Michael A. Fisch, Michael Johnston, Claire Attai, Deanna J. Aase, Lee Miller, Robert Stephen Lee, Thomas Dizon, Don S. TI Disease-specific hashtags for online communication about cancer care SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Radiat Oncol Associates, Lowell, MA USA. Symplur LLC, Los Angeles, CA USA. Univ Michigan, Ann Arbor, MI 48109 USA. Aurora Hlth Care, Aurora Res Inst, Milwaukee, WI USA. AIM Specialty Hlth, Chicago, IL USA. ASCO, Alexandria, VA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Mayo Clin, Rochester, MN USA. Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6520 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901435 ER PT J AU Katz, MS Topham, A Manola, J Scroggins, MJ Smith, ML Mitchell, EP Catalano, RB Marinucci, DM Giantonio, BJ Comis, RL AF Katz, Michael S. Topham, Allan Manola, Judith Scroggins, Mary Jackson Smith, Mary Lou Mitchell, Edith P. Catalano, Robert B. Marinucci, Donna M. Giantonio, Bruce J. Comis, Robert Leo TI Medically Underrepresented Populations In National Cancer Institute (NCI) Sponsored Cancer Clinical Trials: Refining the Calculation of Accrual Targets SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 ECOG ACRIN, North Hollywood, CA USA. Coalit Canc Cooperat Grp, Philadelphia, PA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. My Sisters Care, Washington, DC USA. Res Advocacy Network, Naperville, IL USA. Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA. Drexel Univ, Philadelphia, PA 19104 USA. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e17598 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903564 ER PT J AU Keenan, T Moy, B Mroz, EA Ross, K Niemierko, A Rocco, JW Isakoff, SJ Ellisen, LW Bardia, A AF Keenan, Tanya Moy, Beverly Mroz, Edmund A. Ross, Kenneth Niemierko, Andrzej Rocco, James William Isakoff, Steven J. Ellisen, Leif W. Bardia, Aditya TI Genomic landscape of primary breast cancer in black vs. white women and association with tumor recurrence. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. Ohio State Univ, Columbus, OH 43210 USA. MEEI MGH, Boston, MA USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6553 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901468 ER PT J AU Kim, CC Najita, JS Tan, SYM Varada, S Tong, LX Dunbar, H Lee, MY Seery, VJ Buchbinder, EI Tawa, NE Fuller, J Frankenthaler, RA McDermott, DF Lee, SJ Atkins, MB AF Kim, Caroline C. Najita, Julie S. Tan, Sally Yi-Meng Varada, Sowmya Tong, Lana X. Dunbar, Haili Lee, Mee-young Seery, Virginia J. Buchbinder, Elizabeth Iannotti Tawa, Nicholas E. Fuller, Jennifer Frankenthaler, Robert Andrew McDermott, David F. Lee, Sandra J. Atkins, Michael B. TI Factors associated with worse outcome for patients with AJCC stage IIC relative to stage IIIA melanoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Sidney Kimmel Med Coll, Philadelphia, PA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9078 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901988 ER PT J AU Kim, M Alexander, BM Burke, L Jha, A AF Kim, Miranda Alexander, Brian Michael Burke, Laura Jha, Ashish TI Contribution of cancer care to total spending among high-cost Medicare beneficiaries SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Rad Onc Prog, Boston, MA USA. Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6620 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901534 ER PT J AU Kim, SB Tan, AR Im, SA Villanueva, R Valero, V Saura, C Oliveira, M Isakoff, SJ Singel, SM Dent, RA AF Kim, Sung-Bae Tan, Antoinette R. Im, Seock-Ah Villanueva, Rafael Valero, Vicente Saura, Cristina Oliveira, Mafalda Isakoff, Steven J. Singel, Stina Mui Dent, Rebecca Alexandra TI LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Asan Med Ctr, Seoul, South Korea. Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA. Seoul Natl Univ, Coll Med, Seoul, South Korea. ICO Duran & Reinals, Inst Catala Oncol, Lhospitalet De Llobregat, Spain. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Vall dHebron Univ Hosp, SOLTI, Barcelona, Spain. Vall dHebron Univ Hosp, VHIO, Barcelona, Spain. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Genentech Roche, San Francisco, CA USA. Natl Canc Ctr Singapore, Singapore, Singapore. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS1111 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904667 ER PT J AU Kollmannsberger, CK Sharma, S Shapiro, G Chi, KN Christensen, J Tassell, VR Chao, RC Faltaos, D Hurwitz, H AF Kollmannsberger, Christian K. Sharma, Sunil Shapiro, Geoffrey Chi, Kim N. Christensen, James Tassell, Vanessa Roberts Chao, Richard C. Faltaos, Demiana Hurwitz, Herbert TI Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada. Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. Dana Farber Canc Inst, Boston, MA 02115 USA. BC Canc Agcy, Vancouver, BC, Canada. Mirati Therapeut Inc, San Diego, CA USA. Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 4 Z9 4 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2589 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900622 ER PT J AU Krasner, CN Birrer, MJ Berlin, ST Buss, MK Eliasof, S Garmey, EG Hennessey, M Horowitz, NS Konstantinopoulos, P Matulonis, UA AF Krasner, Carolyn N. Birrer, Michael J. Berlin, Suzanne T. Buss, Mary K. Eliasof, Scott Garmey, Edward Graeme Hennessey, Meliessa Horowitz, Neil S. Konstantinopoulos, Panagiotis Matulonis, Ursula A. TI Targeting VEGFRi resistance through HIF-1 alpha suppression: Phase II clinical trial evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent platinum resistant ovarian cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA. Dana Farber Canc Inst, York, ME USA. Beth Israel Deaconess Med Ctr, Newton, MA USA. Cerulean Pharma Inc, Cambridge, MA USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS5614 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904803 ER PT J AU Kris, MG Johnson, BE Kwiatkowski, DJ Wistuba, II Berry, LD Haura, EB Socinski, MA Ramalingam, SS Glisson, BS Waqar, SN Otterson, GA Schiller, JH Garon, EB Cetnar, JP Politi, KA Brahmer, JR Sequist, LV Lovly, CM Kugler, K Bunn, PA AF Kris, Mark G. Johnson, Bruce E. Kwiatkowski, David J. Wistuba, Ignacio Ivan Berry, Lynne D. Haura, Eric B. Socinski, Mark A. Ramalingam, Suresh S. Glisson, Bonnie S. Waqar, Saiama Naheed Otterson, Gregory Alan Schiller, Joan H. Garon, Edward B. Cetnar, Jeremy Paul Politi, Katerina A. Brahmer, Julie R. Sequist, Lecia V. Lovly, Christine Marie Kugler, Kelly Bunn, Paul A. TI Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Vanderbilt Univ, Nashville, TN 37235 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Univ Pittsburgh, Pittsburgh, PA USA. Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Washington Univ, St Louis, MO USA. Ohio State Univ, Columbus, OH 43210 USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles Translat Res Oncol US Network, Los Angeles, CA 90095 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Yale Univ, Sch Med, New Haven, CT USA. Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Univ Colorado, Colorado Canc Ctr Denver, Aurora, CO USA. Univ Colorado, Ctr Canc, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8094 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901806 ER PT J AU Kulke, MH Niedzwiecki, D Foster, NR Fruth, B Kunz, PL Kennecke, HF Wolin, EM Venook, AP AF Kulke, Matthew H. Niedzwiecki, Donna Foster, Nathan R. Fruth, Briant Kunz, Pamela L. Kennecke, Hagen F. Wolin, Edward M. Venook, Alan P. TI Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E plus B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Duke Univ, Cary, NC USA. North Cent Canc Treatment Grp, Rochester, MN USA. Mayo Clin Canc Ctr, Rochester, MN USA. Stanford Univ Sch Med, Stanford, CA USA. British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. Univ Kentucky, Lexington, KY USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4005 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900844 ER PT J AU Kummar, S Do, KT Coyne, GHO Turkbey, B Meltzer, PS Polley, E Horneffer, Y Juwara, L Antony, R Choyke, PL Mitchell, SA Helman, LJ Chen, A Doroshow, JH AF Kummar, Shivaani Do, Khanh Tu Coyne, Geraldine Helen O'Sullivan Turkbey, Baris Meltzer, Paul S. Polley, Eric Horneffer, Yvonne Juwara, Lamin Antony, Ramya Choyke, Peter L. Mitchell, Sandra A. Helman, Lee J. Chen, Alice Doroshow, James H. TI Phase II trial of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Stanford Univ, Sch Med, Phase Clin Res Program 1, Stanford, CA 94305 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Early Clin Trials Dev Program, Bethesda, MD USA. NCI, Mol Imaging Program, NIH, Bethesda, MD 20892 USA. Ctr Canc Res, Bethesda, MD USA. NCI, Div Canc Treatment & Diag, Rockville, MD USA. NCI, Bethesda, MD 20892 USA. Leidos Biomed Res Inc, Frederick, MD USA. NCI, NIH, Bethesda, MD 20892 USA. NCI, Rockville, MD USA. NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA. NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA. Div Canc Treatment & Diag, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10563 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900203 ER PT J AU Kunz, PL Catalano, PJ Nimeiri, HS Fisher, GA Longacre, TA Schrijver, I Reidy, DL Strosberg, JR O'Dwyer, PJ Benson, A AF Kunz, Pamela L. Catalano, Paul J. Nimeiri, Halla Sayed Fisher, George A. Longacre, Teri A. Schrijver, Iris Reidy, Diane Lauren Strosberg, Jonathan R. O'Dwyer, Peter J. Benson, Al Bowen TI A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Stanford Univ, Sch Med, Stanford, CA 94305 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. Stanford Univ, Med Ctr, Stanford, CA 94305 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Weill Cornell Med Coll, New York, NY USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS4145 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904753 ER PT J AU Kutsch, N Bahlo, J Byrd, JC Dohner, H Eichhorst, B Else, M Geisler, C Grever, MR Lepretre, S Bergman, M Neuberg, DS Oscier, D Rosenquist, R Robak, T Shanafelt, TD Stilgenbauer, S Hallek, MJ AF Kutsch, Nadine Bahlo, Jasmin Byrd, John C. Dohner, Hartmut Eichhorst, Barbara Else, Monica Geisler, Christian Grever, Michael R. Lepretre, Stephane Bergman, Manuela Neuberg, Donna S. Oscier, David Rosenquist, Richard Robak, Tadeusz Shanafelt, Tait D. Stilgenbauer, Stephan Hallek, Michael J. CA Int CLL-IPI Working Grp TI The international Prognostic Index for patients with CLL (CLL-IPI): An international meta-analysis SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany. Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Cologne, Germany. Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany. Inst Canc Res London, Div Mol Pathol, London, England. Rigshosp, DK-2100 Copenhagen, Denmark. Ohio State Univ, Columbus, OH 43210 USA. Henri Becquerel Hosp, Rouen, France. Klinikum Schwabing, Dept Hematol Oncol Immunol Palliat Care Infect Di, Munich, Germany. Dana Farber Canc Inst, Boston, MA 02115 USA. Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England. Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden. Med Univ Lodz, Lodz, Poland. Mayo Clin, Rochester, MN USA. Univ Hosp Ulm, Ulm, Germany. NR 0 TC 3 Z9 3 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7002 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901540 ER PT J AU Kvale, EA Rocque, GB Bevis, KS Acemgil, A Taylor, RA Demark-Wahnefried, W Kenzik, K Li, YF Meneses, K Martin, M Fouad, M Partridge, EE Pisu, M AF Kvale, Elizabeth Ann Rocque, Gabrielle Betty Bevis, Kerri S. Acemgil, Aras Taylor, Richard A. Demark-Wahnefried, Wendy Kenzik, Kelly Li, Yufeng Meneses, Karen Martin, Michelle Fouad, Mona Partridge, Edward E. Pisu, Maria TI Distress in older adult cancer patients approaching end of life SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Birmingham VA Med Ctr, Birmingham, AL USA. Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9548 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902043 ER PT J AU Kwak, EL Lennerz, JK Szymonifka, J Corcoran, RB Clark, JW Russo, AL Borger, DR Blaszkowsky, LS Dias, LE Faris, JE Murphy, JE Fidias, P Lennes, IT Azzoli, CG Gainor, JF Mullen, JT Lauwers, GY Ryan, DP Iafrate, AJ Hong, TS AF Kwak, Eunice Lee Lennerz, Jochen K. Szymonifka, Jackie Corcoran, Ryan Bruce Clark, Jeffrey W. Russo, Andrea Lyn Borger, Darrell R. Blaszkowsky, Lawrence Scott Dias, Lauren Elizabeth Faris, Jason Edward Murphy, Janet E. Fidias, Panos Lennes, Inga Tolin Azzoli, Christopher G. Gainor, Justin F. Mullen, John Thomas Lauwers, Gregory Y. Ryan, David P. Iafrate, A. John Hong, Theodore S. TI Clinical characteristics and treatment outcomes of patients with metastatic, MET-amplified esophagogastric cancers. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Canc Res & Biostat, Seattle, WA USA. Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. Massachusetts Gen North Shore Canc Ctr, Danvers, MA USA. Univ Arizona, Phoenix, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4043 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900882 ER PT J AU Lacouture, ME Keefe, DMK Sonis, ST Giri, N Wang, T Reisman, A Sbar, E Gernhardt, DR Jatoi, A AF Lacouture, Mario E. Keefe, Dorothy Mary Kate Sonis, Stephen T. Giri, Nagdeep Wang, Tao Reisman, Arlene Sbar, Eric Gernhardt, Diana R. Jatoi, Aminah TI Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an EGFR inhibitor with no rash or diarrhea improvement from corticosteroids or probiotics. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Royal Adelaide Hosp, Adelaide, SA 5000, Australia. Dana Farber Canc Inst, Boston, MA 02115 USA. Pfizer Oncol, La Jolla, CA USA. Pfizer Oncol, Groton, CT USA. Pfizer Oncol, New York, NY USA. Pfizer Oncol, Collegeville, PA USA. Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e19049 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903903 ER PT J AU Lagmay, JP Krailo, MD Dang, H Kim, A Hawkins, DS Beaty, O Widemann, BC Zwerdling, T Bomgaars, L Langevin, AM Grier, HE Weigel, B Blaney, S Gorlick, RG Janeway, KA AF Lagmay, Joanne P. Krailo, Mark D. Dang, Ha Kim, AeRang Hawkins, Douglas S. Beaty, Orren Widemann, Brigitte C. Zwerdling, Theodore Bomgaars, Lisa Langevin, Anne-Marie Grier, Holcombe E. Weigel, Brenda Blaney, Susan Gorlick, Richard Greg Janeway, Katherine A. TI Outcome of recurrent osteosarcoma patients enrolled in seven phase II trials through CCG, POG, and COG: Learning from the past to move forward. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Florida, Shands Hosp Children, Gainesville, FL USA. Childrens Onc Grp, Arcadia, CA USA. Childrens Oncol Grp, Arcadia, CA USA. Ctr Canc & Blood Disorders, Washington, DC USA. Seattle Childrens Hosp, Seattle, WA USA. Mission Hosp, Fairview, NC USA. NCI, Ctr Canc Res, Bethesda, MD 20892 USA. Univ Calif Davis, Sacramento, CA USA. Texas Childrens Canc Ctr, Houston, TX USA. Univ Texas Med Hlth Ctr San Antonio, San Antonio, TX USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Minnesota, Minneapolis, MN USA. Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA. Childrens Hosp, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10042 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900049 ER PT J AU Lampson, BL Santos, A Janne, PA Oxnard, GR AF Lampson, Benjamin L. Santos, Abigail Janne, Pasi A. Oxnard, Geoffrey R. TI Reduced-dose versus full-dose erlotinib for advanced EGFR-mutant non-small cell lung carcinoma (NSCLC): A retrospective analysis. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8074 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901786 ER PT J AU Lancet, JE Othus, M DeAngelo, DJ Coutre, S Komrokji, RS Tallman, MS Litzow, MR Appelbaum, FR AF Lancet, Jeffrey E. Othus, Megan DeAngelo, Daniel J. Coutre, Steven Komrokji, Rami S. Tallman, Martin S. Litzow, Mark Robert Appelbaum, Frederick R. TI Safety and tolerability of the combination of ATRA plus arsenic trioxide (ATO) plus gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): Initial report of the SWOG/Alliance/ECOG S0535 trial SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. SWOG Stat Ctr, Seattle, WA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Stanford Univ, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Mayo Clin, Rochester, MN USA. Fred Hutchinson Canc Rsrch Ctr, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7016 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901552 ER PT J AU Land, SR Warren, GW Moinpour, C Ostroff, JS Crafts, J Folz, J Gulley, JL Szabo, E Chollette, V Brandon, TH Duffy, S Hatsukami, DK Dresler, CM Gritz, ER Schnoll, R Sarna, L Rigotti, N Buckner, JC Mitchell, SA Toll, B AF Land, Stephanie R. Warren, Graham Walter Moinpour, Carol Ostroff, Jamie S. Crafts, Jennifer Folz, Jasmine Gulley, James L. Szabo, Eva Chollette, Veronica Brandon, Thomas H. Duffy, Sonia Hatsukami, Dorothy K. Dresler, Carolyn M. Gritz, Ellen R. Schnoll, Robert Sarna, Linda Rigotti, Nancy Buckner, Jan C. Mitchell, Sandra A. Toll, Benjamin TI Standardizing measurement of tobacco use in cancer clinical trials SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. Med Univ S Carolina, Charleston, SC 29425 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Westat Corp, Rockville, MD USA. NCI, NIH, Bethesda, MD 20892 USA. NCI, Potomac, MD USA. NCI, Rockville, MD USA. H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. Univ Michigan, Ann Arbor, MI 48109 USA. Masonic Canc Ctr, Minneapolis, MN USA. Tobacco Cessat & Control Subcomm, Rockville, MD USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Penn, Philadelphia, PA 19104 USA. Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mayo Clin, Rochester, MN USA. Yale Univ, New Haven, CT USA. RI Gulley, James/K-4139-2016 OI Gulley, James/0000-0002-6569-2912 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9550 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902045 ER PT J AU Landry, JC Feng, Y Prabhu, RS Cohen, SJ Staley, CA Whittington, RM Sigurdson, ER Nimeiri, HS Verma, UN Benson, A AF Landry, Jerome Carl Feng, Yang Prabhu, Roshan Sudhir Cohen, Steven J. Staley, Charles A. Whittington, Richard M. Sigurdson, Elin R. Nimeiri, Halla Sayed Verma, Udit N. Benson, Al Bowen TI Phase II trial of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes of a trial of the ECOG-ACRIN Cancer Research Group (E3204) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Southeast Radiat Oncol Grp, Charlotte, NC USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. VA New Jersey Healthcare Syst, E Orange, NJ USA. Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3592 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900811 ER PT J AU Landsburg, DJ Petrich, AM Abramson, JS Sohani, A Press, OW Cassaday, RD Chavez, JC Song, KW Zelenetz, AD Gandhi, M Shah, NM Fenske, T Jasso, J Medeiros, LJ Yang, DT Nabhan, C AF Landsburg, Daniel Jeffrey Petrich, Adam Matthew Abramson, Jeremy S. Sohani, Aliyah Press, Oliver W. Cassaday, Ryan Daniel Chavez, Julio C. Song, Kevin W. Zelenetz, Andrew David Gandhi, Mitul Shah, Namrata Mahendra Fenske, Timothy Jasso, Jesse Medeiros, L. Jeffrey Yang, David T. Nabhan, Chadi TI Analysis of "double-hit" lymphoma cases by genetic subtype SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA. Northwestern Univ, Chicago, IL 60611 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Univ Washington, Seattle, WA 98195 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Vancouver Gen Hosp, Vancouver, BC, Canada. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Northwestern, Chicago, IL USA. Med Coll Wisconsin, W Allis, WI USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA. Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. Univ Chicago, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8543 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901855 ER PT J AU Lassen, UN Mau-Soerensen, M Kung, AL Wen, PY Lee, EQ Plotkin, SR Muhic, A Rashal, T Williams, T McCauley, D Ellis, J Saint-Martin, JR Carlson, R Frenkel, R Shacham, S Mirza, MR Kauffman, M Lassman, AB AF Lassen, Ulrik Niels Mau-Soerensen, Morten Kung, Andrew L. Wen, Patrick Y. Lee, Eudocia Quant Plotkin, Scott R. Muhic, Aida Rashal, Tami Williams, Tony McCauley, Dilara Ellis, Joel Saint-Martin, Jean-Richard Carlson, Robert Frenkel, Ran Shacham, Sharon Mirza, Mansoor Raza Kauffman, Michael Lassman, Andrew B. TI A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Rigshosp, DK-2100 Copenhagen, Denmark. Univ Copenhagen Hosp, Rigshosp, DK-2100 Copenhagen, Denmark. Columbia Univ, Med Ctr, New York, NY USA. Herbert Irving Comprehens Canc Ctr, New York, NY USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Karyopharm Therapeut Inc, Newton, MA USA. Karyopharm Europe GMBH, Munich, Germany. NR 0 TC 0 Z9 0 U1 5 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2044 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900503 ER PT J AU Laubach, J Raje, NS Yee, AJ Armand, P Schlossman, RL Rosenblatt, J Hedlund, JA Martin, MG Reynolds, CH Shain, KH Zackon, I Stampleman, L Boswell, E Chuma, S Liguori, R Handisides, D Kroll, S Anderson, KC Richardson, PG Ghobrial, IM AF Laubach, Jacob Raje, Noopur S. Yee, Andrew Jenho Armand, Philippe Schlossman, Robert L. Rosenblatt, Jacalyn Hedlund, Jacquelyn Ann Martin, Michael Gary Reynolds, Craig H. Shain, Kenneth H. Zackon, Ira Stampleman, Laura Boswell, Erica Chuma, Stacey Liguori, Rebecca Handisides, Damian Kroll, Stew Anderson, Kenneth Carl Richardson, Paul G. Ghobrial, Irene M. TI Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. Beth Israel Deaconess, Boston, MA USA. Maine Ctr Canc Med, Scarborough, ME USA. West Clin, Memphis, TN USA. Ocala Oncol Ctr, Ocala, FL USA. H Lee Moffitt Canc Ctr & Res Inst, St Petersburg, FL USA. Albany Medcl Ctr, New York Onc Hem, Albany, NY USA. Pacific Canc Care, Salinas, CA USA. Blood Canc Res Partnership, Boston, MA USA. Threshold Pharmaceut Inc, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8579 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901891 ER PT J AU Lee, EQ Muzikansky, A Gerstner, ER Kuhn, JG Reardon, DA Nayak, L Norden, AD Doherty, LM Rifenburg, J LaFrankie, DC Pulverenti, J Vardam-Kaur, T Stokes, D Smith, KH McCluskey, CS Gaffey, SC Batchelor, T Duda, DG Jain, RK Wen, PY AF Lee, Eudocia Quant Muzikansky, Alona Gerstner, Elizabeth Robins Kuhn, John G. Reardon, David A. Nayak, Lakshmi Norden, Andrew David Doherty, Lisa M. Rifenburg, Jennifer LaFrankie, Debra C. Pulverenti, Julee Vardam-Kaur, Trupti Stokes, Deirdre Smith, Katrina Howard McCluskey, Christine Sceppa Gaffey, Sarah C. Batchelor, Tracy Duda, Dan G. Jain, Rakesh K. Wen, Patrick Y. TI Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. Dana Farber Canc Ctr Inst, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS2080 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904677 ER PT J AU Lee, TY Ng, CS Zhang, Z Lee, S Marques, H Burgers, K Su, F Bauza, J Mannel, RS Walker, JL Huh, WK Rubin, SC DiSilvestro, P Martin, LP Chan, JK Bookman, MA Coleman, RL AF Lee, Ting-Yim Ng, Chaan S. Zhang, Zheng Lee, Susanna Marques, Helga Burgers, Kyle Su, Feng Bauza, Joseph Mannel, Robert S. Walker, Joan L. Huh, Warner King Rubin, Stephen C. DiSilvestro, Paul Martin, Lainie P. Chan, John K. Bookman, Michael A. Coleman, Robert L. TI CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Lawson Hlth Res Inst, London, ON, Canada. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Brown Univ, Providence, RI 02912 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Western Univ, Robarts Res Inst, London, ON, Canada. Western Univ, Robarts Res Inst, London, England. ACRIN, Philadelphia, PA USA. Univ Oklahoma, Oklahoma City, OK USA. OUHSC, Stephenson Canc Ctr, Oklahoma City, OK USA. Univ Alabama Birmingham, Birmingham, AL USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Brown Univ, Warren Alpert Med Sch, Women & Infants Hosp, Providence, RI 02912 USA. Calif Pacific Palo Alto Med Fdn, Sutter Res Inst, San Francisco, CA USA. Univ Arizona, Tucson, AZ USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5522 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901182 ER PT J AU Lennerz, JK Stenzinger, A AF Lennerz, Jochen K. Stenzinger, Albrecht TI Allelic ratio of KRAS mutations in pancreatic ductal adenocarcinoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany. Natl Ctr Tumor Dis, Heidelberg, Germany. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4023 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900862 ER PT J AU Lheureux, S Weberpals, JI Hendrickson, AEW Fleming, GF Olawaiye, A Brana, I Mackay, H Dhani, NC Wilson, MK Rodriguez-Freixinos, V Martin-Lorente, C Ward, J Chang, K Wang, L Speers, V Karakasis, K Bowering, VL Chen, A Brenton, J Oza, AM AF Lheureux, Stephanie Weberpals, Johanne Ingrid Hendrickson, Andrea Elisabeth Wahner Fleming, Gini F. Olawaiye, Alexander Brana, Irene Mackay, Helen Dhani, Neesha C. Wilson, Michelle K. Rodriguez-Freixinos, Victor Martin-Lorente, Cristina Ward, Jacklyn Chang, Karen Wang, Lisa Speers, Vanessa Karakasis, Katherine Bowering, Valerie Lydia Chen, Alice Brenton, James Oza, Amit M. TI A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Princess Margaret Canc Ctr, Toronto, ON, Canada. Ottawa Gen Hosp, Ottawa, ON K1H 8L6, Canada. Mayo Clin, Rochester, MN USA. Univ Chicago, Med Ctr, Chicago, IL 60637 USA. Massachusetts Gen Hosp, Chestnut Hill, MA USA. UHN Princess Margaret Hosp, Cambridge, ON, Canada. Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. Univ Toronto, Princess Margaret Canc Ctr, Univ Hlth Network, Div Med Oncol & Hematol,Dept Med, Toronto, ON, Canada. Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada. Univ Hlth Network, Toronto, ON, Canada. Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA. Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS5613 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904802 ER PT J AU Lheureux, S Ledermann, JA Runswick, S Hodgson, DR Timms, K Lanchbury, JS Kaye, SB Gourley, C Bowtell, D Kohn, EC Scott, CL Matulonis, U Panzarella, T Dougherty, BA Barrett, JC Lai, ZW O'Connor, M Robertson, JD Ho, TW Oza, AM AF Lheureux, Stephanie Ledermann, Jonathan A. Runswick, Sarah Hodgson, Darren R. Timms, Kirsten Lanchbury, Jerry S. Kaye, Stanley B. Gourley, Charlie Bowtell, David Kohn, Elise C. Scott, Clare L. Matulonis, Ursula Panzarella, Tony Dougherty, Brian Andrew Barrett, J. Carl Lai, Zhongwu O'Connor, Mark Robertson, Jane D. Ho, Tony Weishiu Oza, Amit M. TI Genomic characterization of long-term responders to olaparib. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Princess Margaret Canc Ctr, Toronto, ON, Canada. UCL, Inst Canc, London, England. AstraZeneca, Macclesfield, Cheshire, England. Myriad Genet Inc, Salt Lake City, UT USA. Inst Canc Res, London SW3 6JB, England. Royal Marsden NHS Fdn Trust, London, England. Univ Edinburgh, Canc Res UK Ctr, Edinburgh, Midlothian, Scotland. Peter MacCallum Canc Ctr, East Melbourne, Australia. NIH, NCI, Bethesda, MD 20892 USA. Royal Melbourne Hosp, Parkville, Vic 3050, Australia. Dana Farber Canc Inst, Boston, MA 02115 USA. Princess Margaret Hosp, Dept Biostat, Toronto, ON M4X 1K9, Canada. Univ Toronto, Toronto, ON, Canada. AstraZeneca, Waltham, MA USA. Astra Zeneca, Wilmington, DE USA. Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5566 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901230 ER PT J AU Li, HR Choueiri, TK Wells, C Agarwal, N Donskov, F Lee, JL Broom, RJ Yuasa, T Rini, BI Pal, SK Wood, L Ernst, DS Kollmannsberger, CK Vaishampayan, UN Rha, SY Bjarnason, GA Knox, JJ Saleem, S Beuselinck, B Heng, DYC AF Li, Haoran Choueiri, Toni K. Wells, Connor Agarwal, Neeraj Donskov, Frede Lee, Jae-Lyun Broom, Reuben James Yuasa, Takeshi Rini, Brian I. Pal, Sumanta Kumar Wood, Lori Ernst, D. Scott Kollmannsberger, Christian K. Vaishampayan, Ulka N. Rha, Sun Young Bjarnason, Georg A. Knox, Jennifer J. Saleem, Sadia Beuselinck, Benoit Heng, Daniel Yick Chin TI Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Tom Baker Canc Clin, Calgary, AB, Canada. Dana Farber Canc Inst, Boston, MA 02115 USA. Tom Baker Canc Clin, Calgary, AB, Canada. Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark. Univ Ulsan Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea. Auckland City Hosp, Auckland, New Zealand. Japanese Fdn Canc Res, Canc Inst Hosp, Dept Urol, Tokyo, Japan. Cleveland Clin Taussig Canc Inst, Cleveland, OH USA. City Hope Natl Med Ctr, Duarte, CA USA. Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada. London Reg Canc Ctr, London, ON N6A 4L6, Canada. BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Yonsei Univ Coll Med, Seoul, South Korea. Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium. Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4558 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901029 ER PT J AU Lin, CC Bruinooge, SS Kirkwood, KM Olsen, CC Bajorin, DF Jemal, A Giordano, SH Goldstein, M Guadagnolo, BA Kosty, MP Hopkins, S Yu, JB Arnone, A Hanley, AE Stevens, S Hershman, DL AF Lin, Chun Chieh Bruinooge, Suanna S. Kirkwood, Kelsey M. Olsen, Christine Cecilia Bajorin, Dean F. Jemal, Ahmedin Giordano, Sharon Hermes Goldstein, Michael Guadagnolo, Beverly Ashleigh Kosty, Michael P. Hopkins, Shane Yu, James B. Arnone, Anna Hanley, Amy E. Stevens, Stephanie Hershman, Dawn L. TI Association between geographic access to cancer care and receipt of chemotherapy: Geographic distribution of oncologists and travel distance SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Amer Canc Soc, Atlanta, GA 30329 USA. Amer Soc Clin Oncol, Alexandria, VA USA. Massachusetts Gen Hosp, Newton, MA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Scripps Res Inst, La Jolla, CA 92037 USA. William R Bliss Canc Ctr, Ames, IA USA. Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA. Amer Soc Radiat Oncol, Fairfax, VA USA. Amer Soc Clin Oncol, Chicago, IL USA. Columbia Univ, Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e17561 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903531 ER PT J AU Lin, JJ Cardarella, S Lydon, CA Dahlberg, SE Jackman, DM Janne, PA Johnson, BE AF Lin, Jessica Jiyeong Cardarella, Stephanie Lydon, Christine A. Dahlberg, Suzanne Eleanor Jackman, David Michael Janne, Pasi A. Johnson, Bruce E. TI Clinical predictors of 5-year survival in patients with EGFR-mutant metastatic NSCLC treated with EGFR-TKIs. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Brigham & Womens Hosp, Brighton, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8071 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901783 ER PT J AU Lipton, A Smith, MR Fizazi, K Stopeck, A Henry, DH Shore, N Saad, F Spencer, A Zhu, L Warner, DJ AF Lipton, Allan Smith, Matthew R. Fizazi, Karim Stopeck, Alison Henry, David H. Shore, Neal Saad, Fred Spencer, Andrew Zhu, Li Warner, Douglas J. TI Bone turnover marker (BTM) levels and clinical outcomes in advanced cancer patients (pts) treated with antiresorptive bone therapies. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Penn State Hematol Oncol, Hershey, PA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Paris 11, Dept Canc Med, Inst Gustave Roussy, Villejuif, France. Stony Brook Canc Ctr, Dept Internal Med, Stony Brook, NY USA. Penn Hosp, Joan Karnell Canc Ctr, Philadelphia, PA 19107 USA. Carolina Urol Res Ctr, Myrtle Beach, SC USA. Univ Montreal, Ctr Hosp, Dept Surg, Montreal, PQ, Canada. Monash Univ, Dept Clin Haematol, Clayton, Vic, Australia. Amgen Inc, Thousand Oaks, CA 91320 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e22236 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904605 ER PT J AU Liu, J Lee, JM Luo, WX Birrer, MJ Whalen, C Houston, ND Obermayer, E Spagnoletti, T Barry, WT Kohn, EC Ivy, SP Matulonis, U AF Liu, Joyce Lee, Jung-min Luo, Weixiu Birrer, Michael J. Whalen, Christin Houston, Nicole D. Obermayer, Elizabeth Spagnoletti, Tatum Barry, William Thomas Kohn, Elise C. Ivy, S. Percy Matulonis, Ursula TI A phase 1 study optimizing the dosing of olaparib tablet formulation combined with cediranib in recurrent ovarian cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Newton, MA USA. NIH, Bethesda, MD 20892 USA. Dana Farber Canc Inst, IBCSG Stat Ctr, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA. NCI, NIH, Bethesda, MD 20892 USA. NCI, CTEP, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5559 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901222 ER PT J AU Liu, SV Powderly, JD Camidge, DR Ready, N Heist, RS Hodi, FS Giaccone, G Liu, B Wallin, J Funke, RP Waterkamp, D Gettinger, SN AF Liu, Stephen V. Powderly, John D. Camidge, D. Ross Ready, Neal Heist, Rebecca Suk Hodi, F. Stephen Giaccone, Giuseppe Liu, Bo Wallin, Jeffrey Funke, Roel Peter Waterkamp, Daniel Gettinger, Scott N. TI Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Georgetown Univ Hosp, Washington, DC 20007 USA. Carolina BioOncol Inst, Huntersville, NC USA. Univ Colorado, Ctr Canc, Aurora, CO USA. Duke Univ, Med Ctr, Chapel Hill, NC USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NCI, NIH, Bethesda, MD 20892 USA. Genentech Inc, San Francisco, CA 94080 USA. F Hoffmann La Roche Ltd, Basel, Switzerland. Yale Sch Med, New Haven, CT USA. NR 0 TC 20 Z9 20 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8030 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901743 ER PT J AU Long, GV Stroyakovskiy, D Gogas, H Levchenko, E De Braud, FG Larkin, JMG Garbe, C Jouary, T Hauschild, A Grob, JJ Chiarion-Sileni, V Lebbe, C Mandala, M Millward, M DeMarini, DJ Irani, JG Jin, F Swann, RS Mookerjee, B Flaherty, K AF Long, Georgina V. Stroyakovskiy, Daniil Gogas, Helen Levchenko, Evgeny De Braud, Filippo G. Larkin, James M. G. Garbe, Claus Jouary, Thomas Hauschild, Axel Grob, Jean Jacques Chiarion-Sileni, Vanna Lebbe, Celeste Mandala, Mario Millward, Michael DeMarini, Douglas James Irani, Jhangir G. Jin, Fan Swann, R. Suzanne Mookerjee, Bijoyesh Flaherty, Keith TI Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Melanoma Inst Australia, Sydney, NSW, Australia. Univ Sydney, Sydney, NSW, Australia. Moscow City Oncol Hosp 62, Dept Chemotherapy, Moscow, Russia. Univ Athens, Sch Med, Dept Med 1, GR-11527 Athens, Greece. Petrov Res Inst Oncol, St Petersburg, Russia. Fdn IRCCS Ist Nazl Tumori, Milan, Italy. Royal Marsden NHS Fdn Trust, London, England. Univ Tubingen, Tubingen, Germany. Hop Francois Mitterrand, Pau, France. Univ Kiel, Kiel, Germany. Aix Marseille Univ, Hop Timone, Marseille, France. Veneto Oncol Inst, Padua, Italy. Hop St Louis, AP HP, Dept Dermatol, Paris, France. Papa Giovanni XXIII Hosp, Bergamo, Italy. Sir Charles Gairdner Hosp, Perth, WA, Australia. GlaxoSmithKline, Collegeville, PA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 102 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900101 ER PT J AU Lonial, S Dimopoulos, MA Palumbo, A White, D Grosicki, S Spicka, I Walter-Croneck, A Moreau, P Mateos, MV Magen-Nativ, H Belch, A Reece, DE Beksac, M Taniwaki, M Rollig, C Singhal, AK Katz, J Bleickardt, EW Poulart, V Richardson, PG AF Lonial, Sagar Dimopoulos, Meletios A. Palumbo, Antonio White, Darrell Grosicki, Sebastian Spicka, Ivan Walter-Croneck, Adam Moreau, Philippe Mateos, Maria-Victoria Magen-Nativ, Hila Belch, Andrew Reece, Donna Ellen Beksac, Meral Taniwaki, Masafumi Roellig, Christoph Singhal, Anil K. Katz, Jessica Bleickardt, Eric W. Poulart, Valerie Richardson, Paul G. CA ELOQUENT-2 Investigators TI ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. Univ Athens, Athens 11528, Greece. AOU San Giovanni Battista Torino, Osped Molinette, Turin, Italy. Dalhousie Univ, QEII Hlth Sci Ctr, Halifax, NS, Canada. Silesian Med Univ, Fac Publ Hlth, Dept Canc Prevent, Katowice, Poland. Prague Gen Hosp, Prague, Czech Republic. Med Univ Lublin, Lublin, Poland. Univ Hosp, Nantes, France. Univ Hosp Salamanca IBSAL, Salamanca, Spain. Tel Aviv Univ, Ramat Aviv, Israel. Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada. Univ Alberta, Edmonton, AB, Canada. Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. Ankara Univ, TR-06100 Ankara, Turkey. Kyoto Prefectural Univ Med, Kyoto, Japan. Univ Klinikum TU, Dresden, Germany. AbbVie Biotherapeut Inc ABR, Redwood City, CA USA. Bristol Myers Squibb Co, Princeton, NJ USA. Bristol Myers Squibb Co, Wallingford, CT 06492 USA. Bristol Myers Squibb, Braine Lalleud, Belgium. Dana Farber Canc Inst, Boston, MA 02115 USA. RI richard, chrystelle/K-8595-2015 NR 0 TC 2 Z9 2 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8508 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901821 ER PT J AU Luis, IMVD Oh, C Wang, ZG Dipiro, P Macrae, EM Painter, C Kryukov, G Krop, IE Winer, EP Lin, NU Wagle, N AF Luis, Ines Maria Vaz Duarte Oh, Coyin Wang, Zhigang Dipiro, Pamela Macrae, Erin Macrae Painter, Corrie Kryukov, Gregory Krop, Ian E. Winer, Eric P. Lin, Nancy U. Wagle, Nikhil TI Whole exome sequencing (WES) in HER2+metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Broad Inst, Cambridge, MA USA. Ohio State Univ, Stefanie Spielman Comprehens Breast Ctr, Wexner Med Ctr, Columbus, OH 43210 USA. Broad Inst MIT & Harvard, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 611 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901403 ER PT J AU Luis, IMVD Lin, NU Keating, NL Lii, J Barry, WT Winer, EP Freedman, RA AF Luis, Ines Maria Vaz Duarte Lin, Nancy U. Keating, Nancy Lynn Lii, Joyce Barry, William Thomas Winer, Eric P. Freedman, Rachel A. TI Factors associated with early mortality in metastatic breast cancer (MBC) in a population based cohort SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA. Dana Farber Canc Inst, Brookline, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1577 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900443 ER PT J AU Luke, JJ Donahue, H Nishino, M Giobbie-Hurder, A Davis, M Bailey, N Ott, PA Hodi, FS AF Luke, Jason John Donahue, Hilary Nishino, Mizuki Giobbie-Hurder, Anita Davis, Meredith Bailey, Nancy Ott, Patrick Alexander Hodi, F. Stephen TI Clinical experience and correlates of ipilimumab 3 mg/kg with GM-CSF in advanced melanoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Chicago Med, Chicago, IL USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e20025 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904048 ER PT J AU Madenci, AL Fisher, S Diller, L Goldsby, RE Leisenring, WM Oeffinger, KC Robison, LL Sklar, CA Stovall, M Weathers, R Armstrong, GT Yasui, Y Weldon, CB AF Madenci, Arin L. Fisher, Stacey Diller, Lisa Goldsby, Robert E. Leisenring, Wendy M. Oeffinger, Kevin C. Robison, Leslie L. Sklar, Charles A. Stovall, Marilyn Weathers, Rita Armstrong, Gregory T. Yasui, Yutaka Weldon, Christopher Bertero TI Intestinal obstruction in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Univ Alberta, Edmonton, AB, Canada. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. UCSF Sch Med, Dept Pediat, Greenbrae, CA USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. St Jude Childrens Res Hosp, Memphis, TN 38105 USA. Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA. Boston Childrens Hosp, Dept Surg, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10071 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900081 ER PT J AU Malempati, S Weigel, B Anderson, JR Parham, D Teot, LA Rodeberg, DA Yock, TI Shulkin, BL Hawkins, DS AF Malempati, Suman Weigel, Brenda Anderson, James R. Parham, David Teot, Lisa A. Rodeberg, David A. Yock, Torunn I. Shulkin, Barry L. Hawkins, Douglas S. TI Early results from Children's Oncology Group (COG) ARST08P1: Pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma (RMS). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Univ Minnesota, Minneapolis, MN USA. Univ Nebraska Med Ctr, Omaha, NE USA. Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. Childrens Hosp Boston, Boston, MA USA. E Carolina Univ, Greenville, NC USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. St Jude Childrens Res Hosp, Memphis, TN 38105 USA. Seattle Childrens Hosp, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10015 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900019 ER PT J AU Malhotra, S Huang, K Simeunovic, K Vinnakota, R Gavrancic, T Villanueva, N Dietz, D Fenn, K Beck, K Coker, C Park, YHA Acharyya, S AF Malhotra, Sheetal Huang, Kan Simeunovic, Kosana Vinnakota, Ravi Gavrancic, Tatjana Villanueva, Nicholas Dietz, Donny Fenn, Kathleen Beck, Kristen Coker, Courtney Park, Yeun-Hee Anna Acharyya, Swarnali TI Survival in veterans with lung cancer: Cancer cachexia and the importance of weight. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 North Cent Bronx Hosp, Bronx, NY USA. New York Presbyterian Columbia Med Ctr, Ft Lee, NJ USA. JJ Peters VA Med Ctr, Bronx, NY USA. James J Peters VA Med Ctr, New York, NY USA. Columbia Univ, Dept Med, Med Ctr, New York, NY USA. Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. Columbia Univ, Inst Canc Genet, New York, NY USA. Onc & Hem White Plains, Mt Vernon, NY USA. Columbia Univ, Canc Genet 4Inst, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e20608 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904225 ER PT J AU Malhotra, S Wu, DPH Park, YHA AF Malhotra, Sheetal Wu, David Ping-Hsin Park, Yeun-Hee Anna TI National data on sorafenib therapy adherence for veterans with hepatocellular carcinoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 North Cent Bronx Hosp, Bronx, NY USA. Yale Univ Internal Med, New Haven, CT USA. James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9593 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902088 ER PT J AU Maloney, KW Angiolillo, AL Schore, RJ Devidas, M Lu, XM Wang, C Friedmann, AM Mattano, LA Loh, ML Raetz, EA Stork, LC Winick, NJ Hunger, S Carroll, WL AF Maloney, Kelly W. Angiolillo, Anne L. Schore, Reuven J. Devidas, Meenakshi Lu, Xiaomin Wang, Cindy Friedmann, Alison M. Mattano, Leonard A. Loh, Mignon L. Raetz, Elizabeth A. Stork, Linda C. Winick, Naomi J. Hunger, Stephen Carroll, William L. TI Association of intravenous (IV) and intramuscular (IM) pegaspargase (PEG) administration with rate of adverse events (AE) in standard risk (SR) Acute Lymphoblastic Leukemia (ALL) Children's Oncology Group (COG) trials. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Childrens Hosp Colorado, Aurora, CO USA. Childrens Natl Med Ctr, Washington, DC 20010 USA. Childrens Natl Medcal Ctr, Washington, DC USA. Univ Florida, Gainesville, FL USA. Massachusetts Gen Hosp, Reading, MA USA. HARP Pharma Consulting LLC, Mystic, CT USA. UC San Francisco, San Francisco, CA USA. Univ Utah, Salt Lake City, UT USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. NYU, Langone Med Ctr, New York, NY USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10035 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900041 ER PT J AU Margolin, KA Tawbi, HAH Ernstoff, MS Hodi, FS McDermott, DF Edwards, R Avila, A Atkins, MB AF Margolin, Kim Allyson Tawbi, Hussein Abdul-Hassan Ernstoff, Marc S. Hodi, F. Stephen McDermott, David F. Edwards, Robin Avila, Alexandre Atkins, Michael B. TI A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Stanford Univ, Med Ctr, Stanford, CA 94305 USA. Cytokine Working Grp, Stanford, CA USA. Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Cytokine Working Grp, Cleveland, OH USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Cytokine Working Grp, Boston, MA USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Bristol Myers Squibb, Plainsboro, NJ USA. Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA. Cytokine Working Grp, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS9080 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904878 ER PT J AU Marron, JM Cronin, A Kang, TI Mack, JW AF Marron, Jonathan Michael Cronin, Angel Kang, Tammy I. Mack, Jennifer W. TI Intended and unintended consequences: Ethics, communication, and prognostic disclosure in pediatric oncology SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9515 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902010 ER PT J AU Martinez, A Hernandez, A Arpi, O Menendez, S Iarchouk, N Gavilan, E Bellosillo, B Arum, M Rojo, F Mullane, SA Choueiri, TK Rovira, A Albanell, J Brake, R Bellmunt, J AF Martinez, Alejandro Hernandez, Anna Arpi, Oriol Menendez, Silvia Iarchouk, Natalia Gavilan, Elena Bellosillo, Beatriz Arum, Montserrat Rojo, Federico Mullane, Stephanie A. Choueiri, Toni K. Rovira, Ana Albanell, Joan Brake, Rachael Bellmunt, Joaquim TI Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Hosp del Mar, Canc Res Program, IMIM Hosp del Mar Res Inst, Dept Med Oncol, Barcelona, Spain. Univ Hosp del Mar, IMIM, Barcelona, Spain. Takeda Pharmaceut Int Co, Cambridge, MA USA. Univ Hosp del Mar, Mol Cytogenet Lab, Dept Pathol, Barcelona, Spain. Hosp del Mar, IMIM, Barcelona, Spain. Hosp Univ Fdn Jimenez Diaz, Madrid, Spain. Brigham & Womens Canc Ctr, Bladder Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Hosp del Mar, Dept Med Oncol, Barcelona, Spain. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15520 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903068 ER PT J AU Massarelli, E Haddad, RI Lee, JJ Lin, HY Garden, AS Blumenschein, GR William, WN Tishler, RB Glisson, BS Gold, KA Johnson, FM Rabinowits, G Ginsberg, LE Williams, MD Myers, J Kies, MS Papadimitrakopoulou, V AF Massarelli, Erminia Haddad, Robert I. Lee, J. Jack Lin, Heather Y. Garden, Adam S. Blumenschein, George R. William, William Nassib Tishler, Roy B. Glisson, Bonnie S. Gold, Kathryn A. Johnson, Faye M. Rabinowits, Guilherme Ginsberg, Lawrence E. Williams, Michelle D. Myers, Jeffrey Kies, Merrill S. Papadimitrakopoulou, Vassiliki TI Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA. Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6001 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901313 ER PT J AU Matulonis, U Wright, AA Collins, SA Campos, SM Konstantinopoulos, P MacNeill, K Morrissey, S Patterson, V Whalen, C Liu, J AF Matulonis, Ursula Wright, Alexi A. Collins, Siobhan A. Campos, Susana M. Konstantinopoulos, Panagiotis MacNeill, Kimberley Morrissey, Stephanie Patterson, Victoria Whalen, Christin Liu, Joyce TI A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Newton, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS5618 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904807 ER PT J AU Matulonis, U Friedlander, M Du Bois, A Gourley, C Vergote, I Rustin, GJS Scott, CL Meier, W Shapira-Frommer, R Safra, T Matei, D Fielding, A McMurtry, E Spencer, S Mann, H Parry, D Ledermann, JA AF Matulonis, Ursula Friedlander, Michael Du Bois, Andreas Gourley, Charlie Vergote, Ignace Rustin, Gordon J. S. Scott, Clare L. Meier, Werner Shapira-Frommer, Ronnie Safra, Tamar Matei, Daniela Fielding, Anitra McMurtry, Emma Spencer, Stuart Mann, Helen Parry, David Ledermann, Jonathan A. TI Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Prince Wales Canc Ctr, Randwick, NSW, Australia. AGO, Essen, Germany. Kliniken Essen Mitte, Essen, Germany. Univ Edinburgh, Canc Res UK Ctr, Edinburgh, Midlothian, Scotland. Univ Hosp Leuven, Leuven, Belgium. Mt Vernon Hosp, Northwood, Middx, England. Royal Melbourne Hosp, Parkville, Vic 3050, Australia. Evangel Krankenhaus, Dusseldorf, Germany. Sheba Med Ctr, Ramat Gan, Israel. Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel. Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA. AstraZeneca, Macclesfield, Cheshire, England. UCL, Inst Canc, London, England. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5550 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901213 ER PT J AU Mayer, IA Singer, CF Fasching, PA Holmes, FA Gnant, M Estevez, LG Campone, M Hubalek, M Wolff, AC Perez-Fidalgo, JA Winer, EP Atalla-Vidam, G Kanwal, C Blumenstein, L Fretault, N Diaz-Padilla, I Arteaga, CL AF Mayer, Ingrid A. Singer, Christian F. Fasching, Peter A. Holmes, Frankie Ann Gnant, Michael Estevez, Laura G. Campone, Mario Hubalek, Michael Wolff, Antonio C. Perez-Fidalgo, Jose Alejandro Winer, Eric P. Atalla-Vidam, Gena Kanwal, Charu Blumenstein, Lars Fretault, Nathalie Diaz-Padilla, Ivan Arteaga, Carlos L. TI A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2-, PIK3CA mutant or wild-type breast cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Med Univ Vienna, Vienna, Austria. Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany. US Oncol, Texas, Houston, TX USA. Med Univ Vienna, Vienna, Austria. Comprehens Canc Ctr Clara Campal CIOCC, Madrid, Spain. Canc Inst West ICO, Nantes, France. Med Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria. Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Hosp Clin Univ Valencia, Valencia, Spain. Dana Farber Canc Inst, Boston, MA 02115 USA. Novartis Pharmaceut, E Hanover, NJ USA. Novartis Pharma AG, Basel, Switzerland. Novartis Pharma SAS, Paris, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS633 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904825 ER PT J AU McKay, RR Werner, L Fiorillo, M Dumas, K Roberts, J Mamlouk, K Taplin, ME AF McKay, Rana R. Werner, Lillian Fiorillo, Matthew Dumas, Kathryn Roberts, Jennifer Mamlouk, Khalid Taplin, Mary-Ellen TI Activity of sequential therapies (txs) in patients (pts) with castration resistant prostate cancer (CRPC) previously treated with galeterone SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Tokai Pharma, Cambridge, MA USA. Tokai Pharmaceut Inc, Cambridge, MA USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e16072 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903242 ER PT J AU McKay, RR Werner, L Harshman, LC Bellmunt, J Sweeney, C Rosenberg, JE VanAllen, E Walsh, MK Vaishampayan, UN McDermott, DF Choueiri, TK AF McKay, Rana R. Werner, Lillian Harshman, Lauren Christine Bellmunt, Joaquim Sweeney, Christopher Rosenberg, Jonathan E. VanAllen, Eliezer Walsh, Meghara K. Vaishampayan, Ulka N. McDermott, David F. Choueiri, Toni K. TI A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Stanford Univ, Sch Med, Stanford, CA 94305 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4559 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901030 ER PT J AU McQuade, JL Chen, G Panka, DJ Reuben, A Bassett, RL Joon, A Lazar, AJF Tetzlaff, MT Simpson, L Mouton, R Patel, SP Glitza, IC Hwu, WJ Amaria, RN Diab, A Hwu, P Wargo, JA Sullivan, RJ Kim, K Davies, MA AF McQuade, Jennifer Leigh Chen, Guo Panka, David J. Reuben, Alexandre Bassett, Roland L. Joon, Aron Lazar, Alexander J. F. Tetzlaff, Michael T. Simpson, Lauren Mouton, Rosalind Patel, Sapna Pradyuman Glitza, Isabella Claudia Hwu, Wen-Jen Amaria, Rodabe Navroze Diab, Adi Hwu, Patrick Wargo, Jennifer Ann Sullivan, Ryan J. Kim, Kevin Davies, Michael A. TI Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastatic melanoma: Exploration of clinical and molecular predictors of response. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA. UnMD Anderson Canc Ctr, Houston, TX USA. Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. Calif Pacific Med Ctr, Res Inst, Oakland, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e20051 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904069 ER PT J AU McWilliams, RR Ko, AH Chiorean, EG Kwak, EL Lenz, HJ Nadler, PI Wood, DL Fujimori, M Morita, K Inada, T Kouji, H AF McWilliams, Robert R. Ko, Andrew H. Chiorean, E. Gabriela Kwak, Eunice Lee Lenz, Heinz-Josef Nadler, Paul I. Wood, Debra L. Fujimori, Masamoto Morita, Kohei Inada, Tetsuhi Kouji, Hiroyuki TI A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mayo Clin, Rochester, MN USA. UC San Francisco Helen Diller Family Comprehens C, San Francisco, CA USA. Univ Washington, Seattle, WA 98195 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA. Nadler Pharma Assoc LLC, Randolph, NJ USA. Nadler Pharma Associates LLC, Randolph, NJ USA. PRISM Pharma Co Ltd, Yokohama, Kanagawa, Japan. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15270 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903029 ER PT J AU Meyer, L Cronin, A Sun, CC Bookman, MA Burger, RA Cristea, MC Griggs, JJ Levenback, CF Mantia-Smaldone, G Matulonis, U Niland, JC O'Malley, DM Wright, AA AF Meyer, Larissa Cronin, Angel Sun, Charlotte C. Bookman, Michael A. Burger, Robert Allen Cristea, Mihaela C. Griggs, Jennifer J. Levenback, Charles F. Mantia-Smaldone, Gina Matulonis, Ursula Niland, Joyce C. O'Malley, David M. Wright, Alexi A. TI Use of neoadjuvant chemotherapy in advanced ovarian cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Arizona Oncol, Tucson, AZ USA. Univ Penn, Dept Obstet & Gynecol, Div Gynecol Oncol, Philadelphia, PA 19104 USA. City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Ohio State Univ, Coll Med, Columbus, OH 43210 USA. RI OMalley, David/E-3789-2011 NR 0 TC 1 Z9 1 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5563 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901227 ER PT J AU Miklos, DB Arora, M Cutler, CS Nakamura, R Juretic, M Li, YF Styles, LA James, DF Jaglowski, SM AF Miklos, David Bernard Arora, Mukta Cutler, Corey S. Nakamura, Ryotaro Juretic, Manuela Li, Yunfeng Styles, Lori Appel James, Danelle Frances Jaglowski, Samantha Mary TI A multicenter open-label phase 1b/2 study of ibrutinib in steroid dependent or refractory chronic graft versus host disease (cGVHD) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Stanford Univ, Stanford, CA 94305 USA. Univ Minnesota, Minneapolis, MN USA. Dana Farber Canc Inst, Boston, MA 02115 USA. City Hope Natl Med Ctr, Duarte, CA USA. Pharmacyclics Inc, Sunnyvale, CA USA. Ohio State Univ, Columbus, OH 43210 USA. RI Jaglowski, Samantha/E-3304-2011 NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7024 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901560 ER PT J AU Miller, K Cortes, J Hurvitz, SA Krop, IE Tripathy, D Verma, S Riahi, K Reynolds, JG Wickham, TJ Molnar, I Yardley, DA AF Miller, Kathy Cortes, Javier Hurvitz, Sara A. Krop, Ian E. Tripathy, Debu Verma, Sunil Riahi, Kaveh Reynolds, Joseph G. Wickham, Thomas J. Molnar, Istvan Yardley, Denise A. TI HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA. Vall DHebron Univ Hosp, Barcelona, Spain. UCLA Healthcare Hematol Oncol Breast Oncol Progra, Santa Monica, CA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. Merrimack Pharma, Cambridge, MA USA. Merrimack Pharmaceut Inc, Cambridge, MA USA. Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS641 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904833 ER PT J AU Mok, T Spigel, D Felip, E deMarinis, F Ahn, MJ Groen, HJM Wakelee, HA Hida, T Crino, L Nishio, M Scagliotti, GV Branle, F Emeremni, C Quadrigli, M Zhang, J Shaw, AT AF Mok, Tony Spigel, David Felip, Enriqueta deMarinis, Filippo Ahn, Myung-Ju Groen, Harry J. M. Wakelee, Heather A. Hida, Toyoaki Crino, Lucio Nishio, Makoto Scagliotti, Giorgio V. Branle, Fabrice Emeremni, Chetachi Quadrigli, Massimiliano Zhang, Jie Shaw, Alice Tsang TI ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China. Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA. Vall dHebron Univ, Barcelona, Spain. European Inst Oncol, Thorac Oncol Div, Milan, Italy. Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea. Univ Groningen, Groningen, Netherlands. Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, Groningen, Netherlands. Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA. Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan. Osped S Maria Misericordia, Med Oncol, Perugia, Italy. Japanese Fdn Canc Res, Tokyo, Japan. Univ Turin, Turin, Italy. Novartis Pharma AG, Basel, Switzerland. Novartis Pharmaceut, E Hanover, NJ USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 23 Z9 23 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8059 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901771 ER PT J AU Moore, KN Martin, LP Seward, SM Bauer, TM O'Malley, DM Perez, RP Oza, AM Jeong, W Kirby, MW Zhou, YH Michenzie, MF Ponte, J Ruiz-Soto, R Birrer, MJ AF Moore, Kathleen N. Martin, Lainie P. Seward, Shelly Marie Bauer, Todd Michael O'Malley, David M. Perez, Raymond P. Oza, Amit M. Jeong, Woondong Kirby, Maurice William Zhou, Yinghui Michenzie, Mary F. Ponte, Joseph Ruiz-Soto, Rodrigo Birrer, Michael J. TI Preliminary single agent activity of IMGN853, a folate receptor alpha (FR alpha)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Wayne State Univ, Karmanos Canc Inst, Huntington Woods, MI USA. Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. Ohio State Univ, Coll Med, Columbus, OH 43210 USA. Univ Kansas, Fairway, KS USA. Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. Westchester Hem Onc Grp, Westchester, NY USA. ImmunoGen Inc, Waltham, MA USA. Immunogen, Waltham, MA USA. ImmunoGen Inc, Dedham, MA USA. Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA. RI OMalley, David/E-3789-2011; Perez, Raymond/R-6159-2016 OI Perez, Raymond/0000-0002-7432-2411 NR 0 TC 5 Z9 5 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5518 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901177 ER PT J AU Morris, MJ Higano, CS Scher, HI Sweeney, C Antonarakis, ES Shevrin, DH Ryan, CJ Loriot, Y Fizazi, K Pandit-Taskar, N Garcia-Vargas, JE Lyseng, K Bloma, M Carrasquillo, JA AF Morris, Michael J. Higano, Celestia S. Scher, Howard I. Sweeney, Christopher Antonarakis, Emmanuel S. Shevrin, Daniel H. Ryan, Charles J. Loriot, Yohann Fizazi, Karim Pandit-Taskar, Neeta Garcia-Vargas, Jose E. Lyseng, Kari Bloma, Marianne Carrasquillo, Jorge A. TI Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Evanston Hosp Kellogg Canc Ctr, NorthShore Univ Hlth Syst, Evanston, IL USA. UC San Francisco Helen Diller Family Comprehens C, San Francisco, CA USA. Univ Paris 11, Dept Med Oncol, Inst Gustave Roussy, Villejuif, France. Bayer HealthCare, Whippany, NJ USA. Bayer AS, Oslo, Norway. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5012 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901054 ER PT J AU Mostaghel, EA Cho, EP Wright, JL Loda, M Marck, B Matsumoto, AM Tamae, D Penning, TM Balk, SP Kantoff, PW Nelson, P Taplin, ME Montgomery, RB AF Mostaghel, Elahe A. Cho, Eunpi Wright, Jonathan Lawrence Loda, Massimo Marck, Brett Matsumoto, Alvin M. Tamae, Daniel Penning, Trevor M. Balk, Steven P. Kantoff, Philip W. Nelson, Peter Taplin, Mary-Ellen Montgomery, Robert B. TI Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Univ Washington, Sch Med, Seattle, WA USA. Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. Univ Penn, Philadelphia, PA 19104 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Washington Oncol, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5013 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901055 ER PT J AU Motzer, R Hutson, T Glen, H Michaelson, D Molina, AM Eisen, T Jassem, J Zolnierek, J Maroto, P Mellado, B Melichar, B Tomasek, J Kim, HJ Wood, K Dutcus, C Larkin, JMG AF Motzer, Robert Hutson, Thomas Glen, Hilary Michaelson, Dror Molina, Ana M. Eisen, Timothy Jassem, Jacek Zolnierek, Jakub Maroto, Pablo Mellado, Begona Melichar, Bohuslav Tomasek, Jiri Kim, Han-Joo Wood, Karen Dutcus, Corina Larkin, James M. G. TI Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN plus EVE in patients (pts) with metastatic renal cell carcinoma (mRCC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA. Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. Addenbrookes Hosp, Cambridge, England. Med Univ, Gdansk, Poland. Inst Warszawie, Ctr Onkol, Warsaw, Poland. Dept Oncol Med, Barcelona, Spain. Hosp Clin Barcelona, Dept Med Oncol, IDIBAPS, Translat Genom & Targeted Therapeut Oncol, Barcelona, Spain. Lekarska Fak Univ Palackeho Fak Nemocnice, Onkol Klin, Olomouc, Czech Republic. Masaryk Univ, Masaryk Mem Canc Inst, Brno, Czech Republic. Eisai Inc, Woodcliff Lake, NJ USA. Eisai Ltd, Hatfield, Herts, England. Royal Marsden NHS Hosp, London, England. NR 0 TC 6 Z9 6 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4506 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900974 ER PT J AU Mullane, SA Werner, L Zhou, CW Taplin, ME Choueiri, TK Bellmunt, J Bowden, M AF Mullane, Stephanie A. Werner, Lillian Zhou, Chensheng Willa Taplin, Mary-Ellen Choueiri, Toni K. Bellmunt, Joaquim Bowden, Michaela TI Predicting outcome in metastatic urothelial cancer (UC) receiving docetaxel (DT): miRNA profiling in pre and post therapy. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Brigham & Womens Canc Ctr, Bladder Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15518 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903066 ER PT J AU Murray, B Albiges, L Van Allen, EM Cherniack, A Fay, AP Meyerson, M Choueiri, TK AF Murray, Bradley Albiges, Laurence Van Allen, Eliezer Mendel Cherniack, Andrew Fay, Andre Poisl Meyerson, Matthew Choueiri, Toni K. TI Precision medicine approach in kidney cancer: A pan renal cell carcinoma (RCC) study across three cancer genome atlas (TCGA) datasets for clinically relevant target identification. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Broad Inst, Boston, MA USA. Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Broad Inst, Cambridge, MA USA. HSL PUCRS, Oncol Serv & Oncol Res Unit, Porto Alegre, RS, Brazil. Harvard Univ, Sch Med, Dana Farber Canc Inst,MIT, Massachusetts Gen Hosp,Brigham & Womens Hosp,Broa, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4564 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901035 ER PT J AU Muss, HB Berry, DA Cirrincione, CT Theodoulou, M Hurria, A Cohen, HJ Partridge, A Norton, L Hudis, CA Winer, EP AF Muss, Hyman B. Berry, Donald A. Cirrincione, Constance T. Theodoulou, Maria Hurria, Arti Cohen, Harvey Jay Partridge, Ann Norton, Larry Hudis, Clifford A. Winer, Eric P. TI Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ N Carolina, Chapel Hill, NC USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Duke Univ, Alliance Stat Ctr, Durham, NC USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. City Hope Natl Med Ctr, Duarte, CA USA. Duke Univ, Med Ctr, Durham, NC USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1022 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900104 ER PT J AU Myers, AP Filiaci, VL Zhang, YP Pearl, M Behbakht, K Makker, V Hanjani, P Zweizig, S Burke, JJ Downey, G Leslie, KK Birrer, MJ Fleming, GF AF Myers, Andrea P. Filiaci, Virginia L. Zhang, Yuping Pearl, Michael Behbakht, Kian Makker, Vicky Hanjani, Parviz Zweizig, Susan Burke, James J. Downey, Gordon Leslie, Kimberly K. Birrer, Michael J. Fleming, Gini F. TI Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Novartis Inst Biomed Res, Cambridge, MA USA. NRG Oncol, Buffalo, NY USA. GOG Fdn Inc SDMC, Buffalo, NY USA. Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA. Univ Hosp Stony Brook, New York, NY USA. Rush Univ, Med Ctr, Chicago, IL 60612 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Weill Cornell Med Coll, New York, NY USA. Abington Memor Hosp, Gladwyne, PA USA. Univ Massachusetts Memor Hlth Care, Worcester, MA USA. Mercer Univ, Sch Med, Savannah, GA USA. Gynecol Oncol West Michigan, Grand Rapids, MI USA. Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA. Univ Chicago, Med Ctr, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5592 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901259 ER PT J AU Neal, JW Dahlberg, SE Wakelee, HA Aisner, SC Bowden, M Carbone, DP Ramalingam, SS AF Neal, Joel W. Dahlberg, Suzanne Eleanor Wakelee, Heather A. Aisner, Seena C. Bowden, Michaela Carbone, David Paul Ramalingam, Suresh S. TI Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Rutgers New Jersey Med Sch, Newark, NJ USA. Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8003 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901716 ER PT J AU Nechuta, SJ Caan, BJ Chen, WY Dwek, M Gao, M Flatt, S Poole, E Patterson, RE Pierce, JP Robertson, C Swann, R Zheng, W Shu, XO AF Nechuta, Sarah Jean Caan, Bette J. Chen, Wendy Y. Dwek, Miriam Gao, Min Flatt, Shirley Poole, Elizabeth Patterson, Ruth E. Pierce, John P. Robertson, Claire Swann, Ruth Zheng, Wei Shu, Xiao-Ou TI Post-diagnosis BMI and physical activity in association with triple-negative breast cancer prognosis: Results from 5 prospective cohorts SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Vanderbilt Univ Sch Med, Nashville, TN USA. Kaiser Permanente No Calif, Oakland, CA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Westminster, London W1R 8AL, England. UC San Diego Moores Canc Ctr, La Jolla, CA USA. Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1507 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900374 ER PT J AU Ng, K Venook, AP Sato, K Yuan, C Hollis, BW Niedzwiecki, D Ye, C Chang, IW O'Neil, BH Innocenti, F Lenz, HJ Blanke, CD Mayer, RJ Fuchs, CS Meyerhardt, JA AF Ng, Kimmie Venook, Alan P. Sato, Kaori Yuan, Chen Hollis, Bruce W. Niedzwiecki, Donna Ye, Cynthia Chang, I-Wen O'Neil, Bert H. Innocenti, Federico Lenz, Heinz-Josef Blanke, Charles David Mayer, Robert J. Fuchs, Charles S. Meyerhardt, Jeffrey A. TI Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Med Univ S Carolina, Charleston, SC 29425 USA. Duke Univ, Cary, NC USA. Duke Univ, Durham, NC USA. Southeastern Med Oncol, Goldsboro, NC USA. Indiana Univ, Hlth Univ Hosp, Indianapolis, IN 46204 USA. Univ N Carolina, Chapel Hill, NC USA. Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3503 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900723 ER PT J AU Nipp, RD El-Jawahri, A Pirl, WF Fishbein, JN Moran, S McCarty, C Eusebio, J Gallagher, ER Park, ER Jackson, VA Greer, JA Temel, JS AF Nipp, Ryan David El-Jawahri, Areej Pirl, William F. Fishbein, Joel Nathan Moran, Samantha McCarty, Caitlin Eusebio, Justin Gallagher, Emily R. Park, Elyse R. Jackson, Vicki A. Greer, Joseph A. Temel, Jennifer S. TI Quality of life and mood in patients with advanced cancer: Associations with prognostic understanding and coping style SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Harvard Canc Ctr, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Brookline, MA USA. MGH Canc Ctr, Boston, MA USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9517 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902012 ER PT J AU Nipp, RD Finkelstein, D Powell, E Vittorio, L Birrer, N Chabner, BA Lee, H Moy, B AF Nipp, Ryan David Finkelstein, Daniel Powell, Elizabeth Vittorio, Lisa Birrer, Nicole Chabner, Bruce Allan Lee, Hang Moy, Beverly TI Financial burden of cancer clinical trials: Impact of an equity program intervention SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Harvard Canc Ctr, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6501 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901416 ER PT J AU O'Neill, AF Dearling, JLJ Tupper, T Modiste, R Dai, GP Quang-de Nguyen Kung, AL Packard, A AF O'Neill, Allison Frances Dearling, Jason L. J. Tupper, Tanya Modiste, Rebecca Dai, Guangping Quang-de Nguyen Kung, Andrew L. Packard, Alan TI ImmunoPET compared with conventional imaging modalities for the detection of Ewing sarcoma metastases in a preclinical model. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. Boston Childrens Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA USA. Dana Farber Canc Inst, Lurie Family Imaging Ctr, Ctr Biomed Imaging Oncol, Boston, MA 02115 USA. Columbia Univ, Med Ctr, New York, NY USA. Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10048 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900055 ER PT J AU O'Neill, VJ Enderle, D Wheler, JJ Koestler, T Berking, C Skog, J Noerholm, M Flaherty, K Janku, F AF O'Neill, Vincent J. Enderle, Daniel Wheler, Jennifer J. Koestler, Tina Berking, Carola Skog, Johan Noerholm, Mikkel Flaherty, Keith Janku, Filip TI Detection of low abundant somatic mutations in circulating exosomal RNA and cfDNA with next-generation sequencing. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Exosome Diagnost, Cambridge, MA USA. Exosome Diagnost, Munich, Germany. Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA. Univ Munich LMU, Dept Dermatol, Munich, Germany. Exosome Diagnost, New York, NY USA. Exosome Diagnost GmbH, Martinsried, Germany. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 11061 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900320 ER PT J AU O'Reilly, EM Mahalingam, D Roach, JM Schultes, BC Rosano, ME Miller, PJ Wolf, J Flaherty, K Ryan, DP AF O'Reilly, Eileen Mary Mahalingam, Devalingam Roach, James M. Schultes, Birgit Corinna Rosano, Molly E. Miller, Paul Justin Wolf, Julie Flaherty, Keith Ryan, David P. TI Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, David M Rubenstein Ctr Pancreat Canc Res, New York, NY 10021 USA. Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. Momenta Pharmaceut, Cambridge, MA USA. Momenta Pharmaceut Inc, Cambridge, MA USA. Novella Clin, Boulder, CO USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4114 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900952 ER PT J AU Ohtsu, A Yoshino, T Wahba, MM Benedetti, FM Mayer, RJ Van Cutsem, E AF Ohtsu, Atsushi Yoshino, Takayuki Wahba, Mona M. Benedetti, Fabio M. Mayer, Robert J. Van Cutsem, Eric CA RECOURSE Study Grp TI Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan. Taiho Oncol Inc, Princeton, NJ USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Hosp Leuven, Leuven, Belgium. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3564 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900783 ER PT J AU Oliveira, M Saura, C Gonzalez-Martin, A Andersen, JC Fisher, JG Calvo, I Ciruelos, E Gil, M De La Pena, L Llobet-Canela, M Choi, Y Jia, SD Yalamanchili, S Singel, SM Patel, PH Baselga, J Isakoff, SJ AF Oliveira, Mafalda Saura, Cristina Gonzalez-Martin, Antonio Andersen, Jay C. Fisher, Julie Gottlieb Calvo, Isabel Ciruelos, Eva Gil, Miquel De La Pena, Lorena Llobet-Canela, Marta Choi, YounJeong Jia, Shidong Yalamanchili, Sreenivasu Singel, Stina Mui Patel, Premal H. Baselga, Jose Isakoff, Steven J. TI FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Vall dHebron Univ Hosp, VHIO, Barcelona, Spain. Vall dHebron Univ Hosp, SOLTI, Barcelona, Spain. GEICO, Madrid, Spain. MD Anderson Canc Ctr Spain, Madrid, Spain. Compass Onc, Portland, OR USA. Levine Canc Inst, Charlotte, NC USA. Ctr Integral Oncol Clara Campal, Madrid, Spain. Hosp Univ 12 Octubre, Madrid, Spain. Catalan Inst Oncol, Barcelona, Spain. SOLTI, Breast Canc Res Grp, Barcelona, Spain. Genentech Inc, San Francisco, CA 94080 USA. Genentech Roche, San Francisco, CA USA. Genentech Inc, Redwood City, CA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS1112 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904671 ER PT J AU Olszanski, AJ Middleton, MR Bahleda, R Heist, RS Rangachari, L Zhou, XF Bozon, V Kneissl, M Macarulla, T AF Olszanski, Anthony J. Middleton, Mark R. Bahleda, Rastilav Heist, Rebecca Suk Rangachari, Lakshmi Zhou, Xiaofei Bozon, Viviana Kneissl, Michelle Macarulla, Teresa TI A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Oxford Univ Hosp NHS Trust, Oxford, England. Univ Paris Sud, Gustave Roussy, Villejuif, France. Massachusetts Gen Hosp, Boston, MA 02114 USA. Millennium Pharmaceut Inc, Cambridge, MA USA. Vall dHebron Univ Hosp, VHIO, Barcelona, Spain. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS2609 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904687 ER PT J AU Olszewski, AJ Fallah, J Castillo, JJ AF Olszewski, Adam J. Fallah, Jaleh Castillo, Jorge J. TI Epidemiology and management of HIV-related non-Hodgkin lymphoma (NHL) in the United States (US): Analysis of the National Cancer Data Base (NCDB) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. Mem Hosp Rhode Isl, Providence, RI USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1521 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900388 ER PT J AU Ott, PA Callahan, MK Odunsi, K Park, AJ Pan, LS Venhaus, RR Karakunnel, JJ Hodi, FS Wolchok, JD AF Ott, Patrick Alexander Callahan, Margaret K. Odunsi, Kunle Park, Andrew J. Pan, Linda S. Venhaus, Ralph Rudolph Karakunnel, Joyson Joseph Hodi, F. Stephen Wolchok, Jedd D. TI A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Ludwig Inst Canc Res, New York, NY USA. Medimmune Inc, Gaithersburg, MD 20878 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS3099 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904715 ER PT J AU Ott, PA Fernandez, MEE Hiret, S Kim, DW Moss, RA Winser, T Yuan, S Cheng, JD Piperdi, B Mehnert, JM AF Ott, Patrick Alexander Fernandez, Maria Elena Elez Hiret, Sandrine Kim, Dong-Wan Moss, Rebecca Anne Winser, Tammy Yuan, Sammy Cheng, Jonathan D. Piperdi, Bilal Mehnert, Janice M. TI Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Hosp Valle De Hebron, Barcelona, Spain. ICO Rene Gauducheau, Nantes, France. Seoul Natl Univ Hosp, Seoul 110744, South Korea. Rutgers Canc Inst New Jersey, New Brunswick, NJ USA. Merck & Co Inc, Kenilworth, NJ USA. NR 0 TC 4 Z9 4 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7502 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901632 ER PT J AU Oxnard, GR Ramalingam, SS Ahn, MJ Kim, SW Yu, HA Saka, H Horn, L Goto, K Ohe, Y Cantarini, M Frewer, P Lahn, M Yang, JCH AF Oxnard, Geoffrey R. Ramalingam, Suresh S. Ahn, Myung-Ju Kim, Sang-We Yu, Helena Alexandra Saka, Hideo Horn, Leora Goto, Koichi Ohe, Yuichiro Cantarini, Mireille Frewer, Paul Lahn, Michael Yang, James Chih-Hsin TI Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea. Univ Ulsan Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Nagoya Med Ctr, Nagoya, Aichi, Japan. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan. Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan. AstraZeneca, Macclesfield, Cheshire, England. Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan. Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan. Natl Taiwan Univ, Canc Res Ctr, Taipei 10764, Taiwan. NR 0 TC 4 Z9 4 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2509 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900542 ER PT J AU Oxnard, GR Heng, JC Root, EJ Rainville, IR Sable-Hunt, AL Shane-Carson, KP Carbone, DP Wiesner, GL Garber, JE AF Oxnard, Geoffrey R. Heng, Jennifer C. Root, Elizabeth J. Rainville, Irene R. Sable-Hunt, Alicia L. Shane-Carson, Kate P. Carbone, David Paul Wiesner, Georgia L. Garber, Judy Ellen TI Initial results of a prospective, multicenter trial to study inherited lung cancer risk associated with germline EGFR T790M: INHERIT EGFR SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Addario Lung Canc Med Inst ALCMI, San Carlos, CA USA. Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1505 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900372 ER PT J AU Padron, E Dezern, AE Vaddi, K Scherle, PA Zhang, Q Ma, Y Balasis, M Tinsley, S Ramadan, H Zimmerman, C Steensma, DP Roboz, GJ Lancet, JE List, AF Sekeres, MA Komrokji, RS AF Padron, Eric Dezern, Amy Elizabeth Vaddi, Kris Scherle, Peggy A. Zhang, Qing Ma, Yan Balasis, Maria Tinsley, Sara Ramadan, Hanadi Zimmerman, Casandra Steensma, David P. Roboz, Gail J. Lancet, Jeffrey E. List, Alan F. Sekeres, Mikkael A. Komrokji, Rami S. TI A multi-institution phase I trial of ruxolitinib in chronic myelomonocytic leukemia (CMML) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Incyte Corp, Wilmington, DE USA. Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. Cleveland Clin, Cleveland, OH 44106 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Cornell Univ, Weill Med Coll, New York, NY 10021 USA. New York Presbyterian Hosp, New York, NY USA. Cleveland Clin, Dept Hematol & Oncol, Leukemia Program, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7021 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901557 ER PT J AU Paes, FR Luis, IMVD Costa, RB Metzger, O Hughes, ME Losk, K Camuso, K Bunnell, CA Golshan, M Winer, EP Lin, NU AF Paes, Flavia Rocha Luis, Ines Maria Vaz Duarte Costa, Rafael Brant Metzger Filho, Otto Hughes, Melissa E. Losk, Katya Camuso, Kristen Bunnell, Craig Alan Golshan, Mehra Winer, Eric P. Lin, Nancy U. TI Variation in the use of granulocyte-colony stimulating factor (G-CSF) for dose dense paclitaxel: A single institution retrospective study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Oncoclin Brasil, Belo Horizonte, MG, Brazil. Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 561 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901273 ER PT J AU Pal, SK Ali, SM Chalmers, Z Karam, JA Elvin, JA Chmielecki, J Yelensky, R Van Allen, EM Lipson, D Wang, K Fay, AP Miller, VA Stephens, P Ross, JS Choueiri, TK AF Pal, Sumanta Kumar Ali, Siraj Mahamed Chalmers, Zachary Karam, Jose A. Elvin, Julia Andrea Chmielecki, Juliann Yelensky, Roman Van Allen, Eliezer Mendel Lipson, Doron Wang, Kai Fay, Andre Poisl Miller, Vincent A. Stephens, Phil Ross, Jeffrey S. Choueiri, Toni K. TI Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 City Hope Natl Med Ctr, Duarte, CA USA. Fdn Med Inc, Cambridge, MA USA. Fdn Med Inc, Boston, MA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. HSL PUCRS, Oncol Serv, Porto Alegre, RS, Brazil. HSL PUCRS, Oncol Res Unit, Porto Alegre, RS, Brazil. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4520 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900988 ER PT J AU Palmbos, PL Feng, FYC Tomlins, SA Kelly, WK Morgans, AK Taplin, ME Agarwal, N Antonarakis, ES Twardowski, P Jacobson, J Davenport, MS Daignault, S Knudsen, KE Hussain, M AF Palmbos, Phillip Lee Feng, Felix Yi-Chung Tomlins, Scott A. Kelly, William Kevin Morgans, Alicia Katherine Taplin, Mary-Ellen Agarwal, Neeraj Antonarakis, Emmanuel S. Twardowski, Przemyslaw Jacobson, Jon Davenport, Matthew S. Daignault, Stephanie Knudsen, Karen E. Hussain, Maha TI A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Michigain Hlth Syst, Ypsilanti, MI USA. Univ Michigan Hlth Syst, Dept Radiat Oncol, Ann Arbor, MI USA. Univ Michigan Hlth Syst, Dept Pathol, Ann Arbor, MI USA. Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. City Hope Natl Med Ctr, Duarte, CA USA. Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA. Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS5074 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904783 ER PT J AU Papadimitrakopoulou, V Patnaik, A Borghaei, H Stevenson, J Gandhi, L Gubens, MA Yang, JCH Sequist, LV Ge, JY Bourque, J Bachman, RD Im, E Gadgeel, SM AF Papadimitrakopoulou, Vassiliki Patnaik, Amita Borghaei, Hossein Stevenson, James Gandhi, Leena Gubens, Matthew A. Yang, James Chih-Hsin Sequist, Lecia V. Ge, Joy Yang Bourque, Jennifer Bachman, Robert D. Im, Ellie Gadgeel, Shirish M. TI Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. START, San Antonio, TX USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. UC San Francisco, San Francisco, CA USA. Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan. Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan. Natl Taiwan Univ, Canc Res Ctr, Taipei 10764, Taiwan. Massachusetts Gen Hosp, Boston, MA 02114 USA. Merck & Co Inc, Kenilworth, NJ USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. NR 0 TC 21 Z9 23 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8031 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901744 ER PT J AU Parton, M Bardia, A Kummel, S Estevez, LG Huang, CS Castan, JC Borrego, MR Telli, ML Lluch, A Lopez, R Beck, JT Ismail-Khan, R Chen, SC Hurvitz, SA Mayer, IA Atienza, RS Cameron, S Krygowski, M Kim, SB AF Parton, Marina Bardia, Aditya Kummel, Sherko Estevez, Laura G. Huang, Chiun-Sheng Castan, Javier Cortes Borrego, Manuel Ruiz Telli, Melinda L. Lluch, Ana Lopez, Rafael Beck, J. Thaddeus Ismail-Khan, Roohi Chen, Shin-Cheh Hurvitz, Sara A. Mayer, Ingrid A. Atienza, Rolando S. Cameron, Scott Krygowski, Mizue Kim, Sung-Bae TI A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Royal Marsden Hosp, London SW3 6JJ, England. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Kliniken Essen Mitte KEM, Essen, Germany. Comprehens Canc Ctr Clara Campal CIOCC, Madrid, Spain. Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Taipei 10764, Taiwan. Vall dHebron Inst Oncol VHIO, Barcelona, Spain. Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain. Stanford Univ, Sch Med, Stanford, CA 94305 USA. Hosp Clin Univ Valencia, Valencia, Spain. Hosp Clin Univ Santiago de Compostela, Santiago De Compostela, Spain. Highlands Oncol Grp, Fayetteville, AR USA. H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. Chang Gung Mem Hosp, Taipei 10591, Taiwan. UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Novartis Pharmaceut, E Hanover, NJ USA. Novartis Inst BioMed Res, Cambridge, MA USA. Univ Ulsan, Coll Med, Seoul, South Korea. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1014 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900095 ER PT J AU Partridge, AH Ruddy, KJ Barry, WT Greaney, M Ligibel, JA Sprunck-Harrild, K Rosenberg, SM Baker, E Hoverman, JR Emmons, K AF Partridge, Ann H. Ruddy, Kathryn Jean Barry, William Thomas Greaney, Mary Ligibel, Jennifer A. Sprunck-Harrild, Kim Rosenberg, Shoshana M. Baker, Emily Hoverman, J. Russell Emmons, Karen TI Young and strong: A randomized study to improve care for young women with breast cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Mayo Clin, Rochester, MN USA. Univ Rhode Isl, Kingston, RI 02881 USA. Texas Onc PA, Dallas, TX USA. Kaiser, Oakland, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9588 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902083 ER PT J AU Patel, MR Bauer, TM Liu, SV Drilon, AE Wheler, JJ Shaw, AT Farago, AF Ou, SHI Luo, D Yeh, L Hornby, Z Senderowicz, AM Lim, J AF Patel, Manish R. Bauer, Todd Michael Liu, Stephen V. Drilon, Alexander E. Wheler, Jennifer J. Shaw, Alice Tsang Farago, Anna F. Ou, Sai-Hong Ignatius Luo, David Yeh, Litain Hornby, Zachary Senderowicz, Adrian Mario Lim, Jonathan TI STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA. Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. Georgetown Univ Hosp, Washington, DC 20007 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. UC Irvine Med Ctr, Chao Family Comp Canc Ctr, Orange, CA USA. Ignyta Inc, San Diego, CA USA. Ignyta, San Diego, CO USA. IGNYTA Inc, Somerville, MA USA. NR 0 TC 8 Z9 8 U1 4 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2596 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900629 ER PT J AU Patnaik, A Socinski, MA Gubens, MA Gandhi, L Stevenson, J Bachman, RD Bourque, J Ge, JY Im, E Gadgeel, SM AF Patnaik, Amita Socinski, Mark A. Gubens, Matthew A. Gandhi, Leena Stevenson, James Bachman, Robert D. Bourque, Jennifer Ge, Joy Yang Im, Ellie Gadgeel, Shirish M. TI Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 START, San Antonio, TX USA. Univ Pittsburgh, Pittsburgh, PA USA. UC San Francisco, San Francisco, CA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Merck & Co Inc, Kenilworth, NJ USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. NR 0 TC 1 Z9 1 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8011 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901724 ER PT J AU Penson, RT Berlin, ST Konstantinopoulos, P Krasner, CN Matulonis, U Ambrosio, A Suzin, D Collins, SA Birrer, MJ Cohen, YC AF Penson, Richard T. Berlin, Suzanne T. Konstantinopoulos, Panagiotis Krasner, Carolyn N. Matulonis, Ursula Ambrosio, Allison Suzin, Daphne Collins, Siobhan A. Birrer, Michael J. Cohen, Yael Chava TI A phase I/II trial of multiple dose VB-111 and weekly paclitaxel in recurrent platinum-resistant Mullerian cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Braintree, MA USA. Harvard Univ, Sch Med, Braintree, MA USA. Dana Farber Canc Inst, York, ME USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA. Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5542 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901204 ER PT J AU Petrylak, DP Powles, T Bellmunt, J Braiteh, FS Loriot, Y Zambrano, CC Burris, HA Kim, JW Teng, SLM Bruey, JM Hegde, P Abidoye, OO Vogelzang, NJ AF Petrylak, Daniel Peter Powles, Thomas Bellmunt, Joaquim Braiteh, Fadi S. Loriot, Yohann Zambrano, Cristina Cruz Burris, Howard A. Kim, Joseph W. Teng, Siew-Leng Melinda Bruey, Jean-Marie Hegde, Priti Abidoye, Oyewale O. Vogelzang, Nicholas J. TI A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Yale Canc Ctr, New Haven, CT USA. Barts Hlth, Barts Canc Inst, London, England. Royal Free NHS Trust, London, England. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Nevada, Sch Med, Comprehens Canc Ctr Nevada, Las Vegas, NV 89154 USA. Gustave Roussy, Dept Canc Med, Grand Paris, Villejuif, France. Univ Hosp Vall dHebron, Barcelona, Spain. Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. Yale Univ, Med Ctr, Yale Canc Ctr, New Haven, CT USA. Genentech Inc, San Francisco, CA 94080 USA. Genentech Inc, San Francisco, CA 94080 USA. Genentech Inc, San Francisco, CA USA. US Oncol Network, Carolina Urol Res Ctr, Myrtle Beach, SC USA. NR 0 TC 15 Z9 15 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4501 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900969 ER PT J AU Pili, R Manola, J Carducci, MA Dutcher, JP Appleman, LJ Groteluschen, DL DiPaola, RS AF Pili, Roberto Manola, Judith Carducci, Michael Anthony Dutcher, Janice P. Appleman, Leonard Joseph Groteluschen, David L. DiPaola, Robert S. TI Randomized phase II study of two different doses of AVE0005 (VEGF Trap, aflibercept) in patients (pts) with metastatic renal cell carcinoma (RCC): An ECOG-ACRIN study [E4805]. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Our Lady Mercy Canc Ctr, New York, NY USA. Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. Green Bay Onc, Green Bay, WI USA. Rutgers Canc Inst New Jersey, New Brunswick, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4549 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901020 ER PT J AU Piotrowska, Z Costa, DB Huberman, M Oxnard, GR Gainor, JF Heist, RS Muzikansky, A Shaw, AT Niederst, MJ Fulton, L Engelman, JA Sequist, LV AF Piotrowska, Zofia Costa, Daniel Botelho Huberman, Mark Oxnard, Geoffrey R. Gainor, Justin F. Heist, Rebecca Suk Muzikansky, Alona Shaw, Alice Tsang Niederst, Matthew J. Fulton, Linnea Engelman, Jeffrey A. Sequist, Lecia V. TI Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Charlestown, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8015 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901728 ER PT J AU Pirl, WF Lerner, J Eusebio, J Traeger, L Fields, L El-Jawahri, A Greer, JA Temel, JS AF Pirl, William F. Lerner, Jennifer Eusebio, Justin Traeger, Lara Fields, Lauren El-Jawahri, Areej Greer, Joseph A. Temel, Jennifer S. TI Association between oncologists' dispositional affect and depressive symptoms in their patients with metastatic cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Brookline, MA USA. Harvard Univ, Cambridge, MA 02138 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9559 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902054 ER PT J AU Planchard, D Groen, HJM Kim, TM Rigas, JR Souquet, PJ Baik, CS Barlesi, F Mazieres, J Quoix, EA Curtis, CM Mookerjee, B Bartlett-Pandite, AN Tucker, C D'Amelio, A Johnson, BE AF Planchard, David Groen, Harry J. M. Kim, Tae Min Rigas, James R. Souquet, Pierre Jean Baik, Christina S. Barlesi, Fabrice Mazieres, Julien Quoix, Elisabeth A. Curtis, C. Martin Mookerjee, Bijoyesh Bartlett-Pandite, Arundathy N. Tucker, Christine D'Amelio, Anthony Johnson, Bruce E. TI Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Gustave Roussy, Villejuif, France. Univ Groningen, Groningen, Netherlands. Univ Med Ctr Groningen, Dept Pulm Dis, NL-9713 AV Groningen, Netherlands. Seoul Natl Univ Hosp, Seoul, South Korea. Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. Lyon Sud Hosp, Acute Resp Med & Thorac Oncol Dept, Pierre Benite, France. Lyon Univ, Inst Canc, Lyon Univ Hosp, Pierre Benite, France. Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA. Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France. CHU Toulouse, Hop Larrey, Toulouse, France. Hop Univ Strasbourg, Strasbourg, France. GlaxoSmithKline, Res Triangle Pk, NC USA. GlaxoSmithKline, Collegeville, PA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 11 Z9 14 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8006 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901719 ER PT J AU Plimack, ER Bellmunt, J Gupta, S Berger, R Montgomery, RB Heath, K Juco, J Emancipator, K Pathiraja, K Lunceford, JK Perini, RF O'Donnell, PH AF Plimack, Elizabeth R. Bellmunt, Joaquim Gupta, Shilpa Berger, Raanan Montgomery, Robert B. Heath, Karl Juco, Jonathan Emancipator, Kenneth Pathiraja, Kumudu Lunceford, Jared K. Perini, Rodolfo F. O'Donnell, Peter H. TI Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Fox Chase Canc Ctr, Genitourinary Clin Res, Philadelphia, PA 19111 USA. Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA 02115 USA. Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, Tampa, FL 33612 USA. Chaim Sheba Med Ctr, Div Med Oncol, IL-52621 Tel Hashomer, Israel. Univ Washington Oncol, Seattle, WA USA. Merck & Co Inc, Kenilworth, NJ USA. Univ Chicago, Chicago, IL 60637 USA. NR 0 TC 38 Z9 38 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4502 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900970 ER PT J AU Poorvu, PD Gelber, SI Rosenberg, SM Tamimi, RM Ruddy, KJ Bober, SL Borges, VF Come, SE Schapira, L Partridge, AH AF Poorvu, Philip Daniel Gelber, Shari I. Rosenberg, Shoshana M. Tamimi, Rulla M. Ruddy, Kathryn Jean Bober, Sharon L. Borges, Virginia F. Come, Steven E. Schapira, Lidia Partridge, Ann H. TI Treatment-related amenorrhea among young women one year following diagnosis of early-stage breast cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Mayo Clin, Rochester, MN USA. Univ Colorado, Ctr Canc, Aurora, CO USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9523 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902018 ER PT J AU Powell, SF Liu, SV Sukari, A Chung, CH Bauml, J Haddad, RI Gause, CK Niewood, M Gammage, LL Brown, H Meister, A Cheng, JD Gitau, MM AF Powell, Steven Francis Liu, Stephen V. Sukari, Ammar Chung, Christine H. Bauml, Joshua Haddad, Robert I. Gause, Christine K. Niewood, Michelle Gammage, Linda L. Brown, Holly Meister, Amy Cheng, Jonathan D. Gitau, Mark M. TI KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Sanford Hlth, Sioux Falls, SD USA. Georgetown Univ, Washington, DC USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Johns Hopkins Univ, Baltimore, MD USA. Univ Penn, Perelman Sch Med, Phialdelphia, PA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Merck & Co Inc, Kenilworth, NJ USA. Incyte Corp, Wilmington, DE USA. Sanford Roger Maris Canc Ctr, Fargo, ND USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS3094 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904710 ER PT J AU Quiles, CW Gottsch, S Thakrar, U Fraile, B Billett, A AF Quiles, Chris Wong Gottsch, Stephanie Thakrar, Usha Fraile, Belen Billett, Amy TI Relationship between health care charges and ambulatory central line associated blood stream infections (CLABSI) in pediatric hematology-oncology patients SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e17793 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903726 ER PT J AU Trinh, QD Abdollah, F Sammon, JD Nguyen, PL Choueiri, TK Preston, MA Menon, M Weissman, JS Kibel, AS AF Quoc-Dien Trinh Abdollah, Firas Sammon, Jesse D. Paul Linh Nguyen Choueiri, Toni K. Preston, Mark A. Menon, Mani Weissman, Joel S. Kibel, Adam Stuart TI Prevalence of non-recommended screening for prostate cancer and breast cancer in the United States. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. Vattikuti Urol Inst, Detroit, MI USA. Henry Ford Hosp, Detroit, MI 48202 USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e17528 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903501 ER PT J AU Rafii, S Gourley, C Ang, JE Kumar, R Geuna, E Rye, T Ashcroft, L Powell, B Shapira-Frommer, R Friedlander, M Chen, LM Matulonis, U Kaufman, B De Greve, J Oza, AM Banerjee, SN Gore, ME Molife, LR Kaye, SB Yap, TA AF Rafii, Saeed Gourley, Charlie Ang, Joo Ern Kumar, Rajiv Geuna, Elena Rye, Tzyvia Ashcroft, Linda Powell, Bethan Shapira-Frommer, Ronnie Friedlander, Michael Chen, Lee-may Matulonis, Ursula Kaufman, Bella De Greve, Jacques Oza, Amit M. Banerjee, Susana N. Gore, Martin Eric Molife, L. Rhoda Kaye, Stanley B. Yap, Timothy Anthony TI What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment? SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Inst Canc Res, Sutton, Surrey, England. Royal Marsden NHS Fdn Trust, Sutton, Surrey, England. Univ Edinburgh, Canc Res UK Ctr, Edinburgh, Midlothian, Scotland. Royal Marsden Hosp, Sutton, Surrey, England. Royal Marsden Hosp, London SW3 6JJ, England. Inst Canc Res, Osasco, Italy. Royal Marsden, Osasco, Italy. Univ Edinburgh, Clin Trials Unit, Edinburgh, Midlothian, Scotland. Christie NHS Fdn Trust, Clin Trials Unit, Manchester, Lancs, England. UC San Francisco, San Francisco, CA USA. Sheba Med Ctr, Ramat Gan, Israel. Prince Wales Canc Ctr, Randwick, NSW, Australia. Dana Farber Canc Inst, Boston, MA 02115 USA. Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Ramat Gan, Israel. Oncol Ctr UZBrussel, Brussels, Belgium. Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. Royal Marsden Hosp NHS Trust, London, England. Inst Canc Res, London SW3 6JB, England. Royal Marsden NHS Fdn Trust, London, England. RI De Greve, Jacques/J-4939-2012 OI De Greve, Jacques/0000-0002-2389-0742 NR 0 TC 0 Z9 0 U1 1 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5546 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901208 ER PT J AU Raje, NS Terpos, E Durie, BG Garcia-Sanz, R Shimizu, K Willenbacher, W Zhu, L Warner, DJ Palumbo, A AF Raje, Noopur S. Terpos, Evangelos Durie, Brian G. Garcia-Sanz, Ramon Shimizu, Kazuyuki Willenbacher, Wolfgang Zhu, Li Warner, Douglas J. Palumbo, Antonio TI Denosumab compared with zoledronic acid for the treatment of bone disease in adults with newly diagnosed multiple myeloma: An international, randomized, double-blind trial. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Athens, Sch Med, Alexandra Gen Hosp, GR-11527 Athens, Greece. Cedars Sinai Comp Canc Ctr, Los Angeles, CA USA. Univ Hosp Salamanca, Salamanca, Spain. Tokai Chuo Hosp, Nagoya, Aichi, Japan. Med Univ Innsbruck, A-6020 Innsbruck, Austria. Amgen Inc, Thousand Oaks, CA 91320 USA. AOU San Giovanni Battista Torino, Osped Molinette, Turin, Italy. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS8611 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904873 ER PT J AU Ramalingam, SS Yang, JCH Lee, CK Kurata, T Kim, DW John, T Nogami, N Ohe, Y Rukazenkov, Y Frewer, P Cantarini, M Ghiorghiu, S Janne, PA AF Ramalingam, Suresh S. Yang, James Chih-Hsin Lee, Chee Khoon Kurata, Takayasu Kim, Dong-Wan John, Thomas Nogami, Naoyuki Ohe, Yuichiro Rukazenkov, Yuri Frewer, Paul Cantarini, Mireille Ghiorghiu, Serban Janne, Pasi A. TI AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan. Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan. Natl Taiwan Univ, Canc Res Ctr, Taipei 10764, Taiwan. St George Hosp, Sydney, NSW, Australia. Kansai Med Univ, Hirakata Hosp, Osaka, Japan. Seoul Natl Univ Hosp, Seoul 110744, South Korea. Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia. Natl Hosp Org, Shikoku Canc Ctr, Clin Res Inst, Matsuyama, Ehime, Japan. Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan. AstraZeneca, Macclesfield, Cheshire, England. AstraZeneca, Cambridge, England. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 3 Z9 3 U1 1 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8000 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901713 ER PT J AU Reardon, DA Dietrich, J Kaley, TJ Gan, HK Dunn, GP Cloughesy, TF Lim, M Clarke, JL Park, AJ Pan, LS Lai, DW Karakunnel, JJ Robbins, PB Narwal, R Venhaus, RR AF Reardon, David A. Dietrich, Jorg Kaley, Thomas Joseph Gan, Hui Kong Dunn, Gavin P. Cloughesy, Timothy Francis Lim, Michael Clarke, Jennifer Leigh Park, Andrew J. Pan, Linda S. Lai, Dominic W. Karakunnel, Joyson Joseph Robbins, Paul B. Narwal, Rajesh Venhaus, Ralph Rudolph TI Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Ctr Inst, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Austin Hlth, Heidelberg, Vic, Australia. Washington Univ, Sch Med, St Louis, MO USA. Univ Calif Los Angeles, Los Angeles, CA USA. Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. UC San Francisco, San Francisco, CA USA. Ludwig Inst Canc Res, New York, NY USA. MedImmune, Gaithersburg, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS2077 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904674 ER PT J AU Reardon, DA Schuster, J Tran, DD Fink, KL Nabors, LB Li, G Bota, DA Lukas, RV Desjardins, A Ashby, LS Duic, JP Mrugala, MM Werner, A Hawthorne, T He, Y Green, JA Yellin, MJ Turner, CD Davis, TA Sampson, JH AF Reardon, David A. Schuster, James Tran, David Dinh Fink, Karen L. Nabors, Louis B. Li, Gordon Bota, Daniela Annenelie Lukas, Rimas Vincas Desjardins, Annick Ashby, Lynn Stuart Duic, J. Paul Mrugala, Maciej M. Werner, Andrea Hawthorne, Thomas He, Yi Green, Jennifer A. Yellin, Michael Jay Turner, Christopher D. Davis, Thomas A. Sampson, John H. CA ReACT Study Grp TI ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Penn, Philadelphia, PA 19104 USA. Washington Univ, St Louis, MO USA. Baylor Res Inst, Dallas, TX USA. Univ Alabama Birmingham, Birmingham, AL USA. Stanford Univ, Sch Med, Stanford, CA 94305 USA. UC Irvine Med Ctr, Orange, CA USA. Univ Chicago, Chicago, IL 60637 USA. Duke Univ, Med Ctr, Durham, NC USA. Barrow Neurol Inst, Phoenix, AZ 85013 USA. Neurol Surg PC, Long Isl Brain Tumor Ctr, Lake Success, NY USA. Univ Washington, Seattle, WA 98195 USA. Celldex Therapeut Inc, Hampton, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2009 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900468 ER PT J AU Redig, AJ Taibi, M Oxnard, GR Boucher, D Rabin, MS Marcoux, JP Gandhi, L Huberman, M Rangachari, D Lucca, JV Morse, LK Andan, M Johnson, BE Costa, DB Janne, PA Jackman, DM AF Redig, Amanda J. Taibi, Myriam Oxnard, Geoffrey R. Boucher, David Rabin, Michael S. Marcoux, J. Paul Gandhi, Leena Huberman, Mark Rangachari, Deepa Lucca, Joan Vern Morse, Linda K. Andan, MaChristine Johnson, Bruce E. Costa, Daniel Botelho Janne, Pasi A. Jackman, David Michael TI A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively assess biopsy feasibility and acquired resistance at disease progression. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Sudbury, MA USA. Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. Harvard Univ, Sch Med, Israel Deaconess Medcl Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8076 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901788 ER PT J AU Redig, AJ Mach, SL Capelletti, M Fontes, C Shi, YL Chalasani, P Dahlberg, SE Janne, PA AF Redig, Amanda J. Mach, Stacy L. Capelletti, Marzia Fontes, Caitlin Shi, Yunling Chalasani, Poornima Dahlberg, Suzanne Eleanor Janne, Pasi A. TI Clinical and molecular characteristics of NF1 mutant lung cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 [Redig, Amanda J.; Mach, Stacy L.; Capelletti, Marzia; Fontes, Caitlin; Shi, Yunling; Chalasani, Poornima; Dahlberg, Suzanne Eleanor; Janne, Pasi A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8022 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901735 ER PT J AU Rettig, EM Wentz, A Posner, MR Gross, ND Haddad, RI Gillison, ML Quon, H Sikora, AG Stott, W Lorch, JH Gourin, CG Miles, B Richmon, J Misiukiewicz, K Chung, CH Fakhry, C D'Souza, G AF Rettig, Eleni Marie Wentz, Alicia Posner, Marshall R. Gross, Neil D. Haddad, Robert I. Gillison, Maura L. Quon, Harry Sikora, Andrew Gregory Stott, Will Lorch, Jochen H. Gourin, Christine Gail Miles, Brett Richmon, Jeremy Misiukiewicz, Krzysztof Chung, Christine H. Fakhry, Carole D'Souza, Gypsyamber TI Prognostic implication of persistent HPV16 DNA detection in oral rinses for HPV-positive oropharyngeal carcinoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA. Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. Icahn Sch Med Mt Sinai, Hematol & Med Oncol, New York, NY 10029 USA. Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Ohio State Univ, Columbus, OH 43210 USA. Johns Hopkins Univ, Baltimore, MD USA. Baylor Coll Med, Houston, TX 77030 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA. Mt Sinai Med Ctr, Dept Otolaryngol, New York, NY 10029 USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6005 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901317 ER PT J AU Ribas, A Puzanov, I Gajewski, T Long, GV Dummer, R Kirkwood, JM VanderWalde, A Cebon, JS McArthur, GA Gause, CK Chen, L Kaufman, DR Chou, J Andtbacka, RHI Hodi, FS AF Ribas, Antoni Puzanov, Igor Gajewski, Thomas Long, Georgina V. Dummer, Reinhard Kirkwood, John M. VanderWalde, Ari Cebon, Jonathan S. McArthur, Grant A. Gause, Christine K. Chen, Lisa Kaufman, David Ross Chou, Jeffrey Andtbacka, Robert Hans Ingemar Hodi, F. Stephen TI A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Univ Chicago, Chicago, IL 60637 USA. Melanoma Inst Australia, Sydney, NSW, Australia. Univ Sydney, Sydney, NSW, Australia. Univ Zurich Hosp, CH-8091 Zurich, Switzerland. Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA USA. Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. Austin Hosp, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia. Peter MacCallum Canc Ctr, East Melbourne, Australia. Merck & Co Inc, Kenilworth, NJ USA. Amgen Inc, Thousand Oaks, CA 91320 USA. Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 2 U2 6 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS9081 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904879 ER PT J AU Ribas, A Butler, M Lutzky, J Lawrence, DP Robert, C Miller, W Linette, GP Ascierto, PA Kuzel, T Algazi, AP Postow, MA Nathan, PD Curti, BD Robbins, PB Li, X Blake-Haskins, JA Gordon, MS AF Ribas, Antoni Butler, Marcus Lutzky, Jose Lawrence, Donald P. Robert, Caroline Miller, Wilson Linette, Gerald P. Ascierto, Paolo Antonio Kuzel, Timothy Algazi, Alain Patrick Postow, Michael Andrew Nathan, Paul D. Curti, Brendan D. Robbins, Paul B. Li, Xia Blake-Haskins, John A. Gordon, Michael S. TI Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Calif Los Angeles, Los Angeles, CA USA. Princess Margaret Canc Ctr, Toronto, ON, Canada. Mt Sinai Med Ctr, New York, NY 10029 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Paris Sud, Villejuif, France. McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada. Washington Univ, St Louis, MO USA. Ist Nazl Tumori Fdn Pascale, Naples, Italy. Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. UCSF Med Ctr, San Francisco, CA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Mt Vernon Hosp, Northwood, Middx, England. Earle A Chiles Res Inst, Providence Canc Ctr, Portland, OR USA. Medimmune Inc, Gaithersburg, MD 20878 USA. Pinnacle Oncol Hematol, Scottsdale, AZ USA. NR 0 TC 20 Z9 20 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3003 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900637 ER PT J AU Ribas, A Robert, C Hodi, FS Wolchok, JD Joshua, AM Hwu, WJ Weber, JS Zarour, HM Kefford, R Loboda, A Albright, A Kang, SP Ebbinghaus, S Yearley, J Murphy, E Nebozhyn, M Lunceford, JK McClanahan, T Ayers, M Daud, A AF Ribas, Antoni Robert, Caroline Hodi, F. Stephen Wolchok, Jedd D. Joshua, Anthony M. Hwu, Wen-Jen Weber, Jeffrey S. Zarour, Hassane M. Kefford, Richard Loboda, Andrey Albright, Andrew Kang, Soonmo Peter Ebbinghaus, Scot Yearley, Jennifer Murphy, Erin Nebozhyn, Michael Lunceford, Jared K. McClanahan, Terri Ayers, Mark Daud, Adil TI Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Gustave Roussy, Villejuif, France. Dana Farber Canc Inst, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Princess Margaret Canc Ctr, Toronto, ON, Canada. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Univ Pittsburgh, Pittsburgh, PA USA. Macquarie Univ, Sydney, NSW 2109, Australia. Westmead Hosp, Sydney, NSW, Australia. Merck & Co Inc, Kenilworth, NJ USA. UC San Francisco, San Francisco, CA USA. NR 0 TC 27 Z9 27 U1 2 U2 6 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3001 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900635 ER PT J AU Richardson, PG Bensmaine, A Doerr, T Wang, JM Zaki, MH AF Richardson, Paul G. Bensmaine, Amine Doerr, Thomas Wang, Jianming Zaki, Mohamed H. CA MM-007 Study Investigators TI MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Celgene Corp, Summit, NJ USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS8610 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904872 ER PT J AU Rizvi, NA Garon, EB Leighl, N Hellmann, MD Patnaik, A Gandhi, L Eder, JP Rangwala, RA Lubiniecki, G Zhang, J Emancipator, K Roach, CM Rutledge, R Hui, RN Ahn, MJ Horn, L Felip, E Costa, EC AF Rizvi, Naiyer A. Garon, Edward B. Leighl, Natasha Hellmann, Matthew David Patnaik, Amita Gandhi, Leena Eder, Joseph Paul Rangwala, Reshma A. Lubiniecki, Gregory Zhang, Jin Emancipator, Kenneth Roach, Charlotte M. Rutledge, Ruth Hui, Rina Ahn, Myung-Ju Horn, Leora Felip, Enriqueta Costa, Enric Carcereny TI Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Columbia Univ, Med Ctr, New York, NY USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Princess Margaret Canc Ctr, Toronto, ON, Canada. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. START, San Antonio, TX USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Yale Canc Ctr, New Haven, CT USA. Merck & Co Inc, Kenilworth, NJ USA. Dako, Carpinteria, CA USA. Univ Sydney, Westmead Hosp, Westmead, NSW 2145, Australia. Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Vall dHebron Univ Hosp, Barcelona, Spain. Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain. RI Zhang, Jin/E-8298-2017 NR 0 TC 7 Z9 7 U1 0 U2 6 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8026 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901739 ER PT J AU Robert, C Joshua, AM Kefford, R Joseph, RW Wolchok, JD Hodi, FS Hamid, O Weber, JS Gangadhar, TC Dronca, RS Patnaik, A Zarour, HM Hwu, WJ Hersey, P Daud, A Giannotti, M Li, XN Ebbinghaus, S Kang, SP Ribas, A AF Robert, Caroline Joshua, Anthony M. Kefford, Richard Joseph, Richard Wayne Wolchok, Jedd D. Hodi, F. Stephen Hamid, Omid Weber, Jeffrey S. Gangadhar, Tara C. Dronca, Roxana Stefania Patnaik, Amita Zarour, Hassane M. Hwu, Wen-Jen Hersey, Peter Daud, Adil Giannotti, Maxine Li, Xiaoyun Nicole Ebbinghaus, Scot Kang, Soonmo Peter Ribas, Antoni TI Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Gustave Roussy, Villejuif, France. Princess Margaret Canc Ctr, Toronto, ON, Canada. Macquarie Univ, Sydney, NSW 2109, Australia. Westmead Hosp, Sydney, NSW, Australia. Mayo Clin, Jacksonville, FL 32224 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Angeles Clin & Res Inst, Los Angeles, CA USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Mayo Clin, Rochester, MN USA. START, San Antonio, TX USA. Univ Pittsburgh, Pittsburgh, PA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Sydney, Sydney, NSW 2006, Australia. UC San Francisco, San Francisco, CA USA. Merck & Co Inc, Kenilworth, NJ USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 4 Z9 4 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9050 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901960 ER PT J AU Rosenberg, AR Bradford, M Bona, KO Shaffer, M Wolfe, J Syrjala, K Baker, KS AF Rosenberg, Abby R. Bradford, Miranda Bona, Kira O'Neil Shaffer, Michele Wolfe, Joanne Syrjala, Karen Baker, Kevin Scott TI Screening for self-efficacy and distress: A report from the "Resilience in Adolescents and Young Adults with Cancer" study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA. Seattle Childrens Hosp, Seattle, WA USA. Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Fred Hutchinson Canc Rsrch Ctr, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e21037 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904373 ER PT J AU Rosenberg, AR Bradford, M Bona, KO Shaffer, M Wolfe, J Syrjala, K Baker, KS AF Rosenberg, Abby R. Bradford, Miranda Bona, Kira O'Neil Shaffer, Michele Wolfe, Joanne Syrjala, Karen Baker, Kevin Scott TI Risky behaviors during cancer therapy: A report from the "Resilience in Adolescents and Young adults with Cancer" study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA. Seattle Childrens Hosp, Seattle, WA USA. Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Fred Hutchinson Canc Rsrch Ctr, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e21035 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904371 ER PT J AU Rosenberg, SM Ruddy, KJ Tamimi, RM Gelber, SI Schapira, L Borges, VF Come, SE Meyer, ME Winer, EP Partridge, AH AF Rosenberg, Shoshana M. Ruddy, Kathryn Jean Tamimi, Rulla M. Gelber, Shari I. Schapira, Lidia Borges, Virginia F. Come, Steven E. Meyer, Meghan E. Winer, Eric P. Partridge, Ann H. TI Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Mayo Clin, Rochester, MN USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Colorado, Ctr Canc, Aurora, CO USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 515 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901122 ER PT J AU Rosenblat, TL Jurcic, JG Heaney, ML Raza, A Mears, JG Santos, R Carrillo, D Gonzales, J Harwood, K Santos, M Zhang, R Ibanez, G Hogdal, L Crombie, JL Djaballah, H Scandura, JM Letai, AG Frattini, MG AF Rosenblat, Todd Louis Jurcic, Joseph G. Heaney, Mark L. Raza, Azra Mears, J. Gregory Santos, Ruth Carrillo, Diana Gonzales, Jacquelyn Harwood, Katherine Santos, Martin Zhang, Rong Ibanez, Glorymar Hogdal, Leah Crombie, Jennifer Leigh Djaballah, Hakim Scandura, Joseph M. Letai, Anthony G. Frattini, Mark G. TI A phase I trial of a pharmacodynamically-conceived decitabine/thioguanine combination in patients with advanced myeloid malignancies SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Columbia Univ, Medcl Ctr, New York, NY USA. Columbia Univ, Med Ctr, New York, NY USA. Columbia Univ, New York, NY USA. CUMC, New York, NY USA. MSKCC, New York, NY USA. DFCI, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Inst Pasteur Korea, Bundang, South Korea. Weill Cornell Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e18025 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903758 ER PT J AU Rubinstein, MMZ Gray, RJ Sparano, JA Zujewski, J Whelan, TJ Albain, KS Hayes, DF Geyer, CE Dees, EC Perez, EA Keane, MM Vallejos, C Goggins, TF Mayer, IA Brufsky, A Toppmeyer, D Kaklamani, VG Atkins, JN Berenberg, JL Sledge, GW AF Rubinstein, Maria M. Zlobinsky Gray, Robert James Sparano, Joseph A. Zujewski, JoAnne Whelan, Timothy Joseph Albain, Kathy S. Hayes, Daniel F. Geyer, Charles E. Dees, Elizabeth Claire Perez, Edith A. Keane, Maccon M. Vallejos, Carlos Goggins, Timothy F. Mayer, Ingrid A. Brufsky, Adam Toppmeyer, Deborah Kaklamani, Virginia G. Atkins, James Norman Berenberg, Jeffrey L. Sledge, George W. TI Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Montefiore Med Ctr, Bronx, NY 10467 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NIH, Bethesda, MD 20892 USA. Canc Care Ontario, Hamilton, ON, Canada. SWOG, NRG Oncol NSABP, Maywood, IL USA. Loyola Univ, Chicago Stritch Sch Med, Maywood, IL 60153 USA. Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA. Univ N Carolina, Chapel Hill, NC USA. Mayo Clin, Jacksonville, FL 32224 USA. West Ireland Canc Ctr, Galway, Ireland. Inst Nacl Enfermedades Neoplas, Lima, Peru. Fox Valley Hem Onc, Appleton, WI USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. NRG Oncol NSABP, Pittsburgh, PA USA. Magee Womens Hosp, Pittsburgh, PA USA. Canc Inst New Jersey, New Brunswick, NJ USA. Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA. Southeastern Medcl Ctr, Goldsboro, NC USA. Tripler Army Medcl Ctr, Honolulu, HI USA. Stanford Univ, Med Ctr, Stanford, CA 94305 USA. RI Whelan, Timothy/D-3185-2017 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 533 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901140 ER PT J AU Ruddy, KJ Guo, H Baker, E Goldstein, M Mullaney, EE Shulman, LN Partridge, AH AF Ruddy, Kathryn Jean Guo, Hao Baker, Emily Goldstein, Matthew Mullaney, Erin E. Shulman, Lawrence N. Partridge, Ann H. TI Coordinated follow-up Breast Cancer Survivorship Care Program study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mayo Clin, Rochester, MN USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Stanford Univ, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e17727 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903674 ER PT J AU Ryan, CJ Kheoh, T Li, JH Molina, A De Porre, P Carles, J Efstathiou, E Kantoff, PW Mulders, PFA Saad, F Griffin, TW Chi, KN AF Ryan, Charles J. Kheoh, Thian Li, Jinhui Molina, Arturo De Porre, Peter Carles, Joan Efstathiou, Eleni Kantoff, Philip W. Mulders, Peter F. A. Saad, Fred Griffin, Thomas W. Chi, Kim N. TI Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. Janssen Res & Dev, San Diego, CA USA. Johnson & Johnson Med China, Shanghai, Peoples R China. Janssen Res & Dev, Menlo Pk, CA USA. Janssen Res & Dev, Beerse, Belgium. Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands. Univ Montreal, Montreal, PQ, Canada. Janssen Res & Dev, Los Angeles, CA USA. BC Canc Agcy, Vancouver, BC, Canada. RI Mulders, Peter/H-8076-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5047 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901090 ER PT J AU Ryan, CJ Crawford, ED Shore, ND Underwood, W Londhe, A Black, SC McGowan, T Kantoff, PW AF Ryan, Charles J. Crawford, E. David Shore, Neal D. Underwood, Willie Londhe, Anil Black, Shawn C. McGowan, Tracy Kantoff, Philip W. TI IMAAGEN trial update: Effect of abiraterone acetate and low dose prednisone on PSA and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. Univ Colorado, Denver, CO 80202 USA. Carolina Urol Res Ctr, Myrtle Beach, SC USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Janssen Res & Dev, Horsham, PA USA. Janssen Pharmaceut, Horsham, PA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5053 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901097 ER PT J AU Sabado, RL Pavlick, AC Gnjatic, S Hasan, F Spadaccia, M Oner, BS Dong, HQ Holman, RM Vengco, I Muren, C Escano, C Yepes, E Stein, C Jungbluth, AA Pan, LS Venhaus, RR Salazar, AM Ott, PA Bhardwaj, N AF Sabado, Rachel Lubong Pavlick, Anna C. Gnjatic, Sacha Hasan, Farah Spadaccia, Meredith Oner, Bike Su Dong, Hanqing Holman, Rose Marie Vengco, Isabelita Muren, Caroline Escano, Crystal Yepes, Ethel Stein, Claire Jungbluth, Achim A. Pan, Linda S. Venhaus, Ralph Rudolph Salazar, Andres M. Ott, Patrick Alexander Bhardwaj, Nina TI Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Icahn Sch Med Mt Sinai, New York, NY 10029 USA. NYU, Ctr Canc, New York, NY USA. NYU, Sch Med, Inst Canc, New York, NY USA. NYU, Inst Canc, New York, NY USA. Ludwig Inst Canc Res, New York, NY USA. Oncovir Inc, Washington, DC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Mt Sinai Med Ctr, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e14034 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902623 ER PT J AU Sacher, AG Sholl, LM Mach, SL Johnson, BE Hammerman, PS Janne, PA Oxnard, GR AF Sacher, Adrian G. Sholl, Lynette M. Mach, Stacy L. Johnson, Bruce E. Hammerman, Peter S. Janne, Pasi A. Oxnard, Geoffrey R. TI Feasibility of next-generation sequencing (NGS) for squamous non-small cell lung cancer (NSCLC): Implications for the NCI LungMAP study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Cambridge, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Newton Ctr, MA USA. RI Sacher, Adrian/I-8080-2016 OI Sacher, Adrian/0000-0001-7865-2701 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8096 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901808 ER PT J AU Sacher, AG Paweletz, C Alden, R O'Connell, A Mach, SL Janne, PA Oxnard, GR AF Sacher, Adrian G. Paweletz, Cloud Alden, Ryan O'Connell, Allison Mach, Stacy L. Janne, Pasi A. Oxnard, Geoffrey R. TI A prospective validation of plasma ddPCR for rapid EGFR and KRAS genotyping of advanced NSCLC patients (pts). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Cambridge, MA USA. Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. RI Sacher, Adrian/I-8080-2016 OI Sacher, Adrian/0000-0001-7865-2701 NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 11089 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900347 ER PT J AU Sagara, Y Barry, WT Mallory, MA Wong, SM Aydogan, F DeSantis, S Golshan, M AF Sagara, Yasuaki Barry, William Thomas Mallory, Melissa Anne Wong, Stephanie M. Aydogan, Fatih DeSantis, Stephen Golshan, Mehra TI The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1006 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900068 ER PT J AU Saha, S Berbiglia, L Shaik, M Gernand, J Saha, SK Hicks, M Arora, ML Wiese, D AF Saha, Sukamal Berbiglia, Lindsay Shaik, Mohammed Gernand, Jill Saha, Supriya Kumar Hicks, Michael Arora, Madan L. Wiese, David TI Biological difference of right versus left colon cancer: An analysis of the National Cancer Data Base and Surveillance, Epidemiology and End Results. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Michigan State Univ, McLaren Reg Med Ctr, Flint, MI USA. McLaren Reg Med Ctr, Flint, MI USA. Michigan State Univ, E Lansing, MI 48824 USA. Massachusetts Gen Hosp, Brookline, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e14624 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902721 ER PT J AU Sampson, JH Vlahovic, G Sahebjam, S Omuro, AMP Baehring, JM Hafler, DA Voloschin, AD Paliwal, P Grosso, J Coric, V Cloughesy, TF Lim, M Reardon, DA AF Sampson, John H. Vlahovic, Gordana Sahebjam, Solmaz Omuro, Antonio Marcilio Padula Baehring, Joachim M. Hafler, David A. Voloschin, Alfredo Daniel Paliwal, Prashni Grosso, Joseph Coric, Vlad Cloughesy, Timothy F. Lim, Michael Reardon, David A. TI Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Duke Univ, Med Ctr, Durham, NC USA. H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Yale Univ, Sch Med, New Haven, CT USA. Emory Univ, Sch Med, Atlanta, GA USA. Bristol Myers Squibb Co, Princeton, NJ USA. Univ Calif Los Angeles, Los Angeles, CA USA. Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 2 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3010 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900644 ER PT J AU San Miguel, JF Hungria, VTM Yoon, SS Beksac, M Dimopoulos, MA Elghandour, A Jedrzejczak, WW Guenther, A Nakorn, TN Siritanaratkul, N Schlossman, RL Hou, J Moreau, P Lonial, S Lee, JH Einsele, H Sopala, M Bengoudifa, BR Corrado, C Richardson, PG AF San Miguel, Jesus F. Hungria, Vania T. M. Yoon, Sung-Soo Beksac, Meral Dimopoulos, Meletios A. Elghandour, Ashraf Jedrzejczak, Wieslaw W. Guenther, Andreas Nakorn, Thanyaphong Na Siritanaratkul, Noppadol Schlossman, Robert L. Hou, Jian Moreau, Philippe Lonial, Sagar Lee, Jae Hoon Einsele, Hermann Sopala, Monika Bengoudifa, Bourras-Rezki Corrado, Claudia Richardson, Paul G. TI Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Navarra Clin, Pamplona, Spain. Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil. Seoul Natl Univ Hosp, Seoul 110744, South Korea. Ankara Univ, TR-06100 Ankara, Turkey. Hellen Cooperat Oncol Grp HeCOG, Athens, Greece. Univ Alexandria, Alexandria, Egypt. Med Univ Warsaw, Warsaw, Poland. Dept Med 2, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany. Chulalongkorn Univ, Bangkok, Timor Leste, Thailand. Siriraj Hosp, Bangkok, Thailand. Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. Chang Zheng Hosp, Shanghai, Peoples R China. CHU Nantes, Hotel Dieu HME, F-44035 Nantes 01, France. Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. Gachon Univ, Inchon, South Korea. Univ Hosp Wuerzburg, Wurzburg, Germany. Novartis Pharma AG, Basel, Switzerland. Dana Farber Canc Inst, Boston, MA 02115 USA. RI richard, chrystelle/K-8595-2015 NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8526 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901838 ER PT J AU Sarantopoulos, J Mita, AC He, AR Wade, JL Hsueh, CT Morris, JC Lockhart, AC Quinn, D Hwang, JJ Mier, JW Zhang, WP Wack, C Yin, J Clot, PF Rixe, O AF Sarantopoulos, John Mita, Alain C. He, Aiwu Ruth Wade, James Lloyd Hsueh, Chung-Tsen Morris, John Charles Lockhart, Albert C. Quinn, David Hwang, Jimmy J. Mier, James Walter Zhang, Wenping Wack, Claudine Yin, Jian Clot, Pierre-Francois Rixe, Olivier TI Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX 78229 USA. Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med & Oncol, Washington, DC USA. Georgetown Univ, Lombardi Comprehens Canc Ctr, Innovat Ctr Biomed Informat, Washington, DC USA. Canc Care Ctr Decatur, Decatur, IL USA. Loma Linda Univ, Div Med Oncol Hematol, Loma Linda, CA 92350 USA. Univ Cincinnati, Dept Med, Inst Canc, Div Hematol Oncol, Cincinnati, OH USA. Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA. Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA. Beth Israel Deaconess Med Ctr, Dana Farber Harvard Canc Ctr, Dept Med, Boston, MA 02215 USA. Sanofi Rech, Bridgewater, NJ USA. Sanofi Rech, Chilly Mazarin, France. Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2538 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900571 ER PT J AU Sartor, AO Fernandez, DC Morris, MJ Iagaru, A Brown, A Almeida, F Sweeney, C Smith, MR Dicker, A Wong, YN Shore, ND Gratt, J Petrenciuc, O Germino, J Vogelzang, NJ AF Sartor, A. Oliver Fernandez, Daniel Celestino Morris, Michael J. Iagaru, Andrei Brown, Alan Almeida, Fabio Sweeney, Christopher Smith, Matthew Raymond Dicker, Adam Wong, Yu-Ning Shore, Neal D. Gratt, Jeremy Petrenciuc, Oana Germino, Joseph Vogelzang, Nicholas J. TI Ra-223 experience in pretreated patients: EAP setting. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Tulane Canc Ctr, New Orleans, LA USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Stanford Univ, Stanford, CA 94305 USA. 21st Century Oncol, Ft Myers, FL USA. Arizona Mol Imaging Ctr, Phoenix, AZ USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA. Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA. Carolina Urol Res Ctr, Myrtle Beach, SC USA. Bayer HealthCare, Whippany, NJ USA. Comprehens Canc Ctr Nevada, Las Vegas, NV USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5063 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901108 ER PT J AU Scher, HI Morris, MJ Stadler, WM Higano, CS Halabi, S Smith, MR Basch, EM Fizazi, K Ryan, CJ Antonarakis, ES Corn, PG Liu, G De Bono, JS Schwartz, LH Beer, TM Kelly, WK Hussain, M Sartor, AO Kantoff, PW Armstrong, AJ AF Scher, Howard I. Morris, Michael J. Stadler, Walter Michael Higano, Celestia S. Halabi, Susan Smith, Matthew Raymond Basch, Ethan M. Fizazi, Karim Ryan, Charles J. Antonarakis, Emmanuel S. Corn, Paul Gettys Liu, Glenn De Bono, Johann Sebastian Schwartz, Lawrence H. Beer, Tomasz M. Kelly, William Kevin Hussain, Maha Sartor, A. Oliver Kantoff, Philip W. Armstrong, Andrew J. TI The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Chicago, Chicago, IL 60637 USA. Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. Duke Univ Med Ctr, Durham, NC USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ N Carolina, Chapel Hill, NC USA. Univ Paris 11, Inst Gustave Roussy, Dept Canc Med, Villejuif, France. Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Wisconsin Carbone Canc Ctr, Madison, WI USA. Inst Canc Res, Sutton, Surrey, England. Royal Marsden NHS Fdn Trust, Sutton, Surrey, England. Columbia Univ Med Ctr, New York Presbyterian Hosp, New York, NY USA. Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Portland, OR 97201 USA. Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA. Univ Michigan Comprehens Canc Ctr, Ann Arbor, MI USA. Tulane Canc Ctr, New Orleans, LA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Duke Univ, Duke Canc Inst, Durham, NC USA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5000 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901042 ER PT J AU Schlumberger, M Elisei, R Muller, S Schoffski, P Brose, MS Shah, MH Licitra, LF Jarzab, B Medvedev, V Kreissl, M Cohen, EEW Wirth, LJ Ali, HY Hessel, C Yaron, Y Ball, DW Nelkin, B Sherman, SI AF Schlumberger, Martin Elisei, Rossella Mueller, Stefan Schoeffski, Patrick Brose, Marcia S. Shah, Manisha H. Licitra, Lisa F. Jarzab, Barbara Medvedev, Viktor Kreissl, Michael Cohen, Ezra E. W. Wirth, Lori J. Ali, Haythem Y. Hessel, Colin Yaron, Yifah Ball, Douglas Wilmot Nelkin, Barry Sherman, Steven I. TI Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Inst Gustave Roussy, Villejuif, France. Univ Pisa, Dept Endocrinol, Pisa, Italy. Univ Klinikum Essen, Essen, Germany. Univ Hosp Leuven, Leuven, Belgium. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. Fdn IRCCS Ist Nazl Tumori, Milan, Italy. Maria Sklodowska Curie Mem Canc Ctr, Gliwice, Poland. Inst Oncol, Gliwice, Poland. Med Radiol Res Ctr, Obninsk, Russia. Klinikum Augsburg, Augsburg, Germany. Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Henry Ford Hlth Syst, Detroit, MI USA. Exelixis Inc, San Francisco, CA USA. Johns Hopkins Univ, Baltimore, MD USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 2 Z9 2 U1 1 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6012 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901324 ER PT J AU Schoffski, P Maki, RG Italiano, A Gelderblom, H Grignani, G De Camargo, VP Bauer, S Rha, SY Chawla, SP Blay, JY Hohenberger, P D'Adamo, DR Wang, B Chmielowski, B Le Cesne, A Demetri, GD Patel, S AF Schoeffski, Patrick Maki, Robert G. Italiano, Antoine Gelderblom, Hans Grignani, Giovanni De Camargo, Veridiana Pires Bauer, Sebastian Rha, Sun Young Chawla, Sant P. Blay, Jean-Yves Hohenberger, Peter D'Adamo, David R. Wang, Benjamin Chmielowski, Bartosz Le Cesne, Axel Demetri, George D. Patel, Shreyaskumar TI Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Hosp Leuven, Leuven, Belgium. Mt Sinai Med Ctr, New York, NY 10029 USA. CLCC Inst Bergonie, Bordeaux, France. Leiden Univ, Med Ctr, Leiden, Netherlands. Fdn Piemonte Oncol IRCC, Candiolo, Italy. Hosp Sirio Libanes, Sao Paulo, Brazil. West German Canc Ctr, Essen, Germany. Severance Hosp, Seoul, South Korea. Sarcoma Oncol Ctr, Santa Monica, CA USA. Univ Lyon 1, F-69365 Lyon, France. Ctr Leon Berard, F-69373 Lyon, France. Univ Mannheim, Med Ctr, D-68131 Mannheim, Germany. Eisai Inc, Woodcliff Lake, NJ USA. Eisai, Woodcliff Lake, NJ USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. Inst Gustave Roussy, Villejuif, France. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RI Blay, Jean-Yves/N-3966-2016 OI Blay, Jean-Yves/0000-0001-7190-120X NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA LBA7005 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904641 ER PT J AU Schrag, D Dueck, AC Naughton, MJ Niedzwiecki, D Earle, C Shaw, JE Grothey, A Hochster, HS Blanke, CD Venook, AP AF Schrag, Deborah Dueck, Amylou C. Naughton, Michelle Joy Niedzwiecki, Donna Earle, Craig Shaw, James Edward Grothey, Axel Hochster, Howard S. Blanke, Charles David Venook, Alan P. TI Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Mayo Clin, Alliance Stat & Data Ctr, Scottsdale, AZ USA. Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. Duke Univ, Cary, NC USA. Inst Clin Evaluat Sci, Toronto, ON, Canada. Medstar Washington Hosp Ctr, Washington, DC USA. Mayo Clin, Rochester, MN USA. Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6504 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901419 ER PT J AU Schwartz, GK Adkins, D Heist, RS Abbott, M Barber, SL Chao, RC Neuteboom, STC Chen, I Christensen, J Bauer, TM AF Schwartz, Gary K. Adkins, Douglas Heist, Rebecca Suk Abbott, Maura Barber, Stephanie L. Chao, Richard C. Neuteboom, Saskia T. C. Chen, Isan Christensen, James Bauer, Todd Michael TI A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Columbia Univ, Med Ctr, New York, NY USA. Washington Univ, Sch Med, St Louis, MO USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Mirati Therapeut Inc, San Diego, CA USA. Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS2621 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904699 ER PT J AU Sequist, LV Goldman, JW Wakelee, HA Camidge, DR Yu, HA Varga, A Solomon, B Oxnard, GR Ou, SHI Papadimitrakopoulou, V Chao, BH Liu, SV Reckamp, KL Spira, AI Piotrowska, Z Despain, D Karlovich, CA Yurasov, S Soria, JC AF Sequist, Lecia V. Goldman, Jonathan Wade Wakelee, Heather A. Camidge, D. Ross Yu, Helena Alexandra Varga, Andrea Solomon, Ben Oxnard, Geoffrey R. Ou, Sai-Hong Ignatius Papadimitrakopoulou, Vassiliki Chao, Bo H. Liu, Stephen V. Reckamp, Karen L. Spira, Alexander I. Piotrowska, Zofia Despain, Darrin Karlovich, Chris Alan Yurasov, Sergey Soria, Jean-Charles TI Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Calif Los Angeles, Santa Monica, CA USA. Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA. Univ Colorado, Ctr Canc, Aurora, CO USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Inst Gustave Roussy, Villejuif, France. Peter MacCallum Canc Ctr, East Melbourne, Australia. Dana Farber Canc Inst, Boston, MA 02115 USA. UC Irvine Med Ctr, Chao Family Comp Canc Ctr, Orange, CA USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Ohio State Univ, Columbus, OH 43210 USA. Georgetown Univ Hosp, Washington, DC 20007 USA. City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA. US Oncol Res, Virginia Canc Specialists Res Inst, Fairfax, VA USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Clovis Oncol Inc, San Francisco, CA USA. Clovis Onc, San Francisco, CA USA. Drug Dev Dept, Villejuif, France. NR 0 TC 13 Z9 13 U1 1 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8001 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901714 ER PT J AU Shapiro, G Mier, JW Hilton, JF Gandhi, L Chau, NG Bullock, AJ Supko, JG Verselis, SJ Murgo, K Sze, C Gotthardt, S Wolanski, A Alexander, WJ Kumar, A Holden, SA Chafai-Fadela, K Ram, S Menon, KE AF Shapiro, Geoffrey Mier, James Walter Hilton, John Frederick Gandhi, Leena Chau, Nicole G. Bullock, Andrea J. Supko, Jeffrey G. Verselis, Sigitas Jonas Murgo, Kayla Sze, Cameron Gotthardt, Susan Wolanski, Andrew Alexander, W. James Kumar, Ashok Holden, Sylvia Adell Chafai-Fadela, Karima Ram, Siya Menon, Krishna E. TI A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Dept Med, Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Cellceutix Corp, Beverly, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS2613 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904691 ER PT J AU Shapiro, G LoRusso, P Vaishampayan, UN Kittaneh, M Hilton, JF Cleary, JM Velastegui, K Xuan, DW Hua, S Shazer, RL Borghaei, H AF Shapiro, Geoffrey LoRusso, Patricia Vaishampayan, Ulka N. Kittaneh, Muaiad Hilton, John Frederick Cleary, James M. Velastegui, Karen Xuan, Dawei Hua, Steven Shazer, Ronald L. Borghaei, Hossein TI First-in-human, dose-escalation, safety, and PK study of a novel 5T4-ADC in patients with advanced solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Yale Canc Ctr, New Haven, CT USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Karmanos Canc Inst, Detroit, MI USA. Univ Ottawa, Ottawa, ON, Canada. Pfizer, La Jolla, CA USA. Pfizer Inc, Clin Pharmacol, Biotechnol Clin Dev, La Jolla, CA USA. Pfizer, San Diego, CA USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS2603 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904681 ER PT J AU Sharma, M Gray, E Mehrotra, S Wu, KH Barry, WT Hudis, CA Winer, EP Lyss, AP Toppmeyer, D Moreno-Aspitia, A Rugo, HS Ratain, MJ Gobburu, J AF Sharma, Manish Gray, Elizabeth Mehrotra, Shailly Wu, Kehua Barry, William Thomas Hudis, Clifford A. Winer, Eric P. Lyss, Alan P. Toppmeyer, Deborah Moreno-Aspitia, Alvaro Rugo, Hope S. Ratain, Mark J. Gobburu, Jogarao TI A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Chicago Med, Chicago, IL USA. Univ Maryland, Baltimore, MD 21201 USA. Peking Univ, Beijing 100871, Peoples R China. Dana Farber Canc Inst, Boston, MA 02115 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Heartland Canc Res NCORP, St Louis, MO USA. Canc Inst New Jersey, New Brunswick, NJ USA. Mayo Clin, Jacksonville, FL 32224 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Chicago, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1041 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900124 ER PT J AU Shaw, AT Bauer, TM Felip, E Besse, B James, LP Clancy, JS Mugundu, G Martini, JF Abbattista, A Solomon, BJ AF Shaw, Alice Tsang Bauer, Todd Michael Felip, Enriqueta Besse, Benjamin James, Leonard Philip Clancy, Jill S. Mugundu, Ganesh Martini, Jean-Francois Abbattista, Antonello Solomon, Benjamin J. TI Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+NSCLC. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. Vall dHebron Univ Hosp, Barcelona, Spain. Gustave Roussy, Villejuif, France. Pfizer, New York, NY USA. Invent Clin, Princeton, NJ USA. Pfizer, San Diego, CA USA. Pfizer, Milan, Italy. Peter MacCallum Canc Ctr, East Melbourne, Australia. NR 0 TC 14 Z9 14 U1 2 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8018 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901731 ER PT J AU Shore, ND Concepcion, RS Smith, MR Pieczonka, CM Nguyen, S Belkoff, LH Firlit, R McCoy, C DeVries, T Freedland, SJ AF Shore, Neal D. Concepcion, Raoul S. Smith, Matthew Raymond Pieczonka, Christopher Michael Son Nguyen Belkoff, Laurence H. Firlit, Robert McCoy, Candice DeVries, Todd Freedland, Stephen J. TI PREDICT, a study evaluating baseline (BL) disease characteristics predictive of a positive imaging study for distant metastases in patients (pts) with castration-resistant prostate cancer (CRPC): Preliminary data. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Carolina Urol Res Ctr, Myrtle Beach, SC USA. Urol Associates PC, Nashville, TN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Associated Med Profess, Syracuse, NY USA. Kansas City Urol Care, Kansas City, KS USA. Urol Consultants Southeastern Penn, Bala Cynwyd, PA USA. Dendreon Corp, Seattle, WA USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e16028 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903203 ER PT J AU Shu, CA Pike, MC Jotwani, AR Friebel, TM Soslow, RA Levine, DA Robson, ME Konner, JA Blum, JL Neuhausen, SL Garber, JE Daly, MB Isaacs, C Eeles, RA Ganz, PA Aghajanian, C Offit, K Domchek, SM Rebbeck, TR Kauff, ND AF Shu, Catherine A. Pike, Malcolm C. Jotwani, Anjali R. Friebel, Tara M. Soslow, Robert A. Levine, Douglas A. Robson, Mark E. Konner, Jason A. Blum, Joanne Lorraine Neuhausen, Susan L. Garber, Judy Ellen Daly, Mary Beryl Isaacs, Claudine Eeles, Ros A. Ganz, Patricia A. Aghajanian, Carol Offit, Kenneth Domchek, Susan M. Rebbeck, Timothy R. Kauff, Noah D. TI Uterine cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations (BRCA plus ): A multicenter, prospective study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Penn, Philadelphia, PA 19104 USA. Texas Onc PA, Dallas, TX USA. City Hope Natl Med Ctr, Duarte, CA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA. Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England. UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA. Weill Cornell Med Coll, New York, NY USA. Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1504 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900371 ER PT J AU Shusterman, S London, WB Hank, JA Parisi, MT Shulkin, BL Servaes, SEN Naranjo, A Shimada, H Gan, J Gillies, S Maris, JM Park, JR Sondel, PM AF Shusterman, Suzanne London, Wendy B. Hank, Jacquelyn A. Parisi, Marguerite T. Shulkin, Barry L. Servaes, Sabah-E-Noor Naranjo, Arlene Shimada, Hiroyuki Gan, Jacek Gillies, Stephen Maris, John M. Park, Julie R. Sondel, Paul M. TI A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children's Oncology Group study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Childrens Hosp Canc Ctr, Boston, MA USA. Univ Wisconsin, Madison, WI USA. Seattle Childrens Hosp, Seattle, WA USA. Jude Childrens Res Hosp, Memphis, TN USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. Univ Florida, Childrens Oncol Grp, Stat & Data Ctr, Gainesville, FL USA. Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. Provenance Biopharmaceut Corp, Carlisle, ME USA. Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. Seattle Childrens Hosp, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10017 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900021 ER PT J AU Silverman, LR Fenaux, P Al-Kali, A Baer, MR Sekeres, MA Roboz, GJ Gaidano, G Scott, BL Greenberg, P Platzbecker, U Steensma, DP Kreuzer, KA Godley, LA Collins, R Atallah, EL Azarnia, N Garcia-Manero, G AF Silverman, Lewis R. Fenaux, Pierre Al-Kali, Aref Baer, Maria R. Sekeres, Mikkael A. Roboz, Gail J. Gaidano, Gianluca Scott, Bart L. Greenberg, Peter Platzbecker, Uwe Steensma, David P. Kreuzer, Karl A. Godley, Lucy A. Collins, Robert Atallah, Ehab L. Azarnia, Nozar Garcia-Manero, Guillermo TI Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mt Sinai Med Ctr, New York, NY 10029 USA. Hosp St Louis, Paris, France. Mayo Clin, Rochester, MN USA. Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA. Cleveland Clin, Dept Hematol & Oncol, Leukemia Program, Cleveland, OH 44106 USA. Weill Cornell Med Coll, New York, NY USA. Amedeo Avogadro Univ Eastern Piedmont, Novara, Italy. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Stanford Univ, Stanford, CA 94305 USA. TUD, Univ Hosp Carl Gustav Carus, Dresden, Germany. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Hosp Cologne, Cologne, Germany. Univ Chicago, Chicago, IL 60637 USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Onconova Therapeut Inc, Pennington, NJ USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7092 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901628 ER PT J AU Singh, S Buzzoni, R Carnaghi, C Fazio, N Pavel, ME Wolin, EM Tomasek, J Raderer, M Lahner, H Lam, DH Cauwel, H Valle, JW Delle Fave, G Van Cutsem, E Strosberg, JR Tesselaar, ME Shimada, Y Oh, DY Kulke, MH Yao, JC AF Singh, Simron Buzzoni, Roberto Carnaghi, Carlo Fazio, Nicola Pavel, Marianne E. Wolin, Edward M. Tomasek, Jiri Raderer, Markus Lahner, Harald Lam, Du Hung Cauwel, Helene Valle, Juan W. Delle Fave, Gianfranco Van Cutsem, Eric Strosberg, Jonathan R. Tesselaar, Margot Et Shimada, Yasuhiro Oh, Do-Youn Kulke, Matthew H. Yao, James C. CA RADIANT-4 Study Grp TI Baseline demographics of patients from the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. Fdn IRCCS Ist Nazl Tumori, Milan, Italy. IRCCS Ist Clin Humanitas, Rozzano, Italy. European Inst Oncol, Milan, Italy. Charite Berlin Campus Virchow Klinikum, Berlin, Germany. Univ Kentucky, Markey Canc Ctr, Lexington, KY USA. Masaryk Univ, Fac Med, Masaryk Mem Canc Inst, Brno, Czech Republic. AKH, Univ Klin Innere Med 1, Vienna, Austria. Univ Klinikum Essen, Zentrum Innere Med, Essen, Germany. Novartis Pharmaceut, E Hanover, NJ USA. Novartis Pharma AG, Basel, Switzerland. Univ Manchester, Christie Hosp, Inst Canc Studies, Manchester, Lancs, England. Univ Roma La Sapienza, Azienda Osped St Andrea, Rome, Italy. Univ Hosp Gasthuisberg Leuven, Digest Oncol, Leuven, Belgium. KULeuven, Leuven, Belgium. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Nederlands Kanker Inst Antoni van Leeuwenhoek, Amsterdam, Netherlands. Natl Canc Ctr, Tokyo, Japan. Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15197 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902962 ER PT J AU Siravegna, G Mussolin, B Buscarino, M Corti, G Crisafulli, G Ponzetti, A Cremolini, C Lamba, S Avallone, A Rospo, G Veronese, S Budillon, A Montagut, C Racca, P Corcoran, RB Di Nicolantonio, F Loupakis, F Siena, S Sartore-Bianchi, A Bardelli, A AF Siravegna, Giulia Mussolin, Benedetta Buscarino, Michela Corti, Giorgio Crisafulli, Giovanni Ponzetti, Agostino Cremolini, Chiara Lamba, Simona Avallone, Antonio Rospo, Giuseppe Veronese, Silvio Budillon, Alfredo Montagut, Clara Racca, Patrizia Corcoran, Ryan Bruce Di Nicolantonio, Federica Loupakis, Fotios Siena, Salvatore Sartore-Bianchi, Andrea Bardelli, Alberto TI Raise and decline of KRAS mutant clones in colorectal cancers (CRCs) treated with multiple rounds of anti-EGFR antibodies. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Fdn Piemonte Oncol IRCCS, Ist Candiolo, Candiolo, Italy. IRCCS, Candiolo Canc Inst FPO, Turin, Italy. San Giovanni Battista Hosp, Montalto Dora, Italy. Azienda Osped Univ Pisana, Ist Toscano Tumori, Pisa, Italy. Inst Canc Res & Treatment, IRCC, Candiolo, Italy. Natl Canc Inst Naples, Naples, Italy. Osped Niguarda Ca Granda, Niguarda Canc Ctr, Milan, Italy. Hosp del Mar, Dept Med Oncol, Res Inst, Canc Res Program,IMIM, Barcelona, Spain. Hosp del Mar, Dept Med Oncol, Barcelona, Spain. San Giovanni Battista Hosp, Turin, Italy. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Turin, Candiolo, Italy. RI Di Nicolantonio, Federica/A-2503-2011 OI Di Nicolantonio, Federica/0000-0001-9618-2010 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 11073 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900331 ER PT J AU Smith, MR Parker, C Tombal, BF Miller, K Saad, F Fang, F Zhang, A Kornacker, M Higano, CS AF Smith, Matthew Raymond Parker, Chris Tombal, Bertrand F. Miller, Kurt Saad, Fred Fang, Fang Zhang, Amily Kornacker, Martin Higano, Celestia S. TI ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Royal Marsden NHS Fdn Trust, Sutton, Surrey, England. Inst Canc Res, Sutton, Surrey, England. Clin Univ St Luc, B-1200 Brussels, Belgium. Charite, D-13353 Berlin, Germany. Univ Montreal, Montreal, PQ, Canada. Bayer HealthCare, Whippany, NJ USA. Bayer Pharma AG, Berlin, Germany. Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS5082 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904791 ER PT J AU Somaiah, N Block, MS Kim, JW Shapiro, G Hwu, P Eder, JP Jones, RL Gnjatic, S Lu, HL Hsu, FJ Pollack, S AF Somaiah, Neeta Block, Matthew Stephen Kim, Joseph W. Shapiro, Geoffrey Hwu, Patrick Eder, Joseph Paul Jones, Robin Lewis Gnjatic, Sacha Lu, Hailing Hsu, Frank James Pollack, Seth TI Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA. Mayo Clin, Rochester, MN USA. Yale Univ, Sch Med, New Haven, CT USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA. Seattle Canc Care Alliance, Seattle, WA USA. Icahn Sch Med Mt Sinai, New York, NY 10029 USA. Immune Design, Seattle, WA USA. FHCRC, Seattle, WA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3021 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900655 ER PT J AU Sonpavde, G Pond, GR Rosenberg, JE Bajorin, DF Regazzi, AM Mullane, SA Niegisch, G Albers, P Necchi, A di Lorenzo, G Fougeray, R Ko, YJ Rozzi, A Matsumoto, K Lee, JL Kitamura, H Kume, H Milowsky, MI Choueiri, TK Bellmunt, J AF Sonpavde, Guru Pond, Gregory Russell Rosenberg, Jonathan E. Bajorin, Dean F. Regazzi, Ashley Marie Mullane, Stephanie A. Niegisch, Guenter Albers, Peter Necchi, Andrea di Lorenzo, Giuseppe Fougeray, Ronan Ko, Yoo-Joung Rozzi, Antonio Matsumoto, Kazumasa Lee, Jae-Lyun Kitamura, Hiroshi Kume, Haruki Milowsky, Matthew I. Choueiri, Toni K. Bellmunt, Joaquim TI Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. Ontario Clin Oncol Grp OCOG, Hamilton, ON, Canada. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Bladder Canc Ctr, Brigham & Womens Canc Ctr, Boston, MA 02115 USA. Univ Dusseldorf, Dept Urol, Dusseldorf, Germany. Ist Nazl Tumori Milan, Milan, MI, Italy. Univ Naples Federico II, Med Oncol Unit, Dept Clin Med, Naples, Italy. Inst Rech Pierre Fabre, Boulogne, France. Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada. Ist Neurotraumatol Italiano Grottaferrata, Clin Oncol Unit, Grottaferrata, Italy. Kitasato Inst, Dept Urol, Sch Med, Sagamihara, Kanagawa, Japan. Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea. Sapporo Med Univ, Chuo Ku, Sapporo, Hokkaido, Japan. Univ Tokyo, Fac Med, Dept Urol, Tokyo 113, Japan. Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4527 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900995 ER PT J AU Spigel, DR Reckamp, KL Rizvi, NA Poddubskaya, E West, HJ Eberhardt, WEE Baas, P Antonia, SJ Pluzanski, A Vokes, EE Holgado, E Waterhouse, DM Ready, N Gainor, JF Aren, OR Horn, L Paz-Ares, L Baudelet, C Lestini, BJ Brahmer, JR AF Spigel, David R. Reckamp, Karen L. Rizvi, Naiyer A. Poddubskaya, Elena West, Howard Jack Eberhardt, Wilfried Ernst Erich Baas, Paul Antonia, Scott Joseph Pluzanski, Adam Vokes, Everett E. Holgado, Esther Waterhouse, David Michael Ready, Neal Gainor, Justin F. Aren, Osvaldo Rudy Horn, Leora Paz-Ares, Luis Baudelet, Christine Lestini, Brian Joseph Brahmer, Julie R. TI A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NN Blokhin Russian Canc Res Ctr, Moscow, Russia. Swedish Canc Inst, Seattle, WA USA. Univ Hosp Essen, Dept Med Oncol, West German Canc Ctr, Ruhrlandklin, Essen, Germany. Univ Duisburg Essen, Essen, Germany. Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands. Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. Inst Marii Sklodowskiej Curie, Ctr Onkol, Warsaw, Poland. Univ Chicago, Med Ctr, Chicago, IL 60637 USA. Hosp Madrid, Norte Sanchinarro, Spain. Oncol Hematol Care, Blue Ash, OH USA. Duke Univ, Med Ctr, Durham, NC USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Ctr Int Estudios Clin, Santiago, Chile. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Hosp Univ Virgen Del Rocio, Seville, Spain. Bristol Myers Squibb Co, Princeton, NJ USA. Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. NR 0 TC 8 Z9 8 U1 0 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8009 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901722 ER PT J AU Starodub, A Ocean, AJ Messersmith, WA Picozzi, VJ Guarino, MJ Bardia, A Thomas, SS Berlin, J Shah, MA Maliakal, PP Wegener, WA Sharkey, RM Wilhelm, F Goldenberg, DM AF Starodub, Alexander Ocean, Allyson J. Messersmith, Wells A. Picozzi, Vincent J. Guarino, Michael J. Bardia, Aditya Thomas, Sajeve Samuel Berlin, Jordan Shah, Manish A. Maliakal, Pius P. Wegener, William A. Sharkey, Robert M. Wilhelm, Francois Goldenberg, David M. TI Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Indiana Univ Hlth, Goshen Ctr Canc Care, Goshen, IN USA. Weill Cornell Med Coll, New York, NY USA. Univ Colorado, Ctr Canc, Aurora, CO USA. Virginia Mason Med Ctr, Seattle, WA 98101 USA. Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Univ Florida, Windermere, FL USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Immunomedics Inc, Morris Plains, NJ USA. Garden State Canc Ctr, Ctr Mol Med & Immunol, Morris Plains, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3546 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900765 ER PT J AU Steinestel, J Luedeke, M Arndt, A Schnoeller, T Lennerz, JK Maier, C Cronauer, M Steinestel, K Boegemann, M Schrader, AJ AF Steinestel, Julie Luedeke, Manuel Arndt, Annette Schnoeller, Thomas Lennerz, Jochen K. Maier, Christiane Cronauer, Marcus Steinestel, Konrad Boegemann, Martin Schrader, Andres Jan TI Detecting predictive androgen receptor modifications in circulating prostate cancer cells. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Hosp Muenster, Urol Clin, Munster, Germany. Univ Hosp Ulm, Urol Clin, Ulm, Germany. Bundeswehrkrankenhaus Ulm, Inst Pathol & Mol Pathol, Ulm, Germany. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Ulm, Dept Urol, Sch Med, D-89069 Ulm, Germany. Univ Munster, Gerhard Domagk Inst Pathol, D-48149 Munster, Germany. Univ Munster, Dept Urol, D-48149 Munster, Germany. Univ Munster, Dept Urol, Med Ctr, D-48149 Munster, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5067 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901112 ER PT J AU Stover, DG Selfors, LM Coloff, JL Brugge, JS Winer, EP AF Stover, Daniel G. Selfors, Laura M. Coloff, Jonathan L. Brugge, Joan S. Winer, Eric P. TI Meta-analysis of breast cancer expression data using published gene signatures to reveal key cellular processes implicated in chemosensitivity and resistance. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Brookline, MA USA. Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 509 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901116 ER PT J AU Strickland, K Howitt, BE Rodig, SJ Ritterhouse, L D'Andrea, AD Matulonis, U Konstantinopoulos, P AF Strickland, Kyle Howitt, Brooke E. Rodig, Scott J. Ritterhouse, Lauren D'Andrea, Alan D. Matulonis, Ursula Konstantinopoulos, Panagiotis TI Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematopathol,Dept Pathol, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5512 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901171 ER PT J AU Sullivan, RJ O'Neill, VJ Brinkmann, K Enderle, D Koestler, T Spiel, A Emenegger, J Noerholm, M Skog, J Berking, C Flaherty, K AF Sullivan, Ryan J. O'Neill, Vincent J. Brinkmann, Kay Enderle, Daniel Koestler, Tina Spiel, Alexandra Emenegger, Jennifer Noerholm, Mikkel Skog, Johan Berking, Carola Flaherty, Keith TI Plasma-based monitoring of BRAF mutations during therapy for malignant melanoma (MM) using combined exosomal RNA and cell-free DNA analysis SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. Exosome Diagnost, Cambridge, MA USA. Exosome Diagnost, Munich, Germany. Exosome Diagnost GmbH, Martinsried, Germany. Exosome Diagnost, New York, NY USA. Univ Munich, Munich, Germany. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9017 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901927 ER PT J AU Sullivan, RJ Weber, JS Patel, SP Dummer, R Miller, WH Cosgrove, D Carlino, MS Tan, DSW Lebbe, C Cipani, T Elez, E Maacke, H Nikolopoulos, P Aout, M De Parseval, LA Ascierto, PA AF Sullivan, Ryan J. Weber, Jeffrey S. Patel, Sapna Pradyuman Dummer, Reinhard Miller, Wilson H. Cosgrove, David Carlino, Matteo S. Tan, Daniel Shao-Weng Lebbe, Celeste Cipani, Tiziana Elez, Elena Maacke, Heiko Nikolopoulos, Panagiotis Aout, Mounir De Parseval, Laure A. Ascierto, Paolo Antonio TI A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ Zurich Hosp, CH-8091 Zurich, Switzerland. McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada. Sidney Kimmel Comp Canc Ctr, Baltimore, MD USA. Westmead Hosp, Baulkham Hills, Australia. Natl Canc Ctr Singapore, Singapore, Singapore. Hop St Louis, Assistance Publ Hop Paris, Dept Dermatol, Paris, France. Osped Niguarda Ca Granda, Milan, Italy. VHIO, Barcelona, Spain. Novartis, Holm, Germany. Novartis Pharma AG, Basel, Switzerland. Ist Nazl Tumori IRCCS, Naples, Italy. NR 0 TC 10 Z9 10 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9007 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901917 ER PT J AU Sun, T Du, Z Fei, T Brown, M Lee, GSM Chen, YW Liu, XS Kantoff, PW AF Sun, Tong Du, Zhou Fei, Teng Brown, Myles Lee, Gwo-Shu Mary Chen, Yiwen Liu, Xiaole Shirley Kantoff, Philip W. TI Long non-coding RNA-mediated PTEN regulation in prostate cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e16081 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903251 ER PT J AU Sweeney, C Sartor, AO Vogelzang, NJ Shore, ND Cislo, P Bangerter, K Morris, MJ AF Sweeney, Christopher Sartor, A. Oliver Vogelzang, Nicholas J. Shore, Neal D. Cislo, Paul Bangerter, Keith Morris, Michael J. TI Effect of radium-223 dichloride (Ra-223) on pain from US EAP. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Tulane Canc Ctr, New Orleans, LA USA. Comprehens Canc Ctr Nevada, Las Vegas, NV USA. Carolina Urol Res Ctr, Myrtle Beach, SC USA. Bayer HealthCare, Whippany, NJ USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e16086 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903253 ER PT J AU Sweeney, C Gray, KP Harshman, LC Taplin, ME Pace, AF Dumas, K Supko, JG Zukotynski, KA Bernard, BD Pomerantz, M Elfiky, A Kantoff, PW AF Sweeney, Christopher Gray, Kathryn P. Harshman, Lauren Christine Taplin, Mary-Ellen Pace, Amanda Fredericks Dumas, Kathryn Supko, Jeffrey G. Zukotynski, Katherine A. Bernard, Brandon David Pomerantz, Mark Elfiky, Aymen Kantoff, Philip W. TI Phase 1 study with expansion cohorts of cabozantinib (C) plus abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigator-sponsored study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Stanford Univ, Sch Med, Stanford, CA 94305 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ Toronto, Sunnybrook Hosp, Toronto, ON, Canada. Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5037 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901079 ER PT J AU Tan, DSW Seto, T Leighl, NB Riely, GJ Sequist, LV Felip, E Wolf, J Yang, JCH Matushansky, I Yu, XL Schmitz, SFH Cui, XM Kim, DW AF Tan, Daniel Shao-Weng Seto, Takashi Leighl, Natasha B. Riely, Gregory J. Sequist, Lecia V. Felip, Enriqueta Wolf, Juergen Yang, James Chih-Hsin Matushansky, Igor Yu, Xiaolu Schmitz, Shu-Fang Hsu Cui, Xiaoming Kim, Dong-Wan TI First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Natl Canc Ctr Singapore, Singapore, Singapore. Kyushu Natl Canc Ctr, Fukuoka, Japan. Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Vall dHebron Univ Hosp, Barcelona, Spain. Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany. Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Cologne, Germany. Natl Taiwan Univ Hosp, Taipei, Taiwan. Natl Taiwan Univ, Taipei 10764, Taiwan. Novartis Pharmaceut, E Hanover, NJ USA. China Novartis Inst BioMed Res, Shanghai, Peoples R China. Novartis Pharma AG, Basel, Switzerland. Seoul Natl Univ Hosp, Seoul 110744, South Korea. NR 0 TC 1 Z9 1 U1 2 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8013 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901726 ER PT J AU Taplin, ME Antonarakis, ES Dransfield, DT Ferrante, KJ De Bono, JS AF Taplin, Mary-Ellen Antonarakis, Emmanuel S. Dransfield, Daniel T. Ferrante, Karen J. De Bono, Johann Sebastian TI Androgen receptor modulation optimized for response: Splice variant (ARMOR3-SV)-Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Tokai Pharma, Cambridge, MA USA. Inst Canc Res, Sutton, Surrey, England. Royal Marsden NHS Fdn Trust, Sutton, Surrey, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS5069 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904778 ER PT J AU Taplin, ME Jacobus, SJ Fiorillo, M Ledet, EM Cotogno, P Steinberger, AE Jacene, HA Sartor, O McKay, RR AF Taplin, Mary-Ellen Jacobus, Susanna J. Fiorillo, Matthew Ledet, Elisa M. Cotogno, Patrick Steinberger, Allie E. Jacene, Heather A. Sartor, Oliver McKay, Rana R. TI Clinical practice patterns of Radium-223 (R223) utilization and variables associated with completion of therapy. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Tulane Canc Ctr, New Orleans, LA USA. Tulane Canc Ctr, Off Clin Res, New Orleans, LA USA. Tulane Univ, Sch Med, New Orleans, LA 70112 USA. Dana Farber Canc Inst, Dept Radiol, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e16076 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903246 ER PT J AU Temel, JS Currow, DC Fearon, K Yan, Y Friend, J Abernethy, AP AF Temel, Jennifer S. Currow, David Christopher Fearon, Kenneth Yan, Ying Friend, John Abernethy, Amy Pickar TI Phase III trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Flinders Univ S Australia, Adelaide, SA 5001, Australia. Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland. Helsinn Therapeut US Inc, Bridgewater, NJ USA. Duke Univ, Durham, NC USA. NR 0 TC 3 Z9 3 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9500 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901989 ER PT J AU Ter-Minassian, M Brooks, NV Brais, LK Chan, JA Christiani, DC Lin, XH Gabriel, S Dinet, J Kulke, MH AF Ter-Minassian, Monica Brooks, Nichole V. Brais, Lauren K. Chan, Jennifer A. Christiani, David C. Lin, Xihong Gabriel, Sylvie Dinet, Jerome Kulke, Matthew H. TI Association of progression-free survival with overall survival (OS) in patients (pts) with neuroendocrine tumor (NET) treated with somatostatin analogs SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Ipsen Pharma, Boulougne Billancourt, France. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4090 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900928 ER PT J AU Thompson, JA Motzer, R Molina, AM Choueiri, TK Heath, EI Kollmannsberger, CK Redman, BG Sangha, RS Ernst, DS Pili, R Butturini, A Wiseman, A Trave, F Anand, B Huang, Y Reyno, LM AF Thompson, John A. Motzer, Robert Molina, Ana M. Choueiri, Toni K. Heath, Elisabeth I. Kollmannsberger, Christian K. Redman, Bruce G. Sangha, Randeep S. Ernst, D. Scott Pili, Roberto Butturini, Anna Wiseman, Aya Trave, Fabio Anand, Banmeet Huang, Yao Reyno, Leonard M. TI Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Seattle Canc Care Alliance, Seattle, WA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Weill Cornell Medcl Coll, New York, NY USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. BC Canc Agcy, Vancouver Canc Ctr, Vancouver, BC, Canada. Univ Michigan, Ann Arbor, MI 48109 USA. Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada. London Reg Canc Ctr, London, ON N6A 4L6, Canada. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Agensys, Santa Monica, CA USA. Agensys Inc, Santa Monica, CA USA. NR 0 TC 4 Z9 4 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2503 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900536 ER PT J AU Tolaney, SM Beeram, M Beck, JT Conlin, AK Dees, EC Dickler, MN Helsten, TL Conkling, PR Edenfield, WJ Richards, DA Turner, PK Cai, N Chan, EM Pant, S Becerra, C Kalinsky, K Puhalla, S Rexer, BN Burris, HA Goetz, MP AF Tolaney, Sara M. Beeram, Muralidhar Beck, J. Thaddeus Conlin, Alison Katherine Dees, Elizabeth Claire Dickler, Maura N. Helsten, Teresa L. Conkling, Paul R. Edenfield, William Jeffery Richards, Donald A. Turner, P. Kellie Cai, Na Chan, Edward Michael Pant, Shubham Becerra, Carlos Kalinsky, Kevin Puhalla, Shannon Rexer, Brent Neil Burris, Howard A. Goetz, Matthew P. TI A phase Ib study of abemaciclib with therapies for metastatic breast cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. START Ctr Canc Care, San Antonio, TX USA. Highlands Oncol Grp, Fayetteville, AR USA. Providence Canc Ctr, Oncol & Hematol Care Clin, Portland, OR USA. Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Calif San Diego, La Jolla, CA USA. Virginia Oncol Associates, Norfolk, VA USA. ITOR Greenville Hosp Syst, Clin Res Unit, Greenville, SC USA. Texas Oncol Tyler, Tyler, TX USA. Eli Lilly & Co, Indianapolis, IN 46285 USA. Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Oklahoma Canc Ctr, Oklahoma City, OK USA. Texas Oncol Baylor Sammons Canc Ctr, Dallas, TX USA. Columbia Univ, Med Ctr, New York, NY USA. Univ Pittsburgh, Med Ctr, Womens Canc Program, Magee Womens Hosp UMPC, Pittsburgh, PA USA. Vanderbilt Univ, Med Ctr, Nashville, TN USA. Sarah Cannon Res Inst SCRI, Nashville, TN USA. Mayo Clin, Rochester, MN USA. NR 0 TC 3 Z9 3 U1 1 U2 8 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 522 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901129 ER PT J AU Tolaney, SM Ziehr, DR Guo, H Barry, WT Higgins, MJ Isakoff, SJ Brock, JE Ivanova, E Paweletz, C Demeo, M Ramaiya, NH Overmoyer, B Jain, RK Duda, DG Winer, EP AF Tolaney, Sara M. Ziehr, David R. Guo, Hao Barry, William Thomas Higgins, Michaela Jane Isakoff, Steven J. Brock, Jane E. Ivanova, Elena Paweletz, Cloud Demeo, Michelle Ramaiya, Nikhil H. Overmoyer, Beth Jain, Rakesh K. Duda, Dan G. Winer, Eric P. TI A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Mater Misericordiae Univ Hosp, Dublin, Ireland. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1080 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900240 ER PT J AU Traeger, L McDonnell, TM McCarty, C Greer, JA Temel, JS AF Traeger, Lara McDonnell, Theresa Margaret McCarty, Caitlin Greer, Joseph A. Temel, Jennifer S. TI Patient-reported outcomes of a nurse practitioner-led intervention to enhance chemotherapy symptom management. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e20732 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904328 ER PT J AU Tripathy, D Bardia, A Hurvitz, SA Harbeck, N Colleoni, M Franke, FA Chow, LWC Im, SA Shao, ZM Keyserlingk, JR Soler, LM Horan, M Dhuria, SV Hughes, G Lu, YS AF Tripathy, Debu Bardia, Aditya Hurvitz, Sara A. Harbeck, Nadia Colleoni, Marco Franke, Fabio A. Chow, Louis W. C. Im, Seock-Ah Shao, Zhimin Keyserlingk, John R. Soler, Lidia Mongay Horan, Melissa Dhuria, Shyeilla V. Hughes, Gareth Lu, Yen-Shen TI Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2-advanced breast cancer (aBC): MONALEESA-7. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. UCLA Jonsson Comprehens Ctr, Los Angeles, CA USA. Univ Munich, Breast Ctr, Munich, Germany. Ist Europeo Oncol, Unita Ric Senol Med, Milan, Italy. CACON, Hosp Caridade Ijui, Ijui, Brazil. Org Oncol & Translat Res, Hong Kong, Hong Kong, Peoples R China. Seoul Natl Univ, Coll Med, Seoul, South Korea. Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China. Ville Marie Med Ctr, Montreal, PQ, Canada. Novartis Pharmaceut, E Hanover, NJ USA. Novartis Pharma AG, Basel, Switzerland. Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan. NR 0 TC 1 Z9 1 U1 3 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS625 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904817 ER PT J AU Trippa, L Wen, PY Alexander, BM AF Trippa, Lorenzo Wen, Patrick Y. Alexander, Brian Michael TI Incorporating biomarkers into adaptive clinical trials. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e13009 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902462 ER PT J AU Trudeau, ME Winer, EP Steinberg, JL Liosatos, M Poondru, S Dydo, MN Peterson, AC Gradishar, WJ AF Trudeau, Maureen E. Winer, Eric P. Steinberg, Joyce Leta Liosatos, Maggie Poondru, Srinivasu Dydo, Michael Nicholas Peterson, Amy C. Gradishar, William John TI A phase 2 single-arm study to assess clinical activity, efficacy and safety of enzalutamide (ENZA) with trastuzumab in HER2+AR+ metastatic or locally advanced breast cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. Dana Farber Canc Inst, Boston, MA 02115 USA. Astellas Pharma US Inc, Northbrook, IL USA. Astellas, Northbrook, IL USA. Astellas Pharma Global Dev, Northbrook, IL USA. Astellas, Deerfield, IL USA. Medivation Inc, San Francisco, CA USA. Northwestern Univ, Lurie Comp Canc Ctr, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS640 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904832 ER PT J AU Tung, NM Garber, JE Torous, V Hacker, MR Freeman, GJ Rodig, SJ Poles, E Alexander, BM Lee, LJ Collins, LC Schnitt, SJ AF Tung, Nadine M. Garber, Judy Ellen Torous, Vanda Hacker, Michele R. Freeman, Gordon James Rodig, Scott J. Poles, Emily Alexander, Brian Michael Lee, Larissa Janeen Collins, Laura C. Schnitt, Stuart J. TI Prevalence and predictors of androgen receptor (AR) and programmed death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic triple negative breast cancer (TNBC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Harvard Univ, Brigham & Womens Hosp, Div Hematopathol, Dept Pathol,Med Sch, Boston, MA 02115 USA. Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. Harvard Rad Onc Prog, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1005 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900057 ER PT J AU Tutt, ANJ Kaufman, B Gelber, RD Mc Fadden, E Goessl, CD Viale, G Arahmani, A Fumagalli, D Azim, HA Wu, WT Grocholewicz, A Costantino, JP Rastogi, P Garber, JE Geyer, CE AF Tutt, Andrew Nicholas James Kaufman, Bella Gelber, Richard D. Mc Fadden, Eleanor Goessl, Carsten Dietrich Viale, Giuseppe Arahmani, Amal Fumagalli, Debora Azim, Hatem Abdel Wu, Wenting Grocholewicz, Anna Costantino, Joseph P. Rastogi, Priya Garber, Judy Ellen Geyer, Charles E. TI OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Kings Coll London, Sch Med, London WC2R 2LS, England. Chaim Sheba Med Ctr, Ramat Gan, Israel. Tel Aviv Univ, Sackler Fac Med, Ramat Gan, Israel. Dana Farber Canc Inst, Boston, MA 02115 USA. Frontier Sci, Kingussie, Inverness, Scotland. AstraZeneca, Gaithersburg, MD USA. European Inst Oncol, Div Pathol, Milan, Italy. Breast Int Grp, Brussels, Belgium. Inst Jules Bordet, B-1000 Brussels, Belgium. AstraZeneca, Gaithersburg, MD USA. AstraZeneca, Warsaw, Poland. NRG Oncol, Pittsburgh, PA USA. Univ Pittsburgh, Pittsburgh, PA USA. NRG Oncol, NSABP, Pittsburgh, PA USA. UPMC, Ctr Canc, Pittsburgh, PA USA. Virginia Commonwealth Univ, Massey Canc Ctr, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS1109 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904664 ER PT J AU Van Allen, EM Kryukov, G Bielski, C Samocha, K Fromer, M Seepo, S Gentry, C Neale, B Sweeney, C Garraway, LA Taplin, ME AF Van Allen, Eliezer Mendel Kryukov, Gregory Bielski, Craig Samocha, Kaitlin Fromer, Menachem Seepo, Sara Gentry, Carleen Neale, Benjamin Sweeney, Christopher Garraway, Levi A. Taplin, Mary-Ellen TI Transgenerational genomic effect of chemotherapy exposure in testicular cancer survivors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Broad Inst MIT & Harvard, Cambridge, MA USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1543 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900410 ER PT J AU Van Cutsem, E Benedetti, FM Mizuguchi, H Mayer, RJ Ohtsu, A AF Van Cutsem, Eric Benedetti, Fabio M. Mizuguchi, Hirokazu Mayer, Robert J. Ohtsu, Atsushi CA RECOURSE Study Grp TI TAS-102 vs placebo (PBO) in patients (pts) >= 65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the RECOURSE trial SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Hosp Leuven, Leuven, Belgium. Taiho Oncol Inc, Princeton, NJ USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3595 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900814 ER PT J AU Van Loon, K Zhang, L Creasman, JM Choti, MA Yao, JC Kulke, MH Nakakura, EK Bloomston, M Benson, A Shah, MH Strosberg, JR Zornosa, CC Bobiak, S Bergsland, EK AF Van Loon, Katherine Zhang, Li Creasman, Jennifer M. Choti, Michael A. Yao, James C. Kulke, Matthew H. Nakakura, Eric K. Bloomston, Mark Benson, Al Bowen Shah, Manisha H. Strosberg, Jonathan R. Zornosa, Carrie C. Bobiak, Sarah Bergsland, Emily K. TI Recurrence following surgical resection of gastroenteropancreatic neuroendocrine tumors (NETs): An analysis from the NCCN oncology outcomes database SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. UC San Francisco, San Francisco, CA USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Univ Texas SW Med Ctr Dallas, Dept GI Med Oncol, Dallas, TX 75390 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA. Richard J Solove Res Inst, Columbus, OH USA. Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Natl Comp Canc Network, Ft Washington, MD USA. Natl Comprehens Canc Network, Ft Washington, MD USA. UC San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4107 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900945 ER PT J AU VanDusen, H Traeger, L Fishbein, JN Keenan, T Greer, JA Pirl, WF Jackson, VA Eusebio, J Gallagher, ER Graubert, TA Peppercorn, JM Spitzer, TR Ballen, KK McAfee, SL Dey, B Chen, YB Temel, JS El-Jawahri, A AF VanDusen, Harry Traeger, Lara Fishbein, Joel Nathan Keenan, Tanya Greer, Joseph A. Pirl, William F. Jackson, Vicki A. Eusebio, Justin Gallagher, Emily R. Graubert, Timothy A. Peppercorn, Jeffrey M. Spitzer, Thomas R. Ballen, Karen K. McAfee, Steven L. Dey, Bimalangshu Chen, Yi-Bin Albert Temel, Jennifer S. El-Jawahri, Areej TI Psychological distress during hospitalization for hematopoietic stem cell transplantation to predict lower quality of life and high post-traumatic stress disorder symptoms at 6 months post-transplant. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Massachusetts Gen Hosp, Brookline, MA USA. Washington Univ, St Louis, MO USA. Duke Canc Inst, Durham, NC USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. Massachusetts Gen Hosp, Needham, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9557 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902052 ER PT J AU Varga, A Piha-Paul, SA Ott, PA Mehnert, JM Berton-Rigaud, D Johnson, EA Cheng, JD Yuan, S Rubin, EH Matei, DE AF Varga, Andrea Piha-Paul, Sarina Anne Ott, Patrick Alexander Mehnert, Janice M. Berton-Rigaud, Dominique Johnson, Elizabeth A. Cheng, Jonathan D. Yuan, Sammy Rubin, Eric H. Matei, Daniela E. TI Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Inst Gustave Roussy, Villejuif, France. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Rutgers Canc Inst New Jersey, New Brunswick, NJ USA. ICO Ctr Rene Gauducheau, St Herblain, France. Merck & Co Inc, Kenilworth, NJ USA. Indiana Univ, Indianapolis, IN 46204 USA. NR 0 TC 13 Z9 13 U1 1 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 5510 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901169 ER PT J AU Visvanathan, K Fackler, MJ Zhang, Z Lopez-Bujanda, Z Jeter, S Sokoll, LJ Cope, L Umbricht, C Euhus, D Carpenter, JT Storniolo, AM Nanda, R Lin, NU Carey, LA Ingle, JN Sukumar, S Wolff, AC AF Visvanathan, Kala Fackler, Mary Jo Zhang, Zhe Lopez-Bujanda, Zoila Jeter, Stacie Sokoll, Lori J. Cope, Leslie Umbricht, Christopher Euhus, David Carpenter, John T. Storniolo, Anna Maria Nanda, Rita Lin, Nancy U. Carey, Lisa A. Ingle, James N. Sukumar, Saraswati Wolff, Antonio C. TI DNA methylation in serum as an independent marker of outcome and treatment response in TBCRC 005: A prospective study in metastatic breast cancer (MBC) patients. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA. Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Johns Hopkins, Baltimore, MD USA. Univ Alabama Birmingham, Birmingham, AL USA. Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA. Univ Chicago, Chicago, IL 60637 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ N Carolina, Chapel Hill, NC USA. Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 518 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901125 ER PT J AU Wagner, AJ Banerji, U Mahipal, A Somaiah, N Hirsch, HA Fancourt, C Levonas, A Lam, R Meister, A Kemp, RK Knox, C Rose, S Hong, DS AF Wagner, Andrew J. Banerji, Udai Mahipal, Amit Somaiah, Neeta Hirsch, Heather Anne Fancourt, Craig Levonas, Amy Lam, Raymond Meister, Amy Kemp, Ramon Karmel Knox, Clayton Rose, Shelonitda Hong, David S. TI A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Inst Canc Res, London SW3 6JB, England. Royal Marsden NHS Fdn Trust, London, England. H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA. Merck & Co Inc, Kenilworth, NJ USA. Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA. NR 0 TC 3 Z9 3 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 10564 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900204 ER PT J AU Wainberg, ZA Shapiro, G Curigliano, G Leong, S Kristeleit, RS Maqueda, MA Britten, CD Milella, M Middleton, MR Olszanski, AJ Vaishampayan, UN Lopez-Martin, JA Gelmon, KA Brega, N Pierce, KJ Perea, R Houk, BE Pathan, N Gollerkeri, A Razak, ARA AF Wainberg, Zev A. Shapiro, Geoffrey Curigliano, Giuseppe Leong, Stephen Kristeleit, Rebecca Sophie Maqueda, Maria Alsina Britten, Carolyn D. Milella, Michele Middleton, Mark R. Olszanski, Anthony J. Vaishampayan, Ulka N. Lopez-Martin, Jose A. Gelmon, Karen A. Brega, Nicoletta Pierce, Kristen J. Perea, Rachelle Houk, Brett Edward Pathan, Nuzhat Gollerkeri, Ashwin Razak, Albiruni R. A. TI Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Ist Europeo Oncol, Milan, Italy. Univ Colorado, Ctr Canc, Aurora, CO USA. UCL, Inst Canc, London, England. Hosp Valle De Hebron, Barcelona, Spain. Med Univ S Carolina, Charleston, SC 29425 USA. Regina Elena Inst Canc Res, Med Oncol A, Rome, Italy. Oxford NIHR Biomed Res Ctr, Oxford, England. Temple Hlth, Fox Chase Canc Ctr, Philadelphia, PA USA. Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. Hosp 12 Octubre, E-28041 Madrid, Spain. British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. Pfizer Italia, Milan, Italy. Pfizer Oncol, Groton, CT USA. Pfizer Worldwide Res & Dev, San Diego, CA USA. Pfizer Inc, Carlsbad, CA USA. Pfizer, San Diego, CA USA. Pfizer BioTherapeut, Cambridge, MA USA. Princess Margaret Canc Ctr, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2590 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900623 ER PT J AU Wanebo, HJ Liss, A Bowen, W AF Wanebo, Harold J. Liss, Andrew Bowen, Wayne TI Effect of C6Ceramide on chemotoxicity of gemcitabine against chemoresistant pancreatic cell lines. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Landmark Med Ctr, Bristol, RI USA. Massachusets Gen Hosp, Boston, MA USA. Brown Univ, Providence, RI 02912 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e15286 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903041 ER PT J AU Wang, EH Corso, CD Park, HSM Chen, AB Kim, AW Wilson, LD Decker, RH Yu, JB AF Wang, Elyn H. Corso, Christopher D. Park, Henry Soo-Min Chen, Aileen B. Kim, Anthony W. Wilson, Lynn D. Decker, Roy H. Yu, James B. TI Association between radiation dose and outcomes with postoperative radiotherapy for N0-N1 non-small-cell-lung cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA. Yale New Haven Med Ctr, New Haven, CT 06504 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Yale Univ, Sch Med, Dept Surg, Thorac Surg Sect, New Haven, CT 06510 USA. Yale Univ, Sch Med, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 7538 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901668 ER PT J AU Wargo, JA Lawrence, DP Cooper, ZA Frederick, DT Giobbie-Hurder, A Piris, A Rubin, KM Fadden, R Reuben, A Starker, L Flaherty, K Sharpe, A Sullivan, RJ AF Wargo, Jennifer Ann Lawrence, Donald P. Cooper, Zachary A. Frederick, Dennie T. Giobbie-Hurder, Anita Piris, Adriano Rubin, Krista M. Fadden, Riley Reuben, Alexandre Starker, Lee Flaherty, Keith Sharpe, Arlene Sullivan, Ryan J. TI A phase II study of combined therapy with vemurafenib (vem) and high-dose interleukin-2 (aldesleukin; HD IL-2) in patients with metastatic melanoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e20074 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904089 ER PT J AU Warren, LE Chen, MH Denham, JW Steigler, A Renshaw, AA Loffredo, MJ Kantoff, PW D'Amico, AV AF Warren, Laura Elizabeth Chen, Ming-Hui Denham, James William Steigler, Allison Renshaw, Andrew A. Loffredo, Marian J. Kantoff, Philip W. D'Amico, Anthony Victor TI Gleason grade 5 and the risk of death from prostate cancer following radiation with or without 6 months of conventional androgen deprivation therapy. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Radiat Oncol Program, Boston, MA 2300 USA. Univ Connecticut, Storrs, CT USA. Calvary Mater Newcastle, Waratah, NSW 02115, Australia. Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 02115, Australia. Baptist Hosp Miami, Miami, FL USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e16099 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903264 ER PT J AU Watters, JW Dickson, MA Schwartz, GK Le Cesne, A Bahleda, R Wagner, AJ Choy, E De Jonge, MJ Light, M Jung, J Lee, JS Mace, S AF Watters, James Wilson Dickson, Mark Andrew Schwartz, Gary K. Le Cesne, Axel Bahleda, Rastislav Wagner, Andrew J. Choy, Edwin De Jonge, Maja J. Light, Madelyn Jung, Joonil Lee, Joon Sang Mace, Sandrine TI TP53 mutations emerge in circulating cell-free DNA obtained from patients undergoing treatment with the HDM2 antagonist SAR405838. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Sanofi, Cambridge, MA USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Columbia Univ Med Ctr, New York, NY USA. Inst Gustave Roussy, Villejuif, France. Inst Gustave Roussy, Drug Dev Dept, Villejuif, France. Dana Farber Canc Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands. Sanofi Oncol, Cambridge, MA USA. Sanofi Oncol, Vitry Sur Seine, France. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2515 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900548 ER PT J AU Wheeler, HE Travis, LB Budnick, A Feldman, DR Einhorn, LH Hamilton, RJ Vaughn, DJ Beard, C Fung, C Johnson, E Moore, MJ Sahasrabudhe, DM Fossa, SD Sesso, HD Dolan, ME Frisina, RD AF Wheeler, Heather E. Travis, Lois B. Budnick, Amy Feldman, Darren Richard Einhorn, Lawrence H. Hamilton, Robert James Vaughn, David J. Beard, Clair Fung, Chunkit Johnson, Eileen Moore, Malcolm J. Sahasrabudhe, Deepak M. Fossa, Sophie D. Sesso, Howard D. Dolan, M. Eileen Frisina, Robert D. CA Platinum Study Grp TI Comprehensive characterization of cisplatin-related hearing loss in US and Canadian Testicular Cancer Survivors (TCS). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA. Univ Rochester, Sch Med & Dent, Rochester, NY USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Indiana Univ Sch Med, Indianapolis, IN 46202 USA. Univ Hlth Network, Toronto, ON, Canada. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA. Princess Margaret Canc Ctr, Toronto, ON, Canada. Univ Rochester, Wilmot Canc Ctr, Rochester, NY USA. Oslo Univ Hosp, Oslo, Norway. Univ Oslo, Oslo, Norway. Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA USA. Univ Chicago, Chicago, IL 60637 USA. Univ S Florida, Tampa, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9570 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902065 ER PT J AU Williams, SG Davis, ID Sweeney, C Stockler, MR Martin, AJ Marchesin, V Deignan, O McDermott, R Long, AP Roncolato, FT Yip, S Hague, W Tu, E Coskinas, X Nguyen, PL AF Williams, Scott G. Davis, Ian D. Sweeney, Christopher Stockler, Martin R. Martin, Andrew James Marchesin, Vittorio Deignan, Olwyn McDermott, Ray Long, Anne Poh Roncolato, Felicia T. Yip, Sonia Hague, Wendy Tu, Emily Coskinas, Xanthi Nguyen, Paul Linh TI Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Peter MacCallum Canc Ctr, East Melbourne, Australia. Monash Univ, Eastern Hlth Clin Sch, Box Hill, Vic, Australia. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia. Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia. ICORG, Dublin, Ireland. Royal Perth Hosp, Willetton, WA, Australia. NHMRC Clin Trials Ctr, Camperdown, NSW, Australia. Sydney Catalyst Translat Canc Res Ctr, Sydney, NSW, Australia. NHMRC Clin Trials Ctr, Sydney, NSW, Australia. Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. RI Stockler, Martin/N-3859-2016 OI Stockler, Martin/0000-0003-3793-8724 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS5078 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904787 ER PT J AU Winkfield, KM Osuagwu, C Powell, E Freeman, E Sprague-Martinez, L AF Winkfield, Karen Marie Osuagwu, Chidinma Powell, Elizabeth Freeman, Elmer Sprague-Martinez, Linda TI A multi-level community engaged study exploring barriers to cancer care and clinical trial participation among black Bostonians. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. CCHERS Inc, Boston, MA USA. Boston Univ, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e17536 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903509 ER PT J AU Winton, EF Devos, T Oh, ST Platzbecker, U Wadleigh, M Jun, S Lee, P Deng, W Gupta, V AF Winton, Elliott F. Devos, Timothy Oh, Stephen T. Platzbecker, Uwe Wadleigh, Martha Jun, Susie Lee, Peter Deng, Wei Gupta, Vikas TI Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Emory Univ, Sch Med, Atlanta, GA USA. Univ Ziekenhuizen Leuven UZ Leuven, Leuven, Belgium. Washington Univ, St Louis, MO USA. TUD, Univ Hosp Carl Gustav Carus, Dresden, Germany. Dana Farber Canc Inst, Boston, MA 02115 USA. Gilead Sci Inc, Foster City, CA USA. Princess Margaret Canc Ctr, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS7101 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904844 ER PT J AU Wolchok, JD Hamid, O Ribas, A Robert, C Kefford, R Hwu, WJ Weber, JS Joshua, AM Gangadhar, TC Dronca, RS Daud, A Patnaik, A Joseph, RW Zarour, HM Li, XN Xue, DH Ebbinghaus, S Kang, SP Perrone, AM Hodi, FS AF Wolchok, Jedd D. Hamid, Omid Ribas, Antoni Robert, Caroline Kefford, Richard Hwu, Wen-Jen Weber, Jeffrey S. Joshua, Anthony M. Gangadhar, Tara C. Dronca, Roxana Stefania Daud, Adil Patnaik, Amita Joseph, Richard Wayne Zarour, Hassane M. Li, Xiaoyun Nicole Xue, Dahai Ebbinghaus, Scot Kang, Soonmo Peter Perrone, Andrea Marie Hodi, F. Stephen TI Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Angeles Clin & Res Inst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. Gustave Roussy, Villejuif, France. Macquarie Univ, Sydney, NSW 2109, Australia. Westmead Hosp, Sydney, NSW, Australia. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Princess Margaret Canc Ctr, Toronto, ON, Canada. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Mayo Clin, Rochester, MN USA. UC San Francisco, San Francisco, CA USA. START, San Antonio, TX USA. Mayo Clin, Jacksonville, FL 32224 USA. Univ Pittsburgh, Pittsburgh, PA USA. Merck & Co Inc, Kenilworth, NJ USA. Merck & Co Inc, West Point, PA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 3000 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900634 ER PT J AU Wong, SM Freedman, RA Stamell, E Sagara, Y Brock, JE DeSantis, S Golshan, M AF Wong, Stephanie M. Freedman, Rachel A. Stamell, Emily Sagara, Yasuaki Brock, Jane E. DeSantis, Stephen Golshan, Mehra TI Risk of axillary node metastasis in Paget disease with invasive ductal carcinoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. Dana Farber Canc Inst, Brookline, MA USA. Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 1054 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900177 ER PT J AU Wong, YN Epstein, AJ Mitra, N Vachani, A Hin, S Yang, L Smith-McLallen, A Armstrong, K Groeneveld, PW AF Wong, Yu-Ning Epstein, Andrew J. Mitra, Nandita Vachani, Anil Hin, Sakhena Yang, Lin Smith-McLallen, Aaron Armstrong, Katrina Groeneveld, Peter W. TI Impact of age on the associations between genomic testing in breast cancer (BrCA) and chemotherapy (chemo) use and costs SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Philadelphia, PA 19104 USA. Independence Blue Cross, Philadelphia, PA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6528 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901443 ER PT J AU Wright, AA Keating, NL Ayanian, J Chrischilles, EA Kahn, KL Ritchie, C Earle, C Landrum, MB AF Wright, Alexi A. Keating, Nancy Lynn Ayanian, John Chrischilles, Elizabeth A. Kahn, Katherine Leslie Ritchie, Christine Earle, Craig Landrum, Mary Beth TI Family perspectives on aggressive cancer care near the end of life SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Iowa, Coll Publ Hlth, Iowa City, IA USA. Univ Calif Los Angeles, David Geffen Sch Medcn, Los Angeles, CA USA. Univ Calif, Oakland, CA USA. Inst Clin Evaluat Sci, Toronto, ON, Canada. Harvard Univ, Sch Med, Dept Healh Care Policy, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6517 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901432 ER PT J AU Yabroff, KR Dowling, E Guy, G Banegas, M McNeel, TS Davidoff, AJ Chawla, N Hartigan, DB Han, XS Kent, EE Li, CY Virgo, KS Rodriguez, J de Moor, J Zheng, ZY Jemal, A Ekwueme, DU AF Yabroff, K. Robin Dowling, Emily Guy, Gery Banegas, Matthew McNeel, Timothy S. Davidoff, Amy J. Chawla, Neetu Hartigan, Danielle Blanch Han, Xuesong Kent, Erin E. Li, Chunyu Virgo, Katherine S. Rodriguez, Juan de Moor, Janet Zheng, Zhiyuan Jemal, Ahmedin Ekwueme, Donatus U. TI Financial hardship associated with cancer in the United States SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 NCI, Rockville, MD USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. IMS, Rockville, MD USA. Yale Univ, Sch Publ Hlth, New Haven, CT USA. Kaiser Permanente No Calif, Oakland, CA USA. Bentley Univ, Saugus, MA USA. Amer Canc Soc, Atlanta, GA 30329 USA. Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6608 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901522 ER PT J AU Yanagita, M Paweletz, C O'Connell, A Jackman, DM Kuang, Y Oxnard, GR Janne, PA AF Yanagita, Masahiko Paweletz, Cloud O'Connell, Allison Jackman, David Michael Kuang, Yanan Oxnard, Geoffrey R. Janne, Pasi A. TI A prospective evaluation of cell free DNA (cfDNA) genotyping and circulating tumor cells (CTC) in EGFR mutant NSCLC patients (pts) treated with erlotinib. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Faber Canc Inst, Boston, MA USA. Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 11068 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900327 ER PT J AU Yao, JC Guthrie, K Moran, C Strosberg, JR Kulke, MH Chan, JA LoConte, NK McWilliams, RR Wolin, EM Mattar, BI McDonough, S Chen, HX Blanke, CD Hochster, HS AF Yao, James C. Guthrie, Katherine Moran, Cesar Strosberg, Jonathan R. Kulke, Matthew H. Chan, Jennifer A. LoConte, Noelle K. McWilliams, Robert R. Wolin, Edward M. Mattar, Bassam Ibrahim McDonough, Shannon Chen, Helen X. Blanke, Charles David Hochster, Howard S. TI SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA. Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Wisconsin, Madison, WI USA. Mayo Clin, Rochester, MN USA. Univ Kentucky, Lexington, KY USA. Canc Ctr Kansas PA, Wichita, KS USA. SWOG Stat Ctr, Seattle, WA USA. CTEP Natl Canc Inst, Rockville, MD USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Yale Univ Sch Med, Dept Med Oncol, New Haven, CT USA. NR 0 TC 6 Z9 6 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4004 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900843 ER PT J AU Yen, CC Chen, WM Chen, PCH Wu, HTH Shiau, CY Chen, TH Liu, CL Chao, TC Tzeng, CH Chang, WYH Chiou, HJ Fletcher, JA AF Yen, Chueh-Chuan Chen, Wei-Ming Chen, Paul Chih-Hsueh Wu, Hung-Ta Hondar Shiau, Cheng-Ying Chen, Tain-Hsiung Liu, Chien-Lin Chao, Ta-Chung Tzeng, Cheng-Hwai Chang, Wayne Yen-Hwa Chiou, Hong-Jen Fletcher, Jonathan A. TI The role of AURKA in liposarcoma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Taipei Vet Gen Hosp, Dept Med, Div Hematol Oncol, Taipei, Taiwan. Taipei Vet Gen Hosp, Dept Orthopaed & Traumatol, Taipei, Taiwan. Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Taipei, Taiwan. Taipei Vet Gen Hosp, Dept Radiol, Taipei, Taiwan. Taipei Vet Gen Hosp, Taipei, Taiwan. Taipei Vet Gen Hosp, Dept Med, Div Hematol & Oncol, Taipei, Taiwan. Taipei Vet Gen Hosp, Dept Urol, Taipei, Taiwan. Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e21512 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904388 ER PT J AU Yock, TI Weyman, EA Goldberg, S Eaton, BR Kasper, HB MacDonald, SM Pulsifer, MB Ebb, D Srichankij, SP Delahaye, J Tarbell, N Kuhlthau, K AF Yock, Torunn I. Weyman, Elizabeth A. Goldberg, Saveli Eaton, Bree Ruppert Kasper, Hallie Bieber MacDonald, Shannon M. Pulsifer, Margaret B. Ebb, David Srichankij, Sean P. Delahaye, Jennifer Tarbell, Nancy Kuhlthau, Karen TI HRQoL in medulloblastoma patients enrolled on a prospective phase II study of proton radiation. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Emory Univ, Atlanta, GA 30322 USA. Francis H Burr Proton Ctr, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e21029 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904367 ER PT J AU Yopp, AC Singal, AG Arriaga, YE Verma, UN Shan, J Kallinteris, NL Beg, MS Mansour, JC Zhu, H AF Yopp, Adam Charles Singal, Amit G. Arriaga, Yull Edwin Verma, Udit N. Shan, Joseph Kallinteris, Nikoletta L. Beg, Muhammad Shaalan Mansour, John C. Zhu, Hao TI A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Peregrine Pharmaceut Inc, Tustin, CA USA. Univ Texas SW Med Ctr Dallas, Div Hematol Oncol, Dallas, TX 75390 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4109 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900947 ER PT J AU Yu, HA Oxnard, GR Spira, AI Horn, L Weiss, J Feng, Y West, HJ Giaccone, G Evans, TL Kelly, RJ Fleege, T Poondru, S Jie, F Aoyama, K Foley, MA Whitcomb, D Keating, AT Krivoshik, AP AF Yu, Helena Alexandra Oxnard, Geoffrey R. Spira, Alexander I. Horn, Leora Weiss, Jared Feng, Yan West, Howard Jack Giaccone, Giuseppe Evans, Tracey L. Kelly, Ronan Joseph Fleege, Tanya Poondru, Srinivasu Jie, Fei Aoyama, Koji Foley, Margaret A. Whitcomb, Debbie Keating, Anne Therese Krivoshik, Andrew P. TI Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. US Oncol Res, Virginia Canc Specialists Res Inst, Fairfax, VA USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. Case Western Reserve Univ, Univ Hosp, Broadview Hts, OH USA. Swedish Canc Inst, Seattle, WA USA. NCI, NIH, Bethesda, MD 20892 USA. Univ Penn, Wynnewood, PA USA. Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. Astellas Pharma Global Dev, Northbrook, IL USA. Astellas Pharma Inc, Northbrook, IL USA. Astellas Pharma, Tokyo, Japan. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8083 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901795 ER PT J AU Yu, HA Sima, CS Reales, D Jordan, S Rudin, CM Kris, MG Michor, F Pao, W Riely, GJ AF Yu, Helena Alexandra Sima, Camelia S. Reales, Dalicia Jordan, Shomari Rudin, Charles M. Kris, Mark G. Michor, Franziska Pao, William Riely, Gregory J. TI A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Vanderbilt Univ, Nashville, TN 37235 USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8017 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901730 ER PT J AU Zanna, C Vaslin, A Voss, MH Heist, RS Hierro, C Supko, JG Nakai, K Ishii, N Menetrey, A Roubaudi-Fraschini, MC Cordier, J Douchain, J Nicolas-Metral, V AF Zanna, Claudio Vaslin, Anne Voss, Martin Henner Heist, Rebecca Suk Hierro, Cinta Supko, Jeffrey G. Nakai, Kiyohiko Ishii, Nobuya Menetrey, Annick Roubaudi-Fraschini, Marie-Claude Cordier, Julien Douchain, Jerome Nicolas-Metral, Valerie TI Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Debiopharm Int SA, Lausanne, Switzerland. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. VHIO, Barcelona, Spain. Chugai Pharmaceut Co Ltd, Kamakura, Kanagawa, Japan. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 2540 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900573 ER PT J AU Zhang, Y Sestak, I Cuzick, JM Dowsett, M Schnabel, CA Sgroi, D AF Zhang, Yi Sestak, Ivana Cuzick, Jack M. Dowsett, Mitchell Schnabel, Catherine A. Sgroi, Dennis TI Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2 and prediction of relative endocrine benefit from tamoxifen and anastrozole in HR plus breast cancer: A TransATAC study. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 BioTheranostics, San Diego, CA USA. Queen Mary Univ London, Ctr Canc Prevent, London, England. Royal Marsden Hosp, London SW3 6JJ, England. Massachusetts Gen Hosp, Avon Fdn, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 526 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901133 ER PT J AU Zhou, CW Mullane, SA Werner, L Taplin, ME Fay, AP Choueiri, TK Takeda, DY Bowden, M Bellmunt, J AF Zhou, Chensheng Willa Mullane, Stephanie A. Werner, Lillian Taplin, Mary-Ellen Fay, Andre Poisl Choueiri, Toni K. Takeda, David Yoshio Bowden, Michaela Bellmunt, Joaquim TI Role of miR-21, miR372, and E2F1 as biomarkers predicting outcome in cisplatin-treated bladder cancer patients. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. HSL PUCRS, Oncol Serv, Porto Alegre, RS, Brazil. HSL PUCRS, Oncol Res Unit, Porto Alegre, RS, Brazil. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4530 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901001 ER PT J AU Zhou, Y Gottlieb, L Cartmel, B Li, FY Ercolano, EA Harrigan, M McCorkle, R Ligibel, JA Von Gruenigen, VE Gogoi, R Schwartz, PE Risch, HA Irwin, ML AF Zhou, Yang Gottlieb, Linda Cartmel, Brenda Li, Fangyong Ercolano, Elizabeth A. Harrigan, Maura McCorkle, Ruth Ligibel, Jennifer A. Von Gruenigen, Vivian E. Gogoi, Radhika Schwartz, Peter E. Risch, Harvey A. Irwin, Melinda L. TI Randomized trial of exercise on quality of life and fatigue in women diagnosed with ovarian cancer: The Women's Activity and Lifestyle Study in Connecticut (WALC) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Yale Canc Ctr, New Haven, CT USA. Yale Univ, Sch Publ Hlth, New Haven, CT USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Summa Akron City Hosp, Akron, OH USA. Geisinger Med Ctr, Danville, PA 17822 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9505 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901994 ER PT J AU Zhu, AX Baron, AD Malfertheiner, P Kudo, M Kawazoe, S Pezet, D Weissinger, F Brandi, G Barone, C Okusaka, T Wada, Y Park, JO Ryoo, BY Cho, JY Chung, HC Li, CP Yen, CJ Lee, KD Yang, L Chau, I AF Zhu, Andrew X. Baron, Ari David Malfertheiner, Peter Kudo, Masatoshi Kawazoe, Seiji Pezet, Denis Weissinger, Florian Brandi, Giovanni Barone, Carlo Okusaka, Takuji Wada, Yoshiyuki Park, Joon Oh Ryoo, Baek-Yeol Cho, Jae Yong Chung, Hyun Cheol Li, Chung-Pin Yen, Chia-Jui Lee, Kuan-Der Yang, Ling Chau, Ian TI Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. Calif Pacific Med Ctr, San Francisco, CA USA. Univ Magdeburg, D-39106 Magdeburg, Germany. Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, Osaka 589, Japan. Saga Ken Med Ctr Koseikan, Saga, Japan. CHU Estaing, Clermont Ferrand, France. Evangel Krankenhaus Bielefeld, Bielefeld, Germany. Policlin St Orsola Malpighi, Bologna, Italy. Univ Cattolica Sacro Cuore, I-00168 Rome, Italy. Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan. Natl Hosp Org, Kyushu Med Ctr, Fukuoka, Japan. Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea. Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea. Gangnam Severance Hosp, Seoul, South Korea. Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Yonsei Canc Ctr, Shinchon Dong, South Korea. Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol, Taipei, Taiwan. Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan. Chang Gung Mem Hosp, Chiayi, Taiwan. Eli Lilly & Co, Bridgewater, NJ USA. Royal Marsden, London, England. Royal Marsden, Surrey, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 4108 PG 2 WC Oncology SC Oncology GA CM9OA UT WOS:000358036900946 ER PT J AU Zimmerman, TM Griffith, KA Jasielec, J Rosenbaum, CA McDonnell, K Waite-Marin, J Berdeja, JG Raje, NS Reece, DE Vij, R Alonge, M Rosebeck, S Gurbuxani, S Faham, M Kong, KA Levy, J Jakubowiak, AJ AF Zimmerman, Todd M. Griffith, Kent A. Jasielec, Jagoda Rosenbaum, Cara Ann McDonnell, Kathryn Waite-Marin, Jessica Berdeja, Jesus G. Raje, Noopur S. Reece, Donna Ellen Vij, Ravi Alonge, Mattina Rosebeck, Shaun Gurbuxani, Sandeep Faham, Malek Kong, Katherine A. Levy, Joan Jakubowiak, Andrzej J. TI Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Chicago, Chicago, IL 60637 USA. Univ Michigan, Ann Arbor, MI 48109 USA. Northshore Univ Hlth Syst, Evanston, IL USA. Sarah Cannon Res Inst, Nashville, TN USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. Washington Univ, Sch Med, St Louis, MO USA. Sequenta Inc, San Francisco, CA USA. Multiple Myeloma Res Consortium, Norwalk, CT USA. Univ Chicago, Med Ctr, Chicago, IL 60637 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 8510 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901823 ER PT J AU Zonder, JA Raje, NS Scott, EC Hofmeister, CC Lendvai, N Anderson, LD Hari, P Orloff, GJ Berdeja, JG Singhal, S Craig, M Valent, JN Ptaszynski, M Schreiber, J Aitchison, R Usmani, SZ AF Zonder, Jeffrey A. Raje, Noopur S. Scott, Emma Catherine Hofmeister, Craig C. Lendvai, Nikoletta Anderson, Larry Don Hari, Parameswaran Orloff, Gregory Joshua Berdeja, Jesus G. Singhal, Seema Craig, Michael Valent, Jason Neil Ptaszynski, Mieke Schreiber, Jennifer Aitchison, Roger Usmani, Saad Zafar TI A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Karmanos Canc Inst, Detroit, MI USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Ohio State Univ, Columbus, OH 43210 USA. Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Fairfax Northern Virginia Hem Onc, Fairfax, VA USA. Sarah Cannon Res Inst, Nashville, TN USA. Northwestern Univ, Sch Med, Chicago, IL USA. W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA. Cleveland Clin, Eastlake, OH USA. Array BioPharma Inc, Boulder, CO USA. Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA TPS8612 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904874 ER PT J AU Tan, XY Li, BB Lu, XG Jia, F Santori, C Menon, P Li, H Zhang, BH Zhao, JJ Zhang, K AF Tan, Xuyu Li, Ben B. Lu, Xueguang Jia, Fei Santori, Clarissa Menon, Priyanka Li, Hui Zhang, Bohan Zhao, Jean J. Zhang, Ke TI Light-Triggered, Self-Immolative Nucleic Acid-Drug Nanostructures SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY LA English DT Article ID GOLD NANOPARTICLES; CELLULAR UPTAKE; BINDING-PROPERTIES; BLOCK-COPOLYMERS; DNA; DELIVERY; DOXORUBICIN AB The simultaneous intracellular delivery of multiple types of payloads, such as hydrophobic drugs and nucleic acids, typically requires complex carrier systems. Herein; we demonstrate a, self-deliverable form of nucleic acid-drug nanostructure that is composed almost entirely of payload molecules. Upon light activation, the nanostructure sheds the nucleic acid shell, while the core, which consists of prodrug molecules, disintegrates via an irreversible self-immolative process, releasing free drug molecules and small molecule fragments. We demonstrate that the nanostructures exhibit enhanced stability against DNase I compared with free DNA, and that the model drug (camptothecin) released exhibits similar efficacy as free, unmodified drugs toward cancer cells. C1 [Tan, Xuyu; Lu, Xueguang; Jia, Fei; Santori, Clarissa; Menon, Priyanka; Zhang, Ke] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA. [Li, Hui; Zhang, Bohan; Zhang, Ke] Hunan Univ, Inst Chem Biol & Nanomed, Changsha 410081, Hunan, Peoples R China. [Li, Ben B.; Zhao, Jean J.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. [Li, Ben B.; Zhao, Jean J.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02215 USA. RP Zhang, K (reprint author), Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA. EM k.zhang@neu.edu FU Northeastern University start-up; NEU-DFCI seed grant; NSF CAREER award [1453255] FX The authors thank William Fowle at the NEU Biology Department for help with the TEM. Financial support from Northeastern University start-up, NEU-DFCI seed grant, and NSF CAREER award (1453255) is gratefully acknowledged. NR 39 TC 37 Z9 38 U1 19 U2 133 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0002-7863 J9 J AM CHEM SOC JI J. Am. Chem. Soc. PD MAY 20 PY 2015 VL 137 IS 19 BP 6112 EP 6115 DI 10.1021/jacs.5b00795 PG 4 WC Chemistry, Multidisciplinary SC Chemistry GA CI8WT UT WOS:000355053100001 PM 25924099 ER PT J AU Izgu, EC Fahrenbach, AC Zhang, N Li, L Zhang, W Larsen, AT Blain, JC Szostak, JW AF Izgu, Enver Cagri Fahrenbach, Albert C. Zhang, Na Li, Li Zhang, Wen Larsen, Aaron T. Blain, J. Craig Szostak, Jack W. TI Uncovering the Thermodynamics of Monomer Binding for RNA Replication SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY LA English DT Article ID TEMPLATE-DIRECTED SYNTHESIS; NUCLEIC-ACID; HAIRPIN OLIGONUCLEOTIDES; MOLECULAR-DYNAMICS; CIRCULAR-DICHROISM; NMR; DNA; HYDRATION; RESIDUES; COMPLEX AB The nonenzymatic replication of primordial RNA is thought to have been a critical step in the origin of life. However, despite decades of effort, the poor rate and fidelity of model template copying reactions have thus far prevented an experimental demonstration of nonenzymatic RNA replication. The overall rate and fidelity of template copying depend, in part, on the affinity of free ribonucleotides to the RNA primer-template complex. We have now used H-1 NMR spectroscopy to directly measure the thermodynamic association constants, K(a)s, of the standard ribonucleotide monophosphates (rNMPs) to native RNA primer-template complexes. The binding affinities of rNMPs to duplexes with a complementary single-nucleotide overhang follow the order C > G > A > U. Notably, these monomers bind more strongly to RNA primer-template complexes than to the analogous DNA complexes. The relative binding affinities of the rNMPs for complementary RNA primer-template complexes are in good quantitative agreement with the predictions of a nearest-neighbor analysis. With respect to G:U wobble base-pairing, we find that the binding of rGMP to a primer-template complex with a 5'-U overhang is approximately 10-fold weaker than to the complementary 5'-C overhang. We also find that the binding of rGMP is only about 2-fold weaker than the binding of rAMP to 5'-U, consistent with the poor fidelity observed in the nonenzymatic copying of U residues in RNA templates. The accurate K-a measurements for ribonudeotides obtained in this study will be useful for designing higher fidelity, more effective RNA replication systems. C1 [Izgu, Enver Cagri; Fahrenbach, Albert C.; Zhang, Na; Li, Li; Zhang, Wen; Larsen, Aaron T.; Blain, J. Craig; Szostak, Jack W.] Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA. [Izgu, Enver Cagri; Fahrenbach, Albert C.; Zhang, Na; Li, Li; Zhang, Wen; Larsen, Aaron T.; Blain, J. Craig; Szostak, Jack W.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Izgu, Enver Cagri; Fahrenbach, Albert C.; Li, Li; Zhang, Wen; Larsen, Aaron T.; Szostak, Jack W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Fahrenbach, Albert C.; Szostak, Jack W.] Tokyo Inst Technol, Earth Life Sci Inst, Meguro Ku, Tokyo 1528550, Japan. [Szostak, Jack W.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA. RP Szostak, JW (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, 185 Cambridge St, Boston, MA 02114 USA. EM szostak@molbio.mgh.harvard.edu FU Research Fellowship from the Earth-Life Science Institute at the Tokyo Institute of Technology; Simons Foundation [290363] FX We thank Dr. Ayan Pal, Dr. Anders Bjorkbom, and Weicheng Zhang for providing technical assistance; Dr. Aaron Engelhart, Dr. Victor Lelyveld, and Noam Prywes for helpful discussions. J.W.S. is an Investigator of the Howard Hughes Medical Institute. A.C.F. is supported by a Research Fellowship from the Earth-Life Science Institute at the Tokyo Institute of Technology. This work was supported in part by a grant (290363) from the Simons Foundation to J.W.S. NR 38 TC 7 Z9 7 U1 2 U2 19 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0002-7863 J9 J AM CHEM SOC JI J. Am. Chem. Soc. PD MAY 20 PY 2015 VL 137 IS 19 BP 6373 EP 6382 DI 10.1021/jacs.5b02707 PG 10 WC Chemistry, Multidisciplinary SC Chemistry GA CI8WT UT WOS:000355053100040 PM 25901790 ER PT J AU Zhou, YB Han, C Li, DL Yu, ZJ Li, FM Li, F An, Q Bai, HL Zhang, XJ Duan, ZF Kan, QC AF Zhou, Yubing Han, Chao Li, Duolu Yu, Zujiang Li, Fengmei Li, Feng An, Qi Bai, Huili Zhang, Xiaojian Duan, Zhenfeng Kan, Quancheng TI Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth SO SCIENTIFIC REPORTS LA English DT Article ID MUTANT P53; TARGETED THERAPY; ER-ALPHA; PROTEIN; GENE; CARCINOMA; CDK11; AMPLIFICATION; TRANSCRIPTION; RESISTANCE AB Cyclin-dependent kinases (CDKs) play important roles in the development of many types of cancers by binding with their paired cyclins. However, the function of CDK11 larger protein isomer, CDK11(p110), in the tumorigenesis of human breast cancer remains unclear. In the present study, we explored the effects and molecular mechanisms of CDK11(p110) in the proliferation and growth of breast cancer cells by determining the expression of CDK11(p110) in breast tumor tissues and examining the phenotypic changes of breast cancer cells after CDK11(p110) knockdown. We found that CDK11(p110) was highly expressed in breast tumor tissues and cell lines. Tissue microarray analysis showed that elevated CDK11(p110) expression in breast cancer tissues significantly correlated with poor differentiation, and was also associated with advanced TNM stage and poor clinical prognosis for breast cancer patients. In vitro knockdown of CDK11(p110) by siRNA significantly inhibited cell growth and migration, and dramatically induced apoptosis in breast cancer cells. Flow cytometry demonstrated that cells were markedly arrested in G1 phase of the cell cycle after CDK11(p110) downregulation. These findings suggest that CDK11(p110) is critical for the proliferation and growth of breast cancer cells, which highlights CDK11(p110) may be a promising therapeutic target for the treatment of breast cancer. C1 [Zhou, Yubing; Han, Chao; Li, Duolu; Li, Feng; An, Qi; Zhang, Xiaojian; Duan, Zhenfeng; Kan, Quancheng] Zhengzhou Univ, Affiliated Hosp 1, Dept Pharm, Zhengzhou 450052, Peoples R China. [Duan, Zhenfeng] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Mol Biol Lab, Boston, MA 02114 USA. [Duan, Zhenfeng] Harvard Univ, Sch Med, Boston, MA USA. [Yu, Zujiang] Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, Zhengzhou 450052, Peoples R China. [Li, Fengmei] Zhengzhou Univ, Zhengzhou Cent Hosp, Dept Obstet & Gynecol, Zhengzhou 450007, Peoples R China. [Bai, Huili] Zhengzhou Univ, Zhengzhou Cent Hosp, Dept Pathol, Zhengzhou 450007, Peoples R China. RP Kan, QC (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Pharm, 1 Jianshe East Rd, Zhengzhou 450052, Peoples R China. EM qckan19632012@163.com FU National Natural Science Foundation of China [81402266, 81372875]; Key Project of Scientific and Technological Research of the Education Department of Henan Province [14B320036]; Medical Science and Technology Research Projects of Henan Province [201403074]; Youth Innovation Fund of the First Affiliated Hospital of Zhengzhou University FX This work was supported by the National Natural Science Foundation of China (No.: 81402266 and 81372875), the Key Project of Scientific and Technological Research of the Education Department of Henan Province (No.: 14B320036) and Medical Science and Technology Research Projects of Henan Province (No.: 201403074). This study was also supported by the Youth Innovation Fund of the First Affiliated Hospital of Zhengzhou University. NR 59 TC 6 Z9 6 U1 3 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD MAY 20 PY 2015 VL 5 AR 10433 DI 10.1038/srep10433 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ3PE UT WOS:000355395500001 PM 25990212 ER PT J AU Gandhi, PU Gaggin, HK Belcher, AM Harisiades, JE Basile, A Falco, A Rosati, A Piscione, F Januzzi, JL Turco, MC AF Gandhi, Parul U. Gaggin, Hanna K. Belcher, Arianna M. Harisiades, Jamie E. Basile, Anna Falco, Antonia Rosati, Alessandra Piscione, Federico Januzzi, James L., Jr. Turco, M. Caterina TI Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure SO CLINICA CHIMICA ACTA LA English DT Article DE BAG3; BCL-2 athanogene 3; Heart failure; Prognosis ID SENSITIVITY TROPONIN-T; NATRIURETIC PEPTIDE; RISK STRATIFICATION; PROTEIN; BIOMARKER; STRESS AB Background: BCL-2-associated athanogene 3 (BAG3) is a protein implicated in the cardiomyocyte stress response and genesis of cardiomyopathy. Extracellular BAG3 is measurable in patients with heart failure (HF), but the relationship of BAG3 with HF prognosis is unclear. Methods: BAG3 plasma concentrations were measured in 39 acutely decompensated HF patients; the primary endpoint was death at 1 year. Baseline characteristics were compared by vital status and median BAG3 concentration. Correlation of BAG3 with left ventricular ejection fraction (LVEF) and other biomarkers was performed. Prognostic value was assessed using Cox proportional hazards regression and Kaplan-Meier analysis. Results: At baseline, median BAG3 was significantly higher in decedents (N = 11) than survivors (N = 28; 1489 ng/mL versus 50 ng/mL; P = 0.04); decedents also had worse renal function and higher median natriuretic peptide (NP) and sST2.BAG3 was not significantly correlated with NPs, mid-regional pro-adrenomedullin, sST2, or eGFR, however. Mortality was increased in patients with supra-median BAG3 (>336 ng/mL; 42.1% versus 15.0%, P = 0.06). In age and LVEF-adjusted Cox proportional hazards, BAG3 remained a significant mortality predictor (HR = 3.20; 95% CI = 134-7.65; P = 0.02); those with supra-median BAG3 had significantly shorter time-to-death (P = 0.04). Conclusion: The stress response protein BAG3 is measurable in patients with ADHF and may be prognostic for death. (C) 2015 Elsevier B.V. All rights reserved. C1 [Gandhi, Parul U.; Gaggin, Hanna K.; Belcher, Arianna M.; Harisiades, Jamie E.; Januzzi, James L., Jr.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Basile, Anna; Falco, Antonia; Rosati, Alessandra] Univ Salerno, Dept Pharm, I-84084 Fisciano, SA, Italy. [Basile, Anna; Falco, Antonia; Rosati, Alessandra; Turco, M. Caterina] Univ Salerno, BIOUNIVERSA Srl, I-84084 Fisciano, SA, Italy. [Piscione, Federico; Turco, M. Caterina] Univ Salerno, Dept Med & Surg, Baronissi, SA, Italy. RP Turco, MC (reprint author), Univ Salerno, Via Ponte don Melillo, I-84084 Fisciano, Italy. EM mcturco@unisa.it FU Dennis and Marilyn Barry Fellowship in Cardiology; Clark Fund for Cardiac Research Innovation; Roman W. DeSanctis Clinical Scholar Endowment; Hutter Family Professorship FX Dr. Gandhi is supported by the Dennis and Marilyn Barry Fellowship in Cardiology, Dr. Gaggin is supported in part by the Clark Fund for Cardiac Research Innovation, and Dr. Januzzi is supported in part by the Roman W. DeSanctis Clinical Scholar Endowment and the Hutter Family Professorship. NR 28 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 EI 1873-3492 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD MAY 20 PY 2015 VL 445 BP 73 EP 78 DI 10.1016/j.cca.2015.02.048 PG 6 WC Medical Laboratory Technology SC Medical Laboratory Technology GA CI8LP UT WOS:000355024100014 PM 25753466 ER PT J AU Rodriguez-Reyna, TS Mercado-Velazquez, P Yu, N Alosco, S Ohashi, M Lebedeva, T Cruz-Lagunas, A Nunez-Alvarez, C Cabiedes-Contreras, J Vargas-Alarcon, G Granados, J Zuniga, J Yunis, E AF Rodriguez-Reyna, Tatiana S. Mercado-Velazquez, Pamela Yu, Neng Alosco, Sharon Ohashi, Marina Lebedeva, Tatiana Cruz-Lagunas, Alfredo Nunez-Alvarez, Carlos Cabiedes-Contreras, Javier Vargas-Alarcon, Gilberto Granados, Julio Zuniga, Joaquin Yunis, Edmond TI HLA Class I and II Blocks Are Associated to Susceptibility, Clinical Subtypes and Autoantibodies in Mexican Systemic Sclerosis (SSc) Patients SO PLOS ONE LA English DT Article ID DNA TOPOISOMERASE-I; HLA-DQB1 1ST DOMAIN; ANTICENTROMERE ANTIBODY; JAPANESE PATIENTS; DISEASE SEVERITY; ETHNIC-GROUPS; SCLERODERMA; HAPLOTYPES; FEATURES; ALLELES AB Introduction Human leukocyte antigen (HLA) polymorphism studies in Systemic Sclerosis (SSc) have yielded variable results. These studies need to consider the genetic admixture of the studied population. Here we used our previously reported definition of genetic admixture of Mexicans using HLA class I and II DNA blocks to map genetic susceptibility to develop SSc and its complications. Methods We included 159 patients from a cohort of Mexican Mestizo SSc patients. We performed clinical evaluation, obtained SSc-associated antibodies, and determined HLA class I and class II alleles using sequence-based, high-resolution techniques to evaluate the contribution of these genes to SSc susceptibility, their correlation with the clinical and autoantibody profile and the prevalence of Amerindian, Caucasian and African alleles, blocks and haplotypes in this population. Results Our study revealed that class I block HLA-C*12:03-B*18:01 was important to map susceptibility to diffuse cutaneous (dc) SSc, HLA-C*07:01-B*08:01 block to map the susceptibility role of HLA-B*08:01 to develop SSc, and the C*07:02-B*39:05 and C*07:02-B*39:06 blocks to map the protective role of C*07: 02 in SSc. We also confirmed previous associations of HLA-DRB1*11:04 and -DRB1*01 to susceptibility to develop SSc. Importantly, we mapped the protective role of DQB1*03:01 using three Amerindian blocks. We also found a significant association for the presence of anti-Topoisomerase I antibody with HLA-DQB1*04:02, present in an Amerindian block (DRB1*08:02-DQB1*04:02), and we found several alleles associated to internal organ damage. The admixture estimations revealed a lower proportion of the Amerindian genetic component among SSc patients. Conclusion This is the first report of the diversity of HLA class I and II alleles and haplotypes Mexican patients with SSc. Our findings suggest that HLA class I and class II genes contribute to the protection and susceptibility to develop SSc and its different clinical presentations as well as different autoantibody profiles in Mexicans. C1 [Rodriguez-Reyna, Tatiana S.; Mercado-Velazquez, Pamela; Nunez-Alvarez, Carlos; Cabiedes-Contreras, Javier] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Immunol & Rheumatol, Mexico City, DF, Mexico. [Yu, Neng; Alosco, Sharon; Ohashi, Marina; Lebedeva, Tatiana] Amer Red Cross Northeast Div, HLA Lab, Dedham, MA USA. [Cruz-Lagunas, Alfredo; Zuniga, Joaquin] Inst Nacl Enfermedades Respiratorias Ismael Cosio, Dept Immunol, Mexico City, DF, Mexico. [Vargas-Alarcon, Gilberto] Inst Nacl Cardiol Ignacio Chavez, Basic & Technol Res Subdirect, Mexico City, DF, Mexico. [Granados, Julio] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Transplant Dept, Mexico City, DF, Mexico. [Yunis, Edmond] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol, Boston, MA 02115 USA. [Yunis, Edmond] Harvard Univ, Sch Med, Dana Farber Canc Inst, AIDS, Boston, MA 02115 USA. [Yunis, Edmond] Harvard Univ, Sch Med, Boston, MA USA. RP Zuniga, J (reprint author), Inst Nacl Enfermedades Respiratorias Ismael Cosio, Dept Immunol, Mexico City, DF, Mexico. EM joazu@yahoo.com; eyunis@partners.org FU Mexican Council of Science and Technology (CONACYT) [SALUD-2013-1-202576]; Research Funds of the National Institute of Respiratory Diseases Ismael Cosio Villegas, Mexico City, Mexico FX This work was supported by the Mexican Council of Science and Technology (CONACYT), [Grant number SALUD-2013-1-202576], www.conacyt.mx; and by the Research Funds of the National Institute of Respiratory Diseases Ismael Cosio Villegas, Mexico City, Mexico, www.iner.salud.gob.mx. NR 56 TC 3 Z9 3 U1 0 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 20 PY 2015 VL 10 IS 5 AR UNSP e0126727 DI 10.1371/journal.pone.0126727 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CI7CV UT WOS:000354921400074 PM 25993664 ER PT J AU Herman, JD Pepper, LR Cortese, JF Estiu, G Galinsky, K Zuzarte-Luis, V Derbyshire, ER Ribacke, U Lukens, AK Santos, SA Patel, V Clish, CB Sullivan, WJ Zhou, HH Bopp, SE Schimmel, P Lindquist, S Clardy, J Mota, MM Keller, TL Whitman, M Wiest, O Wirth, DF Mazitschek, R AF Herman, Jonathan D. Pepper, Lauren R. Cortese, Joseph F. Estiu, Guillermina Galinsky, Kevin Zuzarte-Luis, Vanessa Derbyshire, Emily R. Ribacke, Ulf Lukens, Amanda K. Santos, Sofia A. Patel, Vishal Clish, Clary B. Sullivan, William J., Jr. Zhou, Huihao Bopp, Selina E. Schimmel, Paul Lindquist, Susan Clardy, Jon Mota, Maria M. Keller, Tracy L. Whitman, Malcolm Wiest, Olaf Wirth, Dyann F. Mazitschek, Ralph TI The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID ANTIMALARIAL-DRUG DISCOVERY; AMINO-ACID STARVATION; MESH EWALD METHOD; PLASMODIUM-FALCIPARUM; SACCHAROMYCES-CEREVISIAE; LIVER STAGE; CRYPTOSPORIDIUM-PARVUM; HALOFUGINONE LACTATE; MOLECULAR-DYNAMICS; RODENT MALARIA AB The emergence of drug resistance is a major limitation of current antimalarials. The discovery of new druggable targets and pathways including those that are critical for multiple life cycle stages of the malaria parasite is a major goal for developing next-generation antimalarial drugs. Using an integrated chemogenomics approach that combined drug resistance selection, whole-genome sequencing, and an orthogonal yeast model, we demonstrate that the cytoplasmic prolyl-tRNA (transfer RNA) synthetase (PfcPRS) of the malaria parasite Plasmodium falciparum is a biochemical and functional target of febrifugine and its synthetic derivative halofuginone. Febrifugine is the active principle of a traditional Chinese herbal remedy for malaria. We show that treatment with febrifugine derivatives activated the amino acid starvation response in both P. falciparum and a transgenic yeast strain expressing PfcPRS. We further demonstrate in the Plasmodium berghei mouse model of malaria that halofuginol, a new halofuginone analog that we developed, is active against both liver and asexual blood stages of the malaria parasite. Halofuginol, unlike halofuginone and febrifugine, is well tolerated at efficacious doses and represents a promising lead for the development of dual-stage next-generation antimalarials. C1 [Herman, Jonathan D.; Cortese, Joseph F.; Galinsky, Kevin; Lukens, Amanda K.; Clish, Clary B.; Clardy, Jon; Wirth, Dyann F.; Mazitschek, Ralph] Broad Inst, Program Infect Dis, Cambridge, MA 02142 USA. [Herman, Jonathan D.; Lukens, Amanda K.; Bopp, Selina E.; Wirth, Dyann F.; Mazitschek, Ralph] Harvard Univ, TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. [Herman, Jonathan D.] Harvard MIT Div Hlth Sci & Technol, Boston, MA 02115 USA. [Herman, Jonathan D.] Harvard Univ, Sch Med, Harvard MIT PhD Program, Boston, MA 02115 USA. [Pepper, Lauren R.; Lindquist, Susan] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [Estiu, Guillermina; Wiest, Olaf] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA. [Estiu, Guillermina; Wiest, Olaf] Univ Notre Dame, Ctr Rare & Neglected Dis, Notre Dame, IN 46556 USA. [Zuzarte-Luis, Vanessa; Mota, Maria M.] Univ Lisbon, Fac Med, Inst Mol Med, P-1649028 Lisbon, Portugal. [Derbyshire, Emily R.; Patel, Vishal; Clardy, Jon] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Santos, Sofia A.; Mazitschek, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Santos, Sofia A.] Univ Lisbon, Fac Farm, Inst Invest Med iMed ULisbon, P-1640003 Lisbon, Portugal. [Sullivan, William J., Jr.] Indiana Univ Sch Med, Dept Pharmacol, Indianapolis, IN 46202 USA. [Sullivan, William J., Jr.] Indiana Univ Sch Med, Dept Toxicol, Indianapolis, IN 46202 USA. [Sullivan, William J., Jr.] Indiana Univ Sch Med, Dept Microbiol, Indianapolis, IN 46202 USA. [Sullivan, William J., Jr.] Indiana Univ Sch Med, Dept Immunol, Indianapolis, IN 46202 USA. [Schimmel, Paul] Scripps Res Inst, Skaggs Inst Chem Biol, Dept Mol Biol, La Jolla, CA 92037 USA. [Schimmel, Paul] Scripps Res Inst, Jupiter, FL 33458 USA. [Lindquist, Susan] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA. [Keller, Tracy L.; Whitman, Malcolm] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA. [Wiest, Olaf] Peking Univ, Shenzhen Grad Sch, Sch Chem Biol & Biotechnol, Lab Computat Chem & Drug Design, Shenzhen 518055, Peoples R China. RP Mazitschek, R (reprint author), Broad Inst, Program Infect Dis, Cambridge, MA 02142 USA. EM dfwirth@hsph.harvard.edu; rmazitschek@mgh.harvard.edu RI ZHOU, HUIHAO/L-6133-2016; OI Zuzarte-Luis, Vanessa/0000-0003-0023-5953; Mota, Maria Manuel/0000-0002-2858-1041 FU Gates Foundation [OPP1086203]; NIH [AI105786, 5F32AI084440-02, CA92577, GM099796]; Center for Rare and Neglected Diseases at the University of Notre Dame; NSF through TeraGrid grant [TG-CHE090124]; National Foundation for Cancer Research [SFRH/BD/80162/2011, PTDC/SAU-MIC/113697/2009]; Fundacao para a Ciencia e Tecnologia, Portugal [EXCL/IMI-MIC/0056/2012]; Howard Hughes Medical Institute; Center for Systems Biology, Massachusetts General Hospital FX We gratefully acknowledge financial support from the Gates Foundation (D.F.W. and R.M., OPP1086203), the NIH (D.F.W.) AI105786 (W.J.S.), 5F32AI084440-02 (L.R.P.), CA92577 (P.S.), and GM099796 (E.R.D.), the Center for Rare and Neglected Diseases at the University of Notre Dame (O.W. and G.E.), generous allocation of computing resources by the NSF through TeraGrid grant TG-CHE090124 (O.W.), a fellowship from the National Foundation for Cancer Research (P.S.), SFRH/BD/80162/2011 (S.A.S.), PTDC/SAU-MIC/113697/2009 (V.Z.-L.), and EXCL/IMI-MIC/0056/2012 (M.M.M.) (Fundacao para a Ciencia e Tecnologia, Portugal), Howard Hughes Medical Institute (S.L.), and start-up funding provided by the Center for Systems Biology, Massachusetts General Hospital (R.M.). NR 70 TC 11 Z9 11 U1 2 U2 24 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 EI 1946-6242 J9 SCI TRANSL MED JI Sci. Transl. Med. PD MAY 20 PY 2015 VL 7 IS 288 AR 288ra77 DI 10.1126/scitranslmed.aaa3575 PG 9 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA CI5PA UT WOS:000354808900005 PM 25995223 ER PT J AU Sandler, HM Hu, C Rosenthal, SA Sartor, O Gomella, LG Amin, M Purdy, J Michalski, JM Garzotto, M Pervez, N Balogh, AG Rodrigues, G Souhami, L Reaume, MN Williams, SG Hannan, R Horwitz, EM Raben, A Paulus, R Shipley, WU AF Sandler, Howard M. Hu, Chen Rosenthal, Seth A. Sartor, Oliver Gomella, Leonard G. Amin, Mahul Purdy, James Michalski, Jeff M. Garzotto, Mark Pervez, Nadeem Balogh, Alexander G. Rodrigues, George Souhami, Luis Reaume, M. Neil Williams, Scott G. Hannan, Raquibul Horwitz, Eric M. Raben, Adam Paulus, Rebecca Shipley, William U. TI A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA. NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA. Sutter Canc Ctr, Sacramento, CA USA. Tulane Univ, Sch Med, New Orleans, LA 70112 USA. Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. Univ Calif Davis, Sacramento, CA USA. Washington Univ, St Louis, MO USA. Portland VA Med Ctr, Portland, OR USA. Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada. Tom Baker Canc Clin, Calgary, AB, Canada. London Reg Canc Program, Dept Radiat Oncol, London, ON, Canada. McGill Univ, Ctr Hlth, Dept Radiat Oncol, Montreal, PQ, Canada. Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada. Peter MacCallum Canc Ctr, East Melbourne, Australia. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Helen F Graham Canc Ctr, Newark, DE USA. Ctr Stat, Radiat Therapy Oncol Grp, Philadelphia, PA USA. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA LBA5002 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904638 ER PT J AU Seiwert, TY Haddad, RI Gupta, S Mehra, R Tahara, M Berger, R Lee, SH Burtness, B Le, DT Heath, K Blum, A Dolled-Filhart, M Emancipator, K Pathiraja, K Cheng, JD Chow, LQ AF Seiwert, Tanguy Y. Haddad, Robert I. Gupta, Shilpa Mehra, Ranee Tahara, Makoto Berger, Raanan Lee, Se-Hoon Burtness, Barbara Le, Dung T. Heath, Karl Blum, Amy Dolled-Filhart, Marisa Emancipator, Kenneth Pathiraja, Kumudu Cheng, Jonathan D. Chow, Laura Q. TI Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Chicago, Chicago, IL 60637 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan. Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel. Seoul Natl Univ Hosp, Seoul 110744, South Korea. Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA. JHU, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Merck & Co Inc, Kenilworth, NJ USA. Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA LBA6008 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904640 ER PT J AU Wolchok, JD Chiarion-Sileni, V Gonzalez, R Rutkowski, P Grob, JJ Cowey, CL Lao, CD Schadendorf, D Ferrucci, PF Smylie, M Dummer, R Hill, AG Haanen, JBAG Maio, M McArthur, GA Yang, A Rollin, L Horak, CE Larkin, JMG Hodi, FS AF Wolchok, Jedd D. Chiarion-Sileni, Vanna Gonzalez, Rene Rutkowski, Piotr Grob, Jean Jacques Cowey, Charles Lance Lao, Christopher D. Schadendorf, Dirk Ferrucci, Pier Francesco Smylie, Michael Dummer, Reinhard Hill, Andrew Graham Haanen, John B. A. G. Maio, Michele McArthur, Grant A. Yang, Arvin Rollin, Linda Horak, Christine E. Larkin, James M. G. Hodi, F. Stephen TI Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Weill Cornell Med Coll, New York, NY USA. Oncol Inst Veneto IRCCS, Padua, Italy. Univ Colorado, Ctr Canc, Denver, CO 80262 USA. Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland. Inst Oncol, Warsaw, Poland. Hosp Timone, Marseille, France. Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Essen Gesamthsch, Dept Dermatol, Essen, Germany. European Inst Oncol, Milan, Italy. Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada. Univ Spital Zurich, Zurich, Switzerland. Tasman Oncol Res, Southport, Qld, Australia. Netherlands Canc Inst, Amsterdam, Netherlands. Univ Hosp Siena, Siena, Italy. Peter MacCallum Canc Ctr, East Melbourne, Australia. Bristol Myers Squibb Co, Princeton, NJ USA. Bristol Myers Squibb Co, Wallingford, CT 06492 USA. Royal Marsden Hosp, London SW3 6JJ, England. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA LBA1 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904630 ER PT J AU Medaglia, JD VanKirk, KK Oswald, CB Church, LWP AF Medaglia, John D. VanKirk, Kathryn K. Oswald, Cameron B. Church, L. W. Preston TI Interdisciplinary Differential Diagnosis and Care of a Patient with Atypical Delusional Parasitosis due to early HIV-related Dementia SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Neuropsychological assessment; Treatment planning.; HIV ID NEUROCOGNITIVE DISORDERS; INFESTATION; DISEASE; ERA AB Objective: To provide a differential diagnosis and recommendations for care for an individual with suspected delusional parasitosis secondary to human immunodeficiency virus (HIV). Method: A 62-year-old male with sexually acquired, chronic, and well-managed HIV infection was referred for neuropsychological evaluation and treatment recommendations following extensive self-manipulation of a sternoclavicular cystic mass and superficial skin lesions over most of his body. The patient reported that he had pulled long calcified tendrils out of the mass over a period of several weeks and that "encapsulated fat" was flowing beneath his skin. Results: Numerous lab panels were negative for any acute medical pathology. Clinical neuroimaging was unremarkable. Neuropsychological evaluation revealed a profile consistent with mild neurocognitive disorder due to HIV. Medical and behavioral recommendations were made for the management of delusional thought processes consistent with atypical delusional parasitosis and other symptoms. The patient was responsive to carefully crafted provider feedback and his delusional and somatic symptoms decreased significantly with risperidone. Conclusions: This case illustrates the utility of neuropsychological assessment and provider feedback in the diagnosis and care of HIV-related neurocognitive disorder, the context of a delusional disorder. C1 [Medaglia, John D.] Moss Rehabil Res Inst, Elkins Pk, PA USA. [Medaglia, John D.] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA. [VanKirk, Kathryn K.; Oswald, Cameron B.; Church, L. W. Preston] Ralph H Johnson VA Med Ctr, Dept Neuropsychol, Charleston, SC USA. [VanKirk, Kathryn K.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Church, L. W. Preston] Med Univ S Carolina, Div Infect Dis, Charleston, SC 29425 USA. RP Medaglia, JD (reprint author), Univ Penn, Moss Rehabil Res Inst, Translat Neurosci, 316 Hayden Hall, Philadelphia, PA 19104 USA. EM medaglia@seas.upenn.edu NR 24 TC 0 Z9 0 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1385-4046 EI 1744-4144 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PD MAY 19 PY 2015 VL 29 IS 4 BP 559 EP 569 DI 10.1080/13854046.2015.1042921 PG 11 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA CM8FZ UT WOS:000357935100011 PM 25978635 ER PT J AU Yetisen, AK Montelongo, Y Qasim, MM Butt, H Wilkinson, TD Monteiro, MJ Yun, SH AF Yetisen, Ali K. Montelongo, Yunuen Qasim, Malik M. Butt, Haider Wilkinson, Timothy D. Monteiro, Michael J. Yun, Seok Hyun TI Photonic Nanosensor for Colorimetric Detection of Metal Ions SO ANALYTICAL CHEMISTRY LA English DT Article ID FUNCTIONALIZED GOLD NANOPARTICLES; TURN-ON; MERCURY(II) DETECTION; HOLOGRAPHIC SENSORS; AQUEOUS-SOLUTION; LIVING CELL; LEAD; FLUORESCENT; CADMIUM; LABEL AB The real-time sensing of metal ions at point of care requires integrated sensors with low energy and sample consumption, reversibility, and rapid recovery. Here, we report a photonic nanosensor that reversibly and quantitatively reports on variation in the concentrations of Pb2+ and Cu2+ ions in aqueous solutions (<500 mu L) in the visible region of the spectrum (lambda(max) approximate to 400-700 nm). A single 6 ns laser pulse (lambda = 532 nm) was used to pattern an similar to 10 mu m thick photosensitive recording medium. This formed periodic AgBr nanocrystal (phi similar to 5-20 nm) concentrated regions, which produced Bragg diffraction upon illumination with a white light source. The sensor functionalized with 8-hydroxyquinoline allowed sensing through inducing Donnan osmotic pressure and tuning its lattice spacing. The sensor quantitatively measured Pb2+ and Cu2+ ion concentrations within the dynamic range of 0.1-10.0 mM with limits of detection of 11.4 and 18.6 mu M in under 10 min. The sensor could be reset in 3 min and was reused at least 100 times without compromising its accuracy. The plasmonic nanosensor represents a simple and label-free analytical platform with potential scalability for applications in medical diagnostics and environmental monitoring. C1 [Yetisen, Ali K.; Yun, Seok Hyun] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Yetisen, Ali K.; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Montelongo, Yunuen; Qasim, Malik M.; Wilkinson, Timothy D.] Univ Cambridge, Dept Engn, Ctr Mol Mat Photon & Elect, Cambridge CB3 0FA, England. [Butt, Haider] Univ Birmingham, Sch Mech Engn, Birmingham B15 2TT, W Midlands, England. [Monteiro, Michael J.] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld 4072, Australia. RP Yetisen, AK (reprint author), Harvard Univ, Sch Med, 50 Blossom St, Boston, MA 02114 USA. EM ay283@cam.ac.uk RI Montelongo, Yunuen/H-4955-2012; Monteiro, Michael/C-5658-2009; OI Montelongo, Yunuen/0000-0002-1266-183X; Monteiro, Michael/0000-0001-5624-7115; Butt, Haider/0000-0003-2434-9525 NR 74 TC 23 Z9 23 U1 4 U2 87 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD MAY 19 PY 2015 VL 87 IS 10 BP 5101 EP 5108 DI 10.1021/ac504274q PG 8 WC Chemistry, Analytical SC Chemistry GA CI8YN UT WOS:000355057700015 PM 25710792 ER PT J AU Balaj, L Atai, NA Chen, WL Mu, D Tannous, BA Breakefield, XO Skog, J Maguire, CA AF Balaj, Leonora Atai, Nadia A. Chen, Weilin Mu, Dakai Tannous, Bakhos A. Breakefield, Xandra O. Skog, Johan Maguire, Casey A. TI Heparin affinity purification of extracellular vesicles SO SCIENTIFIC REPORTS LA English DT Article ID HEAT-SHOCK PROTEINS; SULFATE PROTEOGLYCANS; PROTEOMIC ANALYSIS; CARCINOMA CELLS; EXOSOMES; MICROVESICLES; CANCER; RNA; IDENTIFICATION; BIOMARKERS AB Extracellular vesicles (EVs) are lipid membrane vesicles released by cells. They carry active biomolecules including DNA, RNA, and protein which can be transferred to recipient cells. Isolation and purification of EVs from culture cell media and biofluids is still a major challenge. The most widely used isolation method is ultracentrifugation (UC) which requires expensive equipment and only partially purifies EVs. Previously we have shown that heparin blocks EV uptake in cells, supporting a direct EV-heparin interaction. Here we show that EVs can be purified from cell culture media and human plasma using ultrafiltration (UF) followed by heparin-affinity beads. UF/heparinpurified EVs from cell culture displayed the EV marker Alix, contained a diverse RNA profile, had lower levels of protein contamination, and were functional at binding to and uptake into cells. RNA yield was similar for EVs isolated by UC. We were able to detect mRNAs in plasma samples with comparable levels to UC samples. In conclusion, we have discovered a simple, scalable, and effective method to purify EVs taking advantage of their heparin affinity. C1 [Balaj, Leonora; Atai, Nadia A.; Chen, Weilin; Mu, Dakai; Tannous, Bakhos A.; Breakefield, Xandra O.; Maguire, Casey A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Balaj, Leonora; Atai, Nadia A.; Chen, Weilin; Mu, Dakai; Tannous, Bakhos A.; Breakefield, Xandra O.; Maguire, Casey A.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA. [Breakefield, Xandra O.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Atai, Nadia A.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1012 WX Amsterdam, Netherlands. [Skog, Johan] Exosome Diagnost Inc, Cambridge, MA USA. RP Maguire, CA (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. EM cmaguire@mgh.harvard.edu FU NIH/NINDS [1 R21 NS081374-01]; American Brain Tumor Association Discovery Grant; NIH/NCI [CA069246, CA141226, CA156009, CA141150]; FMD MGH ECOR Fellowship; Richard Floor Biorepository; PHS [P30NS045776] FX This work was supported by NIH/NINDS 1 R21 NS081374-01 (C.A.M.) and an American Brain Tumor Association Discovery Grant (C.A.M.); NIH/NCI grants CA069246 (X.O.B), CA141226 (X.O.B.); CA156009 (X.O.B.) CA141150 (X.O.B.); LB is supported by an FMD MGH ECOR Fellowship and the Richard Floor Biorepository. We gratefully acknowledge the Neuroscience Center PCR Core facility, which is funded by PHS grant P30NS045776. We thank Maria Ericsson of the Harvard Conventional Electron Microscopy Core for performing the TEM analysis of EV samples. We thank Ross Tomaino of the Harvard Medical School's Taplin Biological Mass Spectrometry facility for performing the mass spectrometry analysis of EV proteins NR 47 TC 21 Z9 21 U1 3 U2 19 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD MAY 19 PY 2015 VL 5 AR 10266 DI 10.1038/srep10266 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ2EK UT WOS:000355296800001 PM 25988257 ER PT J AU Kerlikowske, K Zhu, WW Tosteson, ANA Sprague, BL Tice, JA Lehman, CD Miglioretti, DL AF Kerlikowske, Karla Zhu, Weiwei Tosteson, Anna N. A. Sprague, Brian L. Tice, Jeffrey A. Lehman, Constance D. Miglioretti, Diana L. CA Breast Canc Surveillance TI Identifying Women With Dense Breasts at High Risk for Interval Cancer A Cohort Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID POSTMENOPAUSAL HORMONE-THERAPY; CARCINOMA IN-SITU; SCREENING MAMMOGRAPHY; DIGITAL MAMMOGRAPHY; TUMOR CHARACTERISTICS; UNITED-STATES; TOMOSYNTHESIS; PERFORMANCE; ULTRASOUND; OUTCOMES AB Background: Twenty-one states have laws requiring that women be notified if they have dense breasts and that they be advised to discuss supplemental imaging with their provider. Objective: To better direct discussions of supplemental imaging by determining which combinations of breast cancer risk and Breast Imaging Reporting and Data System (BI-RADS) breast density categories are associated with high interval cancer rates. Design: Prospective cohort. Setting: Breast Cancer Surveillance Consortium (BCSC) breast imaging facilities. Patients: 365 426 women aged 40 to 74 years who had 831 455 digital screening mammography examinations. Measurements: BI-RADS breast density, BCSC 5-year breast cancer risk, and interval cancer rate (invasive cancer <= 12 months after a normal mammography result) per 1000 mammography examinations. High interval cancer rate was defined as more than 1 case per 1000 examinations. Results: High interval cancer rates were observed for women with 5-year risk of 1.67% or greater and extremely dense breasts or 5-year risk of 2.50% or greater and heterogeneously dense breasts (24% of all women with dense breasts). The interval rate of advanced-stage disease was highest (> 0.4 case per 1000 examinations) among women with 5-year risk of 2.50% or greater and heterogeneously or extremely dense breasts (21% of all women with dense breasts). Five-year risk was low to average (0% to 1.66%) for 51.0% of women with heterogeneously dense breasts and 52.5% with extremely dense breasts, with interval cancer rates of 0.58 to 0.63 and 0.72 to 0.89 case per 1000 examinations, respectively. Limitation: The benefit of supplemental imaging was not assessed. Conclusion: Breast density should not be the sole criterion for deciding whether supplemental imaging is justified because not all women with dense breasts have high interval cancer rates. BCSC 5-year risk combined with BI-RADS breast density can identify women at high risk for interval cancer to inform patientprovider discussions about alternative screening strategies. C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Grp Hlth Cooperat Puget Sound, Seattle, WA USA. Univ Washington, Sch Med, Seattle, WA 98109 USA. Geisel Sch Med Dartmouth, Lebanon, NH 03756 USA. Univ Vermont, Burlington, VT USA. Univ Calif Davis, Davis, CA 95616 USA. RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. FU National Cancer Institute [P01 CA154292, HHSN261201100031C, U54 CA163303] FX This work was supported by the National Cancer Institute-funded BCSC (P01 CA154292, HHSN261201100031C, and U54 CA163303). The collection of cancer data used in this study was supported in part by several state public health departments and cancer registries throughout the United States. A full description of these sources is available at http://breastscreening.cancer.gov/work/acknowledgement.html. NR 40 TC 32 Z9 32 U1 0 U2 18 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 19 PY 2015 VL 162 IS 10 BP 673 EP + DI 10.7326/M14-1465 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA CI8IF UT WOS:000355015200016 PM 25984843 ER PT J AU Thomas, MP Liu, X Whangbo, J McCrossan, G Sanborn, KB Basar, E Walch, M Lieberman, J AF Thomas, Marshall P. Liu, Xing Whangbo, Jennifer McCrossan, Geoffrey Sanborn, Keri B. Basar, Emre Walch, Michael Lieberman, Judy TI Apoptosis Triggers Specific, Rapid, and Global mRNA Decay with 3 ' Uridylated Intermediates Degraded by DIS3L2 SO CELL REPORTS LA English DT Article ID GENOME-WIDE DETERMINATION; CELL-DEATH; SACCHAROMYCES-CEREVISIAE; TRANSLATION INHIBITION; DEGRADATION PATHWAY; CASPASE ACTIVATION; CYTOPLASMIC RNA; NUCLEIC-ACIDS; ZCCHC11 TUT4; CYTOCHROME-C AB Apoptosis is a tightly coordinated cell death program that damages mitochondria, DNA, proteins, and membrane lipids. Little is known about the fate of RNA as cells die. Here, we show that mRNAs, but not noncoding RNAs, are rapidly and globally degraded during apoptosis. mRNA decay is triggered early in apoptosis, preceding membrane lipid scrambling, genomic DNA fragmentation, and apoptotic changes to translation initiation factors. mRNA decay depends on mitochondrial outer membrane permeabilization and is amplified by caspase activation. 3 ' truncated mRNA decay intermediates with nontemplated uridylate-rich tails are generated during apoptosis. These tails are added by the terminal uridylyl transferases (TUTases) ZCCHC6 and ZCCHC11, and the uridylated transcript intermediates are degraded by the 3 ' to 5 ' exonuclease DIS3L2. Knockdown of DIS3L2 or the TUTases inhibits apoptotic mRNA decay, translation arrest, and cell death, whereas DIS3L2 overexpression enhances cell death. Our results suggest that global mRNA decay is an overlooked hallmark of apoptosis. C1 [Thomas, Marshall P.; Liu, Xing; Whangbo, Jennifer; McCrossan, Geoffrey; Sanborn, Keri B.; Basar, Emre; Walch, Michael; Lieberman, Judy] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. RP Lieberman, J (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. EM judy.lieberman@childrens.harvard.edu OI Sanborn, Keri/0000-0002-5071-4349 FU NSF; NIH [AI045587] FX We thank Nancy Kedersha, Ashish Lal, and Aaron Deutsch for advice and technical assistance; Paul Anderson and Steve Buratowski for valuable advice; and Andrej Dziembowski and Britt Glaunsinger for plasmids. This work was supported by an NSF graduate research fellowship to M.P.T. and NIH grant AI045587 to J.L. NR 44 TC 20 Z9 20 U1 0 U2 5 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD MAY 19 PY 2015 VL 11 IS 7 BP 1079 EP 1089 DI 10.1016/j.celrep.2015.04.026 PG 11 WC Cell Biology SC Cell Biology GA CI4LI UT WOS:000354719900009 PM 25959823 ER PT J AU Givertz, MM Anstrom, KJ Redfield, MM Deswal, A Haddad, H Butler, J Tang, WHW Dunlap, ME LeWinter, MM Mann, DL Felker, GM O'Connor, CM Goldsmith, SR Ofili, EO Saltzberg, MT Margulies, KB Cappola, TP Konstam, MA Semigran, MJ McNulty, SE Lee, KL Shah, MR Hernandez, AF AF Givertz, Michael M. Anstrom, Kevin J. Redfield, Margaret M. Deswal, Anita Haddad, Haissam Butler, Javed Tang, W. H. Wilson Dunlap, Mark E. LeWinter, Martin M. Mann, Douglas L. Felker, G. Michael O'Connor, Christopher M. Goldsmith, Steven R. Ofili, Elizabeth O. Saltzberg, Mitchell T. Margulies, Kenneth B. Cappola, Thomas P. Konstam, Marvin A. Semigran, Marc J. McNulty, Steven E. Lee, Kerry L. Shah, Monica R. Hernandez, Adrian F. CA NHLBI Heart Failure Clinical Res TI Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study SO CIRCULATION LA English DT Article DE allopurinol; clinical trial; heart failure; xanthine oxidase ID NITROSO-REDOX IMBALANCE; LEFT-VENTRICULAR MASS; URIC-ACID; OXIDATIVE STRESS; ALLOPURINOL USE; HEALTH-STATUS; OXYPURINOL; SURVIVAL; TRIAL; CARDIOMYOPATHY AB Background-Oxidative stress may contribute to heart failure (HF) progression. Inhibiting xanthine oxidase in hyperuricemic HF patients may improve outcomes. Methods and Results-We randomly assigned 253 patients with symptomatic HF, left ventricular ejection fraction <= 40%, and serum uric acid levels >= 9.5 mg/dL to receive allopurinol (target dose, 600 mg daily) or placebo in a double-blind, multicenter trial. The primary composite end point at 24 weeks was based on survival, worsening HF, and patient global assessment. Secondary end points included change in quality of life, submaximal exercise capacity, and left ventricular ejection fraction. Uric acid levels were significantly reduced with allopurinol in comparison with placebo (treatment difference, -4.2 [-4.9, -3.5] mg/dL and -3.5 [-4.2, -2.7] mg/dL at 12 and 24 weeks, respectively, both P<0.0001). At 24 weeks, there was no significant difference in clinical status between the allopurinol-and placebo-treated patients (worsened 45% versus 46%, unchanged 42% versus 34%, improved 13% versus 19%, respectively; P=0.68). At 12 and 24 weeks, there was no significant difference in change in Kansas City Cardiomyopathy Questionnaire scores or 6-minute walk distances between the 2 groups. At 24 weeks, left ventricular ejection fraction did not change in either group or between groups. Rash occurred more frequently with allopurinol (10% versus 2%, P=0.01), but there was no difference in serious adverse event rates between the groups (20% versus 15%, P=0.36). Conclusions-In high-risk HF patients with reduced ejection fraction and elevated uric acid levels, xanthine oxidase inhibition with allopurinol failed to improve clinical status, exercise capacity, quality of life, or left ventricular ejection fraction at 24 weeks. C1 [Givertz, Michael M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Anstrom, Kevin J.; Felker, G. Michael; O'Connor, Christopher M.; McNulty, Steven E.; Lee, Kerry L.; Hernandez, Adrian F.] Duke Univ, Med Ctr, Durham, NC USA. [Redfield, Margaret M.] Mayo Clin, Rochester, MN USA. [Deswal, Anita] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Haddad, Haissam] Ottawa Heart Inst, Ottawa, ON, Canada. [Butler, Javed] Emory Univ, Atlanta, GA 30322 USA. [Tang, W. H. Wilson] Cleveland Clin, Cleveland, OH USA. [Dunlap, Mark E.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [LeWinter, Martin M.] Univ Vermont, Burlington, VT 05405 USA. [Mann, Douglas L.] Washington Univ, St Louis, MO USA. [Goldsmith, Steven R.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Ofili, Elizabeth O.] Morehouse Sch Med, Atlanta, GA 30310 USA. [Saltzberg, Mitchell T.] Christiana Care Hlth Syst, Newark, DE USA. [Margulies, Kenneth B.; Cappola, Thomas P.] Univ Penn, Philadelphia, PA 19104 USA. [Konstam, Marvin A.] Tufts Med Ctr, Boston, MA USA. [Semigran, Marc J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Shah, Monica R.] NHLBI, Bethesda, MD 20892 USA. RP Givertz, MM (reprint author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. EM mgivertz@partners.org RI Hernandez, Adrian F./A-7818-2016 OI Hernandez, Adrian F./0000-0003-3387-9616 FU National Institutes of Health: NHLBI [U10HL084904, U01HL084861, U10HL110312, U109HL110337, U01HL084889, U01HL084890, U01HL084891, U10HL110342, U10HL110262, U01HL084931, U10HL110297, U10HL110302, U10 HL110309, U10HL110336, U10HL110338]; National Center for Advancing Translational Sciences [UL1TR000454, UL1TR000439]; National Institute on Minority Health and Health Disparities [8 U54 MD007588] FX This work was supported by grants from the National Institutes of Health: NHLBI (coordinating center: U10HL084904; regional clinical centers: U01HL084861, U10HL110312, U109HL110337, U01HL084889, U01HL084890, U01HL084891, U10HL110342, U10HL110262, U01HL084931, U10HL110297, U10HL110302, U10 HL110309, U10HL110336, U10HL110338); the National Center for Advancing Translational Sciences (UL1TR000454, UL1TR000439); and the National Institute on Minority Health and Health Disparities (8 U54 MD007588). NR 41 TC 34 Z9 34 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD MAY 19 PY 2015 VL 131 IS 20 BP 1763 EP 1771 DI 10.1161/CIRCULATIONAHA.114.014536 PG 9 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CI2XC UT WOS:000354610300013 PM 25986447 ER PT J AU Schuster, C Gerold, KD Schober, K Probst, L Boerner, K Kim, MJ Ruckdeschel, A Serwold, T Kissler, S AF Schuster, Cornelia Gerold, Kay D. Schober, Kilian Probst, Lilli Boerner, Kevin Kim, Mi-Jeong Ruckdeschel, Anna Serwold, Thomas Kissler, Stephan TI The Autoimmunity-Associated Gene CLEC16A Modulates Thymic Epithelial Cell Autophagy and Alters T Cell Selection SO IMMUNITY LA English DT Article ID MHC CLASS-II; PROTEIN; SUSCEPTIBILITY; MOLECULES; COMPLEX; ANTIGEN; IDENTIFICATION; COMPARTMENTS; THYMOCYTES; EXPRESSION AB CLEC16A variation has been associated with multiple immune-mediated diseases, including type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, celiac disease, Crohn's disease, Addison's disease, primary biliary cirrhosis, rheumatoid arthritis, juvenile idiopathic arthritis, and alopecia areata. Despite strong genetic evidence implicating CLEC16A in autoimmunity, this gene's broad association with disease remains unexplained. We generated Clec16a knock-down (KD) mice in the nonobese diabetic (NOD) model for type 1 diabetes and found that Clec16a silencing protected against autoimmunity. Disease protection was attributable to T cell hyporeactivity, which was secondary to changes in thymic epithelial cell (TEC) stimuli that drive thymocyte selection. Our data indicate that T cell selection and reactivity were impacted by Clec16a variation in thymic epithelium owing to Clec16a's role in TEC autophagy. These findings provide a functional link between human CLEC16A variation and the immune dysregulation that underlies the risk of autoimmunity. C1 [Schuster, Cornelia; Schober, Kilian; Boerner, Kevin; Kim, Mi-Jeong; Ruckdeschel, Anna; Serwold, Thomas; Kissler, Stephan] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. [Gerold, Kay D.; Probst, Lilli; Kissler, Stephan] Univ Wurzburg, DFG Res Ctr Expt Biomed, Rudolf Virchow Ctr, D-97080 Wurzburg, Germany. RP Kissler, S (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA. EM stephan.kissler@joslin.harvard.edu OI , /0000-0003-3062-7800 FU NIH [P30DK036836]; Deutsche Forschungsgemeinschaft [DFG FZ82]; JDRF [2-2010-383]; Mary K. Iacocca Fellowship by Iacocca Foundation FX The authors thank Nicole Hain for technical assistance, Daniela Blassfeld for help with the initial cloning and validation of lentiviral vectors, Jennifer Hollister-Lock for advice with islet purification and insulin measurements, and the Joslin DRC (NIH Award Number P30DK036836) Flow Cytometry Core facility for help with cell sorting. This work was supported in part by funding from the Deutsche Forschungsgemeinschaft to the Rudolf Virchow Center (DFG FZ82), by a Career Development Award from JDRF to S.K. (2-2010-383), and by a Mary K. Iacocca Fellowship provided by the Iacocca Foundation to C.S. NR 40 TC 12 Z9 12 U1 6 U2 13 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1074-7613 EI 1097-4180 J9 IMMUNITY JI Immunity PD MAY 19 PY 2015 VL 42 IS 5 BP 942 EP 952 DI 10.1016/j.immuni.2015.04.011 PG 11 WC Immunology SC Immunology GA CI5VH UT WOS:000354827400019 PM 25979422 ER PT J AU Anahtar, MN Byme, EH Doherty, KE Bowman, BA Yamamoto, HS Soumillon, M Padavattan, N Ismail, N Moodley, A Sabatini, ME Ghebremichael, MS Nusbaum, C Huttenhower, C Virgin, HW Ndung'u, T Dong, KL Walker, BD Fichorova, RN Kwon, DS AF Anahtar, Melis N. Byme, Elizabeth H. Doherty, Kathleen E. Bowman, Brittany A. Yamamoto, Hidemi S. Soumillon, Magali Padavattan, Nikita Ismail, Nasreen Moodley, Amber Sabatini, Mary E. Ghebremichael, Musie S. Nusbaum, Chad Huttenhower, Curtis Virgin, Herbert W. Ndung'u, Thumbi Dong, Krista L. Walker, Bruce D. Fichorova, Raina N. Kwon, Douglas S. TI Cervicovaginal Bacteria Are a Major Modulator of Host Inflammatory Responses in the Female Genital Tract SO IMMUNITY LA English DT Article ID TUMOR-NECROSIS-FACTOR; NEISSERIA-GONORRHOEAE; VAGINAL MICROBIOME; EPITHELIAL-CELLS; PREGNANT-WOMEN; INFECTION; VAGINOSIS; INTERLEUKIN-6; EXPRESSION; PROTECTION AB Colonization by Lactobacillus in the female genital tract is thought to be critical for maintaining genital health. However, little is known about how genital microbiota influence host immune function and modulate disease susceptibility. We studied a cohort of asymptomatic young South African women and found that the majority of participants had genital communities with low Lactobacillus abundance and high ecological diversity. High-diversity communities strongly correlated with genital pro-inflammatory cytokine concentrations in both cross-sectional and longitudinal analyses. Transcriptional profiling suggested that genital antigen-presenting cells sense gram-negative bacterial products in situ via Toll-like receptor 4 signaling, contributing to genital inflammation through activation of the NF-kappa B signaling pathway and recruitment of lymphocytes by chemokine production. Our study proposes a mechanism by which cervicovaginal microbiota impact genital inflammation and thereby might affect a woman's reproductive health, including her risk of acquiring HIV. C1 [Anahtar, Melis N.; Byme, Elizabeth H.; Doherty, Kathleen E.; Bowman, Brittany A.; Ghebremichael, Musie S.; Ndung'u, Thumbi; Dong, Krista L.; Walker, Bruce D.; Kwon, Douglas S.] Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA. [Anahtar, Melis N.] Harvard Univ, Sch Med, Div Med Sci, Boston, MA 02115 USA. [Yamamoto, Hidemi S.; Fichorova, Raina N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. [Soumillon, Magali; Nusbaum, Chad] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA. [Padavattan, Nikita; Ismail, Nasreen; Ndung'u, Thumbi] Univ KwaZulu Natal, Nelson R Mandela Sch Med, HIV Pathogenesis Programme, ZA-4001 Durban, KwaZulu Natal, South Africa. [Moodley, Amber; Dong, Krista L.] Females Rising Educ Support & Hlth, ZA-4066 Durban, KwaZulu Natal, South Africa. [Sabatini, Mary E.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Huttenhower, Curtis] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Virgin, Herbert W.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA. [Ndung'u, Thumbi] Univ KwaZulu Natal, Nelson R Mandela Sch Med, KwaZulu Natal Res Inst TB & HIV K RITH, ZA-4001 Durban, KwaZulu Natal, South Africa. [Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. [Walker, Bruce D.; Kwon, Douglas S.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02115 USA. RP Kwon, DS (reprint author), Massachusetts Gen Hosp, Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA. EM dkwon@mgh.harvard.edu OI Ndung'u, Thumbi/0000-0003-2962-3992 FU Bill and Melinda Gates Foundation; International AIDS Vaccine Initiative (IAVI) [UKZNRSA1001]; NIAID [1R01AI111918, RO1AI067073, 5R01AI079085]; Burroughs Wellcome Fund; NIGMS [T32GM007753]; Paul and Daisy Soros Fellowship; South African Research Chairs Initiative; Howard Hughes Medical Institute FX We would like to thank the FRESH participants; T. Cele for performing the pelvic exams; T. Sikhakhane, S. Ngcobo, and S. Zungu for clinical support; H. Shen for flow cytometric assistance; A. Lisanti for performing tissue staining; B. Corleis, C. Gosmann, and G. Olson for critical feedback and assistance; S. Karim, L. Liebenberg, N. Samsunder, and N. Garrett for helpful discussions regarding mucosal sampling; C. Monaco and S. Handley for discussions about sample preparation and sequencing; and L. Hoisington-Lopez for sequencing support. This work was supported by the Collaboration for AIDS Vaccine Discovery of the Bill and Melinda Gates Foundation, the International AIDS Vaccine Initiative (IAVI) (UKZNRSA1001), and the NIAID (1R01AI111918 and RO1AI067073). D.S.K. received additional support from the Burroughs Wellcome Fund. M.N.A. was supported by award number T32GM007753 from the NIGMS, and the Paul and Daisy Soros Fellowship. R.N.F. and H.S.Y were supported by the NIAID (5R01AI079085). T.N. received additional support from the South African Research Chairs Initiative and an International Early Career Scientist Award from the Howard Hughes Medical Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIGMS or the NIH. NR 46 TC 46 Z9 46 U1 4 U2 12 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1074-7613 EI 1097-4180 J9 IMMUNITY JI Immunity PD MAY 19 PY 2015 VL 42 IS 5 BP 965 EP 976 DI 10.1016/j.immuni.2015.04.019 PG 12 WC Immunology SC Immunology GA CI5VH UT WOS:000354827400021 PM 25992865 ER PT J AU Ganguli, I Wasfy, JH Ferris, TG AF Ganguli, Ishani Wasfy, Jason H. Ferris, Timothy G. TI What Is the Right Number of Clinic Appointments? Visit Frequency and the Accountable Care Organization SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Ganguli, Ishani; Wasfy, Jason H.; Ferris, Timothy G.] Harvard Univ, Sch Med, Boston, MA USA. [Ganguli, Ishani; Wasfy, Jason H.; Ferris, Timothy G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ferris, Timothy G.] Partners HealthCare, Boston, MA USA. RP Ganguli, I (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Bulfinch 205, Boston, MA 02114 USA. EM ishani.ganguli@gmail.com NR 8 TC 5 Z9 5 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 19 PY 2015 VL 313 IS 19 BP 1905 EP 1906 DI 10.1001/jama.2015.3356 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CI4BK UT WOS:000354691200007 PM 25844726 ER PT J AU Rao, RC Ballard, TNS Chen, TC AF Rao, Rajesh C. Ballard, Tiffany N. S. Chen, Teresa C. TI Iris Heterochromia and Unilateral Eyelash Hypertrichosis SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID BIMATOPROST; GLAUCOMA; MECHANISM; GROWTH C1 [Rao, Rajesh C.] Univ Michigan, Dept Ophthalmol & Visual Sci, WK Kellogg Eye Ctr, Ann Arbor, MI 48105 USA. [Rao, Rajesh C.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48105 USA. [Ballard, Tiffany N. S.] Univ Michigan, Dept Surg, Sect Plast Surg, Ann Arbor, MI 48105 USA. [Chen, Teresa C.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Rao, RC (reprint author), Univ Michigan, Dept Ophthalmol & Visual Sci, WK Kellogg Eye Ctr, 1000 Wall St,Brehm Room 8326, Ann Arbor, MI 48105 USA. EM rajeshr@med.umich.edu FU NEI NIH HHS [K12EY022299, K12 EY022299] NR 10 TC 0 Z9 0 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 19 PY 2015 VL 313 IS 19 BP 1967 EP 1968 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CI4BK UT WOS:000354691200019 PM 25988467 ER PT J AU Richard, J Veillette, M Brassard, N Iyerc, SS Roger, M Martin, L Pazgier, M Schon, A Freire, E Routy, JP Smith, AB Park, J Jones, DM Courter, JR Melillo, BN Kaufmann, DE Hahn, BH Permar, SR Haynes, BF Madani, N Sodroski, JG Finzi, A AF Richard, Jonathan Veillette, Maxime Brassard, Nathalie Iyerc, Shilpa S. Roger, Michel Martin, Loic Pazgier, Marzena Schoen, Arne Freire, Ernesto Routy, Jean-Pierre Smith, Amos B., III Park, Jongwoo Jones, David M. Courter, Joel R. Melillo, Bruno N. Kaufmann, Daniel E. Hahn, Beatrice H. Permar, Sallie R. Haynes, Barton F. Madani, Navid Sodroski, Joseph G. Finzi, Andres TI CD4 mimetics sensitize HIV-1-infected cells to ADCC SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE HIV-1; envelope glycoproteins; gp120; CD4 mimetics; ADCC ID HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXICITY-MEDIATING ANTIBODIES; VACCINE EFFICACY TRIAL; HIV-1 ENTRY INHIBITORS; STRUCTURE-BASED DESIGN; VPU PROTEIN; GP120; ENVELOPE; EPITOPES; BINDING AB HIV-1-infected cells presenting envelope glycoproteins (Env) in the CD4-bound conformation on their surface are preferentially targeted by antibody-dependent cell-mediated cytotoxicity (ADCC). HIV-1 has evolved a sophisticated mechanism to avoid exposure of ADCC-mediating Env epitopes by down-regulating CD4 and by limiting the overall amount of Env at the cell surface. Here we report that small-molecule CD4-mimetic compounds induce the CD4-bound conformation of Env, and thereby sensitize cells infected with primary HIV-1 isolates to ADCC mediated by antibodies present in sera, cervicovaginal lavages, and breast milk from HIV-1-infected individuals. Importantly, we identified one CD4 mimetic with the capacity to sensitize endogenously infected ex vivo-amplified primary CD4 T cells to ADCC killing mediated by autologous sera and effector cells. Thus, CD4 mimetics hold the promise of therapeutic utility in preventing and controlling HIV-1 infection. C1 [Richard, Jonathan; Veillette, Maxime; Brassard, Nathalie; Roger, Michel; Finzi, Andres] Univ Montreal, Ctr Hosp, Ctr Rech, Montreal, PQ H3C 3J7, Canada. [Richard, Jonathan; Veillette, Maxime; Roger, Michel; Finzi, Andres] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ H2X 0A9, Canada. [Iyerc, Shilpa S.; Hahn, Beatrice H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Iyerc, Shilpa S.; Hahn, Beatrice H.] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA. [Martin, Loic] Inst Biol & Technol Saclay, Serv Ingn Mol Proteines, Commissariat Eergie Atom, F-91191 Gif Sur Yvette, France. [Pazgier, Marzena] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA. [Pazgier, Marzena] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA. [Schoen, Arne; Freire, Ernesto] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA. [Routy, Jean-Pierre; Finzi, Andres] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada. [Smith, Amos B., III; Park, Jongwoo; Jones, David M.; Courter, Joel R.; Melillo, Bruno N.] Univ Penn, Sch Arts & Sci, Dept Chem, Philadelphia, PA 19104 USA. [Kaufmann, Daniel E.] Harvard Univ, Massachusetts Gen Hosp, Massachusetts Inst, Ragon Inst, Cambridge, MA 02139 USA. [Kaufmann, Daniel E.] Univ Montreal, Dept Med, Montreal, PQ H2X 0A9, Canada. [Kaufmann, Daniel E.] Scripps Res Inst, Ctr HIV AIDS Vaccine Immunol & Immunogen Discover, La Jolla, CA 92037 USA. [Permar, Sallie R.; Haynes, Barton F.] Duke Univ, Med Ctr, Duke Human Vaccine Inst, Durham, NC 27710 USA. [Madani, Navid; Sodroski, Joseph G.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Madani, Navid; Sodroski, Joseph G.] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Div Aids, Boston, MA 02115 USA. [Madani, Navid; Sodroski, Joseph G.] Harvard Univ, Sch Med, Dept Immunol & Infect Dis, Boston, MA 02115 USA. RP Finzi, A (reprint author), Univ Montreal, Ctr Hosp, Ctr Rech, Montreal, PQ H3C 3J7, Canada. EM bhahn@upenn.edu; andres.finzi@umontreal.ca RI MARTIN, loic/E-1627-2011 OI MARTIN, loic/0000-0002-7940-2955 FU Canada Foundation; Canadian Institutes of Health Research operating [119334, 134117]; Fonds de Recherche Quebec Sante Establishment of Young Scientist [26702]; FRQS AIDS and Infectious Diseases Network; CIHR Doctoral Research Award [291485]; CIHR Fellowship Award [135349]; Research Scholar Career Award of the Quebec Health Research Fund [25131]; NIH [R01AI111789, R01AI114266, R01AI087181, R01HL092565, P30AI045008, GM56550, AI100645, UM1AI24755, UM1AI100663, AI106380, AI090682]; International AIDS Vaccine Initiative; Bill and Melinda Gates Foundation [OPP1033109]; National Science Foundation [MCB-1157506]; amfAR [107431-45-RFNT]; Ragon Institute Innovation Award FX We thank Yvette McLaughlin and Elizabeth Carpelan for help in manuscript preparation. We also thank the Centre de Recherche du CHUM Flow Cytometry Platform for technical assistance, Mario Legault for cohort coordination, and Mathieu Coutu for producing sCD4. We thank Kimberly Barbas from Children's Hospital Boston for providing the samples from the uninfected women. We are thankful for all subjects' participation and collaboration. This work was supported by a Canada Foundation for Innovation Program Leader grant, by Canadian Institutes of Health Research operating Grants 119334 and 134117, by Fonds de Recherche Quebec Sante Establishment of Young Scientist Grant 26702 (to A.F.), and by the FRQS AIDS and Infectious Diseases Network. A.F. is the recipient of a Canada Research Chair on Retroviral Entry. M.V. was supported by CIHR Doctoral Research Award 291485. J.R. is the recipient of CIHR Fellowship Award 135349. J.-P.R. is the holder of the Louis Lowenstein Chair in Hematology and Oncology. D.E.K. is supported by Research Scholar Career Award of the Quebec Health Research Fund 25131. This study was also supported by NIH Grants R01AI111789, R01AI114266, R01AI087181, R01HL092565, P30AI045008, GM56550, AI100645, UM1AI24755, UM1AI100663, and AI106380; the International AIDS Vaccine Initiative; the Bill and Melinda Gates Foundation (Grant OPP1033109); the National Science Foundation (Grant MCB-1157506); and the late William F. McCarty-Cooper. N.M. was supported by amfAR Grant 107431-45-RFNT, NIH Grant AI090682, and a Ragon Institute Innovation Award. NR 52 TC 26 Z9 26 U1 0 U2 11 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAY 19 PY 2015 VL 112 IS 20 BP E2687 EP E2694 DI 10.1073/pnas.1506755112 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CI4OD UT WOS:000354729500019 PM 25941367 ER PT J AU Sjolin-Goodfellow, H Frushicheva, MP Ji, QQ Cheng, DA Kadlecek, TA Cantor, AJ Kuriyan, J Chakraborty, AK Salomon, AR Weiss, A AF Sjoelin-Goodfellow, Hanna Frushicheva, Maria P. Ji, Qinqin Cheng, Debra A. Kadlecek, Theresa A. Cantor, Aaron J. Kuriyan, John Chakraborty, Arup K. Salomon, Arthur R. Weiss, Arthur TI The catalytic activity of the kinase ZAP-70 mediates basal signaling and negative feedback of the T cell receptor pathway SO SCIENCE SIGNALING LA English DT Article ID PHOSPHOTYROSINE-BINDING DOMAIN; SYK ACTIVATION SWITCH; TYROSINE PHOSPHORYLATION; MASS-SPECTROMETRY; STRUCTURAL BASIS; ZETA-CHAIN; IMMUNOLOGICAL SYNAPSE; AUTOIMMUNE ARTHRITIS; INTERDOMAIN B; IMMUNE CELLS AB T cell activation by antigens binding to the T cell receptor (TCR) must be properly regulated to ensure normal T cell development and effective immune responses to pathogens and transformed cells while avoiding autoimmunity. The Src family kinase Lck and the Syk family kinase ZAP-70 (zeta chain-associated protein kinase of 70 kD) are sequentially activated in response to TCR engagement and serve as critical components of the TCR signaling machinery that leads to T cell activation. We performed amass spectrometry-based phosphoproteomic study comparing the quantitative differences in the temporal dynamics of phosphorylation in stimulated and unstimulated T cells with or without inhibition of ZAP-70 catalytic activity. The data indicated that the kinase activity of ZAP-70 stimulates negative feedback pathways that target Lck and thereby modulate the phosphorylation patterns of the immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD3 and zeta chain components of the TCR and of signaling molecules downstream of Lck, including ZAP-70. We developed a computational model that provides a mechanistic explanation for the experimental findings on ITAM phosphorylation in wild-type cells, ZAP-70-deficient cells, and cells with inhibited ZAP-70 catalytic activity. This model incorporated negative feedback regulation of Lck activity by the kinase activity of ZAP-70 and predicted the order in which tyrosines in the ITAMs of TCR z chains must be phosphorylated to be consistent with the experimental data. C1 [Sjoelin-Goodfellow, Hanna; Cheng, Debra A.; Kadlecek, Theresa A.; Weiss, Arthur] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA. [Sjoelin-Goodfellow, Hanna; Cheng, Debra A.; Kadlecek, Theresa A.; Weiss, Arthur] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Frushicheva, Maria P.; Chakraborty, Arup K.] MIT, Dept Chem Engn, Cambridge, MA 02142 USA. [Ji, Qinqin; Salomon, Arthur R.] Brown Univ, Dept Chem, Providence, RI 02912 USA. [Cantor, Aaron J.; Kuriyan, John] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA. [Cantor, Aaron J.; Kuriyan, John] Univ Calif Berkeley, Calif Inst Quantitat Biosci, Berkeley, CA 94720 USA. [Kuriyan, John] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA. [Kuriyan, John] Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA. [Kuriyan, John] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA. [Chakraborty, Arup K.] MIT, Dept Phys, Cambridge, MA 02142 USA. [Chakraborty, Arup K.] MIT, Dept Chem, Cambridge, MA 02142 USA. [Chakraborty, Arup K.] MIT, Dept Biol Engn, Cambridge, MA 02142 USA. [Chakraborty, Arup K.] MIT, Inst Med Engn & Sci, Cambridge, MA 02142 USA. [Chakraborty, Arup K.] MIT, Massachusetts Gen Hosp, Ragon Inst, Cambridge, MA 02139 USA. [Chakraborty, Arup K.] Harvard Univ, Cambridge, MA 02139 USA. [Salomon, Arthur R.] Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA. RP Salomon, AR (reprint author), Brown Univ, Dept Chem, Providence, RI 02912 USA. EM arupc@mit.edu; as@brown.edu; aweiss@medicine.ucsf.edu OI Kadlecek, Theresa/0000-0002-1020-8169 FU NIH [P01 AI91580, R01 AI083636]; Wenner-Gren Foundations, Sweden; Stiftelsen Blanceflor Boncompagni Ludovisi, fodd Bildt; Sweden-America Foundation; Cancer Research Institute Irvington Fellowship FX This work was supported in part by NIH grants P01 AI91580 and R01 AI083636; Wenner-Gren Foundations, Sweden (to H.S.-G.); Stiftelsen Blanceflor Boncompagni Ludovisi, fodd Bildt (to H.S.-G.); Sweden-America Foundation (to H.S.-G.); and Cancer Research Institute Irvington Fellowship (to M.P.F.). NR 94 TC 4 Z9 4 U1 0 U2 10 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1945-0877 EI 1937-9145 J9 SCI SIGNAL JI Sci. Signal. PD MAY 19 PY 2015 VL 8 IS 377 AR ra49 DI 10.1126/scisignal.2005596 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CI5DG UT WOS:000354772500003 PM 25990959 ER PT J AU Aragam, KG Dai, D Neely, ML Bhatt, DL Roe, MT Rumsfeld, JS Gurm, HS AF Aragam, Krishna G. Dai, Dadi Neely, Megan L. Bhatt, Deepak L. Roe, Matthew T. Rumsfeld, John S. Gurm, Hitinder S. TI Gaps in Referral to Cardiac Rehabilitation of Patients Undergoing Percutaneous Coronary Intervention in the United States SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE cardiac rehabilitation; percutaneous coronary intervention; quality of care; secondary prevention ID ACUTE MYOCARDIAL-INFARCTION; ARTERY-DISEASE PATIENTS; SECONDARY PREVENTION; HEART-DISEASE; AMERICAN-COLLEGE; EXERCISE; ASSOCIATION; GUIDELINES; OUTCOMES; PROGRAM AB BACKGROUND Rates of referral to cardiac rehabilitation after percutaneous coronary intervention (PCI) have been historically low despite the evidence that rehabilitation is associated with lower mortality in PCI patients. OBJECTIVES This study sought to determine the prevalence of and factors associated with referral to cardiac rehabilitation in a national PCI cohort, and to assess the association between insurance status and referral patterns. METHODS Consecutive patients who underwent PCI and survived to hospital discharge in the National Cardiovascular Data Registry between July 1, 2009 and March 31, 2012 were analyzed. Cardiac rehabilitation referral rates, and patient and institutional factors associated with referral were evaluated for the total study population and for a subset of Medicare patients presenting with acute myocardial infarction. RESULTS Patients who underwent PCI (n = 1,432,399) at 1,310 participating hospitals were assessed. Cardiac rehabilitation referral rates were 59.2% and 66.0% for the overall population and the AMI/Medicare subgroup, respectively. In multivariable analyses, presentation with ST-segment elevation myocardial infarction (odds ratio 2.99; 95% confidence interval: 2.92 to 3.06) and non-ST-segment elevation myocardial infarction (odds ratio: 1.99; 95% confidence interval: 1.94 to 2.03) were associated with increased odds of referral to cardiac rehabilitation. Models adjusted for insurance status showed significant site-specific variability in referral rates, with more than one-quarter of all hospitals referring <20% of patients. CONCLUSIONS Approximately 60% of patients undergoing PCI in the United States are referred for cardiac rehabilitation. Site-specific variation in referral rates is significant and is unexplained by insurance coverage. These findings highlight the potential need for hospital-level interventions to improve cardiac rehabilitation referral rates after PCI. (C) 2015 by the American College of Cardiology Foundation. C1 [Aragam, Krishna G.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Dai, Dadi; Neely, Megan L.; Roe, Matthew T.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Bhatt, Deepak L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Gurm, Hitinder S.] Univ Michigan, Med Ctr, Div Cardiovasc Med, Ann Arbor, MI USA. RP Aragam, KG (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,GRB 8-852, Boston, MA 02114 USA. EM karagam@gmail.com RI 刘, 李陆/H-8469-2015; OI Gurm, Hitinder/0000-0002-1646-0218 FU Amarin; AstraZeneca; Bristol-Myers Squibb; Eisai; Ethicon; Medtronic; Sanofi; Medicines Company; Eli Lilly; Revalesio; American College of Cardiology; American Heart Association; Familial Hyperlipidemia Foundation; National Institutes of Health; Agency for Health Care Research and Quality FX Institute, Mayo Clinic, and the Population and Health Research Institute; has received research grants from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi, and The Medicines Company; and has taken part in unfunded research at FlowCo, PLx Pharma, and Takeda. Dr. Roe has received research funding from Eli Lilly, Revalesio, Sanofi, American College of Cardiology, American Heart Association, and the Familial Hyperlipidemia Foundation; and has received consulting or honoraria from Eli Lilly, AstraZeneca, Sanofi, Janssen Pharmaceuticals, Merck, Regeneron, and Daiichi-Sankyo. Dr. Gurm has received research funding from the National Institutes of Health and the Agency for Health Care Research and Quality. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 43 TC 14 Z9 14 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAY 19 PY 2015 VL 65 IS 19 BP 2079 EP 2088 DI 10.1016/j.jacc.2015.02.063 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CH8DA UT WOS:000354265100006 PM 25975470 ER PT J AU Jorgenson, LA Newsome, WT Anderson, DJ Bargmann, CI Brown, EN Deisseroth, K Donoghue, JP Hudson, KL Ling, GSF MacLeish, PR Marder, E Normann, RA Sanes, JR Schnitzer, MJ Sejnowski, TJ Tank, DW Tsien, RY Ugurbil, K Wingfield, JC AF Jorgenson, Lyric A. Newsome, William T. Anderson, David J. Bargmann, Cornelia I. Brown, Emery N. Deisseroth, Karl Donoghue, John P. Hudson, Kathy L. Ling, Geoffrey S. F. MacLeish, Peter R. Marder, Eve Normann, Richard A. Sanes, Joshua R. Schnitzer, Mark J. Sejnowski, Terrence J. Tank, David W. Tsien, Roger Y. Ugurbil, Kamil Wingfield, John C. TI The BRAIN Initiative: developing technology to catalyse neuroscience discovery SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES LA English DT Article DE BRAIN Initiative; neural circuitry; neurotechnology ID RETINAL CELL-TYPES; NEURAL CIRCUITS; FUNCTIONAL ARCHITECTURE; SENSORY STIMULATION; CEREBRAL-CORTEX; VISUAL-CORTEX; RESOLUTION; NEURONS; RECONSTRUCTION; OPTOGENETICS AB The evolution of the field of neuroscience has been propelled by the advent of novel technological capabilities, and the pace at which these capabilities are being developed has accelerated dramatically in the past decade. Capitalizing on this momentum, the United States launched the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative to develop and apply new tools and technologies for revolutionizing our understanding of the brain. In this article, we review the scientific vision for this initiative set forth by the National Institutes of Health and discuss its implications for the future of neuroscience research. Particular emphasis is given to its potential impact on the mapping and study of neural circuits, and how this knowledge will transform our understanding of the complexity of the human brain and its diverse array of behaviours, perceptions, thoughts and emotions. C1 [Jorgenson, Lyric A.; Hudson, Kathy L.] NIH, Off Director, Bethesda, MD 20892 USA. [Newsome, William T.; Deisseroth, Karl; Schnitzer, Mark J.] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA. [Newsome, William T.] Stanford Univ, Stanford Neurosdences Inst, Stanford, CA 94305 USA. [Anderson, David J.] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA. [Anderson, David J.] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA. [Bargmann, Cornelia I.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA. [Bargmann, Cornelia I.] Rockefeller Univ, Lulu & Anthony Wang Lab Neural Circuits & Behav, New York, NY 10065 USA. [Brown, Emery N.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA. [Brown, Emery N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Brown, Emery N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Deisseroth, Karl] Stanford Univ, Dept Psychiat & Behav Sci, Dept Bioengn, Stanford, CA 94305 USA. [Donoghue, John P.] Brown Univ, Brown Inst Brain Sci, Providence, RI 02912 USA. [Ling, Geoffrey S. F.] Def Adv Res Projects Agcy, Biol Technol Off, Arlington, VA 22203 USA. [MacLeish, Peter R.] Morehouse Sch Med, Neurosci Inst, Dept Neurobiol, Atlanta, GA 30310 USA. [Marder, Eve] Brandeis Univ, Dept Biol, Waltham, MA 02454 USA. [Marder, Eve] Brandeis Univ, Volen Ctr, Waltham, MA 02454 USA. [Normann, Richard A.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA. [Sanes, Joshua R.] Harvard Univ, Ctr Brain Sci, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA. [Schnitzer, Mark J.] Stanford Univ, James H Clark Ctr Biomed Engn & Sci, CNC Program, Stanford, CA 94305 USA. [Sejnowski, Terrence J.] Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA. [Sejnowski, Terrence J.] Salk Inst Biol Studies, Computat Neurobiol Lab, La Jolla, CA 92037 USA. [Tank, David W.] Princeton Univ, Princeton Neurosci Inst, Bezos Ctr Neural Circuit Dynam, Princeton, NJ 08544 USA. [Tank, David W.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA. [Tsien, Roger Y.] Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA. [Tsien, Roger Y.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA. [Ugurbil, Kamil] Univ Minnesota, Ctr Magnet Resonance Res, Minneapolis, MN 55454 USA. [Wingfield, John C.] Natl Sci Fdn, Directorate Biol Sci, Arlington, VA 22230 USA. RP Jorgenson, LA (reprint author), NIH, Off Director, Bldg 10, Bethesda, MD 20892 USA. EM bnewsome@stanford.edu OI Bargmann, Cornelia/0000-0002-8484-0618 FU National Institutes of Health; Howard Hughes Medical Institute FX The authors thank the National Institutes of Health and the Howard Hughes Medical Institute for supporting the publication of this article. NR 82 TC 22 Z9 23 U1 5 U2 37 PU ROYAL SOC PI LONDON PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND SN 0962-8436 EI 1471-2970 J9 PHILOS T R SOC B JI Philos. Trans. R. Soc. B-Biol. Sci. PD MAY 19 PY 2015 VL 370 IS 1668 BP 8 EP 19 AR UNSP 20140164 DI 10.1098/rstb.2014.0164 PG 12 WC Biology SC Life Sciences & Biomedicine - Other Topics GA CH5JH UT WOS:000354071400002 ER PT J AU Tsai, TY Li, JS Wang, SB Li, PY Kwon, YM Li, GA AF Tsai, Tsung-Yuan Li, Jing-Sheng Wang, Shaobai Li, Pingyue Kwon, Young-Min Li, Guoan TI Principal component analysis in construction of 3D human knee joint models using a statistical shape model method SO COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING LA English DT Article DE fluoroscopic images; 3D knee model; statistical shape model; knee ID PROXIMAL FEMUR; RECONSTRUCTION; SURFACE; REGISTRATION; IMAGES; ARTHROPLASTY; PELVIS AB The statistical shape model (SSM) method that uses 2D images of the knee joint to predict the three-dimensional (3D) joint surface model has been reported in the literature. In this study, we constructed a SSM database using 152 human computed tomography (CT) knee joint models, including the femur, tibia and patella and analysed the characteristics of each principal component of the SSM. The surface models of two in vivo knees were predicted using the SSM and their 2D bi-plane fluoroscopic images. The predicted models were compared to their CT joint models. The differences between the predicted 3D knee joint surfaces and the CT image-based surfaces were 0.30 +/- 0.81mm, 0.34 +/- 0.79mm and 0.36 +/- 0.59mm for the femur, tibia and patella, respectively (average +/- standard deviation). The computational time for each bone of the knee joint was within 30s using a personal computer. The analysis of this study indicated that the SSM method could be a useful tool to construct 3D surface models of the knee with sub-millimeter accuracy in real time. Thus, it may have a broad application in computer-assisted knee surgeries that require 3D surface models of the knee. C1 [Tsai, Tsung-Yuan; Li, Jing-Sheng; Wang, Shaobai; Li, Pingyue; Kwon, Young-Min; Li, Guoan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab,Dept Orthopaed Surg, Boston, MA 02114 USA. [Li, Pingyue] Guangzhou Mil Command, Guangzhou Gen Hosp, Dept Orthopaed Surg, Guangzhou 510010, Guangdong, Peoples R China. RP Li, GA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab,Dept Orthopaed Surg, 55 Fruit St,GRJ-1215, Boston, MA 02114 USA. EM gli1@partners.org OI Tsai, Tsung-Yuan/0000-0003-1522-2987 FU NIAMS NIH HHS [R01 AR055612] NR 34 TC 2 Z9 2 U1 1 U2 68 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1025-5842 EI 1476-8259 J9 COMPUT METHOD BIOMEC JI Comput. Methods Biomech. Biomed. Eng. PD MAY 19 PY 2015 VL 18 IS 7 BP 721 EP 729 DI 10.1080/10255842.2013.843676 PG 9 WC Computer Science, Interdisciplinary Applications; Engineering, Biomedical SC Computer Science; Engineering GA AT7UD UT WOS:000345141700004 PM 24156375 ER PT J AU Honda, JR Hess, T Malcolm, KC Ovrutsky, AR Bai, XY Irani, VR Dobos, KM Chan, ED Flores, SC AF Honda, Jennifer R. Hess, Tamara Malcolm, Kenneth C. Ovrutsky, Alida R. Bai, Xiyuan Irani, Vida R. Dobos, Karen M. Chan, Edward D. Flores, Sonia C. TI Pathogenic Nontuberculous Mycobacteria Resist and Inactivate Cathelicidin: Implication of a Novel Role for Polar Mycobacterial Lipids SO PLOS ONE LA English DT Article ID AVIUM COMPLEX; CELL-WALL; LUNG-DISEASE; ANTIMICROBIAL PEPTIDES; COLONY MORPHOLOGY; EPITHELIAL-CELLS; TUBERCULOSIS; EXPRESSION; SURFACE; GLYCOPEPTIDOLIPIDS AB Nontuberculous mycobacteria (NTM) are a large group of environmental organisms with worldwide distribution, but only a relatively few are known to be pathogenic. Chronic, debilitating lung disease is the most common manifestation of NTM infection, which is often refractory to treatment. The incidence and prevalence of NTM lung disease are increasing in the United States and in many parts of the world. Hence, a more complete understanding of NTM pathogenesis will provide the foundation to develop innovative approaches to treat this recalcitrant disease. Herein, we demonstrate that several species of NTM show broad resistance to the antimicrobial peptide, cathelicidin (LL-37). Resistance to LL-37 was not significantly different between M. avium that contain serovar-specific glycopeptidolipid (GPL, M. avium(ssGPL)) and M. avium that do not (M. avium(Delta ssGPL)). Similarly, M. abscessus containing non-specific GPL (M. abscessus(nsGPL(+))) or lacking nsGPL (M. abscessus(nsGPL(-))) remained equally resistant to LL-37. These findings would support the notion that GPL are not the components responsible for NTM resistance to LL-37. Unexpectedly, the growth of M. abscessus(nsGPL(-)) increased with LL-37 or scrambled LL-37 peptide in a dose-dependent fashion. We also discovered that LL-37 exposed to NTM had reduced antimicrobial activity, and initial work indicates that this is likely due to inactivation of LL-37 by lipid component(s) of the NTM cell envelope. We conclude that pathogenic NTM resist and inactivate LL-37. The mechanism by which NTM circumvent the antimicrobial activity of LL-37 remains to be determined. C1 [Honda, Jennifer R.; Malcolm, Kenneth C.; Chan, Edward D.; Flores, Sonia C.] Univ Colorado, Div Pulm Sci & Crit Care Med, Dept Med, Aurora, CO USA. [Honda, Jennifer R.; Malcolm, Kenneth C.; Ovrutsky, Alida R.; Bai, Xiyuan; Chan, Edward D.] Natl Jewish Hlth, Denver, CO USA. [Hess, Tamara] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Irani, Vida R.] Indiana Univ Penn, Dept Biol, Indiana, PA USA. [Honda, Jennifer R.; Ovrutsky, Alida R.; Bai, Xiyuan; Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Honda, JR (reprint author), Univ Colorado, Div Pulm Sci & Crit Care Med, Anschutz Med Campus, Aurora, CO 80045 USA. EM Jennifer.Honda@ucdenver.edu RI Dobos, Karen/D-1170-2017 OI Dobos, Karen/0000-0001-7115-8524 FU National Institutes of Health (NIH) [3R01HL059785-09S1]; University of Colorado Anschutz Medical Campus Pulmonary and Critical Care Division; NIH NRSA Infectious Disease Training Award [T32-AI007447-19]; Tim Gill Endowment for AIDS Research, NIH NRSA Pulmonary and Critical Care Medicine Training Award [T32 HL 7085-83]; Potts Memorial Foundation FX Study support was provided in part by Institutional Funds and the National Institutes of Health (NIH) Supplement 3R01HL059785-09S1 for SCF, University of Colorado Anschutz Medical Campus Pulmonary and Critical Care Division. JRH is supported by a NIH NRSA Infectious Disease Training Award (T32-AI007447-19), the Tim Gill Endowment for AIDS Research, NIH NRSA Pulmonary and Critical Care Medicine Training Award (T32 HL 7085-83), and the Potts Memorial Foundation. NR 54 TC 0 Z9 0 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 18 PY 2015 VL 10 IS 5 AR e0126994 DI 10.1371/journal.pone.0126994 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CI7BG UT WOS:000354917300075 PM 25993058 ER PT J AU Yang, KS Kohler, RH Landon, M Giedt, R Weissleder, R AF Yang, Katherine S. Kohler, Rainer H. Landon, Matthieu Giedt, Randy Weissleder, Ralph TI Single cell resolution in vivo imaging of DNA damage following PARP inhibition SO SCIENTIFIC REPORTS LA English DT Article ID ADP-RIBOSE POLYMERASE; POLY(ADP-RIBOSE) POLYMERASE; BREAST-CANCER; OVARIAN-CANCER; TUMOR-CELLS; OPEN-LABEL; CHROMATIN; OLAPARIB; REPAIR; IDENTIFICATION AB Targeting DNA repair pathways is a powerful strategy to treat cancers. To gauge efficacy in vivo, typical response markers include late stage effects such as tumor shrinkage, progression free survival, or invasive repeat biopsies. These approaches are often difficult to answer critical questions such as how a given drug affects single cell populations as a function of dose and time, distance from microvessels or how drug concentration (pharmacokinetics) correlates with DNA damage (pharmacodynamics). Here, we established a single-cell in vivo pharmacodynamic imaging read-out based on a truncated 53BP1 double-strand break reporter to determine whether or not poly(ADPribose) polymerase (PARP) inhibitor treatment leads to accumulation of DNA damage. Using this reporter, we show that not all PARP inhibitor treated tumors incur an increase in DNA damage. The method provides a framework for single cell analysis of cancer therapeutics in vivo. C1 [Yang, Katherine S.; Kohler, Rainer H.; Landon, Matthieu; Giedt, Randy; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Landon, Matthieu; Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. RP Weissleder, R (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5206, Boston, MA 02114 USA. EM rweissleder@mgh.harvard.edu FU NIH [P50 CA086355, R01CA164448]; [T32 CA 79443] FX We would like to thank Alex Zaltsman for assistance in DeltaVision imaging and Matt Sebas for assistance in mouse surgical procedures. This study was supported by the following grants from the NIH: P50 CA086355 and R01CA164448. K.Y. was supported by T32 CA 79443. NR 51 TC 4 Z9 4 U1 4 U2 13 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD MAY 18 PY 2015 VL 5 AR 10129 DI 10.1038/srep10129 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ1UJ UT WOS:000355269800001 PM 25984718 ER PT J AU Atri, A Hendrix, SB Pejovic, V Hofbauer, RK Edwards, J Molinuevo, JL Graham, SM AF Atri, Alireza Hendrix, Suzanne B. Pejovic, Vojislav Hofbauer, Robert K. Edwards, John Luis Molinuevo, Jose Graham, Stephen M. TI Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis SO ALZHEIMERS RESEARCH & THERAPY LA English DT Article ID SEVERE IMPAIRMENT BATTERY; CONTROLLED-TRIAL; CHOLINESTERASE-INHIBITORS; RECEIVING DONEPEZIL; DISEASE; VALIDITY; DRUGS; INVENTORY; EFFICACY; THERAPY AB Introduction: Treatment in moderate or severe Alzheimer's disease (AD) often involves adding memantine to a cholinesterase-inhibitor (ChEI: donepezil, galantamine, rivastigmine). Evidence from six-month randomized trials and long-term observational studies supports superiority of memantine-ChEI combination to ChEI monotherapy. We utilized area-under-the-curve (AUC) analysis to assess six-month cumulative treatment efficacy of memantine-donepezil combination versus component monotherapies on individual clinical domains and on a composite index. Methods: Data were pooled from 1,408 individuals with moderate to severe AD from four six-month randomized trials of memantine monotherapy (n = 570) or add-on therapy (donepezil-only subset: n = 847). AUC changes from baseline on measures of cognition (SIB), function (ADCS-ADL(19)), behavior (NPI), global status (CIBIC-Plus), and a composite index (4D-CI: equally weighted composite of four domain measures) were calculated using the trapezoidal rule and evaluated via analysis of covariance (ANCOVA) (2-sided-alpha = 0.05). AUC results were contrasted with visit-by-visit changes from baseline ("snapshot analysis"), performed using a mixed-effects model with repeated measures (MMRM). Results: Over the entire six-month period, placebo-only treatment was associated with significant cumulative worsening on all outcomes. Memantine-donepezil combination showed significantly greater AUC improvements (point x week) on the SIB, NPI, and CIBIC-Plus than placebo-donepezil (SIB: 68.4 versus 32.0, P = 0.019; NPI: -74.3 versus -28.2, P = 0.003; CIBIC-Plus: -2.5 versus 1.4, P = 0.006) and memantine-only monotherapies (SIB: 68.4 versus 12.0, P < 0.001; NPI: -74.3 versus -7.4, P < 0.001; CIBIC-Plus: -2.5 versus 2.7, P < 0.001), whereas these comparisons were not significant for the ADCS-ADL(19) (memantine-donepezil (1.4) versus placebo-donepezil (-0.9), P = 0.407; versus memantine-only (-12.2), P = 0.310). Composite index analysis demonstrated significant cumulative advantages of memantine-donepezil combination (630.0) over placebo-donepezil (344.7, P < 0.001) and memantine-only (152.1, P < 0.001) treatments. Combining memantine and donepezil had an additive effect. Compared with AUC analysis, baseline-to-endpoint change-score analysis underestimated effects of combination therapy, monotherapies, or both. Conclusions: This large pooled area-under-the-curve analysis of randomized-trial data in moderate to severe AD provides ecologically valid support that adding memantine to stable donepezil results in overall clinical benefits that are additive compared with individual monotherapies, continue to accumulate through six-month treatment, and are at least 50% greater than those of monotherapies. C1 [Atri, Alireza] Ray Dolby Brain Hlth Ctr, San Francisco, CA 94114 USA. [Atri, Alireza] Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94114 USA. [Atri, Alireza] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Atri, Alireza] Harvard Univ, Sch Med, Boston, MA USA. [Hendrix, Suzanne B.] Pentara Corp, Salt Lake City, UT USA. [Pejovic, Vojislav] Prescott Med Commun Grp, Chicago, IL USA. [Hofbauer, Robert K.; Edwards, John; Graham, Stephen M.] Forest Res Inst Inc, Jersey City, NJ USA. [Luis Molinuevo, Jose] Hosp Clin Barcelona, Alzheimers Dis & Other Cognit Disorders Unit, Barcelona, Spain. [Luis Molinuevo, Jose] Barcelona Beta Brain Res Ctr, Barcelona, Spain. RP Atri, A (reprint author), Ray Dolby Brain Hlth Ctr, CPMC Davies Campus,45 Castro St,Suite 220, San Francisco, CA 94114 USA. EM atria@cpmcri.org OI Molinuevo, Jose Luis/0000-0003-0485-6001 FU Forest Research Institute; Forest Laboratories, Inc., New York FX The study was funded by Forest Research Institute, an affiliate of Actavis Inc, the US marketer of memantine. The reported analyses were performed by Pentara Corporation biostatisticians under the direction of S. Hendrix and in collaboration with A. Atri. The original studies included in the analysis were supported by funding from Forest Laboratories, Inc., New York. The authors wish to acknowledge the invaluable contribution of the principal investigators in the original trials [5-8], the administrative and editorial assistance of Prescott Medical Communications Group, Chicago, IL (especially Dr. Michael L. Miller, formerly of the Prescott Group), Dr. Michael Tocco (previously of FRI) for early discussions and input in the study's design and coordination, Dr. Victor Otcheretko (FRI) for the coordination and completion of the study analyses and manuscript, and Noel Ellison, MS, of Pentara Corporation for assistance with data analyses. Finally, and most importantly, we express our deep gratitude for the commitment of the study participants and their caregivers, whose dedication and generous participation in clinical trials made this research possible. NR 32 TC 11 Z9 11 U1 5 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1758-9193 J9 ALZHEIMERS RES THER JI Alzheimers Res. Ther. PD MAY 18 PY 2015 VL 7 AR 28 DI 10.1186/s13195-015-0109-2 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CI7FM UT WOS:000354928300001 PM 25991927 ER PT J AU Kim, M Choi, W Choi, Y Yoon, C Choi, W AF Kim, Moonseok Choi, Wonjun Choi, Youngwoon Yoon, Changhyeong Choi, Wonshik TI Transmission matrix of a scattering medium and its applications in biophotonics SO OPTICS EXPRESS LA English DT Article ID MULTIMODE OPTICAL-FIBER; DISORDERED MEDIUM; PHASE MICROSCOPY; FULL-FIELD; REAL-TIME; LIGHT; ILLUMINATION; SYSTEMS; LOCALIZATION; CONJUGATION AB A conventional lens has well-defined transfer function with which we can form an image of a target object. On the contrary, scattering media such as biological tissues, multimode optical fibers and layers of disordered nanoparticles have highly complex transfer function, which makes them impractical for the general imaging purpose. In recent studies, we presented a method of experimentally recording the transmission matrix of such media, which is a measure of the transfer function. In this review paper, we introduce two major applications of the transmission matrix: enhancing light energy delivery and imaging through scattering media. For the former, we identified the eigenchannels of the transmission matrix with large eigenvalues and then coupled light to those channels in order to enhance light energy delivery through the media. For the latter, we solved matrix inversion problem to reconstruct an object image from the distorted image by the scattering media. We showed the enlargement of the numerical aperture of imaging systems with the use of scattering media and demonstrated endoscopic imaging through a single multimode optical fiber working in both reflectance and fluorescence modes. Our approach will pave the way of using scattering media as unique optical elements for various biophotonics applications. (C) 2015 Optical Society of America C1 [Kim, Moonseok] Harvard Univ, Sch Med, Cambridge, MA 02139 USA. [Kim, Moonseok] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA 02139 USA. [Choi, Wonjun] Univ Exeter, Dept Phys & Astron, Exeter EX4 4QL, Devon, England. [Choi, Youngwoon] Korea Univ, Sch Biomed Engn, Seoul 136701, South Korea. [Kim, Moonseok; Choi, Wonjun; Yoon, Changhyeong; Choi, Wonshik] Korea Univ, Dept Phys, Seoul 136701, South Korea. [Choi, Wonshik] Ctr Mol Spect & Dynam, Seoul 136701, South Korea. RP Choi, W (reprint author), Korea Univ, Dept Phys, Seoul 136701, South Korea. EM wonshik@korea.ac.kr FU IT RD Program [R2013080003]; Global Frontier Program [2014M3A6B3063710, IBS-R023-D1-2015-a00]; Basic Science Research Program [2013R1A1A2062560, 2013R1A1A2062808]; Nano-Material Technology Development Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [2011-0020205]; Korea Health Technology R&D Project - Ministry of Health & Welfare, South Korea [HI14C0748] FX This research was supported by the IT R&D Program (R2013080003), the Global Frontier Program (2014M3A6B3063710), IBS-R023-D1-2015-a00, the Basic Science Research Program (2013R1A1A2062560, 2013R1A1A2062808) and the Nano-Material Technology Development Program (2011-0020205) through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning. It was also supported by the Korea Health Technology R&D Project (HI14C0748) funded by the Ministry of Health & Welfare, South Korea. NR 47 TC 11 Z9 11 U1 5 U2 27 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 1094-4087 J9 OPT EXPRESS JI Opt. Express PD MAY 18 PY 2015 VL 23 IS 10 BP 12648 EP 12668 DI 10.1364/OE.23.012648 PG 21 WC Optics SC Optics GA CI4GQ UT WOS:000354706800018 PM 26074520 ER PT J AU Kim, M Choi, W Yoon, C Kim, GH Kim, SH Yi, GR Park, QH Choi, W AF Kim, Moonseok Choi, Wonjun Yoon, Changhyeong Kim, Guang Hoon Kim, Seung-hyun Yi, Gi-Ra Park, Q-Han Choi, Wonshik TI Exploring anti-reflection modes in disordered media SO OPTICS EXPRESS LA English DT Article ID TIME-REVERSAL; FLUCTUATIONS; TOMOGRAPHY; SYSTEMS; REGIME; PHASE; PULSE AB Sensing and manipulating targets hidden under scattering media are universal problems that take place in applications ranging from deep-tissue optical imaging to laser surgery. A major issue in these applications is the shallow light penetration caused by multiple scattering that reflects most of incident light. Although advances have been made to eliminate image distortion by a scattering medium, dealing with the light reflection has remained unchallenged. Here we present a method to minimize reflected intensity by finding and coupling light into the anti-reflection modes of a scattering medium. In doing so, we achieved more than a factor of 3 increase in light penetration. Our method of controlling reflected waves makes it readily applicable to in vivo applications in which detector sensors can only be positioned at the same side of illumination and will therefore lay the foundation of advancing the working depth of many existing optical imaging and treatment technologies. (C) 2015 Optical Society of America C1 [Kim, Moonseok] Harvard Univ, Sch Med, Cambridge, MA 02139 USA. [Kim, Moonseok] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA 02139 USA. [Choi, Wonjun] Univ Exeter, Dept Phys & Astron, Exeter EX4 4QL, Devon, England. [Kim, Moonseok; Choi, Wonjun; Yoon, Changhyeong; Park, Q-Han; Choi, Wonshik] Korea Univ, Dept Phys, Seoul 136701, South Korea. [Kim, Guang Hoon] RSS Ctr, Korea Electrotechnol Res Inst, Seoul 121835, South Korea. [Kim, Seung-hyun; Yi, Gi-Ra] Sungkyunkwan Univ, Sch Chem Engn, Suwon 440746, South Korea. [Choi, Wonshik] Ctr Mol Spect & Dynam, Seoul 136701, South Korea. RP Choi, W (reprint author), Korea Univ, Dept Phys, Seoul 136701, South Korea. EM wonshik@korea.ac.kr FU IT RD Program [R2013080003]; Global Frontier Program [2014M3A6B3063710]; Basic Science Research Program [2013R1A1A2062560, 2013R1A1A2062808]; Nano-Material Technology Development Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [2011-0020205]; Korea Health Technology R&D Project - Ministry of Health & Welfare, South Korea [HI14C0748]; [IBS-R023-D1-2015-a00] FX This research was supported by the IT R&D Program (R2013080003), the Global Frontier Program (2014M3A6B3063710), IBS-R023-D1-2015-a00, the Basic Science Research Program (2013R1A1A2062560, 2013R1A1A2062808) and the Nano-Material Technology Development Program (2011-0020205) through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning. It was also supported by the Korea Health Technology R&D Project (HI14C0748) funded by the Ministry of Health & Welfare, South Korea. NR 29 TC 4 Z9 4 U1 0 U2 9 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 1094-4087 J9 OPT EXPRESS JI Opt. Express PD MAY 18 PY 2015 VL 23 IS 10 BP 12740 EP 12749 DI 10.1364/OE.23.012740 PG 10 WC Optics SC Optics GA CI4GQ UT WOS:000354706800026 PM 26074528 ER PT J AU Yang, B Qu, ML Wang, RG Chatterton, JE Liu, XB Zhu, B Narisawa, S Millan, JL Nakanishi, N Swoboda, K Lipton, SA Zhang, DX AF Yang, Bo Qu, Mingliang Wang, Rengang Chatterton, Jon E. Liu, Xiao-Bo Zhu, Bing Narisawa, Sonoko Millan, Jose Luis Nakanishi, Nobuki Swoboda, Kathryn Lipton, Stuart A. Zhang, Dongxian TI The critical role of membralin in postnatal motor neuron survival and disease SO ELIFE LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; HEREDITARY SPASTIC PARAPLEGIA; ER-ASSOCIATED DEGRADATION; SPINAL MUSCULAR-ATROPHY; RECEPTOR SUBUNIT NR3B; MOUSE MODEL; NEURODEGENERATIVE DISEASES; MISFOLDED GLYCOPROTEINS AB Hitherto, membralin has been a protein of unknown function. Here, we show that membralin mutant mice manifest a severe and early-onset motor neuron disease in an autosomal recessive manner, dying by postnatal day 5-6. Selective death of lower motor neurons, including those innervating the limbs, intercostal muscles, and diaphragm, is predominantly responsible for this fatal phenotype. Neural expression of a membralin transgene completely rescues membralin mutant mice. Mechanistically, we show that membralin interacts with Erlin2, an endoplasmic reticulum (ER) membrane protein that is located in lipid rafts and known to be important in ER-associated protein degradation (ERAD). Accordingly, the degradation rate of ERAD substrates is attenuated in cells lacking membralin. Membralin mutations or deficiency in mouse models induces ER stress, rendering neurons more vulnerable to cell death. Our study reveals a critical role of membralin in motor neuron survival and suggests a novel mechanism for early-onset motor neuron disease. C1 [Yang, Bo; Qu, Mingliang; Wang, Rengang; Chatterton, Jon E.; Zhu, Bing; Nakanishi, Nobuki; Lipton, Stuart A.; Zhang, Dongxian] Sanford Burnham Med Res Inst, Neurosci & Aging Res Ctr, La Jolla, CA USA. [Liu, Xiao-Bo] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, Electron Microscopy Lab, Davis, CA 95616 USA. [Narisawa, Sonoko; Millan, Jose Luis] Sanford Burnham Med Res Inst, Sanford Childrens Hlth Res Ctr, La Jolla, CA USA. [Swoboda, Kathryn] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Lipton, Stuart A.] Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA. RP Zhang, DX (reprint author), Sanford Burnham Med Res Inst, Neurosci & Aging Res Ctr, La Jolla, CA USA. EM dzhang@sbmri.org FU National Institutes of Health (NIH) [R01 NS43434, P01 HD29587, P30 NS076411, R01 NS086890] FX National Institutes of Health (NIH) R01 NS43434 Dongxian Zhang; National Institutes of Health (NIH) P01 HD29587 Stuart A Lipton; National Institutes of Health (NIH) P30 NS076411 Stuart A Lipton; National Institutes of Health (NIH) R01 NS086890 Stuart A Lipton NR 72 TC 0 Z9 2 U1 2 U2 2 PU ELIFE SCIENCES PUBLICATIONS LTD PI CAMBRIDGE PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND SN 2050-084X J9 ELIFE JI eLife PD MAY 15 PY 2015 VL 4 AR e06500 DI 10.7554/eLife.06500 PG 19 WC Biology SC Life Sciences & Biomedicine - Other Topics GA DJ5RM UT WOS:000374267600001 ER PT J AU Calderwood, SB Collier, TL Gouverneur, V Liang, SH Vasdev, N AF Calderwood, Samuel B. Collier, Thomas L. Gouverneur, Veronique Liang, Steven H. Vasdev, Neil TI Continuous-Flow Microfluidic [F-18]Radiofluorination of Spirocyclic Iodonium(III) Ylides SO JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS LA English DT Meeting Abstract C1 [Calderwood, Samuel B.; Gouverneur, Veronique] Univ Oxford, Chem Res Lab, Oxford, Oxon, England. [Collier, Thomas L.; Liang, Steven H.; Vasdev, Neil] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. NR 3 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0362-4803 EI 1099-1344 J9 J LABELLED COMPD RAD JI J. Label. Compd. Radiopharm. PD MAY 15 PY 2015 VL 58 SU 1 MA 174 BP S174 EP S174 PG 1 WC Biochemical Research Methods; Chemistry, Medicinal; Chemistry, Analytical SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry GA DD5GH UT WOS:000369950200175 ER PT J AU Rotstein, BH Bonab, AA Livni, E Perlis, RH Liang, SH Vasdev, N AF Rotstein, Benjamin H. Bonab, Ali A. Livni, Eli Perlis, Roy H. Liang, Steven H. Vasdev, Neil TI Radiosynthesis and evaluation of [C-11]isradipine, a calcium channel antagonist, for PET neuroimaging SO JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS LA English DT Meeting Abstract C1 [Rotstein, Benjamin H.; Bonab, Ali A.; Livni, Eli; Liang, Steven H.; Vasdev, Neil] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Nucl Med & Mol Imaging, Boston, MA USA. [Perlis, Roy H.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Perlis, Roy H.] Massachusetts Gen Hosp, Ctr Human Genet Res, Ctr Expt Drugs & Diagnost, Boston, MA 02114 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0362-4803 EI 1099-1344 J9 J LABELLED COMPD RAD JI J. Label. Compd. Radiopharm. PD MAY 15 PY 2015 VL 58 SU 1 MA 298 BP S298 EP S298 PG 1 WC Biochemical Research Methods; Chemistry, Medicinal; Chemistry, Analytical SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry GA DD5GH UT WOS:000369950200299 ER PT J AU Hsieh, CL Botta, G Gao, S Li, TT Van Allen, EM Treacy, DJ Cai, CM He, HH Sweeney, CJ Brown, M Balk, SP Nelson, PS Garraway, LA Kantoff, P AF Hsieh, Chen-Lin Botta, Ginevra Gao, Shuai Li, Tiantian Van Allen, Eliezer M. Treacy, Daniel J. Cai, Changmeng He, Housheng Hansen Sweeney, Christopher J. Brown, Myles Balk, Steven P. Nelson, Peter S. Garraway, Levi A. Kantoff, PhilipW. TI PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy SO CANCER RESEARCH LA English DT Article ID TARGETED THERAPY; MECHANISMS; PROTEIN; AXIS; GENE; MYC AB Whole-exome sequencing of metastatic castration-resistant prostate cancer (mCRPC) reveals that 5% to 7% of tumors harbor promyelocytic leukemia zinc finger (PLZF) protein homozygous deletions. PLZF is a canonical androgen-regulated putative tumor suppressor gene whose expression is inhibited by androgen deprivation therapy (ADT). Here, we demonstrate that knockdown of PLZF expression promotes a CRPC and enzalutamide-resistant phenotype in prostate cancer cells. Reintroduction of PLZF expression is sufficient to reverse androgen-independent growth mediated by PLZF depletion. PLZF loss enhances CRPC tumor growth in a xenograft model. Bioinformatic analysis of the PLZF cistrome shows that PLZF negatively regulates multiple pathways, including the MAPK pathway. Accordingly, our data support an oncogenic program activated by ADT. This acquired mechanism together with the finding of genetic loss in CRPC implicates PLZF inactivation as a mechanism promoting ADT resistance and the CRPC phenotype. (C) 2015 AACR. C1 [Hsieh, Chen-Lin; Botta, Ginevra; Li, Tiantian; Van Allen, Eliezer M.; Treacy, Daniel J.; Sweeney, Christopher J.; Brown, Myles; Garraway, Levi A.; Kantoff, PhilipW.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Van Allen, Eliezer M.; Brown, Myles] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA. [Van Allen, Eliezer M.; Brown, Myles] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Botta, Ginevra; Garraway, Levi A.] Broad Inst, Cambridge, MA USA. [Gao, Shuai; Cai, Changmeng; Balk, Steven P.] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA. [Gao, Shuai; Cai, Changmeng; Balk, Steven P.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [He, Housheng Hansen] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada. [He, Housheng Hansen] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. [Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Nelson, Peter S.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Kantoff, P (reprint author), Dana Farber Canc Inst, Suite D1230,450 Brookline Ave, Boston, MA 02215 USA. EM levi_garraway@dfci.harvard.edu; philip_kantoff@dfci.harvard.edu OI Brown, Myles/0000-0002-8213-1658; Cai, Changmeng/0000-0002-8701-2586 FU DF/HCC Prostate Cancer SPORE [P50 CA090381-12]; DoD Postdoctoral Training Award [W81XWH-13-1-0383, PC121543]; Starr Cancer Consortium; Prostate SPORE; PCF/Mazzone Award; PNW SPORE [P50 CA097186]; NIH [P01CA163227, P01CA085859, P01 CA163227, K99CA166507]; Cancer-Prostate Cancer Foundation Prostate Dream Team Translational Research Grant [SU2C-AACR-DT0712] FX The work from the laboratory of P.W. Kantoff was supported by DF/HCC Prostate Cancer SPORE (P50 CA090381-12) and C.-L. Hsieh was supported by DoD Postdoctoral Training Award (W81XWH-13-1-0383). The work from the laboratory of L.A. Garraway was supported by Starr Cancer Consortium, Prostate SPORE, PCF/Mazzone Award, and G. Botta was supported by DoD Postdoctoral Training Award (PC121543). The rapid autopsy program and tissue/tumor collection and analyses were supported by PNW SPORE (P50 CA097186), NIH (P01CA163227), and NIH (P01CA085859). S.P. Balk was supported by NIH (P01 CA163227). M. Brown was supported by NIH (P01CA163227). C. Cai was supported by NIH K99CA166507. E.M. Van Allen was supported by NIH 1 K08 CA188615-01 and a Stand Up To Cancer-Prostate Cancer Foundation Prostate Dream Team Translational Research Grant (SU2C-AACR-DT0712). StandUp To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. NR 16 TC 6 Z9 6 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD MAY 15 PY 2015 VL 75 IS 10 BP 1944 EP 1948 DI 10.1158/0008-5472.CAN-14-3602 PG 5 WC Oncology SC Oncology GA CL9XP UT WOS:000357332700004 PM 25808865 ER PT J AU Maiso, P Huynh, D Moschetta, M Sacco, A Aljawai, Y Mishima, Y Asara, JM Roccaro, AM Kimmelman, AC Ghobrial, IM AF Maiso, Patricia Huynh, Daisy Moschetta, Michele Sacco, Antonio Aljawai, Yosra Mishima, Yuji Asara, John M. Roccaro, Aldo M. Kimmelman, Alec C. Ghobrial, Irene M. TI Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma SO CANCER RESEARCH LA English DT Article ID INDUCIBLE FACTOR 1-ALPHA; CANCER-CELLS; GLUCOSE-METABOLISM; LYSYL OXIDASE; IN-VIVO; HYPOXIA; TUMOR; GLYCOLYSIS; INHIBITOR; PATHWAY AB Drug resistance remains a major clinical challenge for cancer treatment. Multiple myeloma is an incurable plasma cell cancer selectively localized in the bone marrow. The main cause of resistance in myeloma is the minimal residual disease cells that are resistant to the original therapy, including bortezomib treatment and high-dose melphalan in stem cell transplant. In this study, we demonstrate that altered tumor cell metabolism is essential for the regulation of drug resistance in multiple myeloma cells. We show the unprecedented role of the metabolic phenotype in inducing drug resistance through LDHA and HIF1A in multiple myeloma, and that specific inhibition of LDHA and HIF1A can restore sensitivity to therapeutic agents such as bortezomib and can also inhibit tumor growth induced by altered metabolism. Knockdown of LDHA can restore sensitivity of bortezomib resistance cell lines while gain-of-function studies using LDHA or HIF1A induced resistance in bortezomib-sensitive cell lines. Taken together, these data suggest that HIF1A and LDHA are important targets for hypoxia-driven drug resistance. Novel drugs that regulate metabolic pathways in multiple myeloma, specifically targeting LDHA, can be beneficial to inhibit tumor growth and overcome drug resistance. (C) 2015 AACR. C1 [Maiso, Patricia; Huynh, Daisy; Moschetta, Michele; Sacco, Antonio; Aljawai, Yosra; Mishima, Yuji; Roccaro, Aldo M.; Ghobrial, Irene M.] Dana Farber Canc Inst, Med Oncol, Boston, MA USA. [Maiso, Patricia; Huynh, Daisy; Moschetta, Michele; Sacco, Antonio; Aljawai, Yosra; Mishima, Yuji; Roccaro, Aldo M.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Asara, John M.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA. [Kimmelman, Alec C.] Dana Farber Canc Inst, Dept Radiat Oncol, Div Genom Stabil & DNA Repair, Boston, MA 02115 USA. RP Ghobrial, IM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brooklyn Ave, Boston, MA 02115 USA. EM irene_ghobrial@dfci.harvard.edu RI Sacco, Antonio/K-4681-2016; OI Sacco, Antonio/0000-0003-2945-9416; Maiso, Patricia/0000-0003-3745-1924; Roccaro, Aldo/0000-0002-1872-5128 FU EHA (European Hematology Association); SPORE [P50 CA100707]; NIH [R01CA154648]; Leukemia and Lymphoma Society; Miguel Servet program from Instituto de Salud Carlos III FX This work was supported in part by EHA (European Hematology Association), SPORE P50 CA100707, NIH R01CA154648, Leukemia and Lymphoma Society, and Miguel Servet program from Instituto de Salud Carlos III. NR 45 TC 21 Z9 23 U1 1 U2 10 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD MAY 15 PY 2015 VL 75 IS 10 BP 2071 EP 2082 DI 10.1158/0008-5472.CAN-14-3400 PG 12 WC Oncology SC Oncology GA CL9XP UT WOS:000357332700016 PM 25769724 ER PT J AU Klingler, S Guo, BF Yao, J Yan, HY Zhang, L Vaseva, AV Chen, SD Canoll, P Horner, J Wang, YA Paik, JH Ying, HQ Zheng, HW AF Klingler, Stefan Guo, Baofeng Yao, Jun Yan, Haiyan Zhang, Ling Vaseva, Angelina V. Chen, Sida Canoll, Peter Horner, James W. Wang, Y. Alan Paik, Ji-Hye Ying, Haoqiang Zheng, Hongwu TI Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms SO CANCER RESEARCH LA English DT Article ID INTEGRATED GENOMIC ANALYSIS; LUNG-CANCER; RECEPTOR GENE; MUTANT EGFR; HUMAN GLIOBLASTOMAS; KINASE INHIBITORS; MET AMPLIFICATION; STEM-CELLS; MUTATIONS; GEFITINIB AB Epidermal growth factor receptor (EGFR) is highly amplified, mutated, and overexpressed in human malignant gliomas. Despite its prevalence and growth-promoting functions, therapeutic strategies to inhibit EGFR kinase activity have not been translated into profound beneficial effects in glioma clinical trials. To determine the roles of oncogenic EGFR signaling in glioma-genesis and tumor maintenance, we generated a novel glioma mouse model driven by inducible expression of a mutant EGFR (EGFR*). Using combined genetic and pharmacologic interventions, we revealed that EGFR*-driven gliomas were insensitive to EGFR tyrosine kinase inhibitors, although they could efficiently inhibit EGFR* autophosphorylation in vitro and in vivo. This is in contrast with the genetic suppression of EGFR* induction that led to significant tumor regression and prolonged animal survival. However, despite their initial response to genetic EGFR* extinction, all tumors would relapse and propagate independent of EGFR*. We further showed that EGFR*-independent tumor cells existed prior to treatment and were responsible for relapse following genetic EGFR* suppression. And, the addition of a PI3K/mTOR inhibitor could significantly delay relapse and prolong animal survival. Our findings shed mechanistic insight into EGFR drug resistance in glioma and provide a platform to test therapies targeting aberrant EGFR signaling in this setting. (C) 2015 AACR. C1 [Klingler, Stefan; Guo, Baofeng; Zhang, Ling; Vaseva, Angelina V.; Chen, Sida; Zheng, Hongwu] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA. [Yao, Jun; Ying, Haoqiang] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA. [Yan, Haiyan] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Canoll, Peter] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA. [Horner, James W.; Wang, Y. Alan] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA. [Paik, Ji-Hye] Weill Cornell Med Coll, Dept Pathol, New York, NY USA. RP Zheng, HW (reprint author), Cold Spring Harbor Lab, One Bungtown Rd, Cold Spring Harbor, NY 11724 USA. EM hzheng@cshl.edu FU V Foundation Scholar Grant; Sontag Foundation Distinguished Scientist Grant; Bradley Zankel Foundation; Sidney Kimmel Foundation Scholars Award; National Cancer Institute Cancer Center Support Grant Development Funds [CA45508]; SPORE [P50CA127001] FX This work is supported by a V Foundation Scholar Grant and a Sontag Foundation Distinguished Scientist Grant (H. Zheng). Additional funding was provided by the Bradley Zankel Foundation. H. Zheng is also supported by Sidney Kimmel Foundation Scholars Award and National Cancer Institute Cancer Center Support Grant Development Funds (Grant CA45508). Y.A. Wang is supported by SPORE (P50CA127001). NR 44 TC 3 Z9 4 U1 0 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD MAY 15 PY 2015 VL 75 IS 10 BP 2109 EP 2119 DI 10.1158/0008-5472.CAN-14-3122 PG 11 WC Oncology SC Oncology GA CL9XP UT WOS:000357332700019 PM 25808866 ER PT J AU Xiao, YP Freeman, GJ AF Xiao, Yanping Freeman, Gordon J. TI A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2 SO CLINICAL CANCER RESEARCH LA English DT Editorial Material ID B7 FAMILY; MEMBER; IDENTIFICATION AB HHLA2 is a newly identified B7 family member that modulates T-cell functions through interaction with TMIGD2 and possibly a second receptor, with coinhibition in two studies and costimulation in one study. HHLA2 is expressed on a variety of human cancers, and its coinhibitory function makes it a candidate for cancer immunotherapy. (C)2015 AACR. C1 [Xiao, Yanping; Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Freeman, GJ (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM Gordon_Freeman@dfci.harvard.edu FU NCI NIH HHS [P50CA101942, P50 CA101942, U54 CA163125, U54CA163125]; NIAID NIH HHS [AI100665, HHSN272201100018C, P01 AI056299, P01AI056299]; PHS HHS [HHSN272201100018C] NR 9 TC 7 Z9 7 U1 1 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 15 PY 2015 VL 21 IS 10 BP 2201 EP 2203 DI 10.1158/1078-0432.CCR-14-2658 PG 3 WC Oncology SC Oncology GA CL9YQ UT WOS:000357335500003 PM 25869386 ER PT J AU Katayama, R Lovly, CM Shaw, AT AF Katayama, Ryohei Lovly, Christine M. Shaw, Alice T. TI Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine SO CLINICAL CANCER RESEARCH LA English DT Article ID LARGE-CELL LYMPHOMA; REARRANGED NSCLC PATIENTS; ALK INHIBITOR ALECTINIB; NON-HODGKINS-LYMPHOMA; ROS ONCOGENE 1; GROWTH-FACTOR; CRIZOTINIB RESISTANCE; ACQUIRED-RESISTANCE; FUSION GENE; MUTATIONS AB The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase was initially discovered as a component of the fusion protein nucleophosmin (NPM)-ALK in anaplastic large-cell lymphoma (ALCL). Genomic alterations in ALK, including rearrangements, point mutations, and genomic amplification, have now been identified in several malignancies, including lymphoma, non-small cell lung cancer (NSCLC), neuroblastoma, inflammatory myofibroblastic tumor, and others. Importantly, ALK serves as a validated therapeutic target in these diseases. Several ALK tyrosine kinase inhibitors (TKI), including crizotinib, ceritinib, and alectinib, have been developed, and some of them have already been approved for clinical use. These ALK inhibitors have all shown remarkable clinical outcomes in ALK-rearranged NSCLC. Unfortunately, as is the case for other kinase inhibitors in clinical use, sensitive tumors inevitably relapse due to acquired resistance. This review focuses on the discovery, function, and therapeutic targeting of ALK, with a particular focus on ALK-rearranged NSCLC. (C)2015 AACR. C1 [Katayama, Ryohei] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1358550, Japan. [Lovly, Christine M.] Vanderbilt Univ, Dept Med, Nashville, TN USA. [Shaw, Alice T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Shaw, Alice T.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Katayama, R (reprint author), Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan. EM ryohei.katayama@jfcr.or.jp FU JSPS KAKENHI [25710015]; Ministry of Health Labour and Welfare; NIH [R01CA121210, P01CA129243, R01CA164273]; Damon Runyon Clinical Investigator award; LUNGevity career development award; National Foundation for Cancer Research FX R. Katayama was supported by JSPS KAKENHI grant number 25710015 and the Ministry of Health Labour and Welfare. C.M. Lovly was supported by the NIH under award numbers R01CA121210 and P01CA129243 and also by a Damon Runyon Clinical Investigator award and LUNGevity career development award. A.T. Shaw was supported by the NIH under award number R01CA164273 and by the National Foundation for Cancer Research. NR 80 TC 50 Z9 50 U1 2 U2 9 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 15 PY 2015 VL 21 IS 10 BP 2227 EP 2235 DI 10.1158/1078-0432.CCR-14-2791 PG 9 WC Oncology SC Oncology GA CL9YQ UT WOS:000357335500009 PM 25979929 ER PT J AU Gandara, DR Hammerman, PS Sos, ML Lara, PN Hirsch, FR AF Gandara, David R. Hammerman, Peter S. Sos, Martin L. Lara, Primo N., Jr. Hirsch, Fred R. TI Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics SO CLINICAL CANCER RESEARCH LA English DT Article ID PHASE-III; PLUS CARBOPLATIN; GEMCITABINE; MUTATIONS; THERAPY; CHEMOTHERAPY; CARCINOMAS; PACLITAXEL; ERLOTINIB; SURVIVAL AB Squamous cell lung cancer (SCC) represents an area of unmet need in lung cancer research. For the past several years, therapeutic progress in SCC has lagged behind the now more common non-small cell lung cancer histologic subtype of adenocarcinoma. However, recent efforts to define the complex biology underlying SCC have begun to bear fruit in a multitude of ways, including characterization of previously unknown genomic and signaling pathways, delineation of new, potentially actionable molecular targets, and subsequent development of a large number of agents directed against unique SCC-associated molecular abnormalities. For the first time, SCC-specific prognostic gene signatures and predictive biomarkers of new therapeutic agents are emerging. In addition, recent and ongoing clinical trials, including the Lung-MAP master protocol, have been designed to facilitate approval of targeted therapy-biomarker combinations. In this comprehensive review, we describe the current status of SCC therapeutics, recent advances in the understanding of SCC biology and prognostic gene signatures, and the development of innovative new clinical trials, all of which offer new hope for patients with advanced SCC. (C)2015 AACR. C1 [Gandara, David R.; Lara, Primo N., Jr.] Calif State Univ Sacramento, Davis Comprehens Canc Ctr, Sacramento, CA 95819 USA. [Hammerman, Peter S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Sos, Martin L.] Univ Cologne, Ctr Integrated Oncol Koln Bonn, Dept Translat Genom, D-50931 Cologne, Germany. [Sos, Martin L.] Univ Hosp Cologne, Ctr Integrated Oncol Koln Bonn, Network Genom Med, Cologne, Germany. [Hirsch, Fred R.] Univ Colorado Denver, Dept Med Med Oncol & Pathol, Aurora, CO USA. RP Gandara, DR (reprint author), Univ Calif Davis, Ctr Comprehens Canc, Div Hematol & Oncol, Suite 3016,4501 X St, Sacramento, CA 95817 USA. EM david.gandara@ucdmc.ucdavis.edu FU NIH [P30CA93373, K08CA163677]; German Federal Ministry of Education and Research (BMBF) [01ZX1406]; NCI/SPECS [UO1CA157715] FX D.R. Gandara and P.N. Lara Jr were supported by the NIH under award number P30CA93373. P.S. Hammerman was supported by the NIH under award number K08CA163677. M.L. Sos was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (grant #01ZX1406). F.R. Hirsch and D.R. Gandara were supported by the NCI/SPECS under award number UO1CA157715. NR 44 TC 16 Z9 16 U1 1 U2 11 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 15 PY 2015 VL 21 IS 10 BP 2236 EP 2243 DI 10.1158/1078-0432.CCR-14-3039 PG 8 WC Oncology SC Oncology GA CL9YQ UT WOS:000357335500010 PM 25979930 ER PT J AU Carvajal, RD Lawrence, DP Weber, JS Gajewski, TF Gonzalez, R Lutzky, J O'Day, SJ Hamid, O Wolchok, JD Chapman, PB Sullivan, RJ Teitcher, JB Ramaiya, N Giobbie-Hurder, A Antonescu, CR Heinrich, MC Bastian, BC Corless, CL Fletcher, JA Hodi, FS AF Carvajal, Richard D. Lawrence, Donald P. Weber, Jeffrey S. Gajewski, Thomas F. Gonzalez, Rene Lutzky, Jose O'Day, Steven J. Hamid, Omid Wolchok, Jedd D. Chapman, Paul B. Sullivan, Ryan J. Teitcher, Jerrold B. Ramaiya, Nikhil Giobbie-Hurder, Anita Antonescu, Cristina R. Heinrich, Michael C. Bastian, Boris C. Corless, Christopher L. Fletcher, Jonathan A. Hodi, F. Stephen TI Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition SO CLINICAL CANCER RESEARCH LA English DT Article ID GASTROINTESTINAL STROMAL TUMORS; METASTATIC MELANOMA; IMATINIB RESISTANCE; COMPLETE RESPONSE; MUCOSAL MELANOMA; MAJOR RESPONSE; MUTATIONS; SUNITINIB; THERAPY; MULTICENTER AB Purpose: Although durable responses can be achieved with tyrosine kinase inhibitors such as imatinib in melanomas harboring KIT mutations, the efficacy of alternative inhibitors after progression to imatinib and the activity of these agents on brain metastases are unknown. Experimental Design: We conducted a phase II study of nilotinib 400 mg twice a day in two cohorts of patients with melanomas harboring KIT mutations or amplification: (A) those refractory or intolerant to a prior KIT inhibitor; and (B) those with brain metastases. The primary endpoint was 4-month disease control rate. Secondary endpoints included response rate, time-to-progression (TTP), and overall survival (OS). A Simon two-stage and a single-stage design was planned to assess for the primary endpoint in cohorts A and B, respectively. Results: Twenty patients were enrolled and 19 treated (11 in cohort A; 8 in cohort B). Three patients on cohort A [27%; 95% confidence interval (CI), 8%-56%] and 1 on cohort B (12.5%; 90% CI, 0.6%-47%) achieved the primary endpoint. Two partial responses were observed in cohort A (18.2%; 90% CI, 3%-47%); none were observed in cohort B. The median TTP and OS was 3.3 (90% CI, 2.1-3.9 months) and 9.1 months (90% CI, 4.3-14.2 months), respectively, in all treated patients. Conclusions: Nilotinib may achieve disease control in patients with melanoma harboring KIT alterations and whose disease progressed after imatinib therapy. The efficacy of this agent in KIT-altered melanoma with brain metastasis is limited. (C)2015 AACR. C1 [Carvajal, Richard D.; Wolchok, Jedd D.; Chapman, Paul B.; Teitcher, Jerrold B.; Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Carvajal, Richard D.; Wolchok, Jedd D.; Chapman, Paul B.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. [Lawrence, Donald P.; Sullivan, Ryan J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Weber, Jeffrey S.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Gajewski, Thomas F.] Univ Chicago, Chicago, IL 60637 USA. [Gonzalez, Rene] Univ Colorado, Ctr Canc, Aurora, CO USA. [Lutzky, Jose] Mt Sinai Comprehens Canc Ctr, Miami Beach, FL USA. [O'Day, Steven J.] Beverly Hills Canc Ctr, Beverly Hills, CA USA. [Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA. [Ramaiya, Nikhil; Giobbie-Hurder, Anita; Fletcher, Jonathan A.; Hodi, F. Stephen] Dana Farber Canc Inst, Boston, MA 02215 USA. [Heinrich, Michael C.; Corless, Christopher L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Bastian, Boris C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Hodi, FS (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM Stephen_hodi@dfci.harvard.edu FU Novartis; NIH/NCI [P01 CA025874] FX Funding for this trial was provided by Novartis. R.D. Carvajal and B.C. Bastian received funding from NIH/NCI grant P01 CA025874. NR 29 TC 14 Z9 14 U1 0 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 15 PY 2015 VL 21 IS 10 BP 2289 EP 2296 DI 10.1158/1078-0432.CCR-14-1630 PG 8 WC Oncology SC Oncology GA CL9YQ UT WOS:000357335500016 PM 25695690 ER PT J AU Lum, LG Thakur, A Al-Kadhimi, Z Colvin, GA Cummings, FJ Legare, RD Dizon, DS Kouttab, N Maizel, A Colaiace, W Liu, Q Rathore, R AF Lum, Lawrence G. Thakur, Archana Al-Kadhimi, Zaid Colvin, Gerald A. Cummings, Francis J. Legare, Robert D. Dizon, Don S. Kouttab, Nicola Maizel, Abby Colaiace, William Liu, Qin Rathore, Ritesh TI Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial SO CLINICAL CANCER RESEARCH LA English DT Article ID TYROSINE KINASE INHIBITOR; NON-HODGKINS-LYMPHOMA; BISPECIFIC ANTIBODIES; MONOCLONAL-ANTIBODY; HIGH-RISK; CAPECITABINE; CHEMOTHERAPY; TRASTUZUMAB; CYTOTOXICITY; TOLERABILITY AB Purpose: This study reports a phase I immunotherapy trial in 23 women with metastatic breast cancer consisting of eight infusions of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed anti-CD3-activated T cells (ATC) in combination with low-dose IL-2 and granulocyte-macrophage colony-stimulating factor to determine safety, maximum tolerated dose (MTD), technical feasibility, T-cell trafficking, immune responses, time to progression, and overall survival (OS). Experimental Design: ATC were expanded from leukapheresis product using IL2 and anti-CD3 monoclonal antibody and armed with HER2Bi. In 3+3 dose escalation design, groups of 3 patients received 5, 10, 20, or 40 x 10(9) armed ATC (aATC) per infusion. Results: There were no dose-limiting toxicities and the MTD was not defined. It was technically feasible to grow 160 x 10(9) ATC from a single leukapheresis. aATC persisted in the blood for weeks and trafficked to tumors. Infusions of aATC induced anti-breast cancer responses and increases in immunokines. At 14.5 weeks after enrollment, 13 of 22 (59.1%) evaluable patients had stable disease and 9 of 22 (40.9%) had progressive disease. The median OS was 36.2 months for all patients, 57.4 months for HER2 3+ patients, and 27.4 months for HER2 0-2+ patients. Conclusions: Targeting HER2(+) and HER2(-) tumors with aATC infusions induced antitumor responses, increases in Th1 cytokines, and IL12 serum levels that suggest that aATC infusions vaccinated patients against their own tumors. These results provide a strong rationale for conducting phase II trials. (C)2015 AACR. C1 [Lum, Lawrence G.; Thakur, Archana; Al-Kadhimi, Zaid] Wayne State Univ, Dept Oncol, Detroit, MI 48201 USA. [Lum, Lawrence G.; Thakur, Archana; Al-Kadhimi, Zaid] Karmanos Canc Inst, Detroit, MI USA. [Lum, Lawrence G.; Al-Kadhimi, Zaid] Wayne State Univ, Dept Med, Detroit, MI 48201 USA. [Lum, Lawrence G.] Wayne State Univ, Dept Immunol & Microbiol, Detroit, MI 48201 USA. [Colvin, Gerald A.] South Cty Hosp, Wakefield, RI USA. [Cummings, Francis J.; Rathore, Ritesh] Roger Williams Hosp, Dept Med, Div Hematol & Oncol, Providence, RI USA. [Legare, Robert D.; Maizel, Abby] Brown Univ, Women & Infants Hosp, Providence, RI USA. [Dizon, Don S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Canc Ctr,Dept Med, Boston, MA USA. [Kouttab, Nicola] Roger Williams Med Ctr, Dept Pathol, Providence, RI USA. [Colaiace, William] Roger Williams Med Ctr, Dept Nucl Med, Providence, RI USA. [Liu, Qin] Wistar Inst Anat & Biol, Dept Med, Philadelphia, PA 19104 USA. RP Lum, LG (reprint author), Wayne State Univ, 4100 John R St, Detroit, MI 48201 USA. EM luml@karmanos.org FU National Cancer Institute of the NIH [CA092344, CA140314]; NIH [P30CA22453]; Young Family Foundation; Raymond Neag Foundation FX This study was supported by the National Cancer Institute of the NIH under award numbers CA092344 (to L.G. Lum) and CA140314 (to L.G. Lum). The Microscopy, Imaging and Cytometry Resources Core is supported, in part, by NIH Center grant P30CA22453 to The Karmanos Cancer Institute, Wayne State University and the Perinatology Research Branch of the National Institutes of Child Health and Development, Wayne State University. The studies were also supported by the Young Family Foundation and the Raymond Neag Foundation. NR 33 TC 14 Z9 15 U1 1 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 15 PY 2015 VL 21 IS 10 BP 2305 EP 2314 DI 10.1158/1078-0432.CCR-14-2280 PG 10 WC Oncology SC Oncology GA CL9YQ UT WOS:000357335500018 PM 25688159 ER PT J AU Hasegawa, M Sinha, RK Kumar, M Alam, M Yin, L Raina, D Kharbanda, A Panchamoorthy, G Gupta, D Singh, H Kharbanda, S Kufe, D AF Hasegawa, Masanori Sinha, Raj Kumar Kumar, Manoj Alam, Maroof Yin, Li Raina, Deepak Kharbanda, Akriti Panchamoorthy, Govind Gupta, Dikshi Singh, Harpal Kharbanda, Surender Kufe, Donald TI Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation SO CLINICAL CANCER RESEARCH LA English DT Article ID BREAST-CANCER CELLS; DOWN-REGULATING TIGAR; BETA-CATENIN; ONCOPROTEIN; PEPTIDE; INHIBITION; DELIVERY; TRANSCRIPTION; ACTIVATION; EXPRESSION AB Purpose: The MUC1-C oncoprotein is an intracellular target that is druggable with cell-penetrating peptide inhibitors. However, development of peptidyl drugs for treating cancer has been a challenge because of unfavorable pharmacokinetic parameters and limited cell-penetrating capabilities. Experimental Design: Encapsulation of the MUC1-C inhibitor GO-203 in novel polymeric nanoparticles was studied for effects on intracellular targeting of MUC1-C signaling and function. Results: Our results show that loading GO-203 into tetrablock polylactic acid (PLA)-polyethylene glycol (PEG)-polypropylene glycol (PPG)-PEG copolymers is achievable and, notably, is enhanced by increasing PEG chain length. In addition, we found that release of GO-203 from these nanoparticles is controllable over at least 7 days. GO-203/nanoparticle treatment of MUC1-C-positive breast and lung cancer cells in vitro was more active with less frequent dosing than that achieved with nonencapsulated GO-203. Moreover, treatment with GO-203/nanoparticles blocked MUC1-C homodimerization, consistent with on-target effects. GO-203/nanoparticle treatment was also effective in downregulating TIGAR, disrupting redox balance, and inhibiting the self-renewal capacity of cancer cells. Significantly, weekly administration of GO-203/nanoparticles to mice bearing syngeneic or xenograft tumors was associated with regressions that were comparable with those found when dosing on a daily basis with GO-203. Conclusions: These findings thus define an effective approach for (i) sustained administration of GO-203 in polymeric PLA(PEG-PPG-PEG) nanoparticles to target MUC1-C in cancer cells and (ii) the potential delivery of other anticancer peptide drugs. (C)2015 AACR. C1 [Hasegawa, Masanori; Alam, Maroof; Yin, Li; Kharbanda, Akriti; Kufe, Donald] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA. [Sinha, Raj Kumar; Kumar, Manoj; Gupta, Dikshi; Singh, Harpal] Indian Inst Technol, Ctr Biomed Engn, New Delhi 110016, India. [Raina, Deepak; Panchamoorthy, Govind; Kharbanda, Surender] Genus Oncol, Boston, MA USA. RP Kufe, D (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA. EM harpal2000@yahoo.com; donald_kufe@dfci.harvard.edu FU NCI of the NIH [CA166480, CA97098]; Lung Cancer Research Foundation; Department of Science and Technology, Government of India FX This study was supported by the NCI of the NIH under award numbers CA166480 and CA97098, the Lung Cancer Research Foundation, and the Department of Science and Technology, Government of India. NR 44 TC 6 Z9 6 U1 0 U2 13 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 15 PY 2015 VL 21 IS 10 BP 2338 EP 2347 DI 10.1158/1078-0432.CCR-14-3000 PG 10 WC Oncology SC Oncology GA CL9YQ UT WOS:000357335500021 PM 25712682 ER PT J AU Stubbs, MC Kim, W Bariteau, M Davis, T Vempati, S Minehart, J Witkin, M Qi, J Krivtsov, AV Bradner, JE Kung, AL Armstrong, SA AF Stubbs, Matthew C. Kim, Wonil Bariteau, Megan Davis, Tina Vempati, Sridhar Minehart, Janna Witkin, Matthew Qi, Jun Krivtsov, Andrei V. Bradner, James E. Kung, Andrew L. Armstrong, Scott A. TI Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL SO CLINICAL CANCER RESEARCH LA English DT Article ID HISTONE DEACETYLASE INHIBITORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-DAMAGE RESPONSE; CANCER-THERAPY; CELLS; EXPRESSION; APOPTOSIS; ACETYLATION; MAINTENANCE; COMBINATION AB Purpose: Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematologic malignancies. One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may be highly dependent on epigenetic regulation for leukemia development and maintenance, and thus sensitive to small-molecule inhibitors that target epigenetic mechanisms. Experimental Design: A panel of B-ALL cell lines was tested for sensitivity to HDACi with varying isoform sensitivity. Isoform-specific shRNAs were used as further validation of HDACs as relevant therapeutic targets in B-ALL. Mouse xenografts of B-cell malignancy-derived cell lines and a pediatric B-ALL were used to demonstrate pharmacologic efficacy. Results: Nonselective HDAC inhibitors were cytotoxic to a panel of B-ALL cell lines as well as to xenografted human leukemia patient samples. Assessment of isoform-specific HDACi indicated that targeting HDAC1-3 with class I HDAC-specific inhibitors was sufficient to inhibit growth of B-ALL cell lines. Furthermore, shRNA-mediated knockdown of HDAC1 or HDAC2 resulted in growth inhibition in these cells. We then assessed a compound that specifically inhibits only HDAC1 and HDAC2. This compound suppressed growth and induced apoptosis in B-ALL cell lines in vitro and in vivo, whereas it was far less effective against other B-cell-derived malignancies. Conclusions: Here, we show that HDAC inhibitors are a potential therapeutic option for B-ALL, and that a more specific inhibitor of HDAC1 and HDAC2 could be therapeutically useful for patients with B-ALL. (C)2015 AACR. C1 [Stubbs, Matthew C.; Kim, Wonil; Bariteau, Megan; Davis, Tina; Vempati, Sridhar; Krivtsov, Andrei V.; Kung, Andrew L.; Armstrong, Scott A.] Boston Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Div Hematol Oncol, Boston, MA USA. [Stubbs, Matthew C.; Kim, Wonil; Bariteau, Megan; Davis, Tina; Vempati, Sridhar; Qi, Jun; Krivtsov, Andrei V.; Bradner, James E.; Kung, Andrew L.; Armstrong, Scott A.] Harvard Univ, Sch Med, Boston, MA USA. [Minehart, Janna; Witkin, Matthew; Krivtsov, Andrei V.; Armstrong, Scott A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [Qi, Jun; Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Kung, Andrew L.; Armstrong, Scott A.] Harvard Stem Cell Inst, Boston, MA USA. RP Stubbs, MC (reprint author), Incyte Corp, 1801 Augustine Cut Off, Wilmington, DE 19803 USA. EM mstubbs@incyte.com OI Kung, Andrew/0000-0002-9091-488X FU NCI [CA068484]; NIH [CA128972]; Leukemia and Lymphoma Society; MMRF FX This work was supported by NCI grant CA068484 (to S.A. Armstrong), NIH grant CA128972 (to J. Qi and J.E. Bradner), the Leukemia and Lymphoma Society, and the MMRF (to J.E. Bradner). NR 44 TC 9 Z9 9 U1 1 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD MAY 15 PY 2015 VL 21 IS 10 BP 2348 EP 2358 DI 10.1158/1078-0432.CCR-14-1290 PG 11 WC Oncology SC Oncology GA CL9YQ UT WOS:000357335500022 PM 25688158 ER PT J AU Pandol, SJ Edderkaoui, M AF Pandol, Stephen J. Edderkaoui, Mouad TI What are the macrophages and stellate cells doing in pancreatic adenocarcinoma? SO FRONTIERS IN PHYSIOLOGY LA English DT Review DE stellate cells; macrophages; pancreatic cancer; periostin; TGF-beta ID EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; DUCTAL ADENOCARCINOMA; GROWTH-FACTOR; INTRAEPITHELIAL NEOPLASIA; INDUCE FIBROSIS; TRANSGENIC MICE; NAB-PACLITAXEL; ACINAR-CELLS; TUMOR-GROWTH AB Pancreatic ductal adenocarcinoma is a devastating disease characterized by a dense desmoplastic stroma. Chemo- and radio-therapeutic strategies based on targeting cancer cells have failed in improving the outcome of this cancer suggesting important roles for stroma in therapy resistance. Cells in the tumor stroma have been shown to regulate proliferation, resistance to apoptosis and treatments, epithelial to mesenchymal transition (EMT) and stemness of cancer cells. Stellate cells in their activated state have been thought over the past decade to only have tumor promoting roles. However, recent findings suggest that stellate cells may have protective roles as well. The present review highlights the latest findings on the role of two major components of tumor stroma, pancreatic stellate cells and macrophages, in promoting or inhibiting pancreatic cancer, focused on their effects on EMT and cancer stemness. C1 [Pandol, Stephen J.; Edderkaoui, Mouad] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. [Pandol, Stephen J.; Edderkaoui, Mouad] Cedars Sinai Med Ctr, Dept Biol Sci, Los Angeles, CA 90048 USA. [Pandol, Stephen J.; Edderkaoui, Mouad] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Pandol, Stephen J.; Edderkaoui, Mouad] Univ Calif Los Angeles, Los Angeles, CA USA. RP Edderkaoui, M (reprint author), Cedars Sinai Med Ctr, Dept Med, Vet Affairs Los Angeles, 8700 Beverly Blvd,Davis Bldg,Suite 3100, Los Angeles, CA 90048 USA. EM mouad.edderkaoui@cshs.org FU Department of Veterans Affairs [K01AA019996, P01CA163200] FX Supported by K01AA019996, P01CA163200 and Department of Veterans Affairs. NR 52 TC 2 Z9 2 U1 1 U2 8 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-042X J9 FRONT PHYSIOL JI Front. Physiol. PD MAY 15 PY 2015 VL 6 AR 125 DI 10.3389/fphys.2015.00125 PG 6 WC Physiology SC Physiology GA CM3NN UT WOS:000357589200001 PM 26029109 ER PT J AU Tsai, AC Weiser, SD Dilworth, SE Shumway, M Riley, ED AF Tsai, Alexander C. Weiser, Sheri D. Dilworth, Samantha E. Shumway, Martha Riley, Elise D. TI Violent Victimization, Mental Health, and Service Utilization Outcomes in a Cohort of Homeless and Unstably Housed Women Living With or at Risk of Becoming Infected With HIV SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE depressive disorder; HIV; partner violence; quality of life; rape ID INTIMATE PARTNER VIOLENCE; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; DIAGNOSTIC INTERVIEW SCHEDULE; ANTIDEPRESSANT MEDICATION TREATMENT; POISSON REGRESSION APPROACH; LONGITUDINAL DATA-ANALYSIS; SUB-SAHARAN AFRICA; DOMESTIC VIOLENCE; ANTIRETROVIRAL THERAPY AB Most studies about the association between exposure to violence and higher psychological vulnerability have been cross-sectional in nature. Using longitudinal data from the Shelter, Health, and Drug Outcomes Among Women Study on 300 homeless or unstably housed women infected with or at risk of becoming infected with human immunodeficiency virus who were living in San Francisco, California, in 2008-2012, we examined the relationship between recent violent victimization and mental health status, mental health-related emergency department visits, and psychiatric hospitalization. We used generalized estimating equations to account for potentially confounding time-invariant and time-varying variables, including comorbid psychiatric conditions and lifetime history of child abuse. A total of 207 (69%) women experienced childhood abuse. The median number of psychiatric diagnoses per woman at baseline was 8 (interquartile range, 5-11). Recent exposure to violence was associated with lower mental health status (b = -1.85, 95% confidence interval: -3.02, -0.68) and higher risks of mental health-related emergency department visits (adjusted risk ratio = 2.96, 95% confidence interval: 1.51, 5.78) and psychiatric hospitalizations (adjusted risk ratio = 2.32, 95% confidence interval: 1.10, 4.91). We did not find strong evidence of a reciprocal relationship. Among homeless or unstably housed women with severe preexisting comorbid psychiatric conditions, recent violence has adverse mental health consequences. Reducing ongoing violence may improve mental health in this population. C1 [Tsai, Alexander C.] Massachusetts Gen Hosp, Div Global Psychiat, Boston, MA 02114 USA. [Tsai, Alexander C.] Harvard Univ, Sch Med, Boston, MA USA. [Tsai, Alexander C.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA. [Tsai, Alexander C.] Mbarara Univ Sci & Technol, Mbarara, Uganda. [Weiser, Sheri D.; Dilworth, Samantha E.; Riley, Elise D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shumway, Martha] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Tsai, AC (reprint author), Massachusetts Gen Hosp, Ctr Global Hlth, 100 Cambridge St,15th Floor, Boston, MA 02114 USA. EM actsai@partners.org OI Tsai, Alexander/0000-0001-6397-7917 FU National Institute on Drug Abuse [R01DA015605]; National Institute of Mental Health at the US National Institutes of Health [K23MH096620]; Robert Wood Johnson Foundation Health and Society Scholars Program FX The Shelter, Health, and Drug Outcomes Among Women Study was funded by the National Institute on Drug Abuse (grant R01DA015605). Additional salary support was provided by the National Institute of Mental Health (grant K23MH096620 to A.C.T.) at the US National Institutes of Health and by the Robert Wood Johnson Foundation Health and Society Scholars Program (A.C.T.). NR 91 TC 9 Z9 9 U1 8 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAY 15 PY 2015 VL 181 IS 10 BP 817 EP 826 DI 10.1093/aje/kwu350 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CK4FY UT WOS:000356179700011 PM 25834138 ER PT J AU Khan, M Shunmugavel, A Dhammu, TS Matsuda, F Singh, AK Singh, I AF Khan, Mushfiquddin Shunmugavel, Anandakumar Dhammu, Tajinder S. Matsuda, Fumiyo Singh, Avtar K. Singh, Inderjit TI Oral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in rats SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Lumbar spinal canal stenosis; Cauda equina compression; Cytosolic phospholipase A2; Neuroinflammation; Arachidonyl trifluoromethyl ketone; Pain; Motor function ID SPINAL-CORD-INJURY; NITRIC-OXIDE SYNTHASE; LOW-BACK-PAIN; PHOSPHOLIPASE A(2); NEUROPATHIC PAIN; LYSOPHOSPHATIDIC ACID; THERAPEUTIC TARGETS; SECONDARY INJURY; POTENT INHIBITOR; NERVE LIGATION AB Background: Phospholipase A2 (PLA2)-derived proinflammatory lipid mediators such as prostaglandin E2 (PGE2), leukotrienes B4 (LTB4), lysophosphatidylcholine (LPC), and free fatty acids (FFA) are implicated in spinal cord injury (SCI) pathologies. Reducing the levels of these injurious bioactive lipid mediators is reported to ameliorate SCI. However, the specific role of the group IVA isoform of PLA2 cytosolic PLA2 (cPLA2) in lumbar spinal canal stenosis (LSS) due to cauda equina compression (CEC) injury is not clear. In this study, we investigated the role of cPLA2 in a rat model of CEC using a non-toxic cPLA2-preferential inhibitor, arachidonyl trifluoromethyl ketone (ATK). Methods: LSS was induced in adult female rats by CEC procedure using silicone blocks within the epidural spaces of L4 to L6 vertebrae. cPLA2 inhibitor ATK (7.5 mg/kg) was administered by oral gavage at 2 h following the CEC. cPLA2-derived injurious lipid mediators and the expression/activity of cPLA2, 5-lipoxygenase (5-LOX), and cyclooxygenase-2 (COX-2) were assessed. ATK-treated (CEC + ATK) were compared with vehicle-treated (CEC + VEH) animals in terms of myelin levels, pain threshold, and motor function. Results: ATK treatment of CEC animals reduced the phosphorylation of cPLA2 (pcPLA2) determined by Western blot, improved locomotor function evaluated by rotarod task, and reduced pain threshold evaluated by mechanical hyperalgesia method. Levels of FFA and LPC, along with PGE2 and LTB4, were reduced in CEC + ATK compared with CEC + VEH group. However, ATK treatment reduced neither the activity/expression of 5-LOX nor the expression of COX-2 in CEC + VEH animals. Increased cPLA2 activity in the spinal cord from CEC + VEH animals correlated well with decreased spinal cord as well as cauda equina fiber myelin levels, which were restored after ATK treatment. Conclusion: The data indicate that cPLA2 activity plays a significant role in tissue injury and pain after LSS. Reducing the levels of proinflammatory and tissue damaging eicosanoids and the deleterious lipid mediator LPC shows therapeutic potential. ATK inhibits cPLA2 activity, thereby decreasing the levels of injurious lipid mediators, reducing pain, improving functional deficits, and conferring protection against LSS injury. Thus, it shows potential for preclinical evaluation in LSS. C1 [Khan, Mushfiquddin; Shunmugavel, Anandakumar; Dhammu, Tajinder S.; Matsuda, Fumiyo; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Matsuda, Fumiyo] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan. [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Khan, M (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. EM khanm@musc.edu; singhi@musc.edu FU Extramural Research Facilities Program of the National Center for Research Resources [CO6 RR018823, CO6 RR0015455]; NIH [07506]; [NS-72511]; [NS-22576]; [NS-37766]; [DC00422] FX This work was supported by grants NS-72511, NS-22576, and NS-37766 and DC00422; 07506 from the NIH, CO6 RR018823 and CO6 RR0015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We are grateful to Dr. Thomas G. Smith from the MUSC Writing Center for his valuable editing and correction of the manuscript. We would like to thank Ms. Danielle Lowe for assistance with statistical analysis and manuscript review. We would also like to thank Ms. Joyce Bryan for procurement of animals and chemicals and Ms. Terry Hope for secretarial assistance. NR 70 TC 1 Z9 1 U1 2 U2 76 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD MAY 15 PY 2015 VL 12 AR 94 DI 10.1186/s12974-015-0311-y PG 12 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA CK4SQ UT WOS:000356213900001 PM 25971887 ER PT J AU Orr, N Dudbridge, F Dryden, N Maguire, S Novo, D Perrakis, E Johnson, N Ghoussaini, M Hopper, JL Southey, MC Apicella, C Stone, J Schmidt, MK Broeks, A Van't Veer, LJ Hogervorst, FB Fasching, PA Haeberle, L Ekici, AB Beckmann, MW Gibson, L Aitken, Z Warren, H Sawyer, E Tomlinson, I Kerin, MJ Miller, N Burwinkel, B Marme, F Schneeweiss, A Sohn, C Guenel, P Truong, T Cordina-Duverger, E Sanchez, M Bojesen, SE Nordestgaard, BG Nielsen, SF Flyger, H Benitez, J Zamora, MP Perez, JIA Menendez, P Anton-Culver, H Neuhausen, SL Brenner, H Dieffenbach, AK Arndt, V Stegmaier, C Hamann, U Brauch, H Justenhoven, C Bruning, T Ko, YD Nevanlinna, H Aittomaki, K Blomqvist, C Khan, S Bogdanova, N Dork, T Lindblom, A Margolin, S Mannermaa, A Kataja, V Kosma, VM Hartikainen, JM Chenevix-Trench, G Beesley, J Lambrechts, D Moisse, M Floris, G Beuselinck, B Chang-Claude, J Rudolph, A Seibold, P Flesch-Janys, D Radice, P Peterlongo, P Peissel, B Pensotti, V Couch, FJ Olson, JE Slettedahl, S Vachon, C Giles, GG Milne, RL McLean, C Haiman, CA Henderson, BE Schumacher, F Le Marchand, L Simard, J Goldberg, MS Labreche, F Dumont, M Kristensen, V Alnaes, GG Nord, S Borresen-Dale, AL Zheng, W Deming-Halverson, S Shrubsole, M Long, JR Winqvist, R Pylkas, K Jukkola-Vuorinen, A Grip, M Andrulis, IL Knight, JA Glendon, G Tchatchou, S Devilee, P Tollenaar, RAEM Seynaeve, CM Van Asperen, CJ Garcia-Closas, M Figueroa, J Chanock, SJ Lissowska, J Czene, K Darabi, H Eriksson, M Klevebring, D Hooning, MJ Hollestelle, A van Deurzen, CHM Kriege, M Hall, P Li, JM Liu, JJ Humphreys, K Cox, A Cross, SS Reed, MWR Pharoah, PDP Dunning, AM Shah, M Perkins, BJ Jakubowska, A Lubinski, J Jaworska-Bieniek, K Durda, K Ashworth, A Swerdlow, A Jones, M Schoemaker, MJ Meindl, A Schmutzler, RK Olswold, C Slager, S Toland, AE Yannoukakos, D Muir, K Lophatananon, A Stewart-Brown, S Siriwanarangsan, P Matsuo, K Ito, H Iwata, H Ishiguro, J Wu, AH Tseng, CC Van den Berg, D Stram, DO Teo, SH Yip, CH Kang, P Ikram, MK Shu, XO Lu, W Gao, YT Cai, H Kang, D Choi, JY Park, SK Noh, DY Hartman, M Miao, H Lim, WY Lee, SC Sangrajrang, S Gaborieau, V Brennan, P McKay, J Wu, PE Hou, MF Yu, JC Shen, CY Blot, W Cai, QY Signorello, LB Luccarini, C Bayes, C Ahmed, S Maranian, M Healey, CS Gonzalez-Neira, A Pita, G Alonso, MR Alvarez, N Herrero, D Tessier, DC Vincent, D Bacot, F Hunter, DJ Lindstrom, S Dennis, J Michailidou, K Bolla, MK Easton, DF Silva, ID Fletcher, O Peto, J AF Orr, Nick Dudbridge, Frank Dryden, Nicola Maguire, Sarah Novo, Daniela Perrakis, Eleni Johnson, Nichola Ghoussaini, Maya Hopper, John L. Southey, Melissa C. Apicella, Carmel Stone, Jennifer Schmidt, Marjanka K. Broeks, Annegien Van't Veer, Laura J. Hogervorst, Frans B. Fasching, Peter A. Haeberle, Lothar Ekici, Arif B. Beckmann, Matthias W. Gibson, Lorna Aitken, Zoe Warren, Helen Sawyer, Elinor Tomlinson, Ian Kerin, Michael J. Miller, Nicola Burwinkel, Barbara Marme, Frederik Schneeweiss, Andreas Sohn, Chistof Guenel, Pascal Truong, Therese Cordina-Duverger, Emilie Sanchez, Marie Bojesen, Stig E. Nordestgaard, Borge G. Nielsen, Sune F. Flyger, Henrik Benitez, Javier Zamora, Maria Pilar Perez, Jose Ignacio Arias Menendez, Primitiva Anton-Culver, Hoda Neuhausen, Susan L. Brenner, Hermann Dieffenbach, Aida Karina Arndt, Volker Stegmaier, Christa Hamann, Ute Brauch, Hiltrud Justenhoven, Christina Bruning, Thomas Ko, Yon-Dschun Nevanlinna, Heli Aittomaki, Kristiina Blomqvist, Carl Khan, Sofia Bogdanova, Natalia Dork, Thilo Lindblom, Annika Margolin, Sara Mannermaa, Arto Kataja, Vesa Kosma, Veli-Matti Hartikainen, Jaana M. Chenevix-Trench, Georgia Beesley, Jonathan Lambrechts, Diether Moisse, Matthieu Floris, Guiseppe Beuselinck, Benoit Chang-Claude, Jenny Rudolph, Anja Seibold, Petra Flesch-Janys, Dieter Radice, Paolo Peterlongo, Paolo Peissel, Bernard Pensotti, Valeria Couch, Fergus J. Olson, Janet E. Slettedahl, Seth Vachon, Celine Giles, Graham G. Milne, Roger L. McLean, Catriona Haiman, Christopher A. Henderson, Brian E. Schumacher, Fredrick Le Marchand, Loic Simard, Jacques Goldberg, Mark S. Labreche, France Dumont, Martine Kristensen, Vessela Alnaes, Grethe Grenaker Nord, Silje Borresen-Dale, Anne-Lise Zheng, Wei Deming-Halverson, Sandra Shrubsole, Martha Long, Jirong Winqvist, Robert Pylkas, Katri Jukkola-Vuorinen, Arja Grip, Mervi Andrulis, Irene L. Knight, Julia A. Glendon, Gord Tchatchou, Sandrine Devilee, Peter Tollenaar, Robertus A. E. M. Seynaeve, Caroline M. Van Asperen, Christi J. Garcia-Closas, Montserrat Figueroa, Jonine Chanock, Stephen J. Lissowska, Jolanta Czene, Kamila Darabi, Hatef Eriksson, Mikael Klevebring, Daniel Hooning, Maartje J. Hollestelle, Antoinette van Deurzen, Carolien H. M. Kriege, Mieke Hall, Per Li, Jingmei Liu, Jianjun Humphreys, Keith Cox, Angela Cross, Simon S. Reed, Malcolm W. R. Pharoah, Paul D. P. Dunning, Alison M. Shah, Mitul Perkins, Barbara J. Jakubowska, Anna Lubinski, Jan Jaworska-Bieniek, Katarzyna Durda, Katarzyna Ashworth, Alan Swerdlow, Anthony Jones, Michael Schoemaker, Minouk J. Meindl, Alfons Schmutzler, Rita K. Olswold, Curtis Slager, Susan Toland, Amanda E. Yannoukakos, Drakoulis Muir, Kenneth Lophatananon, Artitaya Stewart-Brown, Sarah Siriwanarangsan, Pornthep Matsuo, Keitaro Ito, Hidema Iwata, Hiroji Ishiguro, Junko Wu, Anna H. Tseng, Chiu-Chen Van den Berg, David Stram, Daniel O. Teo, Soo Hwang Yip, Cheng Har Kang, Peter Ikram, Mohammad Kamran Shu, Xiao-Ou Lu, Wei Gao, Yu-Tang Cai, Hui Kang, Daehee Choi, Ji-Yeob Park, Sue K. Noh, Dong-Young Hartman, Mikael Miao, Hui Lim, Wei Yen Lee, Soo Chin Sangrajrang, Suleeporn Gaborieau, Valerie Brennan, Paul McKay, James Wu, Pei-Ei Hou, Ming-Feng Yu, Jyh-Cherng Shen, Chen-Yang Blot, William Cai, Qiuyin Signorello, Lisa B. Luccarini, Craig Bayes, Caroline Ahmed, Shahana Maranian, Mel Healey, Catherine S. Gonzalez-Neira, Anna Pita, Guillermo Alonso, M. Rosario Alvarez, Nuria Herrero, Daniel Tessier, Daniel C. Vincent, Daniel Bacot, Francois Hunter, David J. Lindstrom, Sara Dennis, Joe Michailidou, Kyriaki Bolla, Manjeet K. Easton, Douglas F. Silva, Isabel dos Santos Fletcher, Olivia Peto, Julian CA GENICA Network kConFab Investigators Australian Ovarian Canc Study Grp TI Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2 SO HUMAN MOLECULAR GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; ESTROGEN-RECEPTOR-ALPHA; CONFER SUSCEPTIBILITY; FUNCTIONAL VARIANTS; COMMON VARIANTS; ANALYSES REVEAL; RISK LOCUS; EXPRESSION; BINDING; FOXA1 AB We recently identified a novel susceptibility variant, rs865686, for estrogen-receptor positive breast cancer at 9q31.2. Here, we report a fine-mapping analysis of the 9q31.2 susceptibility locus using 43 160 cases and 42 600 controls of European ancestry ascertained from 52 studies and a further 5795 cases and 6624 controls of Asian ancestry from nine studies. Single nucleotide polymorphism (SNP) rs676256 was most strongly associated with risk in Europeans (odds ratios [OR] = 0.90 [0.88-0.92]; P-value = 1.58 x 10(-25)). This SNP is one of a cluster of highly correlated variants, including rs865686, that spans 14.5 kb. We identified two additional independent association signals demarcated by SNPs rs10816625 (OR = 1.12 [1.08-1.17]; P-value = 7.89 x 10(-09)) and rs13294895 (OR = 1.09 [1.06-1.12]; P-value = 2.97 x 10(-11)). SNP rs10816625, but not rs13294895, was also associated with risk of breast cancer in Asian individuals (OR = 1.12 [1.06-1.18]; P-value = 2.77 x 10(-05)). Functional genomic annotation using data derived from breast cancer cell-line models indicates that these SNPs localise to putative enhancer elements that bind known drivers of hormone-dependent breast cancer, including ER-alpha, FOXA1 and GATA-3. In vitro analyses indicate that rs10816625 and rs13294895 have allele-specific effects on enhancer activity and suggest chromatin interactions with the KLF4 gene locus. These results demonstrate the power of dense genotyping in large studies to identify independent susceptibility variants. Analysis of associations using subjects with different ancestry, combined with bioinformatic and genomic characterisation, can provide strong evidence for the likely causative alleles and their functional basis. C1 [Orr, Nick; Dryden, Nicola; Maguire, Sarah; Novo, Daniela; Perrakis, Eleni; Johnson, Nichola; Garcia-Closas, Montserrat; Ashworth, Alan; Fletcher, Olivia] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England. [Orr, Nick; Dryden, Nicola; Maguire, Sarah; Novo, Daniela; Perrakis, Eleni; Johnson, Nichola; Garcia-Closas, Montserrat; Ashworth, Alan; Swerdlow, Anthony; Schoemaker, Minouk J.; Fletcher, Olivia] Inst Canc Res, Div Breast Canc Res, London SW3 6JB, England. [Garcia-Closas, Montserrat; Swerdlow, Anthony; Jones, Michael; Schoemaker, Minouk J.] Inst Canc Res, Div Genet & Epidemiol, London SW3 6JB, England. [Dudbridge, Frank; Gibson, Lorna; Aitken, Zoe; Silva, Isabel dos Santos; Peto, Julian] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London WC1, England. [Ghoussaini, Maya; Pharoah, Paul D. P.; Dunning, Alison M.; Shah, Mitul; Perkins, Barbara J.; Luccarini, Craig; Bayes, Caroline; Ahmed, Shahana; Maranian, Mel; Healey, Catherine S.; Easton, Douglas F.] Univ Cambridge, Dept Oncol, Ctr Canc Genet Epidemiol, Cambridge, England. [Dennis, Joe; Michailidou, Kyriaki; Bolla, Manjeet K.] Univ Cambridge, Dept Publ Hlth & Primary Care, Ctr Canc Genet Epidemiol, Cambridge, England. [Hopper, John L.; Apicella, Carmel; Giles, Graham G.; Milne, Roger L.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic 3010, Australia. [Southey, Melissa C.] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia. [Stone, Jennifer] Univ Western Australia, Ctr Genet Origins Hlth & Dis, Perth, WA 6009, Australia. [Schmidt, Marjanka K.; Broeks, Annegien; Hogervorst, Frans B.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands. [Haeberle, Lothar; Beckmann, Matthias W.] Univ Hosp Erlangen, Dept Gynecol & Obstet, Univ Breast Ctr Franconia, D-91054 Erlangen, Germany. [Ekici, Arif B.] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Human Genet, Comprehens Canc Ctr Erlangen EMN, D-91054 Erlangen, Germany. [Fasching, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA. [Warren, Helen] Queen Mary Univ London, Dept Clin Pharmacol, William Harvey Res Inst, Barts & London Sch Med, London, England. [Warren, Helen] Queen Mary Univ London, NIHR Barts Cardiovasc Biomed Res Unit, London, England. [Sawyer, Elinor] Guys Hosp, Kings Coll London, Div Canc Studies, London SE1 9RT, England. [Tomlinson, Ian] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England. [Tomlinson, Ian] Univ Oxford, Oxford Biomed Res Ctr, Oxford OX1 2JD, England. [Kerin, Michael J.; Miller, Nicola] Univ Hosp Galway, Inst Clin Sci, Galway, Ireland. [Burwinkel, Barbara; Marme, Frederik; Schneeweiss, Andreas; Sohn, Chistof] Heidelberg Univ, Dept Obstet & Gynecol, D-69120 Heidelberg, Germany. [Marme, Frederik; Schneeweiss, Andreas] Heidelberg Univ, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany. [Burwinkel, Barbara] German Canc Res Ctr, Mol Epidemiol Grp, D-69120 Heidelberg, Germany. [Guenel, Pascal; Truong, Therese; Cordina-Duverger, Emilie; Sanchez, Marie] CESP Ctr Res Epidemiol & Populat Hlth, Inserm Natl Inst Hlth & Med Res, U1018, Environm Epidemiol Canc, Villejuif, France. [Guenel, Pascal; Truong, Therese; Cordina-Duverger, Emilie; Sanchez, Marie] Univ Paris 11, UMRS 1018, Villejuif, France. [Bojesen, Stig E.; Nordestgaard, Borge G.; Nielsen, Sune F.] Copenhagen Univ Hosp, Herlev Hosp, Copenhagen Gen Populat Study, DK-2730 Herlev, Denmark. [Bojesen, Stig E.; Nordestgaard, Borge G.; Nielsen, Sune F.] Copenhagen Univ Hosp, Herlev Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark. [Flyger, Henrik] Copenhagen Univ Hosp, Herlev Hosp, Dept Breast Surg, DK-2730 Copenhagen, Denmark. [Benitez, Javier] Spanish Natl Canc Res Ctr CNIO, Human Canc Genet Program, Human Genet Grp, Madrid 28029, Spain. [Benitez, Javier] Ctr Invest Red Enfermedades Raras CIBERER, Valencia 46010, Spain. [Zamora, Maria Pilar] Hosp Univ La Paz, Serv Oncol Med, Madrid 28046, Spain. [Perez, Jose Ignacio Arias] Hosp Monte Naranco, Serv Cirugia Gen & Especialidades, Oviedo 33012, Spain. [Menendez, Primitiva] Hosp Monte Naranco, Serv Anat Patol, Oviedo 33012, Spain. [Anton-Culver, Hoda] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA. [Neuhausen, Susan L.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA USA. [Brenner, Hermann; Dieffenbach, Aida Karina; Arndt, Volker] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany. [Brenner, Hermann; Dieffenbach, Aida Karina; Brauch, Hiltrud; Ashworth, Alan] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany. [Hamann, Ute] German Canc Res Ctr, Mol Genet Breast Canc, Heidelberg, Germany. [Chang-Claude, Jenny; Rudolph, Anja; Seibold, Petra] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany. [Stegmaier, Christa] Saarland Canc Registry, Saarbrucken, Germany. [Brauch, Hiltrud; Justenhoven, Christina] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany. [Brauch, Hiltrud; Justenhoven, Christina] Univ Tubingen, Tubingen, Germany. [Bruning, Thomas] Inst Ruhr Univ Bochum IPA, Inst Prevent & Occupat Med German Social Accid In, Bochum, Germany. [Ko, Yon-Dschun] Johanniter Krankenhaus, Evangel Kliniken Bonn gGmbH, Dept Internal Med, Bonn, Germany. Univ Bonn, Inst Pathol, Fac Med, Bonn, Germany. [GENICA Network] Univ Med Ctr Hamburg Eppendorf, Inst Occupat Med & Maritime Med, Hamburg, Germany. [Nevanlinna, Heli; Khan, Sofia] Univ Helsinki, Dept Obstet & Gynecol, Helsinki, Finland. [Aittomaki, Kristiina] Univ Helsinki, Dept Clin Genet, Helsinki, Finland. [Blomqvist, Carl] Univ Helsinki, Dept Oncol, Helsinki, Finland. [Blomqvist, Carl] Helsinki Univ Hosp, Helsinki, Finland. [Bogdanova, Natalia] Hannover Med Sch, Dept Radiat Oncol, Hannover, Germany. [Bogdanova, Natalia; Dork, Thilo] Hannover Med Sch, Dept Obstet & Gynaecol, Hannover, Germany. [Lindblom, Annika] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden. [Margolin, Sara] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden. [Mannermaa, Arto; Kosma, Veli-Matti; Hartikainen, Jaana M.] Univ Eastern Finland, Sch Med, Inst Clin Med Pathol & Forens Med, Kuopio, Finland. [Kataja, Vesa] Univ Eastern Finland, Sch Med, Inst Clin Med, Oncol, Kuopio, Finland. [Mannermaa, Arto; Kosma, Veli-Matti; Hartikainen, Jaana M.] Kuopio Univ Hosp, Dept Clin Pathol, Imaging Ctr, SF-70210 Kuopio, Finland. [Kataja, Vesa] Kuopio Univ Hosp, Ctr Eastern Finland, Bioctr Kuopio, SF-70210 Kuopio, Finland. [Kataja, Vesa] Jyvaskyla Cent Hosp, Cent Finland Hlth Care Dist, Jyvaskyla, Finland. [Chenevix-Trench, Georgia; Beesley, Jonathan] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia. [kConFab Investigators; Australian Ovarian Canc Study Grp] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Lambrechts, Diether; Moisse, Matthieu] VIB, VRC, Leuven, Belgium. [Lambrechts, Diether; Moisse, Matthieu] Univ Leuven, Dept Oncol, Lab Translat Genet, Leuven, Belgium. [Floris, Guiseppe; Beuselinck, Benoit] Univ Hosp Gasthuisberg, Leuven, Belgium. [Flesch-Janys, Dieter] Univ Clin Hamburg Eppendorf, Clin Canc Registry, Dept Canc Epidemiol, Hamburg, Germany. [Flesch-Janys, Dieter] Univ Clin Hamburg Eppendorf, Inst Med Biometr & Epidemiol, Hamburg, Germany. [Radice, Paolo] Fdn IRCCS Ist Nazl Tumori INT, Unit Mol Bases Genet Risk & Genet Testing, Dept Prevent & Predict Med, Milan, Italy. [Peissel, Bernard] Fdn IRCCS Ist Nazl Tumori INT, Unit Med Genet, Dept Prevent & Predict Med, Milan, Italy. [Peterlongo, Paolo; Pensotti, Valeria] Fdn Ist FIRC Oncol Mol, IFOM, Milan, Italy. [Pensotti, Valeria] Cogentech Canc Genet Test Lab, Milan, Italy. [Couch, Fergus J.; Olswold, Curtis; Slager, Susan] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA. [Olson, Janet E.; Slettedahl, Seth; Vachon, Celine] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA. [Giles, Graham G.; Milne, Roger L.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia. [McLean, Catriona] Alfred Hosp, Anat Pathol, Melbourne, Vic, Australia. [Haiman, Christopher A.; Henderson, Brian E.; Schumacher, Fredrick; Wu, Anna H.; Tseng, Chiu-Chen; Van den Berg, David; Stram, Daniel O.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Le Marchand, Loic] Univ Hawaii, Canc Res Ctr, Epidemiol Program, Honolulu, HI 96813 USA. [Simard, Jacques; Dumont, Martine] Ctr Hosp Univ Quebec, Res Ctr, Canc Genom Lab, Quebec City, PQ, Canada. [Simard, Jacques; Dumont, Martine] Univ Laval, Quebec City, PQ, Canada. [Goldberg, Mark S.] McGill Univ, Dept Med, Montreal, PQ, Canada. [Goldberg, Mark S.] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada. [Labreche, France] Univ Montreal, Dept Sante Environm & Sante Travail, Dept Med Sociale & Prevent, Montreal, PQ, Canada. [Kristensen, Vessela; Alnaes, Grethe Grenaker; Nord, Silje; Borresen-Dale, Anne-Lise] Radiumhospitalet, Oslo Univ Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway. [Kristensen, Vessela; Borresen-Dale, Anne-Lise] Univ Oslo UiO, Inst Clin Med, N-0450 Oslo, Norway. [Zheng, Wei; Deming-Halverson, Sandra; Shrubsole, Martha; Long, Jirong; Shu, Xiao-Ou; Cai, Hui; Blot, William; Cai, Qiuyin] Vanderbilt Univ, Sch Med, Vanderbilt Epidemiol Ctr, Div Epidemiol,Dept Med,Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA. [Winqvist, Robert; Pylkas, Katri] Univ Oulu, Oulu Univ Hosp, Lab Canc Genet & Tumor Biol, Dept Clin Genet, Oulu, Finland. [Winqvist, Robert; Pylkas, Katri] Univ Oulu, Oulu Univ Hosp, Bioctr Oulu, Oulu, Finland. [Jukkola-Vuorinen, Arja] Univ Oulu, Oulu Univ Hosp, Dept Oncol, Oulu, Finland. [Grip, Mervi] Univ Oulu, Oulu Univ Hosp, Dept Surg, Oulu, Finland. [Andrulis, Irene L.; Glendon, Gord] Mt Sinai Hosp, Ontario Canc Genet Network, Toronto, ON M5G 1X5, Canada. [Knight, Julia A.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Prosserman Ctr Hlth Res, Toronto, ON M5G 1X5, Canada. [Andrulis, Irene L.] Univ Toronto, Dalla Lana Sch Publ Hlth, Dept Mol Genet, Toronto, ON, Canada. [Knight, Julia A.] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON, Canada. [Tchatchou, Sandrine] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada. [Devilee, Peter] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands. [Devilee, Peter] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands. [Tollenaar, Robertus A. E. M.] Leiden Univ, Med Ctr, Dept Surg Oncol, NL-2300 RC Leiden, Netherlands. [Seynaeve, Caroline M.; Hooning, Maartje J.; Hollestelle, Antoinette; Kriege, Mieke] Erasmus MC Canc Inst, Family Canc Clin, Dept Med Oncol, Rotterdam, Netherlands. [Van Asperen, Christi J.] Leiden Univ, Med Ctr, Dept Clin Genet, NL-2300 RC Leiden, Netherlands. [Figueroa, Jonine; Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. [Lissowska, Jolanta; Klevebring, Daniel] M Sklodowska Curie Mem Canc Ctr, Dept Canc Epidemiol & Prevent, Warsaw, Poland. [Lissowska, Jolanta; Klevebring, Daniel] Inst Oncol, Warsaw, Poland. [Czene, Kamila; Darabi, Hatef; Eriksson, Mikael; Hall, Per; Humphreys, Keith] Karolinska Inst, Dept Med Epidemiol & Biostat, S-17177 Stockholm, Sweden. [van Deurzen, Carolien H. M.] Erasmus Univ, Dept Pathol, Med Ctr, NL-3000 DR Rotterdam, Netherlands. [Li, Jingmei; Liu, Jianjun] Genome Inst Singapore, Div Human Genet, Singapore 138672, Singapore. [Cox, Angela] Univ Sheffield, Dept Oncol, Sheffield Canc Res, Sheffield, S Yorkshire, England. [Cross, Simon S.] Univ Sheffield, Dept Neurosci, Acad Unit Pathol, Sheffield, S Yorkshire, England. [Reed, Malcolm W. R.] Univ Sussex, Brighton & Sussex Med Sch, Brighton, E Sussex, England. [Jakubowska, Anna; Lubinski, Jan; Jaworska-Bieniek, Katarzyna; Durda, Katarzyna] Pomeranian Med Univ, Dept Genet & Pathol, PL-70115 Szczecin, Poland. [Meindl, Alfons] Tech Univ Munich, Div Gynaecol & Obstet, D-81675 Munich, Germany. [Schmutzler, Rita K.] Univ Cologne, Ctr Hereditary Breast & Ovarian Canc, CIO, Fac Med, D-50931 Cologne, Germany. [Schmutzler, Rita K.] Univ Cologne, CMMC, Fac Med, D-50931 Cologne, Germany. [Schmutzler, Rita K.] Univ Hosp Cologne, Cologne, Germany. [Toland, Amanda E.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA. [Yannoukakos, Drakoulis] Natl Ctr Sci Res Demokritos, Aghia Paraskevi Attikis, IRRP, Mol Diagnost Lab, Athens, Greece. [Muir, Kenneth; Stewart-Brown, Sarah] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Coventry CV4 7AL, W Midlands, England. [Muir, Kenneth; Lophatananon, Artitaya] Univ Manchester, Instt Populat Hlth, Manchester, Lancs, England. [Siriwanarangsan, Pornthep] Minist Publ Hlth, Nonthaburi, Thailand. [Matsuo, Keitaro] Kyushu Univ, Fac Med Sci, Dept Prevent Med, Fukuoka 812, Japan. [Ito, Hidema] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi 464, Japan. [Iwata, Hiroji; Ishiguro, Junko] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 464, Japan. [Teo, Soo Hwang; Kang, Peter] Sime Darby Med Ctr, Canc Res Initiat Fdn, Subang Jaya, Selangor, Malaysia. [Teo, Soo Hwang; Yip, Cheng Har] Univ Malaya, Canc Res Inst, Med Ctr, Breast Canc Res Unit, Kuala Lumpur, Malaysia. [Ikram, Mohammad Kamran] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 168751, Singapore. [Lu, Wei] Shanghai Ctr Dis Control & Prevent, Shanghai, Peoples R China. [Gao, Yu-Tang] Shanghai Canc Inst, Dept Epidemiol, Shanghai, Peoples R China. [Kang, Daehee; Park, Sue K.] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea. [Noh, Dong-Young] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea. [Kang, Daehee; Choi, Ji-Yeob; Park, Sue K.] Seoul Natl Univ, Grad Sch, Dept Biomed Sci, Seoul, South Korea. [Kang, Daehee; Choi, Ji-Yeob; Park, Sue K.] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea. [Hartman, Mikael; Miao, Hui; Lim, Wei Yen] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore. [Hartman, Mikael] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore 117595, Singapore. [Hartman, Mikael; Miao, Hui] Natl Univ Hlth Syst, Singapore, Singapore. [Lee, Soo Chin] Natl Univ Hlth Syst, Dept Haematol Oncol, Singapore, Singapore. [Lee, Soo Chin] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore. [Sangrajrang, Suleeporn] Natl Canc Inst, Bangkok, Thailand. [Gaborieau, Valerie; Brennan, Paul; McKay, James] Int Agcy Res Canc, F-69372 Lyon, France. [Wu, Pei-Ei] Acad Sinica, Taiwan Biobank, Taipei 115, Taiwan. [Wu, Pei-Ei] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan. [Hou, Ming-Feng; Shen, Chen-Yang] Kaohsiung Med Univ, Chung Ho Mem Hosp, Ctr Canc, Kaohsiung 804, Taiwan. [Hou, Ming-Feng; Shen, Chen-Yang] Kaohsiung Med Univ, Chung Ho Mem Hosp, Dept Surg, Kaohsiung 804, Taiwan. [Yu, Jyh-Cherng] Triserv Gen Hosp, Dept Surg, Taipei 114, Taiwan. [Yu, Jyh-Cherng] Natl Def Med Ctr, Taipei 114, Taiwan. [Shen, Chen-Yang] China Med Univ, Sch Publ Hlth, Taichung 404, Taiwan. [Blot, William] Int Inst Epidemiol, Rockville, MD USA. [Signorello, Lisa B.] Dana Farber Harvard Canc Ctr, Boston, MA USA. [Signorello, Lisa B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Hunter, David J.; Lindstrom, Sara] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Boston, MA 02115 USA. [Gonzalez-Neira, Anna; Pita, Guillermo; Alonso, M. Rosario; Alvarez, Nuria; Herrero, Daniel] Spanish Natl Canc Res Ctr CNIO, Human Canc Genet Program, Human Genotyping CEGEN Unit, Madrid, Spain. [Gonzalez-Neira, Anna; Pita, Guillermo; Tessier, Daniel C.; Vincent, Daniel; Bacot, Francois] Ctr Innovat Genome Quebec, Montreal, PQ, Canada. [Tessier, Daniel C.; Vincent, Daniel; Bacot, Francois] McGill Univ, Montreal, PQ, Canada. RP Orr, N (reprint author), Inst Canc Res, 237 Fulham Rd, London SW3 6JB, England. EM nicholas.orr@icr.ac.uk RI Bruning, Thomas/G-8120-2015; Garcia-Closas, Montserrat /F-3871-2015; Andrulis, Irene/E-7267-2013; Knight, Julia/A-6843-2012; Yip, Cheng-Har/B-1909-2010; Teo, Soo-hwang/H-2353-2014; Li, Jingmei/I-2904-2012; Shrubsole, Martha/K-5052-2015; Hartikainen, Jaana/E-6256-2015; Hartman, Mikael/B-4324-2011; Dork, Thilo/J-8620-2012; Bowtell, David/H-1007-2016; Nord, Silje/R-5212-2016; Brenner, Hermann/B-4627-2017; Peissel, Bernard/E-8187-2017; OI Bruning, Thomas/0000-0001-9560-5464; Garcia-Closas, Montserrat /0000-0003-1033-2650; Li, Jingmei/0000-0001-8587-7511; Shrubsole, Martha/0000-0002-5591-7575; Bowtell, David/0000-0001-9089-7525; Yannoukakos, Drakoulis/0000-0001-7509-3510; Dunning, Alison Margaret/0000-0001-6651-7166; Ikram, Mohammad Kamran/0000-0003-0173-9571; Giles, Graham/0000-0003-4946-9099; Nord, Silje/0000-0002-3271-5356; Brenner, Hermann/0000-0002-6129-1572; Peissel, Bernard/0000-0001-9233-3571; dos Santos Silva, Isabel/0000-0002-6596-8798; Schoemaker, Minouk/0000-0001-8403-2234; Cross, Simon/0000-0003-2044-1754; Aitken, Zoe/0000-0002-5413-2450; Khan, Sofia/0000-0003-4185-8882; Cox, Angela/0000-0002-5138-1099; Moisse, Matthieu/0000-0001-8880-9311 FU Cancer Research UK [C1287/A10118, C1287/A12014, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565]; European Community [223175 (HEALTH-F2-2009-223175)]; National Institutes of Health [CA128978, R01 CA77398]; Post-Cancer GWAS initiative (GAME-ON initiative) [1U19 CA148537, 1U19 CA148065, 1U19 CA148112]; Department of Defence [W81XWH-10-1-0341]; Canadian Institutes of Health Research (CIHR); Komen Foundation for the Cure; Breast Cancer Research Foundation; Ovarian Cancer Research Fund; National Cancer Institute (USA) [UM1 CA164920]; Dutch Cancer Society [NKI 2007-3839, 2009 4363]; BBMRI-NL - Dutch government [NWO 184.021.007]; Dutch National Genomics Initiative; ELAN-Fond of the University Hospital of Erlangen; Breakthrough Breast Cancer; NHS; National Cancer Research Network (NCRN); NIHR Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, UK; Oxford Biomedical Research Centre; Dietmar-Hopp Foundation; Helmholtz Society; German Cancer Research Center (DKFZ); Fondation de France; Institut National du Cancer (INCa); Ligue Nationale contre le Cancer; Ligue contre le Cancer Grand Ouest; Agence Nationale de Securite Sanitaire (ANSES) Agence Nationale de la Recherche (ANR); Chief Physician Johan Boserup and Lise Boserup Fund; Danish Medical Research Council; Herlev Hospital; Genome Spain Foundation; Red Tematica de Investigacion Cooperativa en Cancer; Asociacion Espanola Contra el Cancer; Fondo de Investigacion Sanitario [PI11/00923, PI081120]; Instituto de Salud Carlos III; California Breast Cancer Act; California Breast Cancer Research Fund [97-10500]; Lon V Smith Foundation [LVS39420]; Baden Wurttemberg Ministry of Science, Research and Arts; German Cancer Aid (Deutsche Krebshilfe); Deutsche Krebshilfe [107 352]; Federal Ministry of Education and Research (BMBF) Germany [01KW9975/5, 01KW9976/8, 01KW9977/0, 01KW0114]; Robert Bosch Foundation, Stuttgart; Deutsches Krebsforschungszentrum (DKFZ), Heidelberg; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance; Institute of the Ruhr University Bochum (IPA), Bochum; Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH; Johanniter Krankenhaus, Bonn, Germany; Helsinki University Central Hospital Research Fund; Academy of Finland [266528, 250083, 122715]; Finnish Cancer Society; Nordic Cancer Union; Sigrid Juselius Foundation; Stockholm County Council; Karolinska Institutet; Swedish Cancer Society; Gustav V Jubilee foundation; Government Funding (EVO) of Kuopio University Hospital; Cancer Fund of North Savo; Finnish Cancer Organizations; University of Eastern Finland; National Breast Cancer Foundation; National Health and Medical Research Council (NHMRC); Queensland Cancer Fund; Cancer Councils of New South Wales, Victoria, Tasmania and South Australia; Cancer Foundation of Western Australia; Stichting tegen Kanker [232-2008, 196-2010]; FWO; Deutsche Krebshilfe e.V. [70-2892-BR I]; Hamburg Cancer Society; German Cancer Research Center; Federal Ministry of Education and Research (BMBF), Germany [01KH0402]; Italian Association for Cancer Research (AIRC); Fondazione IRCCS Istituto Nazionale Tumori; NIH [CA128978, CA116167, CA176785, CA63464, CA54281, CA098758, CA132839, R01CA100374, R01CA64277, R01CA148667, R37CA70867]; NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201]; VicHealth and Cancer Council Victoria; Australian NHMRC [209057, 251553, 504711]; Quebec Breast Cancer Foundation; Canadian Institutes of Health Research [CRN-87521]; Ministry of Economic Development, Innovation and Export Trade [PSR-SIIRI-701]; Norwegian Research council [155218/V40, 175240/S10]; FUGE-NFR [181600/V11]; Swizz Bridge Award; National Health and Medical Research Council of Australia; New South Wales Cancer Council; Victorian Health Promotion Foundation (Australia); Victorian Breast Cancer Research Consortium; Friends of Hannover Medical School; Rudolf Bartling Foundation; Finnish Cancer Foundation; Academy of Finland (Center of Excellence) [251314]; University of Oulu; University of Oulu Support Foundation; EVO funds for Oulu University Hospital; Dutch Cancer Society (RUL) [1997-1505]; Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL) [CP16]; National Cancer Institute, Department of Health and Human Services, USA; Marit and Hans Rausings Initiative Against Breast Cancer; Dutch Cancer Society (DDHK) [2004-3124, 2009-4318]; Agency for Science, Technology and Research of (A*STAR); US National Institute of Health (NIH); Susan G. Komen Breast Cancer Foundation; Yorkshire Cancer Research [S295, S299, S305PA]; UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge; DKFZ; Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201]; National Institutes of Health Grant [P30 CA016056]; Hellenic Cooperative Oncology Group [HR R_BG/04]; Greek General Secretary for Research and Technology (GSRT) Program, Research Excellence II; European Union (European Social Fund-ESF); Greek national funds through the Operational Program 'Education and Lifelong Learning' of the National Strategic Reference Framework (NSRF)-ARISTEIA; Institute of Cancer Research (ICR), London; Breast Cancer Research Trust, UK; Ministry of Education, Science, Sports, Culture and Technology of Japan; Ministry Health, Labour and Welfare of Japan; Health and Labour Sciences Research Grants for Research on Applying Health Technology from Ministry Health, Labour and Welfare of Japan; National Cancer Center Research and Development Fund; California Breast Cancer Research Program [1RB-0287, 3PB-0102, 5PB-0018, 10PB-0098]; California Department of Health; Malaysian Ministry of Science, Technology and Innovation (MOSTI); Malaysian Ministry of Higher Education [UM.C/HlR/MOHE/06]; Cancer Research Initiatives Foundation (CARIF); Biomedical Research Council, Singapore [BMRC08/1/35/19/550]; National Medical Research Council, Singapore (NMRC/CG/SERI); Genetic Associations and Mechanisms in Oncology (GAME-ON) Network [U19 CA148065]; BRL (Basic Research Laboratory) program through National Research Foundation of Korea - Ministry of Education, Science and Technology [2012-0000347]; National Medical Research Council; Biomedical Research Council [05/1/21/19/425]; National Cancer Institute, Thailand; Taiwan Biobank project of the Institute of Biomedical Sciences, Academia Sinica, Taiwan; National Program of Cancer Registries, Centers for Disease Control and Prevention (CDC); Charity Open Access Fund (COAF); [KULPFV/10/016-SymBioSysII]; [P30 CA68485]; [PBZ_KBN_122/P05/2004]; [N01CN25403] FX BCAC is funded by Cancer Research UK (C1287/A10118, C1287/A12014) and by the European Community's Seventh Framework Programme under grant agreement number 223175 (grant number HEALTH-F2-2009-223175). Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement no. 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692 and C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112-the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The Australian Breast Cancer Family Study (ABCFS) was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The ABCS study was supported by the Dutch Cancer Society (grants NKI 2007-3839; 2009 4363); BBMRI-NL, which is a Research Infrastructure financed by the Dutch government (NWO 184.021.007) and the Dutch National Genomics Initiative. The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BBCS is funded by Cancer Research UK and Breakthrough Breast Cancer and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Cancer Research Network (NCRN). E.S. is supported by NIHR Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, UK. I.T. is supported by the Oxford Biomedical Research Centre. The BSUCH study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the German Cancer Research Center (DKFZ). The CECILE study was funded by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Ligue contre le Cancer Grand Ouest, Agence Nationale de Securite Sanitaire (ANSES) Agence Nationale de la Recherche (ANR). The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council and Herlev Hospital. The CNIO-BCS was supported by the Genome Spain Foundation, the Red Tematica de Investigacion Cooperativa en Cancer and grants from the Asociacion Espanola Contra el Cancer and the Fondo de Investigacion Sanitario (PI11/00923 and PI081120). The Human Genotyping-CEGEN Unit (CNIO) is supported by the Instituto de Salud Carlos III. The CTS was initially supported by the California Breast Cancer Act of 1993 and the California Breast Cancer Research Fund (contract 97-10500) and is currently funded through the National Institutes of Health (R01 CA77398). Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. H.A.C receives support from the Lon V Smith Foundation (LVS39420). The ESTHER study was supported by a grant from the Baden Wurttemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). The GC-HBOC was supported by Deutsche Krebshilfe (107 352).; The GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. The HEBCS was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, and The Nordic Cancer Union and the Sigrid Juselius Foundation. Financial support for KARBAC was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, The Swedish Cancer Society and the Gustav V Jubilee foundation. The KBCP was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, and by the strategic funding of the University of Eastern Finland. 'kConFab' is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. LMBC is supported by the 'Stichting tegen Kanker' (232-2008 and 196-2010). Diether Lambrechts is supported by the FWO and the KULPFV/10/016-SymBioSysII. The MARIE study was supported by the Deutsche Krebshilfe e.V. [70-2892-BR I], the Hamburg Cancer Society, the German Cancer Research Center and the Federal Ministry of Education and Research (BMBF), Germany (01KH0402). MBCSG is supported by grants from the Italian Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects '5 x 1000'). The MCBCS was supported by the NIH grants CA128978, CA116167 and CA176785 and NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), and the Breast Cancer Research Foundation and a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553 and 504711 and by infrastructure provided by Cancer Council Victoria. The MEC was support by NIH grants CA63464, CA54281, CA098758 and CA132839. The work of MTLGEBCS was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research for the 'CIHR Team in Familial Risks of Breast Cancer' program-grant # CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade-grant # PSR-SIIRI-701. The NBCS was supported by grants from the Norwegian Research council, 155218/V40, 175240/S10 to A.L.B.D., FUGE-NFR 181600/V11 to V.N.K. and a Swizz Bridge Award to A.L.B.D. The NBHS was supported by NIH grant R01CA100374. Biological sample preparation was conducted by the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485.; The OBCS was supported by research grants from the Finnish Cancer Foundation, the Academy of Finland (grant number 250083, 122715 and Center of Excellence grant number 251314), the Finnish Cancer Foundation, the Sigrid Juselius Foundation, the University of Oulu, the University of Oulu Support Foundation and the special Governmental EVO funds for Oulu University Hospital-based research activities. OFBCR was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The ORIGO study was supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16). The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The pKARMA study was supported by Marit and Hans Rausings Initiative Against Breast Cancer. The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The SASBAC study was supported by funding from the Agency for Science, Technology and Research of (A*STAR), the US National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. The SBCS was supported by Yorkshire Cancer Research S295, S299, S305PA. SEARCH is funded by a programme grant from Cancer Research UK (C490/A10124) and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The SZBCS was supported by Grant PBZ_KBN_122/P05/2004. SKKDKFZS is supported by the DKFZ. The TNBCC was supported by: a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a grant from the Breast Cancer Research Foundation, a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation, the Stefanie Spielman Breast Cancer fund and the OSU Comprehensive Cancer Center, DBBR (a CCSG Share Resource by National Institutes of Health Grant P30 CA016056), the Hellenic Cooperative Oncology Group research grant (HR R_BG/04) and the Greek General Secretary for Research and Technology (GSRT) Program, Research Excellence II, the European Union (European Social Fund-ESF), and Greek national funds through the Operational Program 'Education and Lifelong Learning' of the National Strategic Reference Framework (NSRF)-ARISTEIA. The UKBGS is funded by Breakthrough Breast Cancer and the Institute of Cancer Research (ICR), London. ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. The ACP study is funded by the Breast Cancer Research Trust, UK. The HERPACC was supported by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sports, Culture and Technology of Japan, by a Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from Ministry Health, Labour and Welfare of Japan, by Health and Labour Sciences Research Grants for Research on Applying Health Technology from Ministry Health, Labour and Welfare of Japan and by National Cancer Center Research and Development Fund. LAABC is supported by grants (1RB-0287, 3PB-0102, 5PB-0018 and 10PB-0098) from the California Breast Cancer Research Program. Incident breast cancer cases were collected by the USC Cancer Surveillance Program (CSP) which is supported under subcontract by the California Department of Health. The CSP is also part of the National Cancer Institute's Division of Cancer Prevention and Control Surveillance, Epidemiology, and End Results Program, under contract number N01CN25403.; MYBRCA is funded by research grants from the Malaysian Ministry of Science, Technology and Innovation (MOSTI), Malaysian Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer Research Initiatives Foundation (CARIF). Additional controls were recruited by the Singapore Eye Research Institute, which was supported by a grant from the Biomedical Research Council (BMRC08/1/35/19/550), Singapore and the National Medical Research Council, Singapore (NMRC/CG/SERI/2010). The SBCGS was supported primarily by NIH grants R01CA64277, R01CA148667 and R37CA70867. Biological sample preparation was conducted by the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. The scientific development and funding of this project were, in part, supported by the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network U19 CA148065. SEBCS was supported by the BRL (Basic Research Laboratory) program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012-0000347). SGBCC is funded by the National Medical Research Council start-up Grant and Centre Grant (NMRC/CG/NCIS/2010). Additional controls were recruited by the Singapore Consortium of Cohort Studies-Multi-ethnic cohort (SCCS-MEC), which was funded by the Biomedical Research Council, grant number: 05/1/21/19/425. The TBCS was funded by The National Cancer Institute, Thailand. The TWBCS is supported by the Taiwan Biobank project of the Institute of Biomedical Sciences, Academia Sinica, Taiwan. The NBHS was supported by NIH grant R01CA100374. Biological sample preparation was conducted by the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. The SCCS is supported by a grant from the National Institutes of Health (R01 CA092447). The Arkansas Central Cancer Registry is fully funded by a grant from National Program of Cancer Registries, Centers for Disease Control and Prevention (CDC). Funding to pay the Open Access publication charges for this article was provided by the Charity Open Access Fund (COAF). NR 47 TC 10 Z9 10 U1 3 U2 21 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD MAY 15 PY 2015 VL 24 IS 10 BP 2966 EP 2984 DI 10.1093/hmg/ddv035 PG 19 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA CJ2PK UT WOS:000355326800022 PM 25652398 ER PT J AU Hasegawa, K Jartti, T Mansbach, JM Laham, FR Jewell, AM Espinola, JA Piedra, PA Camargo, CA AF Hasegawa, Kohei Jartti, Tuomas Mansbach, Jonathan M. Laham, Federico R. Jewell, Alan M. Espinola, Janice A. Piedra, Pedro A. Camargo, Carlos A., Jr. TI Respiratory Syncytial Virus Genomic Load and Disease Severity Among Children Hospitalized With Bronchiolitis: Multicenter Cohort Studies in the United States and Finland SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE bronchiolitis; infants; children; genomic load; respiratory syncytial virus; hospitalization; length of stay; intensive care unit; mechanical ventilation; cohort study ID REAL-TIME PCR; LENGTH-OF-STAY; VIRAL LOAD; IMMUNE-RESPONSES; INFECTION; INFANTS; MANAGEMENT; DIAGNOSIS; ETIOLOGY; ASSOCIATION AB Methods.aEuro integral Two multicenter prospective cohort studies in the United States and Finland used the same protocol to enroll children aged < 2 years hospitalized for bronchiolitis and collect nasopharyngeal aspirates. By using real-time polymerase chain reaction analysis, patients were classified into 3 genomic load status groups: low, intermediate, and high. Outcome measures were a length of hospital stay (LOS) of a parts per thousand yen3 days and intensive care use, defined as admission to the intensive care unit or use of mechanical ventilation. Results.aEuro integral Of 2615 enrolled children, 1764 (67%) had RSV bronchiolitis. Children with a low genomic load had a higher unadjusted risk of having a length of stay of a parts per thousand yen3 days (52%), compared with children with intermediate and those with high genomic loads (42% and 51%, respectively). In a multivariable model, the risk of having a length of stay of a parts per thousand yen3 days remained significantly higher in the groups with intermediate (odds ratio [OR], 1.43; 95% confidence interval [CI], 1.20-1.69) and high (OR, 1.58; 95% CI, 1.29-1.94) genomic loads. Similarly, children with a high genomic load had a higher risk of intensive care use (20%, compared with 15% and 16% in the groups with low and intermediate genomic loads, respectively). In a multivariable model, the risk remained significantly higher in the group with a high genomic load (OR, 1.43; 95% CI, 1.03-1.99). Conclusion.aEuro integral Children with a higher RSV genomic load had a higher risk for more-severe bronchiolitis. C1 [Hasegawa, Kohei; Espinola, Janice A.; Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Cambridge, MA 02138 USA. [Mansbach, Jonathan M.] Boston Childrens Hosp, Dept Med, Boston, MA USA. [Laham, Federico R.] Arnold Palmer Hosp Children, Dept Infect Dis, Orlando, FL USA. [Jewell, Alan M.; Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol & Pediat, Houston, TX 77030 USA. [Jartti, Tuomas] Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland. RP Hasegawa, K (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Ste 410, Boston, MA 02114 USA. EM khasegawa1@partners.org FU National Institutes of Health [U01 AI-67693] FX This work was supported by the National Institutes of Health (grant U01 AI-67693). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID or NIH. NR 39 TC 21 Z9 22 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 15 PY 2015 VL 211 IS 10 BP 1550 EP 1559 DI 10.1093/infdis/jiu658 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CI4MG UT WOS:000354723000005 PM 25425699 ER PT J AU Meya, DB Okurut, S Zziwa, G Rolfes, MA Kelsey, M Cose, S Joloba, M Naluyima, P Palmer, BE Kambugu, A Mayanja-Kizza, H Bohjanen, PR Eller, MA Wahl, SM Boulware, DR Manabe, YC Janoff, EN AF Meya, David B. Okurut, Samuel Zziwa, Godfrey Rolfes, Melissa A. Kelsey, Melander Cose, Steve Joloba, Moses Naluyima, Prossy Palmer, Brent E. Kambugu, Andrew Mayanja-Kizza, Harriet Bohjanen, Paul R. Eller, Michael A. Wahl, Sharon M. Boulware, David R. Manabe, Yuka C. Janoff, Edward N. TI Cellular Immune Activation in Cerebrospinal Fluid From Ugandans With Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE cryptococcal meningitis; cryptococcus; HIV; cerebrospinal fluid; immune responses; cell activation ID CENTRAL-NERVOUS-SYSTEM; CD4(+) T-CELLS; HIV-1-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; CLINICAL-FEATURES; INFECTED PATIENTS; HIV-INFECTION; NEOFORMANS; TUBERCULOSIS; MECHANISMS AB Methods.aEuro integral We characterized the lineage and activation status of mononuclear cells in blood and CSF of HIV-infected patients with noncryptococcal meningitis (NCM) (n = 10), those with CM at day 0 (n = 40) or day 14 (n = 21) of antifungal therapy, and those with CM-IRIS (n = 10). Results.aEuro integral At diagnosis, highly activated CD8(+) T cells predominated in CSF in both CM and NCM. CM-IRIS was associated with an increasing frequency of CSF CD4(+) T cells (increased from 2.2% to 23%; P = .06), a shift in monocyte phenotype from classic to an intermediate/proinflammatory, and increased programmed death ligand 1 expression on natural killer cells (increased from 11.9% to 61.6%, P = .03). CSF cellular responses were distinct from responses in peripheral blood. Conclusions.aEuro integral After CM, T cells in CSF tend to evolve with the development of IRIS, with increasing proportions of activated CD4(+) T cells, migration of intermediate monocytes to the CSF, and declining fungal burden. These changes provide insight into IRIS pathogenesis and could be exploited to more effectively treat CM and prevent CM-IRIS. C1 [Meya, David B.; Kambugu, Andrew; Manabe, Yuka C.] Makerere Univ, Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda. [Meya, David B.; Cose, Steve; Mayanja-Kizza, Harriet] Makerere Univ, Coll Hlth Sci, Sch Med, Kampala, Uganda. [Joloba, Moses] Makerere Univ, Dept Microbiol, Sch Biomed Sci, Kampala, Uganda. [Okurut, Samuel; Zziwa, Godfrey] Makerere Univ Reed Project, Kampala, Uganda. [Cose, Steve] Uganda Virus Res Inst, Med Res Council, Uganda Res Unit AIDS, Entebbe, Uganda. [Meya, David B.; Rolfes, Melissa A.; Boulware, David R.] Univ Minnesota, Dept Med, Ctr Infect Dis & Microbiol Translat Res, Minneapolis, MN 55455 USA. [Kelsey, Melander; Janoff, Edward N.] Univ Colorado Denver, Mucosal & Vaccine Res Program Colorado, Aurora, CO USA. [Kelsey, Melander; Janoff, Edward N.] Denver Vet Affairs Med Ctr, Baltimore, MD USA. [Manabe, Yuka C.] Johns Hopkins Univ, Dept Med, Div Infect Dis, Baltimore, MD USA. [Eller, Michael A.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA. [Eller, Michael A.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA. [Wahl, Sharon M.] Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA. [Cose, Steve] London Sch Hyg & Trop Med, London, England. RP Meya, DB (reprint author), Makerere Univ, Coll Hlth Sci, Infect Dis Inst, POB 22418, Kampala, Uganda. EM david.meya@gmail.com OI Mayanja-Kizza, Harriet/0000-0002-9297-6208; Joloba, Moses/0000-0002-0334-9983; Boulware, David/0000-0002-4715-0060; Cose, Stephen/0000-0002-5156-037X FU National Institutes of Health [R01AI078934, U01AI089244, NS065713, R01AI108479, K24AI096925, T32AI055433, R21NS065713]; Wellcome Trust (Training Health Researchers into Vocational Excellence [THRiVE]) in East Africa [087540]; GlaxoSmithKline Collaborative Investigator Research Award; Veterans Affairs Research Service FX This work was supported by the National Institutes of Health (grants R01AI078934, U01AI089244, NS065713, R01AI108479, K24AI096925, T32AI055433, and R21NS065713); the Wellcome Trust (Training Health Researchers into Vocational Excellence [THRiVE]) in East Africa (grant 087540), the GlaxoSmithKline Collaborative Investigator Research Award, and the Veterans Affairs Research Service. NR 45 TC 9 Z9 9 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 15 PY 2015 VL 211 IS 10 BP 1597 EP 1606 DI 10.1093/infdis/jiu664 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CI4MG UT WOS:000354723000010 PM 25492918 ER PT J AU Tanner, NT Silvestri, GA AF Tanner, Nichole T. Silvestri, Gerard A. TI Screening for Lung Cancer Using Low-Dose Computed Tomography Are We Headed for DANTE's Paradise or Inferno? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID TRIAL C1 [Tanner, Nichole T.; Silvestri, Gerard A.] Med Univ S Carolina, Charleston, SC 29425 USA. [Tanner, Nichole T.] Ralph H Johnson Vet Affairs Hosp, Hlth Equity & Rural Outreach Innovat Ctr, Charleston, SC USA. RP Tanner, NT (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA. NR 17 TC 2 Z9 2 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAY 15 PY 2015 VL 191 IS 10 BP 1100 EP 1101 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CI8KO UT WOS:000355021400005 PM 25978569 ER PT J AU Black, JC Atabakhsh, E Kim, J Biette, KM Van Rechem, C Ladd, B Burrowes, PD Donado, C Mattoo, H Kleinstiver, BP Song, B Andriani, G Joung, JK Iliopoulos, O Montagna, C Pillai, S Getz, G Whetstine, JR AF Black, Joshua C. Atabakhsh, Elnaz Kim, Jaegil Biette, Kelly M. Van Rechem, Capucine Ladd, Brendon Burrowes, Paul D. Donado, Carlos Mattoo, Hamid Kleinstiver, Benjamin P. Song, Bing Andriani, Grasiella Joung, J. Keith Iliopoulos, Othon Montagna, Cristina Pillai, Shiv Getz, Gad Whetstine, Johnathan R. TI Hypoxia drives transient site-specific copy gain and drug-resistant gene expression SO GENES & DEVELOPMENT LA English DT Article DE CNV; JmjC; KDM4A; hypoxia; site-specific copy gain; tumor heterogeneity ID HISTONE DEMETHYLASES; NECK-CANCER; HETEROGENEITY; PROGRESSION; PROTEIN; KDM4A; CELLS; CKS1B; REREPLICATION; AMPLIFICATION AB Copy number heterogeneity is a prominent feature within tumors. The molecular basis for this heterogeneity remains poorly characterized. Here, we demonstrate that hypoxia induces transient site-specific copy gains (TSSGs) in primary, nontransformed, and transformed human cells. Hypoxia-driven copy gains are not dependent on HIF1 alpha or HIF2 alpha; however, they are dependent on the KDM4A histone demethylase and are blocked by inhibition of KDM4A with a small molecule or the natural metabolite succinate. Furthermore, this response is conserved at a syntenic region in zebrafish cells. Regions with site-specific copy gain are also enriched for amplifications in hypoxic primary tumors. These tumors exhibited amplification and overexpression of the drug resistance gene CKS1B, which we recapitulated in hypoxic breast cancer cells. Our results demonstrate that hypoxia provides a biological stimulus to create transient site-specific copy alterations that could result in heterogeneity within tumors and cell populations. These findings have major implications in our understanding of copy number heterogeneity and the emergence of drug resistance genes in cancer. C1 [Black, Joshua C.; Atabakhsh, Elnaz; Biette, Kelly M.; Van Rechem, Capucine; Ladd, Brendon; Burrowes, Paul D.; Donado, Carlos; Mattoo, Hamid; Song, Bing; Iliopoulos, Othon; Pillai, Shiv; Whetstine, Johnathan R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Canc Ctr,Dept Med, Charlestown, MA 02129 USA. [Kim, Jaegil; Getz, Gad] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02142 USA. [Kleinstiver, Benjamin P.; Joung, J. Keith; Getz, Gad] Harvard Univ, Massachusetts Gen Hosp, Dept Pathol, Canc Ctr,Med Sch, Charlestown, MA 02129 USA. [Kleinstiver, Benjamin P.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Charlestown, MA 02129 USA. [Andriani, Grasiella; Montagna, Cristina] Yeshiva Univ, Albert Einstein Coll Med, Dept Genet, Pathol, Bronx, NY 10461 USA. [Iliopoulos, Othon] Massachusetts Gen Hosp, Div Hematol Oncol, Dept Med, Boston, MA 02114 USA. RP Whetstine, JR (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Canc Ctr,Dept Med, Charlestown, MA 02129 USA. EM jwhetstine@hms.harvard.edu RI Black, Joshua/Q-2484-2015 FU American Cancer Society [RSG-13-115-01-CCG, CA059267, R01GM097360]; American Lung Association Lung Cancer Discovery Award; National Institutes of Health [U24CA143845]; Massachusetts General Hospital Executive Committee on Research (ECOR) Tosteson Post-doctoral Fellowship; Senior Research Training Fellowship from the American Lung Association; Fund for Medical Discovery; Marsha Rivkin Center for Ovarian Cancer Research; National Sciences and Engineering Research Council of Canada; National Institutes of Health Director's Pioneer Award [DP1 GM105378]; Jim and Ann Orr Research Scholar Award; AbbVie; Canada Foundation for Innovation (CFI); Canadian Institutes of Health Research (CIHR); Genome Canada; Ontario Genomics Institute [OGI-055]; GlaxoSmithKline; Novartis Research Foundation; Ontario Ministry of Economic Development and Innovation; Pfizer; Structural Genomics Consortium; Jane Coffin Childs Memorial Fund for Medical Research; Boehringer Ingelheim; Janssen; Lilly Canada; Takeda; Wellcome Trust [092809/Z/10/Z]; [1RO1CA160458] FX We are grateful to Ravi Mylvaganamand the Massachusetts General Hospital Flow Cytometry core for assistance with the cell sorting. We thank Danette Daniels for providing reagents. We also thank Tony Kossiakoff, Edyta Marcon, Cheryl Arrowsmith, and members of the Structural Genomics Consortium Antibody Team for contributions to generating recombinant KDM4A-P006. This work was supported by funding to J.R.W. from the American Cancer Society (RSG-13-115-01-CCG), CA059267, and R01GM097360. J.R.W. is a Tepper Family Massachusetts General Hospital Research Scholar and Leukemia and Lymphoma Society Scholar. J.R.W. is a recipient of an American Lung Association Lung Cancer Discovery Award. G.G. and J.K. are supported by National Institutes of Health (U24CA143845). J.C.B. was a Fellow of The Jane Coffin Childs Memorial Fund for Medical Research. This investigation has been aided by a grant from The Jane Coffin Childs Memorial Fund for Medical Research. J.C.B. is supported by a Massachusetts General Hospital Executive Committee on Research (ECOR) Tosteson Post-doctoral Fellowship. E.A. is supported by a Senior Research Training Fellowship from the American Lung Association. A post-doctoral fellowship was provided by the Fund for Medical Discovery (C.V.R.). This research was supported in part by a grant from the Marsha Rivkin Center for Ovarian Cancer Research (C.V.R.). B.P.K. is supported by a post-doctoral fellowship from the National Sciences and Engineering Research Council of Canada. This work was supported by a National Institutes of Health Director's Pioneer Award (DP1 GM105378) and The Jim and Ann Orr Research Scholar Award (both to J.K.J.). This work was supported by funding to O.I. from 1RO1CA160458. The Structural Genomics Consortium is a registered charity (no. 1097737) that receives funds from AbbVie, Boehringer Ingelheim, the Canada Foundation for Innovation (CFI), the Canadian Institutes of Health Research (CIHR), Genome Canada, Ontario Genomics Institute (grant OGI-055), GlaxoSmithKline, Janssen, Lilly Canada, the Novartis Research Foundation, the Ontario Ministry of Economic Development and Innovation, Pfizer, Takeda, and Wellcome Trust (grant 092809/Z/10/Z), Work in the Kossiakoff laboratory was funded by the Structural Genomics Consortium and National Institutes of Health. NR 49 TC 12 Z9 13 U1 1 U2 9 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 0890-9369 EI 1549-5477 J9 GENE DEV JI Genes Dev. PD MAY 15 PY 2015 VL 29 IS 10 BP 1018 EP 1031 DI 10.1101/gad.259796.115 PG 14 WC Cell Biology; Developmental Biology; Genetics & Heredity SC Cell Biology; Developmental Biology; Genetics & Heredity GA CI6ND UT WOS:000354875500004 PM 25995187 ER PT J AU Tu, HC Schwitalla, S Qian, ZR LaPier, GS Yermalovich, A Ku, YC Chen, SC Viswanathan, SR Zhu, H Nishihara, R Inamura, K Kim, SA Morikawa, T Mima, K Sukawa, Y Yang, JH Meredith, G Fuchs, CS Ogino, S Daley, GQ AF Tu, Ho-Chou Schwitalla, Sarah Qian, Zhirong LaPier, Grace S. Yermalovich, Alena Ku, Yuan-Chieh Chen, Shann-Ching Viswanathan, Srinivas R. Zhu, Hao Nishihara, Reiko Inamura, Kentaro Kim, Sun A. Morikawa, Teppei Mima, Kosuke Sukawa, Yasutaka Yang, Juhong Meredith, Gavin Fuchs, Charles S. Ogino, Shuji Daley, George Q. TI LIN28 cooperates with WNT signaling to drive invasive intestinal and colorectal adenocarcinoma in mice and humans SO GENES & DEVELOPMENT LA English DT Article DE LIN28; let-7 miRNA; WNT; oncogene cooperation; invasive adenocarcinoma; colorectal cancer ID COLON-CANCER; STEM-CELLS; MICROSATELLITE INSTABILITY; GLUCOSE-METABOLISM; PIK3CA MUTATION; MOUSE MODELS; ASPIRIN USE; LET-7; EXPRESSION; MICRORNA AB Colorectal cancer (CRC) remains a major contributor to cancer-related mortality. LIN28A and LIN28B are highly related RNA-binding protein paralogs that regulate biogenesis of let-7 microRNAs and influence development, metabolism, tissue regeneration, and oncogenesis. Here we demonstrate that overexpression of either LIN28 paralog cooperates with the Wnt pathway to promote invasive intestinal adenocarcinoma in murine models. When LIN28 alone is induced genetically, half of the resulting tumors harbor Ctnnb1 (beta-catenin) mutation. When overexpressed in Apc(Min/+) mice, LIN28 accelerates tumor formation and enhances proliferation and invasiveness. In conditional genetic models, enforced expression of a LIN28-resistant form of the let-7 microRNA reduces LIN28-induced tumor burden, while silencing of LIN28 expression reduces tumor volume and increases tumor differentiation, indicating that LIN28 contributes to tumor maintenance. We detected aberrant expression of LIN28A and/or LIN28B in 38% of a large series of human CRC samples (n = 595), where LIN28 expression levels were associated with invasive tumor growth. Our late-stage CRC murine models and analysis of primary human tumors demonstrate prominent roles for both LIN28 paralogs in promoting CRC growth and progression and implicate the LIN28/let-7 pathway as a therapeutic target. C1 [Tu, Ho-Chou; Schwitalla, Sarah; LaPier, Grace S.; Yermalovich, Alena; Viswanathan, Srinivas R.; Daley, George Q.] Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA. [Tu, Ho-Chou; Schwitalla, Sarah; LaPier, Grace S.; Yermalovich, Alena; Viswanathan, Srinivas R.; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Tu, Ho-Chou; Schwitalla, Sarah; LaPier, Grace S.; Yermalovich, Alena; Viswanathan, Srinivas R.; Daley, George Q.] Harvard Stem Cell Inst, Boston, MA 02115 USA. [Qian, Zhirong; Nishihara, Reiko; Inamura, Kentaro; Kim, Sun A.; Morikawa, Teppei; Mima, Kosuke; Sukawa, Yasutaka; Yang, Juhong; Fuchs, Charles S.; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ku, Yuan-Chieh; Chen, Shann-Ching; Meredith, Gavin] Thermo Fisher Sci Inc, San Francisco, CA 94080 USA. [Zhu, Hao] Univ Texas Southwestern, Childrens Med Ctr, Res Inst, Dallas, TX 75390 USA. [Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Ogino, Shuji] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Ogino, Shuji] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Daley, George Q.] Howard Hughes Med Inst, Boston, MA 02138 USA. RP Daley, GQ (reprint author), Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA. EM george.daley@childrens.harvard.edu RI Zhu, Hao/L-5114-2013 OI Zhu, Hao/0000-0002-8417-9698 FU National Institutes of Health (NIH) [R01GM107536, F31 CA186444-01, K07 CA190673, P01CA127003, RO1CA151993]; Ellison Medical Foundation; American Association for Cancer Research Fight Colorectal Cancer Postdoctoral Fellowship; EMBO post-doctoral fellowship; Agrusa Fund for Colorectal Cancer Research; DFIC Friends FX We thank Achia Urbach, John Powers, Ramesh Shivdasani, and Xi He for invaluable discussion and advice. We thank Michael C.F. Chen for providing E12.5 embryonic intestine tissues, and Roderick Bronson and the Harvard Medical School Rodent Histopathology Core for mouse tissue pathology. G.Q.D. is supported by grants from the National Institutes of Health (NIH; R01GM107536) and the Ellison Medical Foundation and is an affiliate member of the Broad Institute and an investigator of the Howard Hughes Medical Institute and the Manton Center for Orphan Disease Research. H.-C.T. is supported by the American Association for Cancer Research Fight Colorectal Cancer Postdoctoral Fellowship. S.S. is supported by an EMBO post-doctoral fellowship. A.Y. is supported by NIH F31 CA186444-01 predoctoral fellowship. R.N. is supported by NIH K07 CA190673. C.S. F. is supported by NIH P01CA127003 and Agrusa Fund for Colorectal Cancer Research. S.O. is supported by NIH RO1CA151993 and DFIC Friends. NR 65 TC 14 Z9 15 U1 0 U2 11 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 0890-9369 EI 1549-5477 J9 GENE DEV JI Genes Dev. PD MAY 15 PY 2015 VL 29 IS 10 BP 1074 EP 1086 DI 10.1101/gad.256693.114 PG 13 WC Cell Biology; Developmental Biology; Genetics & Heredity SC Cell Biology; Developmental Biology; Genetics & Heredity GA CI6ND UT WOS:000354875500008 PM 25956904 ER PT J AU Boyce, RM Muiru, A Reyes, R Ntaro, M Mulogo, E Matte, M Siedner, MJ AF Boyce, Ross M. Muiru, Anthony Reyes, Raquel Ntaro, Moses Mulogo, Edgar Matte, Michael Siedner, Mark J. TI Impact of rapid diagnostic tests for the diagnosis and treatment of malaria at a peripheral health facility in Western Uganda: an interrupted time series analysis SO MALARIA JOURNAL LA English DT Article DE Malaria; Rapid diagnostic tests; Outcomes; Case management; Antibiotics ID AFRICAN CHILDREN; MICROSCOPY; IMPLEMENTATION; PNEUMONIA; TANZANIA; OVERLAP AB Background: The World Health Organization recommends that all suspected malaria cases receive a parasitological diagnosis prior to treatment with artemisinin-based combination therapy. A recent meta-analysis of clinical trials evaluating RDTs for the management of patients with fever found substantial reductions in anti-malarial prescriptions when health workers adhered to treatment protocols based on test results. However few studies have reported on the impact of RDTs on health systems outside research settings. Methods: The study comprised a retrospective interrupted time series analysis, comparing rates of malaria diagnosis, treatment, and resource utilization before and after introduction of RDTs at a peripheral health facility in rural Western Uganda. The use of malaria diagnostic tests was graphically depicted throughout the study period and fit regression models to identify correlates of three outcomes of interest: (1) length of stay (2) the proportion of patients referred to a higher-level health facility, and (3) administration of antibiotics. Results: Over the course of the study period, 14,357 individuals underwent diagnostic testing for malaria with either a RDT (9,807) or microscopy (4,550). The proportion of patients with parasite-based diagnoses more than tripled to 34 % after the introduction of RDTs. RDTs largely replaced microscopy as the diagnostic method of choice. Compared to patients admitted during the pre-RDT period, patients admitted to the health centre with malaria in the post-RDT period had significantly reduced odds of being referred to another health centre (AOR = 0.49, P = 0.038), receiving antibiotics (AOR = 0.42, P < 0.001), and a significantly shorter mean length of stay (beta = -0.32 days, 95 % CI -0.52 to -0.13). Conclusions: This study is one of the few to demonstrate significant improvement in clinical outcomes and process measures following the introduction of RDTs for the diagnosis of malaria at a rural health facility in Uganda. The results show a reduction in referrals and shorter mean inpatient LOS even as antibiotics were prescribed less frequently. This change greatly increased laboratory throughput and the resultant proportion of patients receiving a parasite-based diagnosis. C1 [Boyce, Ross M.; Muiru, Anthony; Reyes, Raquel; Siedner, Mark J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Muiru, Anthony; Siedner, Mark J.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA. [Ntaro, Moses; Mulogo, Edgar; Matte, Michael] Mbarara Univ Sci & Technol, Dept Community Hlth, Mbarara, Uganda. RP Boyce, RM (reprint author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St, Boston, MA 02114 USA. EM rmboyce@mgh.harvard.edu OI Boyce, Ross/0000-0002-9489-6324 FU NIMH NIH HHS [K23 MH099916] NR 21 TC 7 Z9 7 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAY 15 PY 2015 VL 14 AR 203 DI 10.1186/s12936-015-0725-0 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CI6DI UT WOS:000354848500003 PM 25971788 ER PT J AU Wakabayashi-Ito, N Ajjuri, RR Henderson, BW Doherty, OM Breakefield, XO O'Donnell, JM Ito, N AF Wakabayashi-Ito, Noriko Ajjuri, Rami R. Henderson, Benjamin W. Doherty, Olugbenga M. Breakefield, Xandra O. O'Donnell, Janis M. Ito, Naoto TI Mutant human torsinA, responsible for early-onset dystonia, dominantly suppresses GTPCH expression, dopamine levels and locomotion in Drosophila melanogaster SO BIOLOGY OPEN LA English DT Article DE Dystonia; Drosophila; GTP cyclohydrolase; TorsinA; Movement disorder ID MESSENGER-RNA LOCALIZATION; TYROSINE-HYDROXYLASE; NUCLEAR-ENVELOPE; DYT1 DYSTONIA; PUNCH LOCUS; GENE-EXPRESSION; CELLS; SEQUENCES; BIOSYNTHESIS; INCLUSIONS AB Dystonia represents the third most common movement disorder in humans with over 20 genetic loci identified. TOR1A (DYT1), the gene responsible for the most common primary hereditary dystonia, encodes torsinA, an AAA ATPase family protein. Most cases of DYT1 dystonia are caused by a 3 bp (Delta GAG) deletion that results in the loss of a glutamic acid residue (Delta E302/303) in the carboxyl terminal region of torsinA. This torsinA Delta E mutant protein has been speculated to act in a dominant-negative manner to decrease activity of wild type torsinA. Drosophila melanogaster has a single torsin-related gene, dtorsin. Null mutants of dtorsin exhibited locomotion defects in third instar larvae. Levels of dopamine and GTP cyclohydrolase (GTPCH) proteins were severely reduced in dtorsin-null brains. Further, the locomotion defect was rescued by the expression of human torsinA or feeding with dopamine. Here, we demonstrate that human torsinA Delta E dominantly inhibited locomotion in larvae and adults when expressed in neurons using a pan-neuronal promoter Elav. Dopamine and tetrahydrobiopterin (BH4) levels were significantly reduced in larval brains and the expression level of GTPCH protein was severely impaired in adult and larval brains. When human torsinA and torsinA Delta E were co-expressed in neurons in dtorsin-null larvae and adults, the locomotion rates and the expression levels of GTPCH protein were severely reduced. These results support the hypothesis that torsinA Delta E inhibits wild type torsinA activity. Similarly, neuronal expression of a Drosophila Dtorsin Delta E equivalent mutation dominantly inhibited larval locomotion and GTPCH protein expression. These results indicate that both torsinA Delta E and DtorsinDE act in a dominant-negative manner. We also demonstrate that Dtorsin regulates GTPCH expression at the post-transcriptional level. This Drosophila model of DYT1 dystonia provides an important tool for studying the differences in the molecular function between the wild type and the mutant torsin proteins. C1 [Wakabayashi-Ito, Noriko; Breakefield, Xandra O.; Ito, Naoto] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02129 USA. [Wakabayashi-Ito, Noriko; Breakefield, Xandra O.; Ito, Naoto] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02129 USA. [Ajjuri, Rami R.; Henderson, Benjamin W.; Doherty, Olugbenga M.; O'Donnell, Janis M.] Univ Alabama, Dept Biol Sci, Tuscaloosa, AL 35487 USA. RP Ito, N (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02129 USA. EM iton@helix.mgh.harvard.edu FU National Institute of Neurological Disorders and Stroke (NINDS) [P30-NS045776]; Dystonia Medical Research Foundation; Bachmann-Strauss Dystonia and Parkinson Foundation; University of Alabama; NINDS [the National Institutes of Health (NIH)] [R15 NS078728]; NIH/NINDS [P50 NS037409]; Department of Defense [W81XWH-12-1-0380] FX The RT-PCR core was supported in part by a grant from National Institute of Neurological Disorders and Stroke (NINDS) [P30-NS045776]. The support for this work was provided by Dystonia Medical Research Foundation (to N.I. and X.O.B.); Bachmann-Strauss Dystonia and Parkinson Foundation (to N.I. and X.O.B.); the University of Alabama (to J.M.O., R.R.A., B.W.H., and O.M.D.); NINDS [the National Institutes of Health (NIH)] [R15 NS078728 to J.M.O.; NIH/NINDS P50 NS037409 to N.I. and X.O.B.]; and Department of Defense (Peer Reviewed Medical Research Program) [W81XWH-12-1-0380 to N.I.]. NR 50 TC 0 Z9 0 U1 0 U2 4 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 2046-6390 J9 BIOL OPEN JI Biol. Open PD MAY 15 PY 2015 VL 4 IS 5 BP 585 EP 595 DI 10.1242/bio.201411080 PG 11 WC Biology SC Life Sciences & Biomedicine - Other Topics GA CI3BC UT WOS:000354621400001 PM 25887123 ER PT J AU Cheng, A Owens, D AF Cheng, Andrew Owens, David TI Marfan syndrome, inherited aortopathies and exercise: What is the right answer? SO HEART LA English DT Review ID ARTERIAL BLOOD-PRESSURE; SUDDEN CARDIAC DEATH; AORTIC DISSECTION; CARDIOVASCULAR-DISEASE; HEMODYNAMIC-RESPONSE; SPORTS PARTICIPATION; RESISTANCE EXERCISE; PHYSICAL-ACTIVITY; ASSOCIATION; RECOMMENDATIONS AB Exercise recommendations for those who have Marfan syndrome or other genetic predisposition for thoracic aortic disease remain controversial and at times ambiguous. There are no outcomes studies to help guide recommendations. In this review, we examine the guidelines regarding exercise and inherited aortic conditions, the theoretical reasoning and circumstantial evidence that support the guidelines, as well as the knowledge gaps that continue to exist. C1 [Cheng, Andrew] VA Puget Sound, Dept Cardiol, Seattle, WA 98108 USA. [Cheng, Andrew; Owens, David] Univ Washington, Dept Cardiol, Seattle, WA 98195 USA. RP Cheng, A (reprint author), VA Puget Sound, Dept Cardiol, 1660 S Columbian Way, Seattle, WA 98108 USA. EM ACheng@cardiology.washington.edu OI Owens, David/0000-0002-7293-9688 NR 39 TC 1 Z9 1 U1 0 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1355-6037 EI 1468-201X J9 HEART JI Heart PD MAY 15 PY 2015 VL 101 IS 10 BP 752 EP 757 DI 10.1136/heartjnl-2014-306440 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CH8GR UT WOS:000354274900006 PM 25911666 ER PT J AU Wong, CC Ramanathan, DS Gulati, T Won, SJ Ganguly, K AF Wong, Chelsea C. Ramanathan, Dhakshin S. Gulati, Tanuj Won, Seok Joon Ganguly, Karunesh TI An automated behavioral box to assess forelimb function in rats SO JOURNAL OF NEUROSCIENCE METHODS LA English DT Article DE Motor learning; Reach; Electrophysiology ID FOREBRAIN CHOLINERGIC SYSTEM; SPINAL-CORD-INJURY; MOTOR CORTEX; CORTICAL PLASTICITY; TASK; STROKE; IMPAIRMENT; RECOVERY AB Background: Rodent forelimb reaching behaviors are commonly assessed using a single-pellet reach-to-grasp task. While the task is widely recognized as a very sensitive measure of distal limb function, it is also known to be very labor-intensive, both for initial training and the daily assessment of function. New method: Using components developed by open-source electronics platforms, we have designed and tested a low-cost automated behavioral box to measure forelimb function in rats. Our apparatus, made primarily of acrylic, was equipped with-multiple sensors to control the duration and difficulty of the task, detect reach outcomes, and dispense pellets. Our control software, developed in MATLAB, was also used to control a camera in order to capture and process video during reaches. Importantly, such processing could monitor task performance in near real-time. Results: We further demonstrate that the automated apparatus can be used to expedite skill acquisition, thereby increasing throughput as well as facilitating studies of early versus late motor learning. The setup is also readily compatible with chronic electrophysiological monitoring. Comparison with existing methods: Compared to a previous version of this task, our setup provides a more efficient method to train and test rodents for studies of motor learning and recovery of function after stroke. The unbiased delivery of behavioral cues and outcomes also facilitates electrophysiological studies. Conclusions: In summary, our automated behavioral box will allow high-throughput and efficient monitoring of rat forelimb function in both healthy and injured animals. Published by Elsevier B.V. C1 [Wong, Chelsea C.; Ramanathan, Dhakshin S.; Gulati, Tanuj; Won, Seok Joon; Ganguly, Karunesh] San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA 94158 USA. [Wong, Chelsea C.; Gulati, Tanuj; Won, Seok Joon; Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Ramanathan, Dhakshin S.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94158 USA. [Ramanathan, Dhakshin S.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Ganguly, K (reprint author), San Francisco VA Med Ctr, Neurol & Rehabil Serv, 1700 Owens St,Rm 479, San Francisco, CA 94158 USA. EM karunesh.ganguly@ucsf.edu FU U.S. Department of Veterans Affairs [CDA-2B6674W]; Burroughs Wellcome Fund [1009855]; American Heart Association/Stroke Association [0875016N]; UCSF Department of Neurology FX This work was supported by the U.S. Department of Veterans Affairs (CDA-2B6674W), the Burroughs Wellcome Fund (1009855), the American Heart Association/Stroke Association (0875016N) and departmental funds from the UCSF Department of Neurology. We would also like to thank Roy Tangsombatvisit for assistance with the design and the manufacturing of the reach boxes. NR 33 TC 6 Z9 6 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0270 EI 1872-678X J9 J NEUROSCI METH JI J. Neurosci. Methods PD MAY 15 PY 2015 VL 246 BP 30 EP 37 DI 10.1016/j.jneumeth.2015.03.008 PG 8 WC Biochemical Research Methods; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA CI1KC UT WOS:000354502100004 PM 25769277 ER PT J AU Lowry, KP Gazelle, GS Gilmore, ME Johanson, C Munshi, V Choi, SE Tramontano, AC Kong, CY McMahon, PM AF Lowry, Kathryn P. Gazelle, G. Scott Gilmore, Michael E. Johanson, Colden Munshi, Vidit Choi, Sung Eun Tramontano, Angela C. Kong, Chung Yin McMahon, Pamela M. TI Personalizing Annual Lung Cancer Screening for Patients With Chronic Obstructive Pulmonary Disease: A Decision Analysis SO CANCER LA English DT Article DE lung neoplasms; chronic obstructive pulmonary disease; cancer screening; decision analysis ID NUTRITION-EXAMINATION-SURVEY; MODERATE COPD PATIENTS; SERVICES TASK-FORCE; LOW-DOSE CT; UNITED-STATES; NATIONAL-HEALTH; RISK; MORTALITY; IMPACT; ASSOCIATION AB BACKGROUNDLung cancer screening with annual chest computed tomography (CT) is recommended for current and former smokers with a 30-pack-year smoking history. Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of developing lung cancer and may benefit from screening at lower pack-year thresholds. METHODSWe used a previously validated simulation model to compare the health benefits of lung cancer screening in current and former smokers ages 55-80 with 30 pack-years with hypothetical programs using lower pack-year thresholds for individuals with COPD (20, 10, and 1 pack-years). Calibration targets for COPD prevalence and associated lung cancer risk were derived using the Framingham Offspring Study limited data set. We performed sensitivity analyses to evaluate the stability of results across different rates of adherence to screening, increased competing mortality risk from COPD, and increased surgical ineligibility in individuals with COPD. The primary outcome was projected life expectancy. RESULTSPrograms using lower pack-year thresholds for individuals with COPD yielded the highest life expectancy gains for a given number of screens. Highest life expectancy was achieved when lowering the pack-year threshold to 1 pack-year for individuals with COPD, which dominated all other screening strategies. These results were stable across different adherence rates to screening and increases in competing mortality risk for COPD and surgical ineligibility. CONCLUSIONSCurrent and former smokers with COPD may disproportionately benefit from lung cancer screening. A lower pack-year threshold for screening eligibility may benefit this high-risk patient population. Cancer 2015;121:1556-1562. (c) 2015 American Cancer Society. A microsimulation model was used to evaluate the health benefits of hypothetical lung cancer screening programs targeting individuals with chronic obstructive pulmonary disease compared with programs with eligibility based on smoking history alone. Programs incorporating lower pack-year thresholds for individuals with COPD achieved the highest life expectancy per number of screens. C1 [Lowry, Kathryn P.; Gazelle, G. Scott; Kong, Chung Yin; McMahon, Pamela M.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Lowry, Kathryn P.; Gazelle, G. Scott; Gilmore, Michael E.; Johanson, Colden; Munshi, Vidit; Choi, Sung Eun; Tramontano, Angela C.; Kong, Chung Yin; McMahon, Pamela M.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Gazelle, G. Scott] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. RP Lowry, KP (reprint author), Massachusetts Gen Hosp, 55 Fruit St,FND 216, Boston, MA 02114 USA. EM klowry@partners.org FU American Cancer Society [RSG 2008A060554]; National Cancer Institute [R01 CA97337, R00 CA126147, U01CA152956]; National Institute of Health [R01 DA036497]; Radiological Society of North America; Harvard Medical School FX This research was supported by grants from the American Cancer Society (RSG 2008A060554, to G. Scott Gazelle), the National Cancer Institute (R01 CA97337, to G. Scott Gazelle, R00 CA126147 to G. Scott Gazelle, and U01CA152956 to Pamela M. McMahon and Chung Yin Kong), the National Institute of Health (R01 DA036497 to Chung Yin Kong and Colden Johanson), the Radiological Society of North America (to Kathryn P. Lowry), and Harvard Medical School (to Kathryn P. Lowry). NR 41 TC 5 Z9 5 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAY 15 PY 2015 VL 121 IS 10 BP 1556 EP 1562 DI 10.1002/cncr.29225 PG 7 WC Oncology SC Oncology GA CH7LB UT WOS:000354216800008 PM 25652107 ER PT J AU Percac-Lima, S Cronin, PR Ryan, DP Chabner, BA Daly, EA Kimball, AB AF Percac-Lima, Sanja Cronin, Patrick R. Ryan, David P. Chabner, Bruce A. Daly, Emily A. Kimball, Alexandra B. TI Patient Navigation Based on Predictive Modeling Decreases No-Show Rates in Cancer Care SO CANCER LA English DT Article DE patient navigation; cancer care; predictive modeling; no-show; disparities ID RANDOMIZED-CONTROLLED-TRIAL; NEWLY-DIAGNOSED CANCER; COLORECTAL-CANCER; IMPROVE CARE; BREAST; PROGRAM; WOMEN; ABNORMALITIES; APPOINTMENTS; POPULATION AB BACKGROUNDPatient adherence to appointments is key to improving outcomes in health care. No-show appointments contribute to suboptimal resource use. Patient navigation and telephone reminders have been shown to improve cancer care and adherence, particularly in disadvantaged populations, but may not be cost-effective if not targeted at the appropriate patients. METHODSIn 5 clinics within a large academic cancer center, patients who were considered to be likely (the top 20th percentile) to miss a scheduled appointment without contacting the clinic ahead of time (no-shows) were identified using a predictive model and then randomized to an intervention versus a usual-care group. The intervention group received telephone calls from a bilingual patient navigator 7 days before and 1 day before the appointment. RESULTSOver a 5-month period, of the 40,075 appointments scheduled, 4425 patient appointments were deemed to be at high risk of a no-show event. After the patient navigation intervention, the no-show rate in the intervention group was 10.2% (167 of 1631), compared with 17.5% in the control group (280 of 1603) (P<.001). Reaching a patient or family member was associated with a significantly lower no-show rate (5.9% and 3.0%, respectively; P<.001 and .006, respectively) compared with leaving a message (14.7%: P=.117) or no contact (no-show rate, 21.6%: P=.857). CONCLUSIONSTelephone navigation targeted at those patients predicted to be at high risk of visit nonadherence was found to effectively and substantially improve patient adherence to cancer clinic appointments. Further studies are needed to determine the long-term impact on patient outcomes, but short-term gains in the optimization of resources can be recognized immediately. Cancer 2015;121:1662-1670. (c) 2015 American Cancer Society. Targeted patient navigation over the telephone to patients determined by predictive modeling to be at high risk of being no-shows for appointments can effectively and substantially increase patient adherence to cancer clinic appointments and improve adherence to cancer care. C1 [Percac-Lima, Sanja] Harvard Univ, Sch Med, Dept Med, Div Gen Internal Med,Massachusetts Gen Hosp, Boston, MA USA. [Percac-Lima, Sanja; Ryan, David P.; Chabner, Bruce A.; Daly, Emily A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. [Percac-Lima, Sanja] Massachusetts Gen Hosp, Ctr Community Hlth Improvement, Boston, MA 02114 USA. [Cronin, Patrick R.; Kimball, Alexandra B.] Massachusetts Gen Hosp, Practice Improvement, Boston, MA 02114 USA. [Cronin, Patrick R.] Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. [Kimball, Alexandra B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA USA. RP Percac-Lima, S (reprint author), Massachusetts Gen Hosp, Chelsea HealthCare Ctr, 151 Everett Ave, Chelsea, MA 02150 USA. EM spercaclima@mgh.harvard.edu FU Lazarex Cancer Foundation FX The study was partially funded by Lazarex Cancer Foundation. NR 33 TC 2 Z9 2 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAY 15 PY 2015 VL 121 IS 10 BP 1662 EP 1670 DI 10.1002/cncr.29236 PG 9 WC Oncology SC Oncology GA CH7LB UT WOS:000354216800020 PM 25585595 ER PT J AU Vega, RM Kim, J Hollander, A Hattangadi-Gluth, J Michalski, J Tarbell, NJ Yock, TI Bussiere, M MacDonald, SM AF Vega, Raymond Mailhot Kim, Jane Hollander, Abby Hattangadi-Gluth, Jona Michalski, Jeff Tarbell, Nancy J. Yock, Torunn I. Bussiere, Marc MacDonald, Shannon M. TI Cost Effectiveness of Proton Versus Photon Radiation Therapy With Respect to the Risk of Growth Hormone Deficiency in Children SO CANCER LA English DT Article DE proton therapy; cost effectiveness; pediatric brain tumors; radiation; growth hormone deficiency ID DECISION-MAKING; BEAM THERAPY; REPLACEMENT; UTILITY AB BACKGROUNDProton therapy in pediatrics may improve the risk/benefit profile of radiotherapy at a greater upfront financial cost, but it may prove to be cost effective if chronic medical complications can be avoided. Tools to assist with decision making are needed to aid in selecting pediatric patients for protons, and cost-effectiveness models can provide an objective method for this. METHODSA Markov cohort-simulation model was developed to assess the expected costs and effectiveness for specific radiation doses to the hypothalamus with protons versus photons in pediatric patients. Costing data included cost of investment and the diagnosis and management of growth hormone deficiency. Longitudinal outcomes data were used to inform risk parameters for the model. With costs in 2012 US dollars and effectiveness measured in quality-adjusted life years, incremental cost-effectiveness ratios were used to measure outcomes. RESULTSProton therapy was cost effective for some scenarios based on the difference in hypothalamic sparing. Although some scenarios were not cost effective, others were not only cost effective for proton therapy but also demonstrated that protons were cost saving compared with photons. CONCLUSIONSThe current results provide the first evidence-based guide for identifying children with brain tumors who may benefit the most from proton therapy with respect to endocrine dysfunction. Proton therapy may be more cost effective for scenarios in which radiation dose to the hypothalamus can be spared, but protons may not be cost effective when tumors are involving or directly adjacent to the hypothalamus if there is a high dose to this structure. Cancer 2015;121:1694-1702. (c) 2015 American Cancer Society. Although proton therapy is costly, it may sometimes be cost effective compared with traditional photon therapy, especially when treating pediatric tumors. The authors present data regarding strategy favorability between proton versus photon radiotherapy for pediatric brain tumors and analyze the cost effectiveness and the risk and cost of growth hormone deficiency with specific dose comparisons between modalities. C1 [Vega, Raymond Mailhot] NYU, Sch Med, Dept Radiat Oncol, New York, NY USA. [Kim, Jane] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA. [Hollander, Abby] Washington Univ, Sch Med, St Louis Childrens Hosp, St Louis, MO USA. [Hattangadi-Gluth, Jona] Univ Calif San Diego, Radiat Med & Appl Sci, La Jolla, CA 92093 USA. [Michalski, Jeff] Washington Univ, Siteman Canc Ctr, St Louis Sch Med, St Louis, MO USA. [Tarbell, Nancy J.; Yock, Torunn I.; Bussiere, Marc; MacDonald, Shannon M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP MacDonald, SM (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St,Yawkey 112, Boston, MA 02114 USA. EM smacdonald@partners.org FU Conquer Cancer Foundation FX Dr. Mailhot Vega was supported by a medical student grant from Conquer Cancer Foundation. NR 22 TC 6 Z9 6 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAY 15 PY 2015 VL 121 IS 10 BP 1694 EP 1702 DI 10.1002/cncr.29209 PG 9 WC Oncology SC Oncology GA CH7LB UT WOS:000354216800024 ER PT J AU Shih, HA Sherman, JC Nachtigall, LB Colvin, MK Fullerton, BC Daartz, J Winrich, BK Batchelor, TT Thornton, LT Mancuso, SM Saums, MK Oh, KS Curry, WT Loeffler, JS Yeap, BY AF Shih, Helen A. Sherman, Janet C. Nachtigall, Lisa B. Colvin, Mary K. Fullerton, Barbara C. Daartz, Juliane Winrich, Barbara K. Batchelor, Tracy T. Thornton, Lauren T. Mancuso, Sarah M. Saums, Michele K. Oh, Kevin S. Curry, William T. Loeffler, Jay S. Yeap, Beow Y. TI Proton Therapy for Low-Grade Gliomas: Results From a Prospective Trial SO CANCER LA English DT Article DE low-grade glioma; proton therapy; proton radiation; late effects; neurocognitive function; pituitary function; neuroendocrine function; quality of life ID RADIATION-THERAPY; COGNITIVE FUNCTION; RANDOMIZED-TRIAL; RADIOTHERAPY; SURVIVAL AB BACKGROUNDIn this prospective study, the authors evaluated potential treatment toxicity and progression-free survival in patients with low-grade glioma who received treatment with proton radiation therapy. METHODSTwenty patients with World Health Organization grade 2 glioma who were eligible for radiation therapy were enrolled in a prospective, single-arm trial of proton therapy. The patients received proton therapy at a dose of 54 Gy (relative biological effectiveness) in 30 fractions. Comprehensive baseline and regular post-treatment evaluations of neurocognitive function, neuroendocrine function, and quality of life (QOL) were performed. RESULTSAll 20 patients (median age, 37.5 years) tolerated treatment without difficulty. The median follow-up after proton therapy was 5.1 years. At baseline, intellectual functioning was within the normal range for the group and remained stable over time. Visuospatial ability, attention/working memory, and executive functioning also were within normal limits; however, baseline neurocognitive impairments were observed in language, memory, and processing speed in 8 patients. There was no overall decline in cognitive functioning over time. New endocrine dysfunction was detected in 6 patients, and all but 1 had received direct irradiation of the hypothalamic-pituitary axis. QOL assessment revealed no changes over time. The progression-free survival rate at 3 years was 85%, but it dropped to 40% at 5 years. CONCLUSIONSPatients with low-grade glioma tolerate proton therapy well, and a subset develops neuroendocrine deficiencies. There is no evidence for overall decline in cognitive function or QOL. Cancer 2015;121:1712-1719. (c) 2015 American Cancer Society. Patients with low-grade glioma can safely and effectively receive proton radiation therapy with no added neurocognitive impairment or quality-of-life decrement based on early experience. Radiation dose to the pituitary correlates with early neuroendocrine dysfunction. C1 [Shih, Helen A.; Daartz, Juliane; Winrich, Barbara K.; Oh, Kevin S.; Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Sherman, Janet C.; Colvin, Mary K.; Mancuso, Sarah M.] Massachusetts Gen Hosp, Dept Psychiat & Neurol, Boston, MA 02114 USA. [Nachtigall, Lisa B.] Massachusetts Gen Hosp, Div Endocrinol, Dept Med, Boston, MA 02114 USA. [Fullerton, Barbara C.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Batchelor, Tracy T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Thornton, Lauren T.; Saums, Michele K.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Curry, William T.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Yeap, Beow Y.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Shih, HA (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 30 Fruit St, Boston, MA 02114 USA. EM hshih@mgh.harvard.edu FU Pappas Award in Brain Tumor Research; Massachusetts General Hospital; Federal Share of program by Massachusetts General Hospital on Proton Therapy Research and Treatment Center [C06 CA059267] FX This study was supported by a Pappas Award in Brain Tumor Research sponsored by Massachusetts General Hospital and by the Federal Share of program income earned by Massachusetts General Hospital on Proton Therapy Research and Treatment Center (grant C06 CA059267). NR 21 TC 5 Z9 5 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAY 15 PY 2015 VL 121 IS 10 BP 1712 EP 1719 DI 10.1002/cncr.29237 PG 8 WC Oncology SC Oncology GA CH7LB UT WOS:000354216800026 PM 25585890 ER PT J AU Cluzet, VC Gerber, JS Nachamkin, I Metlay, JP Zaoutis, TE Davis, MF Julian, KG Royer, D Linkin, DR Coffin, SE Margolis, DJ Hollander, JE Mistry, RD Gavin, LJ Tolomeo, P Wise, JA Wheeler, MK Bilker, WB Han, XY Hu, BF Fishman, NO Lautenbach, E AF Cluzet, Valerie C. Gerber, Jeffrey S. Nachamkin, Irving Metlay, Joshua P. Zaoutis, Theoklis E. Davis, Meghan F. Julian, Kathleen G. Royer, David Linkin, Darren R. Coffin, Susan E. Margolis, David J. Hollander, Judd E. Mistry, Rakesh D. Gavin, Laurence J. Tolomeo, Pam Wise, Jacqueleen A. Wheeler, Mary K. Bilker, Warren B. Han, Xiaoyan Hu, Baofeng Fishman, Neil O. Lautenbach, Ebbing TI Duration of Colonization and Determinants of Earlier Clearance of Colonization With Methicillin-Resistant Staphylococcus aureus SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE methicillin-resistant Staphylococcus aureus (MRSA); MRSA colonization; MRSA skin and soft-tissue infection; MRSA decolonization ID SKIN INFECTIONS; HOUSEHOLD CONTACTS; RISK-FACTORS; CARRIAGE; TRANSMISSION; MRSA; ERADICATION; PREVALENCE; CHILDREN; BACTEREMIA AB Background. The duration of colonization and factors associated with clearance of methicillin-resistant Staphylococcus aureus (MRSA) after community-onset MRSA skin and soft-tissue infection (SSTI) remain unclear. Methods. We conducted a prospective cohort study of patients with acute MRSA SSTI presenting to 5 adult and pediatric academic hospitals from 1 January 2010 through 31 December 2012. Index patients and household members performed self-sampling for MRSA colonization every 2 weeks for 6 months. Clearance of colonization was defined as negative MRSA surveillance cultures during 2 consecutive sampling periods. A Cox proportional hazards regression model was developed to identify determinants of clearance of colonization. Results. Two hundred forty-three index patients were included. The median duration of MRSA colonization after SSTI diagnosis was 21 days (95% confidence interval [CI], 19-24), and 19.8% never cleared colonization. Treatment of the SSTI with clindamycin was associated with earlier clearance (hazard ratio [HR], 1.72; 95% CI, 1.28-2.30; P < .001). Older age (HR, 0.99; 95% CI, .98-1.00; P = .01) was associated with longer duration of colonization. There was a borderline significant association between increased number of household members colonized with MRSA and later clearance of colonization in the index patient (HR, 0.85; 95% CI, .71-1.01; P = .06). Conclusions. With a systematic, regular sampling protocol, duration of MRSA colonization was noted to be shorter than previously reported, although 19.8% of patients remained colonized at 6 months. The association between clindamycin and shorter duration of colonization after MRSA SSTI suggests a possible role for the antibiotic selected for treatment of MRSA infection. C1 [Cluzet, Valerie C.; Linkin, Darren R.; Fishman, Neil O.; Lautenbach, Ebbing] Univ Penn, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Gerber, Jeffrey S.; Zaoutis, Theoklis E.; Coffin, Susan E.; Margolis, David J.; Tolomeo, Pam; Wise, Jacqueleen A.; Wheeler, Mary K.; Bilker, Warren B.; Han, Xiaoyan; Lautenbach, Ebbing] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Gerber, Jeffrey S.; Zaoutis, Theoklis E.; Coffin, Susan E.; Margolis, David J.; Bilker, Warren B.; Han, Xiaoyan; Lautenbach, Ebbing] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Gerber, Jeffrey S.; Zaoutis, Theoklis E.; Coffin, Susan E.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Nachamkin, Irving; Hu, Baofeng] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Margolis, David J.] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gerber, Jeffrey S.; Zaoutis, Theoklis E.; Coffin, Susan E.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA. [Linkin, Darren R.] Thomas Jefferson Univ Hosp, Philadelphia Vet Adm Med Ctr, Philadelphia, PA 19107 USA. [Gavin, Laurence J.] Thomas Jefferson Univ Hosp, Dept Emergency Med, Penn Presbyterian Med Ctr, Philadelphia, PA 19107 USA. [Hollander, Judd E.] Thomas Jefferson Univ Hosp, Dept Emergency Med, Philadelphia, PA 19107 USA. [Julian, Kathleen G.] Lincoln Univ, Div Infect Dis, Penn State Hershey Med Ctr, Lincoln Univ, PA USA. [Royer, David] Lincoln Univ, Dept Biol, Lincoln Univ, PA USA. [Metlay, Joshua P.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Metlay, Joshua P.] Harvard Univ, Sch Med, Boston, MA USA. [Davis, Meghan F.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA. [Mistry, Rakesh D.] Childrens Hosp Colorado, Sect Emergency Med, Aurora, CO USA. RP Cluzet, VC (reprint author), Hosp Univ Penn, Div Infect Dis, 3400 Spruce St,Third Floor,Silverstein Bldg,Ste E, Philadelphia, PA 19104 USA. EM valeriec@mail.med.upenn.edu OI Hollander, Judd/0000-0002-1318-2785 FU Pennsylvania State Department of Health; National Institutes of Health (NIH) [K24-AI080942]; Centers for Disease Control and Prevention Epicenters Program [U54-CK000163] FX This work was supported by the Pennsylvania State Department of Health (Commonwealth Universal Research Enhancement Program grant to E. L.), the National Institutes of Health (NIH) (grant K24-AI080942 to E. L.), and the Centers for Disease Control and Prevention Epicenters Program (grant U54-CK000163 to E. L.). NR 36 TC 11 Z9 11 U1 1 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 15 PY 2015 VL 60 IS 10 BP 1489 EP 1496 DI 10.1093/cid/civ075 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0ON UT WOS:000353721300007 PM 25648237 ER PT J AU Evans, CT Safdar, N AF Evans, Charlesnika T. Safdar, Nasia TI Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Clostridium difficile; epidemiology; costs ID CARE-ASSOCIATED INFECTIONS; UNITED-STATES; DIARRHEA; RISK; METAANALYSIS; ANTIBIOTICS; RATES; HOSPITALS; COLITIS; MULTICENTER AB Clostridium difficile is the most frequently identified cause of nosocomial diarrhea and has been associated with epidemics of diarrhea in hospitals and long-term care facilities. The continued increase in C. difficile infection (CDI) suggests that it has surpassed other pathogens in causing healthcare-associated infections. The Centers for Disease Control and Prevention recently identified CDI as an "urgent threat" in its recent report on antibiotic resistance threats in the United States, highlighting the need for urgent and aggressive action to prevent this infection. The impact of antibiotics as a risk factor for new-onset CDI is well established; however, recognizing classes of antibiotics with the highest risks and reducing unnecessary antibiotic use are important strategies for prevention of CDI and subsequent recurrence. In addition, the recognition of the community as an important setting for onset of CDI presents a challenge and is an area for future research. C1 [Evans, Charlesnika T.] Edward Hines Jr VA Hosp, Dept Vet Affairs VA, Ctr Innovat Complex Chron Healthcare, Hines, IL 60141 USA. [Evans, Charlesnika T.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. [Evans, Charlesnika T.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. RP Evans, CT (reprint author), Edward Hines Jr VA Hosp, 5000 S Fifth Ave,151H,Bldg 1,Rm D302, Hines, IL 60141 USA. EM charlesnika.evans@va.gov FU Presidential Early Career Award for Scientists and Engineers [USA 12-564]; VA Health Services Research and Development Service [IIR 10-148] FX This work was supported by the Presidential Early Career Award for Scientists and Engineers (grant number USA 12-564 to C. T. E.) and the VA Health Services Research and Development Service (grant number IIR 10-148 to C. T. E.). NR 43 TC 31 Z9 31 U1 1 U2 24 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 15 PY 2015 VL 60 SU 2 BP S66 EP S71 DI 10.1093/cid/civ140 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0OB UT WOS:000353719500002 PM 25922403 ER PT J AU Kim, MJ Miller, CM Shadrach, JL Wagers, AJ Serwold, T AF Kim, Mi-Jeong Miller, Christine M. Shadrach, Jennifer L. Wagers, Amy J. Serwold, Thomas TI Young, Proliferative Thymic Epithelial Cells Engraft and Function in Aging Thymuses SO JOURNAL OF IMMUNOLOGY LA English DT Article ID HEMATOPOIETIC STEM-CELLS; T-CELL; BONE-MARROW; CLONAL ANALYSIS; IMMUNE-SYSTEM; AGE; MICE; THYMOPOIESIS; REGENERATION; PROGENITOR AB The thymus reaches its maximum size early in life and then begins to shrink, producing fewer T cells with increasing age. This thymic decline is thought to contribute to age-related T cell lymphopenias and hinder T cell recovery after bone marrow transplantation. Although several cellular and molecular processes have been implicated in age-related thymic involution, their relative contributions are not known. Using heterochronic parabiosis, we observe that young circulating factors are not sufficient to drive regeneration of the aged thymus. In contrast, we find that resupplying young, engraftable thymic epithelial cells (TECs) to a middle-aged or defective thymus leads to thymic growth and increased T cell production. Intrathymic transplantation and in vitro colony-forming assays reveal that the engraftment and proliferative capacities of TECs diminish early in life, whereas the receptivity of the thymus to TEC engraftment remains relatively constant with age. These results support a model in which thymic growth and subsequent involution are driven by cell-intrinsic changes in the proliferative capacity of TECs, and further show that young TECs can engraft and directly drive the growth of involuted thymuses. C1 [Kim, Mi-Jeong; Miller, Christine M.; Shadrach, Jennifer L.; Wagers, Amy J.; Serwold, Thomas] Joslin Diabet Ctr, Boston, MA 02215 USA. [Kim, Mi-Jeong; Miller, Christine M.; Shadrach, Jennifer L.; Wagers, Amy J.; Serwold, Thomas] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Miller, Christine M.; Shadrach, Jennifer L.; Wagers, Amy J.] Howard Hughes Med Inst, Cambridge, MA 02138 USA. [Miller, Christine M.; Shadrach, Jennifer L.; Wagers, Amy J.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Paul F Glenn Labs Biol Mech Aging, Sch Med, Cambridge, MA 02138 USA. RP Serwold, T (reprint author), Joslin Diabet Ctr, One Joslin Pl, Boston, MA 02215 USA. EM thomas.serwold@joslin.harvard.edu FU Mary K. Iacocca Foundation Research Fellowship; Harvard Stem Cell Institute seed grant; Harvard Stem Cell Institute program project grant; The Peabody Foundation; Alexander and Margaret Stewart Trust; The Fleischer Foundation; The Pittsburgh Foundation; Glenn Foundation for Medical Research; National Institutes of Health [1R01 AG033053, 1DP2 OD004345, 5U01 HL100402]; National Institutes of Health Diabetes Research Center [P30DK036836] FX This work was supported by a Mary K. Iacocca Foundation Research Fellowship (to M.-J.K.), a Harvard Stem Cell Institute seed grant and a Harvard Stem Cell Institute program project grant (to T.S.), The Peabody Foundation (to T.S.), the Alexander and Margaret Stewart Trust (to T.S.), The Fleischer Foundation (to T.S.), The Pittsburgh Foundation (to T.S.), the Glenn Foundation for Medical Research (to A.J.W.), the National Institutes of Health (Grants 1R01 AG033053, 1DP2 OD004345, and 5U01 HL100402 to A.J.W.), and the National Institutes of Health Diabetes Research Center (Grant P30DK036836). NR 57 TC 5 Z9 6 U1 0 U2 7 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 15 PY 2015 VL 194 IS 10 BP 4784 EP 4795 DI 10.4049/jimmunol.1403158 PG 12 WC Immunology SC Immunology GA CH0RB UT WOS:000353728800021 PM 25870244 ER PT J AU Sise, ME Hirsch, JS Canetta, PA Herlitz, L Mohan, S AF Sise, Meghan E. Hirsch, Jamie S. Canetta, Pietro A. Herlitz, Leal Mohan, Sumit TI Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity SO AIDS LA English DT Article DE antiviral therapy; kidney; nephrotoxicity; proteinuria; reverse transcriptase inhibitors; tenofovir ID HIV-INFECTED PATIENTS; URINARY ALBUMIN; CARDIOVASCULAR RISK; DYSFUNCTION; MICROALBUMINURIA; ABNORMALITIES; THERAPY; WOMEN AB Objective: Tenofovir disoproxil fumarate (TDF) nephrotoxicity is characterized by proximal renal tubular injury and dysmorphic mitochondria resulting in proteinuria, orthoglycemic glycosuria, and other markers of proximal tubular dysfunction. The objective of this study was to determine the pattern of proteinuria in patients with biopsy-proven TDF nephrotoxicity. Design: Retrospective chart review. Methods: Patients with biopsy-proven TDF nephrotoxicity were identified and their medical charts and biopsy reports were reviewed. Comparison was made with HIV-infected patients not on TDF who underwent kidney biopsy. Results: We identified 43 biopsy-proven cases of TDF nephrotoxicity; mean age 54.7 +/- 0.4 years, 53% men, 42% whites. Thirty-seven cases reported proteinuria by dipstick of which only 60% had at least 2+ proteinuria. Twenty-seven patients had urine protein quantified by either 24-h collection or spot urine protein-to-creatinine ratio; median proteinuria was 1742 mg/day [interquartile range (IQR) 1200-2000 mg] and 1667 mg/g creatinine (IQR 851-1967 mg/g), respectively. Ten patients had concurrent urinary albumin measured, with a median 236 mg/g creatinine (IQR 137-343 mg/g). The mean urine albumin-to-urine protein ratio (uAPR) was 0.17 (IQR 0.14-0.19), confirming that TDF nephrotoxicity is primarily associated with nonalbumin proteinuria. Control cases had a uAPR of 0.65 (IQR 0.55-0.79) P< 0.001. Histopathology showed the predominance of proximal tubular injury with characteristic mitochondrial abnormalities. Conclusion: In the largest published cohort of patients with biopsy-proven TDF nephrotoxicity, we show that low uAPR is a reliable feature of this disease. Because of the predominance of nonalbumin proteinuria, dipstick urinalysis may be unreliable in TDF nephrotoxicity. Copyright (c) 2015 Wolters Kluwer Health, Inc. All rights reserved. C1 [Sise, Meghan E.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA. [Hirsch, Jamie S.; Canetta, Pietro A.; Mohan, Sumit] Columbia Univ, Med Ctr, Dept Med, Div Nephrol, New York, NY USA. [Hirsch, Jamie S.] Columbia Univ, Med Ctr, Dept Biomed Informat, New York, NY USA. [Herlitz, Leal] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA. RP Sise, ME (reprint author), 165 Cambridge St,Suite 302, Boston, MA 02114 USA. EM msise@partners.org OI Canetta, Pietro/0000-0003-1130-5486; Mohan, Sumit/0000-0002-5305-9685 NR 23 TC 9 Z9 10 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD MAY 15 PY 2015 VL 29 IS 8 BP 941 EP 946 DI 10.1097/QAD.0000000000000628 PG 6 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA CH2TR UT WOS:000353878100009 PM 25784440 ER PT J AU Robles, LY Singh, S Fisichella, PM AF Robles, Lourdes Y. Singh, Satish Fisichella, Piero Marco TI Emerging enhanced imaging technologies of the esophagus: spectroscopy, confocal laser endomicroscopy, and optical coherence tomography SO JOURNAL OF SURGICAL RESEARCH LA English DT Review DE Spectroscopy; Inelastic (Raman) scattering spectroscopy; Optical coherence tomography; Barrett esophagus; Confocal laser endomicroscopy; Confocal microscopy ID HIGH-GRADE DYSPLASIA; IN-VIVO DIAGNOSIS; INDUCED AUTOFLUORESCENCE SPECTROSCOPY; ELASTIC-SCATTERING SPECTROSCOPY; BARRETTS-ESOPHAGUS; FLUORESCENCE SPECTROSCOPY; RADIOFREQUENCY ABLATION; RAMAN-SPECTROSCOPY; CONTROLLED-TRIAL; GASTROINTESTINAL TISSUES AB Background: Despite advances in diagnoses and therapy, esophageal adenocarcinoma remains a highly lethal neoplasm. Hence, a great interest has been placed in detecting early lesions and in the detection of Barrett esophagus (BE). Advanced imaging technologies of the esophagus have then been developed with the aim of improving biopsy sensitivity and detection of preplastic and neoplastic cells. The purpose of this article was to review emerging imaging technologies for esophageal pathology, spectroscopy, confocal laser endomicroscopy (CLE), and optical coherence tomography (OCT). Methods: We conducted a PubMed search using the search string "esophagus or esophageal or oesophageal or oesophagus" and "Barrett or esophageal neoplasm" and "spectroscopy or optical spectroscopy" and "confocal laser endomicroscopy" and "confocal microscopy" and "optical coherence tomography." The first and senior author separately reviewed all articles. Our search identified: 19 in vivo studies with spectroscopy that accounted for 1021 patients and 4 ex vivo studies; 14 clinical CLE in vivo studies that accounted for 941 patients and 1 ex vivo study with 13 patients; and 17 clinical OCT in vivo studies that accounted for 773 patients and 2 ex vivo studies. Results: Human studies using spectroscopy had a very high sensitivity and specificity for the detection of BE. CLE showed a high interobserver agreement in diagnosing esophageal pathology and an accuracy of predicting neoplasia. We also found several clinical studies that reported excellent diagnostic sensitivity and specificity for the detection of BE using OCT. Conclusions: Advanced imaging technology for the detection of esophageal lesions is a promising field that aims to improve the detection of early esophageal lesions. Although advancing imaging techniques improve diagnostic sensitivities and specificities, their integration into diagnostic protocols has yet to be perfected. (C) 2015 Elsevier Inc. All rights reserved. C1 [Robles, Lourdes Y.] Univ Calif Irvine, Dept Surg, Irvine, CA 92717 USA. [Singh, Satish] Boston Univ, Boston VA Healthcare Syst, Div Gastroenterol, Boston, MA 02215 USA. [Fisichella, Piero Marco] Harvard Univ, Sch Med, Dept Surg, Boston VA Healthcare Syst, Boston, MA 02115 USA. RP Fisichella, PM (reprint author), Harvard Univ, Sch Med, Boston VA Healthcare Syst, Dept Surg, 1400 VFW Pkwy, West Roxbury, MA 02132 USA. EM piero.fisichella@va.gov OI Fisichella, P. Marco/0000-0002-7697-7884 FU Mauna Kea Technologies FX L.Y.R. and P.M.F. have no conflicts of interest to declare. S.S. has received educational support from Mauna Kea Technologies. NR 85 TC 5 Z9 5 U1 6 U2 17 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD MAY 15 PY 2015 VL 195 IS 2 BP 502 EP 514 DI 10.1016/j.jss.2015.02.045 PG 13 WC Surgery SC Surgery GA CG9QH UT WOS:000353651600016 PM 25819772 ER PT J AU Repunte-Canonigo, V Herman, MA Kawamura, T Kranzler, HR Sherva, R Gelernter, J Farrer, LA Roberto, M Sanna, PP AF Repunte-Canonigo, Vez Herman, Melissa A. Kawamura, Tomoya Kranzler, Henry R. Sherva, Richard Gelernter, Joel Farrer, Lindsay A. Roberto, Marisa Sanna, Pietro Paolo TI Nf1 Regulates Alcohol Dependence-Associated Excessive Drinking and Gamma-Aminobutyric Acid Release in the Central Amygdala in Mice and Is Associated with Alcohol Dependence in Humans SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Alcohol dependence; Amygdala; Electrophysiology; GABA; Genetic association; Presynaptic mechanisms ID CHRONIC ETHANOL EXPOSURE; LEARNING-DEFICITS; C57BL/6J MICE; GABA RELEASE; INTERMITTENT; WITHDRAWAL; MODEL; INTOXICATION; INHIBITION; MEMORY AB BACKGROUND: The neurofibromatosis type 1 (Nf1) gene encodes a GTPase activating protein that negatively regulates small GTPases of the Ras family. METHODS: We assessed alcohol-related behaviors including alcohol sensitivity, dependent and nondependent drinking, and basal and alcohol-induced gamma-aminobutyric acid (GABA) release in the central nucleus of the amygdala (CeA) in Nf1 heterozygous null mice (Nf1(+/-)). We also investigated the associations of NF1 polymorphisms with alcohol dependence risk and severity in humans. RESULTS: Nf1(+/-) mice do not differ from wild-type mice in nondependent drinking, such as 24-hour, 2-bottle choice drinking in the dark binge drinking or limited access 2-bottle choice. However, Nf1(+/-) mice failed to escalate alcohol drinking following chronic intermittent ethanol vapor exposure (CIE) to induce dependence. Alcohol acutely increases GABA release in the CeA and alcohol dependence is characterized by increased baseline GABA release in CeA. Interestingly, GABA release in Nf1(+/-) mice is greater at baseline than wild-type mice, is not elevated by induction of dependence by CIE, and failed to show alcohol-induced facilitation both before and after CIE. Additionally, we observed that multiple variants in the human NF1 gene are associated with a quantitative measure of alcohol dependence in both African Americans and European Americans. CONCLUSIONS: In this translational investigation, we found that Nf1 activity regulates excessive drinking and basal and ethanol-stimulated GABA release in the mouse central amygdala. We also found that genetic variation in NF1 may confer an inherent susceptibility to the transition from nondependent to dependent drinking in humans. C1 [Repunte-Canonigo, Vez; Kawamura, Tomoya; Sanna, Pietro Paolo] Scripps Res Inst, Mol & Cellular Neurosci Dept, La Jolla, CA 92037 USA. [Herman, Melissa A.; Roberto, Marisa] Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA. [Kranzler, Henry R.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Vet Integrated Serv Network Mental Illness Res Ed, Philadelphia, PA USA. [Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Ctr Clin, Philadelphia, PA USA. [Sherva, Richard; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02215 USA. [Gelernter, Joel] Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Ctr, Dept Psychiat, West Haven, CT 06516 USA. [Gelernter, Joel] Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Ctr, Dept Genet, West Haven, CT 06516 USA. [Gelernter, Joel] Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Ctr, Dept Neurobiol, West Haven, CT 06516 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Ophthalmol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA. RP Sanna, PP (reprint author), Scripps Res Inst, Mol & Cellular Med, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA. EM psanna@scripps.edu OI Farrer, Lindsay/0000-0001-5533-4225 FU National Institutes of Health [F32 AA020430, AA015566, AA017371, AA020960, AA013191, AA013498, AA021491, AA021667, AA11330, AA17535, DA12690, DA12849, DA18432, DA028909, N01-HG-65403, HHSN268200782096C]; Pearson Center for Alcoholism and Addiction Research; National Institutes of Health Genes, Environment and Health Initiative [U01 HG004422, U01HG004438]; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; Lilly; Lundbeck; AbbVie; Ethypharm; Pfizer FX This work was supported by National Institutes of Health Grants F32 AA020430, AA015566, AA017371, AA020960, AA013191, AA013498, AA021491, AA021667, AA11330, AA17535, DA12690, DA12849, DA18432, and DA028909 and the Pearson Center for Alcoholism and Addiction Research. Genotyping services for a part of our genome-wide association study were provided by the Center for Inherited Disease Research and Yale University (Center for Genome Analysis). Center for Inherited Disease Research is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University (contract number N01-HG-65403). The publicly available datasets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs0 00092.v1.p1 through dbGaP accession number phs000092.v1.p. Funding support for the Study of Addiction: Genetics and Environment was provided through the National Institutes of Health Genes, Environment and Health Initiative (U01 HG004422). Study of Addiction: Genetics and Environment is one of the genome-wide association studies funded as part of the Gene Environment Association Studies under Genes, Environment and Health Initiative. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the Gene Environment Association Studies Coordinating Center (U01 HG004446).; Assistance with data cleaning was provided by the National Center for Biotechnology Information. Support for collection of datasets and samples was provided by the Collaborative Study on the Genetics of Alcoholism (U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (P01 CA089392), and the Family Study of Cocaine Dependence (R01 DA013423). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research, was provided by the National Institutes of Health Genes, Environment and Health Initiative (U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and the National Institutes of Health contract "High throughput genotyping for studying the genetic contributions to human disease" (HHSN268200782096C).; HRK has been a consultant or advisory board member with Alkermes, Lilly, Lundbeck, Otsuka, Pfizer, and Roche. He has also received honoraria from the Alcohol Clinical Trials Initiative of the American Society of Clinical Psychopharmacology, which is supported by Lilly, Lundbeck, AbbVie, Ethypharm, and Pfizer. All other authors report no biomedical financial interests or potential conflicts of interest. NR 33 TC 4 Z9 4 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 15 PY 2015 VL 77 IS 10 BP 870 EP 879 DI 10.1016/j.biopsych.2014.07.031 PG 10 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CG8LP UT WOS:000353559600006 PM 25483400 ER PT J AU Freeman, S Yu, RJ Egorova, N Chen, XY Kirsch, I Claggett, B Kaptchuk, TJ Gollub, RL Kong, J AF Freeman, Sonya Yu, Rongjun Egorova, Natalia Chen, Xiaoyan Kirsch, Irving Claggett, Brian Kaptchuk, Ted J. Gollub, Randy L. Kong, Jian TI Distinct neural representations of placebo and nocebo effects SO NEUROIMAGE LA English DT Article DE Placebo; Nocebo; Expectancy; Positive expectancy; Negative expectancy; fMRI; Pain ID INDIVIDUAL-DIFFERENCES; INDUCED EXPECTATIONS; CLINICAL-TRIALS; DORSAL STRIATUM; BRAIN ACTIVITY; PAIN; ANALGESIA; FMRI; MECHANISMS; ANXIETY AB Expectations shape the way we experience the world. In this study, we used fMRI to investigate how positive and negative expectation can change pain experiences in the same cohort of subjects. We first manipulated subjects' treatment expectation of the effectiveness of three inert creams, with one cream labeled "Lidocaine" (positive expectancy), one labeled "Capsaicin" (negative expectancy) and one labeled "Neutral" by surreptitiously decreasing, increasing, or not changing respectively, the intensity of the noxious stimuli administered following cream application. We then used fMRI to investigate the signal changes associated with administration of identical pain stimuli before and after the treatment and control creams. Twenty-four healthy adults completed the study. Results showed that expectancy significantly modulated subjective pain ratings. After controlling for changes in the neutral condition, the subjective pain rating changes evoked by positive and negative expectancies were significantly associated. fMRI results showed that the expectation of an increase in pain induced significant fMRI signal changes in the insula, orbitofrontal cortex, and periaqueductal gray, whereas the expectation of pain relief evoked significant fMRI signal changes in the striatum. No brain regions were identified as common to both "Capsaicin" and "Lidocaine" conditioning. There was also no significant association between the brain response to identical noxious stimuli in the pain matrix evoked by positive and negative expectancies. Our findings suggest that positive and negative expectancies engage different brain networks to modulate our pain experiences, but, overall, these distinct patterns of neural activation result in a correlated placebo and nocebo behavioral response. (C) 2015 Elsevier Inc. All rights reserved. C1 [Freeman, Sonya; Yu, Rongjun; Egorova, Natalia; Chen, Xiaoyan; Gollub, Randy L.; Kong, Jian] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA. [Kirsch, Irving; Kaptchuk, Ted J.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Program Placebo Studies, Charlestown, MA 02129 USA. [Claggett, Brian] Harvard Univ, Sch Med, Div Cardiovasc Med, Charlestown, MA 02129 USA. [Yu, Rongjun] Natl Univ Singapore, Dept Psychol, Singapore 117548, Singapore. RP Kong, J (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, 120,2nd Ave Suite 101, Charlestown, MA 02129 USA. EM kongj@nmr.mgh.harvard.edu RI Egorova, Natalia/N-9118-2015 OI Egorova, Natalia/0000-0002-9244-2900 FU NCCAM [R01AT006364, R01AT005280]; [P01 AT006663] FX This work was supported by R01AT006364 (NCCAM) to Jian Kong, R01AT005280 (NCCAM) to Randy Gollub, and P01 AT006663 to Bruce Rosen. NR 75 TC 7 Z9 7 U1 1 U2 13 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD MAY 15 PY 2015 VL 112 BP 197 EP 207 DI 10.1016/j.neuroimage.2015.03.015 PG 11 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CG3TV UT WOS:000353203400020 PM 25776211 ER PT J AU Liu, HB Cadaneanu, RM Lai, K Zhang, BH Huo, LH An, DS Li, XM Lewis, MS Garraway, IP AF Liu, Haibo Cadaneanu, Radu M. Lai, Kevin Zhang, Baohui Huo, Lihong An, Dong Sun Li, Xinmin Lewis, Michael S. Garraway, Isla P. TI Differential Gene Expression Profiling of Functionally and Developmentally Distinct Human Prostate Epithelial Populations SO PROSTATE LA English DT Article DE human prostate epithelial microarray; fetal prostate; prostate stem cell; basal cell; prostate tissue regeneration; prostate tubule initiation ID STEM-CELLS; LUMINAL CELLS; BASAL-CELLS; MURINE; CANCER; IDENTIFICATION; SUBPOPULATION; DISEASE; MARKER; TISSUE AB BACKGROUNDHuman fetal prostate buds appear in the 10th gestational week as solid cords, which branch and form lumens in response to androgen 1. Previous in vivo analysis of prostate epithelia isolated from benign prostatectomy specimens indicated that Epcam(+)CD44(-)CD49f(Hi) basal cells possess efficient tubule initiation capability relative to other subpopulations 2. Stromal interactions and branching morphogenesis displayed by adult tubule-initiating cells (TIC) are reminiscent of fetal prostate development. In the current study, we evaluated in vivo tubule initiation by human fetal prostate cells and determined expression profiles of fetal and adult epithelial subpopulations in an effort to identify pathways used by TIC. METHODSImmunostaining and FACS analysis based on Epcam, CD44, and CD49f expression demonstrated the majority (99.9%) of fetal prostate epithelial cells (FC) were Epcam(+)CD44(-) with variable levels of CD49f expression. Fetal populations isolated via cell sorting were implanted into immunocompromised mice. Total RNA isolation from Epcam(+)CD44(-)CD49f(Hi) FC, adult Epcam(+)CD44(-)CD49f(Hi) TIC, Epcam(+)CD44(+)CD49f(Hi) basal cells (BC), and Epcam(+)CD44(-)CD49f(Lo) luminal cells (LC) was performed, followed by microarray analysis of 19 samples using the Affymetrix Gene Chip Human U133 Plus 2.0 Array. Data was analyzed using Partek Genomics Suite Version 6.4. Genes selected showed >2-fold difference in expression and P<5.00E-2. Results were validated with RT-PCR. RESULTSGrafts retrieved from Epcam(+)CD44(-) fetal cell implants displayed tubule formation with differentiation into basal and luminal compartments, while only stromal outgrowths were recovered from Epcam- fetal cell implants. Hierarchical clustering revealed four distinct groups determined by antigenic profile (TIC, BC, LC) and developmental stage (FC). TIC and BC displayed basal gene expression profiles, while LC expressed secretory genes. FC had a unique profile with the most similarities to adult TIC. Functional, network, and canonical pathway identification using Ingenuity Pathway Analysis Version 7.6 compiled genes with the highest differential expression (TIC relative to BC or LC). Many of these genes were found to be significantly associated with prostate tumorigenesis. CONCLUSIONSOur results demonstrate clustering gene expression profiles of FC and adult TIC. Pathways associated with TIC are known to be deregulated in cancer, suggesting a cell-of-origin role for TIC versus re-emergence of pathways common to these cells in tumorigenesis. Prostate 75: 764-776, 2015. (c) The Authors. The Prostate, published by Wiley Periodicals, Inc. C1 [Liu, Haibo; Cadaneanu, Radu M.; Lai, Kevin; Zhang, Baohui; Huo, Lihong; Garraway, Isla P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Liu, Haibo; Cadaneanu, Radu M.; Lai, Kevin; Zhang, Baohui; Huo, Lihong; An, Dong Sun; Li, Xinmin; Garraway, Isla P.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [An, Dong Sun] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [An, Dong Sun; Garraway, Isla P.] Univ Calif Los Angeles, Broad Stem Cell Ctr, Los Angeles, CA USA. [Li, Xinmin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Lewis, Michael S.; Garraway, Isla P.] West Los Angeles VA Hosp, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RP Garraway, IP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. EM igarraway@mednet.ucla.edu FU National Institutes of Health [CA-16042, AI-28697 U54 CA 143931]; Department of Defense [PC073073]; Prostate Cancer Foundation Challenge and Young Investigator Awards; Jean Perkins Foundation; Margaret E. Early Medical Research Trust FX Grant sponsor: National Institutes of Health awards; Grant numbers: CA-16042; AI-28697 U54 CA 143931; Grant sponsor: Department of Defense; Grant number: PC073073; Grant sponsor: Prostate Cancer Foundation Challenge and Young Investigator Awards; Grant sponsor: Jean Perkins Foundation; Grant sponsor: Margaret E. Early Medical Research Trust. NR 25 TC 2 Z9 2 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-4137 EI 1097-0045 J9 PROSTATE JI Prostate PD MAY 15 PY 2015 VL 75 IS 7 BP 764 EP 776 DI 10.1002/pros.22959 PG 13 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA CF7DL UT WOS:000352716300009 PM 25663004 ER PT J AU Aiken, CB Weisler, RH Sachs, GS AF Aiken, Chris B. Weisler, Richard H. Sachs, Gary S. TI The Bipolarity index: a clinician-rated measure of diagnostic confidence SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Bipolar disorder; Mood disorders; Psychiatric diagnosis; Psychometrics ID MOOD DISORDER QUESTIONNAIRE; ADJUNCTIVE ORAL ZIPRASIDONE; II-DISORDER; PRIVATE-PRACTICE; DOUBLE-BLIND; DEPRESSION; SPECTRUM; PREVALENCE; VALIDITY; MANIA AB Background: The Bipolarity Index is a clinician-rated scale that rates cardinal features of the disorder across five domains: signs and symptoms, age of onset, course of illness, response to treatment, and family history. We tested the Index in routine clinical practice to identify the optimal cut-off for distinguishing bipolar from non-bipolar disorders. Method: Sequential patients in a private practice were rated with the Bipolarity Index (n=1903) at intake. Diagnoses were made with the MINI-6.0.0 International Neuropsychiatric Interview according to DSM-IV-TR criteria, except that cases of antidepressant-induced mania and hypomania were included in the bipolar group. A subset completed the self-rated Mood Disorder Questionnaire (MDQ) (n=1620) or Bipolar Spectrum Diagnostic Scale (BSDS) (n=1179). The primary analysis compared Bipolarity Index scores for bipolar vs. non-bipolar patients using receiver operator curves (ROC) to determine the optimal cut-off score. Secondary outcomes repeated this analysis with the MDQ MDQ-7 (using only the symptomatic items of the MDQ) and BSDS. Results: At a cut-off of >= 50, the Bipolarity Index had a high sensitivity (0.91) and specificity (0.90). Optimal cut-offs for self-rated scales were: MDQ >= 7 (sensitivity 0.74, specificity 0.71); MDQ-7: (sensitivity 0.77, specificity 0.77); BSDS: >= 12 (sensitivity 0.71, specificity 0.77). Limitations: The study utilized one rater at a single practice site; the rater was not blinded to the results of the MINI. Conclusion: The Bipolarity Index can enhance the clinical assessment of mood disorders and, at a score >= 50 has good sensitivity and specificity for identifying bipolar disorders. (C) 2015 Elsevier By. All rights reserved. C1 [Aiken, Chris B.] Mood Treatment Ctr, Winston Salem, NC 27106 USA. [Aiken, Chris B.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. [Weisler, Richard H.] Univ N Carolina, Chapel Hill, NC USA. [Weisler, Richard H.] Duke Univ, Med Ctr, Durham, NC USA. [Sachs, Gary S.] Massachusetts Gen Hosp, Bipolar Clin, Boston, MA 02114 USA. [Sachs, Gary S.] Massachusetts Gen Hosp, Res Program, Boston, MA 02114 USA. [Sachs, Gary S.] Bracket LLC, Wayne, PA USA. RP Aiken, CB (reprint author), Mood Treatment Ctr, 1615 Polo Rd, Winston Salem, NC 27106 USA. EM christopher.aiken.med.99@aya.yale.edu FU Abbott; Alcobra; Agency for Toxic Substances and Disease Registry; Astra Zeneca; Biovail; Bristol-Myers Squibb; Burroughs Wellcome; Cenerx; Centers of Disease Control and Prevention; Cephalon; Ciba Geigy; CoMentis; Dainippon Sumitomo Pharma America; Eisai; Elan; Eli Lilly; Forest; GlaxoSmithKline; Janssen; Johnson Johnson; Lundbeck; McNeil Pharmaceuticals; Medicinova; Merck; National Institute of Mental Health; Neurochem; New River Pharmaceuticals; Novartis; Organon; Pfizer; Pharmacia; Repligen; Saegis; Sandoz; Sanofi; Sanofi-Synthelabo; Schwabe/Ingenix; Sepracor; Shire; Solvay; Sunovion; Synaptic; Takeda; TAP; Theravance; Transcept Pharma; UCB Pharma; Vela; Wyeth FX 2. Richard Weisler: Richard Weisler, MD, in his career, has been a consultant to, on the Speaker's Bureaus of, and/or received research support from the following: Abbott: Speaker's Bureau, consultant, received research support; Alcobra: consultant, received research support: Agency for Toxic Substances and Disease Registry: consultant; Astra Zeneca: Speaker's Bureau, consultant, received research support; Biovail: Speaker's Bureau, consultant, received research support; Bristol-Myers Squibb: Speaker's Bureau, consultant, received research support, Stockholder has held or holds stock; Burroughs Wellcome: Speaker's Bureau, received research support; Cenerx: received research support; Centers of Disease Control and Prevention: consultant; Cephalon: Speaker's Bureau, consultant, received research support; Ciba Geigy: Speaker's Bureau, received research support; CoMentis: received research support; Corcept: consultant; Cortex: Stockholder has held or holds stock; Dainippon Sumitomo Pharma America: received research support; Eisai: received research support; Elan: received research support; Eli Lilly: Speaker's Bureau, consultant, received research support; Forest: Speaker's Bureau, consultant, received research support; GlaxoSmithKline: Speaker's Bureau, consultant, received research support; Janssen: Speaker's Bureau, received research support; Johnson & Johnson: Speaker's Bureau, consultant, received research support; Lundbeck: received research support; McNeil Pharmaceuticals: received research support; Medicinova: received research support; Medscape: Advisory Board, consultant; Merck: received research support, Speakers Bureau, stockholder has held or holds stock; National Institute of Mental Health: consultant, received research support; Neurochem: received research support; New River Pharmaceuticals: received research support; Novartis: Speaker's Bureau, received research support; Organon: Speaker's Bureau, consultant, received research support; Otsuka America Pharma: consultant; Pfizer: Speaker's Bureau, consultant, received research support, stockholder has held or holds stock; Pharmacia: consultant, received research support; Repligen: received research support; Saegis: received research support; Sandoz: received research support; Sanofi: Speaker's Bureau, consultant, received research support; Sanofi-Synthelabo: Speaker's Bureau, consultant, received research support; Schwabe/Ingenix: received research support; Sepracor: received research support; Shire: Speaker's Bureau, consultant, received research support; Solvay: Speaker's Bureau, consultant; Sunovion: Speaker's Bureau, consultant, received research support; Synaptic: received research support; Takeda: received research support; TAP: received research support; Theravance: received research support; Transcept Pharma: consultant, received research support; TransTech: consultant; UCB Pharma: received research support; Validus: Speaker's Bureau, consultant; Vela: received research support; Wyeth: Speaker's Bureau, consultant, received research support. NR 42 TC 1 Z9 2 U1 2 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD MAY 15 PY 2015 VL 177 BP 59 EP 64 DI 10.1016/j.jad.2015.02.004 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CF0NM UT WOS:000352240900010 PM 25745836 ER PT J AU Gupta, R Vavvas, D Asaad, WF AF Gupta, Rajiv Vavvas, Demetrios Asaad, Wael F. TI Case 15-2015: A 27-Year-Old Man with a Nail in the Eye SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID DUAL-ENERGY CT; PENETRATING CRANIOCEREBRAL INJURIES; INTERNAL CAROTID-ARTERY; PRINCIPLES; MANAGEMENT; ANEURYSMS; SYSTEM C1 [Gupta, Rajiv] Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA 02114 USA. [Asaad, Wael F.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Vavvas, Demetrios] Massachusetts Eye & Ear Inst, Dept Ophthalmol, Boston, MA USA. [Gupta, Rajiv] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Vavvas, Demetrios] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Asaad, Wael F.] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA. RP Gupta, R (reprint author), Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA 02114 USA. OI Vavvas, Demetrios/0000-0002-8622-6478 NR 27 TC 0 Z9 0 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 14 PY 2015 VL 372 IS 20 BP 1945 EP 1955 DI 10.1056/NEJMcpc1310007 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CI1HB UT WOS:000354493300012 PM 25970053 ER PT J AU Bianchi, G Munshi, NC AF Bianchi, Giada Munshi, Nikhil C. TI Pathogenesis beyond the cancer clone(s) in multiple myeloma SO BLOOD LA English DT Review ID UNDETERMINED SIGNIFICANCE MGUS; BONE-MARROW MICROENVIRONMENT; MESENCHYMAL STEM-CELLS; REGULATORY T-CELLS; MONOCLONAL GAMMOPATHY; HEMATOPOIETIC STEM; DRUG-RESISTANCE; GENE-EXPRESSION; PLASMA-CELLS; OSTEOBLAST DIFFERENTIATION AB Over the past 4 decades, basic research has provided crucial information regarding the cellular and molecular biology of cancer. In particular, the relevance of cancer microenvironment (including both cellular and noncellular elements) and the concept of clonal evolution and heterogeneity have emerged as important in cancer pathogenesis, immunologic escape, and resistance to therapy. Multiple myeloma (MM), a cancer of terminally differentiated plasma cells, is emblematic of the impact of cancer microenvironment and the role of clonal evolution. Although genetic and epigenetic aberrations occur in MM and evolve over time under the pressure of exogenous stimuli, they are also largely present in premalignant plasma cell dyscrasia such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), suggesting that genetic mutations alone are necessary, but not sufficient, for myeloma transformation. The role of bone marrow microenvironment in mediating survival, proliferation, and resistance to therapy in myeloma is well established; and although an appealing speculation, its role in fostering the evolution of MGUS or SMM into MM is yet to be proven. In this review, we discuss MM pathogenesis with a particular emphasis on the role of bone marrow microenvironment. C1 [Bianchi, Giada; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Munshi, Nikhil C.] Vet Affairs Boston Healthcare Syst, West Roxbury, MA USA. RP Munshi, NC (reprint author), 450 Brookline Ave, Boston, MA 02215 USA. EM nikhil_munshi@dfci.harvard.edu FU National Institutes of Health National Cancer Institute [PO1-155258, RO1-124929, P50-100707, PO1-78378]; US Department of Veterans Affairs Merit Review Award [I01 BX001584-01] FX This work was partly supported by National Institutes of Health National Cancer Institute grants PO1-155258, RO1-124929, P50-100707, and PO1-78378 and US Department of Veterans Affairs Merit Review Award I01 BX001584-01 (N.C.M.). NR 135 TC 30 Z9 30 U1 5 U2 17 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD MAY 14 PY 2015 VL 125 IS 20 BP 3049 EP 3058 DI 10.1182/blood-2014-11-568881 PG 10 WC Hematology SC Hematology GA CJ7PJ UT WOS:000355689000008 PM 25838343 ER PT J AU Ciuculescu, MF Park, SY Canty, K Mathieu, R Silberstein, LE Williams, DA AF Ciuculescu, Marioara F. Park, Shin-Young Canty, Kimberly Mathieu, Ronald Silberstein, Leslie E. Williams, David A. TI Perivascular deletion of murine Rac reverses the ratio of marrow arterioles and sinusoid vessels and alters hematopoiesis in vivo SO BLOOD LA English DT Article ID STEM-CELL QUIESCENCE; BONE-MARROW; STROMAL CELLS; OSTEOBLAST DIFFERENTIATION; STEM/PROGENITOR CELLS; PROGENITOR CELLS; RHO GTPASES; NICHE; LOCALIZATION; ACTIVATION AB Hematopoietic stem cells (HSCs) are localized within specialized microenvironments throughout the BM. Nestin-expressing (Nestin(+)) mesenchymal stromal cells (MSCs) are important in the perivascular space. Rac is critical for MSC cell shape in vitro, whereas its function in MSCs in vivo remains poorly characterized. We hypothesized that deletion of Rac in the Nestin(+) cells would perturb the perivascular space, altering HSC localization and hematopoiesis. Nestin-Cre-directed excision of Rac1 in Rac3(-/-) mice reduces Nestin(+) cells in the marrow. We observed a 2.7-fold decrease in homing of labeled wild-type hematopoietic cells into Rac1(Delta/Delta)Rac3(-/-) mice compared with control mice. Rac1(Delta/Delta)Rac3(-/-) mice demonstrated a marked decrease in arterioles and an increase in the number and volume of venous sinusoids in the marrow that was associated with a reduction in the numbers of immunophenotypically and functionally-defined long-term HSCs in the marrow, a decrease in colony-forming cells and a reduction in circulating progenitors. Rac-deleted animals demonstrated a significant increase in trabecular bone. These data demonstrate that Rac GTPases play an important role in the integrity of perivascular space. Increased trabecular bone and sinusoidal space and decreased arteriolar volume in this model were associated with decreased HSC, underscoring the complexity of regulation of hematopoiesis in the perivascular space. C1 [Ciuculescu, Marioara F.; Mathieu, Ronald; Williams, David A.] Harvard Univ, Sch Med, Div Hematol & Oncol, Harvard Stem Cell Inst, Boston, MA USA. [Park, Shin-Young; Canty, Kimberly; Silberstein, Leslie E.] Harvard Univ, Boston Childrens Hosp, Div Transfus Med, Med Sch,Harvard Stem Cell Inst, Boston, MA USA. [Park, Shin-Young; Canty, Kimberly; Silberstein, Leslie E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Harvard Stem Cell Inst, Boston, MA 02115 USA. RP Williams, DA (reprint author), 300 Longwood Ave,Karp 08125 3, Boston, MA 02115 USA. EM dawilliams@childrens.harvard.edu FU National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases [DK062757]; National Heart, Lung, and Blood Institute [R01 HL093139, P01 HL095489]; Day Kimball Healthcare [D/12/03783] FX This work is supported by National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases grant DK062757 (D.A.W.), National Heart, Lung, and Blood Institute grants R01 HL093139 (L.E.S.) and P01 HL095489 (L.E.S.), and Day Kimball Healthcare grant D/12/03783 (M.F.C.). NR 43 TC 4 Z9 4 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD MAY 14 PY 2015 VL 125 IS 20 BP 3105 EP 3113 DI 10.1182/blood-2014-10-604892 PG 9 WC Hematology SC Hematology GA CJ7PJ UT WOS:000355689000014 PM 25824687 ER PT J AU Nonami, A Sattler, M Weisberg, E Liu, QS Zhang, JM Patricelli, MP Christie, AL Saur, AM Kohl, NE Kung, AL Yoon, H Sim, T Gray, NS Griffin, JD AF Nonami, Atsushi Sattler, Martin Weisberg, Ellen Liu, Qingsong Zhang, Jianming Patricelli, Matthew P. Christie, Amanda L. Saur, Amy M. Kohl, Nancy E. Kung, Andrew L. Yoon, Hojong Sim, Taebo Gray, Nathanael S. Griffin, James D. TI Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach SO BLOOD LA English DT Article ID GERMINAL CENTER KINASE; CANCER-CELLS; INHIBITOR; ACTIVATION; PATHWAY; RAS; POLYPHARMACOLOGY; RESISTANCE; DISCOVERY; SURVIVAL AB Oncogenic forms of NRAS are frequently associated with hematologic malignancies and other cancers, making them important therapeutic targets. Inhibition of individual downstream effector molecules (eg, RAF kinase) have been complicated by the rapid development of resistance or activation of bypass pathways. For the purpose of identifying novel targets in NRAS-transformed cells, we performed a chemical screen using mutant NRAS transformed Ba/F3 cells to identify compounds with selective cytotoxicity. One of the compounds identified, GNF-7, potently and selectively inhibited NRAS-dependent cells in preclinical models of acute myelogenous leukemia and acute lymphoblastic leukemia. Mechanistic analysis revealed that its effects were mediated in part through combined inhibition of ACK1/AKT and of mitogen-activated protein kinase kinase kinase kinase 2 (germinal center kinase). Similar to genetic synthetic lethal approaches, these results suggest that small molecule screens can be used to identity novel therapeutic targets in cells addicted to RAS oncogenes. C1 [Nonami, Atsushi; Sattler, Martin; Weisberg, Ellen; Griffin, James D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Nonami, Atsushi; Sattler, Martin; Weisberg, Ellen; Griffin, James D.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Liu, Qingsong; Zhang, Jianming; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Liu, Qingsong; Zhang, Jianming; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Patricelli, Matthew P.] ActivX Biosci Inc, La Jolla, CA USA. [Christie, Amanda L.; Saur, Amy M.; Kohl, Nancy E.; Kung, Andrew L.] Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA USA. [Yoon, Hojong; Sim, Taebo] Korea Inst Sci & Technol, Chem Kinom Res Ctr, Seoul, South Korea. [Sim, Taebo] Korea Univ KIST, Grad Sch Converging Sci & Technol, Seoul, South Korea. RP Sim, T (reprint author), 145 Anam Ro, Seoul 136713, South Korea. EM tbsim@kist.re.kr; nathanael_gray@dfci.harvard.edu OI liu, qing song/0000-0002-7829-2547; Kung, Andrew/0000-0002-9091-488X FU National Institutes of Health, National Cancer Institute [CA66996, CA130876-04, CA154303-01A1, HG005693-01]; Kanae foundation for the promotion of medical science; Korea Institute of Science and Technology; creative/challenging research program of the National Research Foundation of Korea [NRF-2011-0028676]; Korea Basic Science Institute [D33400] FX This study is supported by the National Institutes of Health, National Cancer Institute grants CA66996 (J.D.G), CA130876-04 (N.S.G), and CA154303-01A1 (N.S.G), and HG005693-01 (N.S.G), a grant from the Kanae foundation for the promotion of medical science (A.N.), and grants from the Korea Institute of Science and Technology (T.S.), the creative/challenging research program of the National Research Foundation of Korea (NRF-2011-0028676) (T.S.), and the Korea Basic Science Institute (D33400, T.S.). NR 32 TC 4 Z9 4 U1 2 U2 7 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD MAY 14 PY 2015 VL 125 IS 20 BP 3133 EP 3143 DI 10.1182/blood-2014-12-615906 PG 11 WC Hematology SC Hematology GA CJ7PJ UT WOS:000355689000018 PM 25833960 ER PT J AU Arvey, A Ojesina, AI Pedamallu, CS Ballon, G Jung, J Duke, F Leoncini, L De Falco, G Bressman, E Tam, W Chadburn, A Meyerson, M Cesarman, E AF Arvey, Aaron Ojesina, Akinyemi I. Pedamallu, Chandra Sekhar Ballon, Gianna Jung, Joonil Duke, Fujiko Leoncini, Lorenzo De Falco, Giulia Bressman, Eric Tam, Wayne Chadburn, Amy Meyerson, Matthew Cesarman, Ethel TI The tumor virus landscape of AIDS-related lymphomas SO BLOOD LA English DT Article ID EPSTEIN-BARR-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; NON-HODGKINS-LYMPHOMA; CENTER B-CELLS; BURKITTS-LYMPHOMA; GERMINAL-CENTER; NASOPHARYNGEAL CARCINOMA; KAPOSIS-SARCOMA; READ ALIGNMENT; UNITED-STATES AB Immunodeficiency dramatically increases susceptibility to cancer as a result of reduced immune surveillance and enhanced opportunities for virus-mediated oncogenesis. Although AIDS-related lymphomas(ARLs) are frequently associated with known oncogenic viruses, many cases contain no known transforming virus. To discover novel transforming viruses, we profiled a set of ARL samples using whole transcriptome sequencing. We determined that Epstein-Barr virus (EBV) was the only virus detected in the tumor samples of this cohort, suggesting that if unidentified pathogens exist in this disease, they are present in <10% of cases or undetectable by our methods. To evaluate the role of EBV in ARL pathogenesis, we analyzed viral gene expression and found highly heterogeneous patterns of viral transcription across samples. We also found significant heterogeneity of viral antigen expression across a large cohort, with many patient samples presenting with restricted type I viral latency, indicating that EBV latency proteins are under increased immunosurveillance in the post-combined antiretroviral therapies era. Furthermore, EBV infection of lymphoma cells in HIV-positive individuals was associated with a distinct host gene expression program. These findings provide insight into the joint host-virus regulatory network of primary ARL tumor samples and expand our understanding of virus-associated oncogenesis. Our findings may also have therapeutic implications, as treatment may be personalized to target specific viral and virus-associated host processes that are only present in a subset of patients. C1 [Arvey, Aaron] Mem Sloan Kettering Canc Ctr, Dept Immunol & Microbial Pathogenesis, New York, NY 10021 USA. [Ojesina, Akinyemi I.; Pedamallu, Chandra Sekhar; Duke, Fujiko; Meyerson, Matthew] Broad Inst MIT & Harvard, Canc Program, Cambridge, MA 02139 USA. [Ojesina, Akinyemi I.; Pedamallu, Chandra Sekhar; Jung, Joonil; Duke, Fujiko; Meyerson, Matthew] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ballon, Gianna; Bressman, Eric; Tam, Wayne; Cesarman, Ethel] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY 10065 USA. [Leoncini, Lorenzo; De Falco, Giulia] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy. [Chadburn, Amy] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA. RP Cesarman, E (reprint author), Weill Cornell Med Coll, Dept Pathol & Lab Med, 1300 York Ave, New York, NY 10065 USA. EM ecesarm@med.cornell.edu OI Ojesina, Akinyemi/0000-0003-0755-3639 FU Starr Cancer Consortium; National Institutes of Health (NIH) National Cancer Institute [1RC2CA148317]; Rebecca Ridley Kry Fellowship of the Damon Runyon Cancer Research Foundation; AIDS Malignancy Clinical Trials Consortium (NIH National Cancer Institute) [U01CA121947]; AIDS Cancer Specimen Resource (NIH National Cancer Institute) [1UM1CA181255] FX This project was funded by the Starr Cancer Consortium and National Institutes of Health (NIH) National Cancer Institute grant 1RC2CA148317 (M.M. and E.C.). A.I.O. was supported by the Rebecca Ridley Kry Fellowship of the Damon Runyon Cancer Research Foundation. The AIDS Malignancy Clinical Trials Consortium (NIH National Cancer Institute grant U01CA121947) and the AIDS Cancer Specimen Resource (NIH National Cancer Institute grant 1UM1CA181255) contributed cases of ARL. NR 47 TC 10 Z9 10 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD MAY 14 PY 2015 VL 125 IS 20 BP E14 EP E22 DI 10.1182/blood-2014-11-599951 PG 9 WC Hematology SC Hematology GA CJ7PJ UT WOS:000355689000001 PM 25827832 ER PT J AU Liu, Y Ye, J Ogawa, LS Inoue, T Huang, Q Chu, J Bates, RC Ying, W Sonderfan, AJ Rao, PE Zhou, D AF Liu, Yuan Ye, Josephine Ogawa, Luisa Shin Inoue, Takayo Huang, Qin Chu, John Bates, Richard C. Ying, Weiwen Sonderfan, Andrew J. Rao, Patricia E. Zhou, Dan TI The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus SO PLOS ONE LA English DT Article ID HEAT-SHOCK-PROTEIN; T-CELLS; AUTOIMMUNE-DISEASE; ELEVATED LEVELS; CANCER; ACTIVATION; MICE; AUTOANTIBODIES; SLE; INFLAMMATION AB Systemic lupus erythematosus (SLE) is a complex, systemic autoimmune disease with a diverse range of immunological and clinical manifestations. The introduction of broad spectrum immunosuppressive therapies and better management of acute disease exacerbations have improved outcomes for lupus patients over recent years. However, these regimens are burdened by substantial toxicities and confer significantly higher risks of infection, thus there remains a significant and unmet medical need for alternative treatment options, particularly those with improved safety profiles. Heat shock protein 90 (HSP90) is a ubiquitously expressed molecular chaperone that acts as an important modulator of multiple innate and adaptive inflammatory processes. Of note, accumulating clinical and experimental evidence has implicated a role for HSP90 in the pathogenesis of SLE. Here we evaluated the potential of HSP90 as a therapeutic target for this disease using the selective small molecule inhibitor ganetespib in the well-characterized MRL/lpr autoimmune mouse model. In both the prophylactic and therapeutic dosing settings, ganetespib treatment promoted dramatic symptomatic improvements in multiple disease parameters, including suppression of autoantibody production and the preservation of renal tissue integrity and function. In addition, ganetespib exerted profound inhibitory effects on disease-related lymphadenopathy and splenomegaly, and reduced pathogenic T and B cell lineage populations in the spleen. Ganetespib monotherapy was found to be equally efficacious and tolerable when compared to an effective weekly dosing regimen of the standard-of-care immunosuppressive agent cyclophosphamide. Importantly, co-treatment of ganetespib with a sub-optimal, intermittent dosing schedule of cyclophosphamide resulted in superior therapeutic indices and maximal disease control. These findings highlight the potential of HSP90 inhibition as an alternative, and potentially complementary, strategy for therapeutic intervention in SLE. Such approaches may have important implications for disease management, particularly for limiting or preventing treatment-related toxicities, a major confounding factor in current SLE therapy. C1 [Liu, Yuan; Ye, Josephine; Ogawa, Luisa Shin; Inoue, Takayo; Chu, John; Bates, Richard C.; Ying, Weiwen; Sonderfan, Andrew J.; Rao, Patricia E.; Zhou, Dan] Synta Pharmaceut Corp, Lexington, MA 02421 USA. [Huang, Qin] VA Boston Healthcare Syst, Dept Pharmacol & Lab Med, West Roxbury, MA USA. RP Zhou, D (reprint author), Synta Pharmaceut Corp, Lexington, MA 02421 USA. EM DZhou@syntapharma.com FU Synta Pharmaceuticals Corp FX The author(s) received no specific funding for this work. Synta Pharmaceuticals Corp provided support in the form of salaries for authors YL, JY, LSO, TI, JC, RB, WY, AS, PR and DZ but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section". NR 53 TC 2 Z9 2 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 14 PY 2015 VL 10 IS 5 AR e0127361 DI 10.1371/journal.pone.0127361 PG 22 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CI2AC UT WOS:000354545600112 PM 25974040 ER PT J AU Hur, C Choi, SE Kong, CY Wang, GQ Xu, H Polydorides, AD Xue, LY Perzan, KE Tramontano, AC Richards-Kortum, RR Anandasabapathy, S AF Hur, Chin Choi, Sung Eun Kong, Chung Yin Wang, Gui-Qi Xu, Hong Polydorides, Alexandros D. Xue, Li-Yan Perzan, Katherine E. Tramontano, Angela C. Richards-Kortum, Rebecca R. Anandasabapathy, Sharmila TI High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Cost-effectiveness analysis; Diagnostic imaging; Endoscopy; Esophageal squamous cell cancer; Simulation disease model ID SQUAMOUS-CELL CARCINOMA; GASTROESOPHAGEAL-REFLUX DISEASE; EXTENDED TRANSTHORACIC RESECTION; TIME CONFOCAL MICROSCOPY; HIGH-RISK AREAS; BARRETTS-ESOPHAGUS; EFFECTIVENESS MODEL; AMELANOTIC TISSUE; SURVEILLANCE; DYSPLASIA AB AIM: To study the cost-effectiveness of high-resolution microendoscopy (HRME) in an esophageal squamous cell carcinoma (ESCC) screening program in China. METHODS: A decision analytic Markov model of ESCC was developed. Separate model analyses were conducted for cohorts consisting of an averagerisk population or a high-risk population in China. Hypothetical 50-year-old individuals were followed until age 80 or death. We compared three different strategies for both cohorts: (1) no screening; (2) standard endoscopic screening with Lugol's iodine staining; and (3) endoscopic screening with Lugol's iodine staining and an HRME. Model parameters were estimated from the literature as well as from GLOBOCAN, the Cancer Incidence and Mortality Worldwide cancer database. Health states in the model included non-neoplasia, mild dysplasia, moderate dysplasia, high-grade dysplasia, intramucosal carcinoma, operable cancer, inoperable cancer, and death. Separate ESCC incidence transition rates were generated for the average-risk and high-risk populations. Costs in Chinese currency were converted to international dollars (I$) and were adjusted to 2012dollars using the Consumer Price Index. RESULTS: The main outcome measurements for this study were quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER). For the average-risk population, the HRME screening strategy produced 0.043 more QALYs than the no screening strategy at an additional cost of I$646, resulting in an ICER of I$11808 per QALY gained. Standard endoscopic screening was weakly dominated. Among the high-risk population, when the HRME screening strategy was compared with the standard screening strategy, the ICER was I$8173 per QALY. For both the high-risk and average-risk screening populations, the HRME screening strategy appeared to be the most cost-effective strategy, producing ICERs below the willingness-topay threshold, I$23500 per QALY. One-way sensitivity analysis showed that, for the average-risk population, higher specificity of Lugol's iodine (> 40%) and lower specificity of HRME (< 70%) could make Lugol's iodine screening cost-effective. For the high-risk population, the results of the model were not substantially affected by varying the follow-up rate after Lugol's iodine screening, Lugol's iodine test characteristics (sensitivity and specificity), or HRME specificity. CONCLUSION: The incorporation of HRME into an ESCC screening program could be cost-effective in China. Larger studies of HRME performance are needed to confirm these findings. C1 [Hur, Chin; Choi, Sung Eun; Kong, Chung Yin; Perzan, Katherine E.; Tramontano, Angela C.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Hur, Chin; Kong, Chung Yin] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Hur, Chin; Perzan, Katherine E.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Wang, Gui-Qi] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Endoscopy, Beijing 100021, Peoples R China. [Xu, Hong] Jilin Univ, Hosp 1, Dept Endoscopy, Changchun 130021, Jilin Province, Peoples R China. [Polydorides, Alexandros D.] Icahn Sch Med, Mt Sinai Med Ctr, Dept Pathol, New York, NY 10029 USA. [Xue, Li-Yan] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Pathol, Beijing 100021, Peoples R China. [Richards-Kortum, Rebecca R.] Rice Univ, Dept Bioengn, Houston, TX 77005 USA. [Anandasabapathy, Sharmila] Baylor Coll Med, Baylor Global Initiat, Houston, TX 77030 USA. [Anandasabapathy, Sharmila] Baylor Coll Med, Baylor Global Innovat Ctr, Houston, TX 77030 USA. RP Hur, C (reprint author), Massachusetts Gen Hosp, GI Hlth Outcomes Res, 101 Merrimac St,10th Floor, Boston, MA 02114 USA. EM chur@mgh.harvard.edu OI Hur, Chin/0000-0002-2819-7576 FU National Institutes of Health, United States [R01-CA140574, U01-CA152926, R21-CA156704, R01-CA181275, K25-CA133141] FX Supported by National Institutes of Health, United States, No. R01-CA140574 and No. U01-CA152926 (to Hur C); No. R21-CA156704 and No. R01-CA181275 (to Anandasabapathy S); and No. K25-CA133141 (to Kong CY). NR 37 TC 3 Z9 4 U1 0 U2 8 PU BAISHIDENG PUBLISHING GROUP INC PI PLEASANTON PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA SN 1007-9327 EI 2219-2840 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD MAY 14 PY 2015 VL 21 IS 18 BP 5513 EP 5523 DI 10.3748/wjg.v21.i18.5513 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CI5MF UT WOS:000354800200009 PM 25987774 ER PT J AU Desai, RJ Huybrechts, KF Hernandez-Diaz, S Mogun, H Patorno, E Kaltenbach, K Kerzner, LS Bateman, BT AF Desai, Rishi J. Huybrechts, Krista F. Hernandez-Diaz, Sonia Mogun, Helen Patorno, Elisabetta Kaltenbach, Karol Kerzner, Leslie S. Bateman, Brian T. TI Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study SO BMJ-BRITISH MEDICAL JOURNAL LA English DT Article ID WITHDRAWAL SYNDROME; UNITED-STATES; INFANTS BORN; DRUG-USE; PREGNANCY; METHADONE; OUTCOMES; PREVALENCE; MOTHERS; WOMEN AB OBJECTIVE To provide absolute and relative risk estimates of neonatal abstinence syndrome (NAS) based on duration and timing of prescription opioid use during pregnancy in the presence or absence of additional NAS risk factors of history of opioid misuse or dependence, misuse of other substances, non-opioid psychotropic drug use, and smoking. DESIGN Observational cohort study. SETTING Medicaid data from 46 US states. PARTICIPANTS Pregnant women filling at least one prescription for an opioid analgesic at any time during pregnancy for whom opioid exposure characteristics including duration of therapy: short term (<30 days) or long term (>= 30 days); timing of use: early use (only in the first two trimesters) or late use (extending into the third trimester); and cumulative dose (in morphine equivalent milligrams) were assessed. MAIN OUTCOME MEASURE Diagnosis of NAS in liveborn infants. RESULTS 1705 cases of NAS were identified among 290 605 pregnant women filling opioid prescriptions, corresponding to an absolute risk of 5.9 per 1000 deliveries (95% confidence interval 5.6 to 6.2). Long term opioid use during pregnancy resulted in higher absolute risk of NAS per 1000 deliveries in the presence of additional risk factors of known opioid misuse (220.2 (200.8 to 241.0)), alcohol or other drug misuse (30.8 (26.1 to 36.0)), exposure to other psychotropic medications (13.1 (10.6 to 16.1)), and smoking (6.6 (4.3 to 9.6)) than in the absence of any of these risk factors (4.2 (3.3 to 5.4)). The corresponding risk estimates for short term use were 192.0 (175.8 to 209.3), 7.0 (6.0 to 8.2), 2.0 (1.5 to 2.6), 1.5 (1.0 to 2.0), and 0.7 (0.6 to 0.8) per 1000 deliveries, respectively. In propensity score matched analyses, long term prescription opioid use compared with short term use and late use compared with early use in pregnancy demonstrated greater risk of NAS (risk ratios 2.05 (95% confidence interval 1.81 to 2.33) and 1.24 (1.12 to 1.38), respectively). CONCLUSIONS Use of prescription opioids during pregnancy is associated with a low absolute risk of NAS in the absence of additional risk factors. Long term use compared with short term use and late use compared with early use of prescription opioids are associated with increased NAS risk independent of additional risk factors. C1 [Desai, Rishi J.; Huybrechts, Krista F.; Mogun, Helen; Patorno, Elisabetta; Bateman, Brian T.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA. [Desai, Rishi J.; Huybrechts, Krista F.; Mogun, Helen; Patorno, Elisabetta; Bateman, Brian T.] Harvard Univ, Sch Med, Boston, MA 02120 USA. [Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Kaltenbach, Karol] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Pediat, Philadelphia, PA 19107 USA. [Kerzner, Leslie S.] Harvard Univ, Sch Med, Dept Pediat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Bateman, Brian T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA. RP Desai, RJ (reprint author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA. EM rdesai2@partners.org FU National Institute of Mental Health [K01 MH099141]; Eunice Kennedy Shriver National Institute of Child Health and Human Development of the NIH [K08HD075831]; Agency for Healthcare Research and Quality (AHRQ) [R01HS018533] FX All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: KH is supported by a career development award from the National Institute of Mental Health (K01 MH099141); BB is supported by a career development award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the NIH (K08HD075831). MAX pregnancy cohort creation was supported by the Agency for Healthcare Research and Quality (AHRQ) (Grant R01HS018533). SH-D has consulted for GlaxoSmithKline-Biologics (Middlesex, UK) and AstraZeneca (London, UK) for unrelated projects. The other authors declare no other relationships or activities that could appear to have influenced the submitted work. NR 38 TC 15 Z9 15 U1 1 U2 10 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BMJ-BRIT MED J JI BMJ-British Medical Journal PD MAY 14 PY 2015 VL 350 AR h2102 DI 10.1136/bmj.h2102 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CI5CI UT WOS:000354770100003 PM 25975601 ER PT J AU Cheng, ZY Li, JF Niu, YJ Zhang, XC Woody, OZ Xiong, Y Djonovic, S Millet, Y Bush, J McConkey, BJ Sheen, J Ausubel, FM AF Cheng, Zhenyu Li, Jian-Feng Niu, Yajie Zhang, Xue-Cheng Woody, Owen Z. Xiong, Yan Djonovic, Slavica Millet, Yves Bush, Jenifer McConkey, Brendan J. Sheen, Jen Ausubel, Frederick M. TI Pathogen-secreted proteases activate a novel plant immune pathway SO NATURE LA English DT Article ID GENE-EXPRESSION ANALYSIS; PSEUDOMONAS-AERUGINOSA; ARABIDOPSIS-THALIANA; INNATE IMMUNITY; PROTEIN-KINASE; XANTHOMONAS-CAMPESTRIS; RACK1; TRANSFORMATION; INTERACTS; IDENTIFICATION AB Mitogen-activated protein kinase (MAPK) cascades play central roles in innate immune signalling networks in plants and animals(1,2). In plants, however, the molecular mechanisms of how signal perception is transduced to MAPK activation remain elusive(1). Here we report that pathogen-secreted proteases activate a previously unknown signalling pathway in Arabidopsis thaliana involving the G alpha, G beta, and G gamma subunits of heterotrimeric G-protein complexes, which function upstream of an MAPK cascade. In this pathway, receptor for activated C kinase 1 (RACK1) functions as a novel scaffold that binds to the G beta subunit as well as to all three tiers of the MAPK cascade, thereby linking upstream G-protein signalling to downstream activation of an MAPK cascade. The protease-G-protein-RACK1-MAPK cascade modules identified in these studies are distinct from previously described plant immune signalling pathways such as that elicited by bacterial flagellin, in which G proteins function downstream of or in parallel to an MAPK cascade without the involvement of the RACK1 scaffolding protein. The discovery of the new protease-mediated immune signalling pathway described here was facilitated by the use of the broad host range, opportunistic bacterial pathogen Pseudomonas aeruginosa. The ability of P. aeruginosa to infect both plants and animals makes it an excellent model to identify novel immunoregulatory strategies that account for its niche adaptation to diverse host tissues and immune systems. C1 [Cheng, Zhenyu; Li, Jian-Feng; Niu, Yajie; Zhang, Xue-Cheng; Xiong, Yan; Djonovic, Slavica; Millet, Yves; Bush, Jenifer; Sheen, Jen; Ausubel, Frederick M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Cheng, Zhenyu; Li, Jian-Feng; Niu, Yajie; Zhang, Xue-Cheng; Xiong, Yan; Djonovic, Slavica; Millet, Yves; Bush, Jenifer; Sheen, Jen; Ausubel, Frederick M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Woody, Owen Z.; McConkey, Brendan J.] Univ Waterloo, Dept Biol, Waterloo, ON N2L 3G1, Canada. RP Ausubel, FM (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. EM ausubel@molbio.mgh.harvard.edu FU Natural Sciences and Engineering Research Council of Canada; Banting Postdoctoral Fellowships; National Science Foundation [MCB-0519898, IOS-0929226, IOS-0618292]; National Institutes of Health [R37-GM48707, P30 DK040561, R01-GM70567] FX We thank G. Tena for generating the mekk1/pMEKK1::MEKK1(K361M) transgenic line, Y. Zhang for the summ1-1 mutant, M. C. Suarez-Rodriguez and P. J. Krysan for discussion, the Arabidopsis Biological Resource Center for tDNA insertion lines, and M. Curtis and U. Grossniklaus for the oestradiol-inducible binary vector. We thank S. Lory for P. aeruginosa PAO ADD1976, and M. B. Mudgett for pVSP61. We thank N. Clay, X. Dong, S. Somerville, and Ausubel laboratory members for reading the manuscript. This work was supported by Natural Sciences and Engineering Research Council of Canada and Banting Postdoctoral Fellowships awarded to Z.C., National Science Foundation grants MCB-0519898 and IOS-0929226 and National Institutes of Health grants R37-GM48707 and P30 DK040561 to F.M.A., and National Science Foundation grant IOS-0618292 and National Institutes of Health grant R01-GM70567 to J.S. NR 39 TC 29 Z9 38 U1 18 U2 116 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 EI 1476-4687 J9 NATURE JI Nature PD MAY 14 PY 2015 VL 521 IS 7551 BP 213 EP + DI 10.1038/nature14243 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CH9SY UT WOS:000354377800057 PM 25731164 ER PT J AU Mayer, RJ Van Cutsem, E Falcone, A Yoshino, T Garcia-Carbonero, R Mizunuma, N Yamazaki, K Shimada, Y Tabernero, J Komatsu, Y Sobrero, A Boucher, E Peeters, M Tran, B Lenz, HJ Zaniboni, A Hochster, H Cleary, JM Prenen, H Benedetti, F Mizuguchi, H Makris, L Ito, M Ohtsu, A AF Mayer, Robert J. Van Cutsem, Eric Falcone, Alfredo Yoshino, Takayuki Garcia-Carbonero, Rocio Mizunuma, Nobuyuki Yamazaki, Kentaro Shimada, Yasuhiro Tabernero, Josep Komatsu, Yoshito Sobrero, Alberto Boucher, Eveline Peeters, Marc Tran, Ben Lenz, Heinz-Josef Zaniboni, Alberto Hochster, Howard Cleary, James M. Prenen, Hans Benedetti, Fabio Mizuguchi, Hirokazu Makris, Lukas Ito, Masanobu Ohtsu, Atsushi CA RECOURSE Study Grp TI Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID SOLID TUMORS; PHASE-I; FLUORINATED PYRIMIDINES; ANTITUMOR-ACTIVITY; ANTIMETABOLITE; MECHANISM; CELLS; DNA AB BACKGROUND Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS In this double-blind study, we randomly assigned 800 patients, in a 2: 1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival. RESULTS The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001). CONCLUSIONS In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. C1 [Mayer, Robert J.; Cleary, James M.] Dana Farber Canc Inst, Boston, MA 02215 USA. [Van Cutsem, Eric; Prenen, Hans] Univ Hosp, Leuven, Belgium. [Van Cutsem, Eric; Prenen, Hans] Katholieke Univ Leuven, Leuven, Belgium. [Peeters, Marc] Univ Ziekenhuizen Antwerp, Edegem, Belgium. [Falcone, Alfredo] Univ Pisa, Pisa, Italy. [Sobrero, Alberto] IRCCS Azienda Osped Univ San Martino, Ist Nazl Ric Canc, I-16132 Genoa, Italy. [Zaniboni, Alberto] Fdn Poliambulanza Ist Osped, Brescia, Italy. [Yoshino, Takayuki; Ohtsu, Atsushi] Natl Canc Ctr Hosp East, Chiba, Japan. [Mizunuma, Nobuyuki] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan. [Yamazaki, Kentaro] Shizuoka Canc Ctr, Shizuoka, Japan. [Shimada, Yasuhiro] Natl Canc Ctr, Tokyo, Japan. [Komatsu, Yoshito] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan. [Ito, Masanobu] Taiho Pharmaceut, Tokyo, Japan. [Garcia-Carbonero, Rocio] Hosp Univ Virgen del Rocio, Inst Biomed Sevilla, Seville, Spain. [Tabernero, Josep] Vall dHebron Univ Hosp, Barcelona, Spain. [Tabernero, Josep] Vall dHebron Inst Oncol, Barcelona, Spain. [Boucher, Eveline] Ctr Eugene Marquis, Rennes, France. [Tran, Ben] Royal Melbourne Hosp, Melbourne, Vic, Australia. [Lenz, Heinz-Josef] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA. [Hochster, Howard] Yale Canc Ctr, New Haven, CT USA. [Benedetti, Fabio; Mizuguchi, Hirokazu] Taiho Oncol, Princeton, NJ USA. [Makris, Lukas] Stathmi, New Hope, PA USA. RP Mayer, RJ (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. RI Peeters, Marc/C-5525-2013; IBIS, NUEVAS TERAPIA/P-3415-2015; OI Peeters, Marc/0000-0003-4969-2303; Folprecht, Gunnar/0000-0002-9321-9911 FU Taiho Oncology-Taiho Pharmaceutical FX Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957. NR 19 TC 100 Z9 103 U1 2 U2 14 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 14 PY 2015 VL 372 IS 20 BP 1909 EP 1919 DI 10.1056/NEJMoa1414325 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CI1HB UT WOS:000354493300006 PM 25970050 ER PT J AU Joy, M AF Joy, Mark TI Acid-Base Problems in Diabetic Ketoacidosis SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID LACTIC-ACIDOSIS; BICARBONATE C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Joy, M (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM mark.joy@va.gov NR 4 TC 0 Z9 0 U1 1 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 14 PY 2015 VL 372 IS 20 BP 1968 EP 1968 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CI1HB UT WOS:000354493300022 PM 25970064 ER PT J AU Fernandez, KA Jeffers, PWC Lall, K Liberman, MC Kujawa, SG AF Fernandez, Katharine A. Jeffers, Penelope W. C. Lall, Kumud Liberman, M. Charles Kujawa, Sharon G. TI Aging after Noise Exposure: Acceleration of Cochlear Synaptopathy in "Recovered" Ears SO JOURNAL OF NEUROSCIENCE LA English DT Article DE age-related hearing loss; auditory nerve; cochlear neuropathy; cochlear synaptopathy; noise-induced hearing loss; temporary threshold shift ID INDUCED HEARING-LOSS; HAIR CELL LOSS; SURFACE AMPA RECEPTORS; AUDITORY-NERVE FIBERS; GUINEA-PIG COCHLEA; ACOUSTIC TRAUMA; CAT COCHLEA; DEGENERATION; INNERVATION; SENSITIVITY AB Cochlear synaptic loss, rather than hair cell death, is the earliest sign of damage in both noise-and age-related hearing impairment (Kujawa and Liberman, 2009; Sergeyenko et al., 2013). Here, we compare cochlear aging after two types of noise exposure: one producing permanent synaptic damage without hair cell loss and another producing neither synaptopathy nor hair cell loss. Adult mice were exposed (8-16 kHz, 100 or 91 dB SPL for 2 h) and then evaluated from 1 h to similar to 20 months after exposure. Cochlear function was assessed via distortion product otoacoustic emissions and auditory brainstem responses (ABRs). Cochlear whole mounts and plastic sections were studied to quantify hair cells, cochlear neurons, and the synapses connecting them. The synaptopathic noise (100 dB) caused 35-50 dB threshold shifts at 24 h. By 2 weeks, thresholds had recovered, but synaptic counts and ABR amplitudes at high frequencies were reduced by up to similar to 45%. As exposed animals aged, synaptopathy was exacerbated compared with controls and spread to lower frequencies. Proportional ganglion cell losses followed. Threshold shifts first appeared similar to 1 year after exposure and, by similar to 20 months, were up to 18 dB greater in the synaptopathic noise group. Outer hair cell losses were exacerbated in the same time frame (similar to 10% at 32 kHz). In contrast, the 91 dB exposure, producing transient threshold shift without acute synaptopathy, showed no acceleration of synaptic loss or cochlear dysfunction as animals aged, at least to similar to 1 year after exposure. Therefore, interactions between noise and aging may require an acute synaptopathy, but a single synaptopathic exposure can accelerate cochlear aging. C1 [Fernandez, Katharine A.; Lall, Kumud; Liberman, M. Charles; Kujawa, Sharon G.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. [Fernandez, Katharine A.; Jeffers, Penelope W. C.; Lall, Kumud; Liberman, M. Charles; Kujawa, Sharon G.] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA. [Kujawa, Sharon G.] Massachusetts Eye & Ear Infirm, Dept Audiol, Boston, MA 02114 USA. RP Kujawa, SG (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM sharon_kujawa@meei.harvard.edu FU National Institute on Deafness and other Communication Disorders-National Institutes of Health [R01 DC08577, R01 DC0188, P30 DC05209] FX This work was supported by grants from the National Institute on Deafness and other Communication Disorders-National Institutes of Health (Grants R01 DC08577, R01 DC0188, and P30 DC05209). NR 54 TC 25 Z9 26 U1 2 U2 20 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAY 13 PY 2015 VL 35 IS 19 BP 7509 EP 7520 DI 10.1523/JNEUROSCI.5138-14.2015 PG 12 WC Neurosciences SC Neurosciences & Neurology GA CL0YK UT WOS:000356668800017 PM 25972177 ER PT J AU Wlodarska, M Kostic, AD Xavier, RJ AF Wlodarska, Marta Kostic, Aleksandar D. Xavier, Ramnik J. TI An Integrative View of Microbiome-Host Interactions in Inflammatory Bowel Diseases SO CELL HOST & MICROBE LA English DT Review ID INTESTINAL ALKALINE-PHOSPHATASE; GENOME-WIDE ASSOCIATION; ENTERIC NERVOUS-SYSTEM; HUMAN GUT VIROME; CROHNS-DISEASE; ENVIRONMENTAL ENTEROPATHY; ULCERATIVE-COLITIS; FECAL MICROBIOTA; T-CELLS; COMMENSAL BACTERIA AB The intestinal microbiota, which is composed of bacteria, viruses, and micro-eukaryotes, acts as an accessory organ system with distinct functions along the intestinal tract that are critical for health. This review focuses on how the microbiota drives intestinal disease through alterations in microbial community architecture, disruption of the mucosal barrier, modulation of innate and adaptive immunity, and dysfunction of the enteric nervous system. Inflammatory bowel disease is used as a model system to understand these microbial-driven pathologies, but the knowledge gained in this space is extended to less-well-studied intestinal diseases that may also have an important microbial component, including environmental enteropathy and chronic colitis-associated colorectal cancer. C1 [Wlodarska, Marta; Kostic, Aleksandar D.; Xavier, Ramnik J.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA. [Wlodarska, Marta] Novartis Inst BioMed Res, Dev & Mol Pathways, Cambridge, MA 02139 USA. [Kostic, Aleksandar D.; Xavier, Ramnik J.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Kostic, Aleksandar D.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Xavier, Ramnik J.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Xavier, Ramnik J.] Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA. [Xavier, Ramnik J.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Xavier, Ramnik J.] MIT, Ctr Microbiome Informat & Therapeut, Cambridge, MA 02139 USA. RP Xavier, RJ (reprint author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA. EM xavier@molbio.mgh.harvard.edu OI Kostic, Aleksandar/0000-0002-0837-4360 FU Helen Hay Whitney Foundation Research Fellowship; Lawrence H. Summers Postdoctoral Fellowship; Crohn's and Colitis Foundation of America; Leona M. and Harry B. Helmsley Charitable Trust; JDRF; National Institutes of Health FX A.D.K. is supported by a Helen Hay Whitney Foundation Research Fellowship and the Lawrence H. Summers Postdoctoral Fellowship. R.J.X. is supported by grants from the Crohn's and Colitis Foundation of America, the Leona M. and Harry B. Helmsley Charitable Trust, JDRF, and the National Institutes of Health. We thank Eric M. Brown and Natalia Nedelsky for thorough editing of this manuscript. NR 156 TC 32 Z9 34 U1 9 U2 51 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1931-3128 EI 1934-6069 J9 CELL HOST MICROBE JI Cell Host Microbe PD MAY 13 PY 2015 VL 17 IS 5 BP 577 EP 591 DI 10.1016/j.chom.2015.04.008 PG 15 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA CK3FH UT WOS:000356101500010 PM 25974300 ER PT J AU Bourguignon, LYW Bikle, D AF Bourguignon, Lilly Y. W. Bikle, Daniel TI Selective hyaluronan-CD44 signaling promotes miRNA-21 expression and interacts with vitamin D function during cutaneous squamous cell carcinomas progression following UV irradiation SO FRONTIERS IN IMMUNOLOGY LA English DT Article DE hyaluronan; CD44; RhoGTPase; vitamin D; UVR; miR21; vitamin D; skin cancer ID TUMOR-SUPPRESSOR PDCD4; PROTEIN-KINASE-C; NF-KAPPA-B; BREAST-CANCER CELLS; RHO-KINASE; CD44 INTERACTION; SKIN-CANCER; KERATINOCYTE DIFFERENTIATION; TRANSCRIPTION FACTORS; INHIBITS TRANSLATION AB Hyaluronan (HA), the major extracellular matrix component, is often anchored to CD44, a family of structurally/functionally important cell surface receptors. Recent results indicate that UV irradiation (UVR)-induced cutaneous squamous cell carcinomas (SCC) overexpress a variety of CD44 variant isoforms (CD44v), with different CD44v isoforms appear to confer malignant SCC properties. UVR also stimulates HA degradation in epidermal keratinocytes. Both large HA polymers and their UVR-induced catabolic products (small HA) selectively activate CD44-mediated cellular signaling in normal keratinocytes and SCC cells, with all of the downstream processes being mediated by RhoGTPases (e.g., Rac1 and Rho). Importantly, we found that the hormonally active form of vitamin D 1,25(OH)(2) D-3 not only prevents the UVR-induced small HA activation of abnormal keratinocyte behavior and SCC progression, but also enhances large HA stimulation of normal keratinocyte activities and epidermal function(s). The aim of this hypothesis and theory article is to question whether matrix HA and its UVR-induced catabolic products (e.g., large and small HA) can selectively activate CD44-mediated cellular signaling such as GTPase (Rac and RhA) activation. We suggested that large HA CD44 interaction promotes Rac-signaling and normal keratinocyte differentiation (lipid synthesis), DNA repair, and keratinocyte survival function. Conversely, small HA CD44 interaction stimulates RhoA activation, NFKB/Stat-3 signaling, and miR-21 production, resulting in inflammation and proliferation as well as SCC progression. We also question whether vitamin D treatment displays any effect on small HA CD44v-mediated RhoA signaling, inflammation, and SCC progression, as well as large HA CD44-mediated differentiation, DNA repair, keratinocyte survival, and normal keratinocyte function. In addition, we discussed that the topical application of signaling perturbation agents (e.g., Y27623, a ROK inhibitor) may be used to treat certain skin diseases displaying upregulation of keratinocyte proliferation such as psoriasis and actinic keratoses in order to correct the imbalance between Rac and RhoA signaling during various UV irradiation-induced skin diseases in patients. Finally, we proposed that matrix HA/CD44-signaling strategies and matrix HA (HA(S) vs. HA(L) or HA(S) -> HA(L))-based therapeutic approaches (together with vitamin D) may be used for the treatment of patients suffering a number of UV irradiation-induced skin diseases (e.g., inflammation, skin cancer, and chronic non-healing wounds). C1 [Bourguignon, Lilly Y. W.; Bikle, Daniel] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, Endocrine Unit 111N2, San Francisco, CA 94121 USA. RP Bourguignon, LYW (reprint author), Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Med, Endocrine Unit 111N2, 4150 Clement St, San Francisco, CA 94121 USA. EM lilly.bourguignon@ucsf.edu FU Veterans Affairs (VA) Merit Review Awards [RR & D-1101 RX000601, BLR & D-5101 BX000628]; United States Public Health grants [R01 CA66163]; DOD grant FX We gratefully acknowledge the assistance of Dr. Gerard J. Bourguignon in the preparation and review of this manuscript. This work was supported by Veterans Affairs (VA) Merit Review Awards (RR & D-1101 RX000601 and BLR & D-5101 BX000628), United States Public Health grants (R01 CA66163), and DOD grant. LB is a VA Senior Research Career Scientist. NR 80 TC 2 Z9 2 U1 5 U2 7 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1664-3224 J9 FRONT IMMUNOL JI Front. Immunol. PD MAY 13 PY 2015 VL 6 AR 224 DI 10.3389/fimmu.2015.00224 PG 13 WC Immunology SC Immunology GA CJ2NQ UT WOS:000355322100001 PM 26029210 ER EF